PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MARSHALL, H; NONCHEV, S; SHAM, MH; MUCHAMORE, I; LUMSDEN, A; KRUMLAUF, R				MARSHALL, H; NONCHEV, S; SHAM, MH; MUCHAMORE, I; LUMSDEN, A; KRUMLAUF, R			RETINOIC ACID ALTERS HINDBRAIN HOX CODE AND INDUCES TRANSFORMATION OF RHOMBOMERES 2-3 INTO A 4-5 IDENTITY	NATURE			English	Article							HOMEOBOX-CONTAINING GENES; MOUSE HINDBRAIN; EXPRESSION; SEGMENTATION; DISRUPTION; VERTEBRAE; DEFECTS; HOX-1.1; EMBRYOS; HOX-2.9	IT has been suggested that Hox genes play an important part in the patterning of limbs1-3, vertebrae4-6 and craniofacial structures5,7-9 by providing an ordered molecular system of positional values, termed the Hox code10,11. Little is known about the nature of the signals that govern the establishment and regulation of Hox genes, but retinoic acid can affect the expression of these genes in cell lines12-14 and in embryonic tissues2,11,15-17. On the basis of experimental and clinical evidence, the hindbrain and branchial region of the head are particularly sensitive to the effects of retinoic acid 15,18-21, but the phenotypes are complex and hard to interpret, and how and if they relate to Hox expression has not been clear. Here we follow the changes induced by retinoic acid to hindbrain segmentation and the branchial arches using transgenic mice which contain lacZ reporter genes that reveal the endogenous segment-restricted expression of the Hox-B1 (Hox-2.9), Hox-B2(Hox-2.8) and Krox-20 genes. Our results show that these genes rapidly respond to exposure to retinoic acid at preheadfold stages and undergo a progressive series of changes in segmental expression that are associated with specific phenotypes in hindbrain of first branchial arch. Together the molecular and anatomical alterations indicate that retinoic acid has induced changes in the hindbrain Hox code which result in the homeotic transformation of rhombomeres (r) 2/3 to an r4/5 identity. A main feature of this rhombomeric phenotype is that the trigeminal motor nerve is transformed to a facial identity. Furthermore, in support of this change in rhombomeric identity, neural crest cells derived from r2/3 also express posterior Hox markers suggesting that the retinoic acid-induced transformation extends to multiple components of the first branchial arch.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV ANAT & CELL BIOL,MRC,LONDON SE1 9RT,ENGLAND	MRC National Institute for Medical Research; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	KRUMLAUF, R (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Krumlauf, Robb/AAH-5012-2019; Lumsden, Andrew/C-5146-2009; Sham, Mai Har/AAX-3781-2020	Krumlauf, Robb/0000-0001-9102-7927; Sham, Mai Har/0000-0003-1179-7839; Muchamore, Ian/0000-0003-2121-1539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CANLON R, 1992, DEVELOPMENT, V116, P357; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DOLE P, 1989, NATURE, V342, P767; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; Hogan B., 1986, MANIPULATING MOUSE E; HOLDER N, 1991, DEVELOPMENT, V113, P1159; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Morris G. M., 1978, DEV MAMMALS, V3, P363; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHAM MH, IN PRESS CELL; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	32	427	433	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					737	741		10.1038/360737a0	http://dx.doi.org/10.1038/360737a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1361214				2022-12-24	WOS:A1992KE47200033
J	SELWYN, PA; ALCABES, P; HARTEL, D; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; DAVENNY, K; FRIEDLAND, GH				SELWYN, PA; ALCABES, P; HARTEL, D; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; DAVENNY, K; FRIEDLAND, GH			CLINICAL MANIFESTATIONS AND PREDICTORS OF DISEASE PROGRESSION IN DRUG-USERS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; NEW-YORK-CITY; HIV-INFECTION; MAINTENANCE TREATMENT; BACTERIAL PNEUMONIA; CONTROLLED TRIAL; NATURAL-HISTORY; HOMOSEXUAL MEN; ZIDOVUDINE AZT; UNITED-STATES	Background and Methods. To examine the clinical course of human immunodeficiency virus (HIV) infection in injection-drug users, we conducted a prospective study of a cohort of patients in a methadone-treatment program in New York City from July 1985 through December 1990. The patients underwent standardized evaluations at base line and semiannually thereafter and received on-site primary medical care. Rates of progression to the acquired immunodeficiency syndrome (AIDS) and major outcomes before the development of AIDS were examined by univariate analyses; the risk of AIDS was also assessed by product-limit survival analysis and proportional-hazards regression. Results. Of 318 HIV-seropositive patients who did not yet have AIDS (171 men and 147 women), 90 were black, 179 were Hispanic, and 49 were white; the median age was 33 years. Over a median of 3.0 years of follow-up, 55 (17 percent) received a diagnosis of AIDS (incidence per 100 person-years, 5.8). Major outcomes before the development of AIDS included oral candidiasis (incidence per 100 person-years, 11.2), pyogenic bacterial infections including pneumonia and sepsis (8.0), pulmonary tuberculosis (1.2), multiple constitutional symptoms (13.6), and herpes zoster (1.3). There were 41 deaths from AIDS, and 13 seropositive patients without AIDS (4.1 percent) died of bacterial infections, as compared with only 1 of 411 seronegative patients studied (P<0.001). The incidence of AIDS was 62 percent lower among those who took zidovudine than among those who did not (P = 0.02). In the multivariate analysis, progression to AIDS was best predicted by low numbers and percentages of CD4+ lymphocytes, nonuse of zidovudine, and the presence of oral candidiasis, bacterial infections, or tuberculosis. There was no consistent relation between progression to disease and the continued use of injection drugs. Conclusions. HIV-infected injection-drug users have progression to AIDS at rates comparable to those of other HIV-infected groups, but they have substantial pre-AIDS morbidity and mortality, particularly from bacterial infections, which also appear to predict disease progression.	MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT INTERNAL MED, DIV INFECT DIS, BRONX, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine				Schoenbaum, Ellie/0000-0002-0878-284X	NIDA NIH HHS [DAO4347-05] Funding Source: Medline; PHS HHS [U64CCU200714] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1992, AIDS, V6, P421; [Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BRETTLE RP, 1991, AIDS, V5, P125, DOI 10.1097/00002030-199102000-00001; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; CASABONA J, 1990, J ACQ IMMUN DEF SYND, V3, P272; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; COATES RA, 1990, AM J EPIDEMIOL, V132, P717, DOI 10.1093/oxfordjournals.aje.a115713; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GATES JR, 1991, 7TH INT C AIDS FLOR, V2, P377; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; JARLAIS DCD, 1987, AIDS, V1, P105; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MACDONELL KB, 1990, AM J MED, V89, P706, DOI 10.1016/0002-9343(90)90210-5; MARGOLICK JB, 1992, JAMA-J AM MED ASSOC, V267, P1631, DOI 10.1001/jama.267.12.1631; MIENTJES GH, 1992, AIDS, V6, P207, DOI 10.1097/00002030-199202000-00012; MIENTJES GH, 1991, AIDS, V5, P35, DOI 10.1097/00002030-199101000-00005; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PAYNE SF, 1990, AIDS, V4, P335, DOI 10.1097/00002030-199004000-00008; PERUCCI CA, 1991, AM J PUBLIC HEALTH, V81, P1307, DOI 10.2105/AJPH.81.10.1307; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PHILLIPS AN, 1991, LANCET, V337, P389; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SELIK RM, 1990, J ACQ IMMUN DEF SYND, V3, P73; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SELWYN PA, 1991, 119TH ANN M AM PUBL, P153; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; WILLOCKS L, 1992, J INFECTION, V24, P37, DOI 10.1016/0163-4453(92)90898-G; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; ZANGERLE R, 1991, AIDS, V5, P985, DOI 10.1097/00002030-199108000-00010; 1989, MMWR MORB MORTAL WKL, V38, P165; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, WKLY EPIDEMIOL REC, V66, P33; 1991, REPORT TWIN EPIDEMIC; 1991, MMWR MORB MORTAL WKL, V40, P891	64	299	300	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1697	1703		10.1056/NEJM199212103272401	http://dx.doi.org/10.1056/NEJM199212103272401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1359411				2022-12-24	WOS:A1992KA89700001
J	FAHNESTOCK, ML; TAMIR, I; NARHI, L; BJORKMAN, PJ				FAHNESTOCK, ML; TAMIR, I; NARHI, L; BJORKMAN, PJ			THERMAL-STABILITY COMPARISON OF PURIFIED EMPTY AND PEPTIDE-FILLED FORMS OF A CLASS-I MHC MOLECULE	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; HLA-B-ANTIGENS; HEAVY-CHAIN; VIRAL PEPTIDES; LYMPHOCYTES-T; BETA-2-MICROGLOBULIN; CELLS; BINDING; SURFACE; EXPRESSION	A secreted form of a class I major histocompatibility complex (MHC) molecule was denatured and renatured in vitro in the absence of peptide. The resulting empty class I heterodimer was immunologically reactive and structurally similar to a heterodimer renatured in the presence of an appropriate restricted peptide. Thermal stability profiles indicated that the two forms of heterodimer differed in their resistance to denaturation by heat but that a significant portion of the empty class I heterodimers had a native conformation at physiological temperatures. Free energies calculated from these data gave a direct measure of the stabilization of the class I MHC molecule that resulted from peptide binding.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA; AMGEN INC, BIOPHYS, THOUSAND OAKS, CA 91320 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Amgen					NIAID NIH HHS [AI28931] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028931] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BJORKMAN PJ, 1989, COLD SH Q B, V54, P365; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FAHNESTOCK ML, UNPUB; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GASTINEL LN, UNPUB; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GROVES ML, 1982, J BIOL CHEM, V257, P2619; HARLOW E, 1982, ANTIBODIES LABORATOR, P522; HOCHMAN JH, 1988, J IMMUNOL, V140, P2322; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MCINTOSH K, 1982, J CLIN MICROBIOL, V16, P329, DOI 10.1128/JCM.16.2.329-333.1982; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARHAM P, 1983, J BIOL CHEM, V258, P6179; PARHAM P, 1979, J BIOL CHEM, V254, P8709; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RAGHAVAN M, UNPUB; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YOKOYAMA K, 1985, BIOCHEMISTRY-US, V24, P3002, DOI 10.1021/bi00333a029	39	128	134	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1658	1662		10.1126/science.1360705	http://dx.doi.org/10.1126/science.1360705			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1360705				2022-12-24	WOS:A1992KA89600040
J	CZEISLER, CA; DUMONT, M; DUFFY, JF; STEINBERG, JD; RICHARDSON, GS; BROWN, EN; SANCHEZ, R; RIOS, CD; RONDA, JM				CZEISLER, CA; DUMONT, M; DUFFY, JF; STEINBERG, JD; RICHARDSON, GS; BROWN, EN; SANCHEZ, R; RIOS, CD; RONDA, JM			ASSOCIATION OF SLEEP-WAKE HABITS IN OLDER-PEOPLE WITH CHANGES IN OUTPUT OF CIRCADIAN PACEMAKER	LANCET			English	Article							BRIGHT LIGHT; SUPRACHIASMATIC NUCLEI; TEMPERATURE RHYTHMS; HUMAN-BRAIN; AGE; EXPOSURE; DEMENTIA; MEN; SEX	Many elderly people complain of disturbed sleep patterns but there is no evidence that the need to sleep decreases with age; it seems rather that the timing and consolidation of sleep change. We tried to find out whether there is a concurrent change in the output of the circadian pacemaker with age. The phase and amplitude of the pacemaker's output were assessed by continuous measurement of the core body temperature during 40 h ot sustained wakefulness under constant behavioural and environmental conditions. 27 young men (18-31 years) were compared with 21 older people (65-85 years; 11 men, 10 women); all were healthy and without sleep complaints. The mean amplitude of the endogenous circadian temperature oscillation (ECA) was 40% greater in young men than in the older group. Older men had a lower mean temperature ECA than older women. The minimum of the endogenous phase of the circadian temperature oscillation (ECP) occurred 1 h 52 min earlier in the older than in the young group. Customary bedtimes and waketimes were also earlier in the older group, as was their daily alertness peak. There was a close correlation between habitual waketime and temperature ECP in young men, which may lose precision with age, especially among women. These findings provide evidence for systematic age-related changes in the output of the human circadian pacemaker. We suggest that these changes may underlie the common complaints of sleep disturbance among elderly people. These changes could reflect the observed age-related deterioration of the hypothalmic nuclei that drive mammalian circadian rhythms.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	CZEISLER, CA (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02115, USA.		Duffy, Jeanne F./AAJ-4845-2020	Duffy, Jeanne F./0000-0003-4177-4179	NIA NIH HHS [1-RO1-AG06072, 1-P01-AG09975] Funding Source: Medline; NIMH NIH HHS [H5-ROI-MH45130] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006072, P01AG009975] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BROWN EN, IN PRESS J BIOL RHYT; Campbell S. S, 1991, SLEEP RES, V20, P448; CAMPBELL SS, 1988, PHYSIOL BEHAV, V42, P141, DOI 10.1016/0031-9384(88)90289-2; COBLENTZ JM, 1973, ARCH NEUROL-CHICAGO, V29, P299, DOI 10.1001/archneur.1973.00490290039003; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; CZEISLER CA, 1990, NEW ENGL J MED, V322, P1253, DOI 10.1056/NEJM199005033221801; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; CZEISLER CA, 1978, THESIS STANFORD U ST; DAVIS FC, 1984, J COMP PHYSIOL, V154, P221, DOI 10.1007/BF00604987; Dement W, 1985, HDB BIOL AGING, P692; DUMONT M, 1990, SLEEP RES, V19, P217; DUMONT M, 1990, 2ND M SOC RES BIOL R, P66; HOFMAN MA, 1988, J ANAT, V160, P127; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; JEWETT ME, 1991, NATURE, V350, P59, DOI 10.1038/350059a0; Klein D.C., 1991, SUPRACHIASMATIC NUCL; MANT A, 1988, COMMUNITY HEALTH ST, V12, P192; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; MINORS D S, 1984, Chronobiology International, V1, P205, DOI 10.3109/07420528409063897; MOE KE, 1991, J AM GERIATR SOC, V39, P383, DOI 10.1111/j.1532-5415.1991.tb02904.x; Monk TH, 1992, J GERONTOL PSYCH SCI, V47, P221; MORIN LP, 1988, J BIOL RHYTHM, V3, P237, DOI 10.1177/074873048800300302; PICKARD GE, 1985, J COMP PHYSIOL A, V156, P803, DOI 10.1007/BF00610832; PITTENDRIGH CS, 1974, SCIENCE, V186, P548, DOI 10.1126/science.186.4163.548; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; VITIELLO MV, 1986, NEUROBIOL AGING, V7, P97, DOI 10.1016/0197-4580(86)90146-6; WEITZMAN ED, 1982, NEUROBIOL AGING, V3, P299, DOI 10.1016/0197-4580(82)90018-5; WELSH DK, 1986, J GERONTOL, V41, P579, DOI 10.1093/geronj/41.5.579; Wever RA., 1979, CIRCADIAN SYSTEM MAN, DOI 10.1007/978-1-4612-6142-1	30	313	315	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					933	936		10.1016/0140-6736(92)92817-Y	http://dx.doi.org/10.1016/0140-6736(92)92817-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357348				2022-12-24	WOS:A1992JT82300003
J	AVNI, A; ANDERSON, JD; HOLLAND, N; ROCHAIX, JD; GROMETELHANAN, Z; EDELMAN, M				AVNI, A; ANDERSON, JD; HOLLAND, N; ROCHAIX, JD; GROMETELHANAN, Z; EDELMAN, M			TENTOXIN SENSITIVITY OF CHLOROPLASTS DETERMINED BY CODON-83 OF BETA-SUBUNIT OF PROTON-ATPASE	SCIENCE			English	Article							CHLAMYDOMONAS-REINHARDTII; RHODOSPIRILLUM-RUBRUM; COUPLING FACTOR-1; ESCHERICHIA-COLI; ATPB GENE; POLYPHENOL OXIDASE; H+-ATPASE; SYNTHASE; NICOTIANA; F1-ATPASE	Tentoxin is a naturally occurring phytotoxic peptide that causes seedling chlorosis and arrests growth in sensitive plants and algae. In vitro, it inhibits activity of the beta-subunit of the plastid proton-adenosine triphosphatase (ATPase) from sensitive species. Plastid atpB genes from six closely related, tentoxin-sensitive or -resistant Nicotiana species differ at codon 83, according to their response to the toxin: glutamate correlated with resistance and aspartate correlated with sensitivity. The genetic relevance of this site was confirmed in Chlamydomonas reinhardtii by chloroplast transformation. The alga, normally tentoxin-resistant, was rendered tentoxin-sensitive by mutagenesis of its plastid atpB gene at codon 83. Codon 83 may represent a critical site on the beta-subunit that does not compete with nucleotide binding or other catalytic activities.	WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL; UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA,SWITZERLAND; WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; University of Geneva; Weizmann Institute of Science			Rochaix, Jean-David/ABC-5243-2020					ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; ARNTZEN CJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P539, DOI 10.1016/0005-2728(72)90273-3; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVIV D, 1980, THEOR APPL GENET, V56, P145, DOI 10.1007/BF00286675; AVNI A, 1991, J BIOL CHEM, V266, P7317; AVNI A, 1991, MOL GEN GENET, V225, P273, DOI 10.1007/BF00269859; AVNI A, UNPUB; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BENNETT J, 1976, PHYTOCHEMISTRY, V15, P263, DOI 10.1016/S0031-9422(00)89000-7; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BURK LG, 1978, J HERED, V69, P117, DOI 10.1093/oxfordjournals.jhered.a108892; Clayton R. K., 1963, BACTERIAL PHOTOSYNTH, P495; DURBIN RD, 1977, PHYTOPATHOLOGY, V67, P602, DOI 10.1094/Phyto-67-602; FLICK CE, 1982, J HERED, V73, P264, DOI 10.1093/oxfordjournals.jhered.a109636; FLUHR R, 1981, MOL GEN GENET, V181, P484, DOI 10.1007/BF00428740; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GALUN E, 1982, METHODS CHLOROPLAST, P139; GROMETELHANAN Z, 1985, J BIOL CHEM, V260, P2635; GROMETELHANAN Z, 1986, METHOD ENZYMOL, V126, P528; HOLLAND NB, UNPUB; JAGENDORF AT, 1991, CELL CULTURE SOMAT B, V7, P225; KLOTZ MG, 1988, PHYSIOL PLANTARUM, V74, P575, DOI 10.1111/j.1399-3054.1988.tb02021.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX AR, 1986, PHYSIOL PLANTARUM, V66, P384, DOI 10.1111/j.1399-3054.1986.tb05939.x; LEMAIRE C, 1988, P NATL ACAD SCI USA, V85, P1344, DOI 10.1073/pnas.85.5.1344; MEYER WL, 1974, BIOCHEM BIOPH RES CO, V56, P234, DOI 10.1016/S0006-291X(74)80339-6; OHAD I, 1967, J CELL BIOL, V35, P521, DOI 10.1083/jcb.35.3.521; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; ROBERTSON D, 1989, J BIOL CHEM, V264, P2331; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SELMAN BR, 1978, BIOCHIM BIOPHYS ACTA, V502, P29, DOI 10.1016/0005-2728(78)90128-7; SHINOZAKI K, 1983, GENE, V24, P147; STEELE JA, 1977, BIOCHIM BIOPHYS ACTA, V459, P347, DOI 10.1016/0005-2728(77)90036-6; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; TEMPLETON GE, 1972, MICROB TOXINS, V8, P160; VAUGHN KC, 1984, PHYSIOL PLANTARUM, V60, P257, DOI 10.1111/j.1399-3054.1984.tb04574.x; VAUGHN KC, 1981, PHYSIOL PLANTARUM, V53, P421, DOI 10.1111/j.1399-3054.1981.tb02725.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WALLACH D, 1972, BIOCHIM BIOPHYS ACTA, V267, P124; WOESSNER JP, 1986, GENE, V44, P17; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065; ZUMBRUNN G, 1989, TECHNIQUE, V1, P204; 1991, EMBL DATA LIBRARY RE	46	67	73	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1245	1247		10.1126/science.1387730	http://dx.doi.org/10.1126/science.1387730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1387730				2022-12-24	WOS:A1992JL05000023
J	MASLOV, DA; SIMPSON, L				MASLOV, DA; SIMPSON, L			THE POLARITY OF EDITING WITHIN A MULTIPLE GRNA-MEDIATED DOMAIN IS DUE TO FORMATION OF ANCHORS FOR UPSTREAM GRNAS BY DOWNSTREAM EDITING	CELL			English	Article							KINETOPLAST DNA MINICIRCLES; LEISHMANIA-TARENTOLAE; GUIDE RNAS; CRITHIDIA-FASCICULATA; MESSENGER-RNAS; CYTOCHROME-OXIDASE; SEQUENCE CLASSES; SUBUNIT-III; MITOCHONDRIA; REPLICATION	Seventeen kinetoplast minicircle-encoded and nine maxicircle-encoded gRNA genes have been identified. Six overlapping minicircle-encoded gRNAs mediate editing for the 5'-pan-edited MURF4 gene and two for the 5-edited COIII gene. The pan-edited RPS12 mRNA is edited by seven minicircle-encoded gRNAs and one maxicircle-encoded gRNA. The 3'-most gRNA in each domain forms an anchor with unedited mRNA, whereas upstream gRNAs form anchors only with edited mRNA, thereby explaining the observed 3' to 5' polarity of editing within an editing domain. We suggest that a role of G-U base pairs is to allow breathing of the edited mRNA-gRNA hybrid and formation of the upstream anchor hybrid.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	MASLOV, DA (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009102, R01AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BHAT GJ, 1991, MOL BIOCHEM PARASIT, V48, P139, DOI 10.1016/0166-6851(91)90110-R; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; GOMEZEICHELMANN MC, 1988, MOL BIOCHEM PARASIT, V27, P143, DOI 10.1016/0166-6851(88)90034-5; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; KIDANE GZ, 1984, GENE, V27, P265, DOI 10.1016/0378-1119(84)90071-4; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MUHICH ML, 1985, NUCLEIC ACIDS RES, V13, P3241, DOI 10.1093/nar/13.9.3241; MUHICH ML, 1986, NUCLEIC ACIDS RES, V14, P5531, DOI 10.1093/nar/14.13.5531; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; Parrot L., 1939, Arch Inst Pasteur Alger, V17, P231; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; RAY DS, 1989, MOL CELL BIOL, V9, P1365, DOI 10.1128/MCB.9.3.1365; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; SIMPSON L, 1979, P NATL ACAD SCI USA, V76, P1585, DOI 10.1073/pnas.76.4.1585; SOUZA AE, 1992, MOL CELL BIOL, V12, P2100, DOI 10.1128/MCB.12.5.2100; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; TRAGER W, 1957, J PROTOZOOL, V4, P269, DOI 10.1111/j.1550-7408.1957.tb02519.x; VANDERSPEK H, 1990, EMBO J, V9, P257, DOI 10.1002/j.1460-2075.1990.tb08103.x	40	128	129	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					459	467		10.1016/0092-8674(92)90170-H	http://dx.doi.org/10.1016/0092-8674(92)90170-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1379519	Bronze			2022-12-24	WOS:A1992JH12400011
J	ERICSON, J; THOR, S; EDLUND, T; JESSELL, TM; YAMADA, T				ERICSON, J; THOR, S; EDLUND, T; JESSELL, TM; YAMADA, T			EARLY STAGES OF MOTOR-NEURON DIFFERENTIATION REVEALED BY EXPRESSION OF HOMEOBOX GENE ISLET-1	SCIENCE			English	Article							CHICK-EMBRYO; SPINAL-CORD; NEUROBLASTS; HOMEODOMAIN; ORGANIZATION; MOTONEURONS; INDUCTION; MIGRATION; LINEAGE; ELEGANS	Motor neurons in the embryonic chick spinal cord express a homeobox gene, islet-1, soon after their final mitotic division and before the appearance of other differentiated motor neuron properties. The expression of islet-1 by neural cells is regulated by inductive signals from the floor plate and notochord. These results establish islet-1 as the earliest marker of developing motor neurons. The molecular nature of the Islet-1 protein suggests that it may be involved in the establishment of motor neuron fate.	COLUMBIA UNIV, HAMMER HLTH SCI CTR, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Columbia University; Howard Hughes Medical Institute; Umea University			Thor, Stefan/Y-5804-2019	Thor, Stefan/0000-0001-5095-541X; Ericson, Johan/0000-0002-8019-7127				BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; CARPENTER EM, 1992, DEV BIOL, V150, P144, DOI 10.1016/0012-1606(92)90014-8; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; OPPENHEIM R, 1950, J COMP NEUROL, V210, P174; OPPENHEIM RW, 1988, J COMP NEUROL, V275, P159, DOI 10.1002/cne.902750202; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1991, DEVELOPMENT, P105; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH JL, 1988, CELL TISSUE RES, V252, P491, DOI 10.1007/BF00216636; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	39	573	592	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1992	256	5063					1555	1560		10.1126/science.1350865	http://dx.doi.org/10.1126/science.1350865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1350865				2022-12-24	WOS:A1992HY07500029
J	IRO, H; SCHNEIDER, HT; FODRA, C; WAITZ, G; NITSCHE, N; HEINRITZ, HH; BENNINGER, J; ELL, C				IRO, H; SCHNEIDER, HT; FODRA, C; WAITZ, G; NITSCHE, N; HEINRITZ, HH; BENNINGER, J; ELL, C			SHOCKWAVE LITHOTRIPSY OF SALIVARY DUCT STONES	LANCET			English	Article								Surgical extirpation of the affected gland has been necessary for cases of sialolithiasis in which the stone cannot be removed by dilatation or dissection of the salivary duct. The ability of the piezoelectric lithotripter to deliver shockwaves to a small focus makes extracorporeal shockwave lithotripsy of salivary gland stones potentially safe. Its safety and efficacy have been assessed in 51 patients with symptomatic solitary salivary stones that could not be removed by conservative measures. The stones had a median diameter of 8 (range 4-18) mm and were located in the submandibular gland in 69% of patients and in the parotid gland in 31%. A total of 72 shockwave treatment sessions (maximum 3 per patient) were given under continuous sonographic monitoring. In 45 patients (88%) complete fragmentation (fragments less-than-or-equal-to 3 mm) of the concrements was achieved. No patient needed anaesthesia, sedatives, or analgesics. The only untoward effects were localised petechial haemorrhages after 10 (13%) out of 72 treatments and transient swelling of the gland immediately after delivery of shockwave in 2/72 (3%) sessions. 20 weeks after the first session 90% (46/51) of patients were free of discomfort, and 53% (27/51) were stone free. Stone-clearance rate was higher among patients with stones in the parotid gland (81%) than among those with stones of the submandibular gland (40%). Auxiliary measures such as dilatation or dissection of the salivary duct were required only in patients with stones in the submandibular gland (20%). No long-term damage to the treated salivary gland or to adjacent tissue structures was noted during the median follow-up of 9 (1-24) months. Extracorporeal piezoelectric shockwave therapy seems likely to be a safe, comfortable, and effective minimally-invasive, non-surgical treatment for salivary stones.	UNIV ERLANGEN NURNBERG, DEPT MED, W-8520 ERLANGEN, GERMANY	University of Erlangen Nuremberg	IRO, H (corresponding author), UNIV ERLANGEN NURNBERG, DEPT OTORHINOLARYNGOL HEAD & NECK SURG, W-8520 ERLANGEN, GERMANY.							COLEMAN AJ, 1989, ULTRASOUND MED BIOL, V15, P213, DOI 10.1016/0301-5629(89)90066-5; EPKER BN, 1972, ORAL SURG ORAL MED O, V33, P2, DOI 10.1016/0030-4220(72)90203-4; IRO H, 1989, LANCET, V2, P114; IRO H, 1991, J LITHOTR STONE DIS, V3, P211; IRO H, 1990, LARYNGO RHINO OTOL, V69, P102, DOI 10.1055/s-2007-998153; KENEFICK JS, 1961, BRIT J SURG, V48, P435; PATEY DAVID H., 1961, BRIT JOUR SURG, V48, P435, DOI 10.1002/bjs.18004821015; PATEY DH, 1981, OPERATIVE SURGERY HE, P835; Rauch S, 1970, THOMAS ORAL PATHOLOG, P962; SEIFERT G, 1986, DIS SALIVARY GLANDS, P91; SELDIN HM, 1953, ORAL SURG ORAL MED O, V6, P579, DOI 10.1016/0030-4220(53)90160-1; SEWARD GR, 1968, ORAL SURG ORAL MED O, V26, P137, DOI 10.1016/0030-4220(68)90242-9	12	101	103	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1992	339	8805					1333	1336		10.1016/0140-6736(92)91968-E	http://dx.doi.org/10.1016/0140-6736(92)91968-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349999				2022-12-24	WOS:A1992HW83700011
J	JEANRENAUD, X; GOY, JJ; KAPPENBERGER, L				JEANRENAUD, X; GOY, JJ; KAPPENBERGER, L			EFFECTS OF DUAL-CHAMBER PACING IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY	LANCET			English	Article							ECHOCARDIOGRAPHY; VERAPAMIL; MOTION	Although attempts have been made to treat hypertrophic obstructive cardiomyopathy with right ventricular pacing, the usual treatment for those refractory to medical therapy is open heart surgery. To assess in detail the value of non-surgical therapy the effects of acute and long-term dual-chamber pacing were investigated in 13 patients with hypertrophic obstructive cardiomyopathy refractory to medical treatment. In the first part of the study, atrioventricular (AV) sequential pacing was found to reduce peak subaortic pressure gradient in 12 of the 13 patients, from 82 (SD 42) to 47 (34) mm Hg (p < 0.002), without concomitantly reducing aortic blood pressure or cardiac output. This effect was related to AV interval. In the second part of the study, a dual-chamber pacemaker was implanted in 8 patients and programmed to the optimum AV interval for the individual (50-90 ms). Patients were followed up for up to 62 months. Pacing resulted in a significant and long-lasting reduction in severity of angina pectoris (from NYHA class 3 to 1) and dyspnoea (from NYHA class 3 to 2). Echocardiography showed no significant change in septal thickness or left ventricular contractility but there was a trend to a spontaneous decrease in obstruction. In patients with hypertrophic obstructive cardiomyopathy, synchronised and ventricular pacing at optimum AV interval for the individual reduces the intraventricular pressure gradient and improves functional tolerance. Since the effect is longlasting, such pacing should be deemed an alternative therapy to surgery in selected cases.			JEANRENAUD, X (corresponding author), CHU VAUDOIS,DEPT INTERNAL MED,DIV CARDIOL,CH-1011 LAUSANNE,SWITZERLAND.							ASKENAZI J, 1984, AM J CARDIOL, V53, P99, DOI 10.1016/0002-9149(84)90691-X; BONOW RO, 1983, AM J CARDIOL, V51, P1386, DOI 10.1016/0002-9149(83)90317-X; CANNON RO, 1987, J AM COLL CARDIOL, V10, P53, DOI 10.1016/S0735-1097(87)80159-6; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; Duck H J, 1984, Z Gesamte Inn Med, V39, P437; GOMES JAC, 1977, AM J CARDIOL, V39, P641, DOI 10.1016/S0002-9149(77)80123-9; Hassenstein P, 1967, Verh Dtsch Ges Kreislaufforsch, V33, P242; Hassenstein P, 1975, Thoraxchir Vask Chir, V23, P496; IWASE M, 1986, AM J CARDIOL, V58, P104, DOI 10.1016/0002-9149(86)90251-1; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; KALTENBACH M, 1979, BRIT HEART J, V42, P35; KRACJER Z, 1988, CIRCULATION S1, V78, P35; LEVINE RA, 1989, CIRCULATION S2, V80, P662; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584; MCINTOSH CL, 1988, CIRCULATION, V78, P487, DOI 10.1161/01.CIR.78.3.487; POLLICK C, 1988, AM J CARDIOL, V62, P1252, DOI 10.1016/0002-9149(88)90269-X; POLLICK C, 1984, CIRCULATION, V69, P43, DOI 10.1161/01.CIR.69.1.43; Rothlin M, 1971, Verh Dtsch Ges Kreislaufforsch, V37, P411; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; ZILE MR, 1987, J AM COLL CARDIOL, V10, P702, DOI 10.1016/S0735-1097(87)80215-2; 1989, J AM SOC ECHO, V2, P358	24	238	251	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1318	1323		10.1016/0140-6736(92)91961-7	http://dx.doi.org/10.1016/0140-6736(92)91961-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349992				2022-12-24	WOS:A1992HW83700004
J	BROOK, CGD				BROOK, CGD			DIABETES - WHAT SORT OF PREVENTION	LANCET			English	Editorial Material											BROOK, CGD (corresponding author), UCL, DEPT PAEDIAT ENDOCRINOL, LONDON WC1, ENGLAND.								0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1156	1157		10.1016/0140-6736(92)90745-O	http://dx.doi.org/10.1016/0140-6736(92)90745-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349378				2022-12-24	WOS:A1992HT23600015
J	JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R				JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R			PREDICTING PSYCHIATRIC ADMISSION RATES	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS; INPATIENT CARE; SCHIZOPHRENIA	Objective - To determine the numbers of actual and expected psychiatric admissions for the residents of the district health authorities of England and to develop a model to indicate which social, health status, and service provision factors best explain the variation of the actual from the expected psychiatric admissions; to use this model to predict psychiatric admissions for district health authorities as an aid to resource allocation. Design - The actual psychiatric admissions for district health authority residents were extracted from data of the 1986 Mental Health Enquiry. Expected admissions were calculated using the age, sex, and marital status structure of each district health authority and the national psychiatric admission rates related to age, sex, and marital status. Standardised psychiatric admission ratios were calculated as the ratios of the numbers of actual to expected psychiatric admissions. A wide range of social, health status, and service provision data were used as the explanatory variables in regression analyses to determine which combination of factors best explained the variation between districts of standardised psychiatric admission ratios. Setting - The 168652 psychiatric admissions recorded for the 1986 Mental Health Enquiry, after exclusion of mental handicap and psychogeriatric admissions. Results - The actual number of psychiatric admissions varied from 79% above to 54% below the expected number of admissions from age, sex, and marital status for the districts of England. The most powerful variables to explain this variation were the rate of notification of drug misusers, standardised mortality ratios, and levels of illegitimacy in each district. A complex. model was developed which could be used to predict district psychiatric admissions as an aid to resource allocation. A simpler model was also developed (which was less powerful than the more complex model) based on the under-privileged area score. One advantage of this model was that it could be used at the level of electoral wards as well as district health authorities.	CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND	Imperial College London; Imperial College London			White, Patrick/AAN-7799-2020	White, Patrick/0000-0002-2047-8787				BUGLASS D, 1980, REGISTER SOCIAL MED; BURKE AW, 1976, BRIT J PSYCHIAT, V128, P534, DOI 10.1192/bjp.128.6.534; CHORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; Durkheim E., 1952, SUICIDE; Faris Robert E.L, 1939, MENTAL DISORDERS URB; Goldberg DP, 1980, MENTAL ILLNESS COMMU; GOODMAN AB, 1983, AM J PSYCHIAT, V140, P166; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JARMAN B, 1985, MED ANN, P224; MILLER GH, 1986, CAN J PSYCHIAT, V31, P424, DOI 10.1177/070674378603100508; ODEGAARD O, 1932, ACTA PSYCHIATRICA S, V4; PLATT S, 1985, PSYCHOL MED, V15, P113, DOI 10.1017/S0033291700020973; RICHMAN A, 1984, PSYCHOL MED, V14, P175, DOI 10.1017/S0033291700003184; SAINSBURY P, 1955, SUICIDE; SHEPHERD M, 1957, MAUDSLEY MONOGRAPH, V3; Townsend P., 1986, INEQUALITIES HLTH NO; 1983, INFORMATION NOTE DEP, V2; 1990, HLTH PERSONAL SOCIAL; 1976, SHARING RESOURCES HL; 1986, INPATIENT STATISTICS; 1988, PSYCHIATRIC BEDS RES; 1988, REV RESOURCE ALLOCAT	24	88	88	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1146	1151		10.1136/bmj.304.6835.1146	http://dx.doi.org/10.1136/bmj.304.6835.1146			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT232	1392792	Green Published, Bronze			2022-12-24	WOS:A1992HT23200020
J	CLARK, SG; STERN, MJ; HORVITZ, HR				CLARK, SG; STERN, MJ; HORVITZ, HR			C-ELEGANS CELL-SIGNALING GENE SEM-5 ENCODES A PROTEIN WITH SH2 AND SH3 DOMAINS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; PHOSPHOLIPASE-C; CYTOPLASMIC PROTEIN; SEQUENCE; SRC; SIMILARITY; LINEAGES; ONCOGENE; HOMOLOGY	THE induction of the hermaphrodite vulva 1 and the migration of the sex myoblast 2,3 in the nematode Caenorhabditis elegans are both controlled by intercellular signalling. The gonadal anchor cell induces formation of the vulva from nearby hypodermal cells 4, and a set of somatic gonadal cells attract the migrating sex myoblasts to their final positions 2. Many genes required for vulval induction have been identified 1, including the let-23 receptor tyrosine kinase gene 5-7 and the let-60 ras gene 8-10. We report here the identification and characterization of a new gene, sem-5 (sem, sex muscle abnormal), that acts both in vulval induction and in sex myoblast migration. On the basis of its DNA sequence, sem-5 encodes a novel 228-amino-acid protein which consists almost entirely of one SH2 (SH, src homology region) and two SH3 domains. SH2 and SH3 domains are present in many signalling proteins regulated by receptor and non-receptor tyrosine kinases 11. Mutations that impair sem-5 activity alter residues that are highly conserved among different SH2 and SH3 domains. Our results indicate that the sem-5 gene encodes a novel protein that functions in at least two distinct cell-signalling processes.			CLARK, SG (corresponding author), MIT,DEPT BIOL,HOWARD HUGHES MED INST,ROOM 56-629,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STERN MJ, 1991, DEVELOPMENT, V113, P797; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; [No title captured]	42	577	598	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					340	344		10.1038/356340a0	http://dx.doi.org/10.1038/356340a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1372395				2022-12-24	WOS:A1992HK79400065
J	SONG, KN; WANG, YQ; SASSOON, D				SONG, KN; WANG, YQ; SASSOON, D			EXPRESSION OF HOX-7.1 IN MYOBLASTS INHIBITS TERMINAL DIFFERENTIATION AND INDUCES CELL-TRANSFORMATION	NATURE			English	Article							HOMEOBOX GENE; GROWTH-FACTOR; EMBRYOGENESIS; MYOGENIN; FAMILY	THE terminal differentiation of myogenic cells initiates in the proximal portion of the limb bud whereas the distal region remains undifferentiated and proliferative1-3 . The apical ectodermal ridge maintains the progress zone in an undifferentiated state4 and induces proliferation of limb mesenchymal cells5. Hox-7.1, a homeobox-containing gene, is expressed throughout the limb bud when limb outgrowth begins, whereas transcripts are later restricted to distal limb mesenchyme6,7 which is the proposed site of positional specification2. Transplantation of proximal limb bud tissue into the distal portion of the limb results in a re-expression of Hox-7.1 in the transplanted mesenchyme8. Similar grafts result in a positional reassignment to distal structures9 as well as dedifferentiation of the grafted proximal tissue10. Because of the association of Hox-7.1 expression with proliferative and undifferentiated cells, we tested whether Hox-7.1 regulates differentiation by transfection of Hox-7.1 complementary DNA into determined myogenic cells which represent one mesenchymal lineage in the limb. Here we report that forced expression of Hox-7.1 blocks terminal differentiation and results in a corresponding decrease in steady-state levels of MyoD1. Consistent with the association of Hox-7.1 with proliferation, Hox-7.1-expressing cells also acquire a transformed phenotype. Forced expression of Hox-8.1, a related Hox-gene, does not affect terminal differentiation indicating that the effects of Hox-7.1 are specific.			SONG, KN (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, 80 E CONCORD ST, BOSTON, MA 02118 USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUCKINGHAM ME, 1984, MOL BIOL DEV, V19, P275; CHEVALLIER A, 1978, ROUX ARCH DEV BIOL, V184, P57, DOI 10.1007/BF00848669; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; HAMPE A, 1960, J EMBRYOL EXP MORPH, V8, P241; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; KIENY M, 1986, BIBL ANAT, V29, P65; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MOORE JW, 1991, DEVELOPMENT, V111, P741; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; Sambrook J., 1989, MOL CLONING LAB MANU; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SAUNDERS JW, 1959, DEV BIOL, V1, P281, DOI 10.1016/0012-1606(59)90030-2; SOLURSH M, 1981, DEV BIOL, V86, P471, DOI 10.1016/0012-1606(81)90205-0; SUMMERBELL D, 1972, NATURE-NEW BIOL, V239, P24, DOI 10.1038/newbio239024a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	21	202	204	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1992	360	6403					477	481		10.1038/360477a0	http://dx.doi.org/10.1038/360477a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1360150				2022-12-24	WOS:A1992KA79700064
J	SEMPRINI, AE; LEVISETTI, P; BOZZO, M; RAVIZZA, M; TAGLIORETTI, A; SULPIZIO, P; ALBANI, E; ONETA, M; PARDI, G				SEMPRINI, AE; LEVISETTI, P; BOZZO, M; RAVIZZA, M; TAGLIORETTI, A; SULPIZIO, P; ALBANI, E; ONETA, M; PARDI, G			INSEMINATION OF HIV-NEGATIVE WOMEN WITH PROCESSED SEMEN OF HIV-POSITIVE PARTNERS	LANCET			English	Note								Many HIV-discordant couples want to have children so much that they are willing to abandon condom-protected sexual intercourse irrespective of the risks. Previous testing in our laboratory showed that gradient centrifugation followed by a swim-up procedure effectively removed HIV-1-infected cells from the semen of HIV-seropositive men. 85 HIV-discordant couples were screened for fertility; 29 women were found suitable for a timed in semination course with the processed semen of their HIV-seropositive partner. None of the inseminated women seroconverted, and 17 pregnancies were achieved in 15 women. All 10 babies born to these mothers remain HIV seronegative. The findings may help in the counselling of such couples and also give them hope of having healthy babies.			SEMPRINI, AE (corresponding author), UNIV MILAN,SCH MED,SAN PAOLO BIOMED INST,DEPT OBSTET & GYNAECOL,VIA RUDINI 8,I-21042 MILAN,ITALY.		Setti, Paolo Emanuele Levi/AAB-9718-2019; SEMPRINI, AUGUSTO ENRICO/S-6415-2017	Levi-Setti, Paolo Emanuele/0000-0003-1024-4386; SEMPRINI, AUGUSTO ENRICO/0000-0002-1113-2012				ANDERSON DJ, 1992, 48TH ANN M AM FERT S; ASHIDA ER, 1987, P NATL ACAD SCI USA, V84, P3395, DOI 10.1073/pnas.84.10.3395; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; SARACCO A, IN PRESS J ACQUIR IM; SEMPRINI AE, 1991, SUCCESSFUL REMOVAL H, P534; SEMPRINI AE, 1990, 6 INT C AIDS SAN FRA, P267; Semprini AE, 1987, C INSERM, V154, P462; WOLFF H, 1988, 4 INT C AIDS STOCKH; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; 1992, REPORT AIDS CASES	10	260	267	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1317	1319		10.1016/0140-6736(92)92495-2	http://dx.doi.org/10.1016/0140-6736(92)92495-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360037				2022-12-24	WOS:A1992KA26200006
J	GIESE, KP; MARTINI, R; LEMKE, G; SORIANO, P; SCHACHNER, M				GIESE, KP; MARTINI, R; LEMKE, G; SORIANO, P; SCHACHNER, M			MOUSE P(0) GENE DISRUPTION LEADS TO HYPOMYELINATION, ABNORMAL EXPRESSION OF RECOGNITION MOLECULES, AND DEGENERATION OF MYELIN AND AXONS	CELL			English	Article							CELL-ADHESION MOLECULES; IMMUNOELECTRON MICROSCOPIC LOCALIZATION; L3 CARBOHYDRATE STRUCTURES; PERIPHERAL NERVOUS-SYSTEM; N-CAM; SCIATIC-NERVE; SCHWANN-CELLS; PROTEIN-ZERO; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODIES	We have used homologous recombination in embryonic stem cells to generate mice carrying a mutation in the gene encoding P0, an immunoglobulin-related recognition molecule and the major protein of peripheral nervous system myelin. These mice are deficient in normal motor coordination and exhibit tremors and occasional convulsions. Axons in their peripheral nerves are severely hypomyelinated and a subset of myelin-like figures and axons degenerate. The mutation leads to an abnormal regulation of some, but not all, molecules involved in myelination. These results demonstrate that P0 is essential for the normal spiraling, compaction, and maintenance of the peripheral myelin sheath and the continued integrity of associated axons. They further suggest that this protein conveys a signal that regulates Schwann cell gene expression.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Salk Institute; Baylor College of Medicine; Howard Hughes Medical Institute	GIESE, KP (corresponding author), SWISS FED INST TECHNOL, DEPT NEUROBIOL, CH-8093 ZURICH, SWITZERLAND.		Soriano, Philippe M/E-5797-2015; Giese, Karl P/A-3112-2011	Soriano, Philippe M/0000-0002-0427-926X; Giese, Karl P/0000-0003-4503-7344; Martini, Rudolf/0000-0002-5463-5592	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875, R01HD025326, R37HD025326] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24875, HD 25326] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CERVELLO M, 1991, P NATL ACAD SCI USA, V88, P10548, DOI 10.1073/pnas.88.23.10548; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DURSO D, 1990, NEURON, V4, P449, DOI 10.1016/0896-6273(90)90057-M; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; ISHAQUE A, 1980, CAN J BIOCHEM CELL B, V58, P913, DOI 10.1139/o80-125; JESSEN KR, 1990, DEVELOPMENT, V109, P91; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUCHERER A, 1987, J CELL BIOL, V104, P1597, DOI 10.1083/jcb.104.6.1597; KUHN R, 1990, J NEUROSCI, V10, P205; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINI R, 1991, J NEUROSCI RES, V28, P261, DOI 10.1002/jnr.490280214; MARTINI R, 1990, J NEUROCYTOL, V19, P601, DOI 10.1007/BF01257247; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MARTINI R, 1988, DEV BIOL, V129, P330, DOI 10.1016/0012-1606(88)90380-6; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MIRSKY R, 1986, J NEUROCYTOL, V15, P799, DOI 10.1007/BF01625196; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NEUMANN H, 1990, THESIS U WURZBURG GE; NIEKE J, 1985, DIFFERENTIATION, V30, P141, DOI 10.1111/j.1432-0436.1985.tb00525.x; NORONHA AB, 1986, BRAIN RES, V385, P237, DOI 10.1016/0006-8993(86)91069-3; OWENS GC, 1991, DEVELOPMENT, V112, P639; Palay S. L., 1974, CEREBELLAR CORTEX CY; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; POTTER NT, 1988, J NEUROIMMUNOL, V18, P49, DOI 10.1016/0165-5728(88)90134-8; PUCKETT C, 1987, J NEUROSCI RES, V18, P511, DOI 10.1002/jnr.490180402; RATHJEN FG, 1984, EMBO J, V3, P1; REICHARDT LF, 1990, COLD SPRING HARB SYM, V55, P341; SCHACHNER M, 1991, NERVE GROWTH CONE, P237; Schachner M., 1990, SEMIN NEUROSCI, V2, P497; SCHNEIDERSCHAULIES J, 1990, J NEUROSCI RES, V27, P286, DOI 10.1002/jnr.490270307; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SWASH M, 1991, CLIN NEUROLOGY, P1177; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRAPP BD, 1981, J CELL BIOL, V90, P1, DOI 10.1083/jcb.90.1.1; VONBOHLEN, 1992, IN PRESS EUR J NEURO; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOU KH, 1991, GENOMICS, V9, P751, DOI 10.1016/0888-7543(91)90370-T; ZIMMER A, 1992, ANNU REV NEUROSCI, V15, P115, DOI 10.1146/annurev.neuro.15.1.115	63	430	431	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					565	576		10.1016/0092-8674(92)90591-Y	http://dx.doi.org/10.1016/0092-8674(92)90591-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1384988				2022-12-24	WOS:A1992JY67600005
J	COOPER, SJ; KELLY, CB; KING, DJ				COOPER, SJ; KELLY, CB; KING, DJ			5-HYDROXYINDOLEACETIC ACID IN CEREBROSPINAL-FLUID AND PREDICTION OF SUICIDAL-BEHAVIOR IN SCHIZOPHRENIA	LANCET			English	Note							MONOAMINE METABOLITES; CSF; 5-HIAA	Low concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) are associated with suicidal behaviour in patients with depressive illness, but studies of the relation between CSF 5-HIAA and suicide in schizophrenia have been inconclusive and have not included long-term follow-up. In a prospective study, we measured 5-HIAA in CSF taken from 30 schizophrenic patients in a drug-free state, and followed these patients for 11 years. 10 patients made suicide attempts during follow-up. Suicide attempters had significantly lower concentrations of CSF 5-HIAA at initial evaluation than non-attempters (mean [SE] 6.7 [2.2] vs 23.6 [5.6] ng/ml, p < 0.05). Our findings provide further evidence of the relation between serotoninergic dysfunction and suicide, and suggest a role for drugs with serotoninergic effects in schizophrenia.	QUEENS UNIV BELFAST, DEPT THERAPEUT & PHARMACOL, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND; HOLYWELL HOSP, ANTRIM, NORTH IRELAND	Queens University Belfast	COOPER, SJ (corresponding author), QUEENS UNIV BELFAST, DEPT MENTAL HLTH, 97 LISBURN RD, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND.							ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; BANKI CM, 1984, J AFFECT DISORDERS, V6, P341, DOI 10.1016/S0165-0327(84)80012-9; DRAKE RE, 1985, COMPR PSYCHIAT, V26, P90, DOI 10.1016/0010-440X(85)90053-7; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; LEMUS CZ, 1990, BIOL PSYCHIAT, V27, P923, DOI 10.1016/0006-3223(90)90475-H; NINAN PT, 1984, AM J PSYCHIAT, V141, P566; ROY A, 1989, ARCH GEN PSYCHIAT, V46, P609; ROY A, 1985, PSYCHOL MED, V15, P335, DOI 10.1017/S0033291700023618; TRASKMAN L, 1981, ARCH GEN PSYCHIAT, V38, P631; VANPRAAG HM, 1983, LANCET, V2, P977	10	84	85	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1992	340	8825					940	941		10.1016/0140-6736(92)92819-2	http://dx.doi.org/10.1016/0140-6736(92)92819-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1383659				2022-12-24	WOS:A1992JT82300005
J	HENRY, JA; JEFFREYS, KJ; DAWLING, S				HENRY, JA; JEFFREYS, KJ; DAWLING, S			TOXICITY AND DEATHS FROM 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)	LANCET			English	Article							MDMA ECSTASY; METHYLENEDIOXYMETHAMPHETAMINE MDMA; HYPERTHERMIA; PSYCHOSIS; NEUROTOXICITY; TERMINALS	The risk of adverse reactions to 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as ''ecstasy'', is now widely known in both the USA and UK, but the patterns of illness remain varied. We report our experience during 1990 and 1991. There has been a recent increase in cases of severe toxicity following recreational misuse of small amounts of MDMA. Among 7 fatalities, the pattern of toxicity included fulminant hyperthermia, convulsions, disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. Until now, there have been few reports of this type of toxicity from MDMA, which may be related both to the potential of the drug to alter thermoregulation and to the circumstances of misuse. In addition, we have monitored 7 cases of hepatotoxicity and suspect that the frequency of this complication is increasing; a history of MDMA misuse should be sought in young people presenting with unexplained jaundice or hepatomegaly. We also describe 5 subjects involved in road traffic accidents in whom MDMA was identified. Misuse of MDMA can have severe acute toxic effects; few data are available concerning long-term morbidity, and this deserves close monitoring in future.			HENRY, JA (corresponding author), GUYS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND.							BENAZZI F, 1991, LANCET, V338, P1520, DOI 10.1016/0140-6736(91)92332-V; BROWN C, 1987, JAMA-J AM MED ASSOC, V258, P780, DOI 10.1001/jama.258.6.780; CAMPKIN NTA, 1992, J ROY SOC MED, V85, P61; CHADWICK IS, 1991, J ROY SOC MED, V84, P371, DOI 10.1177/014107689108400622; CREIGHTON FJ, 1991, BRIT J PSYCHIAT, V159, P713, DOI 10.1192/bjp.159.5.713; DOWLING GP, 1987, JAMA-J AM MED ASSOC, V257, P1615, DOI 10.1001/jama.257.12.1615; FAHAL IH, 1992, BRIT MED J, V305, P29, DOI 10.1136/bmj.305.6844.29; GINSBERG MD, 1970, ANN INTERN MED, V73, P81, DOI 10.7326/0003-4819-73-1-81; GORDON CJ, 1991, PHARMACOL BIOCHEM BE, V38, P339, DOI 10.1016/0091-3057(91)90288-D; HOPKINS PM, 1991, LANCET, V338, P1491, DOI 10.1016/0140-6736(91)92304-K; MCGUIRE P, 1991, BRIT MED J, V302, P697, DOI 10.1136/bmj.302.6778.697; OHEARN E, 1988, J NEUROSCI, V8, P2788; PEROUTKA SJ, 1987, NEW ENGL J MED, V317, P1542; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; SCHIFANO F, 1991, LANCET, V338, P1335, DOI 10.1016/0140-6736(91)92633-D; SCHMIDT CJ, 1990, BRAIN RES, V529, P85, DOI 10.1016/0006-8993(90)90813-Q; SUAREZ RV, 1988, AM J FOREN MED PATH, V9, P339, DOI 10.1097/00000433-198812000-00015; WHITAKERAZMITIA PM, 1989, AM J PSYCHIAT, V146, P119	18	546	556	0	66	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					384	387		10.1016/0140-6736(92)91469-O	http://dx.doi.org/10.1016/0140-6736(92)91469-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353554				2022-12-24	WOS:A1992JJ44900002
J	SURPRENANT, A; HORSTMAN, DA; AKBARALI, H; LIMBIRD, LE				SURPRENANT, A; HORSTMAN, DA; AKBARALI, H; LIMBIRD, LE			A POINT MUTATION OF THE ALPHA-2-ADRENOCEPTOR THAT BLOCKS COUPLING TO POTASSIUM BUT NOT CALCIUM CURRENTS	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC RECEPTORS; BINDING PROTEIN; ADENYLYL CYCLASE; LIGAND-BINDING; ALPHA-SUBUNITS; INHIBITION; IDENTIFICATION; GI2; SOMATOSTATIN	The alpha-2A-adrenergic receptor (adrenoceptor) was stably expressed in AtT20 mouse pituitary tumor cells; adrenoceptor agonists inhibited adenylyl cyclase, inhibited voltage-dependent calcium currents, and increased inwardly rectifying potassium currents. An aspartic acid residue (Asp79) highly conserved among guanine nucleotide-binding protein (G protein)-coupled receptors was mutated to asparagine; in cells transfected with the mutant alpha-2-receptor, agonists inhibited adenylyl cyclase and calcium currents but did not increase potassium currents. Because distinct G proteins appear to couple adrenoceptors to potassium and calcium currents, the present findings suggest that the mutant alpha-2-adrenoceptor cannot achieve the conformation necessary to activate G proteins that mediate potassium channel activation.	UNIV CALGARY, DEPT MED PHYSIOL, CALGARY T2N 4N1, ALBERTA, CANADA; VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA	University of Calgary; Vanderbilt University	SURPRENANT, A (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		Akbarali, Hamid/Q-9344-2019; Akbarali, Hamid I/B-3236-2012	Akbarali, Hamid/0000-0003-1423-0774				BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN DA, 1989, ANN NY ACAD SCI, V560, P358; BROWN DA, 1990, ANNU REV PHYSIOL, V52, P215; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HARRIS GC, 1992, J PHARMACOL EXP THER, V261, P476; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEFKOWITZ RJ, 1987, RECENT PROG HORM RES, V43, P469; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LUINI A, 1986, J NEUROSCI, V6, P3128; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; PENNEFATHER PS, 1988, BRAIN RES, V444, P346, DOI 10.1016/0006-8993(88)90944-4; REISINE T, 1985, ENDOCRINOLOGY, V116, P2259, DOI 10.1210/endo-116-6-2259; SHEN KZ, 1990, BRIT J PHARMACOL, V101, P925, DOI 10.1111/j.1476-5381.1990.tb14182.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STACK J, 1990, THESIS OREGON HLTH S; STANDEN NB, 1978, J PHYSIOL-LONDON, V280, P169, DOI 10.1113/jphysiol.1978.sp012379; STARKE K, 1987, REV PHYSIOL BIOCH P, V107, P73, DOI 10.1007/BFb0027645; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SURPRENANT A, 1988, PROC R SOC SER B-BIO, V234, P85, DOI 10.1098/rspb.1988.0039; SURPRENANT A, 1989, SEMIN NEUROSCI, V1, P126; TALLENT M, 1992, MOL PHARMACOL, V41, P452; WANG CD, 1991, MOL PHARMACOL, V40, P168; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	37	132	134	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					977	980		10.1126/science.1354394	http://dx.doi.org/10.1126/science.1354394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1354394				2022-12-24	WOS:A1992JH82700039
J	DANIELS, DL; PLUNKETT, G; BURLAND, V; BLATTNER, FR				DANIELS, DL; PLUNKETT, G; BURLAND, V; BLATTNER, FR			ANALYSIS OF THE ESCHERICHIA-COLI GENOME - DNA-SEQUENCE OF THE REGION FROM 84.5 TO 86.5 MINUTES	SCIENCE			English	Article							DETERMINE ANTIGENIC SPECIFICITY; COMPLETE NUCLEOTIDE-SEQUENCE; DEPENDENT RNA HELICASE; GROUP-D SALMONELLAE; SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL ACTIVITY; POSITIVE REGULATOR; BACILLUS-SUBTILIS	The DNA sequence of 91.4 kilobases of the Escherichia coli K-12 genome, spanning the region between rrnC at 84.5 minutes and rrnA at 86.5 minutes on the genetic map (85 to 87 percent on the physical map), is described. Analysis of this sequence identified 82 potential coding regions (open reading frames) covering 84 percent of the sequenced interval. The arrangement of these open reading frames, together with the consensus promoter sequences and terminator-like sequences found by computer searches, made it possible to assign them to proposed transcriptional units. More than half the open reading frames correlated with known genes or functions suggested by similarity to other sequences. Those remaining encode still unidentified proteins. The sequenced region also contains several RNA genes and two types of repeated sequence elements were found. Intergenic regions include three "gray holes," 0.6 to 0.8 kilobases, with no recognizable functions.			DANIELS, DL (corresponding author), UNIV WISCONSIN, GENET LAB, 445 HENRY MALL, MADISON, WI 53706 USA.		Plunkett, Guy/B-8058-2009	Plunkett, Guy/0000-0003-1422-469X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000301] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00301] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS CW, 1988, J BACTERIOL, V170, P203, DOI 10.1128/jb.170.1.203-212.1988; AIBA H, 1984, NUCLEIC ACIDS RES, V12, P9427, DOI 10.1093/nar/12.24.9427; Bachmann B. J., 1987, ESCHERICHIA COLI SAL, V2, P807; Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BERLYN M, COMMUNICATION; BOELKER M, 1989, EMBO (European Molecular Biology Organization) Journal, V8, P2403; BOYD J, 1990, UNPUB; CASHEL M, COMMUNICATION; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; Church George, COMMUNICATION, V207; COPPOLA G, 1991, GENE, V97, P21, DOI 10.1016/0378-1119(91)90005-V; Daniels D L, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P1009; DANIELS DL, 1990, BACTERIAL CHROMOSOME, P43; DANIELS DL, 1990, NUCLEIC ACIDS RES, V18, P2649, DOI 10.1093/nar/18.9.2649; DANIELS DL, 1987, NATURE, V325, P831, DOI 10.1038/325831a0; DANIELS DL, 1990, STRUCTURE METHODS, V1, P29; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; ENDO F, 1989, J BIOL CHEM, V264, P4476; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOSS TJ, 1985, MOL GEN GENET, V201, P308, DOI 10.1007/BF00425676; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HAGSTROM R, COMMUNICATION; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HENNER DJ, 1988, J BACTERIOL, V170, P5102, DOI 10.1128/jb.170.11.5102-5109.1988; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HLOCH P, 1990, NUCLEIC ACIDS RES, V18, P3045, DOI 10.1093/nar/18.10.3045; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HONORE N, 1990, NUCLEIC ACIDS RES, V18, P653, DOI 10.1093/nar/18.3.653; HULTON CSJ, 1991, MOL MICROBIOL, V5, P825, DOI 10.1111/j.1365-2958.1991.tb00755.x; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; IKEDA M, 1990, NUCLEIC ACIDS RES, V18, P1058, DOI 10.1093/nar/18.4.1058; KALMAN M, 1991, NEW BIOL, V3, P886; KOBAYASHI T, 1985, J BIOCHEM-TOKYO, V98, P1017, DOI 10.1093/oxfordjournals.jbchem.a135347; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KROGER M, 1991, NUCLEIC ACIDS RES, V19, P2023, DOI 10.1093/nar/19.suppl.2023; KROGER M, 1989, NUCLEIC ACIDS RES S, V17, P283; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAWTHER RP, 1981, P NATL ACAD SCI-BIOL, V78, P922, DOI 10.1073/pnas.78.2.922; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LEVENE SD, 1983, J BIOMOL STRUCT DYN, V1, P429, DOI 10.1080/07391102.1983.10507452; LINDER P, 1988, NUCLEIC ACIDS RES, V16, P10359, DOI 10.1093/nar/16.21.10359; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MAGIURE M, COMMUNICATION; MATSUMOTO Y, 1986, J BACTERIOL, V166, P945, DOI 10.1128/jb.166.3.945-958.1986; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MAXON ME, 1989, P NATL ACAD SCI USA, V86, P85, DOI 10.1073/pnas.86.1.85; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P6439, DOI 10.1093/nar/18.21.6439; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; NISHI K, 1989, NATURE, V340, P246, DOI 10.1038/340246a0; OHTA M, 1991, MOL MICROBIOL, V5, P1853, DOI 10.1111/j.1365-2958.1991.tb00809.x; OHTAKE Y, 1988, AGR BIOL CHEM TOKYO, V52, P2753, DOI 10.1080/00021369.1988.10869126; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON C H, 1991, Methods (Orlando), V3, P27, DOI 10.1016/S1046-2023(05)80160-4; OSTROWSKI J, 1987, J BIOL CHEM, V262, P5999; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; REHEMTULLA A, 1986, J BACTERIOL, V166, P651, DOI 10.1128/jb.166.2.651-657.1986; ROTHMEL RK, 1990, J BACTERIOL, V172, P922, DOI 10.1128/jb.172.2.922-931.1990; RUDD KE, 1991, NUCLEIC ACIDS RES, V19, P637, DOI 10.1093/nar/19.3.637; RUDD KE, 1992, SHORT COURSE BACTERI; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SASARMAN A, 1988, J BACTERIOL, V170, P1575; SEOL W, 1991, P NATL ACAD SCI USA, V88, P3802, DOI 10.1073/pnas.88.9.3802; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARMA RC, 1983, J BACTERIOL, V154, P743, DOI 10.1128/JB.154.2.743-747.1983; SHARMA RC, 1987, MUTAT RES, V184, P23, DOI 10.1016/0167-8817(87)90032-0; SHARPLES GJ, 1990, NUCLEIC ACIDS RES, V18, P6503, DOI 10.1093/nar/18.22.6503; SHAVLIK J, 1990, 988 U WISC COMP SCI; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; SOPHIANOPOULOU V, 1989, MOL MICROBIOL, V3, P705, DOI 10.1111/j.1365-2958.1989.tb00219.x; SPARROW CP, 1983, J BIOL CHEM, V258, P9963; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STEIN C, 1989, J BIOL CHEM, V264, P1252; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; SWARTZMAN E, 1990, J BACTERIOL, V172, P6797, DOI 10.1128/jb.172.12.6797-6802.1990; SWARTZMAN E, 1990, J BIOL CHEM, V265, P3513; TAKAGI M, 1990, J BACTERIOL, V172, P411, DOI 10.1128/JB.172.1.411-418.1990; TOONE WM, 1991, J BACTERIOL, V173, P3291, DOI 10.1128/jb.173.11.3291-3302.1991; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WEBSTER TD, 1988, NUCLEIC ACIDS RES, V16, P8192, DOI 10.1093/nar/16.16.8192; WEK RC, 1986, J BIOL CHEM, V261, P2441; YAMADA T, 1978, J BACTERIOL, V133, P536, DOI 10.1128/JB.133.2.536-541.1978; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V99, P1579, DOI 10.1093/oxfordjournals.jbchem.a135631; YANG Y, 1990, BACTERIAL CHROMOSOME, P211	108	235	319	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					771	778		10.1126/science.1379743	http://dx.doi.org/10.1126/science.1379743			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1379743				2022-12-24	WOS:A1992JG85100027
J	SHI, YF; GLYNN, JM; GUILBERT, LJ; COTTER, TG; BISSONNETTE, RP; GREEN, DR				SHI, YF; GLYNN, JM; GUILBERT, LJ; COTTER, TG; BISSONNETTE, RP; GREEN, DR			ROLE FOR C-MYC IN ACTIVATION-INDUCED APOPTOTIC CELL-DEATH IN T-CELL HYBRIDOMAS	SCIENCE			English	Article							GENE-EXPRESSION; MACROMOLECULAR-SYNTHESIS; DNA FRAGMENTATION; SUICIDE PROGRAM; IL-2 ADDICTION; PROTEIN; ANTISENSE; GROWTH; THYMOCYTES; INHIBITION	Immature T cells and some T cell hybridomas undergo apoptotic cell death when activated through the T cell receptor complex, a phenomenon that is probably related to antigen induced negative selection of developing T cells. This activation-induced apoptosis depends on active protein and RNA synthesis in the dying cells, although none of the genes required for this process have previously been identified. Antisense oligonucleotides corresponding to c-myc block the constitutive expression of c-Myc protein in T cell hybridomas and interfere with all aspects of activation-induced apoptosis without affecting lymphokine production in these cells. These data indicate that c-myc expression is a necessary component of activation-induced apoptosis.	LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037; UNIV ALBERTA,DEPT IMMUNOL,EDMONTON T6G 2H7,ALBERTA,CANADA; ST PATRICKS COLL,DEPT BIOL,MAYNOOTH,KILDARE,IRELAND	La Jolla Institute for Immunology; University of Alberta; Maynooth University			Green, Douglas R/N-8083-2018; Shi, Yufang/AAE-4431-2020	Green, Douglas R/0000-0002-7332-1417; Shi, Yufang/0000-0001-8964-319X; Cotter, Thomas/0000-0003-4626-5613	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031591] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31591] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COTTER TG, 1992, CANCER RES, V52, P997; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; HARELBELLAN A, 1988, J IMMUNOL, V140, P2431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Kerr J.F.R., 1987, P93; KERR JFR, 1980, INT REV CYTOL, V68, P251; MCCONKEY DJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P284, DOI 10.1016/0003-9861(90)90261-V; MCMANAWAY ME, 1990, LANCET, V335, P808, DOI 10.1016/0140-6736(90)90934-W; MORRIS RG, 1984, AM J PATHOL, V115, P426; ODAKA C, 1990, J IMMUNOL, V144, P2096; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PALLAVICINI MG, 1990, J CELL PHYSIOL, V143, P372, DOI 10.1002/jcp.1041430223; PENDERGAST GC, 1991, CELL, V65, P395; PULLEN AM, 1989, IMMUNOL REV, V107, P125, DOI 10.1111/j.1600-065X.1989.tb00006.x; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REIGEL JS, 1990, J IMMUNOL, V144, P3611; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Shi Y. G., UNPUB; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; UCKER DS, 1989, J IMMUNOL, V143, P3461; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WATERS CM, 1991, ONCOGENE, V6, P797; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	48	756	774	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					212	214		10.1126/science.1378649	http://dx.doi.org/10.1126/science.1378649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1378649				2022-12-24	WOS:A1992JC58500028
J	SWERDLOW, DL; MINTZ, ED; RODRIGUEZ, M; TEJADA, E; OCAMPO, C; ESPEJO, L; GREENE, KD; SALDANA, W; SEMINARIO, L; TAUXE, RV; WELLS, JG; BEAN, NH; RIES, AA; POLLACK, M; VERTIZ, B; BLAKE, PA				SWERDLOW, DL; MINTZ, ED; RODRIGUEZ, M; TEJADA, E; OCAMPO, C; ESPEJO, L; GREENE, KD; SALDANA, W; SEMINARIO, L; TAUXE, RV; WELLS, JG; BEAN, NH; RIES, AA; POLLACK, M; VERTIZ, B; BLAKE, PA			WATERBORNE TRANSMISSION OF EPIDEMIC CHOLERA IN TRUJILLO, PERU - LESSONS FOR A CONTINENT AT RISK	LANCET			English	Article							BIOTYPE EL-TOR; VIBRIO-CHOLERAE; UNITED-STATES; SLUMS	The epidemic of cholera that began in Peru in January, 1991, marked the first such epidemic in South America this century. Subsequently, over 533 000 cases and 4700 deaths have been reported from nineteen countries in that hemisphere. We investigated the epidemic in Trujillo, the second largest city in Peru. Trujillo's water supply was unchlorinated and water contamination was common. Suspect cholera cases were defined as persons presenting to a health facility with acute diarrhoea between Feb 1, and March 31, 1991. We studied a cohort of 150 patients who had been admitted to hospital and conducted a matched case-control study with 46 cases and 65 symptom-free and serologically uninfected controls; we also carried out a water quality study. By March 31, 1991, 16 400 cases of suspected cholera (attack rate 2.6%), 6673 hospital admissions, and 71 deaths (case-fatality rate 0.4%) had been reported in the province of Trujillo. 79% of stool cultures of patients with diarrhoea presenting to a single hospital yielded Vibrio cholerae O1. In the case-control study, drinking unboiled water (odds ratio [OR] 3.1, 95% confidence interval [CI] 1.3-7.3), drinking water from a household water storage container in which hands had been introduced into the water (4.2, 1.2-14.9), and going to a fiesta (social event) (3.6, 1.1-11.1) were associated with illness. The water quality study showed progressive contamination during distribution and storage in the home: faecal coliform counts were highest in water from household storage containers and lowest in city well water. V cholerae 01, biotype El Tor, serotype Inaba, was isolated from three city water samples. Cholera control measures in Trujillo should focus on treatment of water and prevention of contamination during distribution and in the home. Trujillo's water and sanitation problems are common in South America; similar control measures are needed throughout the continent to prevent spread of epidemic cholera.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; UNIDADE DEPT SALUD,TRUJILLO,PERU; NATL UNIV TRUJILLO,TRUJILLO,PERU; MINIST HLTH,GEN OFF EPIDEMIOL,LIMA,PERU; HOSP BELEN,TRUJILLO,PERU	Centers for Disease Control & Prevention - USA; Universidad Nacional de Trujillo	SWERDLOW, DL (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ENTER DIS BRANCH,ATLANTA,GA 30333, USA.							[Anonymous], 1989, STANDARD METHODS EXA, V17th; BARRETT TJ, 1981, J CLIN MICROBIOL, V13, P126, DOI 10.1128/JCM.13.1.126-129.1981; BARRY AL, 1985, MANUAL CLIN MICROBIO, P878; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; CLEMENTS ML, 1982, J INFECT DIS, V145, P465, DOI 10.1093/infdis/145.4.465; COHEN J, 1971, LANCET, V2, P86; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; DEB BC, 1982, INDIAN J MED RES, V76, P814; Feachem R, 1981, Trop Dis Bull, V78, P865; GERICHTER CB, 1975, ISRAEL J MED SCI, V11, P889; HARRIS JR, 1986, AM J EPIDEMIOL, V123, P424, DOI 10.1093/oxfordjournals.aje.a114257; KOLVIN JL, 1982, J HYG-CAMBRIDGE, V89, P243, DOI 10.1017/S0022172400070777; PAVIA AT, 1987, JAMA-J AM MED ASSOC, V258, P2374, DOI 10.1001/jama.1987.03400170060012; RICE EW, 1991, LANCET, V338, P455, DOI 10.1016/0140-6736(91)91086-A; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SACK DA, 1980, J CLIN MICROBIOL, V11, P35, DOI 10.1128/JCM.11.1.35-40.1980; SNYDER JD, 1981, J INFECT DIS, V143, P182, DOI 10.1093/infdis/143.2.182; SPIRA WM, 1981, APPL ENVIRON MICROB, V42, P730, DOI 10.1128/AEM.42.4.730-733.1981; STLOUIS ME, 1990, AM J EPIDEMIOL, V13, P719; WACHSMUTH IK, 1991, LANCET, V337, P1097; YOUNG CR, 1986, MANUAL CLIN LABORATO, P363; 1991, MMWR, V40, P108; 1991, MMWR, V40, P287; 1991, MMWR, V40, P516; 1991, MMWR, V40, P860	25	156	159	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					28	32		10.1016/0140-6736(92)92432-F	http://dx.doi.org/10.1016/0140-6736(92)92432-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351608				2022-12-24	WOS:A1992JC35400012
J	CLIPSTONE, NA; CRABTREE, GR				CLIPSTONE, NA; CRABTREE, GR			IDENTIFICATION OF CALCINEURIN AS A KEY SIGNALING ENZYME IN LYMPHOCYTE-T ACTIVATION	NATURE			English	Article							CYCLOSPORINE-A; EXPRESSION; BINDING; GENE; CYCLOPHILIN; PHOSPHATASE; CALMODULIN; PROTEINS; ENHANCER; CLONING	THE immunosuppressive drugs cyclosporin A (CsA) and FK506 both interfere with a Ca2+-sensitive T-cell signal transduction pathway 1-4, thereby preventing the activation of specific transcription factors (such as NF-AT and NF-IL2A) 1,5-7 involved in lymphokine gene expression. CsA and FK506 seem to act by interaction with their cognate intracellular receptors 8-10, cyclophilin and FKBP, respectively (see ref. 11 for review). The Ca2+/calmodulin-regulated phosphatase calcineurin is a major target of drug-isomerase complexes in vitro 12. We have therefore tested the hypothesis that this interaction is responsible for the in vivo effects of CsA/FK506. We report here that overexpression of calcineurin in Jurkat cells renders them more resistant to the effects of CsA and FK506 and augments both NFAT- and NFIL2A-dependent transcription. These results identify calcineurin as a key enzyme in the T-cell signal transduction cascade and provide biological evidence to support the notion that the interaction of drug-isomerase complexes with calcineurin underlies the molecular basis of CsA/FK506-mediated immunosuppression.			CLIPSTONE, NA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305, USA.							BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLANAGAN WM, 1992, J BIOL CHEM, V267, P399; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUI J, 1992, BIOCHEMISTRY-US, V31, P3896; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCPARTLIN AE, 1991, BIOCHIM BIOPHYS ACTA, V1088, P308, DOI 10.1016/0167-4781(91)90069-X; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0	23	1499	1560	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					695	697		10.1038/357695a0	http://dx.doi.org/10.1038/357695a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377362				2022-12-24	WOS:A1992JA43000073
J	BRAHAMS, D				BRAHAMS, D			LIFE-SUSTAINING TREATMENT FOR BRAIN-DAMAGED CHILD	LANCET			English	Editorial Material																			0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1472	1473		10.1016/0140-6736(92)92052-H	http://dx.doi.org/10.1016/0140-6736(92)92052-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351139				2022-12-24	WOS:A1992HY31700017
J	JONES, MH; JENKINS, D; CUZICK, J; WOLFENDALE, MR; JONES, JJ; BALOGUNLYNCH, C; USHERWOOD, MM; SINGER, A				JONES, MH; JENKINS, D; CUZICK, J; WOLFENDALE, MR; JONES, JJ; BALOGUNLYNCH, C; USHERWOOD, MM; SINGER, A			MILD CERVICAL DYSKARYOSIS - SAFETY OF CYTOLOGICAL SURVEILLANCE	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; ATYPIA; COLPOSCOPY; EXPERIENCE; DIAGNOSIS; SMEARS	How best to manage women who are found on cervical screening to have mild dyskaryosis remains controversial. Cytological surveillance misses some lesions picked up by colposcopy, but colposcopy is emotionally traumatic for women, the majority of whom will have a normal result. To determine what proportion of lesions are missed by cytological surveillance, and whether any abnormalities persist after colposcopy, we studied, by means of colposcopy and biopsy, the prevalence of cervical intraepithelial neoplasia (CIN) and subclinical human papillomavirus infection (HPVI) in two groups of patients who had had a first smear showing mild dyskaryosis at least 24 months earlier. One group was recruited from a centre practising cytological surveillance, with colposcopy for patients showing persistent or progressive cytological abnormality. The other group all had early colposcopy and treatment. Of 214 patients recruited into the cytological surveillance group, 70 (33%) had been referred for colposcopy within 24 months. Colposcopy of the remaining 144 (after a mean interval of 27 months from presentation) revealed that 54 (38%) were disease free, 64 (44%) had HPVI/CIN1, 8 (6%) had CIN2, and 18 (12%) had CIN3. A smear at that time identified 12 of the 18 (67%) with CIN3 as needing close cytological follow-up (1 patient) or prompt referral for colposcopy (11 patients). 137 women in the early colposcopy group attended for the study colposcopy (after a mean interval of 32 months from presentation). 37% were found to have some abnormality persisting after an earlier colposcopy, but none had CIN3. Cytological surveillance of mild dyskaryosis resulted in a 12% risk of patients having a small CIN3 lesion after 2 years, but this risk was reduced to 4% by the addition of a third repeat smear 12 months after the second. With such a policy only about a third of women would require colposcopy, and the risk of missing serious underlying precancerous changes would be low.	LEICESTER DIST HLTH AUTHOR,20-28 PRINCESS RD W,LEICESTER LE1 6TY,ENGLAND; ROYAL NO HOSP,DEPT COLPOSCOPY,LONDON N7 6LD,ENGLAND; ROYAL NO HOSP,DEPT OBSTET & GYNAECOL,LONDON N7 6LD,ENGLAND; WHITTINGTON HOSP,DEPT HISTOPATHOL,LONDON N19 5NF,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; STOKE MANDEVILLE HOSP,DEPT CYTOL,AYLESBURY,BUCKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT OBSTET & GYNAECOL,AYLESBURY,BUCKS,ENGLAND; MILTON KEYNES DIST GEN HOSP,DEPT OBSTET & GYNAECOL,MILTON KEYNES,BUCKS,ENGLAND	University of London; University College London; Cancer Research UK								BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; BUCKLEY CH, 1982, J CLIN PATHOL, V35, P1, DOI 10.1136/jcp.35.1.1; CAMPION MJ, 1986, LANCET, V2, P237; CAMPION MJ, 1988, BRIT J OBSTET GYNAEC, V95, P175, DOI 10.1111/j.1471-0528.1988.tb06848.x; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; JARMULOWICZ MR, 1989, BRIT J OBSTET GYNAEC, V96, P1061, DOI 10.1111/j.1471-0528.1989.tb03381.x; JENKINS D, 1988, BRIT MED J, V297, P918, DOI 10.1136/bmj.297.6653.918-a; Jenkinson E J, 1990, Semin Immunol, V2, P51; JORDAN JA, 1988, BRIT MED J, V297, P6, DOI 10.1136/bmj.297.6640.6; MCCORMICK JS, 1989, LANCET, V2, P207; MCDONALD TW, 1989, GYNECOL ONCOL, V34, P345, DOI 10.1016/0090-8258(89)90170-4; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Posner T, 1988, PREVENTION CERVICAL; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SANDMIRE HF, 1976, OBSTET GYNECOL, V48, P56; SMITH A, 1988, BRIT MED J, V296, P1670, DOI 10.1136/bmj.296.6637.1670; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; TAY SK, 1987, AUST NZ J OBSTET GYN, V27, P140; 1987, REPORT INTERCOLLEGIA	20	57	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1440	1443		10.1016/0140-6736(92)92031-A	http://dx.doi.org/10.1016/0140-6736(92)92031-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351129				2022-12-24	WOS:A1992HY31700004
J	BLAU, JN				BLAU, JN			MIGRAINE - THEORIES OF PATHOGENESIS	LANCET			English	Article							CEREBRAL BLOOD-FLOW; XE-133 INHALATION; DOUBLE-BLIND; DURA MATER; HEADACHES; ATTACKS; EXTRAVASATION; PAIN				BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND.							ANTHONY M, 1969, RESEARCH CLINICAL ST, V2, P29; BICKERSTAFF ER, 1975, NEUROLOGICAL COMPLIC, P81; BILLE B, 1962, ACTA PAEDIATR S S136, V51, P3; BLAU JN, 1981, CEPHALALGIA, V1, P143, DOI 10.1046/j.1468-2982.1981.0103143.x; BLAU JN, 1991, CEPHALALGIA, V11, P229; BLAU JN, 1970, LANCET, V2, P241; BLAU JN, 1985, J ROY COLL PHYS LOND, V19, P166; Blau JN, 1987, MIGRAINE CLIN THERAP, P3; BLAU JN, IN PRESS PATHOL BIOL; Blau Joseph N., 1987, MIGRAINE CLIN RES AS, P241; BRUYN GW, 1984, PHARM BASIS MIGRAINE, P267; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; COUCH JR, 1983, HEADACHE, V23, P94; DALESSIO DJ, 1982, CEREBRAL HYPOXIA PAT, P28; EADIE MJ, 1985, BIOCH MIGRAINE, P1; EKBOM K, 1991, NEW ENGL J MED, V325, P322, DOI 10.1056/nejm199108013250505; FEATHERSTONE HJ, 1986, HEADACHE, V26, P39, DOI 10.1111/j.1526-4610.1986.hed2601039.x; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; Fisher C M, 1971, Clin Neurosurg, V18, P267; GLOOR P, 1986, TRENDS NEUROSCI, V9, P21, DOI 10.1016/0166-2236(86)90008-1; GOWERS WR, 1988, MANUAL DISEASES NERV, P776; HANINGTON E, 1967, BMJ-BRIT MED J, V2, P550; HAWKING SW, 1988, BRIEF HIST TIME, P9; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LIVEING E, 1873, MEGRIM SICK HEADACHE, P26; MACGREGOR EA, 1990, CEPHALALGIA, V10, P305, DOI 10.1046/j.1468-2982.1990.1006305.x; MARTINS I, 1989, HEADACHE, V29, P660, DOI 10.1111/j.1526-4610.1989.hed2910660.x; MOFFETT A, 1972, J NEUROL NEUROSUR PS, V35, P496, DOI 10.1136/jnnp.35.4.496; MOFFETT AM, 1974, J NEUROL NEUROSUR PS, V37, P445, DOI 10.1136/jnnp.37.4.445; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MRSULJA BB, 1973, SLEEP PHYSL BIOCH PS, P271; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OSTFELD AM, 1960, JAMA-J AM MED ASSOC, V174, P1188, DOI 10.1001/jama.1960.63030090011010; POINCARE H, 1952, SCI HYPOTHESIS, P142; SAITO K, 1988, ANN NEUROL, V24, P732, DOI 10.1002/ana.410240607; SAKAI F, 1978, HEADACHE, V18, P122, DOI 10.1111/j.1526-4610.1978.hed1803122.x; SOKOLOFF L, 1983, HDB NEUROCHEMISTRY, V3, P225; SOMERVILLE BW, 1972, NEUROLOGY, V22, P824, DOI 10.1212/WNL.22.8.824; WAELKENS J, 1982, BRIT MED J, V284, P944, DOI 10.1136/bmj.284.6320.944; WATERS WE, 1983, BRIT MED J, V287, P1442, DOI 10.1136/bmj.287.6403.1442; WOLFF HG, 1963, HEADACHE OTHER HEAD, P269	43	127	129	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1202	1207		10.1016/0140-6736(92)91140-4	http://dx.doi.org/10.1016/0140-6736(92)91140-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349944				2022-12-24	WOS:A1992HU68400010
J	ISOM, LL; DEJONGH, KS; PATTON, DE; REBER, BFX; OFFORD, J; CHARBONNEAU, H; WALSH, K; GOLDIN, AL; CATTERALL, WA				ISOM, LL; DEJONGH, KS; PATTON, DE; REBER, BFX; OFFORD, J; CHARBONNEAU, H; WALSH, K; GOLDIN, AL; CATTERALL, WA			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF THE BETA-1-SUBUNIT OF THE RAT-BRAIN SODIUM-CHANNEL	SCIENCE			English	Article							AMINO-ACID SEQUENCE; PURIFIED CALCIUM CHANNELS; SITE-DIRECTED ANTIBODIES; ALPHA-SUBUNIT; XENOPUS-OOCYTES; ELECTROPHORUS-ELECTRICUS; BIOCHEMICAL-PROPERTIES; SAXITOXIN RECEPTOR; BINDING-PROTEIN; BETA-2 SUBUNITS	Voltage-sensitive sodium channels are responsible for the initiation and propagation of the action potential and therefore are important for neuronal excitability. Complementary DNA clones encoding the beta-1 subunit of the rat brain sodium channel were isolated by a combination of polymerase chain reaction and library screening techniques. The deduced primary structure indicates that the beta-1 subunit is a 22,851 -dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data. Northern blot analysis reveals a 1400-nucleotide messenger RNA in rat brain, heart, skeletal muscle, and spinal cord. Coexpression of beta-1 subunits with alpha-subunits increases the size of the peak sodium current, accelerates its inactivation, and shifts the voltage dependence of inactivation to more negative membrane potentials. These results indicate that the beta-1 subunit is crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the rat brain sodium channel.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of California System; University of California Irvine; University of Washington; University of Washington Seattle			; Goldin, Alan/A-8385-2015	Offord, James/0000-0003-4180-0146; Isom, Lori/0000-0002-9479-6729; Goldin, Alan/0000-0001-7159-0288	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704, R01NS026729, R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704, NS15751, NS26729] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AGNEW WS, 1980, BIOCHEM BIOPH RES CO, V92, P860, DOI 10.1016/0006-291X(80)90782-2; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HARTSHORNE RP, 1981, P NATL ACAD SCI-BIOL, V78, P4620, DOI 10.1073/pnas.78.7.4620; HARTSHORNE RP, 1982, J BIOL CHEM, V257, P3888; Hille B, 1984, IONIC CHANNELS EXCIT; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KRANER SD, 1985, J BIOL CHEM, V260, P6341; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LOMBET A, 1984, EUR J BIOCHEM, V141, P651, DOI 10.1111/j.1432-1033.1984.tb08241.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; REBER BFX, 1987, J BIOL CHEM, V262, P11369; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SUTKOWSKI EM, 1990, J BIOL CHEM, V265, P12393; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P	39	608	621	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					839	842		10.1126/science.1375395	http://dx.doi.org/10.1126/science.1375395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375395				2022-12-24	WOS:A1992HT23500046
J	ARMITAGE, RJ; FANSLOW, WC; STROCKBINE, L; SATO, TA; CLIFFORD, KN; MACDUFF, BM; ANDERSON, DM; GIMPEL, SD; DAVISSMITH, T; MALISZEWSKI, CR; CLARK, EA; SMITH, CA; GRABSTEIN, KH; COSMAN, D; SPRIGGS, MK				ARMITAGE, RJ; FANSLOW, WC; STROCKBINE, L; SATO, TA; CLIFFORD, KN; MACDUFF, BM; ANDERSON, DM; GIMPEL, SD; DAVISSMITH, T; MALISZEWSKI, CR; CLARK, EA; SMITH, CA; GRABSTEIN, KH; COSMAN, D; SPRIGGS, MK			MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; HUMAN B-CELLS; MONOCLONAL-ANTIBODY; CARCINOMA ANTIGEN; GENE-TRANSFER; ACTIVATION; EXPRESSION; CLONING; DIFFERENTIATION	THE CD40 surface molecule is a 277-amino-acid glycoprotein expressed on B lymphocytes, epithelial cells and some carcinoma cell lines. Monoclonal antibodies against CD40 mediate a variety of effects on B lymphocytes, including induction of intercellular adhesion 1,2, short- and long-term proliferation 3-5, differentiation 6,7 and enhanced tyrosine phosphorylation of proteins 8. In addition, germinal centre centrocytes are prevented from undergoing apoptosis by activation through CD40 and receptor for antigen 9. These data indicate that CD40 could be a receptor for an unknown ligand with important functions in B-cell development and activation. This hypothesis is strengthened by the homology of the extracellular region of the CD40 molecule 10 with a family of cell-surface glycoproteins 11,12 that includes the receptors for nerve growth factor 13,14 and tumour necrosis factor 11,15,16. Here we report the cloning of a ligand for CD40 that is expressed on the cell surface of activated T cells and mediates B-cell proliferation in the absence of co-stimulus, as well as IgE production in the presence of interleukin-4.	IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT MICROBIOL SC42,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	ARMITAGE, RJ (corresponding author), IMMUNEX RES & DEV CORP,DEPT IMMUNOL,51 UNIV ST,SEATTLE,WA 98101, USA.			Clark, Edward A/0000-0001-8061-5475				BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BARRETT TB, 1991, J IMMUNOL, V146, P1722; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FANSLOW WC, IN PRESS J IMMUN; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PAULIE S, 1989, J IMMUNOL, V142, P590; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818; ZHANG K, 1991, J IMMUNOL, V146, P1836	25	1050	1157	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					80	82		10.1038/357080a0	http://dx.doi.org/10.1038/357080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1374165				2022-12-24	WOS:A1992HT22900063
J	MALAFOSSE, A; LEHESJOKI, AE; GENTON, P; LABAUGE, P; DURAND, G; TASSINARI, CA; DRAVET, C; MICHELUCCI, R; DELACHAPELLE, A				MALAFOSSE, A; LEHESJOKI, AE; GENTON, P; LABAUGE, P; DURAND, G; TASSINARI, CA; DRAVET, C; MICHELUCCI, R; DELACHAPELLE, A			IDENTICAL GENETIC-LOCUS FOR BALTIC AND MEDITERRANEAN MYOCLONUS	LANCET			English	Note								Genetic linkage analysis shows that Baltic and Mediterranean myoclonus, two forms of progressive myoclonus epilepsy, are closely linked to marker D21S113 on the long arm of chromosome 21. Baltic and Mediterranean myoclonus are most probably due to mutations of the same gene.	CNRS, UPR 8402, INSERM, U249, F-34060 MONTPELLIER, FRANCE; UNIV HELSINKI, DEPT MED GENET, SF-00290 HELSINKI 29, FINLAND; CTR ST PAUL, F-13009 MARSEILLE, FRANCE; HOP INSTRUCT ARMEES VAL DE GRACE, SERV NEUROPHYSIOL, F-75005 PARIS, FRANCE; UNIV BOLOGNA, BELLARIA HOSP, DEPT NEUROL, I-40126 BOLOGNA, ITALY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Helsinki; Val-de-Grace Hospital; AUSL di Bologna; University of Bologna			Michelucci, Roberto/AAB-9074-2020	Tassinari, Carlo Alberto/0000-0002-4183-5165; Michelucci, Roberto/0000-0002-9655-7940				BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; ELRIDGE R, 1983, LANCET, V2, P838; GENTON P, 1990, ACTA NEUROL SCAND, V81, P8; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEHESJOKI AE, 1992, NEUROLOGY, V42, P1545, DOI 10.1212/WNL.42.8.1545; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; PATTERSON D, 1991, CYTOGENET CELL GENET, V58, P168; TASSINARI C A, 1991, Neurology, V41, P281; 1990, ANN NEUROL, V28, P113	9	55	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1080	1081		10.1016/0140-6736(92)90667-R	http://dx.doi.org/10.1016/0140-6736(92)90667-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349105				2022-12-24	WOS:A1992HR44600006
J	RICHMOND, PW; MCCABE, M; DAVIES, JP; THOMAS, DM				RICHMOND, PW; MCCABE, M; DAVIES, JP; THOMAS, DM			PERFORATION OF GLOVES IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article							RISK				RICHMOND, PW (corresponding author), CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF CF2 1SZ,S GLAM,WALES.							BROUGH SJ, 1988, BRIT J SURG, V75, P317, DOI 10.1002/bjs.1800750408; CHAN P, 1989, BRIT J SURG, V76, P1208, DOI 10.1002/bjs.1800761129; Church J, 1980, J Hosp Infect, V1, P84, DOI 10.1016/0195-6701(80)90036-5; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					879	880		10.1136/bmj.304.6831.879	http://dx.doi.org/10.1136/bmj.304.6831.879			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392748	Green Published, Bronze			2022-12-24	WOS:A1992HM83500025
J	NAKAMURA, S; SAKURADA, S; SALAHUDDIN, SZ; OSADA, Y; TANAKA, NG; SAKAMOTO, N; SEKIGUCHI, M; GALLO, RC				NAKAMURA, S; SAKURADA, S; SALAHUDDIN, SZ; OSADA, Y; TANAKA, NG; SAKAMOTO, N; SEKIGUCHI, M; GALLO, RC			INHIBITION OF DEVELOPMENT OF KAPOSIS-SARCOMA RELATED LESIONS BY A BACTERIAL-CELL WALL COMPLEX	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; LONG-TERM CULTURE; HOMOSEXUAL MEN; ANGIOGENESIS; THERAPY; GROWTH	In vitro and in vivo model systems for the study of human immunodeficiency virus (HIV-associated Kaposi's sarcoma (KS) were used to evaluate compounds for their potential as therapeutic agents. A sulfated polysaccharide-peptidoglycan compound (SP-PG) produced by bacteria controlled the in vitro growth of acquired immunodeficiency syndrome (AIDS)-associated, KS-derived spindle-shaped cells (AIDS-KS cells) at noncytotoxic concentrations. Angiogenesis induced by AIDS-KS cells in the chicken chorioallantoic membrane assay was blocked by SP-PG, which also inhibited the vascular hyperpermeability response and the angiogenesis associated with the induction of KS-like lesions that develop after subcutaneous inoculation of AIDS-KS cells into nude mice. Suramin, pentosan polysulfate, and interferon-alpha, which are currently in use for therapy of KS, were either less effective than SP-PG or much more cytotoxic, or both.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; UNIV SO CALIF,DEPT INTERNAL MED,LOS ANGELES,CA 90089; DAIICHI PHARMACEUT CO LTD,TOKYO 103,JAPAN; HUNTINGTON MEM HOSP,INST MOLEC MED & TECHNOL,PASADENA,CA 91105	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California; Daiichi Sankyo Company Limited; University of Southern California; Huntington Memorial Hospital								BIESERT L, 1988, AIDS, V2, P449, DOI 10.1097/00002030-198812000-00007; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; GALLO RC, 1989, 4 C CENT GARD, P113; GILL P, 1990, AM J CLIN ONCOL-CANC, V13, P315, DOI 10.1097/00000421-199008000-00010; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INOUE K, 1982, J BIOCHEM-TOKYO, V92, P1775, DOI 10.1093/oxfordjournals.jbchem.a134107; KROWN SE, 1983, NEW ENGL J MED, V308, P1071, DOI 10.1056/NEJM198305053081806; LEVINE AM, 1986, ANN INTERN MED, V105, P32, DOI 10.7326/0003-4819-105-1-32; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MCNUTT NS, 1983, AM J PATHOL, V111, P62; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; NAKAMURA S, UNPUB; SAKURADA S, UNPUB; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SATO K, 1989, J PHARM SCI, V78, P11, DOI 10.1002/jps.2600780105; TANAKA N, 1989, CANCER RES, V49, P6726; TANAKA NG, 1991, INT J RADIAT BIOL, V60, P79, DOI 10.1080/09553009114551601; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; VOLBERDING PA, 1985, ANN INTERN MED, V103, P335, DOI 10.7326/0003-4819-103-3-335; YARCHOAN R, COMMUNICATION	23	84	90	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1437	1440		10.1126/science.1371891	http://dx.doi.org/10.1126/science.1371891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1371891				2022-12-24	WOS:A1992HH74400058
J	PORTER, SB; SANDE, MA				PORTER, SB; SANDE, MA			TOXOPLASMOSIS OF THE CENTRAL-NERVOUS-SYSTEM IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; MAINTENANCE THERAPY; CEREBRAL TOXOPLASMOSIS; AIDS PATIENTS; ENCEPHALITIS; PYRIMETHAMINE; CLINDAMYCIN; EFFICACY; COMBINATION	Background and Methods. Toxoplasmosis is the most common opportunistic infection of the central nervous system in patients with the acquired immunodeficiency syndrome (AIDS). To investigate its clinical course, we reviewed the records of 115 patients with AIDS and central nervous system toxoplasmosis treated at San Francisco General Hospital between 1981 and 1990. Results. The most common presenting symptoms were headache (in 55 percent), confusion (52 percent), and fever (47 percent). Focal neurologic deficits were present in 79 patients (69 percent). The median CD4 cell count at presentation was 50 per cubic millimeter (50x10(6) per liter). Thirteen of 80 patients with clinical toxoplasmosis (16 percent) and 4 of 18 patients with pathologically proved disease (22 percent) had undetectable antitoxoplasma IgG antibodies by indirect immunofluorescence assay. Of 103 patients, 94 (91 percent) had enhancing lesions on CT. Single lesions were seen in 28 of 103 patients (27 percent) on CT, and such lesions were seen in 3 of 21 patients (14 percent) on magnetic resonance imaging. Over 90 percent of patients who eventually had clinical and radiographic improvement had evidence of improvement by day 14 of therapy. Adverse drug reactions occurred in 71 patients (62 percent) and led to a change in therapy in 50 patients (43 percent). Among the patients who survived a first episode of toxoplasmosis, the median survival was 265 days. Conclusions. Toxoplasmosis occurs in advanced stages of human immunodeficiency virus infection, and the absence of antitoxoplasma antibodies on immunofluorescence assay does not exclude the diagnosis. The clinical and radiographic response to therapy is usually rapid, but treatment is frequently limited by adverse drug effects.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SANDE, MA (corresponding author), SAN FRANCISCO GEN HOSP,MED SERV,RM 5H22,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							CARRAZANA EJ, 1989, CLIN NEUROL NEUROSUR, V91, P291, DOI 10.1016/0303-8467(89)90004-8; CIRICILLO SF, 1971, J NEUROSURG, V74, P1029; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DINA TS, 1991, RADIOLOGY, V179, P823, DOI 10.1148/radiology.179.3.2027999; FOPPA CU, 1991, EUR J CLIN MICROBIOL, V10, P187, DOI 10.1007/BF01964458; GONZALEZCLEMENTE JM, 1990, MED CLIN-BARCELONA, V95, P441; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; KATLAMA C, 1991, EUR J CLIN MICROBIOL, V10, P189, DOI 10.1007/BF01964459; LEPORT C, 1989, J INFECT DIS, V160, P557, DOI 10.1093/infdis/160.3.557; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEVY RM, 1988, J ACQ IMMUN DEF SYND, V1, P41; LUFT BJ, 1984, JAMA-J AM MED ASSOC, V252, P913, DOI 10.1001/jama.252.7.913; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MILLER CN, 1990, 30TH INT C ANT AG CH; NAVIA BA, 1986, ANN NEUROL, V19, P224, DOI 10.1002/ana.410190303; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; WANKE C, 1987, AM J TROP MED HYG, V36, P509, DOI 10.4269/ajtmh.1987.36.509; WONG B, 1984, ANN INTERN MED, V100, P36, DOI 10.7326/0003-4819-100-1-36	20	455	467	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1643	1648		10.1056/NEJM199212033272306	http://dx.doi.org/10.1056/NEJM199212033272306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1359410				2022-12-24	WOS:A1992KA26000006
J	LEHNER, T; BERGMEIER, LA; PANAGIOTIDI, C; TAO, L; BROOKES, R; KLAVINSKIS, LS; WALKER, P; WALKER, J; WARD, RG; HUSSAIN, L; GEARING, AJH; ADAMS, SE				LEHNER, T; BERGMEIER, LA; PANAGIOTIDI, C; TAO, L; BROOKES, R; KLAVINSKIS, LS; WALKER, P; WALKER, J; WARD, RG; HUSSAIN, L; GEARING, AJH; ADAMS, SE			INDUCTION OF MUCOSAL AND SYSTEMIC IMMUNITY TO A RECOMBINANT SIMIAN IMMUNODEFICIENCY VIRAL PROTEIN	SCIENCE			English	Article							VIRUS-LIKE PARTICLES; CHOLERA-TOXIN; MACAQUE MONKEYS; IGG ANTIBODIES; RETROVIRUS; VACCINE; ANTIGEN; AIDS; IMMUNIZATION; EXPRESSION	Heterosexual transmission through the cervico-vaginal mucosa is the principal route of human immunodeficiency virus (HIV) infection in Africa and is increasing in the United States and Europe. Vaginal immunization with simian immunodeficiency virus (SIV) had not yet been studied in nonhuman primates. Immune responses in macaques were investigated by stimulation of the genital and gut-associated lymphoid tissue with a recombinant, particulate SIV antigen. Vaginal, followed by oral, administration of the vaccine elicited three types of immunity: (i) gag protein p27-specific, secretory immunoglobulin A (IgA) and immunoglobulin G (IgG) in the vaginal fluid, (ii) specific CD4+ T cell proliferation and helper function in B cell p27-specific IgA synthesis in the genital lymph nodes, and (iii) specific serum IgA and IgG, with CD4+ T cell proliferative and helper functions in the circulating blood.	BRITISH BIOTECHNOL LTD, COWLEY OX4 5LY, OXON, ENGLAND		LEHNER, T (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DIV IMMUNOL, LONDON BRIDGE, LONDON SE1 9RT, ENGLAND.			Brookes, Roger/0000-0002-5361-0617; Klavinskis, Linda S./0000-0001-5828-6978				ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; ALMOND N, 1990, J VIROL METHODS, V28, P305, DOI 10.1016/0166-0934(90)90124-X; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BELL EB, 1967, NATURE, V214, P423, DOI 10.1038/214423a0; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; BURNS NR, 1990, J MOL BIOL, V216, P207, DOI 10.1016/S0022-2836(05)80308-0; BURNS NR, 1991, METHOD MOL BIOL, V8, P277; CULLITON BJ, 1991, NATURE, V352, P15, DOI 10.1038/352015a0; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; ELSON CO, 1984, J IMMUNOL, V133, P2892; FELLOWES R, 1990, J IMMUNOL METHODS, V132, P165, DOI 10.1016/0022-1759(90)90026-R; GRIFFITHS JC, 1991, J VIROL, V65, P450, DOI 10.1128/JVI.65.1.450-456.1991; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; LANDE IJM, 1986, J REPROD IMMUNOL, V9, P57, DOI 10.1016/0165-0378(86)90025-2; Lehner T, 1992, VACCINE RES, V3, P319; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LYCKE N, 1986, IMMUNOLOGY, V59, P301; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER MD, 1990, J IMMUNOL, V144, P122; MILLS KHG, 1991, J IMMUNOL, V147, P3560; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; OGRA PL, 1973, J IMMUNOL, V110, P1307; PARR EL, 1988, J REPROD IMMUNOL, V14, P165, DOI 10.1016/0165-0378(88)90067-8; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STURN B, 1978, MED MICROBIOL IMMUN, V165, P119, DOI 10.1007/BF02122747; WIRA CR, 1989, IMMUNOLOGY, V68, P24; WIRA CR, 1987, J IMMUNOL, V138, P4159; YANG SL, 1979, FERTIL STERIL, V32, P588	32	144	152	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1992	258	5086					1365	1369		10.1126/science.1360702	http://dx.doi.org/10.1126/science.1360702			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1360702				2022-12-24	WOS:A1992JY95800041
J	WOLLE, D; DEAN, DR; HOWARD, JB				WOLLE, D; DEAN, DR; HOWARD, JB			NUCLEOTIDE IRON-SULFUR CLUSTER SIGNAL TRANSDUCTION IN THE NITROGENASE IRON-PROTEIN - THE ROLE OF ASP(125)	SCIENCE			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; AZOTOBACTER-VINELANDII; FE-PROTEIN; ADENOSINE 5'-TRIPHOSPHATE; KLEBSIELLA-PNEUMONIAE; BINDING; MGATP; MECHANISM; LIGANDS	Electron transfer in nitrogenase involves a gating process initiated by MgATP (magnesium adenosine triphosphate) binding to Fe-protein. The redox site, an 4Fe:4S cluster, is structurally separated from the MgATP binding site. For MgATP hydrolysis to be coupled to electron transfer, a signal transduction mechanism is proposed that is similar to that in guanosine triphosphatase proteins. Based on the three-dimensional structure of Fe-protein, Asp125 is likely to be part of a putative transduction path. Altered Fe-protein with Glu replacing Asp has been prepared and retains the ability for the initial nucleotide-dependent conformational change. However, either MgADP or MgATP can induce the shift and Mg binding to the nucleotide is no longer essential.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT ANAEROB MICROBIOL,BLACKSBURG,VA 24061	Virginia Polytechnic Institute & State University								BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; DEITS TL, 1989, J BIOL CHEM, V264, P6619; ENNOR AH, 1957, METHOD ENZYMOL, V3, P850, DOI 10.1016/S0076-6879(57)03460-6; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HIROSE M, 1971, BIOCHIM BIOPHYS ACTA, V251, P376, DOI 10.1016/0005-2795(71)90125-5; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; IMPERIAL J, 1988, NITROGEN FIXATION 10, P128; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWE D, 1984, MOLYBDENUM ENZYMES, P222; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Press WH, 1986, NUMERICAL RECIPES AR, P521; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; THORNELEY RNF, 1989, BIOCHEM J, V264, P657, DOI 10.1042/bj2640657; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; TSO MYW, 1973, BIOCHIM BIOPHYS ACTA, V309, P263, DOI 10.1016/0005-2744(73)90024-7; WALKER G, 1974, BIOCHEMISTRY-US, V13, P1872; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WOLLE D, 1992, J BIOL CHEM, V267, P3667; YATES G, 1992, BIOL NITROGEN FIXATI, P685; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	33	75	75	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					992	995		10.1126/science.1359643	http://dx.doi.org/10.1126/science.1359643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359643				2022-12-24	WOS:A1992JW79600034
J	VACHON, G; COHEN, B; PFEIFLE, C; MCGUFFIN, ME; BOTAS, J; COHEN, SM				VACHON, G; COHEN, B; PFEIFLE, C; MCGUFFIN, ME; BOTAS, J; COHEN, SM			HOMEOTIC GENES OF THE BITHORAX COMPLEX REPRESS LIMB DEVELOPMENT IN THE ABDOMEN OF THE DROSOPHILA EMBRYO THROUGH THE TARGET GENE DISTAL-LESS	CELL			English	Article							SEGMENT-POLARITY GENE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ULTRABITHORAX PROTEINS; HOMEODOMAIN PROTEINS; IMAGINAL DISKS; FUSHI-TARAZU; MELANOGASTER; EXPRESSION; WINGLESS	Homeotic genes encode transcription factors that are thought to specify segmental identity by regulating expression of subordinate genes. Limb development is repressed in the abdominal segments of the Drosophila embryo by the hometic genes of the Bithorax complex (BX-C). Localized expression of the homeobox gene Distal-less (DII) is required for leg development in thoracic segments. We have identified a minimal cis-regulatory enhancer element that directs DII expression in the larval leg primordia. We present evidence that the BX-C proteins repress DII expression in abdominal segments by binding to a small number of specific sites in this element. Mutating these sites eliminates BX-C protein binding and renders the element insensitive to BX-C-mediated repression in vivo. Repression of limb development in the abdomen appears to be controlled at the DII enhancer. Thus DII may serve as a downstream target gene through which the homeotic genes control abdominal segment identity in the Drosophila embryo.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	VACHON, G (corresponding author), BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; CASANOVA J, 1987, EMBO J, V6, P3103, DOI 10.1002/j.1460-2075.1987.tb02619.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JOHNSON FB, 1990, GENE DEV, V4, P1044, DOI 10.1101/gad.4.6.1044; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SAMSON ML, 1989, CELL, V57, P1045, DOI 10.1016/0092-8674(89)90342-5; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SIMCOX AA, 1991, MECH DEVELOP, V34, P11, DOI 10.1016/0925-4773(91)90087-M; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; SUNKEL CE, 1987, ROUX ARCH DEV BIOL, V196, P124, DOI 10.1007/BF00402034; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THALI M, 1988, NATURE, V336, P598, DOI 10.1038/336598a0; THUMMEL C, 1992, IN PRESS DROS INF SE; TREISMAN J, 1989, CELL, V59, P553; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wieschaus E., 1986, P199; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	57	318	327	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					437	450		10.1016/0092-8674(92)90513-C	http://dx.doi.org/10.1016/0092-8674(92)90513-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1358457				2022-12-24	WOS:A1992JW43500010
J	EKBOM, A; TRICHOPOULOS, D; ADAMI, HO; HSIEH, CC; LAN, SJ				EKBOM, A; TRICHOPOULOS, D; ADAMI, HO; HSIEH, CC; LAN, SJ			EVIDENCE OF PRENATAL INFLUENCES ON BREAST-CANCER RISK	LANCET			English	Article							PREGNANCY; BIRTH; ASSOCIATIONS; HYPOTHESIS; EXCRETION; ESTROGENS; AGE	Intrauterine exposure to high concentrations of endogenous pregnancy oestrogens may be important in the aetiology of breast cancer. In a nested case-control study we have assessed the relation between breast cancer risk and indicators of pregnancy oestrogen concentrations; preeclampsia/eclampsia is negatively related and measures of fetal size are positively related to oestrogen concentrations. Standard records for women born at Uppsala University Hospital between 1874 and 1954 were linked with records of invasive breast cancer cases, identified through their unique national registration numbers in the Swedish Cancer Registry during 1958-90. For each breast cancer case, we selected as potential controls female offspring of the first three mothers admitted to the hospital after the case's mother; only controls still living in Sweden and free from breast cancer when it was diagnosed in the case were finally included. Conditional logistic regression analysis was done for 458 breast cancer cases and 1197 matched controls. Pre-eclampsia/eclampsia was associated with a breast cancer rate ratio of 0.24 (95% confidence interval 0.09-0.70, p = 0.01). Linear trends for breast cancer incidence with increasing birth weight, birth length, and placental weight were positive but not significant. Thus, prenatal factors are important in breast carcinogenesis. Concentrations of pregnancy oestrogens may be one such factor, but other prenatal or perinatal factors cannot be excluded.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	EKBOM, A (corresponding author), UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, S-75185 UPPSALA, SWEDEN.							ALBANES D, 1988, JNCI-J NATL CANCER I, V80, P772, DOI 10.1093/jnci/80.10.772; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BERSTEIN LM, 1988, ADV CANCER RES, V50, P231, DOI 10.1016/S0065-230X(08)60439-X; COLE P, 1969, LANCET, V1, P604; Davies AM., 1983, OBSTETRICAL EPIDEMIO, P167; Davis W, 1980, IARC SCI PUBL, V32, P192; DEWAARD F, 1988, INT J CANCER, V41, P666, DOI 10.1002/ijc.2910410505; EKBOM A, 1991, AM J EPIDEMIOL, V134, P876, DOI 10.1093/oxfordjournals.aje.a116162; GANT NF, 1971, AM J OBSTET GYNECOL, V111, P555, DOI 10.1016/0002-9378(71)90472-8; GAROFF L, 1976, AM J OBSTET GYNECOL, V126, P1027, DOI 10.1016/0002-9378(76)90696-7; GERHARD I, 1987, EUR J OBSTET GYN R B, V26, P313, DOI 10.1016/0028-2243(87)90129-8; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; Gluckman P.D., 1986, OXF REV REPROD BIOL, V8, P1; HSIEH CC, 1991, CANCER CAUSE CONTROL, V2, P95, DOI 10.1007/BF00053127; HSIEH CC, 1991, EUR J CANCER, V27, P131, DOI 10.1016/0277-5379(91)90469-T; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P5; KLOPPER A, 1975, J STEROID BIOCHEM, V6, P651, DOI 10.1016/0022-4731(75)90047-3; LONG PA, 1979, AM J OBSTET GYNECOL, V135, P344, DOI 10.1016/0002-9378(79)90702-6; LUNDE AS, 1980, PHS801358 DEP HLTH H, P5; MARSHALL JR, 1989, STAT MED, V8, P1041, DOI 10.1002/sim.4780080904; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011; ROSING U, 1984, GYNECOL OBSTET INVES, V18, P199, DOI 10.1159/000299081; SANDSON TA, 1992, LANCET, V339, P523, DOI 10.1016/0140-6736(92)90341-Y; TAMBYRAJA RL, 1981, TWIN RES 3 A, V69, P189; THOMPSON JA, 1990, EPIDEMIOLOGY, V1, P101; THOMPSON WD, 1989, JNCI-J NATL CANCER I, V81, P1571, DOI 10.1093/jnci/81.20.1571; Thomson AM, 1983, OBSTETRICAL EPIDEMIO, P89; Tomatis L, 1989, IARC Sci Publ, P1; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; YEN SSC, 1989, MATERNAL FETAL MED P, P375; 1990, CANCER INCIDENCE SWE	35	299	303	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					1015	1018		10.1016/0140-6736(92)93019-J	http://dx.doi.org/10.1016/0140-6736(92)93019-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357410				2022-12-24	WOS:A1992JV01400012
J	RESNICK, JL; BIXLER, LS; CHENG, LZ; DONOVAN, PJ				RESNICK, JL; BIXLER, LS; CHENG, LZ; DONOVAN, PJ			LONG-TERM PROLIFERATION OF MOUSE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							DIFFERENTIATION INHIBITING ACTIVITY; EMBRYOS; GROWTH	PRIMORDIAL germ cells(PGCs) are first identifiable as a population of about eight alkaline phosphatase-positive cells in the 7.0 days postcoitum mouse embryo1. During the next 6 days of development they proliferate to give rise to the 25,000 cells that will establish the meiotic population2. Steel factor is required for PGC survival both in vivo3 and in vitro4,5 and together with leukaemia inhibitory factor stimulates PGC proliferation in vitro6. In feeder-dependent culture, PGCs will proliferate for up to 7 days, but their numbers eventually decline and their proliferative capacity is only a fraction of that seen in vivo6,7. Here we report a further factor that stimulates PGC proliferation in vitro, basic fibroblast growth factor (bFGF). Furthermore, bFGF, in the presence of steel factor and leukaemia inhibitory factor, stimulates long-term proliferation of PGCs, leading to the derivation of large colonies of cells. These embryonic germ cells resemble embryonic stem cells, pluripotent cells derived from preimplantation embryos, or feeder-dependent embryonal carcinoma cells, pluripotent stem cells of PGC-derived tumours (teratomas and teratocarcinomas)8. To our knowledge, these results provide the first system for long-term culture of PGCs.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	RESNICK, JL (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,POB B,FREDERICK,MD 21702, USA.							BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; KOOPMAN P, 1984, EXP CELL RES, V154, P233, DOI 10.1016/0014-4827(84)90683-9; MARTIN GR, 1983, TERATOCARCINOMA STEM, P635; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299	16	680	767	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					550	551		10.1038/359550a0	http://dx.doi.org/10.1038/359550a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1383830				2022-12-24	WOS:A1992JR85900064
J	KOFF, A; GIORDANO, A; DESAI, D; YAMASHITA, K; HARPER, JW; ELLEDGE, S; NISHIMOTO, T; MORGAN, DO; FRANZA, BR; ROBERTS, JM				KOFF, A; GIORDANO, A; DESAI, D; YAMASHITA, K; HARPER, JW; ELLEDGE, S; NISHIMOTO, T; MORGAN, DO; FRANZA, BR; ROBERTS, JM			FORMATION AND ACTIVATION OF A CYCLIN E-CDK2 COMPLEX DURING THE G(1)-PHASE OF THE HUMAN CELL-CYCLE	SCIENCE			English	Article							CLN FUNCTION; YEAST; GENE	Human cyclin E, originally identified on the basis of its ability to function as a G1 cyclin in budding yeast, associated with a cell cycle-regulated protein kinase in human cells. The cyclin E-associated kinase activity peaked during G1, before the appearance of cyclin A, and was diminished during exit from the cell cycle after differentiation or serum withdrawal. The major cyclin E-associated kinase in human cells was Cdk2 (cyclin-dependent kinase 2). The abundance of the cyclin E protein and the cyclin E-Cdk2 complex was maximal in G1 cells. These results provide further evidence that in all eukaryotes assembly of a cyclin-Cdk complex is an important step in the biochemical pathway that controls cell proliferation during G1.	COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOLEC BIOL, FUKUOKA 812, JAPAN; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Cold Spring Harbor Laboratory; University of California System; University of California San Francisco; Kyushu University; Baylor College of Medicine	KOFF, A (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Morgan, David/0000-0001-8753-4416; Harper, Jeffrey/0000-0002-6944-7236				DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FRANZA BR, UNPUB; GARRELS JI, 1989, J BIOL CHEM, V264, P5823; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, UNPUB; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OHTSUBO M, UNPUB; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	1023	1058	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1689	1694		10.1126/science.1388288	http://dx.doi.org/10.1126/science.1388288			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1388288				2022-12-24	WOS:A1992JN50100033
J	BURNASHEV, N; SCHOEPFER, R; MONYER, H; RUPPERSBERG, JP; GUNTHER, W; SEEBURG, PH; SAKMANN, B				BURNASHEV, N; SCHOEPFER, R; MONYER, H; RUPPERSBERG, JP; GUNTHER, W; SEEBURG, PH; SAKMANN, B			CONTROL BY ASPARAGINE RESIDUES OF CALCIUM PERMEABILITY AND MAGNESIUM BLOCKADE IN THE NMDA RECEPTOR	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; GLUTAMATE-ACTIVATED CHANNELS; VOLTAGE-DEPENDENT BLOCK; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; D-ASPARTATE RESPONSES; AMINO-ACID RECEPTORS; MOLECULAR-CLONING; DIVALENT-CATIONS	The N-methyl-D-aspartate (NMDA) receptor forms a cation-selective channel with a high calcium permeability and sensitivity to channel block by extracellular magnesium. These properties, which are believed to be important for the induction of long-term changes in synaptic strength, are imparted by asparagine residues in a putative channel-forming segment of the protein, transmembrane 2 (TM2). In the NR1 subunit, replacement of this asparagine by a glutamine residue decreases calcium permeability of the channel and slightly reduces magnesium block. The same substitution in NR2 subunits strongly reduces magnesium block and increases the magnesium permeability but barely affects calcium permeability. These asparagines are in a position homologous to the site in the TM2 region (Q/R site) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors that is occupied by either glutamine (Q) or arginine (R) and that controls divalent cation permeability of the AMPA receptor channel. Hence AMPA and NMDA receptor channels contain common structural motifs in their TM2 segments that are responsible for some of their ion selectivity and conductance properties.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749				ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOL D, 1987, J NEUROSCI, V7, P369; CHOL DW, 1988, NEURON, V1, P623; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DINGLEDINE R, 1988, CRIT REV NEUROBIOL, V4, P1; GIBB AJ, IN PRESS J PHYSL LON; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VILLARROEL A, IN PRESS P R SOC L B	36	346	351	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1415	1419		10.1126/science.1382314	http://dx.doi.org/10.1126/science.1382314			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382314				2022-12-24	WOS:A1992JL61200039
J	BARNES, DM; HANBY, AM; GILLETT, CE; MOHAMMED, S; HODGSON, S; BOBROW, LG; LEIGH, IM; PURKIS, T; MACGEOCH, C; SPURR, NK; BARTEK, J; VOJTESEK, B; PICKSLEY, SM; LANE, DP				BARNES, DM; HANBY, AM; GILLETT, CE; MOHAMMED, S; HODGSON, S; BOBROW, LG; LEIGH, IM; PURKIS, T; MACGEOCH, C; SPURR, NK; BARTEK, J; VOJTESEK, B; PICKSLEY, SM; LANE, DP			ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT	LANCET			English	Article							LI-FRAUMENI SYNDROME; SKIN FIBROBLASTS; P53; MUTATIONS; ONCOGENE; COLON; DNA	Mutations in the p53 gene are the commonest specific genetic change in human cancer. In normal tissues, p53 protein is present in such low quantities that it is not readily detectable by immunochemical techniques. However, in many tumour cells large amounts of p53 protein accumulate and can be seen by simple immunohistochemical staining; this is generally attributed to the accumulation of stabilised, mutant protein. We have found a mother and daughter, who both have a history of breast cancer, who show strong immunohistochemical staining of p53 in most of their normal epithelial and mesenchymal cells. Their family has a history of multiple cancers developing at an early age. Detailed protein analysis and gene sequencing of material obtained from cultured cells, grown from a skin biopsy taken from the daughter, suggest that her cells contained large quantities of normal (unmutated) p53. We suggest that this phenotype defines a new inherited cancer susceptibility syndrome that is distinct from the germ-line mutations in p53 found in some Li-Fraumeni families. This new syndrome affects p53 tumour suppressor function through an indirect mechanism that stabilises normal p53. It remains to be established whether this mechanism also contributes to the accumulation of p53 in sporadic cancers.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; ROYAL LONDON HOSP, IMPERIAL CANC RES FUND, SKIN LAB, LONDON, ENGLAND; INST HEMATOL & BLOOD TRANSFUS, PRAGUE 10, CZECHOSLOVAKIA; GUYS HOSP, IMPERIAL CANC RES FUND, CLIN ONCOL UNIT, LONDON SE1 9RT, ENGLAND; IMPERIAL CANC RES FUND, HISTOPATHOL UNIT, LONDON WC2A 3PX, ENGLAND; GUYS HOSP, CLIN GENET UNIT, LONDON SE1 9RT, ENGLAND; CLARE HALL LABS, POTTERS BAR, ENGLAND	University of Dundee; Barts Health NHS Trust; Royal London Hospital; Cancer Research UK; Institute of Hematology Prague; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014					BARTEK J, 1990, ONCOGENE, V5, P893; BENNETT WP, 1991, ONCOGENE, V6, P1779; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HARLOW E, 1988, ANTIBODIES LABORATOR; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KASTAN MB, 1991, CANCER RES, V51, P6304; KOPELOVICH L, 1984, CANCER INVEST, V2, P333, DOI 10.3109/07357908409040309; KOPELOVICH L, 1986, J NATL CANCER I, V77, P1241; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARKS JR, 1991, CANCER RES, V51, P2979; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIDGLEY CA, 1992, J CELL SCI, V101, P183; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WARREN W, 1992, ONCOGENE, V7, P1043	23	230	230	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1992	340	8814					259	263		10.1016/0140-6736(92)92354-I	http://dx.doi.org/10.1016/0140-6736(92)92354-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353190				2022-12-24	WOS:A1992JG66500002
J	GRANAI, CO				GRANAI, CO			OVARIAN-CANCER - UNREALISTIC EXPECTATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CA-125 LEVELS; SERUM CA-125; CARCINOMA; AGENT; NEOPLASMS; TUMORS; TAXOL				GRANAI, CO (corresponding author), BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,PROVIDENCE,RI 02905, USA.							ALBERTS DS, 1988, SEMIN ONCOL, V15, P22; ANDOLF E, 1990, OBSTET GYNECOL, V75, P106; [Anonymous], 1991, J CLIN ONCOL, V9, P1668; BAKER TR, 1991, FEMALE PATIENT, V16, P49; BARBER HRK, 1990, FEMALE PATIENT, V15, P11; BELINSON JL, 1990, GYNECOL ONCOL, V37, P66, DOI 10.1016/0090-8258(90)90310-H; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; Chabner B. A., 1991, TAXOL PRINCIPLES PRA, V5, P1; CHEN DX, 1990, OBSTET GYNECOL, V75, P701; CHEN DX, 1988, OBSTET GYNECOL, V72, P23; EINZIG A I, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P187; HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O; HENAHAN JF, 1990, ONCOLOGY BIOTECH AUG, P1; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KREBS HB, 1986, OBSTET GYNECOL, V67, P473; MANETTA A, 1990, GYNECOL ONCOL, V36, P93, DOI 10.1016/0090-8258(90)90115-2; MARECHAL F, 1989, ANTICANCER RES, V9, P593; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; PIVER MS, 1990, GILDA RADNER FAMILIA; PODESTA JS, 1991, PEOPLE          0603, P76; ROWINSKY EK, 1991, J NATL CANCER I, V83, P1778, DOI 10.1093/jnci/83.24.1778; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Song J I, 1991, JAMA, V266, P1281, DOI 10.1001/jama.266.9.1281; STTLE G, 1990, CANCER MANUAL, P245; SUTTON GP, 1989, J CLIN ONCOL, V7, P1672, DOI 10.1200/JCO.1989.7.11.1672; SUTTON GP, 1989, J CLIN ONCOL, V7, P23; SWANSON RA, 1990, LAB LINE         JUL, P2; THIGPEN T, 1990, P AN M AM SOC CLIN, V9, P156; van Nagell J R Jr, 1991, Gynecol Oncol, V43, P89, DOI 10.1016/0090-8258(91)90050-F; VANNAGELL JR, 1991, CANCER, V68, P679, DOI 10.1002/1097-0142(19910815)68:4<679::AID-CNCR2820680402>3.0.CO;2-J; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VARDI JR, 1989, OBSTET GYNECOL, V74, P379; ZURAWSKI VR, 1990, 10TH ANN M NEW ENGL; 1989, CLIN GYNECOLOGIC ONC, P328; 1991, ACOG NEWSLETTER  FEB, P8; 1989, CLIN GYNECOLOGIC ONC, V335, P392; 1990, CANCER FACTS FIGURES, P11; 1991, PROVIDENCE J B, pA21; 1991, BMJ, V303, P884; 1980, TIME            0331, P60	44	31	31	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					197	200		10.1056/NEJM199207163270313	http://dx.doi.org/10.1056/NEJM199207163270313			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1351658				2022-12-24	WOS:A1992JD31900013
J	ROTHSTEIN, JD; MARTIN, LJ; KUNCL, RW				ROTHSTEIN, JD; MARTIN, LJ; KUNCL, RW			DECREASED GLUTAMATE TRANSPORT BY THE BRAIN AND SPINAL-CORD IN AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXCITATORY AMINO-ACIDS; HUNTINGTONS-DISEASE; RAT STRIATUM; D-ASPARTATE; NEUROTOXICITY; INHIBITION; RECEPTORS; DEHYDROGENASE; SYNAPTOSOMES; QUISQUALATE	Background. Amyotrophic lateral sclerosis (ALS) is a chronic degenerative neurologic disorder characterized by the death of motor neurons in the cerebral cortex and spinal cord. Recent studies have suggested that the metabolism of glutamate, a potentially neurotoxic amino acid, is abnormal in patients with ALS. We hypothesized that the high-affinity glutamate transporter is the site of the defect. Methods. We measured high-affinity, sodium-dependent glutamate transport in synaptosomes from neural tissue obtained from 13 patients with ALS, 17 patients with no neurologic disease, and 27 patients with other neurodegenerative diseases (Alzheimer's disease in 15 patients and Huntington's disease in 12 patients). The groups were comparable with respect to age and the interval between death and autopsy. Synaptosomes were prepared from spinal cord, motor cortex, sensory cortex, visual cortex, striatum, and hippocampus. We also measured sodium-dependent transport of gamma-aminobutyric acid and phenylalanine in the synaptosomal preparations. Results. In patients with ALS, there was a marked decrease in the maximal velocity of transport for high-affinity glutamate uptake in synaptosomes from spinal cord (-59 percent, P < 0.001), motor cortex (-70 percent, P < 0.001), and somatosensory cortex (-39 percent, P < 0.05), but not in those from visual cortex, striatum, or hippocampus. The affinity of the transporter for glutamate was not altered. No abnormalities in glutamate transport were found in synaptosomes from patients with other chronic neurodegenerative disorders. The transport of gamma-aminobutyric acid and phenylalanine was normal in patients with ALS. Conclusions. ALS is associated with a defect in high-affinity glutamate transport that has disease, region, and chemical specificity. Defects in the clearance of extracellular glutamate because of a faulty transporter could lead to neurotoxic levels of extracellular glutamate and thus be pathogenic in ALS.	JOHNS HOPKINS UNIV,DEPT NEUROPATHOL,BALTIMORE,MD 21205	Johns Hopkins University	ROTHSTEIN, JD (corresponding author), JOHNS HOPKINS UNIV,DEPT NEUROL,MEYER 5-119,600 N WOLFE ST,BALTIMORE,MD 21205, USA.		rothstein, jeffrey d/C-9470-2013		NINDS NIH HHS [NS30086, NS01355] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030086, K08NS001355] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALCAR VJ, 1977, J NEUROCHEM, V28, P1145, DOI 10.1111/j.1471-4159.1977.tb10682.x; BEBIN EM, 1990, ARCH NEUROL-CHICAGO, V47, P188, DOI 10.1001/archneur.1990.00530020094021; BENJAMIN AM, 1980, J NEUROCHEM, V35, P67, DOI 10.1111/j.1471-4159.1980.tb12490.x; CHASE RA, 1985, NEUROSCI LETT, V55, P89, DOI 10.1016/0304-3940(85)90317-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DEBELLEROCHE J, 1984, NEUROCHEM PATHOL, V2, P1; ERECINSKA M, 1990, J NEUROCHEM, V54, P1335, DOI 10.1111/j.1471-4159.1990.tb01967.x; FLETCHER EJ, 1988, BRIT J PHARMACOL, V95, P585, DOI 10.1111/j.1476-5381.1988.tb11680.x; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; HARDY JA, 1986, J NEUROCHEM, V47, P460; Hughes J T, 1982, Adv Neurol, V36, P61; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MCBEAN GJ, 1985, J NEUROCHEM, V44, P247, DOI 10.1111/j.1471-4159.1985.tb07137.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PERRY TL, 1990, NEUROLOGY, V40, P20, DOI 10.1212/WNL.40.1.20; PERRY TL, 1987, NEUROLOGY, V37, P1845, DOI 10.1212/WNL.37.12.1845; PLAITAKIS A, 1980, ANN NEUROL, V7, P297, DOI 10.1002/ana.410070403; PLAITAKIS A, 1988, LANCET, V1, P1015; PLAITAKIS A, 1988, ANN NEUROL, V24, P446, DOI 10.1002/ana.410240314; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROTHSTEIN JD, 1985, BIOCHEM PHARMACOL, V34, P73, DOI 10.1016/0006-2952(85)90102-9; ROTHSTEIN JD, 1991, ANN NEUROL, V30, P224, DOI 10.1002/ana.410300223; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; SCHWARCZ R, 1982, NEUROSCIENCE, V7, P1771, DOI 10.1016/0306-4522(82)90034-3; SHAW PJ, 1991, BRAIN RES, V539, P164, DOI 10.1016/0006-8993(91)90701-V; SIMPSON MDC, 1988, BRAIN RES, V462, P76, DOI 10.1016/0006-8993(88)90587-2; SPINK DC, 1986, ANAL BIOCHEM, V158, P79, DOI 10.1016/0003-2697(86)90592-0; STEVENS TJ, 1983, IBRO HDB SERIES METH, V2, P171; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TESTA D, 1989, J NEUROL, V236, P445, DOI 10.1007/BF00328503; TSAI GC, 1991, BRAIN RES, V556, P151, DOI 10.1016/0006-8993(91)90560-I; URCA G, 1990, BRAIN RES, V529, P7, DOI 10.1016/0006-8993(90)90805-L; VINCENT SR, 1980, BRAIN RES, V184, P99, DOI 10.1016/0006-8993(80)90589-2; WEISS JH, 1989, BRAIN RES, V497, P64, DOI 10.1016/0006-8993(89)90970-0; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762; ZISKINDCONHAIM L, 1990, J NEUROSCI, V10, P125	38	1022	1041	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1464	1468		10.1056/NEJM199205283262204	http://dx.doi.org/10.1056/NEJM199205283262204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1349424	Bronze			2022-12-24	WOS:A1992HV46900004
J	KAKOURIS, H; EDDIE, LW; SUMMERS, RJ				KAKOURIS, H; EDDIE, LW; SUMMERS, RJ			CARDIAC EFFECTS OF RELAXIN IN RATS	LANCET			English	Article							CULTURE; UTERUS	Relaxin is usually considered to be a hormone of pregnancy, but porcine relaxin has been shown to increase heart rate in rats. We investigated the cardiac effects of synthetic human gene-2 relaxin (hRlx-2) in vitro in isolated rat atria. Synthetic hRlx-2 produced concentration-dependent positive chronotropic effects in spontaneously beating right atria (EC50 [concentration required to produce 50% of the maximal response] = 0.09 [SE 0.03] nmol/l) and concentration-dependent positive inotropic effects in electrically driven left atria (EC50 = 0.31 [0.02] nmol/l). The potency of hRlx-2 is greater than that of endothelin, angiotensin II, and (-)-isoprenaline in isolated rat atria. Relaxin has powerful chronotropic and inotropic effects on the heart that are probably mediated through a direct action on relaxin receptors.	UNIV MELBOURNE,DEPT PHARMACOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,HOWARD FLOREY INST EXPTL PHYSIOL & MED,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne			Summers, Roger J/F-6351-2011	Summers, Roger J/0000-0002-8367-4056				BELL RJ, 1987, OBSTET GYNECOL, V69, P585; HSU CJ, 1985, ENDOCRINOLOGY, V116, P2029, DOI 10.1210/endo-116-5-2029; KRAMER SM, 1990, IN VITRO CELL DEV B, V26, P647; LANGMAN J, 1981, MED EMBRYOLOGY, P74; OSHEROFF PL, IN PRESS P NATL ACAD; PARRY LJ, 1990, J NEUROENDOCRINOL, V2, P53, DOI 10.1111/j.1365-2826.1990.tb00392.x; SANBORN BM, 1980, ENDOCRINOLOGY, V106, P1210, DOI 10.1210/endo-106-4-1210; Sherwood O.D., 1988, P585; STLOUIS J, 1983, BIOL RELAXIN ITS ROL, P128; WEISS G, 1989, BIOL REPROD, V40, P197, DOI 10.1095/biolreprod40.2.197	10	104	106	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1076	1078		10.1016/0140-6736(92)90665-P	http://dx.doi.org/10.1016/0140-6736(92)90665-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349104				2022-12-24	WOS:A1992HR44600004
J	SINGH, BM; JACKSON, DMA; WILLS, R; DAVIES, J; WISE, PH				SINGH, BM; JACKSON, DMA; WILLS, R; DAVIES, J; WISE, PH			DELAYED DIAGNOSIS IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	BRITISH MEDICAL JOURNAL			English	Article											SINGH, BM (corresponding author), CHARING CROSS HOSP,DEPT ENDOCRINOL,LONDON W6 8RF,ENGLAND.							Hillson R M, 1985, Diabet Med, V2, P383; JACKSON DMA, 1991, DIABETIC MED, V8, P971, DOI 10.1111/j.1464-5491.1991.tb01540.x; KNUIMAN MW, 1986, DIABETES, V35, P1332, DOI 10.2337/diabetes.35.12.1332; MINCU I, 1970, MED INTERNAT, V304, P1331; 1990, WHO TECH REP SER, P646	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1154	1155		10.1136/bmj.304.6835.1154	http://dx.doi.org/10.1136/bmj.304.6835.1154			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392794	Green Published, Bronze			2022-12-24	WOS:A1992HT23200022
J	FANTL, WJ; ESCOBEDO, JA; MARTIN, GA; TURCK, CW; DELROSARIO, M; MCCORMICK, F; WILLIAMS, LT				FANTL, WJ; ESCOBEDO, JA; MARTIN, GA; TURCK, CW; DELROSARIO, M; MCCORMICK, F; WILLIAMS, LT			DISTINCT PHOSPHOTYROSINES ON A GROWTH-FACTOR RECEPTOR BIND TO SPECIFIC MOLECULES THAT MEDIATE DIFFERENT SIGNALING PATHWAYS	CELL			English	Article							PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; FACTOR-I RECEPTOR; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; PDGF BETA-RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; ONCOGENE PRODUCT; PHOSPHORYLATION; TRANSDUCTION	The receptor for platelet-derived growth factor (PDGF) binds two proteins containing SH2 domains, GTPase activating protein (GAP) and phosphatidylinositol 3-kinase (Pl3-kinase). The sites on the receptor that mediate this interaction were identified by using phosphotyrosine-containing peptides representing receptor sequences to block specifically binding of either Pl3-kinase or GAP. These results suggested that Pl3-kinase binds two phosphotyrosine residues, each located in a 5 aa motif with an essential methionine at the fourth position C-terminal to the tyrosine. Point mutations at these sites caused a selective elimination of Pl3-kinase binding and loss of PDGF-stimulated DNA synthesis. Mutation of the binding site for GAP prevented the receptor from associating with or phosphorylating GAP, but had no effect on Pl3-kinase binding and little effect on DNA synthesis. Therefore, GAP and Pl3-kinase interact with the receptor by binding to different phosphotyrosine-containing sequence motifs.	CETUS CORP, EMERYVILLE, CA 94608 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	FANTL, WJ (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA51992-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL-32898] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COUGHLIN SR, 1989, SCIENCE, V243, P1191; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EK B, 1982, J BIOL CHEM, V257, P486; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Summers MD, 1987, MANUAL METHODS BACUL; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TURCK CW, 1992, IN PRESS PEPTIDE RES; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	46	630	703	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					413	423		10.1016/0092-8674(92)90444-H	http://dx.doi.org/10.1016/0092-8674(92)90444-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1374684				2022-12-24	WOS:A1992HT07800005
J	KONG, XP; ONRUST, R; ODONNELL, M; KURIYAN, J				KONG, XP; ONRUST, R; ODONNELL, M; KURIYAN, J			3-DIMENSIONAL STRUCTURE OF THE BETA-SUBUNIT OF ESCHERICHIA-COLI DNA POLYMERASE-III HOLOENZYME - A SLIDING DNA CLAMP	CELL			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; ACCESSORY PROTEINS; PRIMED TEMPLATE; REPLICATION; REFINEMENT; CRYSTALLOGRAPHY; CLONING; BINDING; COMPLEX	The crystal structure of the beta-subunit (processivity factor) of DNA polymerase III holoenzyme has been determined at 2.5 angstrom resolution. A dimer of the beta-subunit (M(r) = 2 x 40.6 kd, 2 x 366 amino acid residues) forms a ring-shaped structure lined by 12-alpha-helices that can encircle duplex DNA. The structure is highly symmetrical, with each monomer containing three domains of identical topology. The charge distribution and orientation of the helices indicate that the molecule functions by forming a tight clamp that can slide on DNA, as shown biochemically. A potential structural relationship is suggested between the beta-subunit and proliferating cell nuclear antigen (PCNA, the eukaryotic polymerase-delta [and epsilon] processivity factor), and the gene 45 protein of the bacteriophage T4 DNA polymerase.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, HEARST RES CTR, DEPT MICROBIOL, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University; Cornell University; Howard Hughes Medical Institute	KONG, XP (corresponding author), ROCKEFELLER UNIV, MOLEC BIOPHYS LAB, NEW YORK, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38839, GM 43094] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; Arndt U. W., 1977, ROTATION METHOD CRYS; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1988, XPLOR VERSION 22 MAN; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; FAY PJ, 1981, J BIOL CHEM, V256, P976; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kornberg A., 1991, DNA REPLICATION; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MAKI S, 1988, J BIOL CHEM, V263, P6561; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; NOSSAL NG, 1984, BACTERIOPHAGE T4; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511	44	661	675	2	35	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					425	437		10.1016/0092-8674(92)90445-I	http://dx.doi.org/10.1016/0092-8674(92)90445-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1349852				2022-12-24	WOS:A1992HT07800006
J	JOPLIN, R; LINDSAY, JG; JOHNSON, GD; STRAIN, A; NEUBERGER, J				JOPLIN, R; LINDSAY, JG; JOHNSON, GD; STRAIN, A; NEUBERGER, J			MEMBRANE DIHYDROLIPOAMIDE ACETYLTRANSFERASE (E2) ON HUMAN BILIARY EPITHELIAL-CELLS IN PRIMARY BILIARY-CIRRHOSIS	LANCET			English	Note							CULTURE; LIVER	Primary biliary cirrhosis (PBC) is associated with serum antibodies that react with the dihydrolipoamide acetyltransferase component (E2) of the mitochondrial pyruvate dehydrogenase complex. We have sought the presence of E2 on the surface of human intrahepatic biliary epithelial cells (BEC). Cultured BECs from PBC but not normal liver were found to have E2 on the membrane after three days' culture. Isolated, viable cells examined by laser-scanning confocal microscopy revealed the pattern of E2 staining on the membrane to be similar to that seen with the membrane glycoprotein marker, HEA-125. By contrast, BECs from normal liver showed membrane staining only with HEA-125. When BECs were fixed before incubation with antibody to E2, cytoplasmic staining was observed. Our results suggest that E2 is present on the surface of biliary epithelial cells in PBC, and support the idea of a pathogenetic association between antimitochondrial antibodies and bileduct damage.	QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND	University of Birmingham; University of Birmingham; University of Glasgow			Neuberger, James/ABG-3010-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; GERKEN G, 1988, HEPATOLOGY, V8, P705; GHADIMINEJAD I, 1987, HEPATOLOGY, V7, P743, DOI 10.1002/hep.1840070421; HUNTER A, 1989, EUR J BIOCHEM, V155, P103; JOPLIN R, 1989, IN VITRO CELL DEV B, V25, P1189; JOPLIN R, 1990, J PATHOL, V162, P255, DOI 10.1002/path.1711620312; JOPLIN R, 1991, HEPATOLOGY, V14, P442, DOI 10.1016/0270-9139(91)90181-T; KRAMS SM, 1989, HEPATOLOGY, V9, P414; VANDEWATER R, 1991, J IMMUNOL, V146, P89; YEAMAN SJ, 1986, TRENDS BIOCHEM SCI, V11, P293, DOI 10.1016/0968-0004(86)90033-2	10	94	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					93	94		10.1016/0140-6736(92)91001-O	http://dx.doi.org/10.1016/0140-6736(92)91001-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1370237				2022-12-24	WOS:A1992GZ15600005
J	BARBIR, M; KUSHWAHA, S; HUNT, B; MACKEN, A; THOMPSON, GR; MITCHELL, A; ROBINSON, D; YACOUB, M				BARBIR, M; KUSHWAHA, S; HUNT, B; MACKEN, A; THOMPSON, GR; MITCHELL, A; ROBINSON, D; YACOUB, M			LIPOPROTEIN(A) AND ACCELERATED CORONARY-ARTERY DISEASE IN CARDIAC TRANSPLANT RECIPIENTS	LANCET			English	Article								High concentrations of serum lipoprotein(a) (Lp(a)) are associated with an increased risk of atherosclerotic vascular disease in the non-transplanted population. However its relation with accelerated coronary artery disease (CAD) in cardiac transplant recipients has not been reported. We measured serum Lp(a) in 130 cardiac transplant recipients undergoing routine follow-up, which included annual coronary angiography. The median Lp (a) concentration in 33 patients with CAD was 71 mg/dl, which was significantly higher than the corresponding value of 22 mg/dL in the 97 patients without CAD (p = 0.0006). Multivariant analysis showed the serum Lp(a) value to be a higher significant risk factor for CAD irrespective of the other factors included in the regression analysis. Thus a high concentration of serum Lp(a) is an important, independent risk factor for the development of accelerated CAD in transplant recipients.	HAREFIELD HOSP,THORAC & CARDIAC SURG UNIT,UXBRIDGE UB9 6JH,MIDDX,ENGLAND; HAMMERSMITH HOSP,MRC LIPOPROT TEAM,LONDON W12 0HS,ENGLAND; UNIV SUSSEX,SCH MATH & PHYS SCI,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London; University of Sussex	YACOUB, M (corresponding author), HAREFIELD HOSP,THORAC & CARDIAC SURG UNIT,UXBRIDGE UB9 6JH,MIDDX,ENGLAND.							ALONSO DR, 1977, AM J PATHOL, V87, P415; Altman DG, 1991, PRACTICAL STATISTICS; BARBIR M, 1991, INT J CARDIOL, V32, P51, DOI 10.1016/0167-5273(91)90043-O; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; GAO SZ, 1989, AM J CARDIOL, V64, P1093, DOI 10.1016/0002-9149(89)90858-8; GENEST J, 1991, AM J CARDIOL, V67, P1039, DOI 10.1016/0002-9149(91)90862-F; HESS ML, 1983, CIRCULATION, V68, P94; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; SCHROEDER JS, 1986, NEW ENGL J MED, V315, P961, DOI 10.1056/NEJM198610093151511; SCOTT J, 1991, BRIT MED J, V303, P663, DOI 10.1136/bmj.303.6804.663; STEINBERG D, 1989, NEW ENGL J MED, V320, P1915; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827; WINTER GL, 1990, J HEART TRANSPLANT, V9, P367	16	77	79	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1500	1502		10.1016/0140-6736(92)92756-6	http://dx.doi.org/10.1016/0140-6736(92)92756-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361597				2022-12-24	WOS:A1992KD06900005
J	DAGAN, R; ENGLEHARD, D; PICCARD, E				DAGAN, R; ENGLEHARD, D; PICCARD, E			EPIDEMIOLOGY OF INVASIVE CHILDHOOD PNEUMOCOCCAL INFECTIONS IN ISRAEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCUS-PNEUMONIAE; SEROTYPE DISTRIBUTION; BACTERIAL-MENINGITIS; ANTIMICROBIAL RESISTANCE; POLYSACCHARIDE VACCINE; CEREBROSPINAL-FLUID; CHARLESTON COUNTY; RESPIRATORY-TRACT; SOUTH-CAROLINA; UNITED-STATES	Objective.-To study the epidemiology of childhood pneumococcal invasive infections in Israel as a background for immunization programs. Design.-A 2-year (October 1988 through September 1990) prospective, nationwide surveillance of all invasive pediatric pneumococcal infections. Setting.-All 25 medical centers hospitalizing children in Israel, including all laboratories performing blood cultures from pediatric patients. Patients.-Infants and children aged 0 to 12 years visiting the pediatric emergency department or hospitalized in pediatric departments were included if Streptococcus pneumoniae was isolated from blood or cerebrospinal fluid. Results.-Four hundred sixty-nine invasive infections were diagnosed. Pneumonia, bacteremia without apparent focus, meningitis, and cellulitis were found in 39%, 37%, 17%, and 3%, respectively. The annual incidence was 42 per 100 000 for children younger than 5 years of age (104 per 100 000 for those <12 months old). The two most common serotypes were 1 and 5, which are rare in Western 'Europe and North America. Eight groups comprised 82% of all invasive infections. Extrapolated to a population in which 100 000 live births occur yearly, the total annual hospitalizations for pneumococci infections was calculated to be 1928 days. The overall case-fatality rate was 2.2%, but it was 30% during the first month of life. Conclusions.-Pneumococcal invasive infections are common in children in Israel and carry considerable morbidity.	HADASSAH MED CTR,DEPT PEDIAT,JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,IL-84105 BEER SHEVA,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Ben Gurion University	DAGAN, R (corresponding author), BEN GURION UNIV NEGEV,PEDIAT INFECT DIS UNIT,SOROKA MED CTR,POB 151,IL-84105 BEER SHEVA,ISRAEL.							ANDERSEN AH, 1989, IEEE T MED IMAGING, V8, P50, DOI 10.1109/42.20361; AUSTRIAN R, 1981, REV INFECT DIS, V3, pS1; BAIRD DR, 1976, LANCET, V2, P1344; BARKER J, 1989, J INFECT DIS, V159, P348, DOI 10.1093/infdis/159.2.348; Baron EJ, 1990, BAILEY SCOTTS DIAGNO, P333; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BRIMBLECOMBE FSW, 1958, BRIT MED J, V1, P119, DOI 10.1136/bmj.1.5063.119; BURKE JP, 1971, AM J DIS CHILD, V121, P353, DOI 10.1001/archpedi.1971.02100150127021; BURMAN LA, 1986, SCAND J INFECT DIS, V18, P45, DOI 10.3109/00365548609032305; BURMAN LA, 1985, REV INFECT DIS, V7, P133; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; FENOLL A, 1991, REV INFECT DIS, V13, P56; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; GIEBINK GS, 1985, PEDIATR INFECT DIS J, V4, P343, DOI 10.1097/00006454-198507000-00001; GRAY BM, 1979, J INFECT DIS, V140, P979, DOI 10.1093/infdis/140.6.979; GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009; GREENWOOD BM, 1980, LANCET, V1, P360; GUIRGUIS N, 1983, B WORLD HEALTH ORGAN, V61, P517; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; JACOBS NM, 1979, PEDIATRICS, V64, P296; JETTE LP, 1989, J CLIN MICROBIOL, V27, P1; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KLUGMAN KP, 1988, J INFECT DIS, V158, P956, DOI 10.1093/infdis/158.5.956; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; LAFONG AC, 1988, J INFECTION, V16, P235, DOI 10.1016/S0163-4453(88)97556-1; LEIONEN M, 1986, PEDIAT INFECT DIS, V5, P39; LODA FA, 1975, J PEDIATR-US, V87, P1087, DOI 10.1016/S0022-3476(75)80120-X; LUND E, 1970, ACTA PATHOLOG MICROB, V78, P333; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; ONYEMELUKWE GC, 1983, J INFECTION, V5, P157; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; ROGOT E, 1976, AM J EPIDEMIOL, V103, P198, DOI 10.1093/oxfordjournals.aje.a112218; SARNAIK S, 1990, PEDIATR INFECT DIS J, V9, P181, DOI 10.1097/00006454-199003000-00007; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SCHWARZMANN SW, 1971, ARCH INTERN MED, V127, P1037, DOI 10.1001/archinte.127.6.1037; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; STATES SJ, 1977, INT J BIOMETEOROL, V21, P7, DOI 10.1007/BF01552962; TAKALA AK, 1992, 8TH ANN M EUR SOC PE; VERHAEGEN J, 1990, EUR J CLIN MICROBIOL, V9, P390, DOI 10.1007/BF01979467; 1991, PEDIATRICS, V88, P169; 1989, STATISTICAL ABSTRACT	44	147	154	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3328	3332		10.1001/jama.268.23.3328	http://dx.doi.org/10.1001/jama.268.23.3328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1364814				2022-12-24	WOS:A1992KB73200024
J	JOBST, KA; SMITH, AD; SZATMARI, M; MOLYNEUX, A; ESIRI, ME; KING, E; SMITH, A; JASKOWSKI, A; MCDONALD, B; WALD, N				JOBST, KA; SMITH, AD; SZATMARI, M; MOLYNEUX, A; ESIRI, ME; KING, E; SMITH, A; JASKOWSKI, A; MCDONALD, B; WALD, N			DETECTION IN LIFE OF CONFIRMED ALZHEIMERS-DISEASE USING A SIMPLE MEASUREMENT OF MEDIAL TEMPORAL-LOBE ATROPHY BY COMPUTED-TOMOGRAPHY	LANCET			English	Article							CEREBRAL STRUCTURE; HIPPOCAMPAL; CT; DIAGNOSIS; VOLUME; BRAIN; MRI; AGE	The medial temporal lobe of the brain is important for normal cognitive function, notably for memory, and is the region with the most extensive pathological change in Alzheimer's disease (AD). We wanted to find out if atrophy of the medial temporal lobe could be detected in life in patients in whom a diagnosis of AD was subsequently established histopathologically. The minimum width of the medial temporal lobe, measured by temporal-lobe-oriented computed tomography (CT) about one year before death, in 44 patients with a histopathological diagnosis of AD (cases) was nearly half (0.56 of the median) that in 75 controls of the same age with no clinical evidence of dementia (95% confidence interval 0.51-0.61). There was little overlap between the distributions of measurements in cases and controls. A cut-off (< 0.79 MoM) selected to yield a 5% false-positive rate gave an expected detection rate of 92%. A cut-off selected to yield a false-positive rate of 1% (< 0.70 MoM) yielded a 79% detection rate. 20 of the 44 patients with histopathologically diagosed AD had been scanned more than once before death, and the test (cut-off < 0.79 MoM) was positive in all 20 more than a year before and in 9/10 more than 2 years before death. In 10 subjects with dementia but with histopathology excluding AD, the mean minimum width of the medial temporal lobe was significantly greater than that in the cases with AD, but was not significantly different from that in controls. Medial temporal lobe CT is a non-invasive, rapid, simple and effective test for AD which could have immediate application firstly in improving the accuracy of prevalence and incidence studies and, secondly, for the identification of groups of high-risk patients in the evaluation of novel treatments for AD. In the future, it could be applied as a screening test.	UNIV OXFORD, DEPT PHARMACOL, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; UNIV OXFORD, DEPT PSYCHIAT, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; UNIV OXFORD, DEPT CLIN NEUROL, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1A 7BE, ENGLAND; RADCLIFFE INFIRM, DEPT RADIOL, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, DEPT NEUROPATHOL, OXFORD OX2 6HE, ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of London; Queen Mary University London; Radcliffe Infirmary; Radcliffe Infirmary			Wald, Nicholas/AAY-8924-2021; Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722				ANDERSON JM, 1983, J NEUROL SCI, V58, P235, DOI 10.1016/0022-510X(83)90220-4; BOGERTS B, 1990, SCHIZOPHR RES, V3, P295, DOI 10.1016/0920-9964(90)90013-W; CASCINO GD, 1991, ANN NEUROL, V30, P31, DOI 10.1002/ana.410300107; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DUARA R, 1992, CLIN BRAIN IMAGING P, P294; ESIRI MM, 1989, DIAGNOSTIC NEUROPATH, P109; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GEORGE AE, 1990, AM J NEURORADIOL, V11, P101; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P68, DOI 10.1016/0006-3223(91)90211-4; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P55, DOI 10.1016/0006-3223(91)90210-D; JOBST KA, 1992, J NEUROL NEUROSUR PS, V55, P190, DOI 10.1136/jnnp.55.3.190; KESSLAK JP, 1991, NEUROLOGY, V41, P51, DOI 10.1212/WNL.41.1.51; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KIDO DK, 1989, AM J NEURORADIOL, V10, P551; KUKULL WA, 1990, NEUROLOGY, V40, P1364, DOI 10.1212/WNL.40.9.1364; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; RAPOPORT SI, 1991, CEREBROVAS BRAIN MET, V3, P297; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SEAB JP, 1988, MAGN RESON MED, V8, P200, DOI 10.1002/mrm.1910080210; STRAITON JA, 1991, NEURORADIOLOGY, V33, P19, DOI 10.1007/BF00593327; 1987, DIAGNOSTIC STATISTIC	24	245	246	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1179	1183						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359259				2022-12-24	WOS:A1992JY38600002
J	GHO, M; MCDONALD, K; GANETZKY, B; SAXTON, WM				GHO, M; MCDONALD, K; GANETZKY, B; SAXTON, WM			EFFECTS OF KINESIN MUTATIONS ON NEURONAL FUNCTIONS	SCIENCE			English	Article							TRANSMITTER RELEASE; AXONAL-TRANSPORT; HEAVY-CHAIN; C-ELEGANS; DROSOPHILA; SQUID; MICROTUBULES; IDENTIFICATION; MOTILITY; PROTEINS	Kinesin is believed to generate force for the movement of organelles in anterograde axonal transport. The identification of genes that encode kinesin-like proteins suggests that other motors may provide anterograde force instead of or in addition to kinesin. To gain insight into the specific functions of kinesin, the effects of mutations in the kinesin heavy chain gene (khc) on the physiology and ultrastructure of Drosophila larval neurons were studied. Mutations in khc impair both action potential propagation in axons and neurotransmitter release at nerve terminals but have no apparent effect on the concentration of synaptic vesicles in nerve terminal cytoplasm. Thus kinesin is required in vivo for normal neuronal function and may be active in the transport of ion channels and components of the synaptic release machinery to their appropriate cellular locations. Kinesin appears not to be required for the anterograde transport of synaptic vesicles or their components.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Boulder; Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM046295, R01 GM046295-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRISMAR T, 1987, P NATL ACAD SCI USA, V84, P1459, DOI 10.1073/pnas.84.5.1459; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JOHANSEN J, 1989, J NEUROSCI, V9, P710; MCDONALD K, 1984, J ULTRA MOL STRUCT R, V86, P107, DOI 10.1016/S0022-5320(84)80051-9; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WONDERLIN WF, 1991, P NATL ACAD SCI USA, V88, P4391, DOI 10.1073/pnas.88.10.4391; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	22	107	108	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					313	316		10.1126/science.1384131	http://dx.doi.org/10.1126/science.1384131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384131	Green Accepted			2022-12-24	WOS:A1992JR86000039
J	STOSCHITZKY, K; LINDNER, W; KLEIN, W				STOSCHITZKY, K; LINDNER, W; KLEIN, W			STEREOSELECTIVE RELEASE OF (S)-ATENOLOL FROM ADRENERGIC-NERVE ENDINGS AT EXERCISE	LANCET			English	Note							ATENOLOL; PHARMACOKINETICS; PROPRANOLOL; ENANTIOMERS	In-vitro studies have shown that atenolol, a beta-blocking agent, is stereoselectively taken up by and released from adrenergic nerve endings by membrane depolarisation. To investigate the potential importance of these findings, blood samples were taken at rest and after exercise testing from 10 patients (mean [SE] age 60 [3] years) receiving long-term treatment with racemic atenolol. At rest, mean plasma concentration of (R)-atenolol was higher than that of (S)-atenolol (ratio 1.14, p<0.01), but after exercise there was a stereoselective increase in (S)-atenolol concentration, which changed the ratio to 0.66 (p<0.01 ). Since (S)-atenolol but not (R)-atenolol causes clinically relevant beta-blockade, our findings may have importance for the management of patients receiving beta-blocking drugs.	GRAZ UNIV,INST PHARMACEUT CHEM,A-8036 GRAZ,AUSTRIA	University of Graz	STOSCHITZKY, K (corresponding author), GRAZ UNIV,DEPT MED,DIV CARDIOL,AUANBRUGGERPL 15,A-8036 GRAZ,AUSTRIA.							BAGWELL EE, 1989, J PHARMACOL EXP THER, V249, P476; BOYD RA, 1989, CLIN PHARMACOL THER, V45, P403, DOI 10.1038/clpt.1989.47; BRIGHT PS, 1985, BRIT J PHARMACOL, V84, P499, DOI 10.1111/j.1476-5381.1985.tb12934.x; HURWITZ GA, 1983, BRIT J CLIN PHARMACO, V16, P599, DOI 10.1111/j.1365-2125.1983.tb02228.x; LINDNER W, 1991, 2ND P INT S CHIR DIS, P238; MEHVAR R, 1990, J PHARM SCI, V79, P881, DOI 10.1002/jps.2600791007; STOSCHITZKY K, 1992, CLIN PHARMACOL THER, V51, P445, DOI 10.1038/clpt.1992.45; WALLE T, 1988, BIOCHEM PHARMACOL, V37, P115, DOI 10.1016/0006-2952(88)90763-0; WEBB JG, 1988, J PHARMACOL EXP THER, V247, P958	9	22	23	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					696	697		10.1016/0140-6736(92)92233-6	http://dx.doi.org/10.1016/0140-6736(92)92233-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355800				2022-12-24	WOS:A1992JN78000005
J	ROTH, DB; MENETSKI, JP; NAKAJIMA, PB; BOSMA, MJ; GELLERT, M				ROTH, DB; MENETSKI, JP; NAKAJIMA, PB; BOSMA, MJ; GELLERT, M			V(D)J RECOMBINATION - BROKEN DNA-MOLECULES WITH COVALENTLY SEALED (HAIRPIN) CODING ENDS IN SCID MOUSE THYMOCYTES	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; COMBINED IMMUNE-DEFICIENCY; ANTIGEN RECEPTOR GENES; SUPERCOILED DNA; DELTA-GENES; MICE; REARRANGEMENT; MUTATION; PROTEIN; REPAIR	Lymphoid cells from scid mice initiate V(D)J recombination normally but have a severely reduced ability to join coding segments. Thymocytes from scid mice contain broken DNA molecules at the TCR-delta locus that have coding ends, as well as molecules with signal ends, whereas in normal mice we previously detected only signal ends. Remarkably, these coding (but not signal) ends are sealed into hairpin structures. The formation of hairpins at coding ends may be a universal, early step in V(D)J recombination; this would provide a simple explanation for the origin of P nucleotides in coding joints. These findings may shed light on the mechanism of cleavage and suggest a possible role for the scid factor.	FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center	ROTH, DB (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R01CA004946, R37CA004946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013323] Funding Source: NIH RePORTER; NCI NIH HHS [CA-04946] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NIAID NIH HHS [AI-13323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUILAR LK, 1991, J IMMUNOL, V146, P1348; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CARROLL AM, 1989, CURR TOP MICROBIOL, V152, P63; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; ELLIOTT JF, 1988, NATURE, V331, P627; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; KIENKER LJ, 1991, J IMMUNOL, V147, P4351; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; REDDY MK, 1989, J BIOL CHEM, V264, P443; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1988, EMBO J, V7, P2019, DOI 10.1002/j.1460-2075.1988.tb03041.x; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; VANDERENDE A, 1981, NUCLEIC ACIDS RES, V9, P2037, DOI 10.1093/nar/9.9.2037; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x	35	391	393	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					983	991		10.1016/0092-8674(92)90248-B	http://dx.doi.org/10.1016/0092-8674(92)90248-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356077				2022-12-24	WOS:A1992JN78100013
J	EGAN, M; FLOTTE, T; AFIONE, S; SOLOW, R; ZEITLIN, PL; CARTER, BJ; GUGGINO, WB				EGAN, M; FLOTTE, T; AFIONE, S; SOLOW, R; ZEITLIN, PL; CARTER, BJ; GUGGINO, WB			DEFECTIVE REGULATION OF OUTWARDLY RECTIFYING CL- CHANNELS BY PROTEIN KINASE-A CORRECTED BY INSERTION OF CFTR	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CHLORIDE CHANNELS; EPITHELIAL-CELLS; EXPRESSION; CONDUCTANCE; ACTIVATION; DISEASE	CYSTIC fibrosis (CF) is a lethal genetic disease resulting in a reduced Cl- permeability1, increased mucous sulphation2, increased Na+ absorption3 and defective acidification of lysosomal vesicles4. The CF gene encodes a protein (the cystic fibrosis transmembrane conductance regulator, CFTR5) that can function as a low-conductance Cl- channel with a linear current-voltage relationship whose regulation is defective in CF patients6-8. Larger conductance, outwardly rectifying Cl- channels are also defective in CF and fail to activate when exposed either to cyclic AMP-dependent protein kinase A or to protein kinase C9-13. The role of the outwardly rectifying Cl- channel in CF has been questioned14. We report here that expression of recombinant CF genes using adeno-associated virus vectors in CF bronchial epithelial cells corrects defective Cl- secretion, that it induces the appearance of small, linear conductance Cl- channels, and restores protein kinase A activation of outwardly rectifying Cl- channels. These results re-establish an involvement of outwardly rectifying Cl- channels in CF and suggest that CFTR regulates more than one conductance pathway in airway tissues.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,BALTIMORE,MD 21205; NIDDKD,MOLEC & CELLULAR BIOL LAB,BETHESDA,MD	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Zeitlin, Pamela/0000-0002-2719-1834				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FLOTTE T, 1991, PEDIATR PULM, V6, P247; FLOTTE TR, IN PRESS AM J RESPIR; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	25	401	410	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					581	584		10.1038/358581a0	http://dx.doi.org/10.1038/358581a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1380129				2022-12-24	WOS:A1992JH82900059
J	STURM, NR; MASLOV, DA; BLUM, B; SIMPSON, L				STURM, NR; MASLOV, DA; BLUM, B; SIMPSON, L			GENERATION OF UNEXPECTED EDITING PATTERNS IN LEISHMANIA TARENTOLAE MITOCHONDRIAL MESSENGER-RNAS - MISEDITING PRODUCED BY MISGUIDING	CELL			English	Article							ENCODE GUIDE RNAS; CYTOCHROME-OXIDASE; SUBUNIT-III; MINICIRCLES; MOLECULES; REGION; GENES; GRNA	We have analyzed the generation of unexpected patterns of RNA editing, i.e., those not following a strict 3' to 5' progression, which occur in junction regions between fully edited and preedited sequences. Evidence is presented that these patterns are generated by misediting due to specific events of misguiding. Misediting can occur through the interaction of inappropriate gRNAs with mRNAs or appropriate gRNAs in an incorrect fashion. Four possible mechanisms for the generation of misedited sequences are presented. Chimeric molecules have been detected in steady-state mitochondrial RNAs that are composed of misguiding gRNAs covalently linked to mRNAs at misediting sites by the 3' oligo(U) tail. We propose that misediting within junction regions can be corrected by appropriately acting gRNAs.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles					NIAID NIH HHS [AI-09102] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FEAGIN JE, 1990, J BIOL CHEM, V265, P1; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	23	62	63	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					469	476		10.1016/0092-8674(92)90171-8	http://dx.doi.org/10.1016/0092-8674(92)90171-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1379520				2022-12-24	WOS:A1992JH12400012
J	KARJALAINEN, J; MARTIN, JM; KNIP, M; ILONEN, J; ROBINSON, BH; SAVILAHTI, E; AKERBLOM, HK; DOSCH, HM				KARJALAINEN, J; MARTIN, JM; KNIP, M; ILONEN, J; ROBINSON, BH; SAVILAHTI, E; AKERBLOM, HK; DOSCH, HM			A BOVINE ALBUMIN PEPTIDE AS A POSSIBLE TRIGGER OF INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISLET CELL ANTIBODIES; SERUM-ALBUMIN; NOD MICE; BB-RAT; IDDM; CHILDREN; AUTOANTIBODIES; SUSCEPTIBILITY; DESTRUCTION; CHILDHOOD	Background. Cow's milk has been implicated as a possible trigger of the autoimmune response that destroys pancreatic beta cells in genetically susceptible hosts, thus causing diabetes mellitus. Studies in animals have suggested that bovine serum albumin (BSA) is the milk protein responsible, and an albumin peptide containing 17 amino acids (ABBOS) may be the reactive epitope. Antibodies to this peptide react with p69, a beta-cell surface protein that may represent the target antigen for milk-induced beta-cell-specific immunity. Methods. We used immunoassays and Western blot analysis to analyze anti-BSA antibodies in the serum of 142 children with insulin-dependent diabetes mellitus, 79 healthy children, and 300 adult blood donors. Anti-ABBOS antibodies were measured in 44 diabetic patients at the time of diagnosis, three to four months later, and one to two years later. Results. All the diabetic patients had elevated serum concentrations of IgG anti-BSA antibodies (but not of antibodies to other milk proteins), the bulk of which were specific for ABBOS. The mean (+/-SE) concentration was 8.5+/-0.2 kilofluorescence units (kfU) per microliter, as compared with 1.3+/-0.1 kfU per microliter in the healthy children. IgA antibodies were elevated as well, but not IgM antibodies. The antibody concentrations declined after diagnosis, reaching normal levels in most patients within one to two years. The initial decline involved anti-ABBOS-specific antibodies almost exclusively. Much lower serum concentrations of anti-BSA antibodies were found in all 379 control subjects, but only 2.5 percent of them had small amounts of ABBOS-specific IgG. Conclusions. Patients with insulin-dependent diabetes mellitus have immunity to cow's-milk albumin, with antibodies to an albumin peptide that are capable of reacting with a beta-cell-specific surface protein. Such antibodies could participate in the development of islet dysfunction.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT & IMMUNOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV OULU,DEPT PEDIAT,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT MED MICROBIOL,SF-90100 OULU 10,FINLAND; UNIV TURKU,DEPT VIROL,SF-20500 TURKU 50,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 1,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 2,SF-00100 HELSINKI 10,FINLAND	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Oulu; University of Oulu; University of Turku; University of Helsinki; University of Helsinki			Knip, Mikael/AAL-3773-2020	Knip, Mikael/0000-0003-0474-0033				BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BEPPU H, 1987, DIABETES RES CLIN EX, V6, P67; BRUINING GJ, 1984, DIABETOLOGIA, V26, P24; DANEMAN D, 1987, DIABETES RES CLIN EX, V5, P93; DOSCH HM, 1992, PEDIAT AD E, V21, P202; DOSCH HM, 1988, PANDEX S PCFIA, P5; DRASH AL, 1990, SCHWEIZ MED WSCHR, V120, P39; ELLIOTT RB, 1984, DIABETOLOGIA, V26, P297, DOI 10.1007/BF00283653; ELLIOTT RB, 1988, DIABETOLOGIA, V31, P62; GLERUM M, 1989, DIABETES RES CLIN EX, V10, P103; GORSUCH AN, 1981, LANCET, V2, P1363; HANENBERG H, 1989, DIABETOLOGIA, V32, P126, DOI 10.1007/BF00505185; HUSBY S, 1985, INT ARCH ALLER A IMM, V77, P416, DOI 10.1159/000233819; IHM SH, 1990, DIABETES, V39, P1273, DOI 10.2337/diabetes.39.10.1273; ILONEN J, 1988, TISSUE ANTIGENS, V32, P139, DOI 10.1111/j.1399-0039.1988.tb01649.x; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KARJALAINEN J, 1988, DIABETOLOGIA, V31, P129, DOI 10.1007/BF00276844; KARJALAINEN JK, 1990, DIABETES, V39, P1144, DOI 10.2337/diabetes.39.9.1144; KOLB H, 1988, DIABETOLOGIA, V31, P189, DOI 10.1007/BF00290583; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MARTIN JM, 1991, ANN MED, V23, P447, DOI 10.3109/07853899109148088; MIGLIORESAMOUR D, 1988, EXPERIENTIA, V44, P188, DOI 10.1007/BF01941703; NERUP J, 1988, DIABETES CARE, V11, P16; PAGANO G, 1987, DIABETES, V36, P859, DOI 10.2337/diabetes.36.7.859; POCECCO M, 1991, HORM RES, V35, P67; REIJONEN H, 1991, DIABETES, V40, P1640, DOI 10.2337/diabetes.40.12.1640; SAVILAHTI E, 1988, DIABETES RES CLIN EX, V7, P137; SCOTT FW, 1990, AM J CLIN NUTR, V51, P489; SCOTT FW, 1989, DIABETES 1988, P763; TARN AC, 1988, LANCET, V1, P845; THIVOLET C, 1988, DIABETOLOGIA, V31, P741, DOI 10.1007/BF00274776; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; VIRTANEN SM, 1991, DIABETES CARE, V14, P415, DOI 10.2337/diacare.14.5.415; WALTER MA, 1991, J EXP MED, V174, P335, DOI 10.1084/jem.174.2.335; YOKOTA A, 1990, DIABETES RES CLIN PR, V9, P211, DOI 10.1016/0168-8227(90)90047-W	36	366	373	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					302	307		10.1056/NEJM199207303270502	http://dx.doi.org/10.1056/NEJM199207303270502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1377788				2022-12-24	WOS:A1992JF65500002
J	DEKEYSER, J; DEKLIPPEL, N; MERKX, H; VERVAECK, M; HERROELEN, L				DEKEYSER, J; DEKLIPPEL, N; MERKX, H; VERVAECK, M; HERROELEN, L			SERUM CONCENTRATIONS OF VITAMIN-A AND VITAMIN-E AND EARLY OUTCOME AFTER ISCHEMIC STROKE	LANCET			English	Article							LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; BETA-CAROTENE	Formation of free radicals and subsequent lipid peroxidation may have an important role in tissue injury and neuronal cell death after cerebral ischaemia. We conducted a prospective, controlled study to determine whether the endogenous antioxidant vitamins A and E had a protective function in acute ischaemic stroke. The study population consisted of 80 patients seen at the Free University Hospital in Brussels. Entry criteria were occurrence of sudden focal neurological deficit lasting more than 3 h; deficit due to acute ischaemia in the territory of the middle cerebral artery; and investigation within 24 h of onset of the episode. Outcome was assessed within the first 21 days. 80 controls matched for age and sex had various neurological disorders other than acute ischaemia. Serum concentrations of vitamins A and E were similar in the study and control groups. In the study population a serum vitamin A concentration higher than the mean of 2.27-mu-mol/I was associated with a higher frequency of complete recovery within the first 24 h (p<0.05), decreased mortality (p=0.038), and a better outcome as assessed by the Mathew scale of neurological deficit (p<0.03) and the Barthel index. There was no significant difference in outcome between patients with vitamin E concentrations above or below the mean of 35.3-mu-mol/l. Our results suggest a beneficial effect of a high serum vitamin A concentration on early outcome in ischaemic stroke.			DEKEYSER, J (corresponding author), VRIJE UNIV BRUSSELS, ACAD ZIEKENHUIS, DEPT NEUROL, LAARBEEKLAAN 101, B-1090 BRUSSELS, BELGIUM.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HARPER HA, 1979, REV PHYSL CHEM, P147; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; MAHONEY F I, 1965, Md State Med J, V14, P61; MATHEW NT, 1972, LANCET, V2, P1327; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHMIDLEY JW, 1990, STROKE, V25, P7; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SILVIA RC, 1987, NEUR ABST, V13, P1499; SUNDT TM, 1969, J NEUROSURG, V31, P311, DOI 10.3171/jns.1969.31.3.0311; VUILLEUMIER JP, 1983, INT J VITAM NUTR RES, V53, P265; YAMAMOTO M, 1983, STROKE, V14, P977, DOI 10.1161/01.STR.14.6.977; YOSHIDA S, 1989, ANN NY ACAD SCI, V570, P219; YOSHIDA S, 1985, J NEUROCHEM, V44, P1593, DOI 10.1111/j.1471-4159.1985.tb08800.x; 1991, LANCET, V338, P1129	18	39	40	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1992	339	8809					1562	1565		10.1016/0140-6736(92)91830-2	http://dx.doi.org/10.1016/0140-6736(92)91830-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351549				2022-12-24	WOS:A1992JB20200003
J	CHUNG, J; KUO, CJ; CRABTREE, GR; BLENIS, J				CHUNG, J; KUO, CJ; CRABTREE, GR; BLENIS, J			RAPAMYCIN FKBP SPECIFICALLY BLOCKS GROWTH-DEPENDENT ACTIVATION OF AND SIGNALING BY THE 70 KD S6 PROTEIN-KINASES	CELL			English	Article							PEPTIDYL-PROLYL ISOMERASE; RIBOSOMAL PROTEIN-S6; IMMUNOSUPPRESSANT FK506; MACROLIDES FK-506; DISTINCT; PHOSPHORYLATION; IMMUNOPHILIN; S6-KINASE; HOMOLOGS; CHICKEN	The macrolide rapamycin blocks cell cycle progression in yeast and various animal cells by an unknown mechanism. We demonstrate that rapamycin blocks the phosphorylation and activation of the 70 kd S6 protein kinases (pp70S6K) in a variety of animal cells. The structurally related drug FK506 had no effect on pp70S6K activation but at high concentrations reversed the rapamycin-induced block, confirming the requirement for the rapamycin and FK506 receptor, FKBP. Rapamycin also interfered with signaling by these S6 kinases, blocking serum-stimulated S6 phosphorylation and delaying entry of Swiss 3T3 cells into S phase. Neither rapamycin nor FK506 blocked activation of a distinct family of S6 kinases (RSKs) or the MAP kinases. These studies identify a rapamycin-sensitive signaling pathway, argue for a ubiquitous role for FKBPs in signal transduction, indicate that FK506-FKBP-calcineurin complexes do not interfere with pp70S6K signaling, and show that in fibroblasts pp70S6K, not RSK, is the physiological S6 kinase.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,MOLEC & GENET MED UNIT,STANFORD,CA 94305	Stanford University	CHUNG, J (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R37CA039612, R01CA046595, R01CA039612, R37CA046595] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46595, CA-39612] Funding Source: Medline; NHLBI NIH HHS [HLB-33942] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDRES JL, 1989, J BIOL CHEM, V264, P151; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CHANG JY, 1991, TRENDS PHARMACOL SCI, V12, P218, DOI 10.1016/0165-6147(91)90555-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; TERAO K, 1970, BIOCHEM BIOPH RES CO, V38, P80, DOI 10.1016/0006-291X(70)91086-7; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	44	1071	1100	2	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1227	1236		10.1016/0092-8674(92)90643-Q	http://dx.doi.org/10.1016/0092-8674(92)90643-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1377606				2022-12-24	WOS:A1992JA43100016
J	CHARO, RA				CHARO, RA			MANDATORY CONTRACEPTION	LANCET			English	Editorial Material														Charo, Robin Alta/0000-0003-3710-1043				POTTS N, 1991, LANCET, V338, P303; Shapiro Thomas, 1985, POPULATION CONTROL P; 1992, JAMA-J AM MED ASSOC, V267, P1812	3	1	1	2	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1104	1105						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349114				2022-12-24	WOS:A1992HR44600016
J	FUJITA, N; BABA, T; TOMIYAMA, T; KODAMA, T; KAKO, N				FUJITA, N; BABA, T; TOMIYAMA, T; KODAMA, T; KAKO, N			HYPERINSULINEMIA AND BLOOD-PRESSURE IN PATIENTS WITH INSULINOMA	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION		HIROSAKI UNIV,DEPT INTERNAL MED 3,HIROSAKI,AOMORI 036,JAPAN; HIROSAKI UNIV,DEPT SURG 1,HIROSAKI,AOMORI 036,JAPAN	Hirosaki University; Hirosaki University								FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SKOTT P, 1989, DIABETOLOGIA, V32, P694; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1157	1157		10.1136/bmj.304.6835.1157	http://dx.doi.org/10.1136/bmj.304.6835.1157			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392796	Green Published, Bronze			2022-12-24	WOS:A1992HT23200025
J	CARTER, HB; PEARSON, JD; METTER, J; BRANT, LJ; CHAN, DW; ANDRES, R; FOZARD, JL; WALSH, PC				CARTER, HB; PEARSON, JD; METTER, J; BRANT, LJ; CHAN, DW; ANDRES, R; FOZARD, JL; WALSH, PC			LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; TREATED PATIENTS; ADENOCARCINOMA; HYPERPLASIA; CANCER; DIAGNOSIS	Objective. - To evaluate longitudinal changes in prostate-specific antigen (PSA) levels in men with and without prostate disease. Design. - Case-control study of men with and without prostate disease who were participants in a prospective aging study. Setting. - Gerontology Research Center of the National institute on Aging; the Baltimore (Md) Longitudinal Study of Aging. Patients. - Sixteen men with no prostate disease (control group), 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH), and 18 men with a histologic diagnosis of prostate cancer. Outcome Measures. - Multiple PSA and androgen determinations on serum samples obtained from 7 to 25 years prior to histologic diagnosis or exclusion of prostate disease. Results. - Changes in androgen levels with age did not differ between groups. Control subjects did not show a significant change in PSA levels with age. There was a significant difference in the age-adjusted rate of change in PSA levels between groups (prostate cancer > BPH > control; P < .01). At 5 years before diagnosis when PSA levels did not differ between subjects with BPH and prostate cancer, rate of change in PSA levels (0.75-mu-g/L per year) was significantly greater in subjects with prostate cancer compared with control subjects and subjects with BPH. Also, rate of change in PSA levels distinguished subjects with prostate cancer from subjects with BPH and control subjects with a specificity of 90% and 100%, respectively. Conclusions. - The most significant factor affecting serum PSA levels with age is the development of prostate disease. Rate of change in PSA levels may be a sensitive and specific early clinical marker for the development of prostate cancer.	JOHNS HOPKINS UNIV HOSP,SCH MED,JAMES BUCHANAN BRADY UROL INST,DEPT LAB MED,BALTIMORE,MD 21205; NIA,GERONTOL RES CTR,CLIN PHYSIOL LAB,BETHESDA,MD 20892; NIA,GERONTOL RES CTR,LONGITUDINAL STUDIES BRANCH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	CARTER, HB (corresponding author), JOHNS HOPKINS UNIV HOSP,SCH MED,JAMES BUCHANAN BRADY UROL INST,DEPT UROL,403 MARBURG,BALTIMORE,MD 21205, USA.		Chan, Doris/O-1227-2014; Fozard, James Leonard/B-3660-2009	Chan, Doris/0000-0002-4990-986X; 	NCI NIH HHS [P50 CA058236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGHI HM, 1990, PROSTATE, V16, P253, DOI 10.1002/pros.2990160309; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; GUESS HA, 1990, PROSTATE, V17, P241, DOI 10.1002/pros.2990170308; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; KYPRIANOU N, 1991, ENDOCRINE DEPENDENT, P69; LINDSTROM MJ, 1988, J AM STAT ASSOC, V83, P1014; MEYER JS, 1982, J UROLOGY, V128, P1353, DOI 10.1016/S0022-5347(17)53506-5; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; PEARSON JD, 1991, P SOC STAT, P580; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P79; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; WANG MC, 1979, INVEST UROL, V17, P159; WEBER JP, 1989, J UROLOGY, V141, P987, DOI 10.1016/S0022-5347(17)41083-4; [No title captured]; 1987, NIH882789 PUBL	19	851	888	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2215	2220		10.1001/jama.267.16.2215	http://dx.doi.org/10.1001/jama.267.16.2215			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372942	Green Accepted			2022-12-24	WOS:A1992HN84100032
J	PRESTON, GM; CARROLL, TP; GUGGINO, WB; AGRE, P				PRESTON, GM; CARROLL, TP; GUGGINO, WB; AGRE, P			APPEARANCE OF WATER CHANNELS IN XENOPUS OOCYTES EXPRESSING RED-CELL CHIP28 PROTEIN	SCIENCE			English	Article							MAJOR INTRINSIC PROTEIN; MEMBRANE; TRANSCRIPTION; INVITRO; KIDNEY; SP6	Water rapidly crosses the plasma membrane of red blood cells (RBCs) and renal tubules through specialized channels. Although selective for water, the molecular structure of these channels is unknown. The CHIP28 protein is an abundant integral membrane protein in mammalian RBCs and renal proximal tubules and belongs to a family of membrane proteins with unknown functions. Oocytes from Xenopus laevis microinjected with in vitro-transcribed CHIP28 RNA exhibited increased osmotic water permeability; this was reversibly inhibited by mercuric chloride, a known inhibitor of water channels. Therefore it is likely that CHIP28 is a functional unit of membrane water channels.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048268, R01HL048268, R01HL033991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DEMPSTER JA, 1991, PFLUG ARCH EUR J PHY, V419, P249, DOI 10.1007/BF00371103; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH BL, 1991, J BIOL CHEM, V266, P6407; SOLOMON AK, 1983, ANN NY ACAD SCI, V414, P97, DOI 10.1111/j.1749-6632.1983.tb31678.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; [No title captured]; [No title captured]	33	1635	1767	9	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					385	387		10.1126/science.256.5055.385	http://dx.doi.org/10.1126/science.256.5055.385			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1373524				2022-12-24	WOS:A1992HP03200039
J	CHEN, L; HUANG, LYM				CHEN, L; HUANG, LYM			PROTEIN-KINASE-C REDUCES MG2+ BLOCK OF NMDA-RECEPTOR CHANNELS AS A MECHANISM OF MODULATION	NATURE			English	Article							LONG-TERM POTENTIATION; MOUSE CENTRAL NEURONS; ASPARTATE-ACTIVATED CHANNELS; DIVALENT-CATIONS; CELLS; EXPRESSION; INHIBITION; INDUCTION; RESPONSES; CURRENTS	THF roles of N-methyl-D-aspartate (NMDA) receptors and protein kinase C (PKC) are critical in generating and maintaining a variety of sustained neuronal responses. In the nociceptive (pain-sensing) system, tissue injury or repetitive stimulation of small-diameter afferent fibres triggers a dramatic increase in discharge (wind-up) or prolonged depolarization of spinal cord neurons. This central sensitization can neither be induced nor maintained when NMDA receptor channels are blocked 1,2. In the trigeminal subnucleus caudalis (a centre for processing nociceptive information from the orofacial areas 3), a mu-opioid receptor agonist causes a sustained increase in NMDA-activated currents by activating intracellular PKC 4. There is also evidence that PKC enhances NMDA-receptor-mediated glutamate responses 4-7 and regulates long-term potentiation of synaptic transmission 8-14. Despite the importance of NMDA-receptors and PKC, the mechanism by which PKC alters the NMDA response has remained unclear. Here we examine the actions of intracellularly applied PKC on NMDA-activated currents in isolated trigeminal neurons. We find that PKC potentiates the NMDA response by increasing the probability of channel openings and by reducing the voltage-dependent Mg2+ block of NMDA-receptor channels.	UNIV TEXAS, MED BRANCH, INST MARINE BIOMED, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, DEPT PHYSIOL & BIOPHYS, GALVESTON, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston								ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; Bell R M, 1986, Methods Enzymol, V124, P353; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DUBNER R, 1991, A REV NEUROSCI, V44, P293; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GERBER G, 1989, J NEUROSCI, V9, P3606; Goldberg M, 1976, KIDNEY, P344; GU YP, 1991, NEURON, V6, P777, DOI 10.1016/0896-6273(91)90174-X; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KELSO SR, IN PRESS J PHYSL LON; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; MACDERMOTT AB, 1986, J NEUROSCI, V7, P3230; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PITZER KS, 1974, J AM CHEM SOC, V96, P5701, DOI 10.1021/ja00825a004; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; YAMAMOTO D, 1988, J PHYSIOL-LONDON, V400, P691, DOI 10.1113/jphysiol.1988.sp017144	32	817	852	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 9	1992	356	6369					521	523		10.1038/356521a0	http://dx.doi.org/10.1038/356521a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1373227				2022-12-24	WOS:A1992HN23100058
J	SIMOES, EAF; MCGRATH, EJ				SIMOES, EAF; MCGRATH, EJ			RECOGNITION OF PNEUMONIA BY PRIMARY HEALTH-CARE WORKERS IN SWAZILAND WITH A SIMPLE CLINICAL ALGORITHM	LANCET			English	Note								In developing countries primary health care workers are being trained to manage and treat acute respiratory infections with a protocol developed by the WHO. We tested the ability of nurses and nursing assistants in Swaziland to recognise the signs and symptoms of pneumonia; with the results of a paediatrician's examination as "gold standard", sensitivities and specificities were calculated. Danger signs of stridor and abnormal sleepiness were poorly recognised (sensitivity 0-50%) by the health care workers, as was audible wheeze. Severe undernutrition, tachypnoea, and chest wall indrawing were well recognised. Overall, the recognition of pneumonia was good (sensitivity 71-83%, specificity 84-85%). These findings highlight topics for emphasis in training.	MINIST HLTH, MBABANE, SWAZILAND		SIMOES, EAF (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, 4200 E 9TH AVE, BOX C-227, DENVER, CO 80262 USA.							BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; CHERIAN T, 1990, AM J DIS CHILD, V144, P1026, DOI 10.1001/archpedi.1990.02150330086028; CHERIAN T, 1988, LANCET, V2, P125; HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S; Leowski J, 1986, World Health Stat Q, V39, P138; MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004; SIMOES EAF, 1991, ARCH DIS CHILD, V66, P1199, DOI 10.1136/adc.66.10.1199; SNEDECOR GW, 1980, STATISTICAL METHODS, P121; 1992, ACUTE RESPIRATORY IN; 1990, SUPERVISORY SKILLS M	10	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	1992	340	8834-5					1502	1503		10.1016/0140-6736(92)92757-7	http://dx.doi.org/10.1016/0140-6736(92)92757-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361598				2022-12-24	WOS:A1992KD06900006
J	NI, HL; KNIGHT, AI; CARTWRIGHT, K; PALMER, WH; MCFADDEN, J				NI, HL; KNIGHT, AI; CARTWRIGHT, K; PALMER, WH; MCFADDEN, J			POLYMERASE CHAIN-REACTION FOR DIAGNOSIS OF MENINGOCOCCAL MENINGITIS	LANCET			English	Article							ACUTE BACTERIAL-MENINGITIS	Meningococcal disease is normally suspected on clinical grounds but confirmed by isolation of Neisseria meningitidis from blood or cerebrospinal fluid (CSF), or by detection of gram-negative diplococci in CSF. After parenteral antibiotics are started the isolation rate of meningococci from blood cultures drops from 50% to less than 5% and the chances of CSF being positive by culture or microscopy are also reduced. We used the polymerase chain reaction (PCR) in a blinded study to detect meningococcal DNA in 54 CSF samples from patients with meningococcal disease or from controls. The PCR primers were specific for the meningococcal insertion sequence IS1106. The sensitivity and specificity of this PCR for diagnosis of meningococcal meningitis were both 91%. Sensitivity was not affected by prior antibiotic treatment. The IS1106 PCR is a rapid and sensitive test for confirmation of the diagnosis of meningococcal meningitis.	UNIV SURREY, SCH BIOL SCI, MOLEC MICROBIOL GRP, GUILDFORD GU2 5XH, SURREY, ENGLAND; GLOUCESTERSHIRE ROYAL HOSP, PUBL HLTH LAB, GLOUCESTER, ENGLAND	University of Surrey; Gloucestershire Royal Hospital				McFadden, Johnjoe/0000-0003-2145-0046				BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT KAV, 1986, LANCET, V2, P558; GOLDACRE MJ, 1977, ARCH DIS CHILD, V52, P501, DOI 10.1136/adc.52.6.501; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; HARVEY IM, 1989, HLTH TRENDS, V21, P73; KNIGHT AI, 1992, MOL MICROBIOL, V6, P1565, DOI 10.1111/j.1365-2958.1992.tb00878.x; KRISTIANSEN BE, 1991, LANCET, V337, P1568, DOI 10.1016/0140-6736(91)93262-8; NI H, 1992, EPIDEMIOL INFECT, V109, P227, DOI 10.1017/S0950268800050184; SABOOR SA, 1992, LANCET, V339, P1012, DOI 10.1016/0140-6736(92)90535-B; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; 1988, DHSS PLCMO882 DEP HL	14	106	112	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1992	340	8833					1432	1434		10.1016/0140-6736(92)92622-M	http://dx.doi.org/10.1016/0140-6736(92)92622-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360560				2022-12-24	WOS:A1992KC28400004
J	CHATTERJEE, S; JOHNSON, PR; WONG, KK				CHATTERJEE, S; JOHNSON, PR; WONG, KK			DUAL-TARGET INHIBITION OF HIV-1 INVITRO BY MEANS OF AN ADENOASSOCIATED VIRUS ANTISENSE VECTOR	SCIENCE			English	Article							TRANS-ACTIVATION; GENE-EXPRESSION; RNA; REPLICATION; CELLS; CLONING; DNA; TRANSDUCTION; INTEGRATION; RESISTANCE	An adeno-associated virus vector encoding an antisense RNA was used to transduce stable intracellular resistance to human immunodeficiency virus-1 (HIV-1) in human hemopoietic and non-hemopoietic cell lines. The antisense targets are present in all HIV-1 transcripts and include the TAR sequence, which is critical for transcription and virus replication, and the polyadenylation signal. Cell lines expressing antisense RNA showed up to 95 percent inhibition of gene expression directed by the HIV-1 long terminal repeat and greater than 99 percent reduction in infectious HIV-1 production, with no detectable cellular toxicity. Because of their efficient transcription and inability to recombine with HIV-1, adeno-associated virus vectors represent a promising form of anti-retroviral gene therapy.	NIAID,VIRAL DIS LAB,ROCKVILLE,MD 20852; GEORGETOWN UNIV,DEPT MICROBIOL,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD; NIAID,INFECT DIS LAB,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Johnson, Philip R/A-6892-2009					BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BERNS KI, 1987, ADV VIRUS RES, V32, P243, DOI 10.1016/S0065-3527(08)60479-0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.bi.55.070186.003123; CHATTERJEE S, UNPUB; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FENRICK R, 1989, J VIROL, V63, P5006, DOI 10.1128/JVI.63.12.5006-5012.1989; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GOLDSTEIN S, 1990, J ACQ IMMUN DEF SYND, V3, P98; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERMONAT PL, 1984, P NATL ACAD SCI-BIOL, V81, P6466, DOI 10.1073/pnas.81.20.6466; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; Johnson V., 1990, TECHNIQUES HIV RES; JOSHI S, 1991, J VIROL, V65, P5524, DOI 10.1128/JVI.65.10.5524-5530.1991; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LAFACE D, 1988, VIROLOGY, V162, P483, DOI 10.1016/0042-6822(88)90491-6; LAUGHLIN CA, 1983, GENE, V23, P65, DOI 10.1016/0378-1119(83)90217-2; LEBKOWSKI JS, 1988, MOL CELL BIOL, V8, P3988, DOI 10.1128/MCB.8.10.3988; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MENDELSON E, 1992, VIROLOGY, V187, P453, DOI 10.1016/0042-6822(92)90447-W; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RHODES A, 1990, J GEN VIROL, V71, P1965, DOI 10.1099/0022-1317-71-9-1965; SAMULSKI RJ, 1982, P NATL ACAD SCI-BIOL, V79, P2077, DOI 10.1073/pnas.79.6.2077; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHIMADA T, 1991, Antiviral Chemistry and Chemotherapy, V2, P133; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WEEKS DL, 1983, MOL CELL BIOL, V3, P1222, DOI 10.1128/MCB.3.7.1222; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WILEY JA, 1989, AIDS, V3, pS71, DOI 10.1097/00002030-198901001-00011; WONG KL, UNPUB	37	183	229	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1485	1488		10.1126/science.1359646	http://dx.doi.org/10.1126/science.1359646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1359646	Green Submitted			2022-12-24	WOS:A1992JZ62500029
J	NIWA, M; MACDONALD, CC; BERGET, SM				NIWA, M; MACDONALD, CC; BERGET, SM			ARE VERTEBRATE EXONS SCANNED DURING SPLICE-SITE SELECTION	NATURE			English	Article							MESSENGER-RNAS; POLY(A) SITE; POLYADENYLATION; SEQUENCES; INVITRO; DEFINITION; INTRON; MODEL	PAIRWISE recognition of splice sites as a result of a scanning mechanism is an attractive model to explain the coordination of vertebrate splicing1. Such a mechanism would predict a polarity-of-site recognition in the scanned unit, but no evidence for a polarity gradient across introns has been found2-4. We have suggested that the exon rather than the intron is the unit of recognition in vertebrates5 and that polyadenylation and splicing factors interact during recognition of 3'-terminal exons6-8. Interaction is reflected in maximal rates of in vitro polyadenylation. If scanning across the exon is operating during this interaction, then insertion of a 5' splice site should depress polyadenylation. Here we report recognition in vitro and in vivo of a 5' splice site situated within a 3'-terminal exon, and a concomitant depression of polyadenylation and ultraviolet crosslinking of a polyadenylation factor. Decreased crosslinking was only found when the 3' and 5' splice sites were within 300 nucleotides of each other. These results are consistent with an exon scanning mechanism for splice-site selection.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	NIWA, M (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCCLEAN DEPT BIOCHEM,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			MacDonald, Clinton/0000-0003-3209-1982				ADAMI G, 1988, EMBO J, V7, P2107, DOI 10.1002/j.1460-2075.1988.tb03050.x; AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BRADY HA, 1988, MOL CELL BIOL, V8, P3291, DOI 10.1128/MCB.8.8.3291; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CUNNINGHAM SA, 1991, J MOL BIOL, V217, P265, DOI 10.1016/0022-2836(91)90541-D; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; KUHNE T, 1983, EMBO J, V2, P727, DOI 10.1002/j.1460-2075.1983.tb01492.x; LANG KM, 1983, SCIENCE, V220, P1351, DOI 10.1126/science.6304877; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NIWA M, 1991, GENE EXPRESSION, V1, P5; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112	19	117	118	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					277	280		10.1038/360277a0	http://dx.doi.org/10.1038/360277a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359430				2022-12-24	WOS:A1992JY96000058
J	STACEYCLEAR, A; MCCARTHY, KA; HALL, DA; PILESPELLMAN, E; WHITE, G; HULKA, C; WHITMAN, GJ; MAHONEY, E; KOPANS, DB				STACEYCLEAR, A; MCCARTHY, KA; HALL, DA; PILESPELLMAN, E; WHITE, G; HULKA, C; WHITMAN, GJ; MAHONEY, E; KOPANS, DB			BREAST-CANCER SURVIVAL AMONG WOMEN UNDER AGE 50 - IS MAMMOGRAPHY DETRIMENTAL	LANCET			English	Article							SCREENING TRIAL; MORTALITY; REDUCTION	Great uncertainty exists about the benefit of detecting breast cancer by mammography in women under 50 years of age. We have reviewed the survival of patients aged 49 years or less whose cancers were detected by mammography alone. 117 women under the age of 50 years were diagnosed with breast cancer between 1978 and 1991 based only on an abnormal mammogram. Ductal carcinoma in-situ (DCIS) was found in 47 (40%) of these women, whilst 70 (60%) had infiltrating ductal or infiltrating lobular carcinomas. During the same interval, 928 women in this age group presented with palpable breast cancer. DCIS was diagnosed in 82 (9%) of these women, whilst 846 (91%) had infiltrating carcinoma. Among the infiltrating cancers detected by mammography alone, 50% were stage I, whilst only 30% of the women with palpable cancers were stage I. Five-year survival for all mammographically detected cancer patients was 95%, whereas for women with palpable cancers the survival was 74% (p < 0.00005). If DCIS is not included, the corresponding survivals are 91% for mammographically detected infiltrating cancers and 72% for palpable infiltrating cancers. Only 1 woman who died among those with palpable cancer had had a mammogram before diagnosis. Our data contradict the suggestion that women under 50 are put at a survival disadvantage by undergoing mammography. We believe that investigators who have reported negative results in this age group must examine other causes for their results.	MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIV SURG ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; JOENSUU H, 1992, LANCET, V339, P315, DOI 10.1016/0140-6736(92)91396-P; KOPANS DB, IN PRESS SCREENING M; MARTIN JE, 1979, AM J ROENTGENOL, V132, P737, DOI 10.2214/ajr.132.5.737; MILLER BA, 1991, J NATL CANCER I, V83, P678; MOSKOWITZ M, 1992, RADIOL CLIN N AM, V30, P221; MOSKOWITZ M, 1982, AM J ROENTGENOL, V138, P911, DOI 10.2214/ajr.138.5.911; MUIR BB, 1984, RADIOLOGY, V151, P39, DOI 10.1148/radiology.151.1.6701330; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; SEIDMAN H, 1987, CA-CANCER J CLIN, V37, P258, DOI 10.3322/canjclin.37.5.258; Shapiro S, 1988, PERIODIC SCREENING B; STOMPER PC, 1989, HEMATOL ONCOL CLIN N, V3, P611, DOI 10.1016/S0889-8588(18)30523-9; TABAR L, 1985, DIAGN IMAG CLIN MED, V54, P158; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; WATMOUGH DJ, 1992, LANCET, V340, P122, DOI 10.1016/0140-6736(92)90451-8; WHITE E, 1990, J NATL CANCER I, V82, P1546, DOI 10.1093/jnci/82.19.1546; 1991, LANCET, V337, P1575	21	36	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357448				2022-12-24	WOS:A1992JV01400002
J	GILL, DR; HYDE, SC; HIGGINS, CF; VALVERDE, MA; MINTENIG, GM; SEPULVEDA, FV				GILL, DR; HYDE, SC; HIGGINS, CF; VALVERDE, MA; MINTENIG, GM; SEPULVEDA, FV			SEPARATION OF DRUG TRANSPORT AND CHLORIDE CHANNEL FUNCTIONS OF THE HUMAN MULTIDRUG RESISTANCE P-GLYCOPROTEIN	CELL			English	Article							NUCLEOTIDE-BINDING FOLD; CYSTIC-FIBROSIS; ATP-BINDING; ADENYLATE KINASE; DEPENDENT TRANSPORT; STRUCTURAL MODEL; EPITHELIAL-CELLS; ESCHERICHIA-COLI; R-DOMAIN; EXPRESSION	The human multidrug resistance P-glycoprotein is an active transporter that pumps cytotoxic drugs out of cells. Expression of P-glycoprotein is also associated with a volume-activated chloride channel. Here we address the relationship between these two functions. Drug transport requires ATP hydrolysis while, in contrast, ATP binding is sufficient to enable activation of the chloride channel. The chloride channel and drug transport activities of P-glycoprotein appear to reflect two distinct functional states of the protein that can be interconverted by changes in tonicity. Transportable drugs prevent channel activation but have no effect on channel activity once it has been preactivated by hypotonicity. The transport and channel functions of P-glycoprotein have been separated by directed mutations in the nucleotide-binding domains of the protein. These data provide further evidence that P-glycoprotein is bifunctional with both transport and channel activities. Implications for the design of chemotherapeutic drugs and for the function of the related cystic fibrosis gene product, CFTR, are discussed.	AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	GILL, DR (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND.			Sepulveda Valenzuela, Francisco Leandro/0000-0003-0022-6598; Gill, Deborah/0000-0002-5264-054X; Valverde, Miguel A./0000-0002-6961-3361; Hyde, Stephen/0000-0002-8877-4005				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAAS F, 1990, CANCER RES, V50, P5392; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CANOGAUCI DF, 1990, BIOCHEM BIOPH RES CO, V167, P48, DOI 10.1016/0006-291X(90)91728-B; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DIAZ M, 1992, UNPUB EUR J PHYSL; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8445; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOOS C, 1960, ARCH BIOCHEM BIOPHYS, V88, P183, DOI 10.1016/0003-9861(60)90220-4; OBRIEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1070, P501, DOI 10.1016/0005-2736(91)90093-N; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RONINSON IB, 1990, PEDIATR PULM, V5, P138; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEPPARD DN, 1991, J PHYSIOL-LONDON, V433, P663, DOI 10.1113/jphysiol.1991.sp018449; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4305; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	55	366	371	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					23	32		10.1016/0092-8674(92)90263-C	http://dx.doi.org/10.1016/0092-8674(92)90263-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1382860				2022-12-24	WOS:A1992JQ62300004
J	WEETMAN, AP; TANDON, N; MORGAN, BP				WEETMAN, AP; TANDON, N; MORGAN, BP			ANTITHYROID DRUGS AND RELEASE OF INFLAMMATORY MEDIATORS BY COMPLEMENT-ATTACKED THYROID-CELLS	LANCET			English	Article							GRAVES-DISEASE; HASHIMOTOS THYROIDITIS; MEMBRANE ATTACK; GROWTH-FACTOR; T-CELLS; INTERLEUKIN-6; LYMPHOCYTES; METHIMAZOLE; SURFACE	Thyroid cells are exposed to complement attack in Graves' disease and Hashimoto's thyroiditis, but are resistant to killing by homologous complement. We have examined the effects of sublethal complement attack on thyroid cells in vitro. Extracellular reactive oxygen metabolites were produced and prostaglandin E2, interleukin-1-alpha, and interleukin-6 were released after complement attack. Cells pretreated with interferon-gamma and interleukin-1-alpha, which increase expression of CD59, were more resistant to these effects of complement. Conversely, blockade of CD59 with monoclonal antibody increased complement-mediated oxygen radical production and release of prostaglandin E2, interleukin-1-alpha, and interleukin-6. The antithyroid drugs methimazole and propylthiouracil abolished or reduced oxygen radical production by complement-attacked thyroid cells and reduced cytokine release. These results suggest that sublethal complement attack in autoimmune thyroid diseases exacerbates tissue injury by causing thyroid cells to release potent phlogistic mediators, although some degree of protection may be afforded in vivo by cytokine-mediated upregulation of CD59. Antithyroid drugs, concentrated within thyroid cells, will prevent the release of these inflammatory molecules, which may in turn explain the amelioration of thyroiditis and remission of Graves' disease after such treatment.	UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	WEETMAN, AP (corresponding author), UNIV SHEFFIELD,NO GEN HOSP,CTR CLIN SCI,DEPT MED,SHEFFIELD S5 7AU,ENGLAND.			Morgan, Paul/0000-0003-4075-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALLEN EM, 1986, AM J MED SCI, V29, P267; BANGA JP, 1991, AUTOIMMUNITY, V8, P335, DOI 10.3109/08916939109007642; BELLUR S, 1990, ENDOCRINOLOGY, V127, P1526, DOI 10.1210/endo-127-3-1526; BROWN TR, 1991, J CLIN INVEST, V88, P106, DOI 10.1172/JCI115265; GRUBECKLOEBENSTEIN B, 1989, CLIN EXP IMMUNOL, V77, P324; JANSSON R, 1985, BRIT MED J, V290, P11, DOI 10.1136/bmj.290.6461.11; KALDERON AE, 1977, AM J MED, V63, P729, DOI 10.1016/0002-9343(77)90159-0; KASAI K, 1987, LIFE SCI, V41, P241, DOI 10.1016/0024-3205(87)90499-1; KHOURY EL, 1984, J EXP MED, V159, P577, DOI 10.1084/jem.159.2.577; KHOURY EL, 1981, CLIN EXP IMMUNOL, V45, P316; MARCHANT B, 1972, J CLIN ENDOCR METAB, V34, P847, DOI 10.1210/jcem-34-5-847; MARGOLICK JB, 1988, CLIN IMMUNOL IMMUNOP, V47, P208, DOI 10.1016/0090-1229(88)90073-6; MCGREGOR AM, 1982, BRIT MED J, V284, P1750, DOI 10.1136/bmj.284.6331.1750; MCGREGOR AM, 1980, BRIT MED J, V281, P968, DOI 10.1136/bmj.281.6246.968; MCLACHLAN SM, 1986, CLIN ENDOCRINOL, V24, P223, DOI 10.1111/j.1365-2265.1986.tb00766.x; MORGAN BP, 1989, BIOCHEM J, V264, P1; OLEESKY DA, 1985, CLIN ENDOCRINOL, V25, P623; ROMALDINI JH, 1986, J ENDOCRINOL INVEST, V9, P233, DOI 10.1007/BF03348107; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; TANDON N, 1992, IMMUNOLOGY, V75, P372; TOTTERMAN TH, 1987, NEW ENGL J MED, V316, P15, DOI 10.1056/NEJM198701013160104; VOLPE R, 1987, NEW ENGL J MED, V316, P44, DOI 10.1056/NEJM198701013160109; WEETMAN AP, 1990, J ENDOCRINOL, V127, P357, DOI 10.1677/joe.0.1270357; WEETMAN AP, 1990, CLIN EXP IMMUNOL, V82, P69; WEETMAN AP, 1982, CLIN EXP IMMUNOL, V48, P196; WEETMAN AP, 1989, CLIN EXP IMMUNOL, V77, P25; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x; WERNER SC, 1972, NEW ENGL J MED, V287, P421, DOI 10.1056/NEJM197208312870901; WOOD LC, 1979, J CLIN INVEST, V64, P1429, DOI 10.1172/JCI109601; YOUNG RJ, 1976, J CLIN PATHOL, V29, P398, DOI 10.1136/jcp.29.5.398; ZHENG RQH, 1991, CLIN EXP IMMUNOL, V83, P314	32	83	84	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					633	636						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1381035				2022-12-24	WOS:A1992JM85100004
J	YANAGISAWAMIWA, A; UCHIDA, Y; NAKAMURA, F; TOMARU, T; KIDO, H; KAMIJO, T; SUGIMOTO, T; KAJI, K; UTSUYAMA, M; KURASHIMA, C; ITO, H				YANAGISAWAMIWA, A; UCHIDA, Y; NAKAMURA, F; TOMARU, T; KIDO, H; KAMIJO, T; SUGIMOTO, T; KAJI, K; UTSUYAMA, M; KURASHIMA, C; ITO, H			SALVAGE OF INFARCTED MYOCARDIUM BY ANGIOGENIC ACTION OF BASIC FIBROBLAST GROWTH-FACTOR	SCIENCE			English	Article							CORONARY COLLATERAL VESSELS; DNA-SYNTHESIS; FUNCTIONAL-SIGNIFICANCE; EXTRACELLULAR-MATRIX; CARDIAC MYOCYTES; HEPARIN; CIRCULATION; HEART; ARTERY; LOCALIZATION	Coronary collateral vessels reduce damage to ischemic myocardium after coronary obstruction. Factors that stimulate collateral formation are expected to have ameliorating effects on myocardial infarction. In a canine experimental myocardial infarct model, intracoronary injection of basic fibroblast growth factor (bFGF) improved cardiac systolic function and reduced infarct size. Treatment with bFGF increased the number of arterioles and capillaries in the infarct. Thus, the angiogenic action of bFGF might lead to a reduction in infarct size. The application of bFGF might bring about a therapeutic modality for the salvage of infarcted myocardium.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, ENDOCRINOL & METAB SECT, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT PATHOL, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT BIOCHEM ISOTOPES, ITABASHI KU, TOKYO 173, JAPAN		YANAGISAWAMIWA, A (corresponding author), UNIV TOKYO, FAC MED, DEPT INTERNAL MED, 7-3-1 HONGO, BUNKYO KU, TOKYO 113, JAPAN.							BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; COLLE JP, 1982, ARCH MAL COEUR VAISS, V75, P395; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; FLANAGAN MF, 1991, CIRC RES, V68, P1458, DOI 10.1161/01.RES.68.5.1458; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUJITA M, 1991, AM HEART J, V122, P409, DOI 10.1016/0002-8703(91)90993-R; FUJITA M, 1988, CIRCULATION, V77, P1022, DOI 10.1161/01.CIR.77.5.1022; GOSPODAROWICZ D, 1989, J INVEST DERMATOL, V93, pS39, DOI 10.1111/1523-1747.ep12580907; GREGG DE, 1974, CIRC RES, V35, P335, DOI 10.1161/01.RES.35.3.335; HABIB GB, 1991, CIRCULATION, V83, P739, DOI 10.1161/01.CIR.83.3.739; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; KIDO H, 1991, J JPN COLL ANGIOL, V31, P753; KUMAR S, 1983, LANCET, V2, P364; LEVIN DC, 1974, CIRCULATION, V50, P831, DOI 10.1161/01.CIR.50.4.831; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MOHRI M, 1989, CIRC RES, V64, P287, DOI 10.1161/01.RES.64.2.287; PASYK S, 1982, AM J PHYSIOL, V242, P1031; PIEK JJ, 1988, J AM COLL CARDIOL, V11, P1290, DOI 10.1016/0735-1097(88)90294-X; QUINKLER W, 1989, EUR J BIOCHEM, V181, P67, DOI 10.1111/j.1432-1033.1989.tb14694.x; RAKUSAN K, 1985, CIRC RES, V57, P393, DOI 10.1161/01.RES.57.3.393; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SASAKI H, 1989, J BIOL CHEM, V264, P17606; SCHAPER W, 1990, J AM COLL CARDIOL, V15, P513, DOI 10.1016/0735-1097(90)90618-Y; SCHAPER W, 1978, BASIC RES CARDIOL, V73, P584, DOI 10.1007/BF01906796; SCHAPER W, 1988, PROG CARDIOVASC DIS, V31, P57, DOI 10.1016/0033-0620(88)90011-4; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; SCHWARZ F, 1978, AM HEART J, V95, P570, DOI 10.1016/0002-8703(78)90298-3; THOMPSON JA, 1989, P NATL ACAD SCI USA, V86, P7928, DOI 10.1073/pnas.86.20.7928; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; UNGER EF, 1990, CIRCULATION, V82, P1449, DOI 10.1161/01.CIR.82.4.1449; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; YANAGISAWAMIWA A, UNPUB	36	433	469	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1401	1403		10.1126/science.1382313	http://dx.doi.org/10.1126/science.1382313			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382313				2022-12-24	WOS:A1992JL61200034
J	TSARFATY, I; RESAU, JH; SHEN, RL; KEYDAR, I; FALETTO, DL; VANDEWOUDE, GF				TSARFATY, I; RESAU, JH; SHEN, RL; KEYDAR, I; FALETTO, DL; VANDEWOUDE, GF			THE MET PROTOONCOGENE RECEPTOR AND LUMEN FORMATION	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; SCATTER FACTOR; MOLECULAR-CLONING; KINASE-ACTIVITY; CELL-LINE; EXPRESSION; PROTOONCOGENE; IDENTIFICATION; ACTIVATION	The met proto-oncogene product (Met) and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), have been implicated in cell mitogenic response, cell motility, and the promotion of the ordered spatial arrangement of tissue. By means of confocal laser-scanning microscopy, it was shown that Met is expressed in cells bordering lumen-like structures that resemble ducts in the human mammary cell line T47D. In human breast tissue biopsies, Met staining was intense in normal cells bordering mammary ducts but was reduced in adjacent tumor tissue. Met staining in lumen-forming organs colocalizes with staining of antibody to phosphotyrosine, which suggests that the Met receptor and its substrates may be activated in lumen structures or ducts. HGF/SF treatment of human epithelial carcinoma cell lines resulted in the formation of lumen-like structures in vitro. Reduced expression of Met could be related to the extent ot tumor cell differentiation.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,DIV CANC ETIOL,MOLEC ONCOL LAB,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; TEL AVIV UNIV,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Tel Aviv University			Shen, Rulong/E-4079-2011	Tsarfaty, Ilan/0000-0002-5230-7093	PHS HHS [N01-C0-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FALETTO DL, 1992, ONCOGENE, V7, P1149; FALETTO DL, UNPUB; Freshney RI, 1987, CULTURE ANIMAL CELLS, P57; GERARDI E, 1991, CANCER CELLS, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; Naldini L., 1991, EMBO J, V10, P2876; PADAWER J, 1968, Journal of the Royal Microscopical Society, V88, P305; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TSARFATY I, UNPUB; VANDEWOUDE GF, 1992, JPN J CANCER RES, V83; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	35	251	263	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1258	1261		10.1126/science.1387731	http://dx.doi.org/10.1126/science.1387731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1387731				2022-12-24	WOS:A1992JL05000027
J	DENNING, GM; ANDERSON, MP; AMARA, JF; MARSHALL, J; SMITH, AE; WELSH, MJ				DENNING, GM; ANDERSON, MP; AMARA, JF; MARSHALL, J; SMITH, AE; WELSH, MJ			PROCESSING OF MUTANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS TEMPERATURE-SENSITIVE	NATURE			English	Article							CFTR CHLORIDE CHANNEL; INTRACELLULAR-TRANSPORT; R-DOMAIN; GENE; IDENTIFICATION; EXPRESSION; CELLS; PHOSPHORYLATION; EXERCISE	CYSTIC fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane Cl- channel regulated by cyclic AMP-dependent phosphorylation and by intracellular ATP1-7. Mutations in CFTR cause cystic fibrosis8-10 partly through loss of cAMP-regulated Cl- permeability from the plasma membrane of affected epithelia11,12. The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTR-DELTA-F508) (ref. 10). Studies on the biosynthesis13,14 and localization15 of CFTR-DELTA-F508 indicate that the mutant protein is not processed correctly and, as a result, is not delivered to the plasma membrane. These conclusions are consistent with earlier functional studies which failed to detect cAMP-stimulated Cl- channels in cells expressing CFTR-DELTA-F508 (refs 16, 17). Chloride channel activity was detected, however, when CFTR-DELTA-F508 was expressed in Xenopus oocytes18, Vero cells19 and Sf9 insect cells20. Because oocytes and Sf9 cells are typically maintained at lower temperatures than mammalian cells, and because processing of nascent proteins can be sensitive to temperature21, we tested the effect of temperature on the processing of CFTR-DELTA-F508. Here we show that the processing of CFTR-DELTA-F508 reverts towards that of wild-type as the incubation temperature is reduced. When the processing defect is corrected, cAMP-regulated Cl- channels appear in the plasma membrane. These results reconcile previous contradictory observations and suggest that the mutant most commonly associated with cystic fibrosis is temperature-sensitive.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation	DENNING, GM (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Denning, Gerene M/D-1077-2009	Anderson, Matthew/0000-0003-4602-1811; Marshall, John/0000-0003-1361-2869; Denning, Gerene/0000-0002-2334-993X; Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR C E, 1992, Biophysical Journal, V61, pA127; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOAT TF, 1989, METABOLIC BASIS INHE, V6, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P52; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681, DOI 10.1152/jappl.1987.63.4.1681; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0	25	1065	1094	0	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					761	764		10.1038/358761a0	http://dx.doi.org/10.1038/358761a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380673				2022-12-24	WOS:A1992JK69900055
J	PEARSON, ML; JEREB, JA; FRIEDEN, TR; CRAWFORD, JT; DAVIS, BJ; DOOLEY, SW; JARVIS, WR				PEARSON, ML; JEREB, JA; FRIEDEN, TR; CRAWFORD, JT; DAVIS, BJ; DOOLEY, SW; JARVIS, WR			NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS - A RISK TO PATIENTS AND HEALTH-CARE WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; DRUG RESISTANCE, MICROBIAL; CROSS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME		Objective: To determine the factors associated with the development of multidrug-resistant tuberculosis among patients at a New York City Hospital and to investigate possible nosocomial transmission. Design: A retrospective case-control study and tuberculin skin test survey. Patients: Twenty-three patients with tuberculosis whose isolates were resistant to at least isoniazid and rifampin (case patients) were compared with patients with tuberculosis whose isolates were susceptible to all agents tested (controls). Tuberculin skin test conversion rates were compared among health care workers assigned to wards where patients with tuberculosis were frequently or rarely admitted. Setting: A large, teaching hospital in New York City. Measurements: Mycobacterium tuberculosis isolates from case patients and controls were typed by restriction fragment length polymorphism analysis. Results: Case patients were younger (median age, 34 compared with 42 years; P = 0.006), more likely to be seropositive for HIV (21 of 23 compared with 11 of 23 patients; odds ratio, 11.5; 95% Cl, 1.9 to 117), and more likely to have had a previous hospital admission within 7 months before the onset of tuberculosis (19 of 23 compared with 5 of 23 patients; odds ratio, 17.1; Cl, 3.3 to 97), particularly on one ward (12 of 23 compared with 0 of 23 patients; odds ratio, undefined; P = 0.002). Health care workers assigned to wards housing case patients were more likely to have tuberculin skin test conversions than were health care workers assigned to other wards (11 of 32 compared with 1 of 47 health care workers; P < 0.001). Few (6 of 23) case patients were placed in acid-fast bacilli isolation, and no rooms tested had negative pressure. Of 16 available multidrug-resistant isolates obtained from case patients, 14 had identical banding patterns by restriction fragment length polymorphism analysis. In contrast, M. tuberculosis isolates from controls with drug-susceptible tuberculosis had patterns distinct from each other and from those of case patients. Conclusions: These data suggest nosocomial transmission of multidrug-resistant tuberculosis occurred from patient to patient and from patient to health care worker and underscore the need for effective acid-fast bacilli isolation facilities and adherence to published infection control guidelines in health care institutions.	CTR DIS CONTROL, DIV TB ELIMINAT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, OFF DIRECTOR, ATLANTA, GA 30333 USA; CTR DIS CONTROL, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene	PEARSON, ML (corresponding author), CTR DIS CONTROL, HOSP INFECT PROGRAM, MAILSTOP A-07, ATLANTA, GA 30333 USA.							CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DEAN AG, 1991, EPI INFO VERSION 501; GURDIP FS, 1990, CHEST, V98, P1056; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KENT PT, 1985, PUBLIC HLTH MYCOBACT, P166; NOBLE RC, 1981, AM J INFECT CONTROL, V9, P6, DOI 10.1016/S0196-6553(81)80003-X; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; 1991, MMWR, V40, P585; 1991, MMWR, V40, P129; 1990, MMWR, V39, P1; 1991, LANCET, V337, P852	11	484	494	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					191	196		10.7326/0003-4819-117-3-191	http://dx.doi.org/10.7326/0003-4819-117-3-191			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1352093				2022-12-24	WOS:A1992JF30400003
J	MORGAN, BA; IZPISUABELMONTE, JC; DUBOULE, D; TABIN, CJ				MORGAN, BA; IZPISUABELMONTE, JC; DUBOULE, D; TABIN, CJ			TARGETED MISEXPRESSION OF HOX-4.6 IN THE AVIAN LIMB BUD CAUSES APPARENT HOMEOTIC TRANSFORMATIONS	NATURE			English	Article							SARCOMA; EMBRYO	IN the limb bud the 5' members of the Hox-4 gene cluster are expressed in a nested set of overlapping domains which are progressively restricted in the posterior and distal directions1. These domains arise early in limb bud development and come to approximate the primordia of the major structural elements of the limb along the anterior/posterior axis2 (Fig. 1). This pattern, and the fact that surgical manipulations which lead to mirror image duplications along the anterior/posterior axis give rise to mirror image duplications of the domains of expression of these genes, have led to the proposal that these transcription factors specify positional identity along the anterior/posterior axis3,4. Here we test this hypothesis directly using replication-competent retroviral vectors to expand the domain of expression of the Hox-4.6 gene anteriorly during limb development in vivo. We report that alteration of the domain of expression of the Hox-4.6 gene in the developing limb leads to reproducible pattern alterations consistent with a posterior homeotic transformation.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	MORGAN, BA (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.			duboule, denis/0000-0001-9961-2960				BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; CEPKO C, 1989, NEUROMETHODS, V16, P177; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HURLE JM, 1987, ANAT EMBRYOL, V176, P393, DOI 10.1007/BF00310193; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; MACLEOD M, 1980, J TERATOL, V22, P299; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; ROGINA B, 1992, DEV DYNAM, V193, P92, DOI 10.1002/aja.1001930112; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	15	283	292	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					236	239		10.1038/358236a0	http://dx.doi.org/10.1038/358236a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1352858				2022-12-24	WOS:A1992JD58700054
J	PYLE, AM; MURPHY, FL; CECH, TR				PYLE, AM; MURPHY, FL; CECH, TR			RNA SUBSTRATE BINDING-SITE IN THE CATALYTIC CORE OF THE TETRAHYMENA RIBOZYME	NATURE			English	Article							CIRCULARIZED INTERVENING SEQUENCE; GROUP-I INTRON; RIBOSOMAL-RNA; ACTIVE-SITE; PRE-RRNA; OLIGONUCLEOTIDE; SPECIFICITY; CLEAVAGE; ENZYME; COMPLEMENTARY	In catalysis by group I introns, the helix (P1) containing the RNA cleavage site must be positioned next to the guanosine binding site. We have identified a conserved adenine in the catalytic core that contributes to the stability of this arrangement and propose that it accepts a hydrogen bond from a specific 2'-OH in P1. Such base-backbone tertiary interactions may be generally important to the organization of RNA tertiary structure.	UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CURTISS LA, 1978, J AM CHEM SOC, V100, P79, DOI 10.1021/ja00469a013; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HUANG JF, 1989, J AM CHEM SOC, V111, P6909, DOI 10.1021/ja00200a003; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JANIK B, 1972, BIOCHEM BIOPH RES CO, V46, P1153, DOI 10.1016/S0006-291X(72)80095-0; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MURRAYRUST P, 1983, J AM CHEM SOC, V105, P3206, DOI 10.1021/ja00348a041; PACE NR, 1990, J BIOL CHEM, V265, P3587; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SUGIMOTO N, 1989, CHEM LETT, P2223, DOI 10.1246/cl.1989.2223; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; SULLIVAN FX, 1985, CELL, V42, P639, DOI 10.1016/0092-8674(85)90121-7; TAKAHASHI LH, 1989, J AM CHEM SOC, V111, P3368, DOI 10.1021/ja00191a039; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918; WILLIAMSON CL, 1987, J BIOL CHEM, V262, P14672; WITHERS SG, 1988, ACS SYM SER, V374, P59; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	45	204	209	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					123	131		10.1038/358123a0	http://dx.doi.org/10.1038/358123a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1377367				2022-12-24	WOS:A1992JC58300042
J	FRANKLYN, JA; BETTERIDGE, J; DAYKIN, J; HOLDER, R; OATES, GD; PARLE, JV; LILLEY, J; HEATH, DA; SHEPPARD, MC				FRANKLYN, JA; BETTERIDGE, J; DAYKIN, J; HOLDER, R; OATES, GD; PARLE, JV; LILLEY, J; HEATH, DA; SHEPPARD, MC			LONG-TERM THYROXINE TREATMENT AND BONE-MINERAL DENSITY	LANCET			English	Article							THYROID-HORMONE; SUBCLINICAL HYPERTHYROIDISM; REPLACEMENT TREATMENT; THERAPY; WOMEN	Studies of the effect of thyroxine replacement therapy on bone mineral density have given conflicting results; the reductions in bone mass reported by some have prompted recommendations that prescribed doses of thyroxine should be reduced. We have examined the effect of long-term thyroxine treatment in a large homogeneous group of patients; all had undergone thyroidectomy for differentiated thyroid cancer but had no history of other thyroid disorders. The 49 patients were matched with controls for age, sex, menopausal status, body mass index, smoking history, and calcium intake score; in all subjects bone mineral density at several femoral and vertebral sites was measured by dual-energy X-ray absorptiometry. Despite long-term thyroxine therapy (mean duration 7.9 [range 1-19] years) at doses (mean 191 [SD 50]mu-g/day) that resulted in higher serum thyroxine and lower serum thyrotropin concentrations than in the controls, the patients showed no evidence of lower bone mineral density than the controls at any site. Nor was bone mineral density correlated with dose, duration of therapy, or cumulative intake, or with tests of thyroid function. There was a decrease in bone density with age in both groups. We suggest that thyroxine alone does not have a significant effect on bone mineral density and hence on risk of osteoporotic fractures.	GEN HOSP,THYROID CLIN,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT STAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT NUCL MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham								BARAN DT, 1991, J CLIN ENDOCR METAB, V72, P1182, DOI 10.1210/jcem-72-6-1182; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; FRANKLYN JA, 1990, BRIT MED J, V300, P693, DOI 10.1136/bmj.300.6726.693; FRANKLYN JA, 1992, TRENDS ENDOCRIN MET, V3, P113, DOI 10.1016/1043-2760(92)90098-L; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; Lilley J, 1991, Osteoporos Int, V1, P141, DOI 10.1007/BF01625443; Meunier PJ, 1972, ORTHOPEDIA CLINICS N, V3, P745; PACINI F, 1985, CLIN ENDOCRINOL, V23, P405, DOI 10.1111/j.1365-2265.1985.tb01098.x; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PEARCE CJ, 1984, BRIT MED J, V288, P693, DOI 10.1136/bmj.288.6418.693; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSS DS, 1989, J CLIN ENDOCR METAB, V69, P684, DOI 10.1210/jcem-69-3-684; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TOFT AD, 1991, CLIN ENDOCRINOL, V34, P103, DOI 10.1111/j.1365-2265.1991.tb00278.x; TOH SH, 1990, J BONE MINER RES, V5, P463, DOI 10.1002/jbmr.5650050507; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; UTIGER RD, 1990, NEW ENGL J MED, V323, P126; VONRECKLINGHAUS.F, 1891, R VIRCHOW FESTSCHRIF, P20; 1990, LANCET, V336, P1352	24	180	187	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					9	13		10.1016/0140-6736(92)92423-D	http://dx.doi.org/10.1016/0140-6736(92)92423-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351654				2022-12-24	WOS:A1992JC35400003
J	HAHN, WC; MENU, E; BOTHWELL, ALM; SIMS, PJ; BIERER, BE				HAHN, WC; MENU, E; BOTHWELL, ALM; SIMS, PJ; BIERER, BE			OVERLAPPING BUT NONIDENTICAL BINDING-SITES ON CD2 FOR CD58 AND A 2ND LIGAND CD59	SCIENCE			English	Article							T-CELL ACTIVATION; THYMIC EPITHELIAL-CELLS; MEMBRANE-PROTEIN; SURFACE LIGAND; RECEPTOR CD2; LFA-3; COMPLEMENT; ANTIGEN; EXPRESSION; MOLECULES	The interaction of the T cell glycoprotein CD2 with one ligand, CD58, contributes to T cell function. We have identified CD59, a glycoprotein with complement-inhibitory function, as a second physiological ligand for CD2. Antibodies to CD59 inhibit CD2-dependent T cell activation in murine T cell hybridomas expressing human CD2. In an in vitro binding assay with purified CD58 and CD59, CD2+ cells bind not only immobilized CD58 but also CD59. With two complementary approaches, it was demonstrated that the binding sites on CD2 for CD58 and CD59 are overlapping but nonidentical. These observations suggest that direct interactions between CD2 and both CD58 and CD59 contribute to T cell activation and adhesion.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; OKLAHOMA STATE UNIV,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73104; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oklahoma Medical Research Foundation; Oklahoma State University System; Oklahoma State University Center for Health Sciences; Oklahoma State University - Stillwater; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University			MENU, Elisabeth/B-2886-2010	MENU, Elisabeth/0000-0001-8844-9328; Bierer, Barbara/0000-0001-6448-8170	NHLBI NIH HHS [HL36061] Funding Source: Medline; NIAID NIH HHS [AI28554] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036061, R37HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028554, R01AI028554] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNARD A, 1987, J IMMUNOL, V139, P18; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DECKERT M, 1992, J IMMUNOL, V148, P672; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; GILLIS S, 1978, J IMMUNOL, V120, P2027; GROUX H, 1989, J IMMUNOL, V142, P3013; HAHN W, UNPUB; HAHN WC, 1991, J IMMUNOL, V147, P14; HAHN WC, IN PRESS P NATL ACAD; HARADA R, 1990, J IMMUNOL, V144, P1823; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; KORTY PE, 1991, J IMMUNOL, V146, P4092; LE PT, 1990, J IMMUNOL, V144, P4541; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING 3; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SIMS PJ, 1982, P NATL ACAD SCI USA, V264, P19228; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; VOLLGER LW, 1987, J IMMUNOL, V138, P358; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; WHITLOW MB, 1990, CELL IMMUNOL, V126, P176, DOI 10.1016/0008-8749(90)90310-N; WOLFF HL, 1990, J IMMUNOL, V144, P1215	37	179	183	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1805	1807		10.1126/science.1377404	http://dx.doi.org/10.1126/science.1377404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1377404				2022-12-24	WOS:A1992JA43400032
J	DELMAS, B; GELFI, J; LHARIDON, R; VOGEL, LK; SJOSTROM, H; NOREN, O; LAUDE, H				DELMAS, B; GELFI, J; LHARIDON, R; VOGEL, LK; SJOSTROM, H; NOREN, O; LAUDE, H			AMINOPEPTIDASE-N IS A MAJOR RECEPTOR FOR THE ENTEROPATHOGENIC CORONAVIRUS TGEV	NATURE			English	Article							INTESTINAL BRUSH-BORDER; TRANSMISSIBLE GASTROENTERITIS; VIRUS; EXPRESSION; SEQUENCE; CLONING; KIDNEY; GENE	CORONAVIRUSES, like many animal viruses, are characterized by a restricted host range and tissue tropism 1. Transmissible gastroenteritis virus (TGEV), a major pathogen causing a fatal diarrhoea in newborn pig, replicates selectively in the differentiated enterocytes covering the villi of the small intestine 2. To investigate the molecular determinants of the infection, we characterized the surface molecule used by the virus for binding and entry into host cells. Here we report that aminopeptidase N, an ectoenzyme abundantly expressed at the apical membrane of the enterocytes, serves as a receptor for TGEV. Monoclonal antibodies were selected for their ability to block infection by TGEV of porcine cell lines. They recognized a brush-border membrane protein of M(r) 150K, which was identified as aminopeptidase N by amino-terminal sequencing. Two lines of evidence supported the view that the peptidase itself acts as a receptor. First, virions bound specifically to aminopeptidase N that was purified to homogeneity. Second, recombinant expression of aminopeptidase N conferred infectivity by TGEV to an otherwise non-permissive cell line.	INRA,UNITE VIROL & IMMUNOL MOLEC,DOMAINE VILVERT,F-78350 JOUY EN JOSAS,FRANCE; PANUM INST,DEPT BIOCHEM,DK-2200 COPENHAGEN N,DENMARK	INRAE; UDICE-French Research Universities; Universite Paris Saclay				Vogel, Lotte K./0000-0001-9920-0982				DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; GORVEL JP, 1989, J CELL BIOL, V108, P2193, DOI 10.1083/jcb.108.6.2193; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAELTERMAN EO, 1972, J AM VET MED ASSOC, V160, P534; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KRAMERS MTC, 1979, EUR J BIOCHEM, V99, P345, DOI 10.1111/j.1432-1033.1979.tb13262.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAROUX S, 1973, BIOCHIM BIOPHYS ACTA, V321, P282, DOI 10.1016/0005-2744(73)90083-1; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PENSAERT M, 1970, ARCH GES VIRUSFORSCH, V31, P321, DOI 10.1007/BF01253767; SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761; SJOSTROM H, 1978, EUR J BIOCHEM, V88, P503, DOI 10.1111/j.1432-1033.1978.tb12476.x; SJOSTROM H, 1982, EUR J BIOCHEM, V122, P245, DOI 10.1111/j.1432-1033.1982.tb05873.x	21	504	549	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					417	420		10.1038/357417a0	http://dx.doi.org/10.1038/357417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1350661	Green Published, Bronze			2022-12-24	WOS:A1992HX17200068
J	TURNER, G; ROBINSON, H; LAING, S; VANDENBERK, M; COLLEY, A; GODDARD, A; SHERMAN, S; PARTINGTON, M				TURNER, G; ROBINSON, H; LAING, S; VANDENBERK, M; COLLEY, A; GODDARD, A; SHERMAN, S; PARTINGTON, M			POPULATION SCREENING FOR FRAGILE-X	LANCET			English	Article							LINKED MENTAL-RETARDATION; LOCALIZATION	A screening programme to detect fragile X syndrome has been operating in New South Wales, Australia, since 1984. The aim of this programme is to find previously unidentified individuals with the syndrome so that their extended families can be properly informed of the risks before making decisions about childbearing. 14 225 individuals attending adult and child facilities for the intellectually handicapped have been screened, of whom 8172 have been offered testing for the fragile X syndrome with a 79% uptake of the service. 253 probands were found, and in the extended families 818 females at 25-100% risk of being carriers were interviewed and counselled. Continuing contact was maintained and prenatal diagnosis was offered. The effect of the programme was assessed in a subgroup of 90 individuals, most of whom were appreciative of the service and felt that they had been adequately informed. The influence of knowing the diagnosis and its genetic implications were also assessed, the main consequences being a 26% reduction in births and a 61% uptake of prenatal diagnosis. Improved techniques for diagnosis of fragile X have benefited the families identified and counselled, suggesting that systematic screening for fragile X should be an essential component of community genetic services.	EMORY UNIV,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA 30322; WESTERN SUBURBS HOSP,NEWCASTLE & NO NEW S WALES GENET SERV,NEWCASTLE,NSW,AUSTRALIA	Emory University	TURNER, G (corresponding author), PRINCE WALES CHILDRENS HOSP,FRAGILE X PROGRAMME,SYDNEY,NSW 2031,AUSTRALIA.							COLLINS FA, 1990, CLIN GENET, V37, P18; FISHBURN J, 1983, AM J MED GENET, V14, P713, DOI 10.1002/ajmg.1320140413; GEDEON A, 1991, J MED GENET, V28, P372, DOI 10.1136/jmg.28.6.372; HEITZ D, IN PRESS AM J MED GE; LAING S, 1991, AM J MED GENET, V38, P256, DOI 10.1002/ajmg.1320380219; MODELL B, 1991, 8TH INT C HUM GEN WA; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PARTINGTON MW, 1988, AM J MED GENET, V30, P509, DOI 10.1002/ajmg.1320300153; PARTINGTON MW, 1988, AM J MED GENET, V30, P251, DOI 10.1002/ajmg.1320300127; PARTINGTON MW, 1988, AM J MED GENET, V29, P633, DOI 10.1002/ajmg.1320290322; PARTINGTON MW, IN PRESS AM J MED GE; PURVISSMITH SG, 1988, AM J MED GENET, V30, P337, DOI 10.1002/ajmg.1320300134; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1988, AM J MED GENET, V30, P633, DOI 10.1002/ajmg.1320300164; SUTHERS GK, 1988, AM J MED GENET, V30, P485, DOI 10.1002/ajmg.1320300151; THODE A, 1988, AM J MED GENET, V30, P239, DOI 10.1002/ajmg.1320300125; TURNER G, 1989, AM J MED GENET, V34, P463, DOI 10.1002/ajmg.1320340402; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; TURNER G, 1980, NEW ENGL J MED, V303, P662, DOI 10.1056/NEJM198009183031202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WILSON M, 1991, AM J MED GENET, V40, P406, DOI 10.1002/ajmg.1320400405; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	22	57	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1210	1213		10.1016/0140-6736(92)91142-U	http://dx.doi.org/10.1016/0140-6736(92)91142-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349946				2022-12-24	WOS:A1992HU68400012
J	FACCHINI, FS; HOLLENBECK, CB; JEPPESEN, J; CHEN, YDI; REAVEN, GM				FACCHINI, FS; HOLLENBECK, CB; JEPPESEN, J; CHEN, YDI; REAVEN, GM			INSULIN RESISTANCE AND CIGARETTE-SMOKING	LANCET			English	Article							CORONARY-ARTERY DISEASE; RISK-FACTORS; DENSITY LIPOPROTEIN; GLUCOSE-TOLERANCE; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE; CHOLESTEROL; MEN	Cigarette smoking is associated with increases in plasma triglycerides and decreases in plasma high density-lipoprotein-cholesterol concentration. These changes not only increase risk of coronary heart disease but also are secondary to resistance to insulin-stimulated glucose uptake or hyperinsulinaemia. To see whether there is a relation between cigarette smoking and insulin-mediated glucose uptake we measured plasma lipid and lipoprotein concentrations, plasma glucose and insulin response to an oral glucose challenge, and insulin-mediated glucose uptake in 40 matched healthy volunteers (20 non-smokers, 20 smokers). Smokers had significantly higher mean (SEM) very-low-density-lipoprotein triglycerides (0.66 [0.10] vs 0.39 [0.03] mmol/l, p < 0.02) and cholesterol (0.45 [0.06] vs 0.23 [0.04] mmol/l, p < 0.005) concentrations and lower high-density-lipoprotein cholesterol concentrations (1.16 [0.05] vs l.51 [0.08]mmol/l, p < 0.001). Although plasma glucose concentrations in response to the oral glucose load were similar in the two groups, plasma insulin response of the smokers was significantly higher (p < 0.001). Finally, smokers had higher steady-state plasma glucose concentrations in response to a continuous infusion of glucose, insulin, and somatostatin (8.4 [0.2] vs 5.0 [0.3] mmol/l, p < 0.001), despite similar steady-state plasma insulin concentrations. The findings show that chronic cigarette smokers are insulin resistant, hyperinsulinaemic, and dyslipidaemic compared with a matched group of non-smokers, and may help to explain why smoking increases risk of coronary heart disease.	VET AFFAIRS MED CTR,GERIATR RES EDUC & CLIN CTR,PALO ALTO,CA 94304	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00070] Funding Source: Medline; NHLBI NIH HHS [HL 08506] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; CARLSON LA, 1979, ACTA MED SCAND, V206, P351; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; DEFRONZO RA, 1979, DIABETES, V28, P1095, DOI 10.2337/diab.28.12.1095; FREEDMAN DS, 1986, AM J EPIDEMIOL, V124, P207; HOFFMAN D, 1986, WHO IARC, P45; JANZON L, 1983, DIABETOLOGIA, V25, P86; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; MCGILL CG, 1991, ADV EXP MED BIOL, V273, P9; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; OLEFSKY JM, 1974, AM J MED, V57, P551, DOI 10.1016/0002-9343(74)90006-0; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENTHAL M, 1983, DIABETES, V32, P408, DOI 10.2337/diabetes.32.5.408; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; SHEN SW, 1970, J CLIN INVEST, V49, P2151, DOI 10.1172/JCI106433; SHIRAISHI I, 1991, DIABETOLOGIA, V34, P737, DOI 10.1007/BF00401520; TOBEY TA, 1981, METABOLISM, V30, P165, DOI 10.1016/0026-0495(81)90167-0; WILLETT W, 1983, AM HEART J, V105, P417, DOI 10.1016/0002-8703(83)90358-7; WILLIAMS P, 1979, LANCET, V1, P72; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	22	549	566	1	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1128	1130		10.1016/0140-6736(92)90730-Q	http://dx.doi.org/10.1016/0140-6736(92)90730-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349365				2022-12-24	WOS:A1992HT23600002
J	HOOGENDIJK, JE; HENSELS, GW; GABREELSFESTEN, AAWM; GABREELS, FJM; JANSSEN, EAM; DEJONGHE, P; MARTIN, JJ; VAN BROECKHOVEN, C; VALENTIJN, LJ; BAAS, F; DEVISSER, M; BOLHUIS, PA				HOOGENDIJK, JE; HENSELS, GW; GABREELSFESTEN, AAWM; GABREELS, FJM; JANSSEN, EAM; DEJONGHE, P; MARTIN, JJ; VAN BROECKHOVEN, C; VALENTIJN, LJ; BAAS, F; DEVISSER, M; BOLHUIS, PA			DENOVO MUTATION IN HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE-1	LANCET			English	Note							DISEASE	Isolated cases of hereditary motor and sensory neuropathy type I (HMSN I, Charcot-Marie-Tooth disease type 1) have been thought to be most frequently autosomal recessive. We have found that a recently discovered duplication in chromosome 17, responsible for most cases of autosomal dominant HMSN I, is present as a de-novo mutation in 9 out of 10 sporadic patients. This finding has important implications for genetic counselling of isolated patients with HMSN I.	UNIV HOSP NIJMEGEN, INST NEUROL, NIJMEGEN, NETHERLANDS; UNIV INSTELLING ANTWERP, NEUROGENET LAB, B-2610 WILRIJK, BELGIUM	Radboud University Nijmegen; University of Antwerp	HOOGENDIJK, JE (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROL, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.		Janssen, Emiel A.M./AAM-2357-2020; Baas, Frank/F-9574-2010; Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017	Baas, Frank/0000-0003-3912-5428; Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665				CHANCE PF, 1990, AM J HUM GENET, V47, P915; Dyck P.J., 1984, PERIPHERAL NEUROPATH, P1600; DYCK PJ, 1988, MUSCLE NERVE, V11, P21, DOI 10.1002/mus.880110106; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; HARDING AE, 1980, J MED GENET, V17, P329, DOI 10.1136/jmg.17.5.329; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; TANGSRUD SE, 1988, CLIN GENET, V34, P145; WAPENAAR MC, 1990, NUCLEIC ACIDS RES, V18, P384, DOI 10.1093/nar/18.2.384-a	9	163	167	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1992	339	8801					1081	1082		10.1016/0140-6736(92)90668-S	http://dx.doi.org/10.1016/0140-6736(92)90668-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349106				2022-12-24	WOS:A1992HR44600007
J	HAMPSON, NB; NORKOOL, DM				HAMPSON, NB; NORKOOL, DM			CARBON-MONOXIDE POISONING IN CHILDREN RIDING IN THE BACK OF PICKUP TRUCKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective. - To describe the case characteristics of a series of children poisoned with carbon monoxide while traveling in the back of pickup trucks. Design. - Pediatric cases referred for treatment of carbon monoxide poisoning with hyperbaric oxygen between 1986 and 1991 were reviewed. Those cases that occurred during travel in the back of pickup trucks were selected. Clinical follow-up by telephone interview ranged from 2 to 55 months. Setting. - A private, urban, tertiary care center in Seattle, Wash. Patients. - Twenty children ranging from 4 to 16 years of age. Intervention. - All patients were treated with hyperbaric oxygen. Main Outcome Measures. - Characteristics of the poisoning incident and clinical patient outcome. Results. - Of 68 pediatric patients treated for accidental carbon monoxide poisoning, 20 cases occurred as children rode in the back of pickup trucks. In 17 of these, the children were riding under a rigid closed canopy on the rear of the truck, while three episodes occurred as children rode beneath a tarpaulin. Average carboxyhemoglobin level on emergency department presentation was 18.2% +/- 2.4% (mean +/- SEM; range, 1.6% to 37.0%). Loss of consciousness occurred in 15 of the 20 children. One child died of cerebral edema, one had permanent neurologic deficits, and 18 had no recognizable sequelae related to the episode. In all cases, the truck exhaust system had a previously known leak or a tail pipe that exited at the rear rather than at the side of the pickup truck. Conclusions. - Carbon monoxide poisoning is a significant hazard for children who ride in the back of pickup trucks. If possible, this practice should be avoided.	VIRGINIA MASON MED CTR,DEPT HYPERBAR,SEATTLE,WA 98101	Virginia Mason Medical Center	HAMPSON, NB (corresponding author), VIRGINIA MASON CLIN,DEPT MED,1100 9TH AVE,SEATTLE,WA 98111, USA.							ANGRAN PF, 1990, JAMA-J AM MED ASSOC, V264, P712; BARRET L, 1985, CLIN TOXICOL, V23, P309; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; GUSS DA, 1990, J RESPIR DIS, V11, P773; JOHNSON CJ, 1975, AM J PUBLIC HEALTH, V65, P1327, DOI 10.2105/AJPH.65.12.1327; MYERS RAM, 1983, AM J EMERG MED, V2, P226; PIANTADOSI CA, 1990, UPDATE INTENSIVE CAR, V10, P460; TONG T, 1989, AM J DIS CHILD, V143, P997, DOI 10.1001/archpedi.1989.02150210013004; TURNBULL TL, 1988, ANN EMERG MED, V17, P478, DOI 10.1016/S0196-0644(88)80240-3; 1991, DIGEST MOTOR LAWS; 1982, MMWR, V31, P529	12	39	40	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					538	540		10.1001/jama.267.4.538	http://dx.doi.org/10.1001/jama.267.4.538			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1370334				2022-12-24	WOS:A1992GZ43900031
J	REDD, SC; BLOLAND, PB; KAZEMBE, PN; PATRICK, E; TEMBENU, R; CAMPBELL, CC				REDD, SC; BLOLAND, PB; KAZEMBE, PN; PATRICK, E; TEMBENU, R; CAMPBELL, CC			USEFULNESS OF CLINICAL CASE-DEFINITIONS IN GUIDING THERAPY FOR AFRICAN CHILDREN WITH MALARIA OR PNEUMONIA	LANCET			English	Article							PRIMARY HEALTH-CARE; PERENNIAL TRANSMISSION; PLASMODIUM-FALCIPARUM; EARLY-CHILDHOOD; DIAGNOSIS; POPULATION; INFECTIONS; EFFICACY; DISEASE; INTENSE	The World Health Organisation has developed disease-specific clinical case-definitions to guide management of children with fever or cough, the cardinal signs of malaria and pneumonia. To assess the usefulness of the case-definitions and to investigate their interaction, we studied children with fever or cough brought to a hospital in Lilongwe, Malawi. For all children, a thick blood smear was examined for Plasmodium falciparum parasites. Chest radiography was done only for children with parasitaemia and those who satisfied the clinical case-definition for pneumonia; others were assumed to have normal chest radiographs. Of 1599 enrolled children, 566 (35%) had parasitaemia and 116 had radiographic evidence of pneumonia; 43 had both pneumonia and parasitaemia. Of the 471 children who met the clinical definition for pneumonia, 449 (95%) also met the malaria clinical definition. Among children with radiographic evidence of pneumonia, the clinical definition for malaria was not predictive of parasitaemia (sensitivity 93%, specificity 5%). Whether malaria parasitaemia was present or absent, the pneumonia clinical definition distinguished children with and without radiographic evidence of pneumonia (sensitivity and specificity >60%). Children who satisifed the pneumonia clinical definition were more likely to have radiographic evidence of pneumonia (odds ratio 10.4, 95% confidence interval 5.2-20.7), parasitaemia (1.6, 1.2-2.2), or both at the same time (4.2, 2.1-8.4) than were children who did not meet the definition. Children who satisfy the malaria and pneumonia clinical definitions need treatment for both disorders. Scarce diagnostic methods, especially microscopy, are needed for more specific treatment of children with fever and cough.	CTR DIS CONTROL,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; MALAWI MINIST HLTH,LILONGWE,MALAWI; EMORY UNIV,SCH MED,DEPT RADIOL,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Emory University	REDD, SC (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,MAILSTOP F12,ATLANTA,GA 30333, USA.							BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; CAMPBELL H, 1988, LANCET, V2, P742; CAMPBELL H, 1988, LANCET, V2, P1182; DARAMOLA OO, 1991, T R SOC TROP MED HYG, V84, P345; FREUND RJ, 1982, SAS SYSTEM LINEAR MO, P9; GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91, DOI 10.1080/02724936.1987.11748482; HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S; HENDRICKSE RG, 1971, ANN TROP MED PARASIT, V65, P1; HEYMANN DL, 1987, T ROY SOC TROP MED H, V81, P722, DOI 10.1016/0035-9203(87)90005-8; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KHOROMANA CO, 1986, AM J TROP MED HYG, V35, P465, DOI 10.4269/ajtmh.1986.35.465; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P; RUEBUSH TK, 1986, REV INFECT DIS, V8, P454; SARMA PS, 1989, ANN INTERN MED, V111, P336, DOI 10.7326/0003-4819-111-4-336; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; TRAPE JF, 1987, AM J EPIDEMIOL, V126, P193, DOI 10.1093/aje/126.2.193; TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P435, DOI 10.1016/0035-9203(85)90054-9; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; 1990, SUPERVISORY SKILLS M; 1990, WHOARI905 WORLD HLTH; 1986, SUGI SUPPLEMENTAL LI, P269; 1986, WHO TECH REP SER, V375	23	64	65	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1140	1143		10.1016/0140-6736(92)93160-O	http://dx.doi.org/10.1016/0140-6736(92)93160-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359219	Bronze			2022-12-24	WOS:A1992JX13400012
J	OLSSON, S; EDWARDS, IR				OLSSON, S; EDWARDS, IR			TACHYCARDIA DURING CISAPRIDE TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							METOCLOPRAMIDE				OLSSON, S (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,BOX 26,S-75103 UPPSALA,SWEDEN.							BEVACQUA BK, 1988, ANESTHESIOLOGY, V68, P124, DOI 10.1097/00000542-198801000-00021; CHERON G, 1991, PRESSE MED, V20, P1138; MCCALLUM RW, 1988, DRUGS, V36, P652, DOI 10.2165/00003495-198836060-00002; SHAKLAI M, 1974, BRIT MED J, V2, P385, DOI 10.1136/bmj.2.5915.385-a	4	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					748	749		10.1136/bmj.305.6856.748-a	http://dx.doi.org/10.1136/bmj.305.6856.748-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1384896	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JQ52000023
J	ALBERTI, A; MORSICA, G; CHEMELLO, L; CAVALLETTO, D; NOVENTA, F; PONTISSO, P; RUOL, A				ALBERTI, A; MORSICA, G; CHEMELLO, L; CAVALLETTO, D; NOVENTA, F; PONTISSO, P; RUOL, A			HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV	LANCET			English	Note							NON-B-HEPATITIS; NON-A; BLOOD-DONORS; VIRUS; ANTIBODIES; GENOME	There is controversy about clinical management of patients who persistently have antibodies to hepatitis C virus (anti-HCV) but who have no symptoms and signs of liver disease. We have taken liver biopsy samples from 23 such patients (1 6 of whom had normal alanine aminotransferase [ALT] values) to assess prevalence of liver disease and to see whether anti-HCV and HCV-RNA correlated with histological findings. 16 patients had histological evidence of chronic hepatitis, which was not predicted by serum ALT or by the pattern of specificity of anti-HCV. All 16 cases with hepatitis C viraemia (HCV-RNA detected by polymerase chain reaction), including 9 with normal ALT, had chronic hepatitis on biopsy (p<0.001), whereas 7 HCV-RNA-negative cases had normal liver histology. These findings indicate that serum HCV-RNA is a sensitive and specific marker of liver disease in anti-HCV-positive subjects, independent of ALT values, and challenge the idea of the existence of "true" healthy carriers of HCV.	UNIV PADUA,DEPT INTERNAL MED 2,I-35100 PADUA,ITALY	University of Padua			Morsica, Giulia/AAC-4993-2019; Noventa, Franco/C-1202-2008; chemello, liliana/AAU-9414-2020; PONTISSO, PATRIZIA/K-3574-2018	Morsica, Giulia/0000-0003-4891-5376; Noventa, Franco/0000-0003-4622-5523; ALBERTI, ALFREDO/0000-0001-9926-2382; PONTISSO, PATRIZIA/0000-0003-2077-9202				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; [Anonymous], 1977, Lancet, V2, P914; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; OKAMOTO H, 1990, JPN J EXP MED, V60, P167	9	423	422	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					697	698		10.1016/0140-6736(92)92234-7	http://dx.doi.org/10.1016/0140-6736(92)92234-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355801				2022-12-24	WOS:A1992JN78000006
J	BERGMAN, U; ROSA, FW; BAUM, C; WIHOLM, BE; FAICH, GA				BERGMAN, U; ROSA, FW; BAUM, C; WIHOLM, BE; FAICH, GA			EFFECTS OF EXPOSURE TO BENZODIAZEPINE DURING FETAL LIFE	LANCET			English	Article							PREGNANCY; INUTERO	Dysmorphism and mental retardation have been reported in 7 Swedish children born of mothers who had taken high doses of benzodiazepines regularly during pregnancy. To explore this association further, we examined benzodiazepine use during pregnancy in 104 000 women whose deliveries were registered by the US public health insurance system, Medicaid, during 1980-83. Fetal outcomes were assessed from the health claims profiles of their offspring, up to 6-9 years after delivery. 80 pregnant women had received 10 or more benzodiazepine prescriptions during the 4 years. Their records showed heavy general use of health care and frequent alcohol and substance abuse, and other disorders that could confound any effect of the benzodiazepines. For the 80 pregnancies, 3 intrauterine deaths were identified as well as 2 infants with congenital abnormalities whose curtailed records suggested neonatal death. Records of 64 surviving children could be linked to these 80 pregnancies whilst records for 11 apparent survivors could not be located. 6 of the 64 survivors had diagnoses consistent with teratogenic abnormalities. The high rate of teratogenicity after heavy maternal benzodiazepine use occurs with multiple alcohol and substance exposure and thus may not be due to benzodiazepine exposure.	US FDA, OFF EPIDEMIOL & BIOSTAT, ROCKVILLE, MD 20857 USA; MED PROD AGCY, UPPSALA, SWEDEN	US Food & Drug Administration (FDA); Medical Products Agency	BERGMAN, U (corresponding author), KAROLINSKA INST, HUDDINGE HOSP, DEPT CLIN PHARMACOL, S-14186 HUDDINGE, SWEDEN.							BARRY WS, 1987, LANCET, V1, P1436; BERGMAN U, 1990, J PEDIATR-US, V116, P490, DOI 10.1016/S0022-3476(05)82853-7; Bergman U, 1991, Bratisl Lek Listy, V92, P560; DUKES MNG, 1986, SIDE EFFECTS DRUGS A, V10, P50; FAICH GA, 1989, CLIN PHARMACOL THER, V46, P387, DOI 10.1038/clpt.1989.155; LAEGREID L, 1987, LANCET, V2, P1405; LAEGREID L, 1987, LANCET, V1, P108; LAEGREID L, 1989, J PEDIATR-US, V114, P126, DOI 10.1016/S0022-3476(89)80619-5; LAEGREID L, 1992, NEUROPEDIATRICS, V23, P18, DOI 10.1055/s-2008-1071305; NELSON LB, 1987, AM J DIS CHILD, V141, P175, DOI 10.1001/archpedi.1987.04460020065028; OLEGARD R, 1979, ACTA PAEDIATR SCAND, P112; PIPER JM, 1987, AM J OBSTET GYNECOL, V157, P148, DOI 10.1016/S0002-9378(87)80368-X; STROM BL, 1991, STAT MED, V10, P565, DOI 10.1002/sim.4780100408; WEBER LWD, 1985, BIOL RES PREG PERIN, V6, P151; WINTER RM, 1987, LANCET, V1, P627	15	77	77	4	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1992	340	8821					694	696		10.1016/0140-6736(92)92232-5	http://dx.doi.org/10.1016/0140-6736(92)92232-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355799				2022-12-24	WOS:A1992JN78000004
J	LAYBOURN, PJ; KADONAGA, JT				LAYBOURN, PJ; KADONAGA, JT			THRESHOLD PHENOMENA AND LONG-DISTANCE ACTIVATION OF TRANSCRIPTION BY RNA POLYMERASE-II	SCIENCE			English	Article							GAL4 DERIVATIVES; HYPERSENSITIVE SITES; INVITRO; GENE; NUCLEOSOME; PROTEINS	To explore the underlying mechanisms by which genes are regulated in eukaryotes, long-distance transcriptional activation and threshold effects were reconstituted in vitro. Long-range activation of transcription by GAL4-VP16 protein located 1300 base pairs upstream of the RNA start site was dependent on packaging of the template into histone H1-containing chromatin. A transcriptional threshold effect by GAL4-VP16 was observed with repressed chromatin templates but not naked DNA templates. The experimental data with the chromatin templates were similar to the theoretical activation profile that is predicted if the action of each DNA bound protomer of GAL4-VP16 were independent and additive in terms of free energy.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								BULGER MD, UNPUB; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Croston G.E., 1991, Protein Expression and Purification, V2, P162, DOI 10.1016/1046-5928(91)90066-R; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; CROSTON GE, UNPUB; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HOUGH PVC, 1982, J MOL BIOL, V160, P375, DOI 10.1016/0022-2836(82)90183-8; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LAYBOURN PJ, UNPUB; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SINHA SN, 1982, NUCLEIC ACIDS RES, V10, P5533, DOI 10.1093/nar/10.18.5533; STJOHNSTON D, 1992, CELL, V68, P201; TAMAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024; van Holde KE., 1989, SPRINGER SERIES MOL; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE A P, 1990, New Biologist, V2, P211; ZAWEL L, IN PRESS PROG NUCLEI	36	96	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1682	1685		10.1126/science.1388287	http://dx.doi.org/10.1126/science.1388287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1388287				2022-12-24	WOS:A1992JN50100031
J	LIVINGSTONE, LR; WHITE, A; SPROUSE, J; LIVANOS, E; JACKS, T; TISTY, TD				LIVINGSTONE, LR; WHITE, A; SPROUSE, J; LIVANOS, E; JACKS, T; TISTY, TD			ALTERED CELL-CYCLE ARREST AND GENE AMPLIFICATION POTENTIAL ACCOMPANY LOSS OF WILD-TYPE P53	CELL			English	Article							NUCLEOTIDE-SEQUENCE; DNA AMPLIFICATION; CANCER SYNDROME; HAMSTER-CELLS; CAD GENE; TRANSFORMATION; PROTEIN; MUTATIONS; ONCOGENE; LINES	Gene amplification occurs at high frequency in transformed cells (10(-3)-10(-5)), but is undetectable in normal diploid fibroblasts (<10(-9)). This study examines whether alterations of one or both p53 alleles were sufficient to allow gene amplification to occur. Cells retaining one wild-type p53 allele mimicked the behavior of primary diploid cells: they arrested growth in the presence of drug and failed to demonstrate amplification. Cells losing the second p53 allele failed to arrest when placed in drug and displayed the ability to amplify at a high frequency. Thus, loss of wild-type p53 may lead to amplification, possibly caused by changes in cell cycle progression. Other determinants can bypass this p53 function, however, since tumor cells with wild-type p53 have the ability to amplify genes.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; UNIV N CAROLINA,SCH MED,CURRICULUM GENET,CHAPEL HILL,NC 27599	Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	LIVINGSTONE, LR (corresponding author), UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA051912] Funding Source: NIH RePORTER; NCI NIH HHS [CA51912] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARKER D, 1984, AM J HUM GENET, V36, P1159; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN YM, 1991, ONCOGENE, V6, P1799; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOULDS L, 1959, NEOPLASTIC DEV, V2; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; KASTAN MB, 1991, CANCER RES, V51, P6304; KAVATHAS P, 1983, NATURE, V306, P385, DOI 10.1038/306385a0; KUERBITZ SJ, 1992, IN PRESS P NATL ACAD; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO E, 1989, J BIOL CHEM, V264, P3390; POSTE G, 1986, CANCER TREAT REP, V70, P183; ROBERTSON EJ, 1987, STEM CELLS; ROWLEY JD, 1983, CHROMOSOMES CANCER; SAGER R, 1985, P NATL ACAD SCI USA, V82, P7015, DOI 10.1073/pnas.82.20.7015; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; TISTY TD, 1992, SCIENCE, V255, P1425; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOUNG JL, 1981, NCI MONOGRAPH, V57; ZIEG J, 1983, MOL CELL BIOL, V3, P2089, DOI 10.1128/MCB.3.11.2089	52	1408	1423	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					923	935		10.1016/0092-8674(92)90243-6	http://dx.doi.org/10.1016/0092-8674(92)90243-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356076				2022-12-24	WOS:A1992JN78100008
J	EDWARDS, FA; GIBB, AJ; COLQUHOUN, D				EDWARDS, FA; GIBB, AJ; COLQUHOUN, D			ATP RECEPTOR-MEDIATED SYNAPTIC CURRENTS IN THE CENTRAL-NERVOUS-SYSTEM	NATURE			English	Article							ADENOSINE-TRIPHOSPHATE; HIPPOCAMPAL SLICES; DORSAL HORN; NEURONS; CHANNELS; RELEASE; CELLS	UNTIL now, the only well documented, fast excitatory neurotransmitter in the brain has been glutamate. Although there is evidence for adenosine 5'-triphosphate (ATP) acting as a transmitter in the peripheral nervous system1-4, suggestions for such a role in the central nervous system1,5-11 have so far not been supported by any direct evidence. Here we report the recording of evoked and miniature synaptic currents in the rat medial habenula. The fast rise time of the currents showed that they were mediated by a ligand-activated ion channel rather than a second messenger system, thus limiting the known transmitter candidates. Evidence was found for the presence on the cells of glutamate, gamma-aminobutyric acid, acetylcholine and ATP receptors, but not for 5-hydroxytryptamine (5HT3) or glycine receptors. The evoked currents were unaffected by blockers of glutamate, gamma-aminobutyric acid or acetylcholine receptors but were blocked by the ATP receptor-blocker, suramin and the desensitizing ATP receptor-agonist alpha,beta-methylene-ATP. Our evidence identifies for the first time synaptic currents in the brain, mediated directly by ATP receptors.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London			Edwards, Frances/AAE-1755-2019; Gibb, Alasdair/AAL-1605-2020; Colquhoun, David/C-1664-2008	Colquhoun, David/0000-0002-4263-017X; Gibb, Alasdair/0000-0002-2145-1615	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HOYLE CHV, 1991, ADENOSINE NERVOUS SY, pCH3; INOUE K, 1992, NEUROSCI LETT, V134, P215, DOI 10.1016/0304-3940(92)90520-H; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306-4522(88)90203-5; NAKAZAWA K, 1991, J PHYSIOL-LONDON, V434, P647, DOI 10.1113/jphysiol.1991.sp018491; NEUHAUS R, 1991, J NEUROSCI, V11, P3984; PHILLIS JW, 1974, CAN J PHYSIOL PHARM, V52, P1226, DOI 10.1139/y74-162; POTTER P, 1980, NEUROSCIENCE, V5, P1351, DOI 10.1016/0306-4522(80)90207-9; RICHARDSON PJ, 1986, BIOCHEM SOC T, V14, P1250, DOI 10.1042/bst0141250; SALTER MW, 1985, NEUROSCIENCE, V15, P815, DOI 10.1016/0306-4522(85)90080-6; SCHUBERT P, 1979, BRAIN RES, V168, P419, DOI 10.1016/0006-8993(79)90186-0; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; TOKUNAGA A, 1978, BRAIN RES, V150, P600, DOI 10.1016/0006-8993(78)90823-5; TSCHOPL M, 1992, EUR J PHARMACOL, V213, P71, DOI 10.1016/0014-2999(92)90234-U; WHITE TD, 1978, J NEUROCHEM, V30, P329, DOI 10.1111/j.1471-4159.1978.tb06534.x; WIERASZKO A, 1989, BRAIN RES, V491, P356, DOI 10.1016/0006-8993(89)90070-X; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; WILLIAMS M, 1987, PSYCHOPHARMACOLOGY 3, pCH30	24	729	738	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					144	147		10.1038/359144a0	http://dx.doi.org/10.1038/359144a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1381811				2022-12-24	WOS:A1992JM49400051
J	MOSES, S; MANJI, F; BRADLEY, JE; NAGELKERKE, NJD; MALISA, MA; PLUMMER, FA				MOSES, S; MANJI, F; BRADLEY, JE; NAGELKERKE, NJD; MALISA, MA; PLUMMER, FA			IMPACT OF USER FEES ON ATTENDANCE AT A REFERRAL CENTER FOR SEXUALLY-TRANSMITTED DISEASES IN KENYA	LANCET			English	Article							HEALTH-SERVICES; PRICE; PAY	We investigated the impact of a short-lived policy of charging fees to patients attending public-sector outpatient health facilities in Kenya by collecting data on attendance at Nairobi's Special Treatment Clinic for sexually transmitted diseases (STDs) before (23 months), during (9 months), and after (15 months) the user-charge period. During the user-charge period, the seasonally adjusted total mean monthly attendance of men decreased significantly to 40% (95% CI 36-45) of that before fees were levied. Attendance rose in the post-user-charge period, but reached only 64% (59-68) of the pre-user-charge level. For women, the adjusted total mean monthly attendance during the user-charge period was reduced significantly to 65% (55-77) of the pre-user-charge level. Mean monthly attendance by women rose in the post-user-charge period to 22% (9-37) above the pre-user-charge level. There was no evidence of an increase in attendance over the course of the user-charge period among either men or women. The introduction of user fees probably increased the number of untreated STDs in the population, with potentially serious long-term health implications. The user-fee experience in Kenya should be carefully evaluated before similar measures are introduced elsewhere.	UNIV NAIROBI, DEPT MED MICROBIOL, NAIROBI, KENYA; UNIV MANITOBA, DEPT COMMUNITY HLTH SCI, WINNIPEG R3T 2N2, MANITOBA, CANADA; UNIV MANITOBA, DEPT MED MICROBIOL, WINNIPEG R3T 2N2, MANITOBA, CANADA; UNIV MANITOBA, DEPT MED, WINNIPEG R3T 2N2, MANITOBA, CANADA; INT DEV RES CTR, DIV HLTH SCI, REG OFF EASTERN & SOUTHERN AFRICA, NAIROBI, KENYA; NAIROBI CITY COMMISS, SPECIAL TREATMENT CLIN, NAIROBI, KENYA	University of Nairobi; University of Manitoba; University of Manitoba; University of Manitoba	MOSES, S (corresponding author), UNIV NAIROBI, DEPT COMMUNITY HLTH, POB 19676, NAIROBI, KENYA.							Abel-Smith B, 1991, World Health Forum, V12, P191; ABELSMITH B, 1989, DISCUSSION PAPER ISS; BECK RG, 1980, MED CARE, V18, P787, DOI 10.1097/00005650-198008000-00001; BENNET S, 1989, LESOTHO EPIDEMIOL B, V4; De Bethune X., 1989, Health Policy and Planning, V4, P76, DOI 10.1093/heapol/4.1.76; CAMERON DW, 1989, LANCET, V2, P403; Creese Andrew L., 1990, USER CHARGES HLTH CA; de Ferranti D, 1984, World Health Stat Q, V37, P428; DEFERRANTI D, 1985, 721 WORLD BAND STAFF; GRIFFIN C, 1988, 37 EC DEV I SEM PAP; KANJI N, 1991, SOC SCI MED, V33, P985, DOI 10.1016/0277-9536(91)90003-U; Kanji N., 1989, Health Policy and Planning, V4, P110, DOI 10.1093/heapol/4.2.110; MWABU GM, 1986, SOC SCI MED, V22, P763, DOI 10.1016/0277-9536(86)90228-5; ODADA JE, 1990, SOCIOECONOMIC PROFIL; PEPIN J, 1989, AIDS, V3, P3; STANTON B, 1989, SOC SCI MED, V29, P1119; TEMMERMAN M, 1991, 6TH INT C AIDS AFR D; Waddington C., 1990, International Journal of Health Planning and Management, V5, P287, DOI 10.1002/hpm.4740050405; Waddington C. J., 1989, International Journal of Health Planning and Management, V4, P17, DOI 10.1002/hpm.4740040104; YODER RA, 1989, SOC SCI MED, V29, P35, DOI 10.1016/0277-9536(89)90125-1; 1987, FINANCING HLTH SERVI; 1988, NAIROBI AREA STUDY	22	89	89	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1992	340	8817					463	466		10.1016/0140-6736(92)91778-7	http://dx.doi.org/10.1016/0140-6736(92)91778-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354792				2022-12-24	WOS:A1992JJ87700012
J	WATSON, EK; MAYALL, ES; LAMB, J; CHAPPLE, J; WILLIAMSON, R				WATSON, EK; MAYALL, ES; LAMB, J; CHAPPLE, J; WILLIAMSON, R			PSYCHOLOGICAL AND SOCIAL-CONSEQUENCES OF COMMUNITY CARRIER SCREENING-PROGRAM FOR CYSTIC-FIBROSIS	LANCET			English	Article								We have assessed the effect of screening for cystic fibrosis (CF) carrier status on anxiety levels, attitudes, knowledge and actions of participants in a pilot programme conducted through primary health care services. Over 3000 individuals were screened and 100 carriers with no previous family history were identified. Varying degrees of anxiety were found to be associated initially with a positive result, but most of this was allayed by genetic counselling, and we find no adverse long-term psychological consequences in carriers. Most discussed carrier status with their partner (89%), parents, other relatives and also with friends; 87% of partners to whom testing was suggested have been screened. Those testing positive indicated that knowledge of carrier status would be considered in future reproductive decisions, and after 6 months carriers retained a reasonable level of knowledge about CF and its inheritance. Carriers and non-carriers uniformly approve of screening and are glad to have been tested. Knowledge of CF in the sample of non-carriers has also increased after testing, suggesting screening may improve understanding of CF among the entire target population. Fears of possible social costs of screening may be ill-founded.	IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET, REG DNA LAB, LONDON W2 1PG, ENGLAND	Imperial College London								BONDUELLE M, 1990, HUM GENET, V85, P436; EVERSKIEBOOMS G, 1979, CLIN GENET, V15, P465; HOLTZMAN NA, 1989, PROCEED CAUTION, P174; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; Spielberger C. D., 1970, SELF EVALUATION QUES; TSUI LC, 1992, CYSTIC FIBROSIS GENE; WATSON EK, 1990, HUM GENET, V85, P435, DOI 10.1007/BF02428303; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1990, NEW ENGL J MED, V323, P70	10	91	92	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1992	340	8813					217	220		10.1016/0140-6736(92)90477-K	http://dx.doi.org/10.1016/0140-6736(92)90477-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353144				2022-12-24	WOS:A1992JE75800012
J	MINAKAMI, H; TAKAHASHI, T; IZUMI, A; ITOI, H; TAMADA, T				MINAKAMI, H; TAKAHASHI, T; IZUMI, A; ITOI, H; TAMADA, T			ENLARGEMENT OF THE SALIVARY-GLAND AFTER RITODRINE TREATMENT IN PREGNANT-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							PRETERM				MINAKAMI, H (corresponding author), JICHI MED SCH,DEPT OBSTET & GYNAECOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		MINAKAMI, HISANORI/D-6477-2012					BARDEN TP, 1980, OBSTET GYNECOL, V56, P1; MCPHERSON MA, 1978, BIOCHEM J, V176, P855, DOI 10.1042/bj1760855; MCPHERSON MA, 1986, LANCET, V2, P1007; RUSH RW, 1976, BRIT MED J, V2, P965, DOI 10.1136/bmj.2.6042.965; SELYE H, 1961, SCIENCE, V133, P44, DOI 10.1126/science.133.3445.44	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1668	1668		10.1136/bmj.304.6843.1668	http://dx.doi.org/10.1136/bmj.304.6843.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1378771	Green Published, Bronze			2022-12-24	WOS:A1992JB93900022
J	WINQVIST, O; KARLSSON, FA; KAMPE, O				WINQVIST, O; KARLSSON, FA; KAMPE, O			21-HYDROXYLASE, A MAJOR AUTOANTIGEN IN IDIOPATHIC ADDISONS-DISEASE	LANCET			English	Article							AUTOANTIBODIES; SEQUENCE; ANTIGEN; GENE; IDENTIFICATION; EXPRESSION; PROTEINS; CLONING; P450C21	Sera from patients with idiopathic Addison's disease commonly react with the zona glomerulosa of adrenal cortex. We used high-resolution western blot analysis of an adrenal microsomal fraction to investigate the target of these antibodies. A protein with an apparent molecular weight of 54 kDa was recognised as the common and major component. Sera identifying this autoantigen (from 12 of 16 patients) also showed strong immunofluorescence staining of a steroid-producing human adrenal adrenocortical cell line, NCI-H295. On application of antisera specific for different cytochrome P450 steroidogenic enzymes (side-chain cleavage enzyme, 21-hydroxylase, 17-alpha-hydroxylase, 11-beta-hydroxylase)the mobility of the 54 kDa protein in western blots corresponded to that of 21 -hydroxylase. This parallel behaviour was confirmed by immunoprecipitation, electrophoresis, and autoradiography with the various sera and S-35-methionine-labelled NCI-H295 cell lysates. Preabsorptions of S-35-methionine-labelled cell lysates with the antiserum to 21-hydroxylase, but not with the other enzyme antisera, abolished precipitation of the 54 kDa autoantigen with the patient sera. These results indicate that 21-hydroxylase (P450c21), prominent in the zona glomerulosa of the adrenal cortex, is a major autoantigen in idiopathic Addison's disease.	UNIV HOSP UPPSALA,DEPT INTERNAL MED,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital				winqvist, Ola/0000-0003-0842-4441				ANDERSON J. R., 1968, CLIN EXP IMMUNOL, V3, P107; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BANGA JP, 1991, AUTOIMMUNITY, V9, P177, DOI 10.3109/08916939109006755; BLIZZARD RM, 1962, LANCET, V2, P901; BLIZZARD RM, 1963, J CLIN INVEST, V42, P1653, DOI 10.1172/JCI104851; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRIGHT GM, 1990, J CLIN ENDOCR METAB, V70, P95, DOI 10.1210/jcem-70-1-95; CHOINARD ML, 1990, MOL CELL ENDOCRINOL, V68, P29; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; FURMANIAK J, 1988, FEBS LETT, V231, P25, DOI 10.1016/0014-5793(88)80695-1; GAZDAR AF, 1990, CANCER RES, V50, P5488; GOUDIE R. B., 1968, CLIN EXP IMMUMOL, V3, P119; GOUDIE RB, 1966, LANCET, V1, P1173; JONSSON J, 1981, OPUSC MED, V26, P1; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KROHN K, 1992, LANCET, V339, P770, DOI 10.1016/0140-6736(92)91894-E; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOROHASHI K, 1984, P NATL ACAD SCI-BIOL, V81, P4647, DOI 10.1073/pnas.81.15.4647; MULLER J, 1991, ENDOCR RES, V17, P165; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; SOTSIOU F, 1980, CLIN EXP IMMUNOL, V39, P97; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; WELLER TH, 1954, P SOC EXP BIOL MED, V86, P789, DOI 10.3181/00379727-86-21235; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	27	305	313	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1559	1562		10.1016/0140-6736(92)91829-W	http://dx.doi.org/10.1016/0140-6736(92)91829-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351548				2022-12-24	WOS:A1992JB20200002
J	DUSTAN, HP				DUSTAN, HP			GROWTH-FACTORS AND RACIAL-DIFFERENCES IN SEVERITY OF HYPERTENSION AND RENAL DISEASES	LANCET			English	Note							WHITE PATIENTS; BLACK; FIBROBLASTS		UNIV ALABAMA, SCH MED, BIRMINGHAM, AL 35233 USA	University of Alabama System; University of Alabama Birmingham								[Anonymous], 1992, LANCET, V339, P28; BABU M, 1989, MOL CELL BIOL, V9, P1642, DOI 10.1128/MCB.9.4.1642; BERK BC, 1989, BIOCHEM PHARMACOL, V38, P219, DOI 10.1016/0006-2952(89)90030-0; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; DATUBOBROWN DD, 1990, BRIT J PLAST SURG, V43, P70, DOI 10.1016/0007-1226(90)90047-4; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; DUSTAN HP, 1958, CIRCULATION, V18, P644, DOI 10.1161/01.CIR.18.4.644; FROHLICH ED, 1984, MINER ELECTROL METAB, V10, P173; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; MESSERLI FH, 1979, AM J MED, V67, P27, DOI 10.1016/0002-9343(79)90065-2; MUIRHEAD EE, 1989, CLIN CARDIOL, V12, P58; PITCOCK JA, 1976, HUM PATHOL, V7, P333, DOI 10.1016/S0046-8177(76)80043-3; PITCOCK JA, 1975, CIRC RES, V36, P133, DOI 10.1161/01.RES.36.6.133; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; RUSSELL SB, 1988, P NATL ACAD SCI USA, V85, P587, DOI 10.1073/pnas.85.2.587; SAOUAF R, 1991, J CLIN INVEST, V88, P1182, DOI 10.1172/JCI115420; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SMITH SR, 1991, KIDNEY INT, V40, P815, DOI 10.1038/ki.1991.281; 1990, USRDS1990 NIH US REN	21	22	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1992	339	8805					1339	1340		10.1016/0140-6736(92)91971-A	http://dx.doi.org/10.1016/0140-6736(92)91971-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350001				2022-12-24	WOS:A1992HW83700013
J	SHERMAN, MY; GOLDBERG, AL				SHERMAN, MY; GOLDBERG, AL			HEAT-SHOCK IN ESCHERICHIA-COLI ALTERS THE PROTEIN-BINDING PROPERTIES OF THE CHAPERONIN GROEL BY INDUCING ITS PHOSPHORYLATION	NATURE			English	Article								WHEN bacterial or eukaryotic cells are exposed to high temperatures or other harsh conditions, they respond by synthesis of a specific set of heat-shock proteins 1-3. Certain heat-shock proteins such as groEL, called 'chaperonins', can prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under harmful conditions 2,4. We report here a new aspect of the heat-shock response in Escherichia coli: at high temperatures a fraction of groEL becomes modified covalently, altering its interaction with unfolded proteins. The heat-modified form can be eluted with ATP from an unfolded protein more easily than normal groEL. The critical heat-induced modification seems to be phosphorylation, which is reversed on return to low temperature. Treatment of the modified groEL with phosphatases caused its apparent size, charge and binding properties to resemble those of the unmodified form. Thus during heat shock some groEL is reversibly phosphorylated, which allows its ATP-dependent release from protein substrates in the absence of its usual cofactor (groES), and probably promotes the repair of damaged polypeptides.			SHERMAN, MY (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.							ALTSCHULER M, 1982, HEAT SHOCK BACTERIA, P321; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HELLEBUST H, 1989, J BIOTECHNOL, V12, P275, DOI 10.1016/0168-1656(89)90047-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MACKEY BM, 1990, J APPL BACTERIOL, V69, P373, DOI 10.1111/j.1365-2672.1990.tb01527.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Morimoto RI, 1990, STRESS PROTEINS BIOL; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PHILLIPS TA, 1987, ESCHERICHIA COLI SAL, V2, P919; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN M, 1991, J BACTERIOL, V173, P4249; SHERMAN MY, 1992, EMBO J, V11, P71; SMITH BJ, 1991, P NATL ACAD SCI USA, V88, P11091, DOI 10.1073/pnas.88.24.11091; WATSON K, 1984, FEBS LETT, V169, P267	18	97	98	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					167	169		10.1038/357167a0	http://dx.doi.org/10.1038/357167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1349729				2022-12-24	WOS:A1992HU12200061
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNINGS ON USE OF ACE INHIBITORS IN 2ND AND 3RD TRIMESTER OF PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-24	WOS:A1992HT06800005
J	BRAYDEN, JE; NELSON, MT				BRAYDEN, JE; NELSON, MT			REGULATION OF ARTERIAL TONE BY ACTIVATION OF CALCIUM-DEPENDENT POTASSIUM CHANNELS	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; SENSITIVE K+ CHANNELS; RABBIT PORTAL-VEIN; SKELETAL-MUSCLE; CEREBRAL-ARTERIES; PRESSURE; DEPOLARIZATION; ENDOTHELIUM; CONDUCTANCE; VESSELS	Blood pressure and tissue perfusion are controlled in part by the level of intrinsic (myogenic) vascular tone. However, many of the molecular determinants of this response are unknown. Evidence is now presented that the degree of myogenic tone is regulated in part by the activation of large-conductance calcium-activated potassium channels in arterial smooth muscle. Tetraethylammonium ion (TEA+) and charybdotoxin (CTX), at concentrations that block calcium-activated potassium channels in smooth muscle cells isolated from cerebral arteries, depolarized and constricted pressurized cerebral arteries with myogenic tone. Both TEA+ and CTX had little effect on arteries when intracellular calcium was reduced by lowering intravascular pressure or by blocking calcium channels. Elevation of intravascular pressure through membrane depolarization and an increase in intracellular calcium may activate calcium-activated potassium channels. Thus, these channels may serve as a negative feedback pathway to control the degree of membrane depolarization and vasoconstriction.	UNIV VERMONT,VERMONT CTR VASC RES,COLCHESTER,VT 05446	University of Vermont	BRAYDEN, JE (corresponding author), UNIV VERMONT,DEPT PHARMACOL,MED RES FACIL,55A S PK DR,COLCHESTER,VT 05446, USA.			Nelson, Mark/0000-0002-6608-8784	NHLBI NIH HHS [HL 35911, HL 44455] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL035911, R01HL044455, R01HL035911] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BEECH DJ, 1989, J PHYSIOL-LONDON, V418, P293, DOI 10.1113/jphysiol.1989.sp017841; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BRAYDEN JE, 1989, J CEREBR BLOOD F MET, V9, P256, DOI 10.1038/jcbfm.1989.42; BRAYDEN JE, 1991, CIRCULATION S2, V84, P406; CARL A, 1989, AM J PHYSIOL, V257, pC470, DOI 10.1152/ajpcell.1989.257.3.C470; COLE WC, 1989, AM J PHYSIOL, V257, pC481, DOI 10.1152/ajpcell.1989.257.3.C481; DULING BR, 1981, AM J PHYSIOL, V241, pH108, DOI 10.1152/ajpheart.1981.241.1.H108; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDER DR, 1987, CIRC RES, V60, P102, DOI 10.1161/01.RES.60.1.102; HARDER DR, 1987, AM J PHYSIOL, V253, pF778, DOI 10.1152/ajprenal.1987.253.4.F778; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HU SL, 1989, J GEN PHYSIOL, V94, P849, DOI 10.1085/jgp.94.5.849; INOUE R, 1985, PFLUG ARCH EUR J PHY, V405, P173, DOI 10.1007/BF00582557; JOHNSON PC, 1986, CIRC RES, V59, P483, DOI 10.1161/01.RES.59.5.483; KOVACS RJ, 1991, AM J PHYSIOL, V261, pH604, DOI 10.1152/ajpheart.1991.261.2.H604; KUME H, 1991, AM J PHYSIOL, V261, pC1204, DOI 10.1152/ajpcell.1991.261.6.C1204; LANGTON PD, 1991, AM J PHYSIOL, V260, pH927, DOI 10.1152/ajpheart.1991.260.3.H927; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MCCARRON JG, 1991, AM J PHYSIOL, V261, pH287, DOI 10.1152/ajpheart.1991.261.2.H287; MEININGER GA, 1991, AM J PHYSIOL, V261, pH950, DOI 10.1152/ajpheart.1991.261.3.H950; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; OGDEN DC, 1985, PROC R SOC SER B-BIO, V225, P329, DOI 10.1098/rspb.1985.0065; OSOL G, 1985, AM J PHYSIOL, V249, pH914, DOI 10.1152/ajpheart.1985.249.5.H914; OSOL G, 1986, ESSENTIAL HYPERTENSI, P107; QUAST U, 1989, TRENDS PHARMACOL SCI, V10, P431, DOI 10.1016/S0165-6147(89)80003-3; QUAYLE JM, 1990, BIOPHYS J, V57, pA301; QUAYLE JM, 1988, J PHYSIOL-LONDON, V405, P677, DOI 10.1113/jphysiol.1988.sp017355; RUBANYI GM, 1988, AM J PHYSIOL, V255, pH783, DOI 10.1152/ajpheart.1988.255.4.H783; SINGER JJ, 1987, PFLUG ARCH EUR J PHY, V408, P98, DOI 10.1007/BF00581337; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TORO L, 1991, J BIOENERG BIOMEMBR, V23, P561, DOI 10.1007/BF00785811; TORO L, 1990, AM J PHYSIOL, V258, pH912, DOI 10.1152/ajpheart.1990.258.3.H912; WORLEY JF, 1991, AM J PHYSIOL, V261, pH1951, DOI 10.1152/ajpheart.1991.261.6.H1951	41	825	840	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					532	535		10.1126/science.1373909	http://dx.doi.org/10.1126/science.1373909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373909				2022-12-24	WOS:A1992HQ18700067
J	HAMILTON, KK; KIM, PMH; DOETSCH, PW				HAMILTON, KK; KIM, PMH; DOETSCH, PW			A EUKARYOTIC DNA GLYCOSYLASE LYASE RECOGNIZING ULTRAVIOLET LIGHT-INDUCED PYRIMIDINE DIMERS	NATURE			English	Article							COLI ENDONUCLEASE-IV; SACCHAROMYCES-CEREVISIAE; MICROCOCCUS-LUTEUS; REPAIR; BACTERIOPHAGE-T4; MECHANISM; CLEAVAGE; ENZYME; PHOTOLYASE; INVITRO	CYCLOBUTANE pyrimidine dimers (CPDs) are the predominant product of photodamage in DNA after exposure of cells to ultraviolet light 1,2 and are cytotoxic, mutagenic and carcinogenic in a variety of cellular and animal systems 3-5. In prokaryotes, enzymes and protein complexes have been characterized that remove or reverse CPDs in DNA 6-8. Micrococcus luteus and T4 phage-infected Escherichia coli contain a specific N-glycosylase/apurinic-apyrimidinic lyase that catalyses a two-step DNA incision process at sites of CPDs, thus initiating base excision repair of these lesions 7,9-12. It is we established that CPDs are recognized and removed from eukaryotic DNA by excision repair processes but very little information exists concerning the nature of the proteins involved in CPD recognition and DNA incision events 7,12,13. We report here that an enzyme functionally similar to the prokaryotic N-glycosylase/apurinic-apyrimidinic lyases exists in Saccharomyces cerevisiae. To our knowledge, this is the first time such an activity has been found in a eukaryote and is also the first example of an organism having both direct reversal and base excision repair pathways for the removal of CPDs from DNA.	EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University								[Anonymous], 1985, DNA REPAIR; BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BEKKER ML, 1980, J BACTERIOL, V142, P322, DOI 10.1128/JB.142.1.322-324.1980; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; DOWD DR, 1990, J BIOL CHEM, V265, P3424; Friedberg E C, 1980, Methods Enzymol, V65, P191; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; FRIEDBERG EC, 1981, J SUPRAMOL STR CELL, V16, P91, DOI 10.1002/jsscb.1981.380160109; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GOSSETT J, 1988, BIOCHEMISTRY-US, V27, P2629, DOI 10.1021/bi00407a054; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; Harm W, 1980, BIOL EFFECTS ULTRAVI; HART RW, 1975, MOL MECHANISMS REPAI, P719; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; PATRICK MH, 1976, PHOTOCHEM PHOTOBIOL, V24, P507, DOI 10.1111/j.1751-1097.1976.tb06867.x; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PRAKASH L, 1977, MUTAT RES, V45, P13, DOI 10.1016/0027-5107(77)90038-0; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RADANY EH, 1982, J VIROL, V41, P88, DOI 10.1128/JVI.41.1.88-96.1982; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SEAWALL PC, J VIROL, V35, P790; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; WALDSTEIN EA, 1979, P NATL ACAD SCI USA, V76, P3746, DOI 10.1073/pnas.76.8.3746; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	36	38	38	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					725	728		10.1038/356725a0	http://dx.doi.org/10.1038/356725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1373868				2022-12-24	WOS:A1992HQ14600066
J	CERRETTI, DP; KOZLOSKY, CJ; MOSLEY, B; NELSON, N; VANNESS, K; GREENSTREET, TA; MARCH, CJ; KRONHEIM, SR; DRUCK, T; CANNIZZARO, LA; HUEBNER, K; BLACK, RA				CERRETTI, DP; KOZLOSKY, CJ; MOSLEY, B; NELSON, N; VANNESS, K; GREENSTREET, TA; MARCH, CJ; KRONHEIM, SR; DRUCK, T; CANNIZZARO, LA; HUEBNER, K; BLACK, RA			MOLECULAR-CLONING OF THE INTERLEUKIN-1-BETA CONVERTING ENZYME	SCIENCE			English	Article							ACUTE MYELOBLASTIC-LEUKEMIA; GRANULOCYTE-MACROPHAGE; SEQUENCE; EXPRESSION; RECEPTOR; CELLS; PRECURSOR; PROLIFERATION; SPECIFICITY; STIMULATION	Interleukin-1-beta (IL-1-beta) mediates a wide range of immune and inflammatory responses. The active cytokine is generated by proteolytic cleavage of an inactive precursor. A complementary DNA encoding a protease that carries out this cleavage has been cloned. Recombinant expression in COS-7 cells enabled the cells to process precursor IL-1-beta to the mature form. Sequence analysis indicated that the enzyme itself may undergo proteolytic processing. The gene encoding the protease was mapped to chromosomal band 11q23, a site frequently involved in rearrangement in human cancers.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University	CERRETTI, DP (corresponding author), IMMUNEX CORP, 51 UNIV ST, SEATTLE, WA 98101 USA.							AURON PE, 1987, J IMMUNOL, V138, P1447; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRADBURY D, 1990, LEUKEMIA, V4, P44; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CERRETTI DP, 1986, P NATL ACAD SCI USA, V83, P3223, DOI 10.1073/pnas.83.10.3223; CERRETTI DP, UNPUB; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; COZZOLINO F, 1990, INT J CANCER, V46, P902, DOI 10.1002/ijc.2910460525; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DELWEL R, 1989, BLOOD, V74, P586; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOWER SK, 1992, CHEM IMMUNOL, V51, P33; DRUCK T, UNPUB; ESTROV Z, 1991, BLOOD, V78, P1476; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONHEIM SR, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NETT MA, UNPUB; RAMBALDI A, 1991, BLOOD, V78, P3248; RAY CA, IN PRESS CELL; SAKAI K, 1987, J EXP MED, V166, P1597, DOI 10.1084/jem.166.5.1597; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807	41	994	1052	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1992	256	5053					97	100		10.1126/science.1373520	http://dx.doi.org/10.1126/science.1373520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1373520				2022-12-24	WOS:A1992HL82200035
J	VALVERDE, MA; DIAZ, M; SEPULVEDA, FV; GILL, DR; HYDE, SC; HIGGINS, CF				VALVERDE, MA; DIAZ, M; SEPULVEDA, FV; GILL, DR; HYDE, SC; HIGGINS, CF			VOLUME-REGULATED CHLORIDE CHANNELS ASSOCIATED WITH THE HUMAN MULTIDRUG-RESISTANCE P-GLYCOPROTEIN	NATURE			English	Article							CYSTIC-FIBROSIS; CELL-LINE; EXPRESSION; GENE; IDENTIFICATION; CONDUCTANCE; EPITHELIUM; TRANSPORT; PROTEINS; TISSUES	EXPRESSION of P-glycoprotein, the product of the MDR1 gene, confers multidrug resistance on cell lines and human tumours (reviewed in refs 1, 2). P-glycoprotein (relative molecular mass 170,000) is an ATP-dependent, active transporter which pumps hydrophobic drugs out of cells 3, but its normal physiological role is unknown. It is a member of the ABC (ATP-binding cassette) superfamily of transporters 4, which includes many bacterial transport systems, the putative peptide transporter from the major histocompatibility locus, and the product of the cystic fibrosis gene (the cystic fibrosis transmembrane regulator, CFTR). CFTR is located in the apical membranes of many secretory epithelia 5 and is associated with a cyclic AMP-regulated chloride channel 6-8. At least two other chloride channels are present in epithelial cells, regulated by cell volume and by intracellular Ca2+, respectively 9,10. Because of the structural and sequence similarities between P-glycoprotein and CFTR 4,11, and because P-glycoprotein is abundant in many secretory epithelia 12-14, we examined whether P-glycoprotein might be associated with one or other of these channels. We report here that expression of P-glycoprotein generates volume-regulated, ATP-dependent, chloride-selective channels, with properties similar to channels characterized previously in epithelial cells.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES LABS,OXFORD OX3 9DU,ENGLAND	University of Oxford	VALVERDE, MA (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND.		Diaz, Mario/C-1916-2014	Diaz, Mario/0000-0001-5692-8906; Sepulveda Valenzuela, Francisco Leandro/0000-0003-0022-6598; Hyde, Stephen/0000-0002-8877-4005; Gill, Deborah/0000-0002-5264-054X; Valverde, Miguel A./0000-0002-6961-3361				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BAAS F, 1990, CANCER RES, V50, P5392; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GIRALDEZ F, 1988, BIOCHIM BIOPHYS ACTA, V942, P353, DOI 10.1016/0005-2736(88)90037-5; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARGER BD, 1990, FOCUS, V12, P25; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; MORRIS DI, IN PRESS BIOCHEMISTR; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEPPARD DN, 1991, J PHYSIOL-LONDON, V433, P663, DOI 10.1113/jphysiol.1991.sp018449; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	30	606	620	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					830	833		10.1038/355830a0	http://dx.doi.org/10.1038/355830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1371598				2022-12-24	WOS:A1992HF63600057
J	WANG, RYH; SHIH, JWK; GRANDINETTI, T; PIERCE, PF; HAYES, MM; WEAR, DJ; ALTER, HJ; LO, SC				WANG, RYH; SHIH, JWK; GRANDINETTI, T; PIERCE, PF; HAYES, MM; WEAR, DJ; ALTER, HJ; LO, SC			HIGH-FREQUENCY OF ANTIBODIES TO MYCOPLASMA-PENETRANS IN HIV-INFECTED PATIENTS	LANCET			English	Article							AIDS; PROTEINS; AGENT	Mycoplasma penetrans, a novel mycoplasma isolated from HIV-1-infected patients with AIDS, has pathogenic properties associated with in-vivo virulence. Enzyme-linked immunosorbent assay and western blotting detected a more than 100 times higher frequency of antibodies to the mycoplasma in serum from HIV-1-infected patients with AIDS (40%) than from HIV-negative controls (0.3%). Serum from 20% of HIV-1-infected, symptom-free individuals also had M penetrans specific antibodies. The antibodies major immunoreactivity was directed against P35 and P38, the two main lipid-associated membrane protein antigens of the organism. Patients attending sexually transmitted disease clinics had a low frequency of antibody (0.9%). None of 178 HIV-negative patients with different non-AIDS diseases, many associated with immune dysfunction and/or low white cell counts, tested positive for the antibodies. M penetrans, apparently not a commensal and not a simple opportunist, is uniquely associated with HIV-1 infection and AIDS.	ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,AMER REGISTRY PATHOL,WASHINGTON,DC 20306; NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892; AMER RED CROSS,NATL CAPITAL CHAPTER,WASHINGTON,DC; GEORGETOWN UNIV HOSP,HIV CLIN PROGRAM,WASHINGTON,DC 20007	United States Department of Defense; National Institutes of Health (NIH) - USA; American Red Cross; Georgetown University					NIAID NIH HHS [AI-31830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031830] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORDIER C, 1981, J BIOL CHEM, V256, P1604; COLE BC, 1985, MYCOPLASMAS, V4, P203; DELGIUDICE RA, 1985, INT J SYST BACTERIOL, V35, P285, DOI 10.1099/00207713-35-3-285; HAWKINS RE, 1992, J INFECT DIS, V165, P581, DOI 10.1093/infdis/165.3.581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAITRE M, 1992, INFECT IMMUN, V60, P742; LO SC, 1989, AM J TROP MED HYG, V40, P399, DOI 10.4269/ajtmh.1989.40.399; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LO SC, 1989, AM J TROP MED HYG, V40, P213, DOI 10.4269/ajtmh.1989.40.213; LO SC, 1991, LANCET, V338, P1415, DOI 10.1016/0140-6736(91)92721-D; LO SC, 1992, INT J SYST BACTERIOL, V42, P357, DOI 10.1099/00207713-42-3-357; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; LO SC, 1991, MODERN PATHOL, V6, P750; MONTAGNIER L, 1990, RETROVIRUSES HUMAN A, P9; ROSENGARTEN R, 1990, SCIENCE, V247, P315, DOI 10.1126/science.1688663; RUUTH E, 1989, IMMUNOL REV, V112, P133, DOI 10.1111/j.1600-065X.1989.tb00556.x; Somerson N. L., 1979, MYCOPLASMAS, V2, P191; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WISE KS, 1987, J BACTERIOL, V169, P5546, DOI 10.1128/jb.169.12.5546-5555.1987; Wright K, 1990, Science, V248, P682, DOI 10.1126/science.2333519; 1991, LANCET, V337, P20	22	78	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1312	1316		10.1016/0140-6736(92)92493-Y	http://dx.doi.org/10.1016/0140-6736(92)92493-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360035	Green Submitted			2022-12-24	WOS:A1992KA26200004
J	NAYLOR, JA; GREEN, PM; RIZZA, CR; GIANNELLI, F				NAYLOR, JA; GREEN, PM; RIZZA, CR; GIANNELLI, F			FACTOR-VIII GENE EXPLAINS ALL CASES OF HEMOPHILIA-A	LANCET			English	Note							HEMOPHILIA-A; MUTATIONS; HALF	Using an mRNA-based method to examine haemophilia A mutations we provide an explanation for the puzzling report that half of the mutations causing severe disease are not detected by analysis of the putative promoter, exons, and most exon/intron boundaries of the factor VIII gene. An unusual cluster of mutations involving regions of intron 22 not examined earlier leads to defective joining of exons 22 and 23 in the mRNA and caused haemophilia A in 10/24 severely affected UK patients.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford								GITSCHIER J, 1991, THROMB HAEMOSTASIS, V65, P662; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NAYLOR JA, 1991, LANCET, V337, P635, DOI 10.1016/0140-6736(91)92450-G; RANDALL T, 1991, JAMA-J AM MED ASSOC, V266, P1612, DOI 10.1001/jama.266.12.1612; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331	7	71	72	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1066	1067		10.1016/0140-6736(92)93080-7	http://dx.doi.org/10.1016/0140-6736(92)93080-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357455				2022-12-24	WOS:A1992JV77500005
J	VERITY, CM; ROSS, EM; GOLDING, J				VERITY, CM; ROSS, EM; GOLDING, J			EPILEPSY IN THE 1ST 10 YEARS OF LIFE - FINDINGS OF THE CHILD HEALTH AND EDUCATION STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONVULSIVE DISORDERS; FEBRILE CONVULSIONS; UNPROVOKED SEIZURE; NATIONAL COHORT; RISK-FACTORS; FOLLOW-UP; RECURRENCE; POPULATION; PREVALENCE; PROGNOSIS	Objectives-To identify children with afebrile seizures in a national cohort, classify the seizures, and document progress in the first 10 years of life. Design-Population based birth cohort study. Setting-The child health and education study, which includes 16004 neonatal survivors (98.5% of infants born in the United Kingdom during one week of April 1970). Subjects-14676 children for whom relevant information was available. Main outcome measures-Responses to parental and general practitioner questionnaires and hospital records at 5 and 10 years after birth. Results-84 children (42 boys, 42 girls) had had one or more afebrile seizure (incidence 5.7/1000). 63 children (31 boys, 32 girls) had epilepsy (incidence 4.3/1000). 49 of 55 children had a second seizure within a year of the first. The commonest seizure types were tonic-clonic (42) and complex partial (25). A greater proportion of children with complex partial seizures had recurrences. Children who had infantile spasms or a mixed seizure disorder had a poor outcome. All six children who died had symptomatic seizures in the first year, but seizures were not the direct cause of death. Conclusions-The results of this study are probably representative of seizure patterns in the general population. Outcome after seizures is determined more by the underlying disease than by the seizures themselves.	UNIV LONDON KINGS COLL HOSP, DEPT COMMUNITY PAEDIAT, LONDON SE5 8RX, ENGLAND; UNIV BRISTOL, INST CHILD HLTH, DEPT PAEDIAT & PERINATAL, BRISTOL BS8 1TH, AVON, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1981, Epilepsia, V22, P489; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; CAVAZZUTI GB, 1984, DEV MED CHILD NEUROL, V26, P425; CHADWICK D, 1991, J NEUROL NEUROSUR PS, V54, P385, DOI 10.1136/jnnp.54.5.385; CHAMBERLAIN R, 1978, BRIT BIRTHS 1970, V1; CHEVRIE JJ, 1979, EPILEPSIA, V20, P643, DOI 10.1111/j.1528-1157.1979.tb04848.x; CHEVRIE JJ, 1978, EPILEPSIA, V19, P67; COOPER JE, 1965, BRIT MED J, V1, P1020, DOI 10.1136/bmj.1.5441.1020; ELLENBERG JH, 1984, ANN NEUROL, V15, P127, DOI 10.1002/ana.410150204; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; ROCCA WA, 1987, ANN NEUROL, V21, P22, DOI 10.1002/ana.410210106; ROCCA WA, 1987, NEUROLOGY, V37, P1315, DOI 10.1212/WNL.37.8.1315; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; SILLANPAA M, 1973, ACTA PAEDIATR SC   S, V273, P1; TAYLOR DC, 1971, EPILEPSIA, V12, P33, DOI 10.1111/j.1528-1157.1971.tb03913.x; VANDENBERG BJ, 1969, PEDIATR RES, V3, P298, DOI 10.1203/00006450-196907000-00005; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373	28	60	61	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1992	305	6858					857	861		10.1136/bmj.305.6858.857	http://dx.doi.org/10.1136/bmj.305.6858.857			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1384897	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JT77700022
J	PIERRE, P; SCHEEL, J; RICKARD, JE; KREIS, TE				PIERRE, P; SCHEEL, J; RICKARD, JE; KREIS, TE			CLIP-170 LINKS ENDOCYTIC VESICLES TO MICROTUBULES	CELL			English	Article							SEQUENCE-ANALYSIS; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; TRANSFERRIN RECEPTOR; CYTOPLASMIC DYNEIN; MOLECULAR-CLONING; BINDING-PROTEINS; CARRIER VESICLES; FUSION INVITRO; HEAVY-CHAIN	Binding of endocytic carrier vesicles to microtubules depends on the microtubule-binding protein CLIP-170 in vitro. In vivo, CLIP-170 colocalizes with a subset of transferrin receptor-positive endocytic structures and, more extensively, with endosomal tubules induced by brefeldin A. The structure of CLIP-170 has been analyzed by cloning its cDNA. The predicted non-helical C- and N-terminal domains of the homodimeric protein are connected by a long coiled-coil domain. We have identified a novel motif present in a tandem repeat in the N-terminal domain of CLIP-170 that is involved in binding to microtubules. This motif is also found in the Drosophila Glued and yeast BIK1 proteins. These features, together with its very elongated structure, suggest that CLIP-170 belongs to a novel class of proteins, cytoplasmic linker proteins (CLIPs), mediating interactions of organelles with microtubules.	UNIV GENEVA,DEPT CELL BIOL,SCI 3,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	PIERRE, P (corresponding author), EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY.			pierre, philippe/0000-0003-0863-8255				AIZAWA H, 1990, J BIOL CHEM, V265, P13849; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; BAIROCH A, 1989, EMBL4 EUR MOL BIOL L; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HINZIKER W, 1991, CELL, V67, P5617; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INGOLD AL, 1988, J CELL BIOL, V107, P2659; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEPPERKOK R, 1990, J CELL BIOL, V111, P3003, DOI 10.1083/jcb.111.6.3003; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHLIWA M, 1989, CELL, V56, P719, DOI 10.1016/0092-8674(89)90672-7; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIBBALD PR, 1990, COMPUT APPL BIOSCI, V6, P279; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1992, IN PRESS GUIDEBOOK C; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; WACKER IU, 1992, J CELL BIOL, V117, P813, DOI 10.1083/jcb.117.4.813; WEST RR, 1991, J BIOL CHEM, V266, P21886; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	67	328	340	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					887	900		10.1016/0092-8674(92)90240-D	http://dx.doi.org/10.1016/0092-8674(92)90240-D			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356075				2022-12-24	WOS:A1992JN78100005
J	KUPFER, Y; NAMBA, T; KALDAWI, E; TESSLER, S				KUPFER, Y; NAMBA, T; KALDAWI, E; TESSLER, S			PROLONGED WEAKNESS AFTER LONG-TERM INFUSION OF VECURONIUM BROMIDE	ANNALS OF INTERNAL MEDICINE			English	Note						VECURONIUM; RESPIRATORY INSUFFICIENCY; MUSCULAR WEAKNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; ASTHMA; STATUS ASTHMATICUS	NEUROMUSCULAR BLOCKADE; PATIENT	Neuromuscular blocking agents, increasingly used in intensive care units, have been retrospectively reported to cause weakness after prolonged use. This study prospectively compared ten patients with respiratory failure requiring prolonged muscle relaxation using vecuronium and 18 asthmatic patients with respiratory failure requiring mechanical ventilation without vecuronium. Serial neurologic and electrodiagnostic studies were done. Seven of ten patients (70%; 95% CI, 35% to 93%) experienced weakness 24 hours after discontinuation of vecuronium. The weakness was due to prolonged neuromuscular blockade for up to 3 days in two patients and to polyneuropathy characterized by weakness of all extremities, loss of tendon reflexes, and muscle atrophy lasting 5 days to 6 months in five patients. The only factors that correlated with the development of polyneuropathy were the dose (P = 0.047) and duration (P = 0.047) of vecuronium use, None of the control patients with asthma developed weakness. Caution must be exercised when using large doses of vecuronium for a prolonged period.	MAIMONIDES HOSP, DIV PULM & CRIT CARE MED, 4802 10TH AVE, BROOKLYN, NY 11219 USA; MAIMONIDES HOSP, DIV NEUROMUSCULAR DIS, BROOKLYN, NY 11219 USA	Maimonides Medical Center; Maimonides Medical Center								GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; KUPFER Y, 1987, CRIT CARE MED, V15, P795, DOI 10.1097/00003246-198708000-00019; MORRIS RB, 1983, ANESTHESIOLOGY, V58, P438, DOI 10.1097/00000542-198305000-00008; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHANKS AB, 1985, BRIT J ANAESTH, V57, P807, DOI 10.1093/bja/57.8.807; SLATER RM, 1988, ANAESTHESIA, V43, P250; STARSNIC MA, 1989, CAN J ANAESTH, V36, P35, DOI 10.1007/BF03010884; VANMARLE W, 1980, BRIT MED J, V281, P271, DOI 10.1136/bmj.281.6235.271-a; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819	10	91	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					484	486		10.7326/0003-4819-117-6-484	http://dx.doi.org/10.7326/0003-4819-117-6-484			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1354426				2022-12-24	WOS:A1992JN25700008
J	MATSUI, Y; ZSEBO, K; HOGAN, BLM				MATSUI, Y; ZSEBO, K; HOGAN, BLM			DERIVATION OF PLURIPOTENTIAL EMBRYONIC STEM-CELLS FROM MURINE PRIMORDIAL GERM-CELLS IN CULTURE	CELL			English	Article							GROWTH-FACTOR; DIFFERENTIATION; PROLIFERATION	Steel factor (SF) and LIF (leukemia inhibitory factor) synergistically promote the proliferation and survival of mouse primordial germ cells (PGCs), but only for a limited time period in culture. We show here that addition of bFGF to cultures in the presence of membrane-associated SF and LIF enhances the growth of PGCs and allows their continued proliferation beyond the time when they normally stop dividing in vivo. They form colonies of densely packed, alkaline phosphatase-positive, SSEA-1-positive cells resembling undifferentiated embryonic stem (ES) cells in morphology. These cultures can be maintained on feeder layers for at least 20 passages, and under appropriate conditions give rise to embryoid bodies and to multiple differentiated cell phenotypes in monolayer culture and in tumors in nude mice. PGC-derived ES cells can also contribute to chimeras when injected into host blasto-cysts. The long-term culture of PGCs and their reprogramming to pluripotential ES cells has important implications for germ cell biology and the induction of teratocarcinomas.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Vanderbilt University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FFRENCHCONSTANT C, 1991, DEVELOPMENT, V113, P1365; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, DEVELOPMENT, V113, P1451; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; LAWSON KA, 1992, CIBA F S, V165; MANN JR, 1990, CELL, V62, P251, DOI 10.1016/0092-8674(90)90363-J; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NOGUCHI T, 1982, J NATL CANCER I, V69, P907; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOLTER D, 1975, TERATOMAS DIFFERENTI; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; STEVENS LC, 1961, J NATL CANCER I, V27, P443; Stevens LC, 1983, COLD SPRING HARB C C, P23; SURANI MA, 1990, DEVELOPMENT S, V110, P89; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; TOKSOZ D, 1992, IN PRESS P NATL ACAD, V89	24	962	1159	0	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					841	847		10.1016/0092-8674(92)90317-6	http://dx.doi.org/10.1016/0092-8674(92)90317-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381289				2022-12-24	WOS:A1992JL66300015
J	HEDLUND, JU; ORTQVIST, AB; KALIN, M; SCALIATOMBA, G; GIESECKE, J				HEDLUND, JU; ORTQVIST, AB; KALIN, M; SCALIATOMBA, G; GIESECKE, J			RISK OF PNEUMONIA IN PATIENTS PREVIOUSLY TREATED IN HOSPITAL FOR PNEUMONIA	LANCET			English	Note							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL VACCINE; IMMUNIZATION; CARE	Although elderly patients who are admitted to hospital for any disease have a higher risk of pneumonia subsequently, whether those treated in hospital for pneumonia are at even greater risk is unknown. Therefore we retrospectively assessed morbidity and mortality due to pneumonia after discharge in 573 consecutive patients admitted to hospital for pneumonia, gastrointestinal infection, renal infection, or erysipelas. Average follow-up was 34 months. The incidence rate for pneumonia was 5.45 times higher in the group of patients discharged after pneumonia than in the other groups combined (95% confidence interval 2.89-10.26; p<0.001), and this group also had more deaths due to pneumonia (p=0.06). For patients 50 years or older Streptococcus pneumoniae is the main cause of pneumonia. Pneumococcal vaccination after hospital treatment for an episode of pneumonia might be a cost-effective means of preventing disease in this group.	KAROLINSKA INST,DEPT INFECT DIS,S-10401 STOCKHOLM 60,SWEDEN; UNIV STOCKHOLM,DEPT MATH STAT,S-10691 STOCKHOLM,SWEDEN	Karolinska Institutet; Stockholm University	HEDLUND, JU (corresponding author), KAROLINSKA INST,DANDERYD HOSP,UNIV CLIN INFECT DIS,S-18288 DANDERYD,SWEDEN.							AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; FEDSON D, 1989, INFECTION, V17, P437, DOI 10.1007/BF01645568; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FEDSON DS, 1982, JAMA-J AM MED ASSOC, V248, P1989; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; ORTQVIST A, 1988, SCAND J INFECT DIS, V20, P163, DOI 10.3109/00365548809032433; VENKATESAN P, 1990, THORAX, V45, P254, DOI 10.1136/thx.45.4.254; 1989, JAMA-J AM MED ASSOC, V261, P1265	9	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					396	397		10.1016/0140-6736(92)91473-L	http://dx.doi.org/10.1016/0140-6736(92)91473-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353558				2022-12-24	WOS:A1992JJ44900006
J	DAVIES, M; RAYMAN, G; DAY, J				DAVIES, M; RAYMAN, G; DAY, J			INCREASED INCIDENCE OF CORONARY-DISEASE IN PEOPLE WITH IMPAIRED GLUCOSE-TOLERANCE - LINK WITH INCREASED LIPOPROTEIN(A) CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article											DAVIES, M (corresponding author), IPSWICH DIABET CTR,IPSWICH IP4 5PD,SUFFOLK,ENGLAND.			Davies, Melanie/0000-0002-9987-9371				FULLER JH, 1980, LANCET, V1, P1374; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; SCHRIEWER H, 1984, J CLIN CHEM CLIN BIO, V22, P591; SCOTT J, 1991, BRIT MED J, V303, P663, DOI 10.1136/bmj.303.6804.663; ZIMMET P, 1989, DIABETIC MED, V6, P728, DOI 10.1111/j.1464-5491.1989.tb01266.x	5	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1610	1611		10.1136/bmj.304.6842.1610	http://dx.doi.org/10.1136/bmj.304.6842.1610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1385748	Green Published, Bronze			2022-12-24	WOS:A1992JA43600023
J	RENAUD, S; DELORGERIL, M				RENAUD, S; DELORGERIL, M			WINE, ALCOHOL, PLATELETS, AND THE FRENCH PARADOX FOR CORONARY HEART-DISEASE	LANCET			English	Article							MODERATE ALCOHOL; CONSUMPTION; RISK; MEN; MORTALITY; COUNTRIES; ETHANOL; FARMERS	In most countries, high intake of saturated fat is positively related to high mortality from coronary heart disease (CHD). However, the situation in France is paradoxical in that there is high intake of saturated fat but low mortality from CHD. This paradox may be attributable in part to high wine consumption. Epidemiological studies indicate that consumption of alcohol at the level of intake in France (20-30 g per day) can reduce risk of CHD by at least 40%. Alcohol is believed to protect from CHD by preventing atherosclerosis through the action of high-density-lipoprotein cholesterol, but serum concentrations of this factor are no higher in France than in other countries. Re-examination of previous results suggests that, in the main, moderate alcohol intake does not prevent CHD through an effect on atherosclerosis, but rather through a haemostatic mechanism. Data from Caerphilly, Wales, show that platelet aggregation, which is related to CHD, is inhibited significantly by alcohol at levels of intake associated with reduced risk of CHD. Inhibition of platelet reactivity by wine (alcohol) may be one explanation for protection from CHD in France, since pilot studies have shown that platelet reactivity is lower in France than in Scotland.			RENAUD, S (corresponding author), INSERM,U63,NUTR & VASC PHYSIOPATHOL RES UNIT,22 AVE DOYEN LEPINE,CP 18,F-69675 BRON,FRANCE.							BARAONA E, 1979, J LIPID RES, V20, P289; BLACKBURN H, 1986, AM J CARDIOL, V58, P161, DOI 10.1016/0002-9149(86)90262-6; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; DOUSTEBLAZY P, 1988, REV EPIDEMIOL SANTE, V6, P342; ELWOOD PC, 1991, CIRCULATION, V83, P38, DOI 10.1161/01.CIR.83.1.38; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; JOST JP, 1990, REV EPIDEMIOL SANTE, V38, P517; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KOZAREVIC D, 1988, INT J EPIDEMIOL, V12, P145; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; LITSIE AM, 1976, B WORLD HEALTH ORGAN, V53, P623; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; NORDOY A, 1984, EUR J CLIN INVEST, V14, P339, DOI 10.1111/j.1365-2362.1984.tb01193.x; PUCHOIS P, 1990, ARCH INTERN MED, V150, P1638, DOI 10.1001/archinte.150.8.1638; RENAUD S, 1986, ATHEROSCLEROSIS, V60, P37, DOI 10.1016/0021-9150(86)90085-7; RENAUD S, 1985, CARDIOVASC RES, V19, P155, DOI 10.1093/cvr/19.3.155; RENAUD S, 1989, J INTERN MED, V225, P39, DOI 10.1111/j.1365-2796.1989.tb01434.x; RENAUD S, 1984, DIET DIABETES ATHERO, P177; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; RHOADS GG, 1978, LAB INVEST, V38, P304; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RUDEL LL, 1981, ARTERIOSCLEROSIS, V1, P144, DOI 10.1161/01.ATV.1.2.144; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; THAULOW E, 1991, CIRCULATION, V84, P613, DOI 10.1161/01.CIR.84.2.613; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1989, WORLD HLTH STATISTIC	31	2811	2927	6	357	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1523	1526		10.1016/0140-6736(92)91277-F	http://dx.doi.org/10.1016/0140-6736(92)91277-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351198				2022-12-24	WOS:A1992HZ17500016
J	HART, IR; SAINI, A				HART, IR; SAINI, A			BIOLOGY OF TUMOR-METASTASIS	LANCET			English	Article							ANGIOGENESIS; RECEPTORS; MELANOMA; CELLS; GENE				HART, IR (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ALBELDA SM, 1990, CANCER RES, V50, P6757; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOULDS L, 1954, CANCER RES, V14, P327; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HART IR, 1989, CURR OPIN IMMUNOL, V1, P900, DOI 10.1016/0952-7915(89)90068-X; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LLOTA LA, 1991, CELL, V64, P327; MAHADEVAN V, 1991, BRIT J CANCER, V63, P889, DOI 10.1038/bjc.1991.195; MAHADEVAN V, 1990, ACTA ONCOL, V29, P97, DOI 10.3109/02841869009089997; MATSUSHITA Y, 1991, CLIN EXP METASTAS, V9, P283, DOI 10.1007/BF01753731; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STOKER M, 1991, BICHIM BIOPHYS ACTA, V1072, P88; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	26	339	351	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1453	1457		10.1016/0140-6736(92)92039-I	http://dx.doi.org/10.1016/0140-6736(92)92039-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1376386				2022-12-24	WOS:A1992HY31700012
J	TORPEY, N; WYLIE, CC; HEASMAN, J				TORPEY, N; WYLIE, CC; HEASMAN, J			FUNCTION OF MATERNAL CYTOKERATIN IN XENOPUS DEVELOPMENT	NATURE			English	Article							HUMAN KERATIN-18; OOCYTES; EMBRYOS; CELLS; EXPRESSION; LAEVIS; ORGANIZATION; DEGRADATION; CLONING; MOUSE	INTERMEDIATE filaments are ubiquitous in eukaryotic cells, but their functions are poorly understood. The Xenopus oocyte contains both messenger RNA and protein products of cytokeratin and vimentin genes 1-5 in non-overlapping arrays. The cytokeratin filaments contain dimers of the type I (acidic) subunit XLK3a(19), and the type II (basic) subunit XCK1(8), polymerized to form a cortical network. These are homologues of the human simple epithelial keratins 19 and 8, respectively. After the first few cell cycles following fertilization these filaments become restricted to the superficial cells of the blastula. We have depleted the oocyte's store of the type II cytokeratin mRNA by injecting antisense oligodeoxynucleotides (oligos) and studied the effect on embryonic development. As zygotic transcription does not commence until the late blastula stage 6, there are at least 9 hours in which to see the effect of loss of function of this mRNA. We report here that the cytokeratin filaments become depleted in the cortical cells of the embryo. As a result, there is a loss of the 'compacted' epithelial surface of the blastula, an inability to close a wounded surface and defective gastrulation.	WELLCOME CANC RES CAMPAIGN,INST CANC & DEV BIOL,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND; DEPT ZOOL,CAMBRIDGE CB2 3ED,ENGLAND						Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DOMENJOUD L, 1988, EXP CELL RES, V179, P352, DOI 10.1016/0014-4827(88)90274-1; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HERMANN H, 1989, DEVELOPMENT, V105, P279; HOLWILL S, 1987, DEVELOPMENT, V100, P735; KLYMKOWSKY MW, 1987, DEVELOPMENT, V100, P543; KLYMKOWSKY MW, 1989, DEV BIOL, V134, P479, DOI 10.1016/0012-1606(89)90121-8; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Sambrook J., 1989, MOL CLONING LAB MANU; TANG P, 1988, DEVELOPMENT, V103, P279; TORPEY NP, 1992, J CELL SCI, V101, P151; TORPEY NP, 1990, DEVELOPMENT, V110, P1185; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F	20	71	71	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					413	415		10.1038/357413a0	http://dx.doi.org/10.1038/357413a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1375708				2022-12-24	WOS:A1992HX17200066
J	FALINI, B; BOLOGNESI, A; FLENGHI, L; TAZZARI, PL; BROE, MK; STEIN, H; DURKOP, H; AVERSA, F; CORNELI, P; PIZZOLO, G; BARBABIETOLA, G; SABATTINI, E; PILERI, S; MARTELLI, MF; STIRPE, F				FALINI, B; BOLOGNESI, A; FLENGHI, L; TAZZARI, PL; BROE, MK; STEIN, H; DURKOP, H; AVERSA, F; CORNELI, P; PIZZOLO, G; BARBABIETOLA, G; SABATTINI, E; PILERI, S; MARTELLI, MF; STIRPE, F			RESPONSE OF REFRACTORY HODGKINS-DISEASE TO MONOCLONAL ANTI-CD30 IMMUNOTOXIN	LANCET			English	Note							ANTIGEN	In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to > 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.	FREE UNIV BERLIN,INST PATHOL,W-1000 BERLIN 33,GERMANY; UNIV VERONA,DEPT HAEMATOL,I-37100 VERONA,ITALY; UNIV BOLOGNA,DEPT EXPTL PATHOL,I-40126 BOLOGNA,ITALY; UNIV BOLOGNA,INST HAEMATOL,I-40126 BOLOGNA,ITALY; NATL INST CANC RES,GENOA,ITALY; UNIV PERUGIA,INST HAEMATOL,I-06100 PERUGIA,ITALY; UNIV PERUGIA,INST RADIOL,I-06100 PERUGIA,ITALY	Free University of Berlin; University of Verona; University of Bologna; University of Bologna; University of Genoa; IRCCS AOU San Martino IST; University of Perugia; University of Perugia			Sabattini, Elena/K-6720-2016; Bolognesi, Andrea/Q-6526-2017; TAZZARI, PIER LUIGI/HGC-8394-2022	Sabattini, Elena/0000-0002-4136-3591; TAZZARI, PIER LUIGI/0000-0002-8789-657X; Aversa, Franco/0000-0002-8871-6817; Bolognesi, Andrea/0000-0001-7497-4586; FALINI, Brunangelo/0000-0002-7198-5965				ENGERT A, 1990, CANCER RES, V50, P84; ENGERT A, 1990, CANCER RES, V50, P2929; FALINI B, 1991, EXP HEMATOL, V19, P545; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; SCHWARTING R, 1989, BLOOD, V74, P1678; STEIN H, 1985, BLOOD, V66, P848; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; STIRPE F, 1987, VIRCHOWS ARCH B, V53, P259, DOI 10.1007/BF02890252; TAZZARI PL, IN PRESS BR J HAEMAT; VITETTA ES, 1991, CANCER RES, V51, P4052	10	192	213	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1195	1196		10.1016/0140-6736(92)91135-U	http://dx.doi.org/10.1016/0140-6736(92)91135-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349939				2022-12-24	WOS:A1992HU68400005
J	STRACHAN, DP; ANDERSON, HR				STRACHAN, DP; ANDERSON, HR			TRENDS IN HOSPITAL ADMISSION RATES FOR ASTHMA IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; HEALTH				STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Burr ML, 1989, ARCH DIS CHILD, V64, P1118; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898	5	73	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					819	820		10.1136/bmj.304.6830.819	http://dx.doi.org/10.1136/bmj.304.6830.819			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392711	Green Published, Bronze			2022-12-24	WOS:A1992HL82700023
J	KAGAN, BL; BALDWIN, RL; MUNOZ, D; WISNIESKI, BJ				KAGAN, BL; BALDWIN, RL; MUNOZ, D; WISNIESKI, BJ			FORMATION OF ION-PERMEABLE CHANNELS BY TUMOR-NECROSIS-FACTOR-ALPHA	SCIENCE			English	Article							PLANAR LIPID BILAYERS; DIPHTHERIA-TOXIN; MOLECULAR-CLONING; SKELETAL-MUSCLE; MEMBRANES; RECEPTOR; RESOLUTION; EXPRESSION; MEDIATOR; VESICLES	Tumor necrosis facto-alpha (TNF, cachectin), a protein secreted by activated macrophages, participates in inflammatory responses and in infectious and neoplastic disease states. The mechanisms by which TNF exerts cytotoxic, hormonal, and other specific effects are obscure. Structural studies of the TNF trimer have revealed a central pore-like region. Although several amino acid side chains appear to preclude an open channel, the ability of TNF to insert into lipid vesicles raised the possibility that opening might occur in a bilayer milieu. Acidification of TNF promoted conformational changes concordant with increased surface hydrophobicity and membrane insertion. Furthermore, TNF formed pH-dependent, voltage-dependent, ion-permeable channels in planar lipid bilayer membranes and increased the sodium permeability of human U937 histiocytic lymphoma cells. Thus, some of the physiological effects of TNF may bc elicited through its intrinsic ion channel-forming activity.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,INST NEUROPSYCHIAT,DEPT PSYCHIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles			Kagan, Bruce/ABD-7389-2020		NHLBI NIH HHS [2 T32 HL07386] Funding Source: Medline; NIGMS NIH HHS [GM22240] Funding Source: Medline; NIMH NIH HHS [MH43433] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH043433] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALDWIN RL, 1988, J IMMUNOL, V141, P2352; BALDWIN RL, 1990, THESIS U CALIFORNIA; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Chang M.-W., UNPUB; CHANG MP, 1990, INFECT IMMUN, V58, P2644, DOI 10.1128/IAI.58.8.2644-2650.1990; CUNNINGHAM JN, 1971, J CLIN INVEST, V50, P49, DOI 10.1172/JCI106483; Dawson RMC, 1969, DATA BIOCH RES, P501; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; EARL CQ, 1990, J BIOL RESP MODIF, V9, P361; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FAJARDO LF, 1991, WESTERN J MED, V154, P88; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; JOHNSON JD, 1979, BIOCHEMISTRY-US, V18, P1292, DOI 10.1021/bi00574a027; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KULL FC, 1990, J CELL BIOCHEM, V42, P1, DOI 10.1002/jcb.240420102; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Montal M, 1974, Methods Enzymol, V32, P545; OKU N, 1987, J BIOCHEM-TOKYO, V102, P1303, DOI 10.1093/oxfordjournals.jbchem.a122168; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUSSELL SM, 1990, CANCER RES, V50, P6028; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH JB, 1978, P NATL ACAD SCI USA, V75, P5560, DOI 10.1073/pnas.75.11.5560; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SPRANG SR, 1990, CURRENT RES PROTEIN, pCH35; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TRACEY KJ, 1986, J EXP MED, V164, P1368, DOI 10.1084/jem.164.4.1368; VANHAESEBROECK B, 1990, FEBS LETT, V261, P329; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1; YOSHIMURA T, 1987, J BIOL CHEM, V262, P4597; YOUNG JDE, 1988, IMMUNOL LETT, V19, P287, DOI 10.1016/0165-2478(88)90157-5	38	141	144	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1427	1430		10.1126/science.1371890	http://dx.doi.org/10.1126/science.1371890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1371890				2022-12-24	WOS:A1992HH74400054
J	PITHIE, AD; CHICKSEN, B				PITHIE, AD; CHICKSEN, B			FINE-NEEDLE EXTRATHORACIC LYMPH-NODE ASPIRATION IN HIV-ASSOCIATED SPUTUM-NEGATIVE TUBERCULOSIS	LANCET			English	Note							UGANDA; AIDS	HIV-associated tuberculosis is increasingly seen in Zimbabwe and other developing countries. The clinical and radiological features are often atypical, and diagnostic confusion may arise when sputum smears are negative. Patients with suspected intrathoracic tuberculosis frequently have palpable extrathoracic lymph nodes. In this study, Ziehl-Neelsen staining of aspirates from extrathoracic lymph nodes revealed acid-fast bacilli in 20 (71%) of 28 patients with suspected tuberculosis, and 20 (87%) of 23 patients in whom a final diagnosis of tuberculosis was made Aspiration is simple, rapid, and cheap and may be of value in the diagnosis of tuberculosis, especially in developing countries with limited diagnostic and therapeutic resources.	UNIV ZIMBABWE,DEPT MED,HARARE,ZIMBABWE	University of Zimbabwe	PITHIE, AD (corresponding author), E BIRMINGHAM HOSP NHS TRUST,DEPT INFECT & TROP MED,BORDESLEY GREEN E,BIRMINGHAM B9 5ST,ENGLAND.							ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; MASON PR, 1992, 1ST AFR IMM C HAR; MORRISSEY AB, 1992, J ACQ IMMUN DEF SYND, V5, P477; NAMBUYA A, 1988, J CLIN PATHOL, V41, P93, DOI 10.1136/jcp.41.1.93; OKELLO DO, 1990, J INFECT DIS, V162, P208, DOI 10.1093/infdis/162.1.208; PERRONNE C, 1992, TUBERCLE LUNG DIS, V73, P39, DOI 10.1016/0962-8479(92)90078-X; VOETBERG A, 1991, LANCET, V337, P56, DOI 10.1016/0140-6736(91)93380-R; 1987, MMWR S, V36, pS1	10	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1504	1505		10.1016/0140-6736(92)92758-8	http://dx.doi.org/10.1016/0140-6736(92)92758-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361599				2022-12-24	WOS:A1992KD06900007
J	HALLENBERGER, S; BOSCH, V; ANGLIKER, H; SHAW, E; KLENK, HD; GARTEN, W				HALLENBERGER, S; BOSCH, V; ANGLIKER, H; SHAW, E; KLENK, HD; GARTEN, W			INHIBITION OF FURIN-MEDIATED CLEAVAGE ACTIVATION OF HIV-1 GLYCOPROTEIN-GP160	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; ENDOPROTEOLYTIC CLEAVAGE; BIOSYNTHESIS; PRECURSOR; TRANSPORT; GP160; CELLS	THE envelope glycoprotein of human immunodeficiency virus (HIV) initiates infection1 by mediating fusion of the viral envelope with the cell membrane. Fusion activity requires proteolytic cleavage of the gp160 protein into gp120 and gp41 at a site containing several arginine and lysine residues2. Activation at basic cleavage sites is observed with many membrane proteins of cellular and viral origin. We have recently found that the enzyme activating the haemagglutinin of fowl plague virus (FPV), an avian influenza virus, is furin3. Furin, a subtilisin-like eukaryotic endoprotease4-6, has a substrate specificity for the consensus amino-acid sequence Arg-X-Lys/Arg-Arg at the cleavage site7. We show here that the glycoprotein of HIV-1, which has the same protease recognition motif as the FPV haemagglutinin, is also activated by furin.	DEUTSCH KREBSFORSCHUNGSZENTRUM HEIDELBERG,INST ANGEW TUMORVIROL,W-6900 HEIDELBERG 1,GERMANY; FRIEDRICH MIESCHER INST BASEL,CH-4002 BASEL,SWITZERLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Friedrich Miescher Institute for Biomedical Research	HALLENBERGER, S (corresponding author), UNIV MARBURG,INST VIROL,ROBERT KOCHSTR 17,W-3550 MARBURG,GERMANY.							BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MERGENER K, 1992, VIROLOGY, V186, P25, DOI 10.1016/0042-6822(92)90058-W; MYERS G, 1991, HUMAN RETROVIRUSES A; OWENS RJ, 1989, J VIROL, V63, P978, DOI 10.1128/JVI.63.2.978-982.1989; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; VONDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664; WILK T, 1992, VIRUS GENES, V6, P229, DOI 10.1007/BF01702562; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; WILLEY RL, 1991, VIROLOGY, V184, P319, DOI 10.1016/0042-6822(91)90848-6; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9368	22	483	501	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					358	361		10.1038/360358a0	http://dx.doi.org/10.1038/360358a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1360148				2022-12-24	WOS:A1992JZ63000056
J	XIONG, Y; ZHANG, H; BEACH, D				XIONG, Y; ZHANG, H; BEACH, D			D-TYPE CYCLINS ASSOCIATE WITH MULTIPLE PROTEIN-KINASES AND THE DNA-REPLICATION AND REPAIR FACTOR PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; S-PHASE; AUXILIARY PROTEIN; POLYMERASE-DELTA; CDC2; MITOSIS; ACTIVATION; GENE	Human cyclin D1 has been associated with a wide variety of proliferative diseases but its biochemical role is unknown. In diploid fibroblasts we find that cyclin D1 is complexed with many other cellular proteins. Among them are protein kinase catalytic subunits CDK2, CDK4 (previously called PSK-J3), and CDK5 (also called PSSALRE). In addition, polypeptides of 21 kd and 36 kd are identified in association with cyclin D1. We show that the 36 kd protein is the proliferating cell nuclear antigen, PCNA. Cyclin D3 also associates with multiple protein kinases, p21 and PCNA. It is proposed that there exists a quaternary complex of D cyclin, CDK, PCNA, and p21 and that many combinatorial variations (cyclin D1, D3, CDK2, 4, and 5) may assemble in vivo. These findings link a human putative G1 cyclin that is associated with oncogenesis with a well-characterized DNA replication and repair factor.			XIONG, Y (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA.				NIGMS NIH HHS [GM39620-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039620] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1984, EMBO J, V3, P3177, DOI 10.1002/j.1460-2075.1984.tb02276.x; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1988, ANTIBODIES LABORATOR; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WON KA, 1992, IN PRESS P NATL ACAD; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	1015	1057	12	155	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					505	514		10.1016/0092-8674(92)90518-H	http://dx.doi.org/10.1016/0092-8674(92)90518-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1358458				2022-12-24	WOS:A1992JW43500015
J	TIENARI, PJ; WIKSTROM, J; SAJANTILA, A; PALO, J; PELTONEN, L				TIENARI, PJ; WIKSTROM, J; SAJANTILA, A; PALO, J; PELTONEN, L			GENETIC SUSCEPTIBILITY TO MULTIPLE-SCLEROSIS LINKED TO MYELIN BASIC-PROTEIN GENE	LANCET			English	Article							LENGTH POLYMORPHISM; DNA; AMPLIFICATION; TRANSCRIPTION; POLYMERASE; CRITERIA; MOUSE; RISK; MRI	Genetic factors have been implicated in the aetiology of multiple sclerosis (MS), but the genes conferring susceptibility to MS have not been identified. We carried out genetic linkage and association analyses by studying polymorphism of the myelin basic protein (MBP) gene on chromosome 18, a candidate gene for MS, in 21 MS families, 51 additional unrelated patients with definite MS, and 85 controls. All subjects were Finnish, and 14 of the families were from an area with an exceptional familial clustering of MS. Magnetic resonance imaging (MRI) was used to examine subclinical disease in symptom-free family members. In the association analysis, the allele frequencies between MS patients and controls differed significantly, p = 0.000049), the difference being attributable mainly to a higher frequency of a 1.27 kb allele among patients. In the linkage analysis, based on an autosomal dominant model and penetrance 0.05, a maximum LOD score of 3.42 (theta = 0.00) was obtained when patients with optic neuritis and their symptom-free siblings with abnormal MRI findings were classified as "affected". When these subjects were classified as "unknown" the maximum LOD scores ranged from 2.99 to 3.25 (theta = 0.00). The results suggest that in this population genetic predisposition to MS is closely linked to the MBP gene and that polymorphism at the MBP locus or an adjacent locus has a role in the aetiology of MS.	UNIV HELSINKI,DEPT NEUROL,SF-00100 HELSINKI 10,FINLAND	University of Helsinki	TIENARI, PJ (corresponding author), NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.		Sajantila, Antti/AAY-9084-2021; Tienari, Pentti J/A-4893-2012	Sajantila, Antti/0000-0003-4117-5248				Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BOYLAN KB, 1990, GENOMICS, V6, P16, DOI 10.1016/0888-7543(90)90443-X; BOYLAN KB, 1987, AM J HUM GENET, V40, P387; BOYLAN KB, 1990, ANN NEUROL, V27, P291, DOI 10.1002/ana.410270311; COMPSTON A, 1986, P56; EBERS GC, 1982, LANCET, V2, P88; FAZEKAS F, 1988, NEUROLOGY, V38, P1822, DOI 10.1212/WNL.38.12.1822; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; KAMHOLZ J, 1987, AM J HUM GENET, V40, P365; KASAI K, 1990, J FORENSIC SCI, V35, P1196; KINNUNEN E, 1983, ACTA NEUROL SCAND, V67, P255, DOI 10.1111/j.1600-0404.1983.tb04574.x; KURTZKE JF, 1983, MULTIPLE SCLEROSIS P, P47; MCDONALD WI, 1986, J NEUROL NEUROSUR PS, V49, P434; MCFARLAND HF, 1989, CLIN IMMUNOL IMMUNOP, V50, pS96, DOI 10.1016/0090-1229(89)90116-5; NEVANLINNA HR, 1972, HEREDITAS-GENETISK A, V71, P195; OKANO H, 1988, EMBO J, V7, P77, DOI 10.1002/j.1460-2075.1988.tb02785.x; Ott J., 1991, ANAL HUMAN GENETIC L; PATY DW, 1988, NEUROLOGY, V38, P180, DOI 10.1212/WNL.38.2.180; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RIZZO JF, 1988, NEUROLOGY, V38, P185, DOI 10.1212/WNL.38.2.185; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; Sambrook J., 1989, MOL CLONING; SANDBERG-WOLLHEIM M, 1990, Annals of Neurology, V27, P386, DOI 10.1002/ana.410270406; TIENARI PJ, IN PRESS J NEUROL NE; VISSCHER BR, 1979, NEUROLOGY, V29, P1354, DOI 10.1212/WNL.29.10.1354; WIKSTROM J, 1975, ACTA NEUROL SCAND, V51, P173, DOI 10.1111/j.1600-0404.1975.tb07598.x; WIKSTROM J, 1984, Neuroepidemiology, V3, P74, DOI 10.1159/000110844	29	141	141	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					987	991		10.1016/0140-6736(92)93007-A	http://dx.doi.org/10.1016/0140-6736(92)93007-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1383661				2022-12-24	WOS:A1992JV01400001
J	FOOTE, S; VOLLRATH, D; HILTON, A; PAGE, DC				FOOTE, S; VOLLRATH, D; HILTON, A; PAGE, DC			THE HUMAN Y-CHROMOSOME - OVERLAPPING DNA CLONES SPANNING THE EUCHROMATIC REGION	SCIENCE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN X-CHROMOSOME; SEX-DETERMINING REGION; HUMAN GENOME; PSEUDOAUTOSOMAL REGION; ENZYMATIC AMPLIFICATION; DROSOPHILA GENOME; PHYSICAL MAP; SHORT ARM; LONG ARM	The human Y chromosome was physically mapped by assembling 196 recombinant DNA clones, each containing a segment of the chromosome, into a single overlapping array. This array included more than 98 percent of the euchromatic portion of the Y chromosome. First, a library of yeast artificial chromosome (YAC) clones was prepared from the genomic DNA of a human XYYYY male. The library was screened to identify clones containing 160 sequence-tagged sites and the map was then constructed from this information. In all, 207 Y-chromosomal DNA loci were assigned to 127 ordered intervals on the basis of their presence or absence in the YAC's, yielding ordered landmarks at an average spacing of 220 kilobases across the euchromatic region. The map reveals that Y-chromosomal genes are scattered among a patchwork of X-homologous, Y-specific repetitive, and single-copy DNA sequences. This map of overlapping clones and ordered, densely spaced markers should accelerate studies of the chromosome.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	FOOTE, S (corresponding author), MIT,WHITEHEAD INST,HOWARD HUGHES RES LABS,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Foote, Simon J/F-2802-2013	Foote, Simon/0000-0002-9142-2107				ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; AJIOKA JW, 1991, CHROMOSOMA, V100, P495, DOI 10.1007/BF00352200; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FROMMER M, 1984, NUCLEIC ACIDS RES, V12, P2887, DOI 10.1093/nar/12.6.2887; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; GOUGH NM, 1990, NATURE, V345, P734, DOI 10.1038/345734a0; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GUIOLI S, 1992, NAT GENET, V1, P337, DOI 10.1038/ng0892-337; HENKE A, 1991, AM J HUM GENET, V49, P811; INCERTI B, IN PRESS NATURE GENE; KNOWLTON RG, 1989, NUCLEIC ACIDS RES, V17, P423, DOI 10.1093/nar/17.1.423; KUSPA A, 1989, P NATL ACAD SCI USA, V86, P8917, DOI 10.1073/pnas.86.22.8917; LAU EC, 1989, GENOMICS, V4, P162, DOI 10.1016/0888-7543(89)90295-4; LITTLE RD, 1992, P NATL ACAD SCI USA, V89, P177, DOI 10.1073/pnas.89.1.177; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1987, CELL, V50, P495; PAGE D C, 1987, Genomics, V1, P243, DOI 10.1016/0888-7543(87)90051-6; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PEDICINI A, 1991, GENOMICS, V11, P482, DOI 10.1016/0888-7543(91)90167-D; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; RAPPOLD G, 1988, NUCLEIC ACIDS RES, V16, P5631; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBERG AA, 1985, Y CHROMOSOME A; SCHLESSINGER D, 1991, GENOMICS, V11, P783, DOI 10.1016/0888-7543(91)90001-U; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SIROTA L, 1981, CLIN GENET, V19, P87; SMITH DR, IN PRESS METHODS ENZ; SMITH KD, 1987, DEVELOPMENT, V101, P77; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7	57	403	415	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					60	66		10.1126/science.1359640	http://dx.doi.org/10.1126/science.1359640			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1359640				2022-12-24	WOS:A1992JQ61900025
J	OSIPCHUK, Y; CAHALAN, M				OSIPCHUK, Y; CAHALAN, M			CELL-TO-CELL SPREAD OF CALCIUM SIGNALS MEDIATED BY ATP RECEPTORS IN MAST-CELLS	NATURE			English	Article							MECHANICAL STIMULATION; G-PROTEINS; SECRETION; CA-2+; OSCILLATIONS; IONOPHORES; GLUTAMATE; GRANULES; MEMBRANE; WAVES	RAT basophilic leukaemia cells, like mast cells from which they are derived, have surface Fc-epsilon receptors that trigger secretion of inflammatory mediators when crosslinked. Both GTP-binding proteins and a rise in cytosolic calcium concentration ([Ca2+]i) are implicated in the secretory mechanism1-5. Here we use a video-imaging technique to report that transient rises in [Ca2+]i initiated in an individual cell can spread from cell to cell in a wave-like pattern by means of a secreted intermediate, in the absence of gap-junctional communication. We find that the leukaemia cells, peritoneal mast cells and mucosal mast cells have cell-surface P2-type purinergic receptors that can trigger similar [Ca2+]i transients. We provide evidence that ATP is rapidly released, and that it can amplify [Ca2+]i signals and initial secretory responses during antigen-stimulation of rat basophilic leukaemia cells.			OSIPCHUK, Y (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.							ALI H, 1989, J IMMUNOL, V143, P2626; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; ALTER SC, 1989, BIOCHIM BIOPHYS ACTA, V991, P426, DOI 10.1016/0304-4165(89)90068-8; BORN GVR, 1984, J PHYSIOL-LONDON, V354, P419, DOI 10.1113/jphysiol.1984.sp015385; BROIDE DH, 1988, J IMMUNOL, V141, P4298; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHAKRAVARTY N, 1980, ACTA PHARMACOL TOX, V47, P223; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; COCHRANE DE, 1974, P NATL ACAD SCI USA, V71, P408, DOI 10.1073/pnas.71.2.408; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; LEFF P, 1990, BRIT J PHARMACOL, V101, P645, DOI 10.1111/j.1476-5381.1990.tb14134.x; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; TATHAM PER, 1988, EUR J PHARMACOL, V147, P13, DOI 10.1016/0014-2999(88)90628-0; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; UVNAS B, 1974, LIFE SCI, V14, P2355, DOI 10.1016/0024-3205(74)90131-3; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674	29	338	343	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					241	244		10.1038/359241a0	http://dx.doi.org/10.1038/359241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1388246				2022-12-24	WOS:A1992JN94400063
J	ROSENTHAL, W; SEIBOLD, A; ANTARAMIAN, A; LONERGAN, M; ARTHUS, MF; HENDY, GN; BIRNBAUMER, M; BICHET, DG				ROSENTHAL, W; SEIBOLD, A; ANTARAMIAN, A; LONERGAN, M; ARTHUS, MF; HENDY, GN; BIRNBAUMER, M; BICHET, DG			MOLECULAR-IDENTIFICATION OF THE GENE RESPONSIBLE FOR CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS	NATURE			English	Article							DNA; VASOPRESSIN; POLYMERASE; RECEPTORS; LOCUS	ANTIDIURETIC hormone (arginine vasopressin) binds to and activates V2 receptors in renal collecting tubule cells. Subsequent stimulation of the G(s)/adenylyl cyclase system promotes insertion of water pores into the luminal membrane and thereby reabsorption of fluid. In congenital nephrogenic diabetes insipidus (CNDI)1, an X-linked recessive disorder, the kidney fails to respond to arginine vasopressin. Here we report that an affected male of a family with CNDI2,3 has a deletion in the open reading frame of the V2 receptor gene, causing a frame shift and premature termination of translation in the third intracellular loop of the receptor protein. A normal receptor gene was found in the patient's brother. Both the normal and the mutant allele were detected in his mother. A different mutation, causing a codon change in the third transmembrane domain of the V2 receptor, was found in the open reading frame of an affected male but not in the unaffected brother belonging to another family suffering from CNDI.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; HOP SACRE COEUR,CTR RECH,SERV NEPHROL,MONTREAL H4J 1C5,QUEBEC,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA	Baylor College of Medicine; Universite de Montreal; Universite de Montreal				BICHET, DANIEL-G/0000-0003-2856-6850				BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BICHET DG, IN PRESS AM J HUM GE; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; DILELLA AG, 1987, METHOD ENZYMOL, V152, P199; GIBBS RA, 1991, METHOD MOL BIOL, V8, P9; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; JANS DA, 1990, J BIOL CHEM, V265, P15379; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOSES AM, 1982, J CLIN ENDOCR METAB, V55, P699, DOI 10.1210/jcem-55-4-699; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; REEVES WB, 1989, METABOLIC BASIS INHE, P1985; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIBOLD A, IN PRESS AM J HUM GE; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840	22	260	263	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					233	235		10.1038/359233a0	http://dx.doi.org/10.1038/359233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1356229				2022-12-24	WOS:A1992JN94400060
J	LASKY, LA; SINGER, MS; DOWBENKO, D; IMAI, Y; HENZEL, WJ; GRIMLEY, C; FENNIE, C; GILLETT, N; WATSON, SR; ROSEN, SD				LASKY, LA; SINGER, MS; DOWBENKO, D; IMAI, Y; HENZEL, WJ; GRIMLEY, C; FENNIE, C; GILLETT, N; WATSON, SR; ROSEN, SD			AN ENDOTHELIAL LIGAND FOR L-SELECTIN IS A NOVEL MUCIN-LIKE MOLECULE	CELL			English	Article							NODE HOMING RECEPTOR; CELL-ADHESION; LYMPH-NODES; VASCULAR ADDRESSIN; SPERM RECEPTOR; MEL-14 ANTIGEN; LECTIN DOMAIN; SIALIC-ACID; CARBOHYDRATE; LYMPHOCYTES	The adhesive interaction between circulating lymphocytes and the high endothelial venules (HEV) of lymph nodes (LN) is mediated by lymphocyte L-selectin, a member of the selectin family of cell adhesion proteins. Previous work has identified a sulfated 50 kd glycoprotein (Sgp50) as an HEV ligand for L-selectin. We now report the purification of this glycoprotein and the utilization of the derived N-terminal amino acid sequence to clone a cDNA. The predicted sequence reveals a novel, mucin-like molecule containing two serine/threonine-rich domains. The mRNA encoding this glycoprotein is preferentially expressed in LN. Antibodies against predicted peptides immunoprecipitate Sgp50 and stain the apical surface of LN HEV. These results thus define a tissue-specific mucin-like endothelial glycoprotein that appears to function as a scaffold that presents carbohydrates to the L-selectin lectin domain.	GENENTECH INC, DEPT SAFETY EVALUAT, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM IMMUNOL, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LASKY, LA (corresponding author), GENENTECH INC, DEPT IMMUNOBIOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.		Imai, Yasuyuki/E-8701-2010	Imai, Yasuyuki/0000-0002-8937-0221; Henzel, William/0000-0003-2940-3797	NIGMS NIH HHS [GM23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023547, R37GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; BARGATZE RF, 1990, J CELL BIOCHEM, V42, P219, DOI 10.1002/jcb.240420405; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1990, AM J PATHOL, V136, P3; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CARAS IW, 1991, CELL BIOL INT REP, V15, P815, DOI 10.1016/0309-1651(91)90035-H; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GALLATIN M, 1986, CELL, V44, P673, DOI 10.1016/0092-8674(86)90832-9; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GENDLER SJ, 1991, AM REV RESPIR DIS, V144, pS42, DOI 10.1164/ajrccm/144.3_pt_2.S42; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GUM JR, 1991, J BIOL CHEM, V266, P22733; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDRIKS HR, 1987, EUR J IMMUNOL, V17, P1691, DOI 10.1002/eji.1830171203; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEE YC, 1989, CIBA F S, V145, P80; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MEBIUS RE, 1991, J CELL BIOL, V115, P85, DOI 10.1083/jcb.115.1.85; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PORCHET N, 1991, AM REV RESPIR DIS, V144, pS15, DOI 10.1164/ajrccm/144.3_pt_2.S15; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rosen SD, 1989, CURR OPIN CELL BIOL, V1, P913, DOI 10.1016/0955-0674(89)90058-6; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1989, J IMMUNOL, V142, P1895; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Sambrook J., 1989, MOL CLONING LAB MANU; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHARON N, 1989, LECTINS; SHER BT, 1988, ADV CANCER RES, V51, P361, DOI 10.1016/S0065-230X(08)60226-2; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, J CLIN INVEST, V84, P1196, DOI 10.1172/JCI114285; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1987, BLOOD, V70, P1842; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313, DOI 10.1016/S0065-2776(08)60645-8; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	93	634	662	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					927	938		10.1016/0092-8674(92)90612-G	http://dx.doi.org/10.1016/0092-8674(92)90612-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1376638				2022-12-24	WOS:A1992HY79200005
J	TAN, SL; ROYSTON, P; CAMPBELL, S; JACOBS, HS; BETTS, J; MASON, B; EDWARDS, RG				TAN, SL; ROYSTON, P; CAMPBELL, S; JACOBS, HS; BETTS, J; MASON, B; EDWARDS, RG			CUMULATIVE CONCEPTION AND LIVEBIRTH RATES AFTER INVITRO FERTILIZATION	LANCET			English	Article							MATERNAL AGE; FERTILIZATION; PREGNANCY; PROSPECTS; PROGRAM; EMBRYO	Cumulative conception and livebirth rates related to age and cause of infertility provide the most useful estimate of success after in-vitro fertilisation (IVF), but limited data are available. It is also uncertain whether the probability of pregnancy, livebirth, and pregnancy failure changes with repeated treatment cycles. To assess the effects of patients' age and cause of infertility on these outcomes, we studied the results of 5055 consecutive IVF cycles (773 clinical pregnancies, 518 livebirths) undertaken on 2735 patients in a single IVF unit. Cumulative conception and livebirth rates were analysed by the life-table approach and differences in rates between age-groups and between causes of infertility were measured by the log-rank test and logistic regression modelling. Both conception and livebirth rates per cycle declined with age (p < 0.001), and cumulative conception and livebirth rates after five treatment cycles were about 54% and 45%, respectively, at 20-34 years, compared with 38.7% and 28.9% at 35-39 years and 20.2% and 14.4% at greater-than-or-equal-to 40 years. The two rates were significantly different between causal groups (p < 0.001 and p = 0.02, respectively) and were lowest in patients with male infertility or multiple infertility factors. The pregnancy failure rate was higher (p = 0.006) in women over the age of 34 years and there was a significant decline in the chances of pregnancy and livebirth per cycle with successive treatment cycles. The success of IVF compares favourably with that of spontaneous conception in the natural menstrual cycle. For women up to the age of 34 years, almost 55% will become pregnant and 45% will have a livebirth within five cycles of treatment.	HALLAM MED CTR,LONDON,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED PHYS,LONDON W12 0HS,ENGLAND; MIDDLESEX HOSP,COBBOLD LABS,LONDON W1,ENGLAND	Imperial College London; University of London; University College London	TAN, SL (corresponding author), KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,DENMARK HILL,LONDON SE5 8RX,ENGLAND.		Jacobs, Howard/A-9845-2009; Tan, Seang Lin/I-7710-2012					COOKE ID, 1981, CLIN OBSTET GYNAECOL, V8, P531; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1979, FERTIL STERIL, V32, P80; DEMOUZON J, 1987, CONTRACEPT FERTIL S, V15, P740; GOSDEN RG, 1985, ANN NY ACAD SCI, V442, P45, DOI 10.1111/j.1749-6632.1985.tb37504.x; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HUGHES EG, 1990, J CLIN ENDOCR METAB, V70, P358, DOI 10.1210/jcem-70-2-358; Kalbfleisch JD, 1980, STATISTICAL ANAL FAI, P14; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS GT, 1986, MED J AUSTRALIA, V144, P682, DOI 10.5694/j.1326-5377.1986.tb113694.x; NAVOT D, 1991, LANCET, V337, P1375, DOI 10.1016/0140-6736(91)93060-M; PADILLA SL, 1989, FERTIL STERIL, V52, P270; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706; SHARMA V, 1988, FERTIL STERIL, V49, P468; STEPTOE PC, 1986, HUM REPROD, V1, P89, DOI 10.1093/oxfordjournals.humrep.a136366; STEPTOE PC, 1978, LANCET, V2, P366; TAN SL, IN PRESS AM J OBSTET; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361; 1991, 6TH REPORT INTERIM L; 1991, FERTIL STERIL, V55, P14	21	232	235	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1390	1394		10.1016/0140-6736(92)91205-M	http://dx.doi.org/10.1016/0140-6736(92)91205-M			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350813				2022-12-24	WOS:A1992HX63600012
J	WEIGEL, D; ALVAREZ, J; SMYTH, DR; YANOFSKY, MF; MEYEROWITZ, EM				WEIGEL, D; ALVAREZ, J; SMYTH, DR; YANOFSKY, MF; MEYEROWITZ, EM			LEAFY CONTROLS FLORAL MERISTEM IDENTITY IN ARABIDOPSIS	CELL			English	Article							POLYMORPHISM LINKAGE MAP; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; GENETIC-CONTROL; THALIANA; AMPLIFICATION; MORPHOGENESIS; PRIMER; DNA	The first step in flower development is the generation of a floral meristem by the inflorescence meristem. We have analyzed how this process is affected by mutant alleles of the Arabidopsis gene LEAFY. We show that LEAFY interacts with another floral control gene, APETALA1, to promote the transition from inflorescence to floral meristem. We have cloned the LEAFY gene, and, consistent with the mutant phenotype, we find that LEAFY RNA is expressed strongly in young flower primordia. LEAFY expression precedes expression of the homeotic genes AGAMOUS and APETALA3, which specify organ identity within the flower. Furthermore, we demonstrate that LEAFY is the Arabidopsis homolog of the FLORICAULA gene, which controls floral meristem identity in the distantly related species Antirrhinum majus.	MONASH UNIV,DEPT GENET & DEV BIOL,CLAYTON,VIC 3168,AUSTRALIA	Monash University	WEIGEL, D (corresponding author), CALTECH,DIV BIOL 15629,PASADENA,CA 91125, USA.		Weigel, Detlef/GSJ-0799-2022; Meyerowitz, Elliot M/A-7118-2009; Weigel, Detlef/AAR-3312-2021; Smyth, David R/K-5993-2012; Weigel, Detlef/C-1418-2008	Weigel, Detlef/0000-0002-2114-7963; Smyth, David R/0000-0003-0455-9699; Weigel, Detlef/0000-0002-2114-7963				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BATTEY NH, 1990, BOT REV, V56, P163; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1991, THESIS CALTECH PASAD; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gifford EM., 1988, MORPHOLOGY EVOLUTION; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KLEMM M., 1927, BOT ARCH, V20, P423; KOORNNEEF M, 1990, GENETIC MAPS; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; Muller A., 1961, KULTURPFLANZE, V9, P364, DOI [10.1007/BF02095757, DOI 10.1007/BF02095757]; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OCHMAN H, 1990, PCR PROTOCOLS; POETHIG RS, 1988, GENETICS, V119, P959; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Stevens WL, 1939, J GENET, V39, P171, DOI 10.1007/BF02982823; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Weberling F., 1981, MORPHOLOGIE BLUTEN B; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	1152	1309	1	138	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					843	859		10.1016/0092-8674(92)90295-N	http://dx.doi.org/10.1016/0092-8674(92)90295-N			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1350515	Green Accepted, hybrid			2022-12-24	WOS:A1992HW83800014
J	CROOK, T; WREDE, D; TIDY, JA; MASON, WP; EVANS, DJ; VOUSDEN, KH				CROOK, T; WREDE, D; TIDY, JA; MASON, WP; EVANS, DJ; VOUSDEN, KH			CLONAL P53 MUTATION IN PRIMARY CERVICAL-CANCER - ASSOCIATION WITH HUMAN-PAPILLOMAVIRUS-NEGATIVE TUMORS	LANCET			English	Article							LUNG-CANCER; GENE; CARCINOMAS	Analyses of cancer cell lines and of anal cancers suggest an inverse correlation between infection with human papillomavirus (HPV) and somatic mutation of the p53 tumour-suppressor gene. We have investigated this association in primary cervical tumours. Tumour-tissue samples from 28 women with primary cancer of the cervix were analysed for presence of HPV sequences and for somatic mutations of the p53 gene. Southern blot analysis and the polymerase chain reaction (PCR) showed that 25 of the tumours contained HPV sequences; 20 were HPV16 positive and 5 HPV18 positive. 17 tumours subjected to restriction fragment length polymorphism analysis for the short arm of chromosome 17 showed no evidence of allelic deletion. Sequencing of the entire coding region of the p53 gene by asymmetric PCR detected heterozygous point mutations in only 3 HPV-negative tumours. By contrast, in 21 HPV-positive cancers the p53 sequence was wild-type throughout Our data indicate that loss of wild-type p53 function is important in the pathology of cervical cancer and that in the absence of an HPV-encoded gene product that mediates loss of p53 function, somatic mutation of the gene is required. This pattern of p53 mutation may partly explain the apparently worse prognosis of HPV-negative cervical cancers.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND; SAMARITAN HOSP WOMEN,DEPT GYNAECOL ONCOL,LONDON,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London								AHERNE W., 1967, J ROY NUCROSC SOC, V87, P493; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; HAUSEN HZ, 1989, ADV VIRAL ONCOL, P1; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIGGINS GD, 1991, LANCET, V338, P910, DOI 10.1016/0140-6736(91)91773-N; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARKS JR, 1991, CANCER RES, V51, P2979; NELSON PH, 1989, EMBO J, V8, P3905; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RIOU G, 1990, LANCET, V335, P1171; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAW P, 1991, ONCOGENE, V6, P2121; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VANDENBRULE AJC, 1990, INT J CANCER, V45, P644, DOI 10.1002/ijc.2910450412; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHANG WH, 1988, J MED VIROL, V26, P163, DOI 10.1002/jmv.1890260208	27	325	329	2	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1070	1073		10.1016/0140-6736(92)90662-M	http://dx.doi.org/10.1016/0140-6736(92)90662-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349102				2022-12-24	WOS:A1992HR44600002
J	SCHMIDT, HHHW; WARNER, TD; ISHII, K; SHENG, H; MURAD, F				SCHMIDT, HHHW; WARNER, TD; ISHII, K; SHENG, H; MURAD, F			INSULIN-SECRETION FROM PANCREATIC B-CELLS CAUSED BY L-ARGININE DERIVED NITROGEN-OXIDES	SCIENCE			English	Article							NITRIC-OXIDE; DIABETES-MELLITUS; RELEASE; CALMODULIN; CALCIUM; ISLETS; LIVER; RATS	L-Arginine causes insulin release from pancreatic B cells. Data from three model systems support the hypothesis that L-arginine-derived nitrogen oxides (NOs) mediate insulin release stimulated by L-arginine in the presence of D-glucose and by the hypoglycemic drug tolbutamide. The formation of NO in pancreatic B cells was detected both chemically and by the NO-induced accumulation of guanosine 3',5'-monophosphate. N(G)-substituted L-arginine analogs inhibited the release of both insulin and NO. Protein immunoblot and histochemical analysis with antiserum to type I NO synthase suggest that the formation of NO in pancreatic B cells is catalyzed by an NADPH- (reduced form of nicotinamide adenine dinucleotide phosphate), Ca2+/calmodulin-dependent type I NO synthase of about 150 kilodaltons.	UNIV SHIZUOKA,SCH PHARMACEUT SCI,DEPT PHARMACOL,SHIZUOKA 422,JAPAN; ABBOTT LABS,ABBOTT PK,IL 60064	University of Shizuoka; Abbott Laboratories	SCHMIDT, HHHW (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611, USA.		Warner, Timothy D/A-1980-2009; Schmidt, Harald HHW/B-1549-2008	Warner, Timothy D/0000-0003-3988-4408; Schmidt, Harald HHW/0000-0003-0419-5549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030787] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28474] Funding Source: Medline; NIDDK NIH HHS [DK 30787] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJAALAND T, 1988, BIOCHEM SOC T, V16, P1017, DOI 10.1042/bst0161017; BJAALAND T, 1990, DIABETOLOGIA, V32, pA467; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; FLOYD JC, 1966, J CLIN INVEST, V45, P1487, DOI 10.1172/JCI105456; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GAGLIARDINO JJ, 1980, BIOCHEM J, V192, P919, DOI 10.1042/bj1920919; GANDA OP, 1984, DIABETES, V33, P516, DOI 10.2337/diabetes.33.6.516; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; HELLMAN B, 1971, ENDOCRINOLOGY, V89, P1432, DOI 10.1210/endo-89-6-1432; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUGHES SJ, 1990, BIOCHEM J, V267, P227, DOI 10.1042/bj2670227; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; ISHII K, 1990, EUR J PHARMACOL, V176, P219; KAMATA K, 1989, BRIT J PHARMACOL, V97, P614, DOI 10.1111/j.1476-5381.1989.tb11993.x; KIMURA H, 1975, J BIOL CHEM, V250, P8016; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; LAYCHOCK SG, 1981, ENDOCRINOLOGY, V108, P1197, DOI 10.1210/endo-108-4-1197; LUHESHI GN, 1990, BRIT J PHARMACOL, V101, P411, DOI 10.1111/j.1476-5381.1990.tb12723.x; MANN GE, 1990, NITRIC OXIDE L ARGIN, P331; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MULLOY AL, 1982, HORM METAB RES, V14, P471, DOI 10.1055/s-2007-1019050; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PANTEN U, 1975, P115; PANTEN U, 1973, N-S ARCH PHARMACOL, V276, P55, DOI 10.1007/BF00500778; SCHMIDT H, UNPUB; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V154, P213, DOI 10.1016/0014-2999(88)90101-X; SENER A, 1990, ENDOCRINOLOGY, V127, P107, DOI 10.1210/endo-127-1-107; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; VERSPOHL EJ, 1989, N-S ARCH PHARMACOL, V339, P348; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; WOLLHEIM CB, 1975, J BIOL CHEM, V250, P1354	33	394	403	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					721	723		10.1126/science.1371193	http://dx.doi.org/10.1126/science.1371193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1371193				2022-12-24	WOS:A1992HC50600039
J	FOTHERBY, MD; HARPER, GD; POTTER, JF				FOTHERBY, MD; HARPER, GD; POTTER, JF			GENERAL-PRACTITIONERS MANAGEMENT OF HYPERTENSION IN ELDERLY PATIENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; STROKE; TRIAL; MORTALITY; MORBIDITY; THERAPY	Objective-To assess general practitioners' attitudes to the diagnosis and management of hypertension in elderly patients. Design - Postal questionnaire to all general practitioners in Leicestershire. Results-360 of 451 general practitioners (80%) responded. 81% (292) reported rechecking an initially high blood pressure on two or three occasions before starting treatment, 56% (202) measured sitting blood pressure only, and just 28% (100) took sitting and standing levels. 36% (128) had no upper age limit for starting anti-hypertensive treatment; of the 58% (206) who did, the median was 80 (range 70-99) years. Blood pressure levels reported for starting treatment in patients aged 70-79 years were 180 (150-240)/106 (90-120) mm Hg. 34% of general practitioners (121) would not treat isolated systolic hypertension. The most popular first line treatment for an elderly hypertensive patient was a thiazide diuretic; only 17% of general practitioners (61) initially tried non-pharmacological methods. 34% (122) would continue anti-hypertensive treatment unchanged in the period immediately after stroke. Conclusions-The variation among general practitioners in the criteria for the measurement, diagnosis, and treatment of hypertension in elderly patients emphasises the need for clear management guidelines in this age group.			FOTHERBY, MD (corresponding author), UNIV LEICESTER, LEICESTER GEN HOSP, DEPT MED ELDERLY, LEICESTER LE5 4PW, ENGLAND.							AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BRITTON M, 1980, ACTA MED SCAND, V207, P253; BULPITT CJ, 1989, HDB HYPERTENSION, V12, P153; CAIRD FI, 1973, BRIT HEART J, V35, P527; CARTER AB, 1970, LANCET, V1, P485; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; KOOPMAN H, 1990, J HUM HYPERTENS, V4, P368; MADER SL, 1987, JAMA-J AM MED ASSOC, V258, P1511, DOI 10.1001/jama.258.11.1511; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Meyer JS, 1973, STROKE, V4, P169, DOI 10.1161/01.STR.4.2.169; PATTERSON HR, 1984, J ROY COLL GEN PRACT, V34, P97; SMITH TDW, 1990, BMJ-BRIT MED J, V300, P74, DOI 10.1136/bmj.300.6717.74; SMITH WCS, 1985, BRIT MED J, V291, P1483, DOI 10.1136/bmj.291.6507.1483; WALLACE JD, 1981, JAMA-J AM MED ASSOC, V246, P2177, DOI 10.1001/jama.246.19.2177; WALLER PC, 1990, J HUM HYPERTENS, V4, P509; 1989, BMJ, V298, P294; 1987, DAN MED B S1, V34, P5; 1974, JAMA-J AM MED ASSOC, V229, P409; 1989, J HYPERTENS, V7, P689	23	49	49	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1992	305	6856					750	752		10.1136/bmj.305.6856.750	http://dx.doi.org/10.1136/bmj.305.6856.750			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1358373	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JQ52000024
J	LINDEMANN, F; SCHLIMOK, G; DIRSCHEDL, P; WITTE, J; RIETHMULLER, G				LINDEMANN, F; SCHLIMOK, G; DIRSCHEDL, P; WITTE, J; RIETHMULLER, G			PROGNOSTIC-SIGNIFICANCE OF MICROMETASTATIC TUMOR-CELLS IN BONE-MARROW OF COLORECTAL-CANCER PATIENTS	LANCET			English	Article							LARGE BOWEL-CANCER; MONOCLONAL-ANTIBODIES; MULTIVARIATE-ANALYSIS; MICRO-METASTESES; BREAST-CANCER; RECTAL-CANCER; CARCINOMA; CYTOKERATIN; METASTASES; EXPRESSION	Much of the information recorded at the time of surgery for malignant disease has been used, alone or in combination, to indicate the outlook for that patient, including probability of metastasis. However, direct evidence of tumour seeding in distant organs at that time is not available. An immunocytochemical assay for the epithelial cytokeratin protein (CK18) may fill this gap since it is a feature of epithelial cells but would not normally be in bone marrow. We looked for disseminated tumour cells preoperatively in bone marrow from 88 patients with radically resected colorectal carcinomas. Smears for 28 (32%) patients were positive for cells of epithelial origin, which were absent from aspirates taken from 102 controls with non-malignant disease. The prognostic value was assessed in a follow-up study with a median observation time of 35 (12-58) months. Patients who had bone marrow tumour cells in the aspirate showed a significantly shorter disease-free survival than those without tumour cells (p = 0.0084). In a Cox regression model multivariate analysis demonstrated that the finding of tumour cells in bone marrow is an independent, significant (p = 0.0035) determinant of relapse. Although the skeleton is not a preferred site of overt metastasis in colorectal cancer the demonstration of tumour cells in bone marrow has to be taken as evidence of the general disseminative capability of an individual tumour.	UNIV MUNICH, INST IMMUNOL, W-8000 MUNICH 2, GERMANY; UNIV MUNICH, INST MED INFORMAT BIOMETRY & EPIDEMIOL, W-8000 MUNICH 2, GERMANY; ZENT KLINIKUM, MED CLIN 2, W-8900 AUGSBURG, GERMANY	University of Munich; University of Munich	LINDEMANN, F (corresponding author), ZENT KLINIKUM, ALLGEMEIN & ABDOMINALCHIRURG KLIN, DEPT GEN SURG, STENGLINSTR 2, W-8900 AUGSBURG, GERMANY.							BONNHEIM DC, 1986, AM J SURG, V151, P457, DOI 10.1016/0002-9610(86)90102-9; BURKHARDT R, 1980, B CANCER, V67, P291; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COX DR, 1972, J R STAT SOC B, V34, P187; DEBUS E, 1984, AM J PATHOL, V114, P121; FIELDING LP, 1986, LANCET, V2, P904; FREEDMAN LS, 1984, LANCET, V2, P733; HERMANEK P, 1989, DIS COLON RECTUM, V32, P593, DOI 10.1007/BF02554180; JASS JR, 1986, HISTOPATHOLOGY, V10, P437, DOI 10.1111/j.1365-2559.1986.tb02497.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KILLION JJ, 1989, SEMIN ONCOL, V16, P106; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; MANSI JL, 1987, BRIT MED J, V295, P1093, DOI 10.1136/bmj.295.6606.1093; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Paget S., 1889, LANCET, V1, P571, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; PANTEL K, 1991, CANCER RES, V51, P4712; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RIETHMULLER G, 1989, PROGR IMMUNOLOGY, V7, P1079; Schlimok G, 1990, Semin Cancer Biol, V1, P207; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; SCHLIMOK G, 1990, J CLIN ONCOL, V8, P831, DOI 10.1200/JCO.1990.8.5.831; SCHLIMOK G, 1985, BLUT, V51, P203; SCHMITZMOORMANN P, 1987, J CANCER RES CLIN, V113, P586, DOI 10.1007/BF00390871; TALBOT RW, 1989, EUR J SURG ONCOL, V15, P449; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; WELCH JP, 1979, ANN SURG, V189, P496; WIGGERS T, 1988, CANCER, V61, P386, DOI 10.1002/1097-0142(19880115)61:2<386::AID-CNCR2820610231>3.0.CO;2-J; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; 1991, JAMA-J AM MED ASSOC, V264, P1444	31	506	517	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1992	340	8821					685	689		10.1016/0140-6736(92)92230-D	http://dx.doi.org/10.1016/0140-6736(92)92230-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1381801				2022-12-24	WOS:A1992JN78000002
J	CLARK, SW; MEYER, DI				CLARK, SW; MEYER, DI			CENTRACTIN IS AN ACTIN HOMOLOG ASSOCIATED WITH THE CENTROSOME	NATURE			English	Article							GAMMA-TUBULIN; ASPERGILLUS-NIDULANS; BINDING PROTEINS; IDENTIFICATION; CONSTRUCTION; EXPRESSION; COMPONENT; RNA; TRANSLOCATION; MEMBRANE	ACTIN is one of the most ubiquitous, abundant and well-conserved proteins of eukaryotes, participating in many crucial cellular processes including the maintenance of cell shape, motility and cell division1,2. Actins from the most divergent sources still share amino-acid identities in excess of 70% (ref. 3). This may well explain why low-abundance homologues of actin have been difficult to isolate. Genes encoding distant relatives of actin in budding and fission yeast have now been cloned3,4. We report here the discovery of a vertebrate actin-like protein, which we name centractin. A full-length complementary DNA clone was isolated whose sequence reveals amino-acid identities with actin of over 50%, increasing to more than 70% when conservative amino-acid changes are considered. Northern analysis and western blotting indicate a ubiquitous tissue and species distribution. Morphological and biochemical criteria show that centractin is associated with centrosomes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; MOLEC BIOL INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; BUSH GL, 1991, J BIOL CHEM, V266, P13811; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOSTITESTU F, 1986, EMBO J, V5, P2545, DOI 10.1002/j.1460-2075.1986.tb04533.x; HERZ J, 1990, FEBS LETT, V276, P103, DOI 10.1016/0014-5793(90)80518-N; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARO B, 1980, BIOL CELLULAIRE, V39, P287; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	35	161	167	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					246	250		10.1038/359246a0	http://dx.doi.org/10.1038/359246a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1356230				2022-12-24	WOS:A1992JN94400065
J	COTTRELL, S; BICKNELL, D; KAKLAMANIS, L; BODMER, WF				COTTRELL, S; BICKNELL, D; KAKLAMANIS, L; BODMER, WF			MOLECULAR ANALYSIS OF APC MUTATIONS IN FAMILIAL ADENOMATOUS POLYPOSIS AND SPORADIC COLON CARCINOMAS	LANCET			English	Article							CELL-LINES; PRESYMPTOMATIC DIAGNOSIS; DNA MARKERS; GENE; IDENTIFICATION; CHROMOSOME-5Q21; ESTABLISHMENT; MISMATCHES; LOCUS; FAP	Mutations in the APC gene give rise to familial adenomatous polyposis (FAP) and also occur in many, perhaps most, sporadic colon cancers. By screening with single-strand conformation polymorphism analysis we identified several mutations in a small region of the APC gene in both FAP and sporadic cancers. These mutations were either point mutations or small deletions or insertions causing frameshifts, and all generated stop codons. One 5 base-pair deletion was found in a sporadic colon tumour, a colorectal cancer cell line derived from a sporadic colon tumour, and in four unrelated FAP patients. This mutation produces distinctive heteroduplex bands, which can be detected with a simple non-radioactive assay. Our findings suggest that highly localised short sequences, essentially runs that code for adenine and thymine, may account for up to 20% of all observed APC mutations.	IMPERIAL CANC RES FUND,CANC GENET LAB,POB 123,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,CANC IMMUNOL LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford; University of Oxford				Bodmer, Walter/0000-0001-6244-9792				BISHOP DT, 1990, HEREDITARY COLORECTA, P423; BODMER W, 1992, CANCER SURV, V13, P1; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BODMER WF, 1990, HEREDITARY COLORECTA, P37; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; Cottrel S., 1992, Human Molecular Genetics, V1, P352, DOI 10.1093/hmg/1.5.352-a; DAMICO D, 1992, CANCER RES, V52, P1996; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DREWINKO B, 1976, CANCER RES, V36, P467; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; GREENWALD BD, 1992, CANCER RES, V52, P741; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HEIGHWAY J, 1991, NUCLEIC ACIDS RES, V19, P6966, DOI 10.1093/nar/19.24.6966; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KEEN J, 1991, TRENDS GENET, V7, P5; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KRAUS C, 1992, HUM GENET, V88, P705, DOI 10.1007/BF02265305; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MCBAIN JA, 1984, CANCER RES, V44, P5813; MITELMAN F, 1991, CYTOGENET CELL GENET, V58, P1053, DOI 10.1159/000133721; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SUARDET L, 1992, CANCER RES, V52, P3705; TOPS CMJ, 1989, LANCET, V2, P1361; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	30	207	208	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					626	630		10.1016/0140-6736(92)92169-G	http://dx.doi.org/10.1016/0140-6736(92)92169-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355210				2022-12-24	WOS:A1992JM85100002
J	TONNESEN, H; PETERSEN, KR; HOJGAARD, L; STOKHOLM, KH; NIELSEN, HJ; KNIGGE, U; KEHLET, H				TONNESEN, H; PETERSEN, KR; HOJGAARD, L; STOKHOLM, KH; NIELSEN, HJ; KNIGGE, U; KEHLET, H			POSTOPERATIVE MORBIDITY AMONG SYMPTOM-FREE ALCOHOL MISUSERS	LANCET			English	Article							DELAYED-HYPERSENSITIVITY; ETHANOL; DYSFUNCTION; WITHDRAWAL; SURGERY; INJURY	Retrospective studies suggest that there is an increased postoperative morbidity among alcohol misusers. We have prospectively studied the risk of alcohol intake among patients undergoing surgery. We investigated 15 symptom-free subjects who required colorectal surgery and who were drinking at least 60 g of alcohol per day. These patients were matched for sex, nutrition, age, weight, cardiovascular and pulmonary disease, diagnosis, anaesthesia, and surgery to 15 control subjects who were consuming below 25 g of alcohol daily. Those drinking at least 60 g of alcohol per day developed more postoperative complications than controls (67% vs 20%, p < 0.05) and hospital stay was prolonged (20 vs 12 days, p < 0.05). Preoperatively, alcohol misusers had reduced left ventricular ejection fraction (median, 54% vs 68%, p<0.01). Delayed hypersensitivity responses were smaller in the alcohol group before (53 mm2 vs 78 mm2, p < 0.05) and after (18 mm2 vs 55 mm2, p < 0.01) surgery. Alcohol misusers had longer bleeding times during the first postoperative week (p < 0.01). Surgical stress responses, as assessed by changes in plasma cortisol and catecholamines, were higher among alcoholics (p < 0.05). Postoperative morbidity is increased in symptom-free alcohol misusers. The mechanism is probably subclinical cardiac insufficiency, immunosuppression, and decreased haemostatic function. Preoperative alcohol consumption may be a more important risk factor than previously thought.	UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT CLIN PHYSIOL NUCL MED,DK-2650 HVIDOVRE,DENMARK; UNIV COPENHAGEN,PANUM INST,DEPT MED PHYSIOL C,DK-2200 COPENHAGEN,DENMARK	University of Copenhagen; University of Copenhagen	TONNESEN, H (corresponding author), UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT SURG GASTROENTEROL,DK-2650 HVIDOVRE,DENMARK.		Højgaard, Liselotte/AAK-8329-2020	Tonnesen, Hanne/0000-0002-7161-3416; Kehlet, Henrik/0000-0002-2209-1711				BENJOHATHAN N, 1976, ENDOCRINOLOGY, V98, P1447; BRAUTBAR N, 1987, ALCOHOL CLIN EXP RES, V11, P118, DOI 10.1111/j.1530-0277.1987.tb01274.x; CREGLER LL, 1989, CLIN CARDIOL, V12, P122, DOI 10.1002/clc.4960120302; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRIBALDO RS, 1985, AM J CARDIOL, V56, P825, DOI 10.1016/0002-9149(85)91159-2; HJORTSO NC, 1986, ACTA CHIR SCAND, V152, P175; KATZ AM, 1985, J MOL CELL CARDIOL, V17, P11, DOI 10.1016/0022-2828(85)90004-5; KAWAKAMI M, 1990, J TRAUMA, V30, P27, DOI 10.1097/00005373-199001000-00004; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KRANTZ T, 1990, Ugeskrift for Laeger, V152, P1168; LINNOILA M, 1987, ANN INTERN MED, V107, P875, DOI 10.7326/0003-4819-107-6-875; MACLEAN LD, 1988, SURG GYNECOL OBSTET, V166, P285; MARVING J, 1985, CIRCULATION, V72, P502, DOI 10.1161/01.CIR.72.3.502; MIKHAILIDIS DP, 1986, BRIT MED J, V293, P715, DOI 10.1136/bmj.293.6549.715; MORGAN MY, 1988, P NUTR SOC, V47, P85, DOI 10.1079/PNS19880017; NEIMAN J, 1988, RES EXP MED, V188, P175, DOI 10.1007/BF01852318; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Simms J M, 1982, Clin Nutr, V1, P71, DOI 10.1016/0261-5614(82)90007-3; SMITH AJ, 1990, ALCOHOL CLIN EXP RES, V14, P497, DOI 10.1111/j.1530-0277.1990.tb01187.x; SUN GY, 1985, ALCOHOL CLIN EXP RES, V9, P164, DOI 10.1111/j.1530-0277.1985.tb05543.x; TIERNAN JM, 1985, INT J BIOCHEM, V17, P793, DOI 10.1016/0020-711X(85)90266-6; TONNESEN H, 1988, SCAND J UROL NEPHROL, V22, P175, DOI 10.1080/00365599.1988.11690408; TONNESEN H, 1987, DIS COLON RECTUM, V30, P549, DOI 10.1007/BF02554788; TONNESEN H, 1987, Ugeskrift for Laeger, V149, P285; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701	25	127	128	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					334	337						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353805				2022-12-24	WOS:A1992JH12500004
J	KHABBAZ, RF; ROWE, T; MURPHEYCORB, M; HENEINE, WM; SCHABLE, CA; GEORGE, JR; PAU, CP; PAREKH, BS; LAIRMORE, MD; CURRAN, JW; KAPLAN, JE; SCHOCHETMAN, G; FOLKS, TM				KHABBAZ, RF; ROWE, T; MURPHEYCORB, M; HENEINE, WM; SCHABLE, CA; GEORGE, JR; PAU, CP; PAREKH, BS; LAIRMORE, MD; CURRAN, JW; KAPLAN, JE; SCHOCHETMAN, G; FOLKS, TM			SIMIAN IMMUNODEFICIENCY VIRUS NEEDLESTICK ACCIDENT IN A LABORATORY WORKER	LANCET			English	Note								The macaque monkey infected with simian immunodeficiency virus (SIV) is an animal model of the acquired immunodeficiency syndrome. We investigated a laboratory worker who was exposed by needlestick accident to blood from an SIV-infected macaque. Seroreactivity to SIV developed within 3 months of exposure, with antibody titres peaking from the third to the fifth month and declining thereafter. Polymerase chain reaction for SIV sequences and cultures of peripheral-blood mononuclear cells failed to show infection. Inoculation of an SIV-negative monkey with blood from the worker did not cause infection. Animal-care and laboratory workers should adhere strictly to recommended procedures to avoid accidental exposures when working with SIV-infected animals or specimens.	TULANE UNIV,DELTA REG PRIMATE RES CTR,COVINGTON,LA 70433; OHIO STATE UNIV,DEPT VET PATHOBIOL,COLUMBUS,OH 43210; CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Tulane University; University System of Ohio; Ohio State University; Centers for Disease Control & Prevention - USA	KHABBAZ, RF (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,RETROVIRUS DIS BRANCH,MS-G03,ATLANTA,GA 30333, USA.			PAREKH, BHARAT/0000-0002-1088-4263				ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; MCLURE HM, 1989, VET IMMUNOL IMMUNOP, V21, P13; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; PAREKH BS, 1991, AIDS, V5, P1009, DOI 10.1097/00002030-199108000-00013; SHEN L, 1991, SCIENCE, V252, P440, DOI 10.1126/science.1708168; VILLINGER F, 1991, J VIROL, V65, P1855, DOI 10.1128/JVI.65.4.1855-1862.1991; 1988, MMWR, V37, P693	9	42	46	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					271	273		10.1016/0140-6736(92)92358-M	http://dx.doi.org/10.1016/0140-6736(92)92358-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353193				2022-12-24	WOS:A1992JG66500005
J	ROSEN, GD; SANES, JR; LACHANCE, R; CUNNINGHAM, JM; ROMAN, J; DEAN, DC				ROSEN, GD; SANES, JR; LACHANCE, R; CUNNINGHAM, JM; ROMAN, J; DEAN, DC			ROLES FOR THE INTEGRIN VLA-4 AND ITS COUNTER RECEPTOR VCAM-1 IN MYOGENESIS	CELL			English	Article							CELL-ADHESION MOLECULE; ADULT SKELETAL-MUSCLE; HEPARAN-SULFATE PROTEOGLYCAN; RAT LUMBRICAL MUSCLES; N-CAM; EXTRASYNAPTIC PORTIONS; FIBRONECTIN RECEPTOR; MYOBLAST INTERACTION; SECONDARY MYOTUBES; FIBER NUMBERS	Mammalian myogenesis is biphasic: primary myoblasts fuse to form primary myotubes, then secondary myoblasts align along the primary myotubes and form secondary myotubes, which comprise most of adult muscle. We provide evidence that an integrin (VLA-4) and its counter receptor (VCAM-1) have a role in secondary myogenesis. Both receptors are synthesized by cultured muscle cells: VLA-4 is induced as myotubes form, whereas VCAM-1 is present on myoblasts and myotubes. In vivo, both molecules are expressed at sites of secondary myogenesis, VLA-4 on primary and secondary myotubes, and VCAM-1 on secondary myoblasts and on regions of secondary myotubes apposed to primary myotubes. These patterns suggest that VLA-4-VCAM-1 interactions influence alignment of secondary myoblasts along primary myotubes and/or the fusion of secondary myoblasts. In support of the latter possibility, antibodies to VLA-4 or VCAM-1 inhibit myotube formation in culture.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	ROSEN, GD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 43418, HL 29594] Funding Source: Medline; NINDS NIH HHS [NS 19195] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL043418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019195, R37NS019195] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ASHMORE CR, 1972, EXP NEUROL, V37, P241, DOI 10.1016/0014-4886(72)90071-4; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; CARLOS T, 1991, BLOOD, V77, P2266; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; CASHMAN NR, 1987, ANN NEUROL, V21, P481, DOI 10.1002/ana.410210512; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DUXSON MJ, 1989, DEVELOPMENT, V107, P743; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FREDETTE BJ, 1991, DEV BIOL, V143, P1, DOI 10.1016/0012-1606(91)90050-D; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HARRIS AJ, 1981, PHILOS T ROY SOC B, V293, P257, DOI 10.1098/rstb.1981.0076; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; HARTLEY RS, 1991, DEV BIOL, V148, P249, DOI 10.1016/0012-1606(91)90334-Y; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, IMMUNOL REV, V108, P45, DOI 10.1111/j.1600-065X.1989.tb00012.x; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KELLY AM, 1969, J CELL BIOL, V42, P135, DOI 10.1083/jcb.42.1.135; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; KNUDSEN KA, 1977, DEV BIOL, V58, P328, DOI 10.1016/0012-1606(77)90095-1; KUHL U, 1986, DEV BIOL, V117, P628, DOI 10.1016/0012-1606(86)90331-3; MCLENNAN IS, 1983, DEV BIOL, V98, P287, DOI 10.1016/0012-1606(83)90359-7; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; ONTELL M, 1988, AM J ANAT, V181, P267, DOI 10.1002/aja.1001810305; ONTELL M, 1977, ANAT REC, V189, P669, DOI 10.1002/ar.1091890410; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1991, AM J PATHOL, V138, P385; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSS JJ, 1987, DEVELOPMENT, V100, P395; ROSS JJ, 1987, DEVELOPMENT, V100, P383; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; SCHEEREN RA, 1991, EUR J IMMUNOL, V21, P1101, DOI 10.1002/eji.1830210503; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SOLER AP, 1991, DEV BIOL, V148, P389, DOI 10.1016/0012-1606(91)90346-5; STICKLAND NC, 1982, ANAT EMBRYOL, V164, P379, DOI 10.1007/BF00315759; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TRASK RV, 1988, J BIOL CHEM, V263, P17142; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; WAKELAM MJO, 1985, BIOCHEM J, V228, P1; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WHEELOCK MJ, 1991, DIFFERENTIATION, V46, P35, DOI 10.1111/j.1432-0436.1991.tb00863.x; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	66	329	336	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1107	1119		10.1016/0092-8674(92)90633-N	http://dx.doi.org/10.1016/0092-8674(92)90633-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1377605				2022-12-24	WOS:A1992JA43100006
J	ELLIS, JS; SEYMOUR, RA; MONKMAN, SC; IDLE, JR				ELLIS, JS; SEYMOUR, RA; MONKMAN, SC; IDLE, JR			GINGIVAL SEQUESTRATION OF NIFEDIPINE IN NIFEDIPINE-INDUCED GINGIVAL OVERGROWTH	LANCET			English	Note								The mechanism of gingival overgrowth associated with long-term use of nifedipine and of other drugs that affect calcium homoeostasis, such as cyclosporin and phenytoin, is unknown. With an ultrasensitive assay, we measured the pharmacokinetics of nifedipine in plasma and gingival crevicular fluid (GCF) of nine patients receiving this drug for angina and hypertension. In seven patients, the maximum nifedipine concentration was in the range 15-316 (mean 84 [SD 105]) times greater in GCF than in plasma. The two patients with low (undetectable) GCF nifedipine did not have overgrowth. We propose that gingival tissues sequester nifedipine and that the very high nifedipine concentrations predispose the tissues to overgrowth.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH DENT,DEPT OPERAT DENT,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK			Ellis, Janice/R-5300-2018	Ellis, Janice/0000-0002-4602-6674	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARCLAY S, 1992, J CLIN PERIODONTOL, V19, P311, DOI 10.1111/j.1600-051X.1992.tb00650.x; FERNER RE, 1990, HUM EXP TOXICOL, V9, P309, DOI 10.1177/096032719000900507; GELFAND EW, 1987, J IMMUNOL, V138, P1115; KAPUR RN, 1973, DEV MED CHILD NEUROL, V15, P483; MCGAW T, 1987, ORAL SURG ORAL MED O, V64, P293, DOI 10.1016/0030-4220(87)90007-7; SCHMID BJ, 1988, J CHROMATOGR-BIOMED, V425, P107, DOI 10.1016/0378-4347(88)80011-2; SEYMOUR RA, 1988, J CLIN PERIODONTOL, V15, P1, DOI 10.1111/j.1600-051X.1988.tb01549.x; SEYMOUR RA, 1991, BRIT DENT J, V170, P376, DOI 10.1038/sj.bdj.4807564; VATER W, 1972, ARZNEI-FORSCHUNG, V22, P1	9	39	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1382	1383		10.1016/0140-6736(92)91199-I	http://dx.doi.org/10.1016/0140-6736(92)91199-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350808				2022-12-24	WOS:A1992HX63600006
J	GLICK, BS; BRANDT, A; CUNNINGHAM, K; MULLER, S; HALLBERG, RL; SCHATZ, G				GLICK, BS; BRANDT, A; CUNNINGHAM, K; MULLER, S; HALLBERG, RL; SCHATZ, G			CYTOCHROMES-C1 AND CYTOCHROMES-B2 ARE SORTED TO THE INTERMEMBRANE SPACE OF YEAST MITOCHONDRIA BY A STOP-TRANSFER MECHANISM	CELL			English	Article							PRECURSOR PROTEINS; INNER MEMBRANE; C PEROXIDASE; NUCLEAR GENE; ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE; CONTACT SITES; 2 STEPS; IMPORT; TRANSLOCATION	The pathway by which cytochromes c1 and b2 reach the mitochondrial intermembrane space has been controversial. According to the "conservative sorting" hypothesis, these proteins are first imported across both outer and inner membranes into the matrix, and then are retranslocated across the inner membrane. Our data argue against this model: import intermediates of cytochromes c1 and b2 were found only outside the inner membrane; maturation of these proteins was independent of the matrix-localized hsp60 chaperone; and dihydrofolate reductase linked to the presequence of either cytochrome was imported to the intermembrane space in the absence of ATP. We conclude that cytochromes c1 and b2 are sorted by a mechanism in which translocation through the inner membrane is arrested by a "stop-transfer" signal in the presequence. The arrested intermediates may be associated with a proteinaceous channel in the inner membrane.			GLICK, BS (corresponding author), UNIV BASEL, BIOCTR, CH-4056 BASEL, SWITZERLAND.			Muller, Sabina/0000-0002-4580-2758	NIGMS NIH HHS [2R01 GM 37803, GM 43885] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; CASTELLOT JJ, 1980, INTRO MACROMOLECULES, P297; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3075; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK B, 1991, ANNU REV GENET, V25, P21; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KOZLOWSKI M, 1988, ANAL BIOCHEM, V172, P382; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; Margulis L., 1993, SYMBIOSIS CELL EVOLU; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NICHOLSON DW, 1988, PROTEIN TRANSFER ORG, P677; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; PRATJE E, 1986, EMBO J, V5, P1312; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; REID GA, 1982, J BIOL CHEM, V257, P3068; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SCHERER P, 1988, THESIS U BASEL BASEL; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOMLO M, 1965, BIOCHIM BIOPHYS ACTA, V97, P183, DOI 10.1016/0304-4165(65)90083-8; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; TEINTZE M, 1982, J BIOL CHEM, V257, P364; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VANLOON APG, 1987, EMBO J, V8, P2433; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZIMMERMAN DL, 1990, J BIOL CHEM, V265, P4048	59	315	315	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					809	822		10.1016/0092-8674(92)90292-K	http://dx.doi.org/10.1016/0092-8674(92)90292-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1350514				2022-12-24	WOS:A1992HW83800011
J	GRATTAN, CEH; FRANCIS, DM; SLATER, NGP; BARLOW, RJ; GREAVES, MW				GRATTAN, CEH; FRANCIS, DM; SLATER, NGP; BARLOW, RJ; GREAVES, MW			PLASMAPHERESIS FOR SEVERE, UNREMITTING, CHRONIC URTICARIA	LANCET			English	Note								Histamine-releasing autoantibodies have been identified in chronic idiopathic urticaria. 8 patients with severe disease and histamine-releasing activity in their sera underwent plasmapheresis. Symptoms were abolished for 2 months in 1 patient and for 3 weeks in another, 2 showed almost complete resolution of symptoms, 2 had temporary relief, and the other 2 showed little change. Further investigation in 4 of the patients showed significantly reduced skin-test responses to fresh post-exchange autologous sera after plasmapheresis compared with stored pre-exchange sera, but the response to intradermal histamine remained unchanged. Blood cellular histamine increased as in-vitro serum histamine-releasing activity fell after plasmapheresis. These results favour a pathogenetic role for histamine-releasing autoantibodies in patients with chronic urticaria.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND; ST THOMAS HOSP,DEPT HAEMATOL,LONDON SE1 7EH,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust								CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P221, DOI 10.1111/j.1365-2222.1990.tb02671.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; RORSMAN H, 1962, ACTA ALLERGOL, V4, P265; SMITH CH, 1992, LANCET, V339, P91, DOI 10.1016/0140-6736(92)91000-X	5	175	181	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1078	1080		10.1016/0140-6736(92)90666-Q	http://dx.doi.org/10.1016/0140-6736(92)90666-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1373787				2022-12-24	WOS:A1992HR44600005
J	BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ				BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ			VARIATION IN THE QUALITY OF CARDIOPULMONARY-RESUSCITATION	LANCET			English	Note								During instruction in basic cardiopulmonary resuscitation (CPR) skills, cardiac massage and mouth-to-mouth ventilation are applied without interruption for no longer than a few minutes. The aim of this study was to see if the quality of technique during the first 2 min of CPR reflects the resuscitators ability to perform CPR over a 15 min period. Assessments were done with a resuscitation mannequin from which recordings of several variables were made at 2, 5, 10, and 15 min after the start of CPR. 60 lay volunteers who had received CPR training were studied, and six variables that describe the quality of CPR technique were recorded and scored with a predefined scoring system. No deterioration in CPR skills was seen during 15 min. We conclude that the initial 2 min assessment reflects the resuscitators ability to perform CPR over a longer period.	CATHARINA HOSP,DEPT CARDIOL,POB 1350,5602 ZA EINDHOVEN,NETHERLANDS; DUTCH COLL GEN PRACTIONERS,UTRECHT,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT CARDIOL,NIJMEGEN,NETHERLANDS; UNIV UTRECHT HOSP,DEPT ANAESTHESIA,3511 GV UTRECHT,NETHERLANDS	Catharina Hospital; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center			Berden, Hubert/GQB-0441-2022					BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BERDEN HJJM, 1992, RESUSCITATION, V23, P21, DOI 10.1016/0300-9572(92)90159-A; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; KALMTHOUT P, 1985, BRIT HEART J, V53, P562; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; ROOS L, 1990, CARDIOLOGISCHE PATIE; SEFRIN P, 1987, ANASTH INTENSIVMED, V28, P129; SILVAST T, 1990, AM J EMERG MED, V8, P359; VANHOEYWEGHEN RJ, 1991, ANN EMERG MED, V20, P279, DOI 10.1016/S0196-0644(05)80940-0; 1986, JAMA-J AM MED ASSOC, V255, P2905	10	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1019	1020		10.1016/0140-6736(92)90539-F	http://dx.doi.org/10.1016/0140-6736(92)90539-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349054				2022-12-24	WOS:A1992HQ43500007
J	CHRISTENSEN, J				CHRISTENSEN, J			PATHOPHYSIOLOGY OF THE IRRITABLE-BOWEL-SYNDROME	LANCET			English	Article							MYOELECTRICAL ACTIVITY; COLONIC MOTOR; SYMPTOMS; DIAGNOSIS; MOTILITY; DISEASE				CHRISTENSEN, J (corresponding author), UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.							ALMY TP, 1951, AM J MED, V10, P60, DOI 10.1016/0002-9343(51)90219-7; BARKER LF, 1928, AM J MED SCI, V178, P606; Bockus HL, 1928, AM J MED SCI, V176, P813, DOI 10.1097/00000441-192812000-00006; CHAUDHARY NA, 1962, Q J MED, V31, P307; DINAN TG, 1990, J PSYCHOSOM RES, V34, P575, DOI 10.1016/0022-3999(90)90032-Y; ESLER MD, 1973, NEW ENGL J MED, V288, P16, DOI 10.1056/NEJM197301042880104; HISLOP IG, 1971, GUT, V12, P452, DOI 10.1136/gut.12.6.452; Hurst AF, 1935, LANCET, V1, P1483; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; JORDAN SM, 1929, JAMA-J AM MED ASSOC, V93, P592; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KELLOW JE, 1992, SCAND J GASTROENTERO, V27, P53, DOI 10.3109/00365529209011167; KENDALL GPN, 1990, GUT, V31, P1062, DOI 10.1136/gut.31.9.1062; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; KUMAR D, 1985, LANCET, V2, P973; KUMAR D, 1990, DIGESTION, V45, P80, DOI 10.1159/000200227; LATIMER P, 1981, GASTROENTEROLOGY, V80, P893; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MCALLISTER C, 1990, BIOMED PHARMACOTHER, V44, P399, DOI 10.1016/0753-3322(90)90043-9; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; Ryle JA, 1928, LANCET, V2, P1115; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; SNAPE WJ, 1977, GASTROENTEROLOGY, V72, P383; SNAPE WJ, 1978, GASTROENTEROLOGY, V75, P373; TALLEY NJ, 1990, GASTROENTEROLOGY, V99, P327, DOI 10.1016/0016-5085(90)91012-U; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; THOMPSON WG, 1986, CAN MED ASSOC J, V134, P111; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; THOMPSON WG, 1979, IRRITABLE GUT FUNCTI; TROTMAN IF, 1986, LANCET, V2, P364; TROTMAN IF, 1988, GUT, V29, P218, DOI 10.1136/gut.29.2.218; White BV, 1940, ANN INTERN MED, V14, P854, DOI 10.7326/0003-4819-14-5-854; White WH, 1905, LANCET, V2, P1229; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0	35	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1444	1447						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360568				2022-12-24	WOS:A1992KC28400012
J	MADERAZO, EG; SUN, H; JAY, GT				MADERAZO, EG; SUN, H; JAY, GT			SIMPLIFICATION OF ANTIBIOTIC DOSE ADJUSTMENTS IN RENAL-INSUFFICIENCY - THE DREM SYSTEM	LANCET			English	Article							DOSING GUIDELINES; DRUG-THERAPY; GENTAMICIN; PHARMACOKINETICS; FAILURE; ADULTS; AGENTS	Many clinicians, unassisted by reference books, are unable to make the required dose adjustment of antibiotics needed when a patient has renal insufficiency. We describe the DREM (dosing in renopathy by easy-to-use multipliers) system, which simplifies the understanding and the process of dose adjustment. DREM is a two-step process: Cockcroft and Gault estimation of creatinine clearance (CLcr) from age, sex, and serum creatinine and calculation of the adjusted dose or dosing interval by multipliers. If the normal dose is multiplied by the dose multiplier (CLcr/100) and the dosing interval by the interval multiplier (100/CLcr), the adjusted dose and interval, respectively, are obtained. Theoretical trough concentrations calculated with the DREM system correlated closely (r=0.9) with actual concentrations obtained from doses calculated by the Hull and Sarubbi method in 23 patients. With DREM, gentamicin or tobramycin trough concentrations above 2 mug/ml were less likely to occur. The DREM system is a simple and easily remembered method for dose adjustments of certain anti-infective agents in renal insufficiency. Dose estimates with this method are reasonably accurate and compare favourably with other standard methods of correction.	HARTFORD HOSP,DEPT MED,ANTIBIOT MANAGEMENT PROGRAM,HARTFORD,CT 06115; HARTFORD HOSP,DEPT MED,DIV INFECT DIS,HARTFORD,CT 06115; HARTFORD HOSP,DEPT PHARM SERV,CTR DRUG INFORMAT,HARTFORD,CT 06115; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH PHARM,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH MED,STORRS,CT 06268; UNIV CONNECTICUT,SCH PHARM,STORRS,CT 06268	Hartford Hospital; Hartford Hospital; Hartford Hospital; University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	MADERAZO, EG (corresponding author), HARTFORD HOSP,MED RES LAB,HARTFORD,CT 06115, USA.							BENNETT WM, 1980, ANN INTERN MED, V93, P62, DOI 10.7326/0003-4819-93-1-62; BENNETT WM, 1980, ANN INTERN MED, V93, P286, DOI 10.7326/0003-4819-111-3-286; BOUCHER BA, 1992, REV INFECT DIS, V14, P458; BRATER DC, 1984, PHARMACOKINETIC BASI, P111; CHOW MSS, 1986, DRUG INTELL CLIN PHA, V9, P385; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DAHLGREN JG, 1975, ANTIMICROB AGENTS CH, V8, P58, DOI 10.1128/AAC.8.1.58; GAMBERTOGLIO JG, 1984, PHARMACOKINETIC BASI, P149; GIBSON TP, 1986, APPLIED PHARMACOKINE, P83; HULL JH, 1976, ANN INTERN MED, V85, P183, DOI 10.7326/0003-4819-85-2-183; MATZKE GR, 1984, ANTIMICROB AGENTS CH, V25, P433, DOI 10.1128/AAC.25.4.433; MAWER GE, 1974, BRIT J CLIN PHARMACO, V1, P45, DOI 10.1111/j.1365-2125.1974.tb00205.x; NORRIS S, 1990, PRINCIPLES PRACTICE, P434; PATEL IH, 1984, ANTIMICROB AGENTS CH, V25, P438, DOI 10.1128/AAC.25.4.438; SANFORD JP, 1991, GUIDE ANTIMICROBIAL; 1991, PHYSICIANS DESK REFE	16	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					767	770		10.1016/0140-6736(92)92302-V	http://dx.doi.org/10.1016/0140-6736(92)92302-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356185				2022-12-24	WOS:A1992JP86900011
J	COUTURIER, E; BROSSARD, Y; LARSEN, C; LARSEN, M; DUMAZAUBRUN, C; PARISLLADO, J; GILLOT, R; HENRION, R; BREART, G; BRUNET, JB				COUTURIER, E; BROSSARD, Y; LARSEN, C; LARSEN, M; DUMAZAUBRUN, C; PARISLLADO, J; GILLOT, R; HENRION, R; BREART, G; BRUNET, JB			HIV-INFECTION AT OUTCOME OF PREGNANCY IN THE PARIS AREA, FRANCE	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; NEWBORNS; WOMEN	The prevalence of H IV infection in women at end of pregnancy, irrespective of outcome, was determined in a comprehensive survey of both women and medical centres during successive 4-week periods in four areas of the Paris region, France. Blood samples were tested anonymously for antibodies to human immunodeficiency virus (HIV)-1 and HIV-2. Of the 11 593 blood samples 0.40% (95% confidence interval [CI] 0.28-0.51) were positive for HIV-1 and 0-02% (95% binomial interval [BI] 0.002-0.065) for HIV-2. Seroprevalence was higher among women with ectopic pregnancy (2%) (95% BI 0.24-7.04); the rate in women having an elective or therapeutic abortion was more than twice that in those delivering babies (0.70% vs O.28%, p<0.05, relative risk 2.54, 95% CI 1.36-4.75). Studies with neonatal HIV seroprevalence as a surrogate for HIV prevalence in pregnant women would underestimate prevalence in these women.	CLIN UNIV PORT ROYAL,PARIS,FRANCE; HOP ST ANTOINE,CTR PERINATOL HAEMATOL,F-75571 PARIS 12,FRANCE; INSERM,U149,F-75005 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	COUTURIER, E (corresponding author), HOP NATL ST MAURICE,EUROPEAN CTR EPIDEMIOL MONITORING AIDS,14 RUE VAL DOSNE,F-94410 ST MAURICE,FRANCE.							ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; FAUR B, 1985, COLLECTIONS INSEE D, V106, P109; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; IPPOLITO G, 1991, J ACQ IMMUN DEF SYND, V4, P402; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P1289, DOI 10.1001/jama.261.9.1289; TAPPIN DM, 1991, LANCET, V337, P1565; 1991, B EPIDEMIOL HEBDOMAD, V32, P131; 1991, LANCET, V337, P253	8	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					707	709		10.1016/0140-6736(92)92241-7	http://dx.doi.org/10.1016/0140-6736(92)92241-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355808				2022-12-24	WOS:A1992JN78000013
J	WALD, NJ; KENNARD, A; DENSEM, JW; CUCKLE, HS; CHARD, T; BUTLER, L				WALD, NJ; KENNARD, A; DENSEM, JW; CUCKLE, HS; CHARD, T; BUTLER, L			ANTENATAL MATERNAL SERUM SCREENING FOR DOWNS-SYNDROME - RESULTS OF A DEMONSTRATION PROJECT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; AGE	Objectives-To assess the implementation of antenatal screening for Down's syndrome in practice, using individual risk estimates based on maternal age and the three serum markers: alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin. Design-Demonstration project of Down's syndrome screening; women with a risk estimate at term of 1 in 250 or greater were classified as "screen positive" and offered diagnostic amniocentesis. Setting-Hospital and community antenatal clinics in four health districts in London. Subjects-12 603 women of all ages with singleton pregnancies seen between February 1989 and the end of May 1991, with follow up of the outcome of pregnancy completed to the end of 1991. Main outcome measures-Uptake of screening, detection rate for Down's syndrome, false positive rate, odds of being affected given a positive result, and uptake of amniocentesis in women with positive screening results, together with the costs of the screening programme. Results-The uptake of screening was 74%. The detection rate was 48% (12/25), and the false positive rate was 4.1%, consistent with results expected from previous work based on observational studies. There was a loss of detection due to thc selective use of ultrasound scans among women with positive screening results. One affected pregnancy occurred among 205 reclassified as negative; this illustrated the danger of false negatives occurring in this group and lends weight to the view that if an ultrasound estimate of gestational age is used it should be carried out routinely on all women rather than selectively among those with positive results. The estimated cost of avoiding the birth of a baby with Down's syndrome was about 38000 pounds, substantially less than the lifetime costs of care. Conclusion-Antenatal maternal serum screening for Down's syndrome is effective in practice and can be readily integrated into routine antenatal care. It is cost effective and performs better than selection for amniocentesis on the basis of maternal age alone.	ST BARTHOLOMEWS HOSP, DEPT REPROD PHYSIOL, LONDON EC1M 6EQ, ENGLAND; QUEEN ELIZABETH HOSP, REG CYTOGENET LAB, LONDON E2 8PS, ENGLAND	University of London; Queen Mary University London	WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					[Anonymous], 1977, LANCET, V1, P1323; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; GILL M, 1987, SOC SCI MED, V24, P725, DOI 10.1016/0277-9536(87)90109-2; HADDOW JE, IN PRESS N ENGL J ME; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, IN PRESS PRENATAL DI	9	240	254	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1992	305	6850					391	394		10.1136/bmj.305.6850.391	http://dx.doi.org/10.1136/bmj.305.6850.391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1382768	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JK31400013
J	PRICE, DJ; GROVE, JR; CALVO, V; AVRUCH, J; BIERER, BE				PRICE, DJ; GROVE, JR; CALVO, V; AVRUCH, J; BIERER, BE			RAPAMYCIN-INDUCED INHIBITION OF THE 70-KILODALTON S6 PROTEIN-KINASE	SCIENCE			English	Article							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; RIBOSOMAL PROTEIN-S6; DISTINCT; PHOSPHORYLATION; ACTIVATION; CELLS; PURIFICATION; CYCLOSPORINE; CYCLOPHILIN	The immunosuppressant rapamycin inhibited proliferation of the H4IIEC hepatoma cell line. Rapamycin, but not its structural analog FK506, also inhibited the basal and insulin-stimulated activity of the p70 ribosomal protein S6 kinase. By contrast, insulin stimulation of the p85 Rsk S6 kinase and mitogen-activated protein (MAP) kinase activity were unaffected by drug. Rapamycin treatment of COS cells transfected with recombinant p70 S6 kinase completely inhibited the appearance of the hyperphosphorylated form of p70 S6 kinase concomitant with the inhibition of enzyme activity toward 40S subunits. Thus, rapamycin inhibits a signal transduction element that is necessary for the activation of p70 S6 kinase and mitogenesis but unnecessary for activation of p85 Rsk S6 kinase or MAP kinase.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Calvo, Victor/L-5024-2014; Izquierdo, Manuel/D-2971-2017	Calvo, Victor/0000-0002-5913-7058; Bierer, Barbara/0000-0001-6448-8170; Izquierdo, Manuel/0000-0002-7701-1002	NCI NIH HHS [P01 CA39542] Funding Source: Medline; NIDDK NIH HHS [R01 DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BANERJEE P, UNPUB; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CALVO V, IN PRESS P NATL ACAD; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORDON J, 1982, CURR TOP CELL REGUL, V21, P89; GROVE JF, UNPUB; GROVE JR, 1991, MOL CELL BIOL, V11, P2159; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JIN YJ, 1992, J BIOL CHEM, V26, P10942; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAY JE, 1991, IMMUNOLOGY, V72, P544; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; METCALFE SM, 1990, TRANSPLANTATION, V49, P798, DOI 10.1097/00007890-199004000-00028; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1991, J BIOL CHEM, V266, P16821; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	35	619	632	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					973	977		10.1126/science.1380182	http://dx.doi.org/10.1126/science.1380182			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1380182				2022-12-24	WOS:A1992JH82700038
J	MEYAARD, L; OTTO, SA; JONKER, RR; MIJNSTER, MJ; KEET, RPM; MIEDEMA, F				MEYAARD, L; OTTO, SA; JONKER, RR; MIJNSTER, MJ; KEET, RPM; MIEDEMA, F			PROGRAMMED DEATH OF T-CELLS IN HIV-1 INFECTION	SCIENCE			English	Article							AIDS-RELATED COMPLEX; DNA FRAGMENTATION; HOMOSEXUAL MEN; SELECTIVE LOSS; IMMUNE-SYSTEM; APOPTOSIS; LYMPHOCYTES; EXPRESSION; INDUCTION; RECEPTOR	In human immunodeficiency virus (HIV) infection, functional defects and deletion of antigen-reactive T cells are more frequent than can be explained by direct viral infection. On culturing, both CD4+ and CD8+ T cells from asymptomatic HIV-infected individuals died as a result of programmed cell death (apoptosis). Apoptosis was enhanced by activation with CD3 antibodies. Programmed cell death, associated with impaired T cell reactivity, may thus be responsible for the deletion of reactive T cells that contributes to HIV-induced immunodeficiency.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB, DEPT CLIN VIROIMMUNOL,PLESMANLAAN 125, AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPTL & CLIN IMMUNOL LAB, 1066 CX AMSTERDAM, NETHERLANDS; TNO, INST APPL RADIOBIOL & IMMUNOL, DEPT MOLEC PATHOL, 2280 HV RIJSWIJK, NETHERLANDS; NETHERLANDS INST BRAIN RES, 1095 KJ AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT INFECT DIS, AMSTERDAM, NETHERLANDS	University of Amsterdam; Netherlands Organization Applied Science Research; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)				Keet, Rene/0000-0001-9959-6032; Meyaard, Linde/0000-0003-0707-4793				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; CEFAI D, 1990, J CLIN INVEST, V86, P2117, DOI 10.1172/JCI114950; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; GRUTERS RA, 1991, AIDS, V5, P837, DOI 10.1097/00002030-199107000-00007; GRUTERS RA, 1990, EUR J IMMUNOL, V20, P1039, DOI 10.1002/eji.1830200514; JONKER RR, UNPUB; KEKOW J, 1991, J CLIN INVEST, V87, P1010, DOI 10.1172/JCI115059; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; MEYAARD L, UNPUB; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PRINCE HE, 1991, CELL IMMUNOL, V134, P276, DOI 10.1016/0008-8749(91)90302-R; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; SALAZARGONZALEZ JF, 1985, J IMMUNOL, V135, P1778; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STITES DP, 1989, CLIN IMMUNOL IMMUNOP, V52, P96, DOI 10.1016/0090-1229(89)90196-7; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; VANLIER RAW, 1987, J IMMUNOL, V139, P2873; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	33	905	934	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					217	219		10.1126/science.1352911	http://dx.doi.org/10.1126/science.1352911			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1352911				2022-12-24	WOS:A1992JC58500030
J	MARIOTTI, S; SANSONI, P; BARBESINO, G; CATUREGLI, P; MONTI, D; COSSARIZZA, A; GIACOMELLI, T; PASSERI, G; FAGIOLO, U; PINCHERA, A; FRANCESCHI, C				MARIOTTI, S; SANSONI, P; BARBESINO, G; CATUREGLI, P; MONTI, D; COSSARIZZA, A; GIACOMELLI, T; PASSERI, G; FAGIOLO, U; PINCHERA, A; FRANCESCHI, C			THYROID AND OTHER ORGAN-SPECIFIC AUTOANTIBODIES IN HEALTHY CENTENARIANS	LANCET			English	Note								To investigate the prevalence of thyroid autoantibodies in very old subjects, we assayed sera from 34 healthy centenarians (7 men, 27 women; age range 100-108 years) for these antibodies. There was a clear age-dependent increase in prevalence of thyroid autoantibodies in sera from 549 control subjects aged 7-85 years, prevalence in 40 subjects aged 70-85 being significantly greater (p<0.001, chi-2) than that in 436 subjects aged less than 50. By contrast, prevalence of thyroid autoantibodies in centenarians was not significantly different from that in controls aged less than 50. Cytofluorimetric analysis of peripheral blood lymphocytes showed a striking age-dependent decrease in total and CD5+ B cells (without changes in their ratio), which reached its nadir in centenarians. The age-dependent increase in prevalence of thyroid autoantibodies in the elderly is not seen after the ninth decade of life. What relation this characteristic has to derangement of circulating B cells is unknown.	UNIV MODENA,INST GEN PATHOL,I-41100 MODENA,ITALY; UNIV PARMA,INST GEN CLIN MED,I-43100 PARMA,ITALY; UNIV PADUA,INST INTERNAL MED,I-35100 PADUA,ITALY	Universita di Modena e Reggio Emilia; University of Parma; University of Padua	MARIOTTI, S (corresponding author), UNIV PISA,IST ENDOCRINOL,VIALE TIRRENO 64,I-56018 TIRRENIA,ITALY.		Monti, Daniela/G-9556-2012; Mariotti, Stefano/AAN-1948-2020; Franceschi, Claudio/L-4484-2017	Monti, Daniela/0000-0001-8651-8123; Franceschi, Claudio/0000-0001-9841-6386; Cossarizza, Andrea/0000-0002-5381-1558; Passeri, Giovanni/0000-0002-4039-1160				COSSARIZZA A, 1991, BLOOD, V77, P1263; FRANCESCHI C, 1991, ANN NY ACAD SCI, V261, P428; HACKETT E, 1960, LANCET, V2, P402; HIJMANS W, 1984, MECH AGEING DEV, V26, P83, DOI 10.1016/0047-6374(84)90167-2; HOOPER B, 1972, CLIN EXP IMMUNOL, V12, P79; KASAIAN MT, 1991, P SOC EXP BIOL MED, V197, P226; MARIOTTI S, 1990, J CLIN ENDOCR METAB, V71, P661, DOI 10.1210/jcem-71-3-661; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; ROBUSCHI G, 1987, ENDOCR REV, V8, P142, DOI 10.1210/edrv-8-2-142; Tomer Y, 1988, Autoimmunity, V1, P141, DOI 10.3109/08916938809001927	10	189	192	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1506	1508		10.1016/0140-6736(92)91265-A	http://dx.doi.org/10.1016/0140-6736(92)91265-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351187				2022-12-24	WOS:A1992HZ17500005
J	KEMP, A; SIBERT, JR				KEMP, A; SIBERT, JR			DROWNING AND NEAR DROWNING IN CHILDREN IN THE UNITED-KINGDOM - LESSONS FOR PREVENTION	BRITISH MEDICAL JOURNAL			English	Article							5-YEAR TOTAL POPULATION; ACCIDENTS INVOLVING CHILDREN; SWIMMING POOLS; COUNTY; QUEENSLAND; 10-YEAR	Objectives - To determine the pattern of drowning and near drowning of children in Britain and identify means of prevention. Design - Study of drowned and nearly drowned children under 15 years old. Setting - United Kingdom, 1988 and 1989. Subjects - Children under 15 years either drowning or admitted to hospital after a submersion incident. Main outcome measures - Number of nearly drowned children, obtained from consultant paediatricians returning monthly notification cards through the British Paediatric Surveillance Unit. Number of drowned children notified by the Office of Population Censuses and Surveys and other national epidemiological offices; information from coroners. Results - 306 children had confirmed submersion incidents: 149 died and 157 survived after near drowning. The annual incidence in England and Wales was 1.5/100 000, and mortality 0.7/100 000. Mortality was lowest in public pools 6% (2/32) and highest in rivers, canals, and lakes (78%, 56/73). Most of the children (263, 83%) were unsupervised at the time of the accident. 208 (68%) children were under 5 years old. Conclusions - Drowning and near drowning of children are problems in the British Isles. Appropriate supervision and safety barriers seem important for preventing such accidents. Improving information on dangers of drowning given to parents through the child surveillance programmes, encouraging fencing or draining of garden ponds and domestic swimming pools, and increasing supervision of swimming in lakes, rivers, and beaches should reduce the number of accidents.	UNIV WALES COLL CARDIFF,LANSDOWNE HOSP,COLL MED,DEPT CHILD HLTH,COMMUNITY UNIT,CARDIFF CF1 8UL,WALES	Cardiff University								[Anonymous], 1974, HLTH SAFETY WORK ACT; BARRY W, 1982, BRIT MED J, V285, P542, DOI 10.1136/bmj.285.6341.542; COLVER AF, 1982, BMJ, V285, P1117; CONN AW, 1984, CAN ANAESTH SOC J, V31, P538; HEYWARD K, 1991, HLTH SAFETY STANDARD; KEMP AM, 1991, BRIT MED J, V302, P931, DOI 10.1136/bmj.302.6782.931; LANGLEY J, 1983, COMMUNITY HEALTH ST, V7, P285; MILLINER N, 1980, MED J AUSTRALIA, V2, P510; NIXON J, 1986, ACCIDENT ANAL PREV, V18, P199, DOI 10.1016/0001-4575(86)90003-5; OCARROLL PW, 1988, JAMA-J AM MED ASSOC, V260, P380, DOI 10.1001/jama.260.3.380; ORLOWSKI JP, 1989, PEDIATRICS, V83, P1065; PATRICK M, 1979, MED J AUSTRALIA, V1, P61, DOI 10.5694/j.1326-5377.1979.tb111997.x; PEARN J, 1977, MED J AUSTRALIA, V2, P702, DOI 10.5694/j.1326-5377.1977.tb99227.x; PEARN J, 1976, MED J AUSTRALIA, V2, P942, DOI 10.5694/j.1326-5377.1976.tb115532.x; PEARN JH, 1979, AM J PUBLIC HEALTH, V69, P450, DOI 10.2105/AJPH.69.5.450; QUAN L, 1989, PEDIATRICS, V83, P1035; SIBERT JR, 1991, ARCH DIS CHILD, V66, P890, DOI 10.1136/adc.66.7.890; SIBERT JR, 1987, PRACTITIONER, V232, P439; 1988, MORTALITY STATISTICS; 1985, MMWR, V34, P218; 1983, DROWNING UK; 1990, BEACH SAFETY PRESS P; 1991, HOLIDAY WHICH   0108, P30; 1988, SAFETY SWIMMING POOL	24	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1143	1146		10.1136/bmj.304.6835.1143	http://dx.doi.org/10.1136/bmj.304.6835.1143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392791	Bronze, Green Published			2022-12-24	WOS:A1992HT23200019
J	FALL, CHD; BARKER, DJP; OSMOND, C; WINTER, PD; CLARK, PMS; HALES, CN				FALL, CHD; BARKER, DJP; OSMOND, C; WINTER, PD; CLARK, PMS; HALES, CN			RELATION OF INFANT-FEEDING TO ADULT SERUM-CHOLESTEROL CONCENTRATION AND DEATH FROM ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PLASMA; LIFE; DIET; METABOLISM; MORTALITY; CHILDREN; WEIGHT; MILK; AGE	Objective - To examine whether method of infant feeding is associated with adult serum lipid concentrations and mortality from ischaemic heart disease. Design - Follow up study of men born during 1911-30. Setting - Hertfordshire, England. Subjects - 5718 men, for 5471 of whom information on infant feeding had been recorded by health visitors and 1314 of whom had died. 485 of the men born during 1920-30 and still living in Hertfordshire who had blood lipid measurements. Main outcome measures - Death from ischaemic heart disease; serum cholesterol and apolipoprotein concentrations. Results - 474 men had died from ischaemic heart disease. Standardised mortality ratios were 97 (95% confidence interval 81 to 115) in men who had been breast fed and had not been weaned at 1 year, 79 (69 to 90) in breast fed men who had been weaned at 1 year, and 73 (59 to 89) in men who had been breast and bottle fed. Compared with men weaned before one year men not weaned had higher mean serum concentrations of total cholesterol (6-9 (not weaned) v 6.6 (weaned) mmol/l), low density lipoprotein cholesterol (5.0 v 4.6 mmol/l) and apolipoprotein B (1.14 v 1.08 g/l). Men who had been bottle fed also had a high standardised mortality ratio for ischaemic heart disease (95; 68 to 130) and high mean serum concentrations of total cholesterol (7.0 mmol/l), low density lipoprotein cholesterol (5.1 mmol/l), and apolipoprotein B (1.14 g/l). In all feeding groups serum apolipoprotein B concentrations were lower in men with higher birth weight and weight at 1 year. Conclusions - Age of weaning and method of infant feeding may influence adult serum low density lipoprotein cholesterol concentrations and mortality from ischaemic heart disease. Adult serum apolipoprotein B concentrations are related to growth in fetal life and infancy.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P165, DOI 10.1111/j.1651-2227.1979.tb04983.x; [Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BELTON NR, 1986, ACTA PAEDIATR SC   S, V323, P68; BERENSON GS, 1980, CARDIOVASCULAR RISK, P289; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BHATNAGAR D, 1991, ANN CLIN BIOCHEM, V28, P427, DOI 10.1177/000456329102800501; BURNSIDE EM, 1915, BOUNTY MED OFFICER H, P41; CHAPIN HD, 1909, POSTGRADUATE NY, V24, P272; CHEDALD WB, 1906, ARTIFICIAL FEEDING F; DAGEN MM, 1991, ANN CLIN BIOCHEM, V28, P359, DOI 10.1177/000456329102800408; DARMADY JM, 1972, BMJ-BRIT MED J, V2, P685, DOI 10.1136/bmj.2.5815.685; FOMON SJ, 1984, PEDIATR RES, V18, P1233, DOI 10.1203/00006450-198412000-00001; FOMON SJ, 1960, AM MED ASS J DIS CHI, V99, P43; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN G, 1975, AM J CLIN NUTR, V28, P42, DOI 10.1093/ajcn/28.1.42; HAHN P, 1976, NUTR REP INT, V13, P87; HAHN P, 1989, ATHEROSCLEROSIS PEDI; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAMMONS JL, 1988, J PEDIATR GASTR NUTR, V7, P30, DOI 10.1097/00005176-198801000-00008; HASSAN AS, 1989, ATHEROSCLEROSIS PEDI, P221; HODGSON PA, 1976, METABOLISM, V25, P739, DOI 10.1016/0026-0495(76)90145-1; HUTTUNEN JK, 1983, ATHEROSCLEROSIS, V46, P87, DOI 10.1016/0021-9150(83)90167-3; KANNEL WB, 1978, FRAMINGHAM STUDY EPI; KOLDOVSKY O, 1987, J PEDIATR GASTR NUTR, V6, P172, DOI 10.1097/00005176-198703000-00004; LABARTHE DR, 1991, ANNU REV PUBL HEALTH, V12, P519, DOI 10.1146/annurev.pu.12.050191.002511; LIE RF, 1976, CLIN CHEM, V22, P1627; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MARMOT MG, 1980, J EPIDEMIOL COMMUN H, V34, P164, DOI 10.1136/jech.34.3.164; MILLER GJ, 1986, ATHEROSCLEROSIS, V60, P269, DOI 10.1016/0021-9150(86)90174-7; MOTT GE, 1990, J NUTR, V120, P243, DOI 10.1093/jn/120.3.243; PATERSON D, 1930, CHANCE EVERY CHILD R, P22; SAARINEN UM, 1978, J PEDIATR-US, V93, P177, DOI 10.1016/S0022-3476(78)80490-9; SALTER AM, 1988, ATHEROSCLEROSIS, V71, P77, DOI 10.1016/0021-9150(88)90304-8; SPORIK R, 1991, ARCH DIS CHILD, V66, P134, DOI 10.1136/adc.66.1.134; SUBBIAH MTR, 1985, AM J PHYSIOL, V249, pE251, DOI 10.1152/ajpendo.1985.249.3.E251; VANBIERVLIET JP, 1986, EUR J PEDIATR, V144, P489, DOI 10.1007/BF00441745; WANG XL, 1991, PEDIATR RES, V30, P544, DOI 10.1203/00006450-199112000-00010; WHITEHEAD R, 1987, INFANT FEEDING CARDI, P1; WHITEHEAD RG, 1986, ACTA PAEDIATR SC   S, V323, P14; 1942, SERIES WOMEN PUBLIC, V2, P1	46	257	262	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					801	805		10.1136/bmj.304.6830.801	http://dx.doi.org/10.1136/bmj.304.6830.801			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392706	Green Published, Bronze			2022-12-24	WOS:A1992HL82700018
J	GOLDMAN, E; MILLER, R; LEE, CA				GOLDMAN, E; MILLER, R; LEE, CA			COUNSELING HIV POSITIVE HEMOPHILIC MEN WHO WISH TO HAVE CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							INFECTION		ROYAL FREE HOSP,SCH MED,DEPT HAEMATOL,HAEMOSTASIS UNIT,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	GOLDMAN, E (corresponding author), ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,LONDON NW3 2QG,ENGLAND.							LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEE CA, 1990, LANCET, V335, P425, DOI 10.1016/0140-6736(90)90273-8; 1991, BMJ, V303, P541; [No title captured]	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					829	830		10.1136/bmj.304.6830.829	http://dx.doi.org/10.1136/bmj.304.6830.829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL827	1392714	Green Published, Bronze			2022-12-24	WOS:A1992HL82700028
J	PINOLROMA, S; DREYFUSS, G				PINOLROMA, S; DREYFUSS, G			SHUTTLING OF PRE-MESSENGER-RNA BINDING-PROTEINS BETWEEN NUCLEUS AND CYTOPLASM	NATURE			English	Article							RIBONUCLEOPROTEIN-PARTICLES; MONOCLONAL-ANTIBODIES; NASCENT TRANSCRIPTS; COMPLEXES; CELLS; VISUALIZATION; EXPORT; HNRNP	RNA polymerase II transcripts, heterogeneous nuclear RNAs (hnRNAs), associate in the nucleus with specific proteins that bind premessenger RNA (hnRNP proteins) 1,2 and with small nuclear ribonucleoprotein particles (snRNPs) 3-5. These hnRNA-hnRNP-snRNP complexes assemble on nascent transcripts and hnRNA is processed to mRNA in them 6-8. HnRNP proteins have been localized to the nucleoplasm 9-13 and their functions were presumed to be limited to nuclear events in mRNA biogenesis. It was proposed that an exchange of hnRNP for mRNA-binding proteins accompanies transport of mRNA from the nucleus to the cytoplasm 1,14. We show here that several of the abundant hnRNP proteins, including A1, shuttle between the nucleus and the cytoplasm. HnRNP proteins may thus also have cytoplasmic functions. Furthermore, when in the cytoplasm, A1 is bound to mRNA and RNA polymerase II transcription is necessary before it can return to the nucleus. We propose that the cytoplasmic ribonucleoprotein complex of mRNA with hnRNP proteins is the substrate of nuclear-cytoplasmic transport of mRNA.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				ADAM SA, 1986, J VIROL, V57, P614, DOI 10.1128/JVI.57.2.614-622.1986; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; EGYHAZI E, 1982, EUR J BIOCHEM, V122, P445; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HURWITZ J, 1962, P NATL ACAD SCI USA, V48, P1222, DOI 10.1073/pnas.48.7.1222; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LESER GP, 1984, J BIOL CHEM, V259, P1827; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MARTIN TE, 1981, CELL NUCLEUS, V9, P119; MEHLIN H, 1991, EXP CELL RES, V193, P72, DOI 10.1016/0014-4827(91)90539-7; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; STEITZ JA, 1988, FUNCTIONS ABUNDANT S; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; TAMM I, 1978, ADV VIRUS RES, V22, P188; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465	31	775	784	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					730	732		10.1038/355730a0	http://dx.doi.org/10.1038/355730a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1371331				2022-12-24	WOS:A1992HE60400065
J	SILVER, RA; TRAYNELIS, SF; CULLCANDY, SG				SILVER, RA; TRAYNELIS, SF; CULLCANDY, SG			RAPID-TIME-COURSE MINIATURE AND EVOKED EXCITATORY CURRENTS AT CEREBELLAR SYNAPSES INSITU	NATURE			English	Article							RAT HIPPOCAMPAL SLICES; PATCH-CLAMP; POSTSYNAPTIC CURRENTS; SYNAPTIC CURRENTS; NEURONS; GLUTAMATE; RECEPTORS; ACTIVATION; CELLS	NEUROTRANSMISSION from mossy fibre terminals onto cerebellar granule cells is almost certainly mediated by L-glutamate 1,2. By taking advantage of the small soma size, limited number of processes and short dendrite length of granule cells, we have obtained high-resolution recordings of spontaneous miniature excitatory postsynaptic currents (m.e.p.s.cs) and evoked currents in thin cerebellar slices 3. Miniature currents have a similar time-course and pharmacology to evoked currents and consist of an exceptionally fast non-NMDA (N-methyl-D-aspartate) component (measured rise-time, 200-mu-s; estimated pre-filtered rise-time < 100-mu-s; decay time constant, tau = 1.0 ms), followed by 50 pS NMDA channel openings that are directly resolvable. We could find no evidence for the recent proposal that miniature currents in granule cells are mediated solely by NMDA channels with a novel time course 4. The non-NMDA receptor component of m.e.p.s.cs has a skewed amplitude distribution, which suggests potential complications for quantal analysis. The difference in time course between the m.e.p.s.cs reported here and other synaptic currents in the brain 5-8 could reflect differences in synaptic function or electrotonic filtering; the relative contribution of these possibilities has vet to be established.			SILVER, RA (corresponding author), UNIV LONDON UNIV COLL,DEPT PHARMACOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Cull-Candy, Stuart G/0000-0002-0831-8326; Silver, Robin/0000-0002-5480-6638	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORNSTEIN JC, 1978, J PHYSIOL-LONDON, V282, P375, DOI 10.1113/jphysiol.1978.sp012470; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DANGELO E, 1990, NATURE, V346, P467, DOI 10.1038/346467a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FINKEL AS, 1983, J PHYSIOL-LONDON, V342, P615, DOI 10.1113/jphysiol.1983.sp014872; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GIBB AJ, 1991, P ROY SOC B-BIOL SCI, V243, P39, DOI 10.1098/rspb.1991.0007; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; JAKAB RL, 1988, ANAT EMBRYOL, V179, P81, DOI 10.1007/BF00305102; JI ZQ, 1991, J COMP NEUROL, V307, P296, DOI 10.1002/cne.903070210; Katz B., 1969, RELEASE NEURAL TRANS; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MACGREGOR RJ, 1987, NEURAL BRAIN MODELLI; NELSON PG, 1986, J PHYSIOL-LONDON, V372, P169, DOI 10.1113/jphysiol.1986.sp016003; RALL W, 1969, BIOPHYS J, V9, P1483, DOI 10.1016/S0006-3495(69)86467-2; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P707, DOI 10.1113/jphysiol.1990.sp018236; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1045, DOI 10.1016/0306-4522(86)90121-1; STERN P, IN PRESS J PHYSL; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	32	322	322	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					163	166		10.1038/355163a0	http://dx.doi.org/10.1038/355163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1370344				2022-12-24	WOS:A1992GY62900059
J	LOCOCO, F; DIVERIO, D; PANDOLFI, PP; BIONDI, A; ROSSI, V; AVVISATI, G; RAMBALDI, A; ARCESE, W; PETTI, MC; MELONI, G; MANDELLI, F; GRIGNANI, F; MASERA, G; BARBUI, T; PELICCI, PG				LOCOCO, F; DIVERIO, D; PANDOLFI, PP; BIONDI, A; ROSSI, V; AVVISATI, G; RAMBALDI, A; ARCESE, W; PETTI, MC; MELONI, G; MANDELLI, F; GRIGNANI, F; MASERA, G; BARBUI, T; PELICCI, PG			MOLECULAR EVALUATION OF RESIDUAL DISEASE AS A PREDICTOR OF RELAPSE IN ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Note							LEUKEMIA	Acute promyelocytic leukaemia (APL) is characterised by a unique fusion transcript, PML/RARalpha. We tested for this transcript in 35 APL patients who were in apparent remission after various treatments. 11 of 13 patients who tested positive 4 months after achieving remission were in relapse 1-4 months later. All 22 patients who tested negative at 4 months were disease-free after a further 3 months to five years. The test may therefore prove useful in determining the need for additional treatment during clinical remission.	IST MARIO NEGRI,BERGAMO,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,I-06100 PERUGIA,ITALY; UNIV MILAN,PEDIAT CLIN,I-20122 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Perugia; University of Milan	LOCOCO, F (corresponding author), UNIV LA SAPIENZA,DEPT HUMAN BIOPATHOL,VIA BENEVENTO 6,I-00161 ROME,ITALY.		Biondi, Andrea/K-9997-2016; Rambaldi, Alessandro/M-6172-2019; Rambaldi, Alessandro/P-2603-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Biondi, Andrea/AAX-1865-2020	Rambaldi, Alessandro/0000-0002-3739-7502; Rambaldi, Alessandro/0000-0002-3739-7502; Biondi, Andrea/0000-0002-6757-6173; , Xavier/0000-0002-8083-2127; ARCESE, WILLIAM/0000-0001-5697-366X; Avvisati, Giuseppe/0000-0002-5027-5868				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BIONDI A, 1992, BLOOD, V80, P492; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; ROWLEY JD, 1977, LANCET, V1, P549; Sambrook J., 1989, MOL CLONING LAB MANU	6	206	208	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1437	1438		10.1016/0140-6736(92)92625-P	http://dx.doi.org/10.1016/0140-6736(92)92625-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360562				2022-12-24	WOS:A1992KC28400006
J	BRYDON, WG; FERGUSON, A				BRYDON, WG; FERGUSON, A			HEMOGLOBIN IN GUT LAVAGE FLUID AS A MEASURE OF GASTROINTESTINAL BLOOD-LOSS	LANCET			English	Note							DISEASE	To detect and measure occult gastrointestinal bleeding, we have measured haemoglobin concentrations (by HemoQuant) in the clear fluid obtained after whole-gut lavage. In subjects with healthy gastrointestinal tracts, lavage-fluid haemoglobin concentrations were 0.5-5.1 mg/L, equivalent to daily blood loss of 0.1-1.1 mL. High concentrations were found for patients with colorectal cancer, severe diverticular disease, and rectal varices, in seven of sixteen patients with active inflammatory bowel disease, and in four patients with iron-deficiency anaemia thought to be due to gastrointestinal bleeding. In these four patients, estimated blood loss ranged from 2.6-24.5 mL per day. This method could have various research and clinical applications.	WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh								CAMERON AD, 1960, GUT, V1, P177, DOI 10.1136/gut.1.2.177; GASPARI MM, 1988, J IMMUNOL METHODS, V110, P85, DOI 10.1016/0022-1759(88)90086-5; HARDCASTLE JD, 1989, FAECAL OCCULT BLOOD; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; OMAHONY S, 1990, GUT, V31, P1341, DOI 10.1136/gut.31.12.1341; OMAHONY S, 1991, SCAND J GASTROENTERO, V26, P940, DOI 10.3109/00365529108996246; SALLAM J, 1992, LANCET, V339, P179; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061	9	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1381	1382		10.1016/0140-6736(92)92562-T	http://dx.doi.org/10.1016/0140-6736(92)92562-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360092				2022-12-24	WOS:A1992KB20200006
J	TAI, YT; BUT, PPH; YOUNG, K; LAU, CP				TAI, YT; BUT, PPH; YOUNG, K; LAU, CP			CARDIOTOXICITY AFTER ACCIDENTAL HERB-INDUCED ACONITE POISONING	LANCET			English	Note								Aconitine and its related alkaloids are known cardiotoxins with no therapeutic role in modern western medicine. The rootstocks of Aconitum plants, which contain aconite alkaloids, have been common components of Chinese herbal recipes. We have documented life-threatening intoxication in 17 Chinese subjects after accidental herb-induced aconite poisoning. All patients developed symptoms of aconite toxicity within 2 h of herb ingestion. Most developed tachyarrhythmias, including ventricular tachycardia and fibrillation from which 2 patients died. Toxicological evaluation revealed that aconites from the Aconitum rootstocks were the only plausible casual factor for intoxication. These cases point to the need for strict surveillance of herbal substances with low safety margins.	UNIV HONG KONG,DEPT MED,HONG KONG,HONG KONG; CHINESE UNIV HONG KONG,CHINESE MED MAT RES CTR,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT ANAESTHESIA & INTENS CARE,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT BIOL,SHA TIN,HONG KONG	University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong								BISSET NG, 1981, J ETHNOPHARMACOL, V4, P247, DOI 10.1016/0378-8741(81)90001-5; CHANG HM, 1987, PHARM APPLICATIONS C, V1; CHANG HM, 1987, PHARM APPLICATIONS C, V2; FATOVICH DM, 1992, ANN EMERG MED, V21, P309, DOI 10.1016/S0196-0644(05)80894-7; FIDDES FS, 1958, BRIT MED J, V2, P779, DOI 10.1136/bmj.2.5099.779; Hartung EF, 1930, J AMER MED ASSOC, V95, P1265, DOI 10.1001/jama.1930.27210170005010c; KAPOOR SC, 1969, INDIAN HEART J, V25, P329; PEPPER K, 1967, PFLUGGERS ARCH, V296, P328; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P1538; 1990, PHARMACOPOEIA PEOPLE, V1, P26; 1983, BRIT HERBAL PHARMACO, P12	11	148	153	3	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1254	1256		10.1016/0140-6736(92)92951-B	http://dx.doi.org/10.1016/0140-6736(92)92951-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359321				2022-12-24	WOS:A1992JZ23700005
J	DEMORAES, JC; PERKINS, BA; CAMARGO, MCC; HIDALGO, NTR; BARBOSA, HA; SACCHI, CT; GRAL, IML; GATTAS, VL; VASCONCELOS, HD; PLIKAYTIS, BD; WENGER, JD; BROOME, CV				DEMORAES, JC; PERKINS, BA; CAMARGO, MCC; HIDALGO, NTR; BARBOSA, HA; SACCHI, CT; GRAL, IML; GATTAS, VL; VASCONCELOS, HD; PLIKAYTIS, BD; WENGER, JD; BROOME, CV			PROTECTIVE EFFICACY OF A SEROGROUP-B MENINGOCOCCAL VACCINE IN SAO-PAULO, BRAZIL	LANCET			English	Article							DISEASE	Serogroup B Neisseria meningitidis is the most common cause of epidemic meningococcal disease in developed countries. Until recently no vaccine has been available for prevention of infection with this organism. In an attempt to control epidemic serogroup B meningococcal disease in greater Sao Paulo, Brazil, during 1989 and 1990, a Cuban-produced outer-membrane-protein-based serogroup B meningococcal vaccine was given to about 2.4 million children aged from 3 months to 6 years. We have done a case-control study to estimate the efficacy of the vaccine in greater Sao Paulo. Microbiologically confirmed cases of serogroup B meningococcal disease were identified through hospital-based surveillance. Controls were matched by neighbourhood and age. Vaccination status was confirmed by inspection of vaccination cards. Between June, 1990, and June, 1991, 112 patients and 409 matched controls with confirmed vaccine status were enrolled. Estimated vaccine efficacy varied by age: 48 months or older = 74% (95% CI 16 to 92%), 24 to 47 months = 47% (-72 to 84%), and less than 24 months = -37% (< - 100 to 73%). Our results suggest that the Cuban-produced vaccine may be effective for prevention of serogroup B meningococcal disease in older children and adults.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,BLDG 1,ROOM 4409,ATLANTA,GA 30333; CTR DIS CONTROL,OFF DIRECTOR,ATLANTA,GA 30333; SAO PAULO STATE DEPT HLTH,CTR EPIDEMIOL SURVEILLANCE,SAO PAULO,BRAZIL; SAO PAULO DEPT HLTH,ADOLFO LUTZ INST,SAO PAULO,BRAZIL	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Universidade Estadual Paulista; Instituto Adolfo Lutz			MORAES, JOSE C/H-6788-2012; Gattas, Vera Lucia/B-7956-2018	Gattas, Vera Lucia/0000-0001-5032-4570; Tavares Sacchi, Claudio/0000-0002-5686-7979				BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; Frasch CE, 1983, MED TROP, V43, P177; FRASCH CE, 1983, MED MICROBIOLOGY, V2, P115; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; NOVO MV, 1991, ENFERMEDAD MENINGOCO; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; PELTOLA H, 1983, REV INFECT DIS, V5, P71; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; SIERRA VG, 1991, 7TH P INT PATH NEISS; ZOLLINGER W D, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P211; 1989, MMWR, V38, P205; 1985, MMWR, V34, P255; 1989, MMWR, V38, P219	18	279	308	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1074	1078						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357461				2022-12-24	WOS:A1992JV77500011
J	CHOI, DW				CHOI, DW			BENCH TO BEDSIDE - THE GLUTAMATE CONNECTION	SCIENCE			English	Editorial Material							MOLECULAR-CLONING; NMDA RECEPTOR; NITRIC-OXIDE; ACID; ANIRACETAM; ENCEPHALOPATHY; NEUROTOXICITY; MODULATION; ISCHEMIA; CHANNEL				CHOI, DW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110, USA.							ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; BUCHAN AM, 1991, NEUROSCI LETT, V132, P255, DOI 10.1016/0304-3940(91)90314-J; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CHENG B, 1991, NEURON, V7, P1; CHOI DW, 1990, J NEUROSCI, V10, P2493; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Hory-Lee F., 1992, Society for Neuroscience Abstracts, V18, P46; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISAACSON JS, 1991, P NATL ACAD SCI USA, V88, P10936, DOI 10.1073/pnas.88.23.10936; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCNAMARA JO, 1992, J NEUROSCI, V12, P1555; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OLNEY JW, 1976, NATURE, V264, P659, DOI 10.1038/264659a0; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; PELLEGRINIGIAMP.DE, 1992, FIDIA S EXCITATORY A, P35; PERL TM, 1990, NEW ENGL J MED, V322, P1775, DOI 10.1056/NEJM199006213222504; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; SUN W, 1992, P NATL ACAD SCI USA, V89, P1143; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANG CM, 1991, SCIENCE, V254, P288, DOI 10.1126/science.1681589; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; YAMADA K A, 1991, Society for Neuroscience Abstracts, V17, P896	39	169	221	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					241	243		10.1126/science.1357748	http://dx.doi.org/10.1126/science.1357748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357748				2022-12-24	WOS:A1992JR86000019
J	NICOLAIDES, KH; SNIJDERS, RJM; GOSDEN, CM; BERRY, C; CAMPBELL, S				NICOLAIDES, KH; SNIJDERS, RJM; GOSDEN, CM; BERRY, C; CAMPBELL, S			ULTRASONOGRAPHICALLY DETECTABLE MARKERS OF FETAL CHROMOSOMAL-ABNORMALITIES	LANCET			English	Article							DOWNS-SYNDROME; AGE	Screening for fetal chromosomal abnormalities on the basis of maternal age has not resulted in a substantial fall in the Proportion of infants born with an abnormal karyotype. Most fetuses with major chromosomal abnormalities have defects that can be recognised on detailed ultrasonographic examination. Therefore, provided the cardinal signs of each chromosomal syndrome are recognised, it is possible that screening by ultrasound examination could have a greater impact. We karyotyped 2086 fetuses after ultrasonographic examination had revealed fetal malformations, growth retardation, or both. Chromosomal abnormalities were detected in 301 (14%) cases and were more common among fetuses with multisystem malformations (29%) than among those with isolated defects (2%). The commonest chromosomal abnormality was trisomy 18, followed by trisomy 21, triploidy, Turner's syndrome, unbalanced chromosomal rearrangements, and trisomy 13. Trisomy 18 was associated with strawberry-shaped head, choroid plexus cysts, facial cleft, micrognathia, heart defects, exomphalos, malformations of hands and feet, and growth retardation. In trisomy 21, the associated defects were subtle and included nuchal oedema, macroglossia, atrioventricular septal defects, mild hydronephrosis, clinodactyly, and sandal gap. The frequency of autosomal abnormalities increased with maternal age, but if fetal karyotyping had been restricted to mothers older than 35 years, large proportions of chromosomally abnormal fetuses would not have been diagnosed prenatally (64-97%). Our findings provide guidelines as to which defects to search for in screening studies for the detection of chromosomal abnormalities.	GUYS HOSP,SE THAMES REG GENET CTR,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Guy's & St Thomas' NHS Foundation Trust; University of Edinburgh	NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,HARRIS BIRTHRIGHT RES CTR FETAL MED,DENMARK HILL,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711; Snijders, Rosalinde/0000-0003-1809-7886				AZAR G B, 1991, Fetal Diagnosis and Therapy, V6, P46; BENACERRAF BR, 1990, OBSTET GYNECOL, V976, P59; BERRY S M, 1990, Fetal Diagnosis and Therapy, V5, P92; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; DRIFE JO, 1991, 18TH P STUDY GROUP R; FERGUSONSMITH MA, 1984, PRENATAL DIAG, V4, P5, DOI 10.1002/pd.1970040704; HSU LYF, 1986, GENETIC DISORDERS FE, P115; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; NICOLAIDES K H, 1992, Fetal Diagnosis and Therapy, V7, P1; NICOLAIDES K H, 1990, Fetal Diagnosis and Therapy, V5, P5; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P123, DOI 10.1159/000263659; NICOLAIDES KH, 1986, LANCET, V1, P283; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P132, DOI 10.1159/000263660; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P102, DOI 10.1159/000263657; NICOLAIDES KH, IN PRESS FETAL DIAGN; NYBERG DA, 1989, J ULTRAS MED, V8, P299; RODECK CH, 1984, 11TH P STUD GROUP RO; Thorpe-Beeston G, 1989, FETAL THER, V4, P21; THORPEBEESTON JG, 1990, BRIT J RADIOL, V63, P783, DOI 10.1259/0007-1285-63-754-783; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; YOUINGS S, 1991, PRENATAL DIAG, V11, P419, DOI 10.1002/pd.1970110703; ZEITUNE M, 1991, PRENATAL DIAG, V11, P847, DOI 10.1002/pd.1970111106	22	228	246	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					704	707		10.1016/0140-6736(92)92240-G	http://dx.doi.org/10.1016/0140-6736(92)92240-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355807				2022-12-24	WOS:A1992JN78000012
J	ROCKEN, M; URBAN, JF; SHEVACH, EM				ROCKEN, M; URBAN, JF; SHEVACH, EM			INFECTION BREAKS T-CELL TOLERANCE	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; STIMULATORY FACTOR-I; TRANSGENIC MICE; CLONAL-DELETION; MONOCLONAL-ANTIBODY; SELF-TOLERANCE; RECEPTOR; ANERGY; INDUCTION; REACTIVITY	CLONAL deletion or clonal anergy establish tolerance in T cells that bear potentially autoreactive antigen receptors1-15. Here we report that concomitant infection with the nematode Nippostrongylus brasiliensis breaks an established T-cell tolerance induced by injection of mice with Staphylococcus enterotoxin B (SEB)16,17. CD4+ T cells from SEB-tolerant mice did not produce either interleukin-2 or interleukin-4 when challenged in vitro with SEB. N. brasiliensis infection of SEB-primed animals resulted in a normal expansion of SEB-tolerant CD4+V-beta-8+ T cells in vivo as well as an equivalent increase of SEB-reactive, interleukin-4-producing CD4+V-beta-8+ T cells both in SEB-tolerant and in normal animals. Thus, infection with N. brasiliensis circumvented the tolerance established with SEB. Activation of anergic, potentially autoreactive CD4+ T cells by infectious agents seems to be a major pathway for the initiation of autoimmune diseases15. Our results suggest that infectious agents may break tolerance in potentially autoreactive CD4+ T cells by activation of alternative reaction pathways.	USDA ARS, BELTSVILLE AGR RES CTR, INST LIVESTOCK & POULTRY SCI, HELMINTH DIS LAB, BELTSVILLE, MD 20705 USA	United States Department of Agriculture (USDA)	ROCKEN, M (corresponding author), NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA.			Urban, Joseph/0000-0002-1590-8869; Rocken, Martin/0000-0003-3795-7001				BENSASSON SZ, 1990, J IMMUNOL, V145, P1127; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; HULI J, 1989, J IMMUNOL, V142, P800; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; ROCKEN M, 1992, J IMMUNOL, V148, P47; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SMITH H, 1989, SCIENCE, V245, P749, DOI 10.1126/science.2788921; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; STAERZ UD, 1985, J IMMUNOL, V134, P3994; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135	29	147	147	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					79	82		10.1038/359079a0	http://dx.doi.org/10.1038/359079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1355854				2022-12-24	WOS:A1992JL66200059
J	GOBBI, G; BOUQUET, F; GRECO, L; LAMBERTINI, A; TASSINARI, CA; VENTURA, A; ZANIBONI, MG				GOBBI, G; BOUQUET, F; GRECO, L; LAMBERTINI, A; TASSINARI, CA; VENTURA, A; ZANIBONI, MG			CELIAC-DISEASE, EPILEPSY, AND CEREBRAL CALCIFICATIONS	LANCET			English	Article							STURGE-WEBER SYNDROME; CELIAC-DISEASE; FACIAL NEVUS	There have been anecdotal reports of an association between coeliac disease and epilepsy with cerebral calcifications that resemble those of the Sturge-Weber syndrome. A series of patients who had epilepsy with calcifications, in whom coeliac disease (CD) was incidentally observed, prompted us to study this association. 43 patients (15 male, age range 4.6-30.7 years) were selected from two series. 31 patients with cerebral calcifications of unexplained origin and epilepsy (series A) underwent intestinal biopsy. 12 patients with CD and epilepsy (series B) underwent computed tomography. Antibodies to gluten, folic acid serum concentrations, were measured, and HLA typing was done in most patients. 24 of the series A patients were identified as having CD on the basis of a flat intestinal mucosa (15/22 with a high concentration of serum antigluten), and 5 series B patients showed cerebral calcifications, giving a total of 29 cases with the combination of CD, epilepsy, and cerebral calcifications (CEC). In 27 of these CEC patients, calcifications were located in the parieto-occipital regions. Only 2 of the series A patients had gastrointestinal symptoms at the time of intestinal biopsy; most patients had recurrent diarrhoea, anaemia, and other symptoms suggestive of CD in the first 3 years of life. The epilepsy in CEC patients was poorly responsive to antiepileptic drugs. Gluten-free diet beneficially affected the course of epilepsy only when started soon after epilepsy onset. Cases of "atypical Sturge-Weber syndrome" (characterised by serpiginous cerebral calcifications and epilepsy without facial port-wine naevus) should be reviewed, and CD should be ruled out in all cases of epilepsy and cerebral calcifications of unexplained origin.	UNIV TRIESTE,DIV NEUROPSICHIAT INFANTILE,I-34100 TRIESTE,ITALY; UNIV TRIESTE,PEDIAT CLIN,I-34100 TRIESTE,ITALY; NAPLES UNIV,FAC MED & CHIRURG 2,PEDIAT CLIN,I-80138 NAPLES,ITALY; OSPED MAGGIORE BOLOGNA,DIV PEDIAT,BOLOGNA,ITALY; UNIV BOLOGNA,OSPED BELLARIA,CATTEDRA NEUROL,DIV NEUROL 2,I-40126 BOLOGNA,ITALY	University of Trieste; University of Trieste; University of Naples Federico II; AUSL di Bologna; University of Bologna	GOBBI, G (corresponding author), SERV NEUROPSYCHIAT INFANTILE,USL 9,VIA AMENDOLA 2,I-42100 REGGIO EMILIA,ITALY.			Ventura, Alessandro/0000-0002-4657-1760; Tassinari, Carlo Alberto/0000-0002-4183-5165				ALEXANDER GL, 1972, HDB CLIN NEUROLOGY, P223; AMBROSETTO P, 1983, CHILD BRAIN, V10, P387; [Anonymous], 1981, EPILEPSIA, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389; Auricchio S, 1988, GASTROENTEROL INT, V1, P25; BATTISTELLA PA, 1986, RIV ITAL PED, V12, P417; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CHAPMAN RWG, 1978, BRIT MED J, V2, P250, DOI 10.1136/bmj.2.6132.250; COPPER BT, 1978, BMJ, V1, P537; CORAZZA GR, 1985, GUT, V26, P1210, DOI 10.1136/gut.26.11.1210; CORBEEL L, 1985, EUR J PEDIATR, V143, P284, DOI 10.1007/BF00442302; DELGIUDICE E, 1984, NEUROPEDIATRICS, V15, P218, DOI 10.1055/s-2008-1052371; DELLACELLA G, 1991, MED SURG PEDIATR, V13, P427; DEMARCHI M, 1983, GUT, V24, P706, DOI 10.1136/gut.24.8.706; DUNNILL MS, 1972, J CLIN PATHOL, V25, P243, DOI 10.1136/jcp.25.3.243; Garwicz S, 1976, Pediatr Radiol, V5, P5, DOI 10.1007/BF00988654; GIROUD M, 1990, REV NEUROL, V4, P288; GOBBI G, 1988, NEUROLOGY, V38, P9103; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; ITO M, 1990, BRAIN DEV-JPN, V12, P473, DOI 10.1016/S0387-7604(12)80210-5; JASPER HH, 1958, ELECTROENCEPHALOGRAP, V10, P370, DOI DOI 10.1016/0013-4694(58)90053-1; LAIDLOW JM, 1977, GUT, V18, pA943; LOGAN RFA, 1983, BMJ-BRIT MED J, V286, P95, DOI 10.1136/bmj.286.6359.95; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, 1991, LANCET, V338, P724, DOI 10.1016/0140-6736(91)91445-Z; MAKI Y, 1979, CHILD BRAIN, V5, P51; MCNEISH AS, 1979, ARCH DIS CHILD, V54, P783, DOI 10.1136/adc.54.10.783; MOLTENI N, 1988, AM J GASTROENTEROL, V83, P992; NAMAGUCHI Y, 1975, AM J ROENTGENOL, V123, P27; REYNOLDS EH, 1973, LANCET, V1, P1376; SAMMARITANO M, 1988, Neurology, V38, P239; TALY AB, 1987, NEUROLOGY, V37, P1063, DOI 10.1212/WNL.37.6.1063; TOSI R, 1983, CLIN IMMUNOL IMMUNOP, V28, P395, DOI 10.1016/0090-1229(83)90106-X; VENTURA A, 1991, ACTA PAEDIATR SCAND, V80, P552; YOUNG LW, 1977, AM J DIS CHILD, V131, P1283, DOI 10.1001/archpedi.1977.02120240101022; ZANIBONI MG, 1989, 1ST JOINT M BRIT SOC, P54	36	280	283	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					439	443						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354781				2022-12-24	WOS:A1992JJ87700001
J	PETERS, KG; MARIE, J; WILSON, E; IVES, HE; ESCOBEDO, J; DELROSARIO, M; MIRDA, D; WILLIAMS, LT				PETERS, KG; MARIE, J; WILSON, E; IVES, HE; ESCOBEDO, J; DELROSARIO, M; MIRDA, D; WILLIAMS, LT			POINT MUTATION OF AN FGF RECEPTOR ABOLISHES PHOSPHATIDYLINOSITOL TURNOVER AND CA2+ FLUX BUT NOT MITOGENESIS	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; KINASE-ACTIVITY; BINDING-SITE; PDGF; HYDROLYSIS; SUBSTRATE; C-GAMMA-1	STIMULATION of certain receptor tyrosine kinases results in the tyrosine phosphorylation and activation of phospholipase C(gamma)(PLC-gamma), an enzyme that catalyses the hydrolysis of phosphatidylinositol ( PtdIns)1-8. This hydrolysis generates diacylglycerol and free inositol phosphate, which in turn activate protein kinase C and increase intracellular Ca2+, respectively. PLC-gamma physically associates with activated receptor tyrosine kinases, suggesting that it is a substrate for direct phosphorylation by these kinases7-10. Here we report that a fibroblast growth factor (FGF) receptor with a single point mutation at residue 766 replacing tyrosine with phenylalanine fails to associate with PLC-gamma in response to FGF. This mutant receptor also failed to mediate PtdIns hydrolysis and Ca2+ mobilization after FGF stimulation. However, the mutant receptor phosphorylated itself and several other cellular proteins, and it mediated mitogenesis in response to FGF. These findings show that a point mutation in the FGF receptor selectively eliminates activation of PLC-gamma and that neither Ca2+ mobilization nor PtdIns hydrolysis are required for FGF-induced mitogenesis.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,PROGRAM EXCELLENCE MOLEC BIOL,533 PARNASSUS AVE,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BROWN KD, 1989, FEBS LETT, V247, P227, DOI 10.1016/0014-5793(89)81340-7; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HUANG CL, 1991, J BIOL CHEM, V266, P4045; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	30	366	377	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					678	681		10.1038/358678a0	http://dx.doi.org/10.1038/358678a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379697				2022-12-24	WOS:A1992JJ88200057
J	LIANG, P; PARDEE, AB				LIANG, P; PARDEE, AB			DIFFERENTIAL DISPLAY OF EUKARYOTIC MESSENGER-RNA BY MEANS OF THE POLYMERASE CHAIN-REACTION	SCIENCE			English	Article							CELL-CYCLE; MOLECULAR-CLONING; CDNA SEQUENCES; KINASE; TUMOR; EXPRESSION; CANDIDATE; GENES; G1	Effective methods are needed to identify and isolate those genes that are differentially expressed in various cells or under altered conditions. This report describes a method to separate and clone individual messenger RNAs (mRNAs) by means of the polymerase chain reaction. The key element is to use a set of oligonucleotide primers, one being anchored to the polyadenylate tail of a subset of mRNAs, the other being short and arbitrary in sequence so that it anneals at different positions relative to the first primer. The mRNA subpopulations defined by these primer pairs were amplified after reverse transcription and resolved on a DNA sequencing gel. When multiple primer sets were used, reproducible patterns of amplified complementary DNA fragments were obtained that showed strong dependence on sequence specificity of either primer.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	LIANG, P (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Alberts B., 2017, MOL BIOL CELL; BAND V, 1990, CANCER RES, V50, P7351; Bothwell A., 1990, METHODS CLONING ANAL; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KHAN AS, 1991, NUCLEIC ACIDS RES, V19, P1715, DOI 10.1093/nar/19.7.1715; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIANG P, UNPUB; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SU JY, 1991, NUCLEIC ACIDS RES, V19, P823, DOI 10.1093/nar/19.4.823; VARMUS H, 1989, ONCOGENES MOL ORIGIN, P3; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	21	4592	5472	2	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					967	971		10.1126/science.1354393	http://dx.doi.org/10.1126/science.1354393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1354393				2022-12-24	WOS:A1992JH82700036
J	LAFON, M; LAFAGE, M; MARTINEZARENDS, A; RAMIREZ, R; VUILLIER, F; CHARRON, D; LOTTEAU, V; SCOTTALGARA, D				LAFON, M; LAFAGE, M; MARTINEZARENDS, A; RAMIREZ, R; VUILLIER, F; CHARRON, D; LOTTEAU, V; SCOTTALGARA, D			EVIDENCE FOR A VIRAL SUPERANTIGEN IN HUMANS	NATURE			English	Article							T-CELL; MONOCLONAL-ANTIBODIES; STAPHYLOCOCCAL ENTEROTOXINS; N-PROTEIN; HLA-DR; STIMULATION; MOLECULES; ANTIGEN; NUCLEOPROTEIN; EXPRESSION	SUPERANTIGENS1-4 bind class II major histocompatibility proteins5,6 and stimulate powerful proliferative responses of T lymphocytes bearing particular V-beta sequences as part of their alpha-beta antigen receptor7. Exogenous bacterial superantigens are responsible for food poisoning and toxic shock syndrome. Murine virus-encoded self-superantigens induce clonal deletion of T lymphocytes. Although superantigen-like properties have been suggested for human immunodeficiency virus-1, no viral superantigen has been identified in humans8. Here we report that the nucleocapsid of the rabies virus is an exogenous superantigen specific for V-beta-8 human T lymphocytes which binds to HLA class II alpha-chains.	INST BIOMED CORDELIERS,IMMUNOGENET LAB,F-75006 PARIS,FRANCE; INST PASTEUR,UNITE IMMUNOHEMATOL & IMMUNOPATHOL,F-75724 PARIS 15,FRANCE	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LAFON, M (corresponding author), INST PASTEUR,UNITE RAGE,25-28 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE.		Scott, Daniel/AFK-5428-2022; lotteau, vincent/M-8143-2014; Vuillier, Françoise/T-4699-2019	Vuillier, Francoise/0000-0002-5551-9876; Lafon, Monique/0000-0002-4423-7996; Scott-Algara, Daniel/0000-0003-1851-503X; Rafael, Ramirez/0000-0003-4598-339X; Lotteau, Vincent/0000-0003-0997-3282				BANKAMP B, 1991, J VIROL, V65, P1695, DOI 10.1128/JVI.65.4.1695-1700.1991; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CARREL S, 1981, MOL IMMUNOL, V18, P403, DOI 10.1016/0161-5890(81)90102-4; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; DEMARS R, 1984, DIS MARKERS, V2, P175; DIETZSCHOLD B, 1987, P NATL ACAD SCI USA, V84, P9165, DOI 10.1073/pnas.84.24.9165; DIETZSCHOLD B, 1987, VIRUS RES, V8, P103, DOI 10.1016/0168-1702(87)90023-2; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FLEISCHER B, 1991, IMMUNOL RES, V10, P349, DOI 10.1007/BF02919720; HERZOG M, 1992, VIRUS RES, V24, P77, DOI 10.1016/0168-1702(92)90032-5; HERZOG M, 1991, CLIN EXP IMMUNOL, V85, P224, DOI 10.1111/j.1365-2249.1991.tb05709.x; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; LAFON M, 1985, J GEN VIROL, V66, P2125, DOI 10.1099/0022-1317-66-10-2125; LAFON M, 1990, J GEN VIROL, V71, P1689, DOI 10.1099/0022-1317-71-8-1689; LIBEAU G, 1983, BIOL STANDARD, V57, P213; LIU H, 1991, P NATL ACAD SCI USA, V88, P8705, DOI 10.1073/pnas.88.19.8705; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; PREHAUD C, 1990, VIROLOGY, V178, P486, DOI 10.1016/0042-6822(90)90346-S; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SHERLE PA, 1986, J EXP MED, V169, P1114; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	29	146	154	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					507	510		10.1038/358507a0	http://dx.doi.org/10.1038/358507a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1386410				2022-12-24	WOS:A1992JG73900051
J	CAMERON, PU; FREUDENTHAL, PS; BARKER, JM; GEZELTER, S; INABA, K; STEINMAN, RM				CAMERON, PU; FREUDENTHAL, PS; BARKER, JM; GEZELTER, S; INABA, K; STEINMAN, RM			DENDRITIC CELLS EXPOSED TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMIT A VIGOROUS CYTOPATHIC INFECTION TO CD4+ T-CELLS	SCIENCE			English	Article							HUMAN PERIPHERAL-BLOOD; LYMPHOCYTES-T; LYMPH-NODES; HTLV-III/LAV; AIDS; LYMPHADENOPATHY; EXPRESSION; HIV-1; RETROVIRUS; ANTIGEN	The paucity of virus-laden CD4+ cells in individuals infected with human immunodeficiency virus type-1 (HIV-1) contrasts with the greatly reduced numbers and function of these lymphocytes. A pathway is described whereby dendritic cells carry HIV-1 to uninfected T cells, amplifying the cytopathic effects of small amounts of virus. After exposure to HIV-1, dendritic cells continue to present superantigens and antigens, forming clusters with T cells that are driven to replicate. Infection of the dendritic cells cannot be detected, but the clustered T cells form syncytia, release virions, and die. Carriage of HIV-1 by dendritic cells may facilitate the lysis and loss of antigen specific CD4+ T cells in acquired immunodeficiency syndrome.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University			Steinman, Ralph/F-7729-2012; Cameron, Paul/H-3474-2011	Cameron, Paul Urquhart/0000-0002-1906-6945	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER; NCRR NIH HHS [MOI-RR00102] Funding Source: Medline; NIAID NIH HHS [AI 24775] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARMSTRONG JA, 1984, LANCET, V2, P370; BHARDWAJ N, 1992, J EXP MED, V175, P267, DOI 10.1084/jem.175.1.267; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1992, CLIN EXP IMMUNOL, V88, P226, DOI 10.1111/j.1365-2249.1992.tb03066.x; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLECHNER ER, 1988, CELL IMMUNOL, V111, P183, DOI 10.1016/0008-8749(88)90062-7; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; INABA K, 1987, J EXP MED, V166, P182, DOI 10.1084/jem.166.1.182; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; LANGHOFF E, 1989, J EXP MED, V169, P315, DOI 10.1084/jem.169.1.315; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LEVY JA, 1988, NATURE, V333, P519, DOI 10.1038/333519a0; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; MACATONIA SE, 1989, IMMUNOLOGY, V67, P285; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MCELRATH MJ, 1991, J CLIN INVEST, V87, P27, DOI 10.1172/JCI114981; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; PATTERSON S, 1991, IMMUNOLOGY, V72, P361; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TENNERRACZ K, 1988, NEW ENGL J MED, V318, P49, DOI 10.1056/NEJM198801073180113; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	34	559	571	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					383	386		10.1126/science.1352913	http://dx.doi.org/10.1126/science.1352913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1352913				2022-12-24	WOS:A1992JD67400033
J	LEHMANN, PV; FORSTHUBER, T; MILLER, A; SERCARZ, EE				LEHMANN, PV; FORSTHUBER, T; MILLER, A; SERCARZ, EE			SPREADING OF T-CELL AUTOIMMUNITY TO CRYPTIC DETERMINANTS OF AN AUTOANTIGEN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; ENCEPHALITOGENIC EPITOPES; VACCINATION; SPECIFICITY; RECEPTORS; PEPTIDES	IMMUNIZATION with myelin basic protein (MBP) induces experimental allergic encephalomyelitis (EAE), a prototype of CD4+ T-cell mediated autoimmune disease. In rodents, MBP-reactive T-cell clones are specific for a single, dominant determinant on MBP and use a highly restricted number of T-cell receptor genes 1-3. Accordingly, EAE has been prevented by various receptor-specific treatments 1-8, suggesting similar strategies may be useful for therapy of human autoimmune disease. Here we report that in (SJL x B10.PL)F1 mice, immune dominance of a single determinant, MBP: Ac1-11, is confined to the inductive phase of EAE. In mice with chronic EAE, several additional determinants of MBP in peptides 35-47, 81-100 and 121-140 recall proliferative responses. Most importantly, reactivity to the latter determinants was also detected after induction of EAE with MBP peptide Ac1-11 alone; this demonstrates priming by endogenous MBP determinants. Thus, determinants of MBP that are cryptic 9-11 after primary immunization can become immunogenic in the course of EAE. Diversification of the autoreactive T-cell repertoire due to 'determinant spreading' has major implications for the pathogenesis of, and the therapeutic approach to, T-cell driven autoimmune disease.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles			Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENICHOU G, 1990, J EXP MED, V172, P1341, DOI 10.1084/jem.172.5.1341; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; GAMMON G, 1991, IMMUNOL TODAY, V12, P193, DOI 10.1016/0167-5699(91)90052-U; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HOOD L, 1989, COLD SPRING HARB SYM, V54, P859; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; LINTHICUM DS, 1982, J EXP MED, V156, P31, DOI 10.1084/jem.156.1.31; MCCARRON RM, 1990, J NEUROIMMUNOL, V29, P73, DOI 10.1016/0165-5728(90)90149-H; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; PERRY LL, 1987, J IMMUNOL, V138, P1434; PERRY LL, 1991, J NEUROIMMUNOL, V33, P7, DOI 10.1016/0165-5728(91)90029-7; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	23	1056	1088	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					155	157		10.1038/358155a0	http://dx.doi.org/10.1038/358155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1377368				2022-12-24	WOS:A1992JC58300053
J	VIOLARIS, AG; LINNEMEIER, TJ; CAMPBELL, S; ROTHBAUM, DA; CUMBERLAND, DC				VIOLARIS, AG; LINNEMEIER, TJ; CAMPBELL, S; ROTHBAUM, DA; CUMBERLAND, DC			INTRAVASCULAR ULTRASOUND IMAGING COMBINED WITH CORONARY ANGIOPLASTY	LANCET			English	Note							INVITRO	A novel catheter combining ultrasound imaging and coronary balloon angioplasty was used in the treatment of 69 coronary-artery lesions in 51 patients. The ultrasound transducer enables real-time cross-sectional imaging and qualitative and quantitative assessment of the vessel wall before and after angioplasty. The combination catheter successfully dilated 67 lesions. There was a characteristic three-layered appearance, representing intima, media, and adventitia, in 60 cases. Intravascular imaging provided information on the vessel wall unobtainable by standard contrast angiogaphy in 28 cases and influenced our management in 6 cases.	NO GEN HOSP,CARDIAC UNIT,HERRIES RD,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; ST VINCENT HOSP,INDIANA HEART INST,INDIANAPOLIS,IN	Northern General Hospital								GUSSENHOVEN EJ, 1989, J AM COLL CARDIOL, V14, P947, DOI 10.1016/0735-1097(89)90471-3; NISHIMURA RA, 1990, J AM COLL CARDIOL, V16, P145, DOI 10.1016/0735-1097(90)90472-2; POTKIN BN, 1988, AM J CARDIOL, V62, P41, DOI 10.1016/0002-9149(88)91362-8; TOBIS JM, 1991, CIRCULATION, V83, P913, DOI 10.1161/01.CIR.83.3.913; Yock P G, 1989, J Am Soc Echocardiogr, V2, P296	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1571	1572		10.1016/0140-6736(92)91834-U	http://dx.doi.org/10.1016/0140-6736(92)91834-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351552				2022-12-24	WOS:A1992JB20200006
J	TYLER, A; BALL, D; CRAUFURD, D				TYLER, A; BALL, D; CRAUFURD, D			PRESYMPTOMATIC TESTING FOR HUNTINGTONS-DISEASE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							LINKED DNA MARKERS; ATTITUDES; DIAGNOSIS; CHOREA	Objective-To evaluate the United Kingdom Huntington's disease presymptomatic testing programme. Design-Postal questionnaire survey to collect data on all tests performed by clinical genetics centres between 1987 and 1990. Setting-Genetic centres providing presymptomatic testing in the United Kingdom. Subjects-248 subjects at risk of Huntington's disease who had presymptomatic testing at their request. Main outcome measures-Sex, age, prior risk, and risk after testing. Results-The risk of carrying the Huntington disease gene was reduced for 151 (61%) of the applicants and raised for 97 (39%). 158 (64%) of the subjects were female and 90 (36%) male. The median age at which the results were given was 32.5 years. Conclusions-The demand for testing was lower than expected and may have reached its peak in 1990. The excess of low risk results was not fully explained by the age effect. All the genetics centres concerned have agreed a common service protocol which requires extensive pre-test counselling and post-test follow up. The worth of the procedure remains to be decided. The availability of a large body of pooled data from all the United Kingdom testing centres, which individually are likely to have only a few results, will form a valuable resource for monitoring the long term psychosocial impact of testing.	ST MARYS HOSP,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester	TYLER, A (corresponding author), UNIV WALES COLL MED,DEPT MED GENET,CARDIFF CF4 4XW,S GLAM,WALES.		Craufurd, David/G-5277-2013					BLOCH M, 1989, AM J MED GENET, V32, P217, DOI 10.1002/ajmg.1320320215; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; CRAUFURD D, 1989, LANCET, V2, P603; CRAUFURD DIO, 1986, BRIT MED J, V293, P249, DOI 10.1136/bmj.293.6541.249; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, 1992, J MED GENET, V29, P239, DOI 10.1136/jmg.29.4.239; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22, P373; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22, P251; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; LAM RW, 1988, J CLIN PSYCHIAT, V49, P444; MASTROMAURO C, 1987, AM J MED GENET, V26, P271, DOI 10.1002/ajmg.1320260205; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; MORRIS M, 1988, LANCET, V2, P1069, DOI 10.1016/S0140-6736(88)90078-5; SANDKUYL L, 1989, HUM GENET, V82, P159, DOI 10.1007/BF00284050; TYLER A, 1983, J MED GENET, V20, P179, DOI 10.1136/jmg.20.3.179; TYLER A, 1990, IN PRESS BR J PSYCHI; World Federation of Neurology, 1989, J NEUROL SCI, V94, P327	17	64	64	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1593	1596		10.1136/bmj.304.6842.1593	http://dx.doi.org/10.1136/bmj.304.6842.1593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1385747	Bronze, Green Published			2022-12-24	WOS:A1992JA43600018
J	KHATTAK, MN; MATTHEWS, RC; BURNIE, JP				KHATTAK, MN; MATTHEWS, RC; BURNIE, JP			IS BORDETELLA-PERTUSSIS CLONAL	BRITISH MEDICAL JOURNAL			English	Article							LARGE DNA-MOLECULES	Objective - To establish whether Bordetella pertussis is essentially clonal. Design - Analysis of restriction fragments of XbaI digests of DNA from clinical and control isolates of B pertussis by pulse field gel electrophoresis. Materials - 105 isolates of B pertussis: 67 clinical isolates from throughout the United Kingdom and 23 from Germany (collected during the previous 18 months); vaccine strains 2991 and 3700; and 13 control isolates from Manchester University's culture collection. Main outcome measures - Frequency of DNA types according to country of origin and classical serotyping. Results - 17 DNA types were identified on the basis of the variation in 11 fragments, banding at 200-412 kilobases; 15 types were found in the clinical and control isolates from the United Kingdom and seven in those from Germany. There was no correlation with serotype. DNA type 1 was the commonest overall (22/105 strains, 22%), predominating in serotypes 1,2 and 1,2,3 and including the vaccine strains but not the isolates from Germany. Conclusions - Current infections due to B pertussis are not caused by a clonal pathogen as multiple strains are circulating in a given population at one time. There is also considerable epidemiological variation in the pathogen population between countries. These findings may have implications for the design of acellular vaccines.	UNIV MANCHESTER,SCH MED,DEPT MED MICROBIOL,PERTUSSIS REFERENCE LAB,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1988, LANCET, Vi, P955; CANTOR CR, 1988, ANNU REV BIOPHYS BIO, V17, P287; CHERRY J D, 1988, Pediatrics, V81, P939; KIMURA M, 1990, LANCET, V336, P30, DOI 10.1016/0140-6736(90)91530-N; MCCLELLAND M, 1987, NUCLEIC ACIDS RES, V15, P5985, DOI 10.1093/nar/15.15.5985; MORTIMER E A JR, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P89; MUSSER JM, 1986, J BACTERIOL, V166, P230, DOI 10.1128/jb.166.1.230-237.1986; Preston N W, 1970, Lab Pract, V19, P482; PRESTON NW, 1986, BRIT MED J, V292, P901, DOI 10.1136/bmj.292.6524.901-c; ROBINSON A, 1988, PATHOGENESIS IMMUNIT, P399; SCHWARTZ MO, 1984, ERZMETALL, V37, P65; Smith C.L., 1988, P41; SMITH CL, 1987, METHOD ENZYMOL, V155, P449; WARDLAW AC, 1988, PATHOGENESIS IMMUNIT, P327; 1979, WHO TECH REP SER, V638; 1982, MMWR, V31; 1990, PHLS9041 COMM DIS SU	17	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					813	815		10.1136/bmj.304.6830.813	http://dx.doi.org/10.1136/bmj.304.6830.813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392709	Bronze, Green Published			2022-12-24	WOS:A1992HL82700021
J	CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; RITTER, JM				CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; RITTER, JM			IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATION OF FOREARM RESISTANCE VESSELS IN HYPERCHOLESTEROLEMIA	LANCET			English	Article							NITRIC-OXIDE; CORONARY-ARTERIES; RELAXING FACTOR; ACETYLCHOLINE; RELEASE; RELAXATION; AORTA	Endothelium-dependent vasodilation in response to acetylcholine is impaired in the coronary microvasculature of hypercholesterolaemic subjects. Outside the coronary circulation, however, it has been suggested that hypercholesterolaemia results in a functional abnormality of vascular smooth muscle rather than in endothelial dysfunction. We examined vasodilator responses to acetylcholine, methacholine, and the endothelium-independent vasodilator sodium nitroprusside in the forearm resistance vessels of 12 men with primary hypercholesterolaemia and 12 normocholesterolaemic male controls. Endothelium-dependent vasodilation in response to acetylcholine was impaired in hypercholesterolaemic patients compared with controls: at the highest dose of drug (15 mug per min) mean blood flow in the forearms of the hypercholesterolaemic group was only 52% (95% CI 31-88%) of that in the control group. Responses to sodium nitroprusside and to methacholine in the two study groups were not significantly different. These results indicate that endothelial dysfunction in hypercholesterolaemic subjects is generalised and extends to vascular beds outside the coronary circulation. Selective impairment to acetylcholine suggests that, at a molecular level, the defect is limited to a specific pathway.	ST THOMAS HOSP,DEPT ENDOCRINOL,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT CHEM PATHOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT CLIN PHARMACOL,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	CHOWIENCZYK, PJ (corresponding author), ST THOMAS HOSP,DEPT CLIN PHARMACOL,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.			Chowienczyk, Phil/0000-0003-4507-038X; Watts, Gerald/0000-0003-2276-1524				BOSSALLER C, 1987, J CLIN INVEST, V79, P170, DOI 10.1172/JCI112779; BRAYDEN JE, 1985, CIRC RES, V56, P163; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; KATO T, 1990, HYPERTENSION, V15, P475, DOI 10.1161/01.HYP.15.5.475; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEILD TO, 1990, J PHYSIOL-LONDON, V420, P247, DOI 10.1113/jphysiol.1990.sp017910; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RALEVIC V, 1992, BRIT J PHARMACOL, V106, P650, DOI 10.1111/j.1476-5381.1992.tb14390.x; RUBANYI GM, 1987, J PHARMACOL EXP THER, V240, P802; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; VALLANCE P, 1989, LANCET, V2, P997; WHITNEY RJ, 1953, J PHYSIOL-LONDON, V121, P1	15	441	446	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1430	1432		10.1016/0140-6736(92)92621-L	http://dx.doi.org/10.1016/0140-6736(92)92621-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360559				2022-12-24	WOS:A1992KC28400003
J	POLLOCK, RA; JAY, G; BIEBERICH, CJ				POLLOCK, RA; JAY, G; BIEBERICH, CJ			ALTERING THE BOUNDARIES OF HOX3.1 EXPRESSION - EVIDENCE FOR ANTIPODAL GENE-REGULATION	CELL			English	Article							CENTRAL NERVOUS-SYSTEM; TRANSGENIC MICE; HOMEODOMAIN PROTEIN; DROSOPHILA EMBRYOS; SUBMUCOSAL CYSTS; AUTO-REGULATION; RETINOIC ACID; HOMEOBOX; MOUSE; HOX-3.1	To investigate the function of region-specific patterns of mouse homeobox gene expression during embryogenesis, we programmed a minimal change in the distribution of Hox3.1 transcripts along the antero-posterior body axis in transgenic mice. Regulatory sequences from Hox1.4, a gene normally expressed more anteriorly than Hox3.1, were chosen to direct expression of a Hox3.1 transgene. Offspring of independent transgenic lines expressed the transgene more anteriorly than the Hox3.1 gene. Rather than predicted posterior transformations, we observed anterior transformations of vertebrae in newborn mice. Transgenic mice also developed profound gastrointestinal tissue malformations, which may provide a molecular explanation for human developmental disorders often involving these same two regions. Paradoxically, vertebral transformations in the transgenic mice were strikingly similar to those reported in mice homozygous for a null mutation of the Hox3.1 gene. This observation suggests that Hox genes may be regulated antipodally, with over- or underexpression resulting in similar phenotypes.			POLLOCK, RA (corresponding author), AMER RED CROSS, JEROME H HOLLAND LAB, ROCKVILLE, MD 20855 USA.		Jay, Gregory/C-6346-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD027943] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07522, HD27943] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKAM M, 1987, DEVELOPMENT, V101, P1; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEARDMORE H E, 1958, Pediatr Clin North Am, P457; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIEBERICH C, 1987, MOL CELL BIOL, V7, P4003, DOI 10.1128/MCB.7.11.4003; BIEBERICH CJ, 1991, ANN NY ACAD SCI, V642, P346; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BREIER G, 1988, EMBO J, V7, P1329, DOI 10.1002/j.1460-2075.1988.tb02948.x; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; Danforth CH, 1930, AM J PHYS ANTHROPOL, V14, P463, DOI 10.1002/ajpa.1330140311; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; FERGUSONSMITH AC, 1989, GENOMICS, V5, P250, DOI 10.1016/0888-7543(89)90054-2; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GORDON JW, 1990, J IN VITRO FERTIL EM, V7, P223, DOI 10.1007/BF01129523; GORDON JW, 1990, BIOL REPROD, V42, P869, DOI 10.1095/biolreprod42.6.869; GORDON JW, 1990, DEV BIOL, V137, P349, DOI 10.1016/0012-1606(90)90259-L; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; Green EL, 1941, GENETICS, V26, P192; GREEN EL, 1953, SCIENCE, V117, P81, DOI 10.1126/science.117.3030.81; GREGG BC, 1983, J EMBRYOL EXP MORPH, V73, P135; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUNEBERG H, 1950, J GENET, V50, P112, DOI 10.1007/BF02986799; IGNATIUS JA, 1970, GASTROENTEROLOGY, V59, P610; INOUYE M, 1976, Congenital Anomalies, V16, P171; IWANAGA T, 1975, CANCER, V36, P606, DOI 10.1002/1097-0142(197508)36:2<606::AID-CNCR2820360243>3.0.CO;2-V; JAMES R, 1991, J BIOL CHEM, V266, P3246; Kaufman T C, 1990, Adv Genet, V27, P309; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCLETCHIE NGB, 1954, SURG GYNECOL OBSTET, V99, P135; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MOCHIZUKI Y, 1989, Stomach and Intestine (Tokyo), V24, P1057; NIIZAWA M, 1992, GASTROINTEST RADIOL, V17, P9, DOI 10.1007/BF01888497; PILLAY I, 1976, CANCER, V38, P915, DOI 10.1002/1097-0142(197608)38:2<915::AID-CNCR2820380239>3.0.CO;2-V; Ptashne M., 1986, A GENETIC SWITCH; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; Rotterdam H., 1989, PATHOLOGY STOMACH DU; RUBIO CA, 1989, PATHOL RES PRACT, V184, P418, DOI 10.1016/S0344-0338(89)80037-8; RUSSELL LB, 1956, J EXP ZOOL, V131, P329, DOI 10.1002/jez.1401310308; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCHUGHART K, 1991, DEVELOPMENT, V112, P807; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEARLE AG, 1954, J GENET, V52, P68, DOI 10.1007/BF02981491; SHASHIKANT C S, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P207; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; Struthers J, 1874, J Anat Physiol, V9, P17; Thorington R.W. Jr, 1989, P125; Thorington R.W. Jr., 1972, Nemouria, VNo. 8, P1; THURSTON SE, 1984, CLIN PEDIATR, V23, P652, DOI 10.1177/000992288402301111; TOTH LE, 1987, P NATL ACAD SCI USA, V84, P6790, DOI 10.1073/pnas.84.19.6790; Washburn S, 1952, AM J PHYS ANTHROPOL, V10, P251; WEBER W, 1950, J GENET, V50, P174, DOI 10.1007/BF02986801; WESTERFIELD M, 1992, GENE DEV, V6, P591, DOI 10.1101/gad.6.4.591; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WIECZOREK RL, 1984, AM J GASTROENTEROL, V79, P597; WILLIS RA, 1962, BORDERLAND EMBRYOLOG; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; YAMAGIWA H, 1979, ACTA PATHOL JAPON, V29, P347; YASUDA Y, 1986, TERATOLOGY, V34, P37, DOI 10.1002/tera.1420340106; YOUNG WS, 1991, FOCUS, V13, P46; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	83	133	139	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					911	923		10.1016/0092-8674(92)90388-S	http://dx.doi.org/10.1016/0092-8674(92)90388-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1360875				2022-12-24	WOS:A1992KB99000005
J	CELERMAJER, DS; SORENSEN, KE; GOOCH, VM; SPIEGELHALTER, DJ; MILLER, OI; SULLIVAN, ID; LLOYD, JK; DEANFIELD, JE				CELERMAJER, DS; SORENSEN, KE; GOOCH, VM; SPIEGELHALTER, DJ; MILLER, OI; SULLIVAN, ID; LLOYD, JK; DEANFIELD, JE			NONINVASIVE DETECTION OF ENDOTHELIAL DYSFUNCTION IN CHILDREN AND ADULTS AT RISK OF ATHEROSCLEROSIS	LANCET			English	Article							CORONARY-ARTERY DISEASE; CAROTID-ARTERY; MEN; ACETYLCHOLINE; FLOW; RELAXATION; SMOKING; CHOLESTEROL; REGRESSION; THICKNESS	Endothelial dysfunction is an early event in experimental studies of atherogenesis, preceding formation of plaques. We have devised a non-invasive method for testing endothelial function, to find out whether abnormalities are present in symptom-free children and young adults at high risk of atherosclerosis. With high-resolution ultrasound, we measured the diameter of the superficial femoral and brachial arteries at rest, during reactive hyperaemia (with increased flow causing endothelium-dependent dilatation), and after sublingual glyceryl trinitrate (GTN; causing endothelium-independent dilatation) in 100 subjects-50 controls without vascular risk factors (aged 8-57 years), 20 cigarette smokers (aged 17-62 years), 10 children with familial hypercholesterolaemia (FH; aged 8-16 years), and 20 patients with established coronary artery disease (CAD). Adequate scans were obtained in all but 6 cases. Flow-mediated dilatation was observed in arteries from all control subjects. Dilatation was inversely related to baseline vessel diameter (r=-0.81, p<0.0001); in arteries of 6.0 mm or less, mean dilatation was 10 (SE 2)%. In smokers, FH children, and adults with CAD, flow-mediated dilatation was much reduced or absent (p<0.001 for comparison with each relevant control group). Dilatation in response to GTN was present in all groups. Endothelial dysfunction is present in children and adults with risk factors for atherosclerosis, such as smoking and hypercholesterolaemia, before anatomical evidence of plaque formation in the arteries studied. This may be an important early event in atherogenesis.	HOSP SICK CHILDREN,MED UNIT,LONDON WC1N 3JH,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; MRC Biostatistics Unit	CELERMAJER, DS (corresponding author), HOSP SICK CHILDREN,CARDIOTHORAC UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Deanfield, John E/C-5178-2008; Tanaka, Gohichi/A-1684-2010	Deanfield, John/0000-0001-8806-6052				ANDERSON EA, 1989, CIRCULATION, V79, P93, DOI 10.1161/01.CIR.79.1.93; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CHAVEAU M, 1985, CARDIOVASC RES, V19, P700; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; KWITEROVICH PO, 1990, PEDIATR CLIN N AM, V37, P1489; LAURENT S, 1990, AM J PHYSIOL, V258, pH1004, DOI 10.1152/ajpheart.1990.258.4.H1004; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MCLENACHAN JM, 1990, CIRCULATION, V82, P1169, DOI 10.1161/01.CIR.82.4.1169; NABEL EG, 1990, J AM COLL CARDIOL, V16, P349, DOI 10.1016/0735-1097(90)90584-C; OLSSON AG, 1991, CIRCULATION, V83, P698, DOI 10.1161/01.CIR.83.2.698; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; RENEMAN RS, 1986, ULTRASOUND MED BIOL, V12, P465, DOI 10.1016/0301-5629(86)90218-8; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1115; SALONEN R, 1991, J INTERN MED, V229, P225, DOI 10.1111/j.1365-2796.1991.tb00336.x; STARY HC, 1989, ARTERIOSCLEROSIS, V99, pI19; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x	29	3824	4393	3	170	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1111	1115		10.1016/0140-6736(92)93147-F	http://dx.doi.org/10.1016/0140-6736(92)93147-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359209	Bronze			2022-12-24	WOS:A1992JX13400001
J	BRODY, H				BRODY, H			ASSISTED DEATH - A COMPASSIONATE RESPONSE TO A MEDICAL FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; SUICIDE; ETHICS				BRODY, H (corresponding author), MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, CTR CLIN B100, E LANSING, MI 48824 USA.		Brody, Howard/GQA-6310-2022					ADMIRAAL PV, 1984, JUSTIFIED EUTHANASIA; [Anonymous], 1992, HARVARD LAW REV, V105, P2021; ARRAS JD, 1991, J MED PHILOS, V16, P29, DOI 10.1093/jmp/16.1.29; Battin M, 1992, Law Med Health Care, V20, P133; Benjamin Martin, 1990, SPLITTING DIFFERENCE; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; Brody H., 1987, STORIES SICKNESS; BRODY H, 1992, HEALERS POWER; CALLAHAN D, 1977, HASTINGS CENT REP, V7, P32, DOI 10.2307/3560692; Callahan D., 1987, MED GOALS AGEING SOC; CALLAHAN D, 1991, COMMONWEAL S    0809, P12; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; CRANFORD RE, 1984, I ETHICS COMMITTEES; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Drane JF, 1988, BECOMING GOOD DOCTOR; DUFFY TP, 1992, NEW ENGL J MED, V326, P933, DOI 10.1056/NEJM199204023261406; FENIGSEN R, 1991, ISSUES LAW MED, V7, P339; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gomez Carlos F., 1991, REGULATING DEATH EUT; GOMEZ CF, 1991, COMMONWEAL S, P5; Hampshire Stuart., 1983, MORALITY CONFLICT; Humphry Derek, 1991, FINAL EXIT PRACTICAL; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; JONSEN AR, 1991, THEOR MED, V12, P295, DOI 10.1007/BF00489890; JONSEN AR, 1991, COMMONWEAL S, P2; KANOTI GA, 1987, HLTH CARE ETHICS GUI, P293; KASS LR, 1989, PUBLIC INTEREST, P25; KASS LR, 1991, COMMONWEAL S, P8; KEVORKIAN J, 1991, PRESCRIPTION MEDICID; LADD J, 1980, LANCET, V2, P1127; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; May W E, 1987, Issues Law Med, V3, P203; Miller R J, 1992, Law Med Health Care, V20, P127, DOI 10.1111/j.1748-720X.1992.tb01179.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; Pellegrino E., 1981, PHILOS BASIS MED PRA; Pellegrino E., 1988, PATIENTS GOOD RESTOR; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PENCE GE, 1988, AM J MED, V84, P139, DOI 10.1016/0002-9343(88)90022-8; PUTNAM H, 1983, NOT SOLVE ETHICAL PR; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J., 1986, END LIFE EUTHANASIA; SHAFFER CD, 1986, COLUMBIA LAW REV, V86, P348, DOI 10.2307/1122707; Shelp E. E., 1985, VIRTUE MED EXPLORATI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANCE R, 1985, PERSPECT BIOL MED, V28, P282; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, EUTHANASIA REPORT RE	54	108	108	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1384	1388		10.1056/NEJM199211053271912	http://dx.doi.org/10.1056/NEJM199211053271912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1383820				2022-12-24	WOS:A1992JW07700012
J	GARNER, P; KRAMER, MS; CHALMERS, I				GARNER, P; KRAMER, MS; CHALMERS, I			MIGHT EFFORTS TO INCREASE BIRTH-WEIGHT IN UNDERNOURISHED WOMEN DO MORE HARM THAN GOOD	LANCET			English	Editorial Material							LOW BIRTH-WEIGHT; INFANT-MORTALITY; GESTATIONAL-AGE; DETERMINANTS; PREGNANCY; PRETERM; RISK		MCGILL UNIV,FAC MED,DEPT PEDIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,FAC MED,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3A 2T5,QUEBEC,CANADA; RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	McGill University; McGill University; Radcliffe Infirmary; University of Oxford	GARNER, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH POLICY UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941; Osmond, Clive/0000-0002-9054-4655; Fall, Caroline/0000-0003-4402-5552				BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; BREMS S, 1989, 1988 1989 M ADV GROU; CHALMERS I, 1979, LANCET, V2, P1063; CNATTINGIUS S, 1988, BMJ-BRIT MED J, V297, P258, DOI 10.1136/bmj.297.6643.258; Fleming AF, 1985, BR J OBSTET GYNAE S5, V92, P32; HABICHT JP, 1973, NUTR REP INT, V7, P533; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P100; Kramer M S, 1990, Paediatr Perinat Epidemiol, V4, P381, DOI 10.1111/j.1365-3016.1990.tb00661.x; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KRAMER MS, IN PRESS OXFORD DATA; LOMAS J, 1989, EFFECTIVE CARE PREGN, P1182; LUMLEY J, 1992, OXFORD DATABASE PERI; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; NAEYE RL, 1979, AM J OBSTET GYNECOL, V135, P3; PUFFER RR, 1987, SCI PUBLICATION PAN, V504; SAMMSVAUGHAN ME, 1990, J TROP PEDIATRICS, V36, P171, DOI 10.1093/tropej/36.4.171; TAFFEL S, 1986, DHHS PHS861922 NAT C; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VICTORA CG, 1987, INT J EPIDEMIOL, V16, P239, DOI 10.1093/ije/16.2.239; Villar J, 1982, Obstet Gynecol Surv, V37, P499, DOI 10.1097/00006254-198208000-00001; VILLAR J, 1984, PEDIATRICS, V74, P783; 1985, REPORT COMMITTEE STU; 1990, GESTATIONAL WEIGHT G	24	43	43	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1021	1023		10.1016/0140-6736(92)93022-F	http://dx.doi.org/10.1016/0140-6736(92)93022-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357412				2022-12-24	WOS:A1992JV01400014
J	LINDSTEDT, S; HOLME, E; LOCK, EA; HJALMARSON, O; STRANDVIK, B				LINDSTEDT, S; HOLME, E; LOCK, EA; HJALMARSON, O; STRANDVIK, B			TREATMENT OF HEREDITARY TYROSINEMIA TYPE-I BY INHIBITION OF 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE	LANCET			English	Article							TYROSINEMIA; SUCCINYLACETONE; DEFICIENCY; LIVER; FORM; ACID	Liver transplantation is the only effective treatment for hereditary tyrosinaemia type I (McKusick 276700). We have treated one acute and four subacute-chronic cases with 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione (NTBC), a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), to prevent the formation of maleylacetoacetate and fumarylaceto-acetate and their saturated derivatives. The oral daily dose was 0.1-0.6 mg/kg. The excretion of succinylacetoacetate and succinylacetone decreased from 15-103 mmol/mol creatinine to the detection limit or slightly above (ie, to 20-150 mumol/mol creatinine). The concentration of succinylacetone in plasma decreased from 5.8-43-mumol/l to the detection limit (0.1 mumol/l) over 2-5 months of treatment. The almost complete inhibition of porphobilinogen synthase in erythrocytes was abolished and the excretion of 5-aminolevulinate decreased to within or slightly above the reference range. The concentration of alpha-fetoprotein decreased in four patients to 1.3-7.5% of initially high values over 6-8 months. Improved liver function was reflected by normal concentrations of prothrombin complex and in decreased activities of alkaline phosphatase and gamma-glutamyltransferase in serum. Computed tomography revealed regression of hepatic abnormalities in three patients. One patient developed rickets 6 months before treatment and had excreted high concentrations of markers of tubular dysfunction-after 3 weeks of treatment, this excretion had disappeared. No side-effects were encountered. Inhibition of 4-hydroxyphenylpyruvate dioxygenase may prevent the development of liver cirrhosis and abolish or diminish the risk of liver cancer. Normalisation of porphyrin synthesis will eliminate the risk of porphyric crises. This type of treatment may thus offer an alternative to liver transplantation in hereditary tryosinaemia.	ICI PLC, CENT TOXICOL LAB, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND; GOTHENBURG UNIV, DEPT PAEDIAT, S-41124 GOTHENBURG, SWEDEN	University of Gothenburg	LINDSTEDT, S (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN.		Lock, Edward/AAJ-1334-2020					COLLIER HB, 1971, CLIN BIOCHEM, V4, P222, DOI 10.1016/S0009-9120(71)91692-4; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DEBRAEKELEER M, 1990, AM J HUM GENET, V47, P302; ENDO F, 1983, PEDIATR RES, V17, P92, DOI 10.1203/00006450-198302000-00002; GENTZ J, 1969, CLIN CHIM ACTA, V23, P257, DOI 10.1016/0009-8981(69)90040-0; GENTZ J, 1965, J PEDIATR-US, V66, P670, DOI 10.1016/S0022-3476(65)80002-6; GIARDINI O, 1983, PEDIATR RES, V17, P25, DOI 10.1203/00006450-198301000-00005; GRENIER A, 1982, CLIN CHIM ACTA, V123, P93, DOI 10.1016/0009-8981(82)90117-6; GRETER J, 1987, CLIN CHEM, V33, P473; HOLME E, 1992, LANCET, V340, P850, DOI 10.1016/0140-6736(92)92724-T; KUHLER TC, 1985, THESIS GOTHENBURG U; KVITTINGEN EA, 1986, SCAND J CLIN LAB INV, V46, P27; LAHDENNE P, 1991, J PEDIATR-US, V118, P272, DOI 10.1016/S0022-3476(05)80501-3; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1987, METHOD ENZYMOL, V142, P139; MANOWSKI Z, 1990, MODERN PATHOL, V3, P694; MITCHELL G, 1990, NEW ENGL J MED, V322, P432, DOI 10.1056/NEJM199002153220704; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; TUCHMAN M, 1984, J CHROMATOGR SCI, V22, P211, DOI 10.1093/chromsci/22.5.211; VANSPRONSEN FJ, 1991, 29TH P SSIEM ANN S L; WEINBERG AG, 1976, J PEDIATR-US, V88, P434, DOI 10.1016/S0022-3476(76)80259-4	21	475	493	2	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1992	340	8823					813	817		10.1016/0140-6736(92)92685-9	http://dx.doi.org/10.1016/0140-6736(92)92685-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1383656				2022-12-24	WOS:A1992JR16800004
J	ROTHNAGEL, JA; DOMINEY, AM; DEMPSEY, LD; LONGLEY, MA; GREENHALGH, DA; GAGNE, TA; HUBER, M; FRENK, E; HOHL, D; ROOP, DR				ROTHNAGEL, JA; DOMINEY, AM; DEMPSEY, LD; LONGLEY, MA; GREENHALGH, DA; GAGNE, TA; HUBER, M; FRENK, E; HOHL, D; ROOP, DR			MUTATIONS IN THE ROD DOMAINS OF KERATIN-1 AND KERATIN-10 IN EPIDERMOLYTIC HYPERKERATOSIS	SCIENCE			English	Article							INTERMEDIATE FILAMENTS; HUMAN CHROMOSOME-12; GENE-EXPRESSION; MOUSE EPIDERMIS; CELLS; SEQUENCE; ACID; CYTOKERATIN-18; ULTRASTRUCTURE; KERATINIZATION	Epidermolytic hyperkeratosis is a hereditary skin disorder characterized by blistering and a marked thickening of the stratum corneum. In one family, affected individuals exhibited a mutation in the highly conserved carboxyl terminal of the rod domain of keratin 1. In two other families, affected individuals had mutations in the highly conserved amino terminal of the rod domain of keratin 10. Structural analysis of these mutations predicts that heterodimer formation would be unaffected, although filament assembly and elongation would be severely compromised. These data imply that an intact keratin intermediate filament network is required for the maintenance of both cellular and tissue integrity.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030; CHU VAUDOIS,HOP BEAUMONT,DEPT DERMATOL,CH-1011 LAUSANNE,SWITZERLAND	Baylor College of Medicine; Baylor College of Medicine; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Rothnagel, Joe/A-4874-2010; Hohl, Daniel M/N-7554-2016; Huber, Marcel/M-8822-2016	Rothnagel, Joe/0000-0002-6710-3165; Huber, Marcel/0000-0003-3821-2378	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMAN AB, 1970, ARCH DERMATOL, V102, P253, DOI 10.1001/archderm.102.3.253; ANTONLAMPRECHT I, 1974, ARCH DERMATOL FORSCH, V250, P207, DOI 10.1007/BF00561188; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BONIFAS JM, 1992, J INVEST DERMATOL, V98, P573; Brocq L, 1902, ANN DERMATOL SYPHIL, V4, P1; COLOUMBE PA, 1991, CELL, V66, P1301; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; EPSTEIN EH, 1992, SCIENCE, V256, P799, DOI 10.1126/science.1375393; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; FRITSCH EFJ, 1989, MOL CLONING LABORATO; FROST P, 1966, ARCH DERMATOL, V94, P113, DOI 10.1001/archderm.94.2.113; FROST P, 1966, J INVEST DERMATOL, V47, P561, DOI 10.1038/jid.1966.185; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GEISLER N, 1982, NATURE, V296, P448, DOI 10.1038/296448a0; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; HATZFELD M, 1991, J CELL SCI, V99, P351; HATZFELD M, 1990, J CELL BIOL, V110, P119; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEATH P, 1990, HUM GENET, V85, P669; HIRONE T, 1969, Journal of Electron Microscopy, V18, P63; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOLBROOK KA, 1983, J INVEST DERMATOL, V80, P222, DOI 10.1111/1523-1747.ep12534504; ISHIDAYAMAMOTO A, 1992, J INVEST DERMATOL, V99, P19, DOI 10.1111/1523-1747.ep12611391; JACKSON DP, 1990, J CLIN PATHOL, V43, P499, DOI 10.1136/jcp.43.6.499; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KANITAKIS J, 1987, BRIT J DERMATOL, V117, P479, DOI 10.1111/j.1365-2133.1987.tb04928.x; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P910, DOI 10.1073/pnas.89.3.910; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LAPIERE S, 1932, ANN DERMATOL SYPHIL, V3, P401; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MALI JWH, 1976, BRIT J DERMATOL, V95, P627, DOI 10.1111/j.1365-2133.1976.tb07035.x; OGAWA H, 1979, ARCH DERMATOL RES, V266, P109, DOI 10.1007/BF00694618; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1987, INT J BIOL MACROMOL, V9, P137, DOI 10.1016/0141-8130(87)90041-9; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; ROTHNAGEL JA, UNPUB; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; WILGRAM GF, 1966, ARCH DERMATOL, V94, P127, DOI 10.1001/archderm.94.2.127; WILLIAMS ML, 1988, PEDIAT DERMATOLOGY, V1, P400; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580	51	323	328	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1128	1130		10.1126/science.257.5073.1128	http://dx.doi.org/10.1126/science.257.5073.1128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380725				2022-12-24	WOS:A1992JJ88400036
J	MOHAMMADI, M; DIONNE, CA; LI, W; LI, N; SPIVAK, T; HONEGGER, AM; JAYE, M; SCHLESSINGER, J				MOHAMMADI, M; DIONNE, CA; LI, W; LI, N; SPIVAK, T; HONEGGER, AM; JAYE, M; SCHLESSINGER, J			POINT MUTATION IN FGF RECEPTOR ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS WITHOUT AFFECTING MITOGENESIS	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; FIBROBLAST GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; EGF RECEPTOR; SIGNAL TRANSDUCTION; BINDING-SITE; KINASE; EXPRESSION; ASSOCIATION	STIMULATION of growth factor receptors with tyrosine kinase activity is followed by rapid receptor dimerization, tyrosine autophosphorylation and phosphorylation of signalling molecules such as phospholipase C(gamma)(PLC-gamma) and the ras GTPase-activating protein1,2. PLC-gamma and GTPase-activating protein bind to specific tyrosine-phosphorylated regions in growth factor receptors3-9 through their src-homologous SH2 domains7,8,10,11. Growth factor-induced tyrosine phosphorylation of PLC-gamma is essential for stimulation of phosphatidylinositol hydrolysis in vitro12 and in vivo13. We have shown that a short phosphorylated peptide containing tyrosine at position 766 from a conserved region14-18 of the fibroblast growth factor (FGF) receptor is a binding site for the SH2 domain of PLC-gamma (ref. 8). Here we show that an FGF receptor point mutant in which Tyr 766 is replaced by a phenylalanine residue (Y766F) is unable to associate with and tyrosine-phosphorylate PLC-gamma or to stimulate hydrolysis of phosphatidylinositol. Nevertheless, the Y766F FGF receptor mutant can be autophosphorylated, and can phosphorylate several cellular proteins and stimulate DNA synthesis. Our data show that phosphorylation of the conserved Tyr 766 of the FGF receptor is essential for phosphorylation of PLC-gamma and for hydrolysis of phosphatidylinositol, but that elimination of this hydrolysis does not affect FGF-induced mitogenesis.	RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426		MOHAMMADI, M (corresponding author), NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016, USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Honegger, Annemarie/0000-0002-3378-3967				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; LEE PL, 1989, SCIENCE, V245, P5760; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PATERNO GD, 1989, DEVELOPMENT, V106, P79; RUTA M, 1988, ONCOGENE, V3, P9; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SUTZLMAN L, 1991, MOL CELL BIOL, V11, P2018; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568	34	393	408	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					681	684		10.1038/358681a0	http://dx.doi.org/10.1038/358681a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379698				2022-12-24	WOS:A1992JJ88200058
J	PEETERS, M; GERSHYDAMET, GM; FRANSEN, K; KOFFI, K; COULIBALY, M; DELAPORTE, E; PIOT, P; VANDERGROEN, G				PEETERS, M; GERSHYDAMET, GM; FRANSEN, K; KOFFI, K; COULIBALY, M; DELAPORTE, E; PIOT, P; VANDERGROEN, G			VIROLOGICAL AND POLYMERASE CHAIN-REACTION STUDIES OF HIV-1 HIV-2 DUAL INFECTION IN COTE-DIVOIRE	LANCET			English	Note							IVORY-COAST; ABIDJAN; AIDS	Dual serological reactivity to the human immunodeficiency virus (HIV) types 1 and 2 is common in Cote d'Ivoire. To assess whether dual infection is the reason for dual seropositivity we sought HIV-1 and HIV-2 proviral DNA in primary uncultured peripheral blood mononuclear cells from selected seropositive patients in Cote d'Ivoire with the polymerase chain reaction (PCR). PCR on primary lymphocytes in 36 dually seropositive samples revealed the presence of both HIV-1 and HIV-2 proviral DNA in 12 cases and the presence of HIV-1 only in 24 cases. In 18 of these 36 samples a virus was isolated and identified by PCR. HIV-1 was isolated from the 9 specimens with only HIV-1 proviral DNA in the primary lymphocytes. Among dually PCR-positive samples, 2 viral isolates reacted with both HIV-1 and HIV-2 primers; and only HIV-2 (n = 1) or HIV-1 (n = 6) strains were isolated from the other samples. The findings show that surveys based on serology may overestimate the prevalence of mixed infections in areas where both HIV-1 and HIV-2 occur.	INST PASTEUR,ABIDJAN,COTE IVOIRE; INST MED & EPIDEMIOL AFRICAINES,INSERM,U13,PARIS,FRANCE; CHU TREICHVILLE,ABIDJAN,COTE IVOIRE	Institut National de la Sante et de la Recherche Medicale (Inserm)	PEETERS, M (corresponding author), INST TROP MED PRINCE LEOPOLD,WHO,COLLABORATING CTR AIDS,NATL ST 455,B-2000 ANTWERP,BELGIUM.		Delaporte, Eric/J-5397-2018	Delaporte, Eric/0000-0002-1822-9853				DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1989, LANCET, V2, P408; EVANS LA, 1988, LANCET, V2, P1389; LEONARD G, 1991, 6TH INT C AIDS AFR D; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEPIN JM, 1991, 7 INT C AIDS FLOR; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RAYFIELD M, 1991, 6TH INT C AIDS DAK	9	65	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					339	340		10.1016/0140-6736(92)91407-Y	http://dx.doi.org/10.1016/0140-6736(92)91407-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353807				2022-12-24	WOS:A1992JH12500006
J	HESTRIN, S				HESTRIN, S			DEVELOPMENTAL REGULATION OF NMDA RECEPTOR-MEDIATED SYNAPTIC CURRENTS AT A CENTRAL SYNAPSE	NATURE			English	Article							SUPERIOR COLLICULUS; HIPPOCAMPAL SLICES; VISUAL-CORTEX; TIME COURSE; NEURONS; RAT	THE central nervous system has extraordinary plasticity in early life. This is thought to involve N-methyl-D-aspartate (NMDA) receptors 1 which, along with the non-NMDA receptors, mediate fast excitatory synaptic transmission 2. Although NMDA receptors may be transiently enhanced early in life 3-6, it has not been possible to demonstrate directly a functional change in the NMDA receptor-mediated synaptic response because of the voltage-dependence of the NMDA conductance and the overlapping inhibitory synaptic conductances. Here I report that the duration of evoked NMDA-receptor-mediated excitatory postsynaptic currents (e.p.s.cs) in the superior colliculus is several times longer at early developmental stages compared to that measured in older animals. In contrast, the amplitude of NMDA-receptor-mediated miniature e.p.s.cs does not change during development. The kinetic response of excised membrane patches to a brief activation of NMDA receptors is similar to that of the NMDA e.p.s.c, which suggests that the time course of the NMDA e.p.s.c. in the superior colliculus reflects slow NMDA channel properties as in the hippocampus 7-9. Therefore, these data indicate that the molecular properties of NMDA receptors are developmentally regulated and thus may be controlling the ability of synapses to change in early life.			HESTRIN, S (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.		Hestrin, Shaul/F-4410-2010					BENARI Y, 1988, NEUROSCI LETT, V94, P88, DOI 10.1016/0304-3940(88)90275-3; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FISCHBACH GD, 1980, J PHYSIOL-LONDON, V303, P125, DOI 10.1113/jphysiol.1980.sp013275; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; GIBB AJ, 1991, P ROY SOC B-BIOL SCI, V243, P39, DOI 10.1098/rspb.1991.0007; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KLECKNER NW, 1991, MOL BRAIN RES, V11, P151; KONNERTH A, 1990, EXP BRAIN RES, V81, P209; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LOTURCO JJ, 1991, J NEUROSCI, V11, P792; LUND RD, 1972, BRAIN RES, V42, P1, DOI 10.1016/0006-8993(72)90038-8; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MIYAMOTO T, 1990, BRAIN RES, V518, P166, DOI 10.1016/0006-8993(90)90968-H; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0	26	458	463	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					686	689		10.1038/357686a0	http://dx.doi.org/10.1038/357686a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377360				2022-12-24	WOS:A1992JA43000070
J	HOLM, K; MAKI, M; SAVILAHTI, E; LIPSANEN, V; LAIPPALA, P; KOSKIMIES, S				HOLM, K; MAKI, M; SAVILAHTI, E; LIPSANEN, V; LAIPPALA, P; KOSKIMIES, S			INTRAEPITHELIAL GAMMA-DELTA-T-CELL-RECEPTOR LYMPHOCYTES AND GENETIC SUSCEPTIBILITY TO CELIAC-DISEASE	LANCET			English	Article							CELIAC-DISEASE; HETERODIMER	Although the proportion of gamma-delta T-cell-receptor (TCR)-bearing intraepithelial lymphocytes is increased in the jejunum of patients with active coeliac disease, an abnormality thought to be specific among those with gluten-sensitive enteropathy, the factors influencing gamma-delta TCR expression remain uncertain. We examined the relation between genetic factors associated with coeliac disease and intraepithelial gamma-delta T lymphocyte distribution in both coeliac patients and their healthy first-degree relatives. 41% (45/109) of healthy relatives had an increased density of gamma-delta T cells in their mucosa and 66% had an increased density of alpha-beta T cells. By contrast with alpha-beta T cells, the density of gamma-delta cells was significantly associated with genetic markers for coeliac disease susceptiblity (DR3, DQA, and DQB). We also found a dose effect of DQA and DQB genes on the number of intraepithelial gamma-delta T cells. An increased density of gamma-delta T cells in normal jejunal mucosa of a healthy individual with appropriate genetic determinants might be necessary for the development of the typical lesions of coeliac disease. Routine jejunal histological studies should include gamma-delta T-cell counts, thus allowing early detection of coeliac disease latency.	UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,BIOMETRY UNIT,TAMPERE,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	University of Helsinki; Tampere University	HOLM, K (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,TEISKONTIE 35,POB 607,SF-33101 TAMPERE,FINLAND.							BAND H, 1987, SCIENCE, V238, P6824; BOSNES V, 1990, EUR J IMMUNOL, V20, P1429, DOI 10.1002/eji.1830200704; CUENOD B, 1990, GASTROENTEROLOGY, V99, P1037, DOI 10.1016/0016-5085(90)90624-A; FAURE F, 1988, J IMMUNOL, V141, P3357; HALL MA, 1991, GUT, V32, P487, DOI 10.1136/gut.32.5.487; HALSTENSEN TS, 1989, SCAND J IMMUNOL, V30, P665, DOI 10.1111/j.1365-3083.1989.tb02474.x; KOSKIMIES S, 1991, COELIAC DISEASE 40 Y, P10; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, 1991, LANCET, V337, P763, DOI 10.1016/0140-6736(91)91375-5; MAKI M, 1991, LANCET, V338, P1350, DOI 10.1016/0140-6736(91)92234-S; MAKI M, 1991, GUT, V32, P1412, DOI 10.1136/gut.32.11.1412; MAKI M, 1988, LANCET, V1, P479; PASTERNACK A, 1990, CLIN NEPHROL, V34, P56; RAJASEKAR R, 1990, P NATL ACAD SCI USA, V87, P1767, DOI 10.1073/pnas.87.5.1767; SAVILAHTI E, 1990, PEDIATR RES, V28, P579, DOI 10.1203/00006450-199012000-00005; SAVILAHTI E, 1992, GUT, V33, P206, DOI 10.1136/gut.33.2.206; SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728; SPURKLAND A, 1990, HUM IMMUNOL, V29, P157, DOI 10.1016/0198-8859(90)90111-2; TRIEBEL F, 1989, IMMUNOL TODAY, V10, P186, DOI 10.1016/0167-5699(89)90321-6; WRAY D, 1981, DIGEST DIS SCI, V26, P737, DOI 10.1007/BF01316864	20	114	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1500	1503		10.1016/0140-6736(92)91262-7	http://dx.doi.org/10.1016/0140-6736(92)91262-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351185				2022-12-24	WOS:A1992HZ17500003
J	BUCHWALD, H				BUCHWALD, H			CHOLESTEROL INHIBITION, CANCER, AND CHEMOTHERAPY	LANCET			English	Note							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; PLASMA-CHOLESTEROL; MORTALITY; SUPPRESSION; MEVALONATE; LOVASTATIN; MORBIDITY; MEVINOLIN; PROGRAM	An important feature of malignant transformation is loss of the cholesterol feedback inhibition mechanism that regulates cholesterol synthesis. Cancer cells seem to require an increase in the concentrations of cholesterol and of cholesterol precursors. Therefore, a reasonable assumption is that prevention of tumour-cell growth can be achieved by restricting either cholesterol availability or cholesterol synthesis. In-vivo and cell-culture experiments have shown that lowering the plasma cholesterol concentration or intervening in the mevalonate pathway with 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitors decreases tumour growth. Currently prescribed doses of HMG-CoA reductase inhibitors given orally or continuously by an implantable infusion pump could achieve tumour therapeutic tissue concentrations of these agents. My hypothesis is that cholesterol inhibition can inhibit tumour cell growth, can act as an adjuvant to cancer chemotherapy, and, possibly, can prevent carcinogenesis.			BUCHWALD, H (corresponding author), UNIV MINNESOTA,DEPT SURG,BOX 290 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.							ADDLEMAN W, 1972, NEW ENGL J MED, V287, P1047; BLAU L, 1978, J BIOL CHEM, V253, P8366; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUCHWALD H, 1989, INTERN MED SPECIALIS, V10, P182; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen H W, 1978, Prog Exp Tumor Res, V22, P275; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166; FAIRBANKS KP, 1986, J CELL PHYSIOL, V127, P216, DOI 10.1002/jcp.1041270205; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORE IRENE YOUHOTSKY, 1962, BIOCHEM JOUR, V84, P93; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; KORT WJ, 1989, CLIN EXP METASTAS, V7, P517, DOI 10.1007/BF01753812; LITTMAN M. L., 1966, CANCER CHEMOTHERAP REP, V50, P25; MACDONALD JS, 1988, AM J CARDIOL, V62, pJ16, DOI 10.1016/0002-9149(88)90003-3; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MORRIS PJ, 1992, EFFECT LOVASTATIN AD; MORRIS T J, 1991, Surgical Forum (Chicago), V42, P452; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROSE G, 1980, LANCET, V1, P523; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHNEIDER PD, 1980, SURGERY, V87, P409; SIPERSTEIN MD, 1964, CANCER RES, V24, P1108; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VATTEN LJ, 1990, CANCER RES, V50, P2341; WINGARD DL, 1984, J CHRON DIS, V37, P401, DOI 10.1016/0021-9681(84)90107-3	27	118	120	2	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1154	1156		10.1016/0140-6736(92)90744-N	http://dx.doi.org/10.1016/0140-6736(92)90744-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349377				2022-12-24	WOS:A1992HT23600014
J	PHILLIPS, AN; ELFORD, J; SABIN, C; BOFILL, M; JANOSSY, G; LEE, CA				PHILLIPS, AN; ELFORD, J; SABIN, C; BOFILL, M; JANOSSY, G; LEE, CA			IMMUNODEFICIENCY AND THE RISK OF DEATH IN HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOPHILIC COHORT; NATURAL-HISTORY; VIRUS-INFECTION; AIDS; COUNTS; PROGRESSION; PREDICTORS; MARKERS; TYPE-1; FOLLOW	Objective.-To describe the rate of development of immunodeficiency in human immunodeficiency virus (HIV) infection and to relate this to the risk of death. Design.-Inception cohort followed up for up to 12 years from HIV seroconversion until January 1, 1992. Setting.-A regional hemophilia center based in a major teaching hospital. Patients.-All 111 patients with hemophilia who seroconverted to HIV-1 between 1979 and 1985 were registered at the center. Patients have been closely followed up clinically and immunologically. Outcome Measures.-Development of immunodeficiency, defined by a CD4 lymphocyte count falling beneath 0.20 and 0.05 x 10(9)/L, and death. Results.-Kaplan-Meier estimates suggest that almost half (46%; 95% confidence interval [CI], 26% to 66%) of patients alive 12 years after seroconversion will have a CD4 lymphocyte count that has remained above 0.05 x 10(9)/L. Thirty-five percent (95% CI, 22% to 48%) remain above 0.20 x 10(9)/L. Thirty-seven patients died of HIV-related causes, and there was a 52% probability (95% CI, 35% to 69%) of HIV-related mortality by 12 years from seroconversion. Mortality risk was closely associated with severe immunodeficiency. There was only a 15% chance (95% CI, 6% to 25%) of HIV-related death occurring before a CD4 count of below 0.05 x 10(9)/L had been reached. There was an average of one HIV-related death per 96.7 patient-years of observation before the CD4 count had fallen below 0.05 x 10(9)/L, as compared with one death per 2.5 patient-years of observation after the CD4 count had fallen below this level (P<.0001). Conclusions.-In patients with HIV infection who are closely followed up, the risk of death is low before the CD4 lymphocyte count has fallen to 0.05 x 10(9)/L, a count many patients remain above up to 12 years after seroconversion.	UNIV LONDON ROYAL FREE HOSP,DEPT PUBL HLTH & PRIMARY CARE,LONDON,ENGLAND; UNIV LONDON ROYAL FREE HOSP,DEPT IMMUNOL,LONDON,ENGLAND; UNIV LONDON ROYAL FREE HOSP,CTR HAEMOPHILIA,LONDON,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London	PHILLIPS, AN (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				CAMPANA D, 1987, J IMMUNOL, V138, P648; ESTEBAN JI, 1990, LANCET, V335, P1419; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; EYSTER ME, 1992, 7TH INT C AIDS AMST; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; JANOSSY G, 1985, CLIN EXP IMMUNOL, V59, P257; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LANGHON BE, 1991, J INFECT DIS, V164, P244; LEE C, 1992, BRIT J HAEMATOL, V81, P133, DOI 10.1111/j.1365-2141.1992.tb08191.x; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PHILLIPS AN, 1991, LANCET, V337, P389; PHILLIPS AN, 1992, J ACQ IMMUN DEF SYND, V5, P148; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; TEDDER RS, 1991, BRIT MED J, V302, P1299, DOI 10.1136/bmj.302.6788.1299; WAYNE WF, 1988, CYTOMETRY, V3, P23; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; [No title captured]	25	70	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2662	2666		10.1001/jama.268.19.2662	http://dx.doi.org/10.1001/jama.268.19.2662			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX680	1359163				2022-12-24	WOS:A1992JX68000027
J	[Anonymous]				[Anonymous]			POLIOVACCINE AND AIDS ORIGIN LINK VERY UNLIKELY	LANCET			English	Editorial Material																		CURTIS T, 1992, ROLLING STONE M 0319; KYLE WS, 1992, LANCET, V339, P600, DOI 10.1016/0140-6736(92)90876-5	2	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1992	340	8827					1090	1091						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357471				2022-12-24	WOS:A1992JV77500017
J	SIBLEY, LD; BOOTHROYD, JC				SIBLEY, LD; BOOTHROYD, JC			VIRULENT-STRAINS OF TOXOPLASMA-GONDII COMPRISE A SINGLE CLONAL LINEAGE	NATURE			English	Article							CONGENITAL TOXOPLASMOSIS; DIAGNOSIS; ENCEPHALITIS	THE protozoan Toxoplasma gondii is a prevalent parasite in wild and domestic animals worldwide, being transmitted through the food chain by carnivorous feeding and scavenging1. Toxoplasma normally divides asexually to yield a haploid form that can infect virtually any vertebrate but it also has a well defined sexual cycle that occurs exclusively in cats1. Toxoplasma has become important as an often fatal opportunistic pathogen in patients with AIDS2,3, although the 15-85% of adult human populations that are chronically infected with T. gondii are typically asymptomatic4-7. Infections in immunocompromised hosts have variable outcomes. For example, only 30 to 50% of AIDS patients that are chronically infected with the parasite develop toxoplasmic encephalitis2,3 and only about half of acute maternal infections result in congenital disease of the newborn8. T. gondii strains differ in their virulence in animals1, but the extent to which different strains are related has not been determined. Here we analyse 28 strains from a variety of hosts on five continents and find that the ten virulent strains have an essentially identical genotype, whereas the nonvirulent strains are moderately polymorphic. These data strongly suggest that virulent strains of T. gondii originated from a single lineage which has remained genetically homogeneous despite being globally widespread, and despite the ability of this organism to reproduce sexually.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University			Sibley, L. David/C-4616-2008	Boothroyd, John C./0000-0001-9719-745X				APT WB, 1985, PARASITOL TODAY, V1, P44; BOOTHROYD JC, IN PRESS NATO ASI SE; BUELOW R, 1991, J IMMUNOL, V147, P3496; BURG JL, 1988, J IMMUNOL, V141, P3584; DANNEMANN BR, 1989, HOSP PRACT, V24, P139; DARDE ML, 1988, AM J TROP MED HYG, V39, P551, DOI 10.4269/ajtmh.1988.39.551; DARDE ML, IN PRESS J PARASIT; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; Dubey J.P., 1977, P101; FELDMAN HA, 1965, AM J EPIDEMIOL, V81, P385, DOI 10.1093/oxfordjournals.aje.a120524; GROVER CM, 1990, J CLIN MICROBIOL, V28, P2297, DOI 10.1128/JCM.28.10.2297-2301.1990; Hughes H.P.A., 1985, Parasitology Today, V1, P41, DOI 10.1016/0169-4758(85)90112-7; KASPER LH, 1985, J CLIN INVEST, V75, P1570, DOI 10.1172/JCI111862; KIEHN TE, 1985, J CLIN MICROBIOL, V21, P168, DOI 10.1128/JCM.21.2.168-173.1985; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; PFEFFERKORN ER, 1977, J PARASITOL, V63, P158, DOI 10.2307/3280129; Sabin AB, 1941, J AMER MED ASSOC, V116, P801, DOI 10.1001/jama.1941.02820090001001; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SELANDER RK, 1980, SCIENCE, V210, P545, DOI 10.1126/science.6999623; SIBLEY LD, 1992, MOL BIOCHEM PARASIT, V51, P291, DOI 10.1016/0166-6851(92)90079-Y; SIBLEY LD, IN PRESS GENETICS; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5	24	563	605	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					82	85		10.1038/359082a0	http://dx.doi.org/10.1038/359082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1355855				2022-12-24	WOS:A1992JL66200060
J	VANDERWINDEN, JM; MAILLEUX, P; SCHIFFMANN, SN; VANDERHAEGHEN, JJ; DELAET, MH				VANDERWINDEN, JM; MAILLEUX, P; SCHIFFMANN, SN; VANDERHAEGHEN, JJ; DELAET, MH			NITRIC-OXIDE SYNTHASE ACTIVITY IN INFANTILE HYPERTROPHIC PYLORIC-STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURONAL NADPH-DIAPHORASE; INHIBITORY TRANSMISSION; NERVOUS-SYSTEM; 2ND MESSENGER; GUINEA-PIG; MUSCLE; INVOLVEMENT; PEPTIDE; BRAIN; NO	Background. Hypertrophic pyloric stenosis is a common infantile disorder characterized by enlarged pyloric musculature and gastric-outlet obstruction. Its physiopathologic mechanism is not known, but a defect in pyloric relaxation (pylorospasm) has been postulated. Nitric oxide is a mediator of relaxation in the mammalian digestive tract, raising the possibility that pylorospasm could be caused by a defect in nitric oxide production. Since neuronal nitric oxide synthase and NADPH diaphorase are identical, we used the NADPH diaphorase histochemical reaction to study the distribution of nitric oxide synthase in pyloric tissue from patients with infantile hypertrophic pyloric stenosis. Methods. We studied pyloric tissue from nine infants with infantile hypertrophic pyloric stenosis and seven control infants and children. Cryostat sections were processed for NADPH diaphorase histochemical analysis. A polyclonal tau antiserum was used to identify the enteric nervous system by immunohistochemical methods. Results. NADPH diaphorase activity was restricted to the enteric nervous system and blood vessels. In the pyloric tissues from the control patients, intense diaphorase activity was present in the nerve fibers of the circular musculature, in the neurons and nerve bundles of the myenteric plexus, and in some nerve fibers of the longitudinal musculature. In the pyloric tissues from patients with infantile hypertrophic pyloric stenosis, the enteric nerve fibers in the hypertrophied circular musculature were enlarged and distorted and did not contain diaphorase activity, whereas the activity in the myenteric plexus and the longitudinal musculature was preserved. Conclusions. We suggest that a lack of nitric oxide synthase in pyloric tissue is responsible for pylorospasm in infantile hypertrophic pyloric stenosis.	ERASME ACAD HOSP,DEPT SURG,BRUSSELS,BELGIUM; ERASME ACAD HOSP,NEUROPATHOL & NEUROPEPTIDE RES LAB,BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,CHILDRENS HOSP,DEPT PEDIAT SURG,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,FAC MED,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles				Schiffmann, Serge/0000-0002-0118-9816				BRANCHEK TA, 1989, J COMP NEUROL, V285, P262, DOI 10.1002/cne.902850208; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; COLLIER J, 1989, TRENDS PHARMACOL SCI, V10, P427, DOI 10.1016/S0165-6147(89)80001-X; CROSSIN KL, 1991, TRENDS BIOCHEM SCI, V16, P81, DOI 10.1016/0968-0004(91)90036-U; DALZIEL HH, 1991, AM J PHYSIOL, V260, pG789, DOI 10.1152/ajpgi.1991.260.5.G789; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DIELER R, 1990, ACTA NEUROPATHOL, V80, P295, DOI 10.1007/BF00294648; DIELER R, 1989, ACTA NEUROPATHOL, V78, P649, DOI 10.1007/BF00691292; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GUSTAFSSON LE, 1990, BIOCHEM BIOPH RES CO, V173, P106, DOI 10.1016/S0006-291X(05)81028-9; HAYES MA, 1957, INT ABSTR SURG, V104, P105; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HOPE BT, 1989, J HISTOCHEM CYTOCHEM, V37, P653, DOI 10.1177/37.5.2703701; LEHMANN W, 1931, Z KINDERHEILKD, V50, P691; LI CG, 1990, EUR J PHARMACOL, V191, P303; LYNN HB, 1960, ARCH SURG-CHICAGO, V81, P453; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHUTTLEWORTH CWR, 1991, NEUROSCI LETT, V130, P77, DOI 10.1016/0304-3940(91)90231-H; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; Tam P K, 1985, Ann Acad Med Singap, V14, P523; TAM PKH, 1990, GASTROENTEROLOGY, V99, P1841, DOI 10.1016/0016-5085(90)90499-Q; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; UKABIALA O, 1987, J PEDIATR SURG, V22, P200, DOI 10.1016/S0022-3468(87)80326-3; WATTCHOW DA, 1987, GASTROENTEROLOGY, V92, P443, DOI 10.1016/0016-5085(87)90140-5; YAMASHIRO Y, 1981, EUR J PEDIATR, V136, P187, DOI 10.1007/BF00441922	30	284	290	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					511	515		10.1056/NEJM199208203270802	http://dx.doi.org/10.1056/NEJM199208203270802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1378938				2022-12-24	WOS:A1992JJ45700002
J	ALDER, J; LU, B; VALTORTA, F; GREENGARD, P; POO, MM				ALDER, J; LU, B; VALTORTA, F; GREENGARD, P; POO, MM			CALCIUM-DEPENDENT TRANSMITTER SECRETION RECONSTITUTED IN XENOPUS OOCYTES - REQUIREMENT FOR SYNAPTOPHYSIN	SCIENCE			English	Article							SYNAPTIC VESICLE PROTEIN; MEMBRANE-PROTEIN; MESSENGER-RNA; NEUROMUSCULAR-JUNCTION; LAEVIS OOCYTES; AMINO-ACIDS; RAT-BRAIN; GLUTAMINE; RELEASE; NEUROTRANSMITTER	Calcium-dependent glutamate secretion was reconstituted in Xenopus oocytes by injecting the oocyte with total rat cerebellar messenger RNA (mRNA). Co-injection of total mRNA with antisense oligonucleotides to synaptophysin message decreased the expression of synaptophysin in the oocyte and reduced the calcium-dependent secretion. A similar effect on secretion was observed for oocytes injected with total mRNA together with an antibody to rat synaptophysin. These results indicate that synaptophysin is necessary for transmitter secretion and that the oocyte expression system may be useful for dissecting the molecular events associated with the secretory process.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; UNIV MILAN,NATL RES COUNCIL,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20129 MILAN,ITALY	Columbia University; Rockefeller University; University of Milan			Flavia, Valtorta/F-3450-2012; Lu, Bai/A-4018-2012	Flavia, Valtorta/0000-0001-9556-4746; Alder, Janet/0000-0002-5694-4946; Lu, Bai/0000-0001-5418-9759	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 39327] Funding Source: Medline; NINDS NIH HHS [NS 22764] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; BLAKELY RD, 1991, J NEUROCHEM, V56, P860, DOI 10.1111/j.1471-4159.1991.tb02002.x; BRADFORD HF, 1978, J NEUROCHEM, V30, P1453, DOI 10.1111/j.1471-4159.1978.tb10477.x; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CAVELLI A, 1991, EMBO J, V10, P1671; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P10507, DOI 10.1093/nar/15.24.10507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN D, 1990, BRAIN RES, V509, P1, DOI 10.1016/0006-8993(90)90301-Q; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DECAMILLI P, 1991, EMBO J, V10, P1275; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSON PA, 1989, J BIOL CHEM, V264, P1258; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; JOHNSTON PA, 1990, J BIOL CHEM, V264, P7849; KNAUS P, 1990, FEBS LETT, V261, P358, DOI 10.1016/0014-5793(90)80591-6; KUSHNER L, 1989, METHODS NEUROSCIENCE, V1, P3; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MCMAHON HT, 1990, J NEUROCHEM, V54, P373, DOI 10.1111/j.1471-4159.1990.tb01883.x; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SHUTTLEWORTH J, 1988, GENE, V72, P267, DOI 10.1016/0378-1119(88)90152-7; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SZERB JC, 1985, J NEUROCHEM, V44, P1724, DOI 10.1111/j.1471-4159.1985.tb07160.x; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; VALTORTA F, 1988, J CELL BIOL, V107, P2717, DOI 10.1083/jcb.107.6.2717; VALTORTA F, UNPUB; WARD HK, 1983, J NEUROCHEM, V40, P855, DOI 10.1111/j.1471-4159.1983.tb08058.x; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YOUNG AB, 1974, BRAIN RES, V73, P1, DOI 10.1016/0006-8993(74)91002-6; 1990, PROMEGA PROTOCOLS AP, P116	42	123	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					657	661		10.1126/science.1353905	http://dx.doi.org/10.1126/science.1353905			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1353905				2022-12-24	WOS:A1992JF85200033
J	CHAN, HC; NELSON, DJ				CHAN, HC; NELSON, DJ			CHLORIDE-DEPENDENT CATION CONDUCTANCE ACTIVATED DURING CELLULAR SHRINKAGE	SCIENCE			English	Article							EPITHELIAL-CELLS; CHANNEL	A chloride (Cl-)-dependent, nonselective cation conductance was activated during cellular shrinkage and inhibited during cellular swelling or by extracellular gadolinium. The shrinking-induced, nonselective cation conductance and the swelling-induced anion conductance appear to function in the regulation of cell volume in airway epithelia. The shrinking-induced cation conductance had an unusual dependence on Cl-: partial replacement of extracellular Cl- with aspartate reduced the magnitude of the shrinking-enhanced current without accompanying changes in the reversal potential. The Cl- dependence of the nonselective cation conductance could provide a mechanism that tightly regulates Cl- secretion and sodium reabsorption in cells under osmotic stress.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637	University of Chicago; University of Chicago			Chan, Hsiao Chang/E-1507-2016					BUTT AG, 1990, AM J PHYSIOL, V258, P630; Chamberlin ME, 1989, AM J PHYSIOL, Vl257, P159; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543; GRAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1029, P33, DOI 10.1016/0005-2736(90)90433-O; JORISSEN M, 1990, PFLUG ARCH EUR J PHY, V415, P617, DOI 10.1007/BF02583515; KROUSE ME, 1989, AM J PHYSIOL, V257, P129; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; ROTHSTEIN A, 1990, AM J PHYSIOL, V258, P827; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; SOLC CK, 1991, AM J PHYSIOL, V261, P658; WONG MMY, 1991, SCIENCE, V254, P1014, DOI 10.1126/science.1948071; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	13	64	64	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					669	671		10.1126/science.1379742	http://dx.doi.org/10.1126/science.1379742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1379742				2022-12-24	WOS:A1992JF85200036
J	BURNETT, AL; LOWENSTEIN, CJ; BREDT, DS; CHANG, TSK; SNYDER, SH				BURNETT, AL; LOWENSTEIN, CJ; BREDT, DS; CHANG, TSK; SNYDER, SH			NITRIC-OXIDE - A PHYSIOLOGICAL MEDIATOR OF PENILE ERECTION	SCIENCE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; MONOMETHYL-L-ARGININE; RAT ANOCOCCYGEUS MUSCLE; CORPUS CAVERNOSUM; SMOOTH-MUSCLE; RELAXING FACTOR; RELAXATION; NEUROTRANSMITTER; STIMULATION; LOCALIZATION	Nitric oxide (NO) is a cytotoxic agent of macrophages, a messenger molecule of neurons, and a vasodilator produced by endothelial cells. NO synthase, the synthetic enzyme for NO, was localized to rat penile neurons innervating the corpora cavernosa and to neuronal plexuses in the adventitial layer of penile arteries. Small doses of NO synthase inhibitors abolished electrophysiologically induced penile erections. These results establish NO as a physiologic mediator of erectile function.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Bredt, David/J-4872-2012	Lowenstein, Charles/0000-0003-0485-7514	NIDA NIH HHS [DA-00266] Funding Source: Medline; NIDDK NIH HHS [DK-19300] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENSON GS, 1983, WORLD J UROL, V1, P209, DOI 10.1007/BF00326804; BLANCO R, 1988, AM J PHYSIOL, V254, P468; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; COCKS TM, 1990, N-S ARCH PHARMACOL, V341, P364; DAIL WG, 1989, ANAT RECORD, V224, P94, DOI 10.1002/ar.1092240112; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; EMOND AM, 1980, ARCH INTERN MED, V140, P1434, DOI 10.1001/archinte.140.11.1434; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE J S, 1989, British Journal of Pharmacology, V97, p453P; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V143, P299, DOI 10.1111/j.1748-1716.1991.tb09236.x; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V141, P441, DOI 10.1111/j.1748-1716.1991.tb09103.x; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JUENEMANN KP, 1987, J UROLOGY, V138, P871, DOI 10.1016/S0022-5347(17)43406-9; KIELY EA, 1989, BRIT J UROL, V64, P191, DOI 10.1111/j.1464-410X.1989.tb05986.x; KIM N, 1991, J CLIN INVEST, V88, P112, DOI 10.1172/JCI115266; LI CG, 1990, EUR J PHARMACOL, V191, P303; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NOZAKI K, IN PRESS J CEREB BLO; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PALOMAR JM, 1980, J UROLOGY, V123, P680, DOI 10.1016/S0022-5347(17)56090-5; PICKARD RS, 1991, BRIT J PHARMACOL, V104, P755, DOI 10.1111/j.1476-5381.1991.tb12500.x; POLAK JM, 1981, LANCET, V2, P217; QUINLAN DM, 1989, J UROLOGY, V141, P656, DOI 10.1016/S0022-5347(17)40926-8; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; ROY JB, 1990, J UROLOGY, V143, P302, DOI 10.1016/S0022-5347(17)39939-1; SJOSTRAND NO, 1990, ACTA PHYSIOL SCAND, V140, P297, DOI 10.1111/j.1748-1716.1990.tb09002.x; STEERS WD, 1984, J UROLOGY, V132, P1048, DOI 10.1016/S0022-5347(17)49997-6; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WILLIS EA, 1983, LIFE SCI, V33, P383, DOI 10.1016/S0024-3205(83)80013-7	42	1010	1042	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					401	403		10.1126/science.1378650	http://dx.doi.org/10.1126/science.1378650			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1378650				2022-12-24	WOS:A1992JD67400038
J	WARKENTIN, TE; MOORE, JC; MORGAN, DG				WARKENTIN, TE; MOORE, JC; MORGAN, DG			AORTIC-STENOSIS AND BLEEDING GASTROINTESTINAL ANGIODYSPLASIA - IS ACQUIRED VONWILLEBRANDS DISEASE THE LINK	LANCET			English	Article							INDUCED PLATELET-AGGREGATION; VASCULAR ECTASIAS; PLASMA; MULTIMERS; DEFECTS	An association between aortic stenosis and haemorrhage from gastrointestinal angiodysplasia has been recognised for many years, but no explanation for this link has been found. Remarkably, aortic valve replacement, rather than bowel resection, corrects the bleeding. Aortic stenosis can be complicated by acquired von Willebrand's disease type II(A) (vWD-II(A)), which is corrected after valve replacement, and gastrointestinal angiodysplasia is a common site of bleeding in older patients with acquired or congenital vWD. Could the stenotic aortic valve lead to an acquired, reversible deficiency of the largest multimers of plasma von Willebrand factor (equivalent to vWD-II(A)) and thus explain the association with gastrointestinal haemorrhage?	HAMILTON CIVIC HOSP, HENDERSON DIV, DEPT MED, HAMILTON, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University	WARKENTIN, TE (corresponding author), HAMILTON CIVIC HOSP, DIV GEN, DEPT LAB MED, 237 BARTON ST E, HAMILTON L8L 2X2, ONTARIO, CANADA.							ALAM M, 1991, AM HEART J, V121, P608, DOI 10.1016/0002-8703(91)90739-5; BANERJEE AK, 1990, BRIT J CLIN PRACT, V44, P326; BOLEY SJ, 1977, GASTROENTEROLOGY, V72, P650; CAPPELL MS, 1986, ANN INTERN MED, V105, P54, DOI 10.7326/0003-4819-105-1-54; GILL JC, 1986, BLOOD, V67, P758; GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415; GRALNICK HR, 1988, AM J MED, V85, P806; GREENSTEIN RJ, 1986, AM J SURG, V151, P347, DOI 10.1016/0002-9610(86)90465-4; HEYDE EC, 1958, NEW ENGL J MED, V259, P196; KING RM, 1987, ANN THORAC SURG, V44, P514, DOI 10.1016/S0003-4975(10)62112-1; MARCUARD SP, 1988, J CLIN GASTROENTEROL, V10, P482, DOI 10.1097/00004836-198810000-00003; MATHUSVLIEGEN EMH, 1989, INT J COLORECTAL DIS, V4, P20, DOI 10.1007/BF01648545; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; OBRIEN JR, 1990, LANCET, V335, P711, DOI 10.1016/0140-6736(90)90815-M; RAMSAY DM, 1976, LANCET, V2, P275; ROSBOROUGH TK, 1978, AM J MED, V65, P96, DOI 10.1016/0002-9343(78)90698-8; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; STEWART AK, 1990, POSTGRAD MED J, V66, P560, DOI 10.1136/pgmj.66.777.560; WEINSTEIN M, 1988, BLOOD, V71, P1648, DOI 10.1182/blood.V71.6.1648.1648; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WOODLOCK TJ, 1988, AM J HEMATOL, V27, P125, DOI 10.1002/ajh.2830270211	21	208	217	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1992	340	8810					35	37		10.1016/0140-6736(92)92434-H	http://dx.doi.org/10.1016/0140-6736(92)92434-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351610				2022-12-24	WOS:A1992JC35400014
J	WLODAWER, A				WLODAWER, A			ANOTHER PIECE OF THE HIV PUZZLE FALLS INTO PLACE	SCIENCE			English	Editorial Material							PROTEASE				WLODAWER, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MACROMOLEC STRUCT LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.							APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0	7	5	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1766	1766		10.1126/science.1377402	http://dx.doi.org/10.1126/science.1377402			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1377402				2022-12-24	WOS:A1992JA43400024
J	REGNERY, RL; OLSON, JG; PERKINS, BA; BIBB, W				REGNERY, RL; OLSON, JG; PERKINS, BA; BIBB, W			SEROLOGICAL RESPONSE TO ROCHALIMAEA-HENSELAE ANTIGEN IN SUSPECTED CAT-SCRATCH DISEASE	LANCET			English	Note							ANGIOMATOSIS; AGENT	There are no generally accepted diagnostic tests for cat-scratch disease (CSD), the cause of which is unknown. During the development of an indirect fluorescence antibody (IFA) test for detection of antibodies to "Rochalimaea henselae", sera from patients with CSD were found to have high titres to R henselae antigens. Further tests with this assay showed that 36 (88%) of 41 patients with suspected CSD had serum titres of 64 or more to R henselae antigen, that there was a low prevalence (3%) of substantial titres to R henselae in healthy controls (n = 107), and that the immune responses to R henselae antigens were specific. These data suggest that the R henselae IFA test, or other serological assays based on R henselae, may be useful for diagnosis of CSD.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	REGNERY, RL (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.							BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; KEMPER CA, 1990, AM J MED, V89, P216, DOI 10.1016/0002-9343(90)90301-S; LEBOIT PE, 1988, LANCET, V1, P960; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; TEPPERO JW, 1991, 7 INT C AIDS FLOR, P340; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	10	470	487	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1443	1445		10.1016/0140-6736(92)92032-B	http://dx.doi.org/10.1016/0140-6736(92)92032-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351130				2022-12-24	WOS:A1992HY31700005
J	CHENG, KK; DAY, NE; DUFFY, SW; LAM, TH; FOK, M; WONG, J				CHENG, KK; DAY, NE; DUFFY, SW; LAM, TH; FOK, M; WONG, J			PICKLED VEGETABLES IN THE ETIOLOGY OF ESOPHAGEAL CANCER IN HONG-KONG CHINESE	LANCET			English	Article							HIGH-RISK POPULATION; ESOPHAGEAL CANCER; PRECURSOR LESIONS; IRAN	Oesophageal cancer is common in Chinese populations, but individual-based epidemiological studies have provided little explanation. A case control study with 400 cases and 1598 controls (800 hospital and 798 general practice) was conducted among Hong Kong Chinese. In multivariate analyses, statistically significant effects on risk were detected for several potentially preventable exposures with high attributable risks (ARs). These included preference for consuming drinks or soups at high temperature (AR = 14%), infrequent consumption of green leafy vegetables (AR = 15%) and citrus fruits (AR = 26%), ingestion of pickled vegetables (AR = 29%), tobacco smoking (AR = 44%), and alcohol drinking (AR = 48%). On the assumption of multiplicative risk, the combined AR due to these exposures was 89%. This is the first case control study to show an association between pickled vegetable consumption and oesophageal cancer risk. The finding considerably strengthens the evidence for carcinogenicity of N-nitroso compounds in man and helps to explain the very high risk among Chinese.	ADDENBROOKES HOSP,DEPT COMMUNITY MED,LEVEL 5,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV HONG KONG,DEPT COMMUNITY MED,HONG KONG,HONG KONG; UNIV CAMBRIDGE,DEPT COMMUNITY MED,CAMBRIDGE,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Hong Kong; University of Cambridge; MRC Biostatistics Unit; University of Hong Kong			Lam, Tai Hing/C-4317-2009	Lam, Tai Hing/0000-0002-2033-9971				BENICHOU J, 1991, STAT MED, V10, P1753, DOI 10.1002/sim.4780101113; Breslow N, 1980, STATISTICAL METHODS, V32; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CHEN J, 1987, IARC SCI PUBL, V84, P503; COOKMOZAFFARI PJ, 1979, BRIT J CANCER, V39, P293, DOI 10.1038/bjc.1979.54; DEJONG UW, 1974, INT J CANCER, V13, P291, DOI 10.1002/ijc.2910130304; LEE HP, 1988, IARC SCI PUBL, V91; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; Li M H, 1986, Nutr Cancer, V8, P63, DOI 10.1080/01635588609513877; Lu S H, 1991, IARC Sci Publ, P11; Lu S H, 1987, IARC Sci Publ, P538; LU SH, 1986, CANCER RES, V46, P1485; MARTINEZ I, 1969, J NATL CANCER I, V42, P1069; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; MUNOZ N, 1982, LANCET, V1, P876; MUNOZ N, IN PRESS CANCER EPID; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; VASSALLO A, 1985, J NATL CANCER I, V75, P1005; VICTORA CG, 1987, INT J CANCER, V39, P710, DOI 10.1002/ijc.2910390610; WAHRENDORF J, 1989, LANCET, V2, P1239, DOI 10.1016/S0140-6736(89)91850-3; YANG CS, 1980, CANCER RES, V40, P2633; Yu M C, 1991, IARC Sci Publ, P39	24	112	119	3	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1314	1318		10.1016/0140-6736(92)91960-G	http://dx.doi.org/10.1016/0140-6736(92)91960-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349991				2022-12-24	WOS:A1992HW83700003
J	LEFF, RL; LOVE, LA; MILLER, FW; GREENBERG, SJ; KLEIN, EA; DALAKAS, MC; PLOTZ, PH				LEFF, RL; LOVE, LA; MILLER, FW; GREENBERG, SJ; KLEIN, EA; DALAKAS, MC; PLOTZ, PH			VIRUSES IN IDIOPATHIC INFLAMMATORY MYOPATHIES - ABSENCE OF CANDIDATE VIRAL GENOMES IN MUSCLE	LANCET			English	Article							INCLUSION-BODY MYOSITIS; POLYMYOSITIS; DERMATOMYOSITIS; RNA; AMPLIFICATION; PICORNAVIRUS; MYOCARDITIS; POLYMERASE; RETROVIRUS; MODEL	There is indirect evidence that various viruses have aetiological roles in the idiopathic inflammatory myopathies. By means of a sensitive and specific method based on the polymerase chain reaction (PCR), we sought direct evidence for the presence in affected muscle of nucleic acid sequences from Coxsackie virus, mumps virus, encephalomyocarditis virus, adenovirus, human T-lymphotropic virus types I and II, and human immunodeficiency virus. RNA was extracted from muscle biopsy samples obtained from 44 patients with idiopathic inflammatory myopathies a mean of 45 (range 0-216) months after disease onset. All the subjects were older than 16 years at disease onset. The integrity of the mRNA extracted was confirmed by the successful PCR amplification of insulin receptor mRNA in all samples. The PCR method was able to detect between 1 and 20 molecules of added viral nucleic acid for the picornaviruses sought. No detectable virus sequences were found, however, in any of the patients' muscle samples or in samples from 13 controls. We tested for retroviral DNA in 22 samples (17 patients, 5 controls) that met our criterion for adequate DNA extraction (detectable beta-actin DNA by PCR); again no virus sequences were found. Persistence in muscle of these or closely related viruses is unlikely to be a continuing stimulus for disease in the idiopathic inflammatory myopathies.	ROSWELL PK CANC INST,DEPT NEUROL,BUFFALO,NY; SUNY BUFFALO,BUFFALO,NY 14260; NINCDS,BETHESDA,MD 20892	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	LEFF, RL (corresponding author), NIAMS,ARTHRIT & RHEUMATISM BRANCH,BLDG 10,ROOM 9N228,BETHESDA,MD 20892, USA.		Miller, Frederick/D-2431-2019	Miller, Frederick/0000-0003-2831-9593				BOWLES NE, 1987, LANCET, V1, P1004; CHOU SM, 1970, NEUROLOGY, V20, P205, DOI 10.1212/WNL.20.3.205; CHOU SM, 1986, HUM PATHOL, V17, P765, DOI 10.1016/S0046-8177(86)80197-6; CHRISTENSEN ML, 1986, ARTHRITIS RHEUM, V29, P1365, DOI 10.1002/art.1780291109; CRENNAN JM, 1986, AM J MED, V81, P35, DOI 10.1016/0002-9343(86)90179-8; CRONIN ME, 1988, J EXP MED, V168, P1639, DOI 10.1084/jem.168.5.1639; DALAKAS MC, 1986, JAMA-J AM MED ASSOC, V256, P2381, DOI 10.1001/jama.256.17.2381; DALAKAS MC, 1986, NEUROLOGY, V36, P569, DOI 10.1212/WNL.36.4.569; DENMAN AM, 1988, POLYMYOSITIS DERMATO, P97; EHRLICH GD, 1991, NEUROLOGY, V41, P335, DOI 10.1212/WNL.41.3.335; EHRLICH GD, 1990, PCR PROTOCOLS GUIDE, P325; JIN O, 1990, CIRCULATION, V82, P8, DOI 10.1161/01.CIR.82.1.8; KALLAJOKI M, 1991, HUM PATHOL, V22, P29, DOI 10.1016/0046-8177(91)90057-V; LEFF RL, 1991, ARTHRITIS RHEUM, V11, P1391; LINDLEY IJD, 1977, J GEN VIROL, V34, P177, DOI 10.1099/0022-1317-34-1-177; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MIKOL J, 1982, ANN NEUROL, V11, P576, DOI 10.1002/ana.410110605; MURPHY BR, 1990, VIROLOGY, P1109; NISHINO H, 1989, ANN NEUROL, V25, P260, DOI 10.1002/ana.410250309; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; ROSENBERG NL, 1989, ANN NEUROL, V26, P204, DOI 10.1002/ana.410260204; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON R, 1974, NATURE, V249, P32, DOI 10.1038/249032a0; STRONGWATER SL, 1984, ARTHRITIS RHEUM, V27, P433, DOI 10.1002/art.1780270411; TANG TT, 1975, NEW ENGL J MED, V292, P608, DOI 10.1056/NEJM197503202921203; WILEY CA, 1989, NEW ENGL J MED, V320, P992, DOI 10.1056/NEJM198904133201507; YOUSEF GE, 1990, ANN RHEUM DIS, V49, P310, DOI 10.1136/ard.49.5.310	28	107	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1192	1195		10.1016/0140-6736(92)91134-T	http://dx.doi.org/10.1016/0140-6736(92)91134-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349938				2022-12-24	WOS:A1992HU68400004
J	SCAMBLER, PJ; KELLY, D; LINDSAY, E; WILLIAMSON, R; GOLDBERG, R; SHPRINTZEN, R; WILSON, DI; GOODSHIP, JA; CROSS, IE; BURN, J				SCAMBLER, PJ; KELLY, D; LINDSAY, E; WILLIAMSON, R; GOLDBERG, R; SHPRINTZEN, R; WILSON, DI; GOODSHIP, JA; CROSS, IE; BURN, J			VELO-CARDIO-FACIAL SYNDROME ASSOCIATED WITH CHROMOSOME-22 DELETIONS ENCOMPASSING THE DIGEORGE LOCUS	LANCET			English	Note								The large clinical overlap between DiGeorge syndrome and velo-cardio-facial syndrome suggests an aetiological connection. DiGeorge syndrome is associated with microdeletions of chromosome 22q11 and is therefore likely to be caused by reduced dosage of genes within this region. We present preliminary data that velocardiofacial syndrome patients have similar chromosome deletions, a finding consistent with the hypothesis that these disorders represent part of a spectrum of abnormalities seen with monosomy for 22q11.	MONTEFIORE MED CTR,CTR CRANIOFACIAL DISORDERS,BRONX,NY 10467; UNIV NEWCASTLE UPON TYNE,DIV HUMAN GENET & CYTOGENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Newcastle University - UK	SCAMBLER, PJ (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.		Scambler, Peter/AAZ-6026-2020; Wilson, David/A-6264-2010; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Wilson, David/0000-0001-8779-2060; Scambler, Peter J/0000-0002-1487-4628				CAREY AH, 1990, GENOMICS, V7, P299, DOI 10.1016/0888-7543(90)90161-M; CAREY AH, 1991, THESIS U LONDON UK; CAREY AH, IN PRESS MAMMAL GENO; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; McKusick VA, 1990, MENDELIAN INHERITANC; SCAMBLER PJ, 1991, GENOMICS, V10, P201, DOI 10.1016/0888-7543(91)90501-5; SHARKEY AM, IN PRESS HUM GENET; SHPRINTZEN RJ, 1990, BIRTH DEFECTS ENCY, P1744; STEVENS CA, 1990, PEDIATRICS, V85, P526; WILSON DI, 1991, BRIT HEART J, V66, P308	10	366	372	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1138	1139		10.1016/0140-6736(92)90734-K	http://dx.doi.org/10.1016/0140-6736(92)90734-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349369				2022-12-24	WOS:A1992HT23600006
J	DOOREN, MC; KUIJPERS, RWAM; JOEKES, EC; HUISKES, E; GOLDSCHMEDING, R; OVERBEEKE, MAM; VONDEMBORNE, AEGK; ENGELFRIET, CP; OUWEHAND, WH				DOOREN, MC; KUIJPERS, RWAM; JOEKES, EC; HUISKES, E; GOLDSCHMEDING, R; OVERBEEKE, MAM; VONDEMBORNE, AEGK; ENGELFRIET, CP; OUWEHAND, WH			PROTECTION AGAINST IMMUNE HEMOLYTIC-DISEASE OF NEWBORN-INFANTS BY MATERNAL MONOCYTE-REACTIVE IGG ALLOANTIBODIES (ANTI-HLA-DR)	LANCET			English	Article							HUMAN-SERA; ANTIBODIES	The extent to which maternal anti-Rh(D) antibodies support lysis of erythrocytes by monocytes in the antibody-dependent cell-mediated cytotoxicity (ADCC) assay is closely correlated with the severity of Rh(D) haemolytic disease of the newborn infant (HDN). However, in some cases HDN is much milder than would be predicted from the ADCC value. We postulated that maternal ADCC-blocking alloantibodies against paternal antigens on monocytes can protect these infants against severe haemolysis. We studied 13 severely Rh(D)-alloimmunised mothers whose infants showed unexpectedly mild HDN (group I) and 14 women with similar ADCC values but whose infants had severe HDN (group II), 7 group-I women had monocyte-reactive IgG alloantibodies that inhibited lysis by paternal monocYtes in the ADCC. No such antibodies were found in group II (p < 0.01). In 6 of the 7 serum samples with monocyte-reactive antibodies, the antibodies had HLA-DR specificity. Our findings suggest that Rh(D)-positive children of some severely Rh(D)-alloimmunised women may be protected from severe HDN by maternal non-HLA-class-I, IgG alloantibodies against paternal monocyte blood-group antigens. These antibodies may inhibit the mononuclear phagocyte system of the fetus.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT IMMUNOHAEMATOL,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,CLIN & EXPTL IMMUNOL LAB,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT HAEMATOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT TRANSFUS MED,CAMBRIDGE CB2 2QQ,ENGLAND	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			kuijpers, robert/AAD-5194-2019; Goldschmeding, Roel/I-1723-2014					BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P385; DEBOER M, 1981, J IMMUNOL METHODS, V43, P225, DOI 10.1016/0022-1759(81)90027-2; Engelfriet C P, 1990, Baillieres Clin Haematol, V3, P321, DOI 10.1016/S0950-3536(05)80053-8; Engelfriet CP, 1981, SEMINAR IMMUNE MEDIA, P93; FLEER A, 1978, SCAND J IMMUNOL, V8, P515, DOI 10.1111/j.1365-3083.1978.tb00551.x; KUIJPERS RWAM, 1991, BLOOD, V78, P2150; KURLANDER RJ, 1983, J IMMUNOL, V131, P140; MUELLERECKHARDT G, 1989, HUM IMMUNOL, V25, P125, DOI 10.1016/0198-8859(89)90076-1; NEPPERT J, 1986, VOX SANG, V51, P122, DOI 10.1111/j.1423-0410.1986.tb00227.x; OUWEHAND WH, 1984, THESIS RODOPI AMSTER, P19; OUWEHAND WH, 1984, THESIS AMSTERDAM, P87; Roos D, 1986, Methods Enzymol, V132, P225; SHULMAN NR, 1964, PROG HEMATOL, V4, P222; TERASAKI PI, 1982, DHEW NIH77545 PUBL, P92; URBANIAK SJ, 1991, VOX SANG, V60, P225	15	38	40	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1067	1070		10.1016/0140-6736(92)90661-L	http://dx.doi.org/10.1016/0140-6736(92)90661-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349101				2022-12-24	WOS:A1992HR44600001
J	SCHULTZ, JE; KLUMPP, S; BENZ, R; SCHURHOFFGOETERS, WJC; SCHMID, A				SCHULTZ, JE; KLUMPP, S; BENZ, R; SCHURHOFFGOETERS, WJC; SCHMID, A			REGULATION OF ADENYLYL CYCLASE FROM PARAMECIUM BY AN INTRINSIC POTASSIUM CONDUCTANCE	SCIENCE			English	Article							EXCITABLE CILIARY MEMBRANE; DEPENDENT CALCIUM CHANNELS; CYCLIC-AMP LEVELS; GUANYLATE-CYCLASE; TETRAURELIA INVIVO; IONIC REGULATION; PROTEINS; PURIFICATION; SEPARATION; MUTATION	Hyperpolarization of the cell membrane of Paramecium stimulates adenosine 3',5'monophosphate (cAMP) formation. Manipulations of the K+ resting conductance of the ciliate by adaptation in different buffers affected excitability of the cAMP generating system. Blockade of K+ channels inhibited hyperpolarization-stimulated cAMP formation. A mutant of Paramecium that is unable to control its K+ resting conductance had a defect in cAMP formation. Purified adenylyl cyclase, when incorporated into an artificial lipid bilayer membrane, revealed properties of a voltage-independent K+ channel. This indicates that the adenylyl cyclase of Paramecium has a secondary function as carrier of the K+ resting conductance. A hyperpolarization-activated K+ efflux appears to directly regulate adenylyl cyclase activity in vivo.	UNIV WURZBURG, INST BIOTECHNOL, W-8700 WURZBURG, GERMANY	University of Wurzburg	SCHULTZ, JE (corresponding author), UNIV TUBINGEN, INST PHARMAZEUT, MORGENSTELLE 8, W-7400 TUBINGEN 1, GERMANY.			Benz, Roland/0000-0002-9510-9265				BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BOHEIM G, 1982, TRANSPORT BIOMEMBRAN, P87; BONINI NM, 1986, CELL MOTIL CYTOSKEL, V6, P2256; DELAAGE MA, 1978, MOL BIOL PHARM CYCLI, P155; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EHRLICH BE, 1984, SCIENCE, V225, P427, DOI 10.1126/science.6330895; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HINRICHSEN RD, 1984, J PHYSIOL-LONDON, V351, P397, DOI 10.1113/jphysiol.1984.sp015252; KLUMPP S, 1984, FEBS LETT, V171, P95, DOI 10.1016/0014-5793(84)80466-4; KLUMPP S, UNPUB; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MACHEMER H, 1989, J PROTOZOOL, V36, P463, DOI 10.1111/j.1550-7408.1989.tb01082.x; Machemer H., 1988, P185; MACHEMERROHNISCH S, 1989, EUR J PROTISTOL, V25, P45, DOI 10.1016/S0932-4739(89)80077-X; MAJIMA T, 1980, BIOPHYS CHEM, V11, P101, DOI 10.1016/0301-4622(80)85012-5; Naitoh Y., 1982, P1; OKA T, 1986, J EXP BIOL, V126, P111; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; PRESTON RR, 1991, ANNU REV PHYSIOL, V53, P309, DOI 10.1146/annurev.ph.53.030191.001521; PRESTON RR, 1990, J MEMBRANE BIOL, V115, P61, DOI 10.1007/BF01869106; RICHARD EA, 1985, J NEUROGENET, V2, P239, DOI 10.3109/01677068509102321; SCHONEFELD U, 1986, J PROTOZOOL, V33, P222, DOI 10.1111/j.1550-7408.1986.tb05595.x; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; SCHULTZ JE, 1984, FEBS LETT, V167, P113, DOI 10.1016/0014-5793(84)80843-1; SCHULTZ JE, 1991, METHOD ENZYMOL, V195, P466; SIAMI Y, 1990, J MEMBRANE BIOL, V112, P79; SIAMI Y, 1987, ANNU REV GENET, V21, P47; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sonneborn T. M., 1970, Methods Cell Physiol., V4, P241, DOI 10.1016/S0091-679X(08)61758-6; THIELE J, 1982, EUR J CELL BIOL, V28, P3; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227	35	138	139	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	1992	255	5044					600	603		10.1126/science.1371017	http://dx.doi.org/10.1126/science.1371017			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1371017				2022-12-24	WOS:A1992HB53100044
J	GRANT, SGN; ODELL, TJ; KARL, KA; STEIN, PL; SORIANO, P; KANDEL, ER				GRANT, SGN; ODELL, TJ; KARL, KA; STEIN, PL; SORIANO, P; KANDEL, ER			IMPAIRED LONG-TERM POTENTIATION, SPATIAL-LEARNING, AND HIPPOCAMPAL DEVELOPMENT IN FYN MUTANT MICE	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; ASPARTATE RECEPTOR ANTAGONIST; RAT-BRAIN; SYNAPTIC TRANSMISSION; NITRIC-OXIDE; C-SRC; SELECTIVE IMPAIRMENT; KINASE-ACTIVITY; PDGF RECEPTOR; GROWTH-FACTOR	Mice with mutations in four nonreceptor tyrosine kinase genes, fyn, src, yes, and abl, were used to study the role of these kinases in long-term potentiation (LTP) and in the relation of LTP to spatial learning and memory. All four kinases were expressed in the hippocampus. Mutations in src, yes, and abl did not interfere with either the induction or the maintenance of LTP. However, in fyn mutants, LTP was blunted even though synaptic transmission and two short-term forms of synaptic plasticity, paired-pulse facilitation and post-tetanic potentiation, were normal. In parallel with the blunting of LTP, fyn mutants showed impaired spatial learning, consistent with a functional link between LTP and learning. Although fyn is expressed at mature synapses, its lack of expression during development resulted in an increased number of granule cells in the dentate gyrus and of pyramidal cells in the CA3 region. Thus, a common tyrosine kinase pathway may regulate the growth of neurons in the developing hippocampus and the strength of synaptic plasticity in the mature hippocampus.	BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	GRANT, SGN (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Grant, Seth/0000-0001-8732-8735	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG08702] Funding Source: Medline; NICHD NIH HHS [HD24875] Funding Source: Medline; NIMH NIH HHS [MH45923] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOSS BD, 1987, BRAIN RES, V406, P280, DOI 10.1016/0006-8993(87)90793-1; BROWN TH, 1991, LONG TERM POTENTIATI, P357; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CUDMORE SB, 1991, J NEUROCHEM, V57, P1240, DOI 10.1111/j.1471-4159.1991.tb08285.x; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; EICHENBAUM H, 1989, BEHAV NEUROSCI, V103, P1207, DOI 10.1037/0735-7044.103.6.1207; ESPINO PC, 1990, ONCOGENE, V5, P283; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GURD JW, 1982, J NEUROCHEM, V39, P1117, DOI 10.1111/j.1471-4159.1982.tb11504.x; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HANNIG G, 1991, ONCOGENE, V6, P361; HARVEY J, 1992, NEUROSCI LETT, V139, P197, DOI 10.1016/0304-3940(92)90551-H; HEISENBERG M, 1989, PROGR ZOOLOGY, P3; HSI ED, 1989, J BIOL CHEM, V264, P10836; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNOVSKY MJ, 1969, HISTOCHEM CYTOCHEM, V112, P219; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPP HP, 1989, EXPERIENTIA, V45, P845, DOI 10.1007/BF01954059; LOMO T, 1966, ACTA PHYSIOL SCAND, VS 68, P128; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MORRIS RGM, 1985, COLD SPRING HARB SYM, V50, P161; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, UNPUB; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SORIANO P, UNPUB; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; UPCHURCH M, 1989, BEHAV NEUROSCI, V103, P1251, DOI 10.1037/0735-7044.103.6.1251; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; WOOLSEY TA, 1971, BRAIN RES, V26, P259; ZHAO YH, 1991, ONCOGENE, V6, P1725	69	950	973	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1903	1910		10.1126/science.1361685	http://dx.doi.org/10.1126/science.1361685			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1361685				2022-12-24	WOS:A1992KD08800022
J	DURANDZALESKI, I; BONNET, F; ROCHANT, H; BIERLING, P; LEMAIRE, F				DURANDZALESKI, I; BONNET, F; ROCHANT, H; BIERLING, P; LEMAIRE, F			USEFULNESS OF CONSENSUS CONFERENCES - THE CASE OF ALBUMIN	LANCET			English	Article							PRACTICE GUIDELINES; MEDICINE; TRIAL	The usefulness of consensus conferences has been questioned. We have assessed the impact of a 1989 consensus conference about the treatment of hypovolaemia on prescribing practice at our hospital. Data available from the blood bank enabled us to follow albumin use and costs by department between 1987 and 1991. Medical journals, direct mail, and meetings were used to disseminate the recommendations of the consensus conference, which were that the only indications for albumin are massive haemorrhage, plasmapheresis, massive hypoalbuminaemia, and volume expansion in pregnancy; for hypovolaemia caused by septic shock or vasoplegia, fluid gelatins and crystalloids should be used. In the year after the conference, and in subsequent years, albumin use and costs were 40% lower than before the conference, even though total medical expenditure continued to rise and numbers of patients admitted did not change. We believe that consensus conferences can be a useful means of improving medical practice. The features that ensured success in this programme were the small number of prescribers, the homogeneous setting, and the frequent restatement of the recommendations.	HOP HENRI MONDOR,SURG INTENS CARE UNIT,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,DEPT HAEMATOL,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,MED INTENS CARE UNIT,F-94010 CRETEIL,FRANCE; CDTS,VAL DE MARNE,CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	DURANDZALESKI, I (corresponding author), HOP HENRI MONDOR,DEPT PUBL HLTH,51 AVE MARECHAL DE LATTRE DE TASSIGNY,F-94010 CRETEIL,FRANCE.							BLACKBURN GL, 1992, CRIT CARE MED, V20, P157; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CONSEILLER C, 1983, COMPENSATION PERTES, P49; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GROOTENDORST AF, 1988, INTENS CARE MED, V14, P554, DOI 10.1007/BF00263529; KANOUSE, 1989, CHANGING MED PRACTIS; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; PERRIER JF, 1989, ANN FR ANESTH, V8, P204, DOI 10.1016/S0750-7658(89)80105-4; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; Stocking B, 1992, Qual Health Care, V1, P56, DOI 10.1136/qshc.1.1.56; THOMAS J, 1991, JAMA-J AM MED ASSOC, V65, P2202; 1989, REAN SOINS INTENS ME, V5, P295; 1985, JAMA-J AM MED ASSOC, V253, P551	15	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1388	1390		10.1016/0140-6736(92)92568-Z	http://dx.doi.org/10.1016/0140-6736(92)92568-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360098				2022-12-24	WOS:A1992KB20200012
J	REARDON, W; ROSS, RJM; SWEENEY, MG; LUXON, LM; PEMBREY, ME; HARDING, AE; TREMBATH, RC				REARDON, W; ROSS, RJM; SWEENEY, MG; LUXON, LM; PEMBREY, ME; HARDING, AE; TREMBATH, RC			DIABETES-MELLITUS ASSOCIATED WITH A PATHOGENIC POINT MUTATION IN MITOCHONDRIAL-DNA	LANCET			English	Article							MYOPATHY; GENE; FEATURES; ACIDOSIS; DISEASE; MELAS	Family studies of diabetes mellitus (DM) show that patients are more likely to have affected mothers than affected fathers. Since the inheritance of mitochondrial (mtDNA), unlike nuclear DNA, is exclusively maternal, could it be that defect(s) in mtDNA account for some cases of DM? Such defects have been associated with rare neurological syndromes, in some of which DM has been an accompanying feature. We have looked for glucose intolerance and for a previously known point mutation of mtDNA in a family, some of whose members have a multisystem disorder with DM but not neurological involvement. DNA samples were obtained from fourteen family members. The point mutation (affecting position 3243 in the tRNA leucine mitochondrial gene) was found in all three diabetic patients and post mortem tissues in the proband; it was also found in seven offspring of female patients. It was not found in the two children of the male proband. The contribution of this mutation to DM in general is not known but clinicians ought to be aware of the possibility, especially in families with multisystem disease and maternal transmission.	ST BARTHOLOMEWS HOSP, DEPT ENDOCRINOL, LONDON EC1, ENGLAND; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON WC1, ENGLAND; UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROOTOL, LONDON WC1, ENGLAND	University of London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	REARDON, W (corresponding author), INST CHILD HLTH, MOTHERCARE UNIT CLIN GENET & FETAL MED, LONDON WC1N 1EH, ENGLAND.		Ross, Richard/B-2672-2012	Ross, Richard/0000-0001-9222-9678; Trembath, Richard/0000-0003-0550-3400				ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408; EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7; HAMMANS SR, 1991, BRIT J HOSP MED, V46, P20; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HOLT IJ, 1990, AM J HUM GENET, V46, P428; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; PENROSE LS, 1945, P AM DIABETES ASSOC, V5, P163; PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915; POULTON J, 1989, LANCET, V1, P236; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VULIER C, 1991, NATURE, V354, P155; 1985, TECH REP SER WHO, V727	17	366	379	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1376	1379		10.1016/0140-6736(92)92560-3	http://dx.doi.org/10.1016/0140-6736(92)92560-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360090				2022-12-24	WOS:A1992KB20200004
J	AGNELLO, V; CHUNG, RT; KAPLAN, LM				AGNELLO, V; CHUNG, RT; KAPLAN, LM			A ROLE FOR HEPATITIS-C VIRUS-INFECTION IN TYPE-II CRYOGLOBULINEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIXED CRYOGLOBULINEMIA; RHEUMATOID-FACTOR; CROSS-IDIOTYPE; ANTIBODIES; ASSOCIATION; INTERFERON; DISEASES; CHAINS; HEAVY; ALPHA	Background. Type II cryoglobulinemia is a vasculitis characterized by cryoglobulins consisting of complexes of polyclonal IgG and monoclonal IgM rheumatoid factors. The cause of these immune complexes is unknown, though both the hepatitis B (HBV) and C (HCV) viruses have been suspected. Methods. We studied 19 patients with Type II cryoglobulinemia for markers of HCV and HBV infection. Quantitative HCV antibody and RNA studies were performed on whole serum, cryoprecipitates, and supernatants. Results. Eight patients (42 percent) had HCV antibodies, and 16 (84 percent) had HCV RNA. Of the 19 patients, 5 (26 percent) had HBV markers, but only 1 had evidence of active HBV infection. Control serum samples from nine patients with Type I cryoglobulinemia were negative for HCV antibody and HCV RNA. There was a close, although not exclusive, association of one type of rheumatoid factor (WA) with HCV RNA. HCV antibody and HCV RNA were concentrated approximately 10-fold and 1000-fold, respectively, in the Type II cryoglobulins examined. Conclusions. Type II cryogiobulinemia is strongly associated with concomitant HCV infection and a high rate of false negative serologic tests. HCV virions and HCV antigen-antibody complexes are concentrated in the cryoprecipitates, most commonly in association with the WA type of rheumatoid factor, suggesting a role for HCV in the pathogenesis of mixed cryoglobulinemia.	MASSACHUSETTS GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; EDITH NOURSE ROGERS MEM VET AFFAIRS HOSP,BEDFORD,MA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	AGNELLO, V (corresponding author), LAHEY CLIN MED CTR,DEPT LAB MED,CLIN IMMUNOL LAB,41 MALL RD,BURLINGTON,MA 01805, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042189, T32DK007191] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35487] Funding Source: Medline; NIDDK NIH HHS [5T32DK07191, DK42189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGNELLO V, 1986, J EXP MED, V164, P1809, DOI 10.1084/jem.164.5.1809; AGNELLO V, 1973, KIDNEY INT, V3, P90, DOI 10.1038/ki.1973.15; AGNELLO V, 1980, J EXP MED, V151, P1514, DOI 10.1084/jem.151.6.1514; AGNELLO V, 1981, ANN INTERN MED, V94, P266, DOI 10.7326/0003-4819-94-2-266; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BARNES JL, 1990, ARTHRITIS RHEUM-US, V33, P1710, DOI 10.1002/art.1780331115; BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CHUNG RT, 1991, HEPATOLOGY, V14, pA65; COLTORTI M, 1991, 3RD INT S HCV STRASB; Dienstag J L, 1981, Semin Liver Dis, V1, P45, DOI 10.1055/s-2008-1063929; DIGHIERO G, 1986, ANN NY ACAD SCI, V475, P135, DOI 10.1111/j.1749-6632.1986.tb20863.x; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1991, INFECTION, V19, P417, DOI 10.1007/BF01726453; FERRI C, 1991, ARTHRITIS RHEUM, V34, P1606; FERRI C, 1991, EUR J CANCER, V27, pS81, DOI 10.1016/0277-5379(91)90583-Y; GIUSTI G, 1980, B I SIEROTER MILAN, V59, P571; GOREVIC PD, 1991, SEMIN HEMATOL, V28, P79; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KNOX TA, 1991, AM J MED, V91, P554, DOI 10.1016/0002-9343(91)90196-5; KUNKEL HG, 1973, J EXP MED, V137, P331, DOI 10.1084/jem.137.2.331; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; MAGGIORE Q, 1981, KIDNEY INT, V19, P579, DOI 10.1038/ki.1981.55; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MONTEVERDE A, 1988, ACTA HAEMATOL-BASEL, V79, P20, DOI 10.1159/000205684; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PASCUAL V, 1992, ARTHRITIS RHEUM-US, V35, P11, DOI 10.1002/art.1780350103; PLAGEMANN PGW, 1991, ARCH VIROL, V120, P165, DOI 10.1007/BF01310473; REALDI G, 1974, Z IMMUNITATSFORSCH, V147, P114; SANZ I, 1989, J IMMUNOL, V142, P4054; TANAKA M, 1991, CLIN EXP RHEUMATOL, V9, P308	36	1210	1235	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1490	1495		10.1056/NEJM199211193272104	http://dx.doi.org/10.1056/NEJM199211193272104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1383822				2022-12-24	WOS:A1992JY16500004
J	MARTIN, BC; WARRAM, JH; KROLEWSKI, AS; BERGMAN, RN; SOELDNER, JS; KAHN, CR				MARTIN, BC; WARRAM, JH; KROLEWSKI, AS; BERGMAN, RN; SOELDNER, JS; KAHN, CR			ROLE OF GLUCOSE AND INSULIN RESISTANCE IN DEVELOPMENT OF TYPE-2 DIABETES-MELLITUS - RESULTS OF A 25-YEAR FOLLOW-UP-STUDY	LANCET			English	Article							BETA-CELL; FAT DISTRIBUTION; PIMA-INDIANS; SENSITIVITY; MUSCLE; NIDDM; TRANSPORTERS; TOLERANCE; INVIVO; RISK	Type 2 diabetes mellitus is characterised by resistance of peripheral tissues to insulin and a relative deficiency of insulin secretion. To find out which is the earliest or primary determinant of disease, we used a minimum model of glucose disposal and insulin secretion based on intravenous glucose tolerance tests to estimate insulin sensitivity (S(I)), glucose effectiveness (ie, insulin-independent glucose removal rate, S(G)), and first-phase and second-phase beta-cell responsiveness in normoglycaemic offspring of couples who both had type 2 diabetes. 155 subjects from 86 families were followed-up for 6-25 years. More than 10 years before the development of diabetes, subjects who developed the disease had lower values of both S(I) (mean 3.2 [SD 2.4] vs 8.1 [6.7] 10(-3) l min-1 pmol-1 insulin; p < 0.0001) and S(G) (1.6 [0.9] vs 2.3 [1.2] 10(-2) min-1, p < 0.0001) than did those who remained normoglycaemic). For the subjects with both S(I) and SG below the group median, the cumulative incidence of type 2 diabetes during the 25 years was 76% (95% confidence interval 54-99). By contrast, no subject with both S(I) and S(G) above the median developed the disease. Subjects with low S(I)/high S(G) or high S(I)/low S(G) had intermediate risks. Insulin secretion, especially first phase, tended to be increased rather than decreased in this prediabetic phase and was appropriate for the level of insulin resistance. The development of type 2 diabetes is preceded by and predicted by defects in both insulin-dependent and insulin- independent glucose uptake; the defects are detectable when the patients are normoglycaemic and in most cases more than a decade before diagnosis of disease.	HARVARD UNIV,SCH PUBL HLTH,JOSLIN DIABET CTR 1 JOSLIN PL,DEPT EPIDEMIOL,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV ZURICH,INST SOCIAL & PREVENT MED,CH-8006 ZURICH,SWITZERLAND; UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,LOS ANGELES,CA 90033	Harvard University; Harvard T.H. Chan School of Public Health; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Zurich; University of Southern California			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Bergman, Richard/0000-0003-1539-4471	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, R01DK029867, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33201, DK-29867, DK-36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1985, J CLIN INVEST, V76, P1782, DOI 10.1172/JCI112169; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGMAN RN, 1989, DIABETES, V38, P1512, DOI 10.2337/diabetes.38.12.1512; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; BERGMAN RN, 1981, J CLIN INVEST, V68, P1456, DOI 10.1172/JCI110398; BERGSTROM RW, 1990, DIABETES, V39, P104, DOI 10.2337/diabetes.39.1.104; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FREYMOND D, 1988, J CLIN INVEST, V82, P1503, DOI 10.1172/JCI113758; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HANSEN IL, 1985, DIABETES, V34, P751, DOI 10.2337/diabetes.34.8.751; Hoffman WS, 1937, J BIOL CHEM, V120, P51; JOHNSTON C, 1990, DIABETIC MED, V7, P119, DOI 10.1111/j.1464-5491.1990.tb01345.x; KADISH AH, 1968, CLIN CHEM, V14, P116; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; LEE ET, 1980, STATISTICAL METHODS; LESLIE RDG, 1986, BRIT MED J, V293, P840, DOI 10.1136/bmj.293.6551.840; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MENEILLY GS, 1989, J CLIN ENDOCR METAB, V63, P566; PORTE D, 1989, DIABETES, V38, P1333, DOI 10.2337/diabetes.38.11.1333; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; ROBERTSON RP, 1989, DIABETES, V38, P1501, DOI 10.2337/diabetes.38.12.1501; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P286; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; 1979, DIABETES, V28, P1039	31	951	975	1	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					925	929		10.1016/0140-6736(92)92814-V	http://dx.doi.org/10.1016/0140-6736(92)92814-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357346				2022-12-24	WOS:A1992JT82300001
J	MILLER, C				MILLER, C			ION CHANNEL STRUCTURE AND FUNCTION	SCIENCE			English	Editorial Material							ACETYLCHOLINE-RECEPTOR; K+ CHANNELS; INACTIVATION				MILLER, C (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.							DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MURRELL-LAGNADO R D, 1992, Biophysical Journal, V61, pA290; SINE SM, 1991, J BIOL CHEM, V266, P19369; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	15	21	22	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					240	241		10.1126/science.1384128	http://dx.doi.org/10.1126/science.1384128			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384128				2022-12-24	WOS:A1992JR86000018
J	TURNER, TJ; ADAMS, ME; DUNLAP, K				TURNER, TJ; ADAMS, ME; DUNLAP, K			CALCIUM CHANNELS COUPLED TO GLUTAMATE RELEASE IDENTIFIED BY OMEGA-AGA-IVA	SCIENCE			English	Article							CA2+ CHANNELS; CONOTOXIN GVIA; NERVE-ENDINGS; NEURONS; SYNAPTOSOMES; CURRENTS; BLOCKING; PEPTIDE	Presynaptic calcium channels are crucial elements of neuronal excitation-secretion coupling. In mammalian brain, they have been difficult to characterize because most presynaptic terminals are too small to probe with electrodes, and available pharmacological tools such as dihydropyridines and omega-conotoxin are largely ineffective. Subsecond measurements of synaptosomal glutamate release have now been used to assess presynaptic calcium channel activity in order to study the action of peptide toxins from the venom of the funnel web spider Agelenopsis aperta, which is known to inhibit dihydropyridine and omega-conotoxin-resistant neuronal calcium currents. A presynaptic calcium channel important in glutamate release is shown to be omega-Aga-IVA sensitive and omega-conotoxin resistant.	UNIV CALIF RIVERSIDE, DEPT ENTOMOL, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT NEUROSCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	TURNER, TJ (corresponding author), TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA.		Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113; Turner, Timothy/0000-0001-9770-2647				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; HOFMANN F, 1990, N-S ARCH PHARMACOL, V341, P200; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LINDGREN CA, 1989, J PHYSIOL-LONDON, V414, P201, DOI 10.1113/jphysiol.1989.sp017684; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LUNDY PM, 1991, EUR J PHARM-MOLEC PH, V206, P61, DOI 10.1016/0922-4106(91)90147-A; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; Mintz I. M., 1992, Society for Neuroscience Abstracts, V18, P9; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1991, ANN NY ACAD SCI, V635, P114, DOI 10.1111/j.1749-6632.1991.tb36486.x; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; RIVIER J, 1987, J BIOL CHEM, V262, P1194; STANLEY EF, 1991, J NEUROSCI, V11, P985; SUSZKIW JB, 1989, J NEUROCHEM, V52, P1260, DOI 10.1111/j.1471-4159.1989.tb01874.x; TURNER T J, 1991, Society for Neuroscience Abstracts, V17, P577; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; TURNER TJ, 1989, BIOCHEMISTRY-US, V28, P586, DOI 10.1021/bi00428a026; TURNER TJ, 1992, J CELL BIOCHEM, V16, P225; TURNER TJ, UNPUB; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; VENEMA VJ, 1992, J BIOL CHEM, V267, P2610	28	289	291	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					310	313		10.1126/science.1357749	http://dx.doi.org/10.1126/science.1357749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357749				2022-12-24	WOS:A1992JR86000038
J	LATRON, F; PAZMANY, L; MORRISON, J; MOOTS, R; SAPER, MA; MCMICHAEL, A; STROMINGER, JL				LATRON, F; PAZMANY, L; MORRISON, J; MOOTS, R; SAPER, MA; MCMICHAEL, A; STROMINGER, JL			A CRITICAL ROLE FOR CONSERVED RESIDUES IN THE CLEFT OF HLA-A2 IN PRESENTATION OF A NONAPEPTIDE TO T-CELLS	SCIENCE			English	Article							ANTIGEN-BINDING SITE; TOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; RECOGNITION; MOLECULES	The peptide binding cleft of the class I human histocompatibility antigen, HLA-A2, contains conserved amino acid residues clustered in the two ends of the cleft in pockets A and F as well as polymorphic residues. The function of two conserved tyrosines in the A pocket was investigated by mutating them to phenylalanines and of a conserved tyrosine and threonine in the F pocket by mutating them to phenylalanine and valine, respectively. Presentation of influenza virus peptides and of intact virus to cytolytic T lymphocytes (CTLs) was then examined. The magnitude of the reduction seen by the mutation of the two tyrosines in the A pocket suggests that hydrogen bonds involving them have a critical function in the binding of the NH2-terminal NH3+ of the peptide nonamer and possibly of all bound peptide nonamers. In contrast, the mutations in the F pocket had no effect on CTL recognition.	UNIV OXFORD,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	University of Oxford; Harvard University	LATRON, F (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		Moots, Robert/AAM-8091-2020; Morrison, Jo/AAK-2858-2020	Morrison, Jo/0000-0003-0000-520X	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020182] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47554] Funding Source: Medline; NIAID NIH HHS [AI 20182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH F, 1987, NATURE, V326, P653; LATRON F, 1991, P NATL ACAD SCI USA, V88, P11325, DOI 10.1073/pnas.88.24.11325; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, IN PRESS CELL; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SANTOSAGUADO J, 1989, P NATL ACAD SCI USA, V86, P8936, DOI 10.1073/pnas.86.22.8936; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; VANBLEEK GM, 1990, NATURE, V348, P213	21	77	79	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					964	967		10.1126/science.1380181	http://dx.doi.org/10.1126/science.1380181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1380181				2022-12-24	WOS:A1992JH82700035
J	SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K				SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K			MODULATION OF MULTIDRUG-RESISTANT MULTIPLE-MYELOMA BY CYCLOSPORINE	LANCET			English	Article							ACUTE MYELOCYTIC-LEUKEMIA; PLASMA-CELL MYELOMA; P-GLYCOPROTEIN; DRUG-RESISTANCE; MDR1 GENE; ACCUMULATION; EXPRESSION; CANCER; ANTHRACYCLINES; DOXORUBICIN	Resistance to chemotherapy in refractory multiple myeloma is frequently associated with expression of multidrug resistance (MDR). In resistant cells, intracellular accumulation of doxorubicin and vincristine does not occur because the MDR-1 gene product, a membrane glycoprotein (PgP), is an energy-dependent efflux pump. Cyclosporin is one of several non-cytotoxic drugs that can block the function of PgP. In a prospective study, we assessed the possibility that cyclosporin could be used clinically to modulate MDR. We studied 21 patients with multiple myeloma; disease had progressed during primary chemotherapy in 6 and was resistant to VAD (vincristine, doxorubicin, dexamethasone) in 15, The patients received cyclosporin by continuous infusion during VAD treatment; there were three cyclosporin dosage groups (5, 7.5, 10 mg/kg daily). Serum cyclosporin concentrations adequate for MDR modulation were reached in all patients receiving 7.5 or 10 mg/kg daily. 47% (7) of the VAD-refractory patients and 48% (10) of the whole group responded to VAD. Before treatment, MDR-1 expression was present in 12 patients. After VAD plus cyclosporin, no MDR-1-positive plasma cells were present in 6 of 8 patients tested. The response rate in MDR-1-positive patients was 58% compared with 33% in all our patients. Toxic effects were mild and reversible and did not include nephrotoxic or serious cardiovascular side-effects. 12 months after the start of treatment, survival was 85%, and disease-free survival at a median of 9 months after the response was 65%. Thus, in multiple myeloma clinical resistance to VAD can be circumvented by cyclosporin, which enables the cytotoxic drugs to eliminate resistant myeloma cells.	EUROPEAN ORG RES TREATMENT CANC,CTR DATA,DEPT HAEMATOL,BRUSSELS,BELGIUM; WESTMINSTER & CHARING CROSS MED SCH,DEPT HAEMATOL,LONDON,ENGLAND; INST APPL IMMUNOL & RADIOBIOL,DEPT HAEMATOL,RIJSWIJK,NETHERLANDS; UNIV UTRECHT HOSP,DEPT HAEMATOL,3511 GV UTRECHT,NETHERLANDS; HOP HOTEL DIEU,DEPT HAEMATOL,F-75181 PARIS 04,FRANCE	European Organisation for Research & Treatment of Cancer; Imperial College London; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	SONNEVELD, P (corresponding author), ERASMUS UNIV,HOSP DIJKZIGT,DEPT HAEMATOL,ROOM L407,DR MOLEWARTERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ALEXANIAN R, 1985, ARCH INTERN MED, V145, P2073, DOI 10.1001/archinte.145.11.2073; BARLOGIE B, 1986, BLOOD, V67, P1298; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; BELCH A, 1988, BRIT J CANCER, V57, P94, DOI 10.1038/bjc.1988.17; BUZAID AC, 1988, J CLIN ONCOL, V6, P889, DOI 10.1200/JCO.1988.6.5.889; DALTON WS, 1989, BLOOD, V73, P747; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; EPSTEIN J, 1989, BLOOD, V74, P913; GORE ME, 1989, LANCET, V2, P879; GOSLAND MP, 1991, P AM ASSOC CANC RES, P82; GROGAN T, 1990, LAB INVEST, V63, P815; HERWEIJER H, 1990, JNCI-J NATL CANCER I, V82, P1133, DOI 10.1093/jnci/82.13.1133; KYLE RA, 1986, PROG HEMATOL, V14, P257; NOOTER K, 1990, INT J CANCER, V45, P263, DOI 10.1002/ijc.2910450210; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; SALMON SE, 1991, BLOOD, V78, P44; SALMON SE, 1989, J NATL CANCER I, V81, P696, DOI 10.1093/jnci/81.9.696; SONNEVELD P, 1990, BRIT J HAEMATOL, V75, P208, DOI 10.1111/j.1365-2141.1990.tb02650.x; SPETH PAJ, 1986, J CHROMATOGR, V377, P415, DOI 10.1016/S0378-4347(00)80803-8; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANKALKEN CK, 1991, EUR J CANCER, V27, P739, DOI 10.1016/0277-5379(91)90178-G	23	369	378	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					255	259		10.1016/0140-6736(92)92353-H	http://dx.doi.org/10.1016/0140-6736(92)92353-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353189				2022-12-24	WOS:A1992JG66500001
J	TAYLORROBINSON, D; GILROY, CB; THOMAS, BJ; KEAT, ACS				TAYLORROBINSON, D; GILROY, CB; THOMAS, BJ; KEAT, ACS			DETECTION OF CHLAMYDIA-TRACHOMATIS DNA IN JOINTS OF REACTIVE ARTHRITIS PATIENTS BY POLYMERASE CHAIN-REACTION	LANCET			English	Note								In 1986, Chlamydia trachomatis elementary bodies were found by direct immunofluorescence (DIF) in synovial-fluid cell deposits and synovial-membrane biopsy samples from five of eight patients with sexually acquired reactive arthritis (SARA) but in none of eight controls with other types of arthritis. Cells from the original slides (stored at 4-degrees-C) have now been examined by a polymerase chain reaction (PCR) that amplifies DNA for the major outer membrane protein of C trachomatis. Chlamydial DNA was found in samples from four DIF-positive patients, one DIF-negative patient, and one DIF-negative control. Overall, there was 80% concordance for DIF and PCR results. This study supports our previous finding of chlamydiae in joints in reactive arthritis.	ST MARYS HOSP,LONDON,ENGLAND; WESTMINSTER MED SCH & HOSP,DEPT RHEUMATOL,LONDON SW1P 2AP,ENGLAND	Imperial College London; Imperial College London	TAYLORROBINSON, D (corresponding author), CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							GILROY CB, 1992, J CLIN PATHOL, V45, P531, DOI 10.1136/jcp.45.6.531; HAMMER M, 1992, CLIN EXP RHEUMATOL, V10, P63; KEAT A, 1987, LANCET, V1, P72; KEAT AC, 1978, BRIT MED J, V1, P605, DOI 10.1136/bmj.1.6113.605; PALMER HM, 1991, J CLIN PATHOL, V44, P321, DOI 10.1136/jcp.44.4.321; RAHMAN M U, 1990, Arthritis and Rheumatism, V33, pS25; SCHUMACHER HR, 1988, ARTHRITIS RHEUM, V31, P937; TAYLORROBINSON D, 1988, ANN RHEUM DIS, V47, P295, DOI 10.1136/ard.47.4.295; WONG M L, 1986, Proceedings of the University of Otago Medical School, V64, P77; WORDSWORTH BP, 1990, BRIT J RHEUMATOL, V29, P208	10	202	205	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					81	82		10.1016/0140-6736(92)90399-N	http://dx.doi.org/10.1016/0140-6736(92)90399-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352016				2022-12-24	WOS:A1992JC58200006
J	SILVA, AJ; STEVENS, CF; TONEGAWA, S; WANG, YY				SILVA, AJ; STEVENS, CF; TONEGAWA, S; WANG, YY			DEFICIENT HIPPOCAMPAL LONG-TERM POTENTIATION IN ALPHA-CALCIUM-CALMODULIN KINASE-II MUTANT MICE	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; RAT-BRAIN; EXPRESSION; AUTOPHOSPHORYLATION; TRANSMISSION; GENE	As a first step in a program to use genetically altered mice in the study of memory mechanisms, mutant mice were produced that do not express the alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII). The alpha-CaMKII is highly enriched in postsynaptic densities of hippocampus and neocortex and may be involved in the regulation of long-term potentiation (LTP). Such mutant mice exhibited mostly normal behaviors and presented no obvious neuroanatomical defects. Whole cell recordings reveal that postsynaptic mechanisms, including N-methyl-D-aspartate (NMDA) receptor function, are intact. Despite normal postsynaptic mechanisms, these mice are deficient in their ability to produce LTP and are therefore a suitable model for studying the relation between LTP and learning processes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Salk Institute	SILVA, AJ (corresponding author), MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER; NINDS NIH HHS [5 R01 NS 12961-17] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DAVIS M, 1992, TRENDS PHARMACOL SCI, V13, P35, DOI 10.1016/0165-6147(92)90014-W; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FALLS WA, 1992, J NEUROSCI, V12, P854; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; JAHR CE, 1990, J NEUROSCI, V10, P1830; JAHR CE, 1990, J NEUROSCI, V10, P3178; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGUINESS T, 1985, J BIOL CHEM, V260, P1969; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1991, LONG TERM POTENTIATI; MULLER W, 1991, NATURE, V354, P74; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SILVA AJ, 1992, SCIENCE, V257, P209; SILVA AMS, UNPUB; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7	29	1176	1205	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					201	206		10.1126/science.1378648	http://dx.doi.org/10.1126/science.1378648			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1378648				2022-12-24	WOS:A1992JC58500026
J	SORRENTINO, BP; BRANDT, SJ; BODINE, D; GOTTESMAN, M; PASTAN, I; CLINE, A; NIENHUIS, AW				SORRENTINO, BP; BRANDT, SJ; BODINE, D; GOTTESMAN, M; PASTAN, I; CLINE, A; NIENHUIS, AW			SELECTION OF DRUG-RESISTANT BONE-MARROW CELLS INVIVO AFTER RETROVIRAL TRANSFER OF HUMAN MDR1	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; GENE-TRANSFER; MULTIDRUG RESISTANCE; EXPRESSION; RECIPIENTS; LINE	Experiments were performed to determine if retroviral-mediated transfer of the human multidrug resistance 1 gene (MDR1) into murine bone marrow cells would confer drug resistance to the cells and whether the MDR1 gene could be used as a dominant selectable marker in vivo. When mice transplanted with bone marrow cells containing a transferred MDR1 gene were treated with the cytotoxic drug taxol, a substantial enrichment for transduced bone marrow cells was observed. This demonstration of positive selection establishes the ability to amplify clones of transduced hematopoietic cells in vivo and suggests possible applications in human therapy.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; NCI,DIV CANC BIOL & DIAG,CELL BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC BIOL & DIAG,MOLEC BIOL LAB,BETHESDA,MD 20892	Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SORRENTINO, BP (corresponding author), NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; COREY CA, 1990, BLOOD, V75, P337; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FLETCHER FA, 1991, J EXP MED, V174, P837, DOI 10.1084/jem.174.4.837; GERMANN UA, 1989, J BIOL CHEM, V264, P7418; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCLACHLIN JR, 1990, J NATL CANCER I, V82, P1260, DOI 10.1093/jnci/82.15.1260; MICKISCH GH, 1991, CANCER RES, V51, P5417; MICKISCH GH, 1992, BLOOD, V79, P1087; MICKISCH GH, 1991, P NATL ACAD SCI USA, V88, P547, DOI 10.1073/pnas.88.2.547; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247	17	477	501	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					99	103		10.1126/science.1352414	http://dx.doi.org/10.1126/science.1352414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1352414				2022-12-24	WOS:A1992JC16500040
J	LIFSON, AR; HESSOL, NA; BUCHBINDER, SP; OMALLEY, PM; BARNHART, L; SEGAL, M; KATZ, MH; HOLMBERG, SD				LIFSON, AR; HESSOL, NA; BUCHBINDER, SP; OMALLEY, PM; BARNHART, L; SEGAL, M; KATZ, MH; HOLMBERG, SD			SERUM BETA-2-MICROGLOBULIN AND PREDICTION OF PROGRESSION TO AIDS IN HIV-INFECTION	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; BISEXUAL MEN; ACTIVATION; MARKERS; ANTIGEN; FOLLOW; COHORT; TYPE-1; COUNT; LEVEL	Identification of laboratory tests that can help predict progression to acquired immunodeficiency syndrome (AIDS) in people infected with human immunodeficiency virus (HIV) is important for clinical management and counselling. We have assessed the usefulness of CD4 lymphocyte count, serum beta-2-microglobulin concentration, and the presence of p24 antigen as predictors of AIDS. We studied 214 homosexual and bisexual men with well-defined dates of HIV seroconversion. For each participant we defined the baseline date as the earliest date before the development of AIDS on which the three laboratory tests were done. beta-2-microglobulin concentration at baseline was in all analyses an independent predictor of AIDS, even after stratification by baseline CD4 count, duration of HIV infection, or use of zidovudine before or at baseline. For example, among men with at least 0.5 x 10(9)/l CD4 cells who were negative for p24 antigen, the risks of AIDS at 12 months and 24 months were 1% and 5%, respectively, for those whose beta-2-microglobulin concentrations were below 4.0 mg/l, compared with 17% and 27%, respectively for those with beta-2-microglobulin concentrations above that cut-off point (p<0.001). Among men with an estimated duration of infection of 5 years or less, beta-2-microglobulin concentration was the strongest independent predictor of AIDS. Measurement of serum beta-2-microglobulin adds important prognostic information to CD4 count in determining the risk of progression to AIDS in HIV-infected subjects, including those whose CD4 cell count has not yet fallen.	DEPT PUBL HLTH,AIDS PROGRAM,SAN FRANCISCO,CA; CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	LIFSON, AR (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,BOX 0560,SAN FRANCISCO,CA 94143, USA.				PHS HHS [U62/CCU900523-03-5] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; BASS HZ, 1992, J ACQ IMMUN DEF SYND, V5, P215; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FLEGG PJ, 1991, AIDS, V5, P1021, DOI 10.1097/00002030-199108000-00015; GALLO D, 1986, J CLIN MICROBIOL, V23, P1049, DOI 10.1128/JCM.23.6.1049-1051.1986; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; JACOBSON MA, 1989, J INFECT DIS, V159, P1029, DOI 10.1093/infdis/159.6.1029; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; JORGENSEN AF, 1990, AIDS, V4, P1168; KIN K, 1979, IMMUNOLOGY, V36, P47; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZANGERLE R, 1991, AIDS, V5, P985, DOI 10.1097/00002030-199108000-00010; 1989, MMWR, V38, P1	25	83	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1436	1440		10.1016/0140-6736(92)92030-J	http://dx.doi.org/10.1016/0140-6736(92)92030-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351128				2022-12-24	WOS:A1992HY31700003
J	HALL, A; ANWAR, KS; TOMKINS, AM				HALL, A; ANWAR, KS; TOMKINS, AM			INTENSITY OF REINFECTION WITH ASCARIS-LUMBRICOIDES AND ITS IMPLICATIONS FOR PARASITE CONTROL	LANCET			English	Article							HELMINTH INFECTIONS; SCHISTOSOMA-MANSONI; PREDISPOSITION; HEALTH; HUMANS	Intestinal helminths are among the most common and widespread of human infections. Because it is typical to find that most worms are aggregated in a few potential hosts it has been suggested that some individuals are predisposed to heavy infections and that morbidity could be controlled by the treatment of heavily infected individuals only. We have studied the prevalence and intensity of reinfection with the intestinal nematode Ascaris lumbricoides among people living in Dhaka, Bangladesh. 880 people were treated with pyrantel pamoate three times at six month intervals, and on each occasion they collected all their stools for 48 h after treatment. Worms expelled by each subject were counted and weighed. The prevalence of infection at round 1 of treatment was 89% and the mean burden was 18.5 worms. Reinfection was rapid and at rounds 2 and 3 the prevalence was 82% and 80%, respectively, with mean burdens of 14.0 and 11.5 worms. The intensity of reinfection was not random more subjects than expected became heavily reinfected (greater-than-or-equal-to 15 worms) and more subjects than expected remained lightly infected (less-than-or-equal-to 14 worms) (p < 0.001). Worms were highly aggregated at each round of treatment but although just over 10% of all subjects were heavily infected at each and every round of treatment, over 60% of all subjects were heavily infected at least once. The findings show that some individuals seem to be susceptible to heavy infection whereas others are not, that deworming has a greater effect on the intensity of infection than on the prevalence, and that mass chemotherapy is likely to be a more effective means to control morbidity than is selective treatment of heavily infected individuals only.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL,PRINCE CONSORT RD, LONDON SW7 2BB, ENGLAND; INT CTR DIARRHOEL DIS RES, DHAKA 1000, BANGLADESH; INST PUBL HLTH, DHAKA 1212, BANGLADESH; INST CHILD HLTH, CTR INT CHILD HLTH, LONDON WC1N 1EH, ENGLAND	Imperial College London; International Centre for Diarrhoeal Disease Research (ICDDR); University of London; University College London				Anwar, Kazi Selim/0000-0002-6001-6616; Selim Anwar, Kazi/0000-0002-3437-4014				Anderson R.M., 1982, P204; ANDERSON R M, 1991; ANDERSON RM, 1985, PARASITOLOGY, V90, P629, DOI 10.1017/S0031182000052288; ANDERSON RM, 1982, NATURE, V297, P557, DOI 10.1038/297557a0; BENSTEDSMITH R, 1987, T ROY SOC TROP MED H, V81, P651, DOI 10.1016/0035-9203(87)90442-1; Gustafsson LL, 1987, HDB DRUGS TROPICAL P; HALL A, 1981, T ROY SOC TROP MED H, V75, P682, DOI 10.1016/0035-9203(81)90148-6; HASWELLELKINS MR, 1987, PARASITOLOGY, V95, P323, DOI 10.1017/S0031182000057772; James DM, 1985, HUMAN ANTIPARASITIC; KEYMER A, 1990, HOOKWORM DISEASE : CURRENT STATUS AND NEW DIRECTIONS, P177; Pawlowski Z. S., 1990, Tropical and Geographical Medicine., P369; SINNIAH B, 1981, ANN TROP MED PARASIT, V75, P315, DOI 10.1080/00034983.1981.11687445; THIENHLAING, 1985, ASCARIASIS ITS PUBLI, P83; TINGLEY GA, 1988, T ROY SOC TROP MED H, V82, P448, DOI 10.1016/0035-9203(88)90159-9; WAKELIN D, 1984, IMMUNITY PARASITES; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; Warren K. S., 1990, Tropical and Geographical Medicine., P110; WARREN KS, 1991, LANCET, V338, P686, DOI 10.1016/0140-6736(91)91251-O; 1990, WHO MODEL PRESCRIBIN	19	68	72	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1992	339	8804					1253	1257		10.1016/0140-6736(92)91593-W	http://dx.doi.org/10.1016/0140-6736(92)91593-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349668				2022-12-24	WOS:A1992HV19100003
J	PAN, MG; FLORIO, T; STORK, PJS				PAN, MG; FLORIO, T; STORK, PJS			G-PROTEIN ACTIVATION OF A HORMONE-STIMULATED PHOSPHATASE IN HUMAN TUMOR-CELLS	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; MIA PACA-2; DEPHOSPHORYLATION	The growth-inhibiting peptide hormone somatostatin stimulates phosphotyrosine phosphatase activity in the human pancreatic cell line MIA PaCa-2. This hormonal activation was mediated by a pertussis toxin-sensitive guanosine 5'-triphosphate-binding protein (G protein) in the membranes of these cells. Activation of this G protein by somatostatin stimulated the dephosphorylation of exogenous epidermal growth factor receptor prepared from A-431 cells in vitro. This pathway may mediate the antineoplastic action of somatostatin in these cells and in human tumors and could represent a general mechanism of G protein coupling Mat is utilized by normal cells in the hormonal control of cell growth.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, L474, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012	Florio, Tullio/0000-0002-2394-996X				BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; CIRILLO D, 1988, MOL CELL BIOL, V6, P4641; COHEN S, 1982, J BIOL CHEM, V257, P1523; CUI Z, 1991, J BIOL CHEM, V266, P20276; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; INGEBRITSEN TS, 1989, J BIOL CHEM, V264, P7754; JARVIS MF, 1991, 21ST ANN M SOC NEUR, P45; KARLUND JK, 1985, CELL, V41, P707; LIEBOW C, 1991, P NATL ACAD SCI USA, V88, P2244, DOI 10.1073/pnas.88.6.2244; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; Pan M.-L., UNPUB; STORK PJS, UNPUB; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; YUNIS AA, 1977, INT J CANCER, V19, P128, DOI 10.1002/ijc.2910190118; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	21	232	235	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1215	1217		10.1126/science.256.5060.1215	http://dx.doi.org/10.1126/science.256.5060.1215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1350382				2022-12-24	WOS:A1992HV19200040
J	KELEN, GD; GREEN, GB; PURCELL, RH; CHAN, DW; QAQISH, BF; SIVERTSON, KT; QUINN, TC				KELEN, GD; GREEN, GB; PURCELL, RH; CHAN, DW; QAQISH, BF; SIVERTSON, KT; QUINN, TC			HEPATITIS-B AND HEPATITIS-C IN EMERGENCY DEPARTMENT PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NON-A; HEPATOCELLULAR-CARCINOMA; SEXUAL TRANSMISSION; UNITED-STATES; CIRCULATING ANTIBODIES; RISK; INFECTION; EPIDEMIOLOGY; PREVALENCE	Background. Infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and the human immunodeficiency virus type 1 (HIV-1) are common in inner-city populations, but their frequency and interrelations are not well established. Methods. During a six-week period, excess serum samples were collected, along with information on risk factors, from all adult patients presenting to an inner-city emergency department. The samples were assayed for hepatitis B surface antigen (HBsAg) and antibodies to HCV and HIV-1. Results. Of the 2523 patients tested, 612 (24 percent) were infected with at least one of the three viruses. Five percent were seropositive for HBV, 18 percent for HCV, and 6 percent for HIV-1. HCV was found in 145 of the 175 intravenous drug users (83 percent), 36 of the 171 transfusion recipients (21 percent), and 5 of the 24 homosexual men (21 percent). Among black men 35 to 44 years of age, the seroprevalence of HCV was 51 percent. HBsAg was present in 9 percent of those whose only identifiable risk was possible heterosexual exposure. At least one viral marker was found in about 30 percent of the patients who were actively bleeding or in whom procedures were performed. Testing for HIV-1 alone would have failed to identify 87 percent of the patients infected with HBV and 80 percent of those infected with HCV. Conclusions. In a population of patients in an inner-city emergency room, HBV, HCV, and HIV-1 are all highly prevalent. However, routine screening for HIV-1 alone would identify only a small fraction of the patients who pose risks of severe viral infections, including HBV and HCV, to providers.	JOHNS HOPKINS UNIV,SCH MED,DIV EMERGENCY MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT LAB MED,BALTIMORE,MD 21205; UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC 27514; NIAID,INFECT DIS LAB,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Quinn, Thomas/A-2494-2010	Kelen, Gabor/0000-0002-3236-8286				AHTONE J, 1980, LANCET, V1, P1142; ALEXANDER PG, 1990, PUBLIC HEALTH REP, V105, P610; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; [Anonymous], 1964, SANKHYA INDIAN J STA, DOI DOI 10.2307/25049340; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DIENSTAG JL, 1982, AM J EPIDEMIOL, V115, P26, DOI 10.1093/oxfordjournals.aje.a113277; DONAHUE JG, 1991, AM J EPIDEMIOL, V134, P1206, DOI 10.1093/oxfordjournals.aje.a116023; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; EVATT BL, 1985, NEW ENGL J MED, V312, P483, DOI 10.1056/NEJM198502213120805; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HANDSFIELD HH, 1987, JAMA-J AM MED ASSOC, V258, P3395, DOI 10.1001/jama.258.23.3395; HESS G, 1989, LANCET, V2, P987; HOPF U, 1990, J HEPATOL, V10, P69, DOI 10.1016/0168-8278(90)90075-3; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JOVANOVICH JF, 1983, JAMA-J AM MED ASSOC, V250, P1893; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIANG KY, IN PRESS J R STAT B; LIDDLE C, 1990, MED J AUSTRALIA, V153, P265, DOI 10.5694/j.1326-5377.1990.tb136898.x; MARCUS R, 1990, MAY ANN M SOC AC EM; MAYOSMITH MF, 1987, AM J INFECT CONTROL, V15, P266, DOI 10.1016/0196-6553(87)90120-9; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; NALPAS B, 1991, J HEPATOL, V12, P70, DOI 10.1016/0168-8278(91)90912-U; PARES A, 1990, HEPATOLOGY, V12, P1295, DOI 10.1002/hep.1840120608; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; SAKAMOTO M, 1988, CANCER RES, V48, P7294; SCHLIPKOTER U, 1990, SCAND J INFECT DIS, V22, P757, DOI 10.3109/00365549009027136; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992; WEARS RL, 1991, ANN EMERG MED, V20, P749, DOI 10.1016/S0196-0644(05)80836-4; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M; WERNER AJ, 1990, LANCET, V335, P1; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; 1989, MMWR SS6, V38; 1991, MMWR SRR13, V40, P1; 1990, MMWR SRR2, V39, P5; 1991, MMWR SRR8, V40, P1; 1989, 1ST P INT S HEP C VI, pCH2; 1987, MMWR, V36, P353	54	247	249	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1399	1404		10.1056/NEJM199205213262105	http://dx.doi.org/10.1056/NEJM199205213262105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1373867				2022-12-24	WOS:A1992HU89000005
J	BUELER, H; FISCHER, M; LANG, Y; BLUETHMANN, H; LIPP, HP; DEARMOND, SJ; PRUSINER, SB; AGUET, M; WEISSMANN, C				BUELER, H; FISCHER, M; LANG, Y; BLUETHMANN, H; LIPP, HP; DEARMOND, SJ; PRUSINER, SB; AGUET, M; WEISSMANN, C			NORMAL DEVELOPMENT AND BEHAVIOR OF MICE LACKING THE NEURONAL CELL-SURFACE PRP PROTEIN	NATURE			English	Article							SCRAPIE PRION PROTEINS; EMBRYONIC STEM-CELLS; INCUBATION PERIOD; MOLECULAR-CLONING; TRANSGENIC MICE; CULTURED-CELLS; MOUSE-BRAIN; T-CELLS; GENE; DEFICIENT	PrP(c) is a host protein anchored to the outer surface of neurons and to a lesser extent of lymphocytes and other cells. The transmissible agent (prion) responsible for scrapie is believed to be a modified form of PrP(c). Mice homozygous for disrupted PrP genes have been generated. Surprisingly, they develop and behave normally for at least seven months, and no immunological defects are apparent. It is now feasible to determine whether mice devoid of PrP(c) can propagate prions and are susceptible to scrapie pathogenesis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV ZURICH, INST ANAT, CH-8057 ZURICH, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PRTB, CH-4002 BASEL, SWITZERLAND; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of Zurich; Roche Holding; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BUELER, H (corresponding author), UNIV ZURICH, INST MOLEK BIOL 1, CH-8093 ZURICH, SWITZERLAND.		Büeler, Hansruedi/J-6965-2017	Büeler, Hansruedi/0000-0002-4892-7177				ANISMAN H, 1978, PSYCHOPHARMACOLOGY A, P1; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; DICKINSON AG, 1971, MOL GEN GENET, V112, P73, DOI 10.1007/BF00266934; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON EL, 1989, GENETICS, V123, P109; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; Hogan B., 1986, MANIPULATING MOUSE E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP HP, 1988, J NEUROSCI, V8, P1905; LIPP HP, 1991, BEHAV BRAIN RES, V45, P135, DOI 10.1016/S0166-4328(05)80079-8; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; MANSON J, IN PRESS DEVELOPMENT; MCKINLEY M P, 1990, Journal of Cell Biology, V111, p316A; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PUCKETT C, 1991, AM J HUM GENET, V49, P320; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; Schopke R, 1991, Hippocampus, V1, P315, DOI 10.1002/hipo.450010322; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Siegel S., 1956, NONPARAMETRIC STAT B; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1986, NUCLEIC ACIDS RES, V14, P2035, DOI 10.1093/nar/14.5.2035; WOLFER DP, 1992, J NEUROSCI METH, V41, P65, DOI 10.1016/0165-0270(92)90124-V; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	68	1424	1477	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1992	356	6370					577	582		10.1038/356577a0	http://dx.doi.org/10.1038/356577a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1373228				2022-12-24	WOS:A1992HP03100039
J	FOWKES, FGR; LENG, GC; DONNAN, PT; DEARY, IJ; RIEMERSMA, RA; HOUSLEY, E				FOWKES, FGR; LENG, GC; DONNAN, PT; DEARY, IJ; RIEMERSMA, RA; HOUSLEY, E			SERUM-CHOLESTEROL, TRIGLYCERIDES, AND AGGRESSION IN THE GENERAL-POPULATION	LANCET			English	Article							RISK; DISEASE; HEALTH; MEN	A higher than expected number of violent deaths and suicides in coronary prevention trials has provoked interest in the possibility that low serum cholesterol concentrations are associated in the general population with personality characteristics predisposing to aggressive and suicidal behaviour. We have investigated this possibility in the Edinburgh Artery Study. We measured serum lipid concentrations in blood samples taken from fasting subjects and assessed personality characteristics on the Bedford Foulds Personality Deviance Scales in a random sample of 1592 men and women aged 55-74 years, selected from age-sex registers of ten general practices in Edinburgh. Serum cholesterol concentration was not significantly associated with aggression in men, but it was associated in multivariate analysis (though not univariate analysis) with denigratory attitudes towards others among women. However, serum triglyceride concentration was related, especially in men, to hostile acts (r = 0.13, p < 0.001) and domineering attitude (r = 0.12, p < 0.001) independently of age, total and HDL cholesterol, cigarette smoking, and alcohol consumption. Subjects taking part in prevention trials have higher triglyceride concentrations than the general population and the relation between serum triglyceride concentration and aggression merits further investigation.	UNIV EDINBURGH, DEPT PSYCHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, CARDIOVASC RES UNIT, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh	FOWKES, FGR (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PUBL HLTH SCI, WOLFSON UNIT PREVENT PERIPHERAL VASC DIS, TEVIOT PL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.		Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X; Donnan, Peter/0000-0001-7828-0610				BEDFORD A, 1978, PERSONALITY DEVIANCE; BOLTONSMITH C, 1991, INT J EPIDEMIOL, V20, P95, DOI 10.1093/ije/20.1.95; Brown MS, 1990, PHARMACOL BASIS THER, P874; BRUNNER E, 1992, LANCET, V339, P1001; Caine TM, 1967, MANUAL HOSTILITY DIR; CHAIT A, 1981, DIABETES CARE, V4, P343, DOI 10.2337/diacare.4.3.343; DAYTON S, 1969, CIRCULATION S2, V39, P1; DIXON WJ, 1989, BMDP STATISTICAL SOF; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HEILMAN KM, 1974, ARCH NEUROL-CHICAGO, V31, P67, DOI 10.1001/archneur.1974.00490370093018; KROMHOUT D, 1992, LANCET, V340, P317, DOI 10.1016/0140-6736(92)92415-C; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATHEW NT, 1976, EUR NEUROL, V14, P370, DOI 10.1159/000114761; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; VIKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; VIKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27; ZUCKERMAN M, 1991, PSYCHOBIOLOGY PERSON, P205; 1930, ANN REPORTS REGISTRA; 1990, SCOTTISH HLTH STATIS; 1986, SPSSX USERS GUIDE	30	76	77	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					995	998		10.1016/0140-6736(92)93009-C	http://dx.doi.org/10.1016/0140-6736(92)93009-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357449				2022-12-24	WOS:A1992JV01400003
J	KASPER, W; GEIBEL, A; TIEDE, N; JUST, H				KASPER, W; GEIBEL, A; TIEDE, N; JUST, H			PATENT FORAMEN OVALE IN PATIENTS WITH HEMODYNAMICALLY SIGNIFICANT PULMONARY-EMBOLISM	LANCET			English	Article							PARADOXICAL EMBOLISM; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSIS; LIFE; PREVALENCE; HYPOXEMIA; STROKE	The prevalence of a patent foramen ovale is about 1 in 4. In cases with venous thromboembolism and raised right heart pressures, a patent foramen ovale may permit paradoxical emboli, which could complicate the course of patients with pulmonary embolism. Echocardiography enables detection of a patent foramen ovale in life. We have studied 85 patients who presented with haemodynamically significant pulmonary embolism as judged by clinical, echocardiographic, or haemodynamic indices and who had an echocardiographic evaluation for patent foramen ovale. 33 patients (39%) had a patent foramen ovale. Clinical symptoms suggestive of paradoxical embolism were more likely in patients with than in those without a patent foramen ovale (39% vs 6%, p=0.00034), with new neurological deficits occurring in 11 patients (9 vs 2, p=0.005) and a vascular occlusion in 8(7 vs 1, p=0.0096). Arterial oxygen tension was lower in patients with a patent foramen ovale (mean 55 [SD 14] vs 62 [16] mm Hg, p=0.038). Mortality was not different between the two groups (27% vs 19%). Cardiopulmonary complications in terms of resuscitation, intubation, or the use of catecholamines were more frequently observed in patients with a patent foramen ovale (48% vs 23%, p=0.028). Patients with a patent foramen ovale and haemodynamically significant pulmonary embolism are more likely to have arterial hypoxaemia and vascular occlusions, possibly due to paradoxical emboli.			KASPER, W (corresponding author), UNIV FREIBURG,MED CLIN 3,HUGSTETTERSTR 55,W-7800 FREIBURG,GERMANY.							BARNARD SP, 1991, EUR J CARDIO-THORAC, V5, P105, DOI 10.1016/1010-7940(91)90008-8; BILLER J, 1986, NEUROLOGY, V36, P1356, DOI 10.1212/WNL.36.10.1356; COME PC, 1985, DIAGNOSTIC CARDIOLOG, P281; CROSS SJ, 1992, BRIT MED J, V304, P481, DOI 10.1136/bmj.304.6825.481; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DALONZO GE, 1983, AM REV RESPIR DIS, V128, P170, DOI 10.1164/arrd.1983.128.1.170; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HALE GS, 1979, AUST NZ J MED, V9, P953; HIGGINS JR, 1984, AM HEART J, V107, P375, DOI 10.1016/0002-8703(84)90388-0; HOFMANN T, 1990, LANCET, V336, P1421; JARDIN F, 1979, CIRCULATION, V59, P909, DOI 10.1161/01.CIR.59.5.909; JOHNSON BI, 1951, J CLIN PATHOL, V4, P316, DOI 10.1136/jcp.4.3.316; KASPER W, 1989, HERZ, V14, P82; KASPER W, 1986, AM HEART J, V112, P1284, DOI 10.1016/0002-8703(86)90361-3; KRONIK G, 1989, EUR HEART J, V10, P1046; LANG I, 1988, EUR HEART J, V9, P678, DOI 10.1093/oxfordjournals.eurheartj.a062561; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEONARD RCF, 1982, EUR HEART J, V3, P362, DOI 10.1093/oxfordjournals.eurheartj.a061319; LOSCALZO J, 1986, AM HEART J, V112, P141, DOI 10.1016/0002-8703(86)90692-7; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MCNEIL BJ, 1980, J NUCL MED, V21, P319; MEISTER SG, 1972, AM J MED, V53, P292, DOI 10.1016/0002-9343(72)90171-4; MOON RE, 1989, LANCET, V1, P513; NELLESSEN U, 1985, J AM COLL CARDIOL, V5, P1002, DOI 10.1016/S0735-1097(85)80449-6; SEWARD JB, 1984, MAYO CLIN PROC, V59, P221, DOI 10.1016/S0025-6196(12)61253-1; STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2; Thompson T, 1930, Q J MED, V23, P135, DOI 10.1093/qjmed/os-23.90.135; WEBSTER MWI, 1988, LANCET, V2, P11; WILSON JE, 1971, J CLIN INVEST, V50, P481, DOI 10.1172/JCI106516	29	109	113	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					561	564		10.1016/0140-6736(92)92102-L	http://dx.doi.org/10.1016/0140-6736(92)92102-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355152				2022-12-24	WOS:A1992JM33400001
J	CHOY, DSJ; ALTMAN, P				CHOY, DSJ; ALTMAN, P			THE CARDIOVASCULAR-SYSTEM OF BAROSAURUS - AN EDUCATED GUESS	LANCET			English	Article									COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP CTR,INVEST CARDIOL LAB,NEW YORK,NY 10032	Columbia University; Mount Sinai St. Luke's; Mount Sinai West								GOETZ R H, 1955, S Afr Med J, V29, P773; GOETZ RH, 1960, CIRC RES, V8, P1049, DOI 10.1161/01.RES.8.5.1049; LILLYWHITE HB, 1991, NAT HIST, V100, P33	3	17	17	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					534	536		10.1016/0140-6736(92)91722-K	http://dx.doi.org/10.1016/0140-6736(92)91722-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354287				2022-12-24	WOS:A1992JL23400014
J	AMIGORENA, S; SALAMERO, J; DAVOUST, J; FRIDMAN, WH; BONNEROT, C				AMIGORENA, S; SALAMERO, J; DAVOUST, J; FRIDMAN, WH; BONNEROT, C			TYROSINE-CONTAINING MOTIF THAT TRANSDUCES CELL ACTIVATION SIGNALS ALSO DETERMINES INTERNALIZATION AND ANTIGEN PRESENTATION VIA TYPE-III RECEPTORS FOR IGG	NATURE			English	Article							LAMBDA-REPRESSOR; ENDOCYTOSIS; MACROPHAGE; ANTIBODIES; MOLECULES	TYPE III receptors for IgG (Fc-gamma-RII; ref. 1), high-affinity IgE receptors (Fc-epsilon-RI; ref. 2), as well as the T- and B-cell antigen receptors3,4, consist of multiple components with specialized ligand-binding and signal transduction functions5-10. Fc-gamma-RII-alpha (ligand-binding) and gamma (signal-transducing) subunits are expressed in macrophages1, a cell type involved in the uptake of antigen, its processing and the presentation of the resulting peptides to major histocompatibility complex class II-restricted T lymphocytes11,12. Here we show that murine Fc-gamma-RIII, transfected into Fc-gamma-R-negative antigen-presenting B-lymphoma cells, mediate rapid ligand internalization and strongly increase the efficiency of antigen presentation when antigen is complexed to IgG. Efficient internalization and antigen presentation via Fc-gamma-RIII did not require the cytoplasmic domain of the ligand-binding alpha-chain, but did require the gamma-subunit. Using chimaeric molecules, we show that gamma-chain contains a signal for receptor internalization and that the mutation of either of the two tyrosine residues present in its cytoplasmic domain prevents efficient internalization and antigen presentation of immune complexes. Thus, associated chains and their tyrosine-containing motif are not exclusively involved in cell activation, but also determine multimeric receptor internalization.	INST CURIE, INSERM, U255, IMMUNOL CELLULAIRE & CLIN LAB, F-75005 PARIS, FRANCE; CTR IMMUNOL MARSEILLE LUMINY, CNRS, INSERM, F-13288 MARSEILLE 9, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite				Amigorena, Sebastian/0000-0001-8583-8416; salamero, jean/0000-0002-2610-5826; fridman, wolf herman/0000-0002-1332-0973; Davoust, Jean/0000-0002-3098-7665				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; BREYER RM, 1989, J BIOL CHEM, V264, P13348; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DRAKE JR, 1989, J IMMUNOL, V143, P1768; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISERSKY C, 1983, J IMMUNOL, V131, P388; JONES B, 1986, J IMMUNOL, V136, P348; JUSTEMENT LB, 1989, J IMMUNOL, V143, P881; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KSITAKIS NT, 1990, J CELL BIOL, V111, P1393; LAI MZ, 1987, J IMMUNOL, V139, P3973; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T	26	164	168	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					337	341		10.1038/358337a0	http://dx.doi.org/10.1038/358337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1386408				2022-12-24	WOS:A1992JE68400066
J	MADDEN, BP; HODSON, ME; TSANG, V; RADLEYSMITH, R; KHAGHANI, A; YACOUB, MY				MADDEN, BP; HODSON, ME; TSANG, V; RADLEYSMITH, R; KHAGHANI, A; YACOUB, MY			INTERMEDIATE-TERM RESULTS OF HEART-LUNG TRANSPLANTATION FOR CYSTIC-FIBROSIS	LANCET			English	Article							ADULTS	Between September, 1984, and March, 1991, 79 patients underwent heart-lung transplantation for end-stage cystic fibrosis at the Harefield Hospital. Short-term outcome has already been reported, and we now present intermediate-term results. The overall actuarial patient survival was 69% at 1 year, 52% at 2 years, and 49% at 3 years. 17 patients had diabetes mellitus with a survival of 62% to 1 year and 51% to 2 years. 23 patients had one or more other possible high-risk factors, and survival of these patients was 64% at 1 year and 57% at 2 years, compared with 71% and 49%, respectively, in the low-risk group (n=56). Pseudomonas aeruginosa infection was the most common respiratory infection encountered postoperatively. 92% of patients had at least one episode of acute rejection during the first 3 postoperative months. Lung function was greatly improved after transplantation, the mean forced expiratory volume in 1 s and forced vital capacity increasing from 22% and 35% predicted, respectively, preoperatively to 68% and 70% predicted, respectively, by the sixth postoperative month. This improvement was maintained at 1, 2, and 3 years after transplantation. Lymphoproliferative disorders (4 patients) were successfully treated. Obliterative bronchiolitis developed in 17 patients and the cumulative probability of getting this complication at 1, 2, and 3 years postoperatively was 17%, 23%, and 48%, respectively. Overall, 7 patients were retransplanted. There was no coronary artery disease in the 37 patients who underwent coronary angiography at 1 year, 14 at 2 years, and 9 at 3 years after surgery. 58 patients donated their hearts for subsequent "domino" heart transplantation. Our 5 1/2-year experience with heart-lung transplantation is encouraging but the shortage of donor organs and the complication of obliterative bronchiolitis are the two main obstacles to be overcome.	HAREFIELD HOSP,UXBRIDGE UB9 6JH,MIDDX,ENGLAND; ROYAL BROMPTON HOSP,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital; Imperial College London								ALAJMO F, 1989, ANN THORAC SURG, V48, P536, DOI 10.1016/S0003-4975(10)66857-9; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; HODSON ME, 1989, BRIT MED J, V298, P471, DOI 10.1136/bmj.298.6672.471; HODSON ME, 1991, EUR RESPIR J, V4, P524; NIELSEN OH, 1982, ACTA PAEDIATR SC   S, V301, P107; PATTERSON GA, 1989, PEDIATR PULM, V4, P56; PENKETH ARL, 1987, THORAX, V42, P526, DOI 10.1136/thx.42.7.526; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCOTT J, 1988, LANCET, V2, P1962; SMYTH RL, 1991, THORAX, V46, P213, DOI 10.1136/thx.46.3.213; WOOD A, 1989, AM REV RESPIR DIS, V140, P1645, DOI 10.1164/ajrccm/140.6.1645; YACOUB MH, 1990, J HEART TRANSPLANT, V9, P459; YACOUB MH, 1990, TRANSPLANT REV, P1; 1988, BRIT MED J, V297, P1599; 1990, RECOMMENDATIONS CARE	15	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1583	1587		10.1016/0140-6736(92)91842-V	http://dx.doi.org/10.1016/0140-6736(92)91842-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351559				2022-12-24	WOS:A1992JB20200013
J	REIBNEGGER, G; FUCHS, D; JUDMAIER, G; WEISS, G; WERNERFELMAYER, G; WACHTER, H				REIBNEGGER, G; FUCHS, D; JUDMAIER, G; WEISS, G; WERNERFELMAYER, G; WACHTER, H			CRITICAL-STUDY OF CONSENSUS ANALYSIS	LANCET			English	Article							RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; NEOPTERIN; TESTS	Consensus analysis has been proposed as a statistical method by which the efficacy of clinical and laboratory tests of inflammatory activity can be assessed. This technique is claimed to overcome the need for an external "gold standard" as a reference method; instead, the consensus of all tests is used as the gold standard. We have evaluated the reliability of consensus analysis using data collected from patients with Crohn's disease. Our results demonstrate that the technique depends strongly on the correlation structure underlying the set of measures of disease used for analysis. This observation was supported by a series of conventional cluster analyses of the same set of variables. Furthermore, slight modifications of the algorithm had profound effects on the final result. We conclude that for the evaluation of tests of inflammatory activity, an external reference method, albeit an imperfect one, remains indispensable.	UNIV INNSBRUCK,DEPT INTERNAL MED,A-6020 INNSBRUCK,AUSTRIA	University of Innsbruck	REIBNEGGER, G (corresponding author), UNIV INNSBRUCK,INST MED CHEM & BIOCHEM,FRITZ PREGL STR 3,A-6020 INNSBRUCK,AUSTRIA.		Reibnegger, Gilbert/H-5742-2012; Fuchs, Dietmar/AAL-8011-2021	Reibnegger, Gilbert/0000-0001-7202-2426; Fuchs, Dietmar/0000-0003-1627-9563; Weiss, Guenter/0000-0003-0709-2158; Werner-Felmayer, Gabriele/0000-0002-2340-8063				BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BULL BS, 1986, LANCET, V2, P377; BULL BS, 1989, LANCET, V2, P965; DAWES PT, 1989, LANCET, V2, P1219; DUCLOS B, 1990, GASTROEN CLIN BIOL, V14, P22; LOBO AJ, 1991, EUR J GASTROEN HEPAT, V3, P663; PAWLOTSKY Y, 1989, LANCET, V2, P1532; PRIOR C, 1986, CLIN CHIM ACTA, V155, P11, DOI 10.1016/0009-8981(86)90094-X; PULLAR T, 1989, LANCET, V2, P1532; SCOTT DL, 1989, LANCET, V2, P1531	10	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1394	1397		10.1016/0140-6736(92)91206-N	http://dx.doi.org/10.1016/0140-6736(92)91206-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350814				2022-12-24	WOS:A1992HX63600013
J	PINTO, LH; HOLSINGER, LJ; LAMB, RA				PINTO, LH; HOLSINGER, LJ; LAMB, RA			INFLUENZA-VIRUS M2 PROTEIN HAS ION CHANNEL ACTIVITY	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; PHOTOSYNTHETIC REACTION CENTER; INFECTED-CELL SURFACE; ENDOPLASMIC-RETICULUM; MOLECULAR-BASIS; A VIRUSES; AMANTADINE; HEMAGGLUTININ; RIMANTADINE; RESTRICTION	The influenza virus M2 Protein was expressed in Xenopus laevis oocytes and shown to have an associated ion channel activity selective for monovalent ions. The anti-influenza virus drug amantadine hydrochloride significantly attenuated the inward current induced by hyperpolarization of oocyte membranes. Mutations in the M2 membrane-spanning domain that confer viral resistance to amantadine produced currents that were resistant to the drug. Analysis of the currents of these altered M2 proteins suggests that the channel pore is formed by the transmembrane domain of the M2 protein. The wild-type M2 Channel was found to be regulated by pH. The wild-type M2 ion channel activity is proposed to have a pivotal role in the biology of influenza virus infection.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, HOWARD HUGHES MED INST, EVANSTON, IL 60208 USA	Northwestern University; Howard Hughes Medical Institute; Northwestern University	PINTO, LH (corresponding author), NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA.				NEI NIH HHS [EY-01221] Funding Source: Medline; NIAID NIH HHS [AI-20201] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020201, R37AI020201] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; APPLEYARD G, 1977, J GEN VIROL, V36, P249, DOI 10.1099/0022-1317-36-2-249; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P61, DOI 10.1099/0022-1317-60-1-61; CIAMPOR F, 1992, IN PRESS VIRUS RES; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAY AJ, 1979, J GEN VIROL, V42, P189, DOI 10.1099/0022-1317-42-1-189; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAY AJ, 1986, J ANTIMICROB CHEMOTH, V18, P19, DOI 10.1093/jac/18.Supplement_B.19; HAY AJ, 1989, CONCEPTS VIRAL PATHO, V3, P361; HAY AJ, 1984, ANTIVIRAL DRUGS INTE, P301; Hille B., 1991, IONIC CHANNELS EXCIT; HOSLINGER LJ, 1991, VIROLOGY, V183, P32; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Lamb R.A., 1989, INFLUENZA VIRUSES, P1; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; RUIGROK RWH, 1991, J GEN VIROL, V72, P191, DOI 10.1099/0022-1317-72-1-191; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLTISSEK C, 1979, J GEN VIROL, V44, P807, DOI 10.1099/0022-1317-44-3-807; SKEHEL JJ, 1978, J GEN VIROL, V38, P97, DOI 10.1099/0022-1317-38-1-97; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEINHAUER DA, 1991, P NATL ACAD SCI USA, V88, P11525, DOI 10.1073/pnas.88.24.11525; SUGIMOTO T, 1990, J MEMBRANE BIOL, V113, P39, DOI 10.1007/BF01869604; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V189, P239; WHARTON SA, 1990, USE XRAY CRYSTALLOGR, P112; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985; ZEBEDEE SL, 1989, P NATL ACAD SCI USA, V86, P1061, DOI 10.1073/pnas.86.3.1061; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	55	960	1026	3	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					517	528		10.1016/0092-8674(92)90452-I	http://dx.doi.org/10.1016/0092-8674(92)90452-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1374685				2022-12-24	WOS:A1992HT07800013
J	FU, XD; MANIATIS, T				FU, XD; MANIATIS, T			ISOLATION OF A COMPLEMENTARY-DNA THAT ENCODES THE MAMMALIAN SPLICING FACTOR SC35	SCIENCE			English	Article							RNA; PROTEIN; PURIFICATION; SEQUENCE; INVITRO	The mammalian splicing factor SC35 is required for the first step in the splicing reaction and for spliceosome assembly. The cloning and characterization of a complementary DNA encoding this protein revealed that it is a member of a family of splicing factors that includes mammalian SF2/ASF. This family of proteins is characterized by the presence of a ribonucleoprotein (RNP)-type RNA binding motif and a carboxyl-terminal serine-arginine-rich (SR) domain. A search of the DNA sequence database revealed that the thymus-specific exon (E(T)) of the c-myb proto-oncogene is encoded on the antisense strand of the SC35 gene.			FU, XD (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; Fu X, UNPUB; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; PERBAL B, 1990, CR ACAD SCI III-VIE, V311, P467; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; RUBY SW, 1991, TRENDS GENET, V7, P79; Sambrook J., 1989, MOL CLONING LAB MANU; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Summers MD, 1987, TEXAS AGR EXPT STATI; SUREAU A, 1991, CR ACAD SCI III-VIE, V312, P323; VELLARD M, 1991, CR ACAD SCI III-VIE, V313, P591; VELLARD M, 1991, ONCOGENE, V6, P505; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; ZAHLER A, IN PRESS GENES DEV; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	33	223	235	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					535	538		10.1126/science.1373910	http://dx.doi.org/10.1126/science.1373910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373910				2022-12-24	WOS:A1992HQ18700068
J	WEBER, R; BRYAN, RT; OWEN, RL; WILCOX, CM; GORELKIN, L; VISVESVARA, GS; JURANEK, DD; ADDISS, DG; SPENCER, HC; HIGHTOWER, AW; STEWART, JM; ROBERTS, JM; WAHLQUIST, SP; HORSBURGH, CR; CASTRO, KG; TAUXE, RV; VUGIA, DJ; GLASS, RI; THOMPSON, SE; SCHWARTZ, DA; KOZARSKY, PE; STEINBERG, JP; SHULMAN, JA; DISMUKES, RM; DUPUIS, MH; NICKERSON, JF; RIMLAND, D; HOGAN, SE; JOHNSON, A; ELLIOTT, N				WEBER, R; BRYAN, RT; OWEN, RL; WILCOX, CM; GORELKIN, L; VISVESVARA, GS; JURANEK, DD; ADDISS, DG; SPENCER, HC; HIGHTOWER, AW; STEWART, JM; ROBERTS, JM; WAHLQUIST, SP; HORSBURGH, CR; CASTRO, KG; TAUXE, RV; VUGIA, DJ; GLASS, RI; THOMPSON, SE; SCHWARTZ, DA; KOZARSKY, PE; STEINBERG, JP; SHULMAN, JA; DISMUKES, RM; DUPUIS, MH; NICKERSON, JF; RIMLAND, D; HOGAN, SE; JOHNSON, A; ELLIOTT, N			IMPROVED LIGHT-MICROSCOPIC DETECTION OF MICROSPORIDIA SPORES IN STOOL AND DUODENAL ASPIRATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS PATIENTS; INTESTINAL MICROSPORIDIOSIS; ENTEROCYTOZOON-BIENEUSI; NOSEMATOSIS; DIAGNOSIS; ENCEPHALITOZOONOSIS; DIARRHEA; CORNEA	Background. The diagnosis of infection with Enterocytozoon bieneusi, a microsporidian organism that causes chronic diarrhea in patients infected with the human immunodeficiency virus (HIV), has depended on invasive procedures. We have developed a new method to detect microsporidia spores in feces and duodenal aspirates. Methods. Stool was obtained from four HIV-infected patients with biopsy-confirmed intestinal microsporidiosis. Slides prepared from unconcentrated, formalin-fixed stool specimens were stained with a new chromotrope-based technique and examined by light microscopy. Methods of stool concentration were also compared. The technique was then evaluated by examining 215 specimens from 134 HIV-infected persons with or without diarrhea. In addition, duodenal aspirates from 10 patients with unexplained chronic diarrhea were examined by light microscopy after staining according to the new and the traditional techniques. Results. E. bieneusi spores were found in all unconcentrated stool specimens from the four patients with microsporidiosis. The use of various methods of stool concentration did not improve the detection of microsporidia spores. In the prospective study, microsporidiosis was detected in samples from 6 of 27 patients with chronic diarrhea, but in none of those from 42 patients with acute diarrhea or 65 patients without diarrhea. The presence of microsporidia spores in stool specimens and duodenal aspirates allowed the successful prediction of the presence of microsporidia in small-bowel biopsy specimens from all four patients who subsequently underwent endoscopy. Conclusions. E. bieneusi is an important cause of chronic diarrhea in HIV-infected persons. This new diagnostic technique serves as a practical, noninvasive means to detect microsporidia spores in stool specimens and is also applicable to the examination of duodenal aspirates.	CTR DIS CONTROL,DIV PARASIT DIS,PARASIT DIS BRANCH,MAILSTOP F13,1600 CLIFTON RD,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,SCI RESOURCES PROGRAM,PATHOL BRANCH,ATLANTA,GA 30333; VET AFFAIRS MED CTR,CELL BIOL & AGING SECT,SAN FRANCISCO,CA; EMORY UNIV,GRADY MEM HOSP,SCH MED,DEPT INTERNAL MED,DIV GASTROENTEROL,ATLANTA,GA 30322; EMORY UNIV,CRAWFORD LONG HOSP,SCH MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,VET AFFAIRS MED CTR,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System			Weber, Rainer/D-5175-2012; Castro, Kenneth G/P-1882-2018; Schwartz, David A./AAX-7306-2021	Castro, Kenneth G/0000-0001-7964-6354; Schwartz, David A./0000-0002-7486-8545				ASHTON N, 1973, BRIT J OPHTHALMOL, V57, P669, DOI 10.1136/bjo.57.9.669; BERGQUIST NR, 1984, BRIT MED J, V288, P902, DOI 10.1136/bmj.288.6421.902; Bryan R. T., 1990, Principles and practice of infectious diseases., P2130; Bryan R T, 1991, Prog Clin Parasitol, V2, P1; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CALI A, 1991, J PROTOZOOL, V38, P215; CANNING EU, 1990, T ROY SOC TROP MED H, V84, P181, DOI 10.1016/0035-9203(90)90247-C; Canning EU, 1986, PARASIT PROTOZOA; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; CURRY A, 1988, J CLIN PATHOL, V41, P477, DOI 10.1136/jcp.41.4.477-b; DAVIS RM, 1990, OPHTHALMOLOGY, V97, P953; DIDIER ES, 1991, J INFECT DIS, V163, P617, DOI 10.1093/infdis/163.3.617; DOBBINS WO, 1985, GASTROENTEROLOGY, V88, P738, DOI 10.1016/0016-5085(85)90145-3; FRIEDBERG DN, 1990, ARCH OPHTHALMOL-CHIC, V108, P504, DOI 10.1001/archopht.1990.01070060052047; GOURLEY WK, 1988, LAB INVEST, V58, pA35; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; JOUVENAZ DP, 1981, J INVERTEBR PATHOL, V37, P319, DOI 10.1016/0022-2011(81)90093-8; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LEDFORD DK, 1985, ANN INTERN MED, V102, P628, DOI 10.7326/0003-4819-102-5-628; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; MARGILETH AM, 1973, ARCH PATHOL, V95, P145; MATSUBAYASHI H, 1959, ARCH PATHOL, V67, P181; MODIGLIANI R, 1985, GUT, V26, P179, DOI 10.1136/gut.26.2.179; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN JM, 1990, LANCET, V336, P1127, DOI 10.1016/0140-6736(90)92600-M; Palk G, 1974, MANUAL CLIN MICROBIO, P930; PINNOLIS M, 1981, ARCH OPHTHALMOL-CHIC, V99, P1044, DOI 10.1001/archopht.1981.03930011044012; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; Sheather A. L., 1923, Journal of Comparative Pathology and Therapeutics, V36, P266; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; ULLRICH R, 1989, ANN INTERN MED, V111, P954, DOI 10.7326/0003-4819-111-11-954_1; VANGOOL T, 1990, LANCET, V336, P697, DOI 10.1016/0140-6736(90)92198-Q; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352; 1990, MMWR, V39, P188	38	468	486	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					161	166		10.1056/NEJM199201163260304	http://dx.doi.org/10.1056/NEJM199201163260304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1370122	Bronze			2022-12-24	WOS:A1992GZ21300004
J	LOWEL, S; SINGER, W				LOWEL, S; SINGER, W			SELECTION OF INTRINSIC HORIZONTAL CONNECTIONS IN THE VISUAL-CORTEX BY CORRELATED NEURONAL-ACTIVITY	SCIENCE			English	Article							CAT STRIATE CORTEX; FLUORESCENT LATEX MICROSPHERES; OCULAR DOMINANCE; POSTNATAL-DEVELOPMENT; INHIBITION; ASSOCIATION; PROJECTIONS; EXPERIENCE; AREA-18; COLUMNS	In the visual cortex of the brain, long-ranging tangentially oriented axon collaterals interconnect regularly spaced clusters of cells. These connections develop after birth and attain their specificity by pruning. To test whether there is selective stabilization of connections between those cells that exhibit correlated activity, kittens were raised with artificially induced strabismus (eye deviation) to eliminate the correlation between signals from the two eyes. In area 17, cell clusters were driven almost exclusively from either the right or the left eye and tangential intracortical fibers preferentially connected cell groups activated by the same eye. Thus, circuit selection depends on visual experience, and the selection criterion is the correlation of activity.			LOWEL, S (corresponding author), MAX PLANCK INST HIRNFORSCH,DEUTSCHORDEN STR 46,W-6000 FRANKFURT 71,GERMANY.		Singer, Wolf/D-6874-2012					ANDERSON PA, 1988, J NEUROSCI, V8, P2183; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; Damasio A. R., 1990, SEMIN NEUROSCI, V2, P287; Duke-Elder S, 1973, SYSTEM OPHTHALMOLOGY, V6; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; EYSEL UT, 1987, EXP BRAIN RES, V68, P606; FISKEN RA, 1975, PHILOS T ROY SOC B, V272, P487, DOI 10.1098/rstb.1975.0099; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1985, VISION RES, V25, P365, DOI 10.1016/0042-6989(85)90061-6; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; INNOCENTI GM, 1979, NATURE, V280, P231, DOI 10.1038/280231a0; INNOCENTI GM, 1981, SCIENCE, V212, P824, DOI 10.1126/science.7221566; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KONIG P, 1990, SOC NEUR ABSTR, V16; LOWEL S, 1988, EXP BRAIN RES, V71, P33; LOWEL S, 1987, EXP BRAIN RES, V68, P661; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; LOWEL S, 1991, J PHYSIOL-LONDON, V438, pP157; LUHMANN HJ, 1986, EXP BRAIN RES, V63, P443; LUHMANN HJ, 1990, EUR J NEUROSCI, V2, P344, DOI 10.1111/j.1460-9568.1990.tb00426.x; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MATSUBARA JA, 1987, J NEUROSCI, V7, P1428; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; NELSON JI, 1975, J THEOR BIOL, V49, P1, DOI 10.1016/S0022-5193(75)80020-8; PRICE DJ, 1986, DEV BRAIN RES, V24, P31, DOI 10.1016/0165-3806(86)90170-7; PRICE DJ, 1985, NATURE, V316, P721, DOI 10.1038/316721a0; ROCKLAND KS, 1982, SCIENCE, V215, P1532, DOI 10.1126/science.7063863; SHATZ CJ, 1977, BRAIN RES, V131, P103, DOI 10.1016/0006-8993(77)90031-2; SINGER W, 1976, EXP BRAIN RES, V26, P171; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; SWINDALE NV, 1981, NATURE, V290, P332, DOI 10.1038/290332a0; Von Noorden GK., 1990, BINOCULAR VISION OCU; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0	40	403	408	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					209	212		10.1126/science.1372754	http://dx.doi.org/10.1126/science.1372754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1372754				2022-12-24	WOS:A1992GY70400040
J	BRANCA, F; ROBINS, SP; FERROLUZZI, A; GOLDEN, MHN				BRANCA, F; ROBINS, SP; FERROLUZZI, A; GOLDEN, MHN			BONE TURNOVER IN MALNOURISHED CHILDREN	LANCET			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; URINARY-EXCRETION; COLLAGEN; GROWTH; MALNUTRITION; CROSSLINKS; MARKERS; AGE	Pyridinoline (PYD) and deoxypyridinoline (DPD) are cross-linking aminoacids of collagen that are located mainly in bone and cartilage. When bone matrix is resorbed these cross-links are quantitatively excreted in the urine and therefore represent specific markers. We have measured the urinary excretion rate of PYD and DPD in 46 severely malnourished boys to assess their skeletal turnover and to relate this to their subsequent rate of growth. The children were aged 13 months (SD 6), and height-for-age was -3.6 (1.6) Z-score, and weight-for-height was -2.4 (0.8) Z-score. PYD excretion when malnourished and after "recovery" was 11.2 (4.6) nmol h-1m-2 and 32.2 (10.8) nmol h-1m-2 and DPD excretion was 2.6 (1.3) nmol h-1m-2 and 7.5 (3.0) nmol h-1m-2, respectively. The ratio of the two cross-links did not change with recovery. These data show that cartilage and bone turnover is much lower in the malnourished than in the recovered child. There was no difference in the degree of depression of turnover between the children with marasmus, marasmic-kwashiorkor, or kwashiorkor. The rate of height gain during recovery was significantly related to cross-link excretion, age, and weight-for-height on admission. These three factors accounted for 44% of the variance in the height velocity of the children. PYD and DPD excretion rate could be used to assess therapeutic interventions designed to alleviate stunting.	UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA; IST NAZL NUTR,ROME,ITALY; ROWETT RES INST,BUCKSBURN AB2 9SB,ABERDEEN,SCOTLAND	University West Indies Mona Jamaica; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); University of Aberdeen	GOLDEN, MHN (corresponding author), UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND.		Golden, Michael/AAB-8989-2020	Golden, Michael/0000-0002-4039-7538	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAMAGUNA AI, 1986, PEDIATR RADIOL, V16, P40, DOI 10.1007/BF02387503; BAUMGARTNER RN, 1986, AM J CLIN NUTR, V43, P711, DOI 10.1093/ajcn/43.5.711; BEARDSWORTH LJ, 1990, J BONE MINER RES, V5, P671; BLACK D, 1988, ANAL BIOCHEM, V169, P197, DOI 10.1016/0003-2697(88)90274-6; BROWN KH, 1982, AM J CLIN NUTR, V36, P303; COOPER ES, 1990, EUR J CLIN NUTR, V44, P285; DELMAS PD, 1991, J BONE MINER RES, V6, P639; EASTELL R, 1990, 3RD P INT S OST AALB, P469; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; GARN SM, 1981, AM J ROENTGENOL, V137, P231, DOI 10.2214/ajr.137.2.231; GOLDEN M, 1977, AM J CLIN NUTR, V30, P1345, DOI 10.1093/ajcn/30.8.1345; GOLDEN MHN, 1981, TRACE ELEMENT METABO, V4, P69; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HEIKENS GT, 1989, EUR J CLIN NUTR, V43, P145; Himes J H, 1978, World Rev Nutr Diet, V28, P143; JACKSON AA, 1987, OXFORD TXB MED; LAMPL M, 1978, ANN HUM BIOL, V5, P219, DOI 10.1080/03014467800002841; PICOU D, 1966, CLIN SCI, V30, P345; PICOU D, 1965, CLIN SCI, V29, P517; PRUDHON C, 1991, CR ACAD SCI III-VIE, V313, P233; ROBINS SP, 1988, BAILLIERE CLIN RHEUM, V2, P1, DOI 10.1016/S0950-3579(88)80003-7; ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x; TROTTER M, 1970, AM J PHYS ANTHROPOL, V33, P313, DOI 10.1002/ajpa.1330330305; WALKER SP, 1988, EUR J CLIN NUTR, V42, P395; Wellcome Trust Working Party, 1970, LANCET, V2, P302; WHITEHEAD RG, 1965, LANCET, V2, P567; WILKINSON L, 1990, SYSTAT SYSTEM STATIS	28	61	61	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1493	1496		10.1016/0140-6736(92)92754-4	http://dx.doi.org/10.1016/0140-6736(92)92754-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361595				2022-12-24	WOS:A1992KD06900003
J	ADAM, R; BISMUTH, H; DIAMOND, T; DUCOT, B; MORINO, M; ASTARCIOGLU, I; JOHANN, M; AZOULAY, D; CHICHE, L; BAO, YM; CASTAING, D				ADAM, R; BISMUTH, H; DIAMOND, T; DUCOT, B; MORINO, M; ASTARCIOGLU, I; JOHANN, M; AZOULAY, D; CHICHE, L; BAO, YM; CASTAING, D			EFFECT OF EXTENDED COLD ISCHEMIA WITH UW SOLUTION ON GRAFT FUNCTION AFTER LIVER-TRANSPLANTATION	LANCET			English	Article							EURO-COLLINS SOLUTIONS; HYDROXYETHYL STARCH; PRESERVATION; STORAGE; METABOLISM; 24-HOUR; P-31	Studies in animals on the use of UW solution in liver transplantation have shown an inverse relation between cold ischaemia time (CIT) and graft function. There are few clinical data on this relation in human beings. We have investigated the effect of extended cold ischaemia in a prospective study. We assessed early graft function and subsequent outcome for 306 consecutive elective liver transplantations; for analyses, grafts were grouped according to CIT (< 12 h group A, greater-than-or-equal-to 12 h group B), since a preliminary study identified 12 h as a significant cut-off point. Initial graft function was better in group A than group B, as shown by maximum alanine aminotransferase activity (mean 623 [805] vs 946 [1148], p=0.02), bile production on days 1-3 (p<0.05), maximum serum bilirubin by day 10 (206 [166] vs 244 [163] mumol/l, p=0.04), and frequencies of primary non-function (1 [0.4%] vs 4 [7%], p=0.006) and hepatocyte necrosis on routine biopsy sample after reperfusion (18% vs 31%, p=0.04). Long-term outcome was also better in group A than group B; graft and patient survival rates were higher and fewer retransplantations were needed. These findings suggest that cold ischaemia in UW solution for longer than 12 h is a risk factor for graft function and patient survival. We recommend that the limit of the safe CIT be reconsidered.	HOP BICETRE,INSERM,U292,F-94270 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	ADAM, R (corresponding author), HOP PAUL BROUSSE,HEPATOBILIARY SURG & LIVER TRANSPLANT RES UNIT,F-94800 VILLEJUIF,FRANCE.		Azoulay, Daniel/Q-7887-2018; Morino, Mario/AAI-6437-2020	CHICHE, LAURENCE/0000-0001-9081-4750; Morino, Mario/0000-0003-4540-1409				ADAM R, 1990, TRANSPLANT P, V22, P499; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; BISMUTH H, 1984, SURGERY, V95, P367; BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723; COFER JB, 1990, TRANSPLANTATION, V49, P1088, DOI 10.1097/00007890-199006000-00012; FURUKAWA H, 1991, TRANSPLANT P, V23, P1550; HOWARD TK, 1990, TRANSPLANTATION, V49, P103, DOI 10.1097/00007890-199001000-00023; JAMIESON NV, 1988, TRANSPLANTATION, V46, P512, DOI 10.1097/00007890-198810000-00009; JAMIESON NV, 1989, TRANSPLANT P, V21, P1292; KALAYOGLU M, 1988, LANCET, V1, P617; MORINO M, 1992, CLIN TRANSPLANT, V6, P97; NEDELEC JF, 1990, TRANSPLANT P, V22, P492; NEDELEC JF, 1989, TRANSPLANT P, V21, P1327; OLTHOFF KM, 1990, TRANSPLANTATION, V49, P284, DOI 10.1097/00007890-199002000-00012; SANCHEZURDAZPAL L, 1992, HEPATOLOGY, V16, P49, DOI 10.1002/hep.1840160110; STARZL TE, 1987, SURG GYNECOL OBSTET, V165, P343; STRATTA RJ, 1990, TRANSPLANTATION, V50, P438, DOI 10.1097/00007890-199009000-00015; TODO S, 1989, JAMA-J AM MED ASSOC, V261, P711, DOI 10.1001/jama.261.5.711; TODO S, 1989, CLIN TRANSPLANT, V3, P253; WAHLBERG JA, 1987, TRANSPLANTATION, V43, P5, DOI 10.1097/00007890-198701000-00002	20	179	182	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1373	1376		10.1016/0140-6736(92)92559-X	http://dx.doi.org/10.1016/0140-6736(92)92559-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360089				2022-12-24	WOS:A1992KB20200003
J	YOSHINAGA, SK; PETERSON, CL; HERSKOWITZ, I; YAMAMOTO, KR				YOSHINAGA, SK; PETERSON, CL; HERSKOWITZ, I; YAMAMOTO, KR			ROLES OF SWI1, SWI2, AND SWI3 PROTEINS FOR TRANSCRIPTIONAL ENHANCEMENT BY STEROID-RECEPTORS	SCIENCE			English	Article							TUMOR VIRUS PROMOTER; MAMMALIAN GLUCOCORTICOID RECEPTOR; DEHYDROGENASE-II ISOZYME; YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; PREINITIATION COMPLEX; INVITRO TRANSCRIPTION; UPSTREAM ACTIVATION; CHROMATIN STRUCTURE	The SWI1, SWI2, and SWI3 proteins, which are required for regulated transcription of numerous yeast genes, were found also to be essential for rat glucocorticoid receptor function in yeast; the receptor failed to activate transcription in strains with mutations in the SWI1, SWI2, or SWI3 genes. Certain mutations in genes encoding components of chromatin, identified as suppressors of swi mutations, partially relieved the SWI- requirement for receptor function. Immunoprecipitation of glucocorticoid receptor derivatives from wild-type (SWI+) yeast extracts coprecipitated the SWI3 protein; such receptor-SWI3 complexes were not detected in swi1- or swi2- mutant strains, implying that a complex of multiple SWI proteins may associate with the receptor. Prior incubation of a Drosophila embryo transcription extract with the yeast SWI3-specific antibody inhibited receptor function in vitro whereas the antibody had no effect if added after initiation complex formation. Thus, positive regulation by the glucocorticoid receptor in vivo and in vitro appears to require its interaction, at an early step, with one or more SWI proteins.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; GUARENTE L, 1992, TRENDS GENET, V8, P27, DOI 10.1016/0168-9525(92)90021-U; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; IMAI E, UNPUB; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRUGER W, UNPUB; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MOAZED D, COMMUNICATION; NASMYTH K, COMMUNICATION; NEIGEBORN L, 1984, GENETICS, V108, P845; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PERLMANN T, 1991, MOL CELL BIOL, V11, P5259, DOI 10.1128/MCB.11.10.5259; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PICARD D, 1990, GENE, V86, P257, DOI 10.1016/0378-1119(90)90287-2; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHENA M, 1991, P NATL ACAD SCI USA, V88, P10421, DOI 10.1073/pnas.88.23.10421; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAGUCHI AKW, 1987, GENETICS, V116, P531; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WINSTON F, IN PRESS TRENDS GENE; WOOLFORD J, 1986, MOL CELL BIOL, V6, P674; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; YOSHINAGA SK, 1991, MOL ENDOCRINOL, V5, P844, DOI 10.1210/mend-5-6-844; YOSHINAGA SK, UNPUB; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	74	434	439	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1598	1604		10.1126/science.1360703	http://dx.doi.org/10.1126/science.1360703			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1360703				2022-12-24	WOS:A1992KA89600021
J	CHATELAIN, P; MEIER, B; DELASERNA, F; MOLES, V; PANDE, AK; VERINE, V; URBAN, P				CHATELAIN, P; MEIER, B; DELASERNA, F; MOLES, V; PANDE, AK; VERINE, V; URBAN, P			SUCCESS WITH CORONARY ANGIOPLASTY AS SEEN AT DEMONSTRATIONS OF PROCEDURE	LANCET			English	Article							NATIONAL-HEART; OCCLUSION; REGISTRY; STENTS; LUNG	To assess the real-life results of coronary angioplasty, unidentified participants made notes on 104 cases demonstrated live at twelve international angioplasty courses in 1991. The initially planned procedure was successful in 73% with crossover to another device in 20% for an ultimate success rate of 93%. Interventions lasted an hour on average and two devices on average were used per artery tackled. Rates of success and of complication necessitating reintervention were, for balloon angioplasty (57 cases) 81% and 19%, for directional atherectomy (16 cases) 75% and 0%, for the Rotablator (12 cases) 42% and 42%, for stent implantation (10 cases) 100% and 0%, for excimer laser angioplasty (6 cases) 17% and 33%, and for Rotacs recanalisation (3 cases) 67% and 0%, respectively. The complications were occlusions (threatened, acute, or delayed) and they were usually treated by balloon angioplasty or a stent. No death or myocardial infarction was reported. The observer attending the demonstration tended to take a less favourable view of the outcome than the clinician doing the procedure and in general the results of coronary angioplasty seemed inferior to those reported in journals. Interventions done before an audience will be unusually stressful but this will be outweighed by the fact that difficult cases with a low probability of success are rarely tackled during live courses. This survey suggests that conventional balloon angioplasty, complemented by stent implantation in selected cases, is the treatment of choice.	UNIV GENEVA,HOP CANTONAL,CTR CARDIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			DE LA SERNA, JAVIER/B-1735-2012	DE LA SERNA, JAVIER/0000-0003-3904-1101				DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; ERBEL R, 1986, CATHETER CARDIO DIAG, V12, P116, DOI 10.1002/ccd.1810120211; FOURRIER JL, 1989, J AM COLL CARDIOL, V14, P1278, DOI 10.1016/0735-1097(89)90428-2; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; HINOHARA T, 1990, CIRCULATION, V81, P79; HOLMES DR, 1990, TXB INTERVENTIONAL C, P223; KALTENBACH M, 1989, J INTERVEN CARDIOL, V2, P137; LITVACK F, 1989, LANCET, V1, P102; Meany T B, 1991, J Invasive Cardiol, V3, P19; MEIER B, 1992, JAMA-J AM MED ASSOC, V268, P741, DOI 10.1001/jama.268.6.741; SANBORN TA, 1991, J AM COLL CARDIOL, V17, P94, DOI 10.1016/0735-1097(91)90709-I; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHATZ RA, 1989, CIRCULATION, V79, P445, DOI 10.1161/01.CIR.79.2.445; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; TOPOL E J, 1992, Journal of the American College of Cardiology, V19, p138A; UMANS V, 1992, EUR HEART J, V13, P918, DOI 10.1093/oxfordjournals.eurheartj.a060293; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C	18	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1202	1205		10.1016/0140-6736(92)92900-Z	http://dx.doi.org/10.1016/0140-6736(92)92900-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359269				2022-12-24	WOS:A1992JY38600012
J	WANG, GH; SEEGER, C				WANG, GH; SEEGER, C			THE REVERSE-TRANSCRIPTASE OF HEPATITIS-B VIRUS ACTS AS A PROTEIN PRIMER FOR VIRAL-DNA SYNTHESIS	CELL			English	Article							P-GENE-PRODUCT; RNA ENCAPSIDATION; TERMINAL PROTEIN; POLYMERASE; GENOME; INITIATION; SEQUENCE; IDENTIFICATION; REPLICATION; WOODCHUCK	Hepatitis B viruses (hepadnaviruses) replicate their DNA genomes by reverse transcription of an RNA intermediate. Efforts to examine the biochemical mechanism for viral DNA synthesis have been hampered by the failure to solubilize the reverse transcriptase from virions and to express the polymerase in heterologous systems in an enzymatically active form. Here, we demonstrate that the polymerase of a hepadnavirus synthesized in an in vitro translation reaction exhibits reverse transcriptase activity. Furthermore, our results show that the polymerase acts as a primer for DNA synthesis and remains covalently linked to nascent DNA, a feature that is not known to exist in any other RNA-directed DNA polymerases. Priming of DNA synthesis requires viral RNA but occurs independently of other viral components. The ability to express the hepadnavirus reverse transcriptase in an enzymatically active form will allow detailed biochemical and functional analyses of this complex enzyme, and may facilitate the identification of inhibitors required for antiviral therapy.			WANG, GH (corresponding author), FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111, USA.				NCI NIH HHS [CA-06927] Funding Source: Medline; NIAID NIH HHS [AI-30544, AI-24972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024972, R01AI030544, R29AI024972] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHANG LJ, 1989, NATURE, V337, P364, DOI 10.1038/337364a0; CONDREAY LD, 1992, VIROLOGY, V188, P208, DOI 10.1016/0042-6822(92)90751-A; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GERLICH WH, 1980, CELL, V21, P801, DOI 10.1016/0092-8674(80)90443-2; HELGSTRAND E, 1978, SCIENCE, V201, P819, DOI 10.1126/science.210500; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P550; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973; KHUDYAKOV YE, 1989, FEBS LETT, V243, P115, DOI 10.1016/0014-5793(89)80110-3; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIEN JM, 1987, J VIROL, V61, P3832, DOI 10.1128/JVI.61.12.3832-3840.1987; MANDART E, 1984, J VIROL, V49, P782, DOI 10.1128/JVI.49.3.782-792.1984; Mason W. S., 1987, Hepadna viruses. Proceedings of a Director's Sponsors-UCLA Symposium. Held at Keystone, Colorado, March 29-April 3, 1987, P3; MOLNARKIMBER KL, 1983, J VIROL, V45, P165, DOI 10.1128/JVI.45.1.165-172.1983; PUGH JC, 1988, J VIROL, V62, P3513, DOI 10.1128/JVI.62.9.3513-3516.1988; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; ROYCHOUDHURY S, 1991, J VIROL, V65, P3617, DOI 10.1128/JVI.65.7.3617-3624.1991; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; SEEGER C, 1991, J VIROL, V65, P5190, DOI 10.1128/JVI.65.10.5190-5195.1991; SEEGER C, 1990, J VIROL, V64, P16, DOI 10.1128/JVI.64.1.16-23.1990; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WU TT, 1991, J VIROL, V65, P2155, DOI 10.1128/JVI.65.5.2155-2163.1991	32	313	329	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					663	670		10.1016/0092-8674(92)90599-8	http://dx.doi.org/10.1016/0092-8674(92)90599-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1384989				2022-12-24	WOS:A1992JY67600013
J	CLARK, IA; ROCKETT, KA; COWDEN, WB				CLARK, IA; ROCKETT, KA; COWDEN, WB			POSSIBLE CENTRAL ROLE OF NITRIC-OXIDE IN CONDITIONS CLINICALLY SIMILAR TO CEREBRAL MALARIA	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; ETHANOL; MORPHINE; CALCIUM; INHIBITION; WITHDRAWAL; RECEPTORS; TOLERANCE; SEIZURES; RELEASE	The changes in mental status during cerebral malaria, heat stroke, and recovery from major surgery are clinically similar, and are associated with high circulating concentrations of cytokines that can induce nitric oxide generation in vascular walls. This vascular nitric oxide could diffuse across the blood-brain barrier, causing functional changes that include inhibition of glutamate-induced calcium entry, reduced activity of the calcium-dependent nitric oxide synthase, and thus reduced nitric oxide formation, in post-synaptic neurons. Certain general anaesthetics and ethanol reduce glutamate-induced calcium entry into post-synaptic cells, and so would also reduce the rate of formation of neuronal nitric oxide. In view of the apparent importance of glutamate-induced nitric oxide in excitatory neurotransmission, a reduction in neuronal nitric oxide could help explain why these otherwise unrelated influences alter central nervous system function in a similar manner. In particular, this reduction could rationalise why heat stroke, ethanol excess, morphine poisoning, and conditions with high blood ammonia concentrations are easily confused clinically with cerebral malaria.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research	CLARK, IA (corresponding author), AUSTRALIAN NATL UNIV,SCH LIFE SCI,DIV BIOCHEM & MOLEC BIOL,GPO BOX 4,CANBERRA,ACT 2601,AUSTRALIA.		Clark, Ian A./K-2069-2012					ARN PH, 1990, NEW ENGL J MED, V322, P1652, DOI 10.1056/NEJM199006073222307; BAIGRIE RJ, 1991, LYMPHOKINE CYTOK RES, V10, P253; BIANCHI M, 1991, NEUROCHEM RES, V16, P443, DOI 10.1007/BF00965564; BOUCHAMA A, 1991, J APPL PHYSIOL, V70, P2640, DOI 10.1152/jappl.1991.70.6.2640; CLARK IA, 1991, PARASITOL TODAY, V7, P205, DOI 10.1016/0169-4758(91)90142-B; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; DENICOFF KD, 1987, ANN INTERN MED, V107, P293, DOI 10.7326/0003-4819-107-2-293; DESARRO GB, 1991, FUNDAM CLIN PHARM, V5, P503; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; ECCLES JC, 1946, J NEUROPHYSIOL, V9, P87, DOI 10.1152/jn.1946.9.2.87; FIDECKA S, 1986, POL J PHARMACOL PHAR, V38, P277; FIDECKA S, 1989, POL J PHARMACOL PHAR, V41, P23; FRASER CL, 1985, NEW ENGL J MED, V313, P865, DOI 10.1056/NEJM198510033131406; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; HARRIS RA, 1977, LIFE SCI, V20, P501; HEGESCHEUING G, 1989, ANAESTHESIST, V38, P443; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; JOHNS RA, 1991, ANESTHESIOLOGY, V75, P927; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; ROCKETT KA, 1992, INFECT IMMUN, V60, P3725, DOI 10.1128/IAI.60.9.3725-3730.1992; SIMSON PE, 1991, J PHARMACOL EXP THER, V257, P225; SPRIGGS DR, 1988, J NATL CANCER I, V80, P1039, DOI 10.1093/jnci/80.13.1039; SZERB JC, 1992, PROG NEUROBIOL, V39, P135, DOI 10.1016/0301-0082(92)90008-3; TANG TT, 1975, JAMA-J AM MED ASSOC, V232, P1339, DOI 10.1001/jama.232.13.1339; TANGANELLI S, 1991, NEUROSCI LETT, V122, P270, DOI 10.1016/0304-3940(91)90875-T; 1942, MEMORANDUM 24 MED DI, P154	30	120	122	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					894	896		10.1016/0140-6736(92)93295-X	http://dx.doi.org/10.1016/0140-6736(92)93295-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1383658				2022-12-24	WOS:A1992JT32700014
J	AABY, P				AABY, P			INFLUENCE OF CROSS-SEX TRANSMISSION ON MEASLES MORTALITY IN RURAL SENEGAL	LANCET			English	Article							INTENSIVE EXPOSURE; CHILD-MORTALITY; INFECTION; PATTERN	Previous studies of measles mortality in West Africa have shown a significantly higher case-fatality rate (CFR) among girls than among boys. This study aimed to find out whether the male/female difference in CFR is related to different risks for boys and girls of being infected as secondary rather than index cases and of transmission from someone of the same or the opposite sex. The study was conducted in Niakhar, a rural area of Senegal (population 24 000). All cases of measles reported between March, 1983, and December, 1986, were investigated to determine source of infection and pattern of transmission. For each case, the closest source of infection was judged the most likely. Death was attributed to measles if it occurred within 6 weeks of the onset of rash. Girls had a higher measles CFR than boys (53 deaths/722 cases [7.3%] vs 45/778 [5.8%]); the relative risk of death was 1.30 (95% confidence interval [CI] 0.89-1.90). Secondary cases infected by a child of the opposite sex had a 2.44 (1.48-4.02) times higher risk of death than did secondary cases infected by a child of the same sex. The risk of cross-sex transmission of infection was significantly greater for female than for male secondary cases (1.26 [1.09-1.47]). When this difference in risk of exposure to infection from the opposite sex was taken into account, the difference in risk of death between girls and boys disappeared (1.06 [0.66-1.69]). Within families, the CFR was higher in huts with 1 boy and 1 girl affected than in huts of either 2 boys or 2 girls affected (relative risk 2.16 [0.99-4.70]). Measles infection contracted from a person of the opposite sex is more severe. Variation in exposure may be an important determinant of sex differences in case fatality.	ORSTOM,UNITE RECH POPULAT & SANTE,DAKAR,SENEGAL; STATENS SERUM INST,DEPT EPIDEMIOL,DK-2300 COPENHAGEN,DENMARK	Institut de Recherche pour le Developpement (IRD); Statens Serum Institut				Aaby, Peter/0000-0001-8331-1389				AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5; AABY P, 1991, J INFECTION, V22, P287, DOI 10.1016/S0163-4453(05)80014-3; AABY P, 1988, REV INFECT DIS, V10, P478; AABY P, 1991, ANN TROP PAEDIATR, V11, P397, DOI 10.1080/02724936.1991.11747537; AABY P, 1991, INT J EPIDEMIOL, V20, P504, DOI 10.1093/ije/20.2.504; AABY P, 1984, REV INFECT DIS, V6, P239; AABY P, 1990, BRIT MED J, V301, P143, DOI 10.1136/bmj.301.6744.143; AABY P, 1986, REV INFECT DIS, V8, P138; AABY P, 1983, ANTHR SOC, V7, P47; ARGUES P, 1988, DOUZE ANS MORTALITE; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BHUIYA A, 1984, SOC SCI MED, V24, P439; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; Garenne M. L, 1982, THESIS U PENNSYLVANI; MCGREGOR I A, 1964, West Afr Med J, V13, P251; MONASTIRI H, 1961, Tunis Med, V39, P179; PISON G, 1992, BRIT MED J, V304, P284, DOI 10.1136/bmj.304.6822.284; Rothman K, 1986, MODERN EPIDEMIOLOGY; 1991, WKLY EPIDEMIOL REC, V66, P249; IN PRESS WKLY EPIDEM	20	30	31	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					388	391		10.1016/0140-6736(92)91470-S	http://dx.doi.org/10.1016/0140-6736(92)91470-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353555				2022-12-24	WOS:A1992JJ44900003
J	MENNIE, ME; GILFILLAN, A; COMPTON, M; CURTIS, L; LISTON, WA; PULLEN, I; WHYTE, DA; BROCK, DJH				MENNIE, ME; GILFILLAN, A; COMPTON, M; CURTIS, L; LISTON, WA; PULLEN, I; WHYTE, DA; BROCK, DJH			PRENATAL SCREENING FOR CYSTIC-FIBROSIS	LANCET			English	Article							IDENTIFICATION; GENE	Screening for carriers of CF (cystic fibrosis) is now possible but the best way of delivering such a service is unknown. In one model 4348 women attending antenatal clinics in an Edinburgh maternity hospital were invited to participate in a trial of prenatal screening. Mouthwash samples were tested for six CF alleles (85% of mutant genes) and when a woman was found to be a CF carrier her partner was also tested. Heterozygous couples were offered prenatal diagnosis. 609 (14%) women declined to enter the trial and another 574 (13%) were not screened, usually because of late booking. Among the remaining 3165 women there were 111 carriers of a CF gene (1 in 29). 4 of these 111 had carrier partners and these couples opted for prenatal diagnosis, the 1 pregnancy with an affected fetus being terminated. The psychological impact of screening was assessed by the general health questionnaire. There was a significant increase in stress at the time of the test result among women identified as carriers. However, this disappeared when their male partners tested normal and did not reappear later in the pregnancy. By providing time for couples to discuss the possibility of screening and by offering the test at a point (the antenatal booking clinic) at which most pregnant women are seen, this approach has advantages, provided that counselling is readily available.	UNIV EDINBURGH,HUMAN GENET UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHIAT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT NURSING STUDIES,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh								BROCK DJH, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92013-R; FERRIE RM, 1991, AM J HUM GENET, V49, pA993; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; KEREM B, 1989, SCIENCE, V345, P1073; MARI JD, 1985, PSYCHOL MED, V15, P651; MCINTOSH I, 1989, LANCET, V2, P1404; MENNIE ME, 1992, J MED GENET, V29, P308, DOI 10.1136/jmg.29.5.308; MODELL B, 1990, J MED GENET, V27, P475, DOI 10.1136/jmg.27.8.475; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHAPIRO DA, 1989, NEW YORK STATE J MED, V89, P317; SHARP DJ, 1988, PSYCHOL MED, V18, P503, DOI 10.1017/S0033291700008047; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1989, PRENATAL DIAGNOSIS G	16	121	123	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					214	216		10.1016/0140-6736(92)90476-J	http://dx.doi.org/10.1016/0140-6736(92)90476-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353143				2022-12-24	WOS:A1992JE75800011
J	PALERMO, G; JORIS, H; DEVROEY, P; VANSTEIRTEGHEM, AC				PALERMO, G; JORIS, H; DEVROEY, P; VANSTEIRTEGHEM, AC			PREGNANCIES AFTER INTRACYTOPLASMIC INJECTION OF SINGLE SPERMATOZOON INTO AN OOCYTE	LANCET			English	Note							EMBRYOS; SPERM; ZONA	Intracytoplasmic sperm injection (ICSI) is a promising assisted-fertilisation technique that may benefit women who have not become pregnant by in-vitro fertilisation (IVF) or subzonal insemination (SUZI) of oocytes. We have used ICSI to treat couples with infertility because of severely impaired sperm characteristics, and in whom IVF and SUZI had failed. Direct injection of a single spermatozoon into the ooplasm was done in 47 metaphase-II oocytes: 38 oocytes remained intact after injection, 31 became fertilised, and 15 embryos were replaced in utero. Four pregnancies occurred after eight treatment cycles-two singleton and one twin pregnancy, and a preclinical abortion. Two healthy boys have been delivered from the singleton pregnancies and a healthy boy and girl from the twin pregnancy.			PALERMO, G (corresponding author), VRIJE UNIV BRUSSELS,ACAD ZIEKENHUIS,CTR REPROD MED,LAARBEEKLAAN 101,B-1090 BRUSSELS,BELGIUM.							COHEN J, 1988, LANCET, V2, P162; IRITANI A, 1991, MOL REPROD DEV, V28, P199, DOI 10.1002/mrd.1080280214; LANZENDORF SE, 1988, FERTIL STERIL, V49, P835; NG SC, 1991, FERTIL STERIL, V56, P1117; NG SC, 1988, LANCET, V2, P790; PALERMO G, 1991, MOL REPROD DEV, V30, P339, DOI 10.1002/mrd.1080300408; PALERMO G, 1992, HUM REPROD, V7, P248, DOI 10.1093/oxfordjournals.humrep.a137626; VANSTEIRTEGHEM AC, 1987, HUM REPROD, V2, P593, DOI 10.1093/oxfordjournals.humrep.a136595; VEECK LL, 1990, 45TH P ANN M AM FERT	9	2451	2592	7	130	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					17	18		10.1016/0140-6736(92)92425-F	http://dx.doi.org/10.1016/0140-6736(92)92425-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351601				2022-12-24	WOS:A1992JC35400005
J	GAO, YJ; THOMAS, JO; CHOW, RL; LEE, GH; COWAN, NJ				GAO, YJ; THOMAS, JO; CHOW, RL; LEE, GH; COWAN, NJ			A CYTOPLASMIC CHAPERONIN THAT CATALYZES BETA-ACTIN FOLDING	CELL			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; T-COMPLEX POLYPEPTIDE-1; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; TCP-1; CELLS; GROE; ARCHAEBACTERIA; MITOCHONDRIA; PURIFICATION	We have isolated a cytoplasmic chaperonin based on its ability to catalyze the folding of denatured beta-actin. The cytoplasmic chaperonin is organized as a multisubunit toroid and requires Mg2+ and ATP for activity. The folding reaction proceeds via the rapid ATP-independent formation of a binary complex, followed by a slower ATP-dependent release of the native product. Electron microscopic observations reveal a striking structural change that occurs upon addition of Mg2+ and ATP. The eukaryotic cytoplasm thus contains a chaperonin that is functionally analagous to its prokaryotic, mitochondrial, and chloroplastic counter parts.			GAO, YJ (corresponding author), NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016, USA.							AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUTCHISON EG, 1989, EMBO J, V8, P1484; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVILLIERS N, 1984, BIOCHIMIE, V66, P531, DOI 10.1016/0300-9084(84)90147-0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MILLER SG, 1990, J MOL BIOL, V214, P407, DOI 10.1016/0022-2836(90)90190-W; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHI Y, 1992, IN PRESS MOL CELL BI; SILVER LM, 1979, P NATL ACAD SCI USA, V77, P6077; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRENT JT, 1992, NATURE, V354, P490; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; ZILLIG W, 1987, ANN NY ACAD SCI, V503, P78, DOI 10.1111/j.1749-6632.1987.tb40599.x	40	427	439	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					1043	1050		10.1016/0092-8674(92)90622-J	http://dx.doi.org/10.1016/0092-8674(92)90622-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1351421				2022-12-24	WOS:A1992HY79200015
J	BUSTELO, XR; BARBACID, M				BUSTELO, XR; BARBACID, M			TYROSINE PHOSPHORYLATION OF THE VAV PROTOONCOGENE PRODUCT IN ACTIVATED B-CELLS	SCIENCE			English	Article							ANTI-IGM; STIMULATION	Activation of B lymphocytes by engagement of their immunoglobulin M antigen receptors results in phosphorylation of a number of proteins on tyrosine residues. One such protein is p95vav, the product of the vav proto-oncogene. Tyrosine phosphorylation of p95-vav occurred within seconds of immunoglobulin M cross-linking and was independent of other events induced during stimulation of B cells, such as protein kinase C activation, guanosine triphosphate-binding protein signaling, and calcium mobilization. Moreover, engagement of antigen receptors induced the rapid (approximately 5 seconds) and transient (approximately 60 seconds) association of p95vav with a 70-kilodalton tyrosine-phosphorylated protein, Vap-1, an interaction mediated by the Src homology 2 domain of p95vav. These results suggest that the vav proto-oncogene participates in the signaling processes that mediate the antigen-induced activation of B lymphocytes.			BUSTELO, XR (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				ADAMS JM, IN PRESS ONCOGENE; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, pCH3; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; GALLAND F, 1992, ONCOGENE, V7, P585; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MIZUGUCHI J, 1988, J IMMUNOL, V140, P2495; MIZUGUCHI J, 1986, P NATL ACAD SCI USA, V83, P4474, DOI 10.1073/pnas.83.12.4474; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	18	211	220	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1196	1199		10.1126/science.256.5060.1196	http://dx.doi.org/10.1126/science.256.5060.1196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1375396				2022-12-24	WOS:A1992HV19200034
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REQUIREMENT FOR MANUFACTURERS TO TRACK CERTAIN MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-24	WOS:A1992HT06800004
J	MILLER, B; SARANTIS, M; TRAYNELIS, SF; ATTWELL, D				MILLER, B; SARANTIS, M; TRAYNELIS, SF; ATTWELL, D			POTENTIATION OF NMDA RECEPTOR CURRENTS BY ARACHIDONIC-ACID	NATURE			English	Article							LONG-TERM POTENTIATION; METHYL-D-ASPARTATE; PROTEIN KINASE-C; NORDIHYDROGUAIARETIC ACID; STRIATAL NEURONS; GLUTAMATE UPTAKE; 2ND MESSENGERS; DENTATE GYRUS; FATTY-ACIDS; RAT	ARACHIDONIC acid is released by phospholipase A2 when activation of N-methyl-D-aspartate (NMDA) receptors by neurotransmitter glutamate raises the calcium concentration in neurons 1,2, for example during the initiation of long-term potentiation and during brain anoxia 3,4. Here we investigate the effect of arachidonic acid on glutamate-gated ion channels by whole-cell clamping isolated cerebellar granule cells. Arachidonic acid potentiates, and makes more transient, the current through NMDA receptor channels, and slightly reduces the current through non-NMDA receptor channels. Potentiation of the NMDA receptor current results from an increase in channel open probability, with no change in open channel current. We observe potentiation even with saturating levels of agonist at the glutamate- and glycine-binding sites on these channels; it does not result from conversion of arachidonic acid to lipoxygenase or cyclooxygenase derivatives, or from activation of protein kinase C. Arachidonic acid may act by binding to a site on the NMDA receptor, or by modifying the receptor's lipid environment. Our results suggest that arachidonic acid released by activation of NMDA (or other) receptors will potentiate NMDA receptor currents, and thus amplify increases in intracellular calcium concentration caused by glutamate. This may explain why inhibition of phospholipase A2 blocks the induction of long-term potentiation 5.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	MILLER, B (corresponding author), UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND.		Attwell, David/ABE-6750-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DAVIES J, 1982, COMP BIOCHEM PHYS C, V72, P211, DOI 10.1016/0306-4492(82)90086-7; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; GOPPELTSTRUEBE M, 1986, PROSTAGLANDINS, V32, P373, DOI 10.1016/0090-6980(86)90006-7; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LINDEN DJ, 1987, J NEUROSCI, V7, P3783; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKADA D, 1989, NEUROSCI LETT, V100, P141, DOI 10.1016/0304-3940(89)90674-5; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SPROSEN TS, 1990, EUR J PHARMACOL, V179, P477, DOI 10.1016/0014-2999(90)90193-A; WEAST RC, 1971, CRC HDB CHEM PHYSICS, pF47; WILLIAMS JH, 1988, NEUROSCI LETT, V88, P81, DOI 10.1016/0304-3940(88)90319-9	26	419	432	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					722	725		10.1038/355722a0	http://dx.doi.org/10.1038/355722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1371330				2022-12-24	WOS:A1992HE60400062
J	ZANETTI, M				ZANETTI, M			ANTIGENIZED ANTIBODIES	NATURE			English	Article							RESHAPING HUMAN-ANTIBODIES; 3-DIMENSIONAL STRUCTURE; INTERNAL IMAGE; PROTEIN; PEPTIDE; EPITOPE; MUTAGENESIS; MOLECULES; VACCINES; LIBRARY		UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92103	University of California System; University of California San Diego	ZANETTI, M (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103, USA.							ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ATASSI MZ, 1980, MOL CELL BIOCHEM, V32, P21; BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CO MS, 1991, P NATL ACAD SCI USA, V88, P2869, DOI 10.1073/pnas.88.7.2869; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GEYSEN HM, 1985, IMMUNOL TODAY, V6, P364, DOI 10.1016/0167-5699(85)90096-9; HOFFMAN SL, 1991, SCIENCE, V252, P520, DOI 10.1126/science.2020852; JENNINGS PA, 1989, PROTEIN ENG, V2, P365, DOI 10.1093/protein/2.5.365; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KABAT EA, 1987, PROTEINS IMMUNOLOGIC; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWAJIMA G, 1988, BIO-TECHNOL, V6, P1080, DOI 10.1038/nbt0988-1080; LERNER RA, 1983, SCI AM, V248, P66, DOI 10.1038/scientificamerican0283-66; NEWMARK P, 1983, NATURE, V305, P9, DOI 10.1038/305009a0; NEWTON SMC, 1989, SCIENCE, V244, P70, DOI 10.1126/science.2468182; NOVOTNY J, 1975, NATURE, V258, P641, DOI 10.1038/258641a0; OLLIER P, 1985, EMBO J, V4, P3681, DOI 10.1002/j.1460-2075.1985.tb04135.x; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SOLLAZZO M, 1990, PROTEIN ENG, V4, P215, DOI 10.1093/protein/4.2.215; SPANGLER BD, 1991, J IMMUNOL, V146, P1591; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; VAN CV, 1988, J EXP, V167, P1841; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; ZANETTI M, 1991, ANTIIDOTYPIC VACCINE, P123	30	44	64	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					476	477		10.1038/355476a0	http://dx.doi.org/10.1038/355476a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1370860				2022-12-24	WOS:A1992HB53000079
J	SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C				SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C			RED-BLOOD-CELL TRANSFUSION IN WARM-TYPE AUTOIMMUNE HEMOLYTIC-ANEMIA	LANCET			English	Article							HEMOLYTIC-ANEMIA; AUTOANTIBODIES	Blood transfusions are regarded as hazardous in patients with warm-type autoimmune haemolytic anaemia (AIHA) because of potential intensification of haemolysis and a presumed high incidence of alloimmunisation. We have retrospectively analysed data of 79 multitransfused patients (74 adults, 5 children) with detectable warm autoantibodies and transitory or persisting haemolytic anaemia. All patients had received blood transfusions on at least two occasions. Patients were reexamined at least twice within the first 6 months of transfusion (duration of follow-up 6 months-12 years). 53 patients had received blood transfusions because of decompensated AIHA, all of whom presented with detectable autoantibodies against red blood cells. None of these patients had transfusion-related alloimmunisation or a definite increase in haemolysis, even when the transfused red cells were serologically incompatible because of free serum autoantibodies. The other 26 patients had no signs of AIHA at presentation (negative direct and indirect antiglobulin test), but received blood transfusions for anaemia due to various other causes. 23 of these 26 patients went on to develop alloantibodies as well as autoantibodies upon transfusion, and 3 patients developed autoantibodies alone. Our findings do not support the generally accepted notion that transfusion therapy should be avoided in AIHA patients. Rather, they indicate that the incidence of alloimmunisation as well as adverse haemolytic transfusion reactions are less common in AIHA patients than in other multitransfused patients.	UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY; UNIV GIESSEN,DEPT INTERNAL MED,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen; Justus Liebig University Giessen	MUELLERECKHARDT, C (corresponding author), UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY.							BELL CA, 1973, AM J CLIN PATHOL, V60, P903; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; CROOKSTON JH, 1975, ARCH INTERN MED, V135, P1314, DOI 10.1001/archinte.135.10.1314; HABIBI B, 1974, AM J MED, V56, P61, DOI 10.1016/0002-9343(74)90751-7; ISSITT P, 1985, APPLIED BLOOD GROUP; LEDDY JP, 1970, J IMMUNOL, V105, P677; NESS PM, 1990, TRANSFUSION, V30, P688, DOI 10.1046/j.1537-2995.1990.30891020325.x; Petz LD, 1980, ACQUIRED IMMUNE HEMO; PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167; ROSENFIELD RE, 1976, SEMIN HEMATOL, V13, P311; SALAMA A, 1987, BRIT J HAEMATOL, V65, P67, DOI 10.1111/j.1365-2141.1987.tb06137.x; SALAMA A, 1984, TRANSFUSION, V24, P188, DOI 10.1046/j.1537-2995.1984.24384225018.x; WALLHERMFECHTEL MA, 1984, TRANSFUSION, V24, P482, DOI 10.1046/j.1537-2995.1984.24685066805.x	13	53	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1515	1517		10.1016/0140-6736(92)92766-9	http://dx.doi.org/10.1016/0140-6736(92)92766-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361607				2022-12-24	WOS:A1992KD06900015
J	WEBER, FH; MCCALLUM, RW				WEBER, FH; MCCALLUM, RW			CLINICAL APPROACHES TO IRRITABLE-BOWEL-SYNDROME	LANCET			English	Article							DOUBLE-BLIND; DISORDERS; PLACEBO; DIAGNOSIS; MOTILITY; TRANSIT		UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA 22908	University of Virginia								BYRNE S, 1987, J CLIN PSYCHIAT, V48, P388; CAMILLERI M, 1989, AM J PHYSIOL, V257, pG284, DOI 10.1152/ajpgi.1989.257.2.G284; CHAUDHARY NA, 1962, Q J MED, V31, P307; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; FIELDING JF, 1981, DIGESTION, V22, P155, DOI 10.1159/000198627; Froguel E., 1990, J GASTROINTEST MOTIL, V2, P176; GREENBAUM DS, 1987, DIGEST DIS SCI, V32, P257, DOI 10.1007/BF01297051; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HARVEY RF, 1983, LANCET, V1, P632; HASLER W, 1992, Gastroenterology, V102, pA457; KEELING PWN, 1975, J IRISH COLL PHYS S, V4, P91; KELLOW JE, 1987, GASTROENTEROLOGY, V92, P1885, DOI 10.1016/0016-5085(87)90620-2; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KREVSKY B, 1992, DIGEST DIS SCI, V37, P919, DOI 10.1007/BF01300391; LAVO B, 1987, SCAND J GASTROENTERO, V22, P77, DOI 10.3109/00365528709091003; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MATHIAS JR, 1989, DIGEST DIS SCI, V34, P761, DOI 10.1007/BF01540350; MAXTON DG, 1991, GUT, V32, P662, DOI 10.1136/gut.32.6.662; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; PASSARETTI S, 1989, ALIMENT PHARM THERAP, V3, P267; PASSARETTI S, 1987, PROG MED, V43, P121; PRIOR A, 1987, GUT, V28, P1510, DOI 10.1136/gut.28.11.1510; RITSEMA GH, 1991, CLIN RADIOL, V43, P113, DOI 10.1016/S0009-9260(05)81589-2; SASAKI D, 1986, GASTROINTEST ENDOSC, V32, P185, DOI 10.1016/S0016-5107(86)71801-4; SCHAFFSTEIN W, 1990, CURR THER RES CLIN E, V47, P136; SCIARRETTA G, 1987, GUT, V28, P970, DOI 10.1136/gut.28.8.970; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; STAFANINI GF, 1992, AM J GASTROENTEROL, V87, P55; STEADMAN C J, 1990, Gastroenterology, V98, pA394; SUTBBS JB, 1991, J NUCL MED, V32, P1375; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1987, LANCET, V2, P1144; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VANOUTRYVE M, 1991, J CLIN GASTROENTEROL, V13, P49; WALSH P, 1986, BR J CLIN PRACT, V40, P292; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1485, DOI 10.1016/0016-5085(90)91079-L; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423	39	24	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1447	1452		10.1016/0140-6736(92)92632-P	http://dx.doi.org/10.1016/0140-6736(92)92632-P			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360569				2022-12-24	WOS:A1992KC28400013
J	SUN, XF; CARSTENSEN, JM; ZHANG, H; STAL, O; WINGREN, S; HATSCHEK, T; NORDENSKJOLD, B				SUN, XF; CARSTENSEN, JM; ZHANG, H; STAL, O; WINGREN, S; HATSCHEK, T; NORDENSKJOLD, B			PROGNOSTIC-SIGNIFICANCE OF CYTOPLASMIC-P53 ONCOPROTEIN IN COLORECTAL ADENOCARCINOMA	LANCET			English	Article							P53 EXPRESSION; BREAST-CANCER; ONCOGENE; TUMORS	Mutation of p53, a tumour-suppressor protein, leads to overexpression of the protein and loss of its tumour-suppressive properties. In some tumours (eg, breast) p53 expression is related to well-known prognostic factors, but findings in colorectal tumours are equivocal. We have used the polyclonal antibody CM1 to investigate nuclear and cytoplasmic p53 expression in colorectal tumours and to assess their relations with prognosis. Of 293 colorectal adenocarcinomas, 71 (24%) showed p53 expression in the nucleus alone, 30 (10%) showed p53 in the cytoplasm alone, and 43 (15%) showed both nuclear and cytoplasmic expression. Nuclear p53 expression showed no relation with survival or Dukes' stage of the tumour. However, the frequency of cytoplasmic expression increased with advancing Dukes' stage (chi2 for trend 11.18, 1 df, p=0.0008) and cytoplasmic expression was associated with poor survival (rate ratio 2.3 [95% Cl 1.6-3.3], p<0.0001). Among tumours of Dukes' stage A-C, cytoplasmic expression showed prognostic value independent of nuclear staining, grade of differentiation, and Dukes' stage (2.3 [1.4-3.7], p=0.0021). We conclude that cytoplasmic expression of p53 may be a useful biological indicator of prognosis in colorectal adenocarcinoma.	LINKOPING UNIV HOSP,DEPT PATHOL,S-58185 LINKOPING,SWEDEN	Linkoping University	SUN, XF (corresponding author), LINKOPING UNIV HOSP,DEPT ONCOL,S-58185 LINKOPING,SWEDEN.			Carstensen, John/0000-0003-2256-8089				ARMITAGE P, 1987, STATISTICAL METHODS; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; COSSMAN J, 1991, J NATL CANCER I, V83, P980, DOI 10.1093/jnci/83.14.980; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIDOFF AM, 1991, SURGERY, V110, P259; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARRIS AL, 1990, J PATHOL, V162, P5, DOI 10.1002/path.1711620103; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; PURDIE CA, 1991, AM J PATHOL, V138, P807; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REMVIKOS Y, 1990, INT J CANCER, V45, P450, DOI 10.1002/ijc.2910450313; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1991, ADV ONCOL, V7, P3	20	234	237	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1369	1373		10.1016/0140-6736(92)92558-W	http://dx.doi.org/10.1016/0140-6736(92)92558-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360088				2022-12-24	WOS:A1992KB20200002
J	SCHOLEFIELD, JH; HICKSON, WGE; SMITH, JHF; ROGERS, K; SHARP, F				SCHOLEFIELD, JH; HICKSON, WGE; SMITH, JHF; ROGERS, K; SHARP, F			ANAL INTRAEPITHELIAL NEOPLASIA - PART OF A MULTIFOCAL DISEASE PROCESS	LANCET			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN-REACTION; PREVALENCE; CERVIX; WARTS; WOMEN	Invasive carcinomas of the anogenital epithelium share a common aetiological facto-human papillomavirus (HPV) type 16. Although genital intraepithelial neoplasia may be multifocal, there have been no studies of the prevalence of anal intraepithelial neoplasia in women with intraepithelial neoplasia of the genital tract. We tested the hypothesis that women with high-grade cervical intraepithelial neoplasia are at higher risk of disease in the anus than are control women of similar age with no history of anogenital neoplasia. 29 (19%) of 152 women with cervical intraepithelial neoplasia grade III had histological evidence of anal intraepithelial neoplasia. Of the 29 patients, 11 had grade III anal lesions; 2 of those women had concomitant invasive anal squamous-cell carcinomas. Only 7% (8/115) women with high-grade lesions of the cervix alone had evidence of anal intraepithelial neoplasia; by contrast, 57% (21/37) of those with more than one focus of intraepithelial neoplasia (cervix plus vulva, vagina, or both) had anal lesions. HPV 16 DNA was identified in 18 (51%) of 35 anal biopsy samples in the study group. No evidence of anal intraepithelial neoplasia was found in the control group (50 women), although 2 patients had grade I cervical lesions. HPV 16 DNA was identified in 12 (24%) of biopsy samples from the cervix and 7 (14%) from the anus in the control group; all 7 women with anal HPV16 had concomitant cervical infection. The role of anal examination in the assessment of women with any focus of genital intraepithelial neoplasia requires further investigation.	NO GEN HOSP,CTR CLIN SCI,DEPT GYNAECOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT HISTOPATHOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	Northern General Hospital; Northern General Hospital	SCHOLEFIELD, JH (corresponding author), NO GEN HOSP,CTR CLIN SCI,DEPT SURG,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							Bancroft J.D., 1996, THEORY PRACTICE HIST, VVolume 6; CAMPION MJ, 1986, LANCET, V2, P237; CORNELISSEN MTE, 1989, J GEN VIROL, V70, P2555, DOI 10.1099/0022-1317-70-10-2555; GOORNEY BP, 1987, GENITOURIN MED, V63, P216; HAUSEN HZ, 1987, MED ONCOL TUMOR PHAR, V4, P187; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1991, THESIS U LIVERPOOL; SHARP F, 1991, TEXT ATLAS INTEGRATE, P186; SONNEX C, 1991, BRIT MED J, V303, P1243, DOI 10.1136/bmj.303.6812.1243; WATERHOUSE J, 1982, CANCER INCIDENCE 5 C, P675; WEXNER SD, 1987, DIS COLON RECTUM, V30, P942, DOI 10.1007/BF02554281; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14	16	98	101	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1271	1273		10.1016/0140-6736(92)92961-E	http://dx.doi.org/10.1016/0140-6736(92)92961-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359331				2022-12-24	WOS:A1992JZ23700015
J	EMSON, HE				EMSON, HE			A RIGHT TO REPRODUCE	LANCET			English	Editorial Material											EMSON, HE (corresponding author), ROYAL UNIV HOSP SASKATOON,DEPT PATHOL,SASKATOON S7N 0X0,SASKATCHEWAN,CANADA.							[Anonymous], 1992, LANCET, V339, P1515; EMSON HE, 1992, J APPL PHILOS, V9, P3	2	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1083	1083		10.1016/0140-6736(92)93089-6	http://dx.doi.org/10.1016/0140-6736(92)93089-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357463				2022-12-24	WOS:A1992JV77500013
J	LUFKIN, T; MARK, M; HART, CP; DOLLE, P; LEMEUR, M; CHAMBON, P				LUFKIN, T; MARK, M; HART, CP; DOLLE, P; LEMEUR, M; CHAMBON, P			HOMEOTIC TRANSFORMATION OF THE OCCIPITAL BONES OF THE SKULL BY ECTOPIC EXPRESSION OF A HOMEOBOX GENE	NATURE			English	Article							VERTEBRAL COLUMN; DROSOPHILA; DISRUPTION; DEFECTS; HOX-1.1; MICE	MURINE Hox genes have been postulated to play a role in patterning of the embryonic body plan1-3. Gene disruption studies have suggested that for a given Hox complex, patterning of cell identity along the antero-posterior axis is directed by the more 'posterior' (having a more posterior rostral boundary of expression) Hox proteins expressed in a given cell4-6. This supports the 'posterior prevalence' model2, which also predicts that ectopic expression of a given Hox gene would result in altered structure only in regions anterior to its normal domain of expression. To test this model further, we have expressed the Hox-4.2 gene more rostrally than its normal mesoderm anterior boundary of expression, which is at the level of the first cervical somites. This ectopic expression results in a homeotic transformation of the occipital bones towards a more posterior phenotype into structures that resemble cervical vertebrae, whereas it has no effect in regions that normally express Hox-4.2. These results are similar to the homeotic posteriorization phenomenon generated in Drosophila by ectopic expression of genes of the homeotic complex HOM-C (refs 7-10; reviewed in ref. 3).	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Dolle, Pascal/A-8037-2010; Lufkin, Thomas/AAG-7476-2019; Lufkin, Thomas/B-5352-2011	Dolle, Pascal/0000-0002-9294-9090; Lufkin, Thomas/0000-0002-7902-4771; Lufkin, Thomas/0000-0002-7902-4771; Hart, Charles/0000-0003-4440-726X				BAGNALL KM, 1988, DEVELOPMENT, V103, P69; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; de Beer G.R, 1971, DEV VERTEBRATE SKULL; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; EVANS FRANCIS GAYNOR, 1939, ANN NEW YORK ACAD SCI, V39, P29, DOI 10.1111/j.1749-6632.1939.tb55370.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FERGUSON MWJ, 1978, J ANAT, V125, P555; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gruss P, 1991, CURR OPIN GENET DEV, V1, P204, DOI 10.1016/S0959-437X(05)80071-1; Hogan B., 1986, MANIPULATING MOUSE E; JENKINS FA, 1969, ANAT REC, V164, P173, DOI 10.1002/ar.1091640205; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KURIORA MA, 1988, CELL, V55, P477; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NODEN DM, 1988, DEVELOPMENT, V103, P121; PIVETEAU J, 1954, TRAITE ZOOLOGIE, V12; Remak R., 1855, UNTERSUCHUNGEN ENTWI; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; VERBOUT AJ, 1985, ADV ANAT EMBRYOL CEL, V90, P1; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	31	247	252	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					835	841		10.1038/359835a0	http://dx.doi.org/10.1038/359835a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1359423				2022-12-24	WOS:A1992JV77700066
J	PSATY, BM; FURBERG, CD; KULLER, LH; BORHANI, NO; RAUTAHARJU, PM; OLEARY, DH; BILD, DE; ROBBINS, J; FRIED, LP; REID, C				PSATY, BM; FURBERG, CD; KULLER, LH; BORHANI, NO; RAUTAHARJU, PM; OLEARY, DH; BILD, DE; ROBBINS, J; FRIED, LP; REID, C			ISOLATED SYSTOLIC HYPERTENSION AND SUBCLINICAL CARDIOVASCULAR-DISEASE IN THE ELDERLY - INITIAL FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNRECOGNIZED MYOCARDIAL-INFARCTION; CAROTID ATHEROSCLEROSIS; RISK-FACTORS; POPULATION; DETERMINANTS; HYPERTROPHY; PREVALENCE; MORTALITY; TRIAL	Objective.-To assess the association between isolated systolic hypertension (ISH) and subclinical disease in adults aged 65 years and above. Design.-Medicare eligibility lists were used to obtain a representative sample of 5201 community-dwelling elderly persons for the Cardiovascular Health Study, a National Heart, Lung, and Blood Institute-sponsored cohort study of risk factors for coronary heart disease and stroke. In this cross-sectional analysis of baseline data, we excluded 3012 participants who were receiving antihypertensive medications, had clinical cardiovascular disease, or had a diastolic blood pressure of at least 90 mm Hg. Main Outcome Measures.-For electrocardiogram: myocardial infarction, left ventricular hypertrophy, and left ventricular mass as measures of myocardial damage and strain; for echocardiography: left ventricular mass, fractional shortening, and Doppler flow velocities as measures of cardiac systolic and diastolic function; and for carotid sonography: carotid arterial intima-media thickness as a measure of atherosclerosis. Results.-Among the 2189 men and women in this analysis, 195 (9%) had ISH (systolic blood pressure, greater-than-or-equal-to 160 mm Hg) and 596 (23%) had borderline ISH (systolic blood pressure, 140 to 159 mm Hg). Systolic blood pressure was associated with myocardial infarction by electrocardiogram (P=.02). Borderline and definite ISH were strongly associated with left ventricular mass (P<.001). While there was little association with cardiac systolic function, borderline and definite ISH were associated with cardiac diastolic function (P<.001). Isolated systolic hypertension was also strongly associated with increased intima-media thickness of the carotid artery (P<.001). Conclusions.-While cohort analyses of future repeated measures will provide a better assessment of risk, both borderline and definite ISH were strongly related to a variety of measures of subclinical disease in elderly men and women.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98105; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98105; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103; UNIV PITTSBURGH,DEPT EPIDEMIOL,PITTSBURGH,PA 15260; CARDIOVASC HLTH STUDY COORDINATING CTR,SEATTLE,WA; UNIV ALBERTA,DEPT MED,EDMONTON T6G 2E1,ALBERTA,CANADA; GEISINGER MED CTR,DANVILLE,PA 17822; NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,EPIDEMIOL & BIOMETRY PROGRAM,BETHESDA,MD 20892; UNIV CALIF DAVIS,DEPT MED,DAVIS,CA 95616; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alberta; Geisinger Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Davis; Johns Hopkins University; University of California System; University of California Irvine	PSATY, BM (corresponding author), UNIV WASHINGTON,COORDINATING CTR,DEPT MED,JD-30,1107 NE 45TH ST,SUITE 530,SEATTLE,WA 98105, USA.				NHLBI NIH HHS [N01-HC-85081, N01-HC-85080, N01-HC-85079] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085079, N01HC085080, N01HC085081] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Cochran W.G, 1957, STAT METHODS, V6th ed; COLANDREA MA, 1970, CIRCULATION, V41, P239, DOI 10.1161/01.CIR.41.2.239; DAHLOF B, 1986, J HYPERTENS, V4, P511, DOI 10.1097/00004872-198608000-00019; DEVEREUX RB, 1989, AM J HYPERTENS, V2, pS186, DOI 10.1093/ajh/2.6.186S; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; GARLAND C, 1983, AM J EPIDEMIOL, V118, P365, DOI 10.1093/oxfordjournals.aje.a113644; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KITABATAKE A, 1989, Heart and Vessels, V5, P33, DOI 10.1007/BF02058356; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; NORUSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; OLEARY DH, 1988, STROKE, V19, P143; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; RAUTAHARJU PM, 1990, METHOD INFORM MED, V29, P362; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; RUTAN GH, 1988, CIRCULATION, V77, P504, DOI 10.1161/01.CIR.77.3.504; SALONEN R, 1991, ANN MED, V23, P23, DOI 10.3109/07853899109147926; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; Schlesselman JJ, 1982, CASE CONTROL STUDIES; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; Stamler J, 1989, Hypertension, V13, pI2; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; TELL GS, 1989, J CLIN EPIDEMIOL, V42, P551, DOI 10.1016/0895-4356(89)90151-0; VERDECCHIA P, 1990, EUR HEART J, V11, P679, DOI 10.1093/oxfordjournals.eurheartj.a059783; 1985, BMJ, V291, P97; 1967, JAMA-J AM MED ASSOC, V202, P116; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	32	149	152	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1287	1291		10.1001/jama.268.10.1287	http://dx.doi.org/10.1001/jama.268.10.1287			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1387172				2022-12-24	WOS:A1992JL60800029
J	THOMAS, SJ; MACLENNAN, R				THOMAS, SJ; MACLENNAN, R			SLAKED LIME AND BETEL NUT CANCER IN PAPUA-NEW-GUINEA	LANCET			English	Note							TOBACCO	Oral squamous cell cancer is the most common malignant tumour in Papua New Guinea. We have found that oral cancer in this region is concentrated at the corner of the mouth and cheek, by striking contrast with western populations, and corresponds precisely with the site of application of lime in 77% of 169 cases. Powdered slaked lime applied to the chewed Areca nut with Piper betle inflorescence at the comer of the mouth causes the mean pH to rise to 10, at which reactive oxygen species are generated from betel quid ingredients in vitro. Reactive oxygen species, together with sustained lime-induced cell proliferation, suggest a possible mechanism of carcinogenesis for this tumour.			THOMAS, SJ (corresponding author), QUEENSLAND INST MED RES,300 HERSTON RD,BRISBANE 4029,AUSTRALIA.							COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COOKE RA, 1969, CANCER, V24, P397, DOI 10.1002/1097-0142(196908)24:2<397::AID-CNCR2820240223>3.0.CO;2-6; Henderson BE, 1979, NATL CANCER I MONOGR, V53, P67; LANGDON JD, 1985, MALIGNANT TUMOURS OR, P3; MOORE C, 1967, AM J SURG, V114, P510, DOI 10.1016/0002-9610(67)90008-6; NAIR UJ, 1990, CARCINOGENESIS, V11, P2145, DOI 10.1093/carcin/11.12.2145; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; SCRIMGEOUR EM, 1983, BRIT MED J, V286, P1414, DOI 10.1136/bmj.286.6375.1414; STICH HF, 1989, MUTAT RES, V214, P47, DOI 10.1016/0027-5107(89)90197-8	9	106	110	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					577	578		10.1016/0140-6736(92)92109-S	http://dx.doi.org/10.1016/0140-6736(92)92109-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355157				2022-12-24	WOS:A1992JM33400006
J	SEGREDO, V; CALDWELL, JE; MATTHAY, MA; SHARMA, ML; GRUENKE, LD; MILLER, RD				SEGREDO, V; CALDWELL, JE; MATTHAY, MA; SHARMA, ML; GRUENKE, LD; MILLER, RD			PERSISTENT PARALYSIS IN CRITICALLY ILL PATIENTS AFTER LONG-TERM ADMINISTRATION OF VECURONIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORG NC 45; RENAL-FAILURE; BLOCKING ACTIONS; PHARMACOKINETICS; PANCURONIUM; BROMIDE; CAT; 3-DESACETYLVECURONIUM; PHARMACODYNAMICS; PHARMACOLOGY	Background. The muscle relaxant vecuronium is sometimes administered to facilitate mechanical ventilation. Neuromuscular paralysis lasting up to seven days may occur after the termination of long-term administration (i.e., more than two days) of vecuronium in critically ill patients. We investigated the role of clinical factors and plasma concentrations of vecuronium and its metabolite in causing this prolonged neuromuscular blockade. Methods. We studied 16 critically ill adult patients (8 women and 8 men) who had received vecuronium to facilitate mechanical ventilation for at least two consecutive days. Clinical factors and plasma concentrations of vecuronium and 3-desacetylvecuronium, the active metabolite of vecuronium, were compared in patients with and without prolonged neuromuscular blockade. In addition, we performed detailed pharmacokinetic studies in the patients without prolonged neuromuscular blockade. Results. Seven of the 16 patients had prolonged neuromuscular blockade, lasting from six hours to more than seven days, after the termination of vecuronium therapy. These seven patients, six of whom were women, had higher plasma magnesium concentrations and lower arterial blood pH values than the nine patients without prolonged neuromuscular blockade. They also had higher plasma concentrations of 3-desacetylvecuronium and a higher frequency of renal failure (seven of seven patients vs. four of nine patients, P<0.03). In the patients without prolonged neuromuscular blockade, the mean (+/-SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5+/-1.0 ml per kilogram of body weight per minute, 299+/-154 minutes, and 1.1+/-0.6 liters per kilogram, respectively. Conclusions. Prolonged neuromuscular blockade after the termination of long-term treatment with vecuronium is associated with metabolic acidosis, elevated plasma magnesium concentrations, female sex, and probably more important, the presence of renal failure and high plasma concentrations of 3-desacetylvecuronium.	UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026403] Funding Source: NIH RePORTER; NIGMS NIH HHS [R0I GM 26403-0648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDEN JR, 1988, ANESTHESIOLOGY, V68, P771, DOI 10.1097/00000542-198805000-00016; BENCINI AF, 1985, BRIT J ANAESTH, V57, P782, DOI 10.1093/bja/57.8.782; BENCINI AF, 1985, BRIT J ANAESTH, V57, P789, DOI 10.1093/bja/57.8.789; CANNON JE, 1987, ANESTHESIOLOGY, V67, P503, DOI 10.1097/00000542-198710000-00010; COURSIN DB, 1989, ANESTH ANALG, V69, P518; DANON MJ, 1991, MUSCLE NERVE, V14, P1131, DOI 10.1002/mus.880141115; DARRAH WC, 1989, CRIT CARE MED, V17, P1297, DOI 10.1097/00003246-198912000-00010; DIXON WJ, 1985, BMDP STATISTICAL SOF, P237; FAHEY MR, 1981, BRIT J ANAESTH, V53, P1049, DOI 10.1093/bja/53.10.1049; FUNK DI, 1980, ACTA ANAESTH SCAND, V24, P119, DOI 10.1111/j.1399-6576.1980.tb01518.x; FURUTA T, 1988, J CHROMATOGR-BIOMED, V427, P41, DOI 10.1016/0378-4347(88)80103-8; GIBALDI M, 1975, PHARMACOKINETICS, P27; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015; LEBRAULT C, 1985, ANESTHESIOLOGY, V62, P601, DOI 10.1097/00000542-198505000-00010; LYNAM DP, 1988, ANESTHESIOLOGY, V69, P227, DOI 10.1097/00000542-198808000-00012; MARSHALL IG, 1983, BRIT J ANAESTH, V55, P703, DOI 10.1093/bja/55.8.703; MATTHAY MA, 1989, TXB PULMONARY DISEAS, V2, P1055; MEISTELMAN C, 1986, EUR J ANAESTH, V3, P153; MILLER RD, 1984, ANESTHESIOLOGY, V61, P444, DOI 10.1097/00000542-198410000-00014; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; ONO K, 1988, ANESTHESIOLOGY, V68, P357, DOI 10.1097/00000542-198803000-00006; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SEGREDO V, 1991, ANESTHESIOLOGY, V74, P1052, DOI 10.1097/00000542-199106000-00013; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHEARER ES, 1991, BRIT J ANAESTH, V67, P569, DOI 10.1093/bja/67.5.569; SMITH CL, 1987, ANAESTHESIA, V42, P387, DOI 10.1111/j.1365-2044.1987.tb03980.x; SMITH CL, 1987, ANAESTHESIA, V42, P925; UPTON RA, 1982, ANESTH ANALG, V61, P313; VIBYMOGENSEN J, 1982, BRIT J ANAESTH, V54, P209, DOI 10.1093/bja/54.2.209; WASER PG, 1987, BRIT J ANAESTH, V59, P1044, DOI 10.1093/bja/59.8.1044; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176	33	336	342	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					524	528		10.1056/NEJM199208203270804	http://dx.doi.org/10.1056/NEJM199208203270804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1353252				2022-12-24	WOS:A1992JJ45700004
J	LUNNISS, PJ; ARMSTRONG, P; BARKER, PG; REZNEK, RH; PHILLIPS, RKS				LUNNISS, PJ; ARMSTRONG, P; BARKER, PG; REZNEK, RH; PHILLIPS, RKS			MAGNETIC-RESONANCE-IMAGING OF ANAL FISTULAS	LANCET			English	Note							IN-ANO	Success of surgery for an anal fistula depends on accurate assessment of the fistula; however, such assessment is technically difficult. We have done a prospective study that determined the accuracy of magnetic resonance imaging (MRI) in demonstrating the course of fistulae, by comparing MRI scan interpretations with subsequent operative findings. 16 patients (mean [range] age 42 [24-66] years) had MRI followed by surgery within a mean of 22 (1-101) days. MRI scan interpretations agreed precisely with independently documented operative findings in 14 of 16 patients. MRI is an accurate method of delineating anal fistulae, and should be considered for patients with difficult fistulae that recur despite skilled attention because it demonstrates abnormalities that might otherwise be missed.	ST MARKS HOSP,CITY RD,LONDON EC1V 2PS,ENGLAND; LONDON CLIN,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,PROF SURG UNIT,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RADIOL,LONDON EC1A 7BE,ENGLAND	Imperial College London; University of London; University College London; University of London; Queen Mary University London; University of London; Queen Mary University London								COEN S, 1991, BRIT J SURG, V78, P445; KUIJPERS HC, 1985, DIS COLON RECTUM, V28, P103, DOI 10.1007/BF02552656; LAW PJ, 1989, BRIT J SURG, V76, P752, DOI 10.1002/bjs.1800760737; PARKS AG, 1976, BRIT J SURG, V63, P1, DOI 10.1002/bjs.1800630102; POMMERI F, 1988, RADIOL MED, V75, P632; SAINIO P, 1984, ANN CHIR GYNAECOL FE, V73, P219; SEOWCHOEN F, 1991, BRIT J SURG, V78, P539; SHOULER PJ, 1986, INT J COLORECTAL DIS, V1, P113, DOI 10.1007/BF01648418	8	141	144	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					394	396		10.1016/0140-6736(92)91472-K	http://dx.doi.org/10.1016/0140-6736(92)91472-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353557				2022-12-24	WOS:A1992JJ44900005
J	SHEAN, CS; GOTTESMAN, ME				SHEAN, CS; GOTTESMAN, ME			TRANSLATION OF THE PROPHAGE-LAMBDA CL TRANSCRIPT	CELL			English	Article								Mutations in rpsB that reduce the levels of the ribosomal protein S2 enhance the translation of cl in lambda lysogens. Two features of the cl transcript are required for enhanced translation: the absence of a leader and the presence of a downstream box, a sequence within the cl coding region that is complementary to the 16S rRNA. 30S ribosomal subunits deficient in S2 form ternary complexes with the cl transcript more efficiently than wild-type subunits. The absence of S2 may change the structure of the 16S rRNA, improving contacts with the cl downstream box.			SHEAN, CS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, 701 W 168TH ST, NEW YORK, NY 10032 USA.				NIGMS NIH HHS [5 R01 GM 37219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; BAYLIS HA, 1987, NUCLEIC ACIDS RES, V15, P7176, DOI 10.1093/nar/15.17.7176; BOLLEN A, 1979, J MOL BIOL, V132, P219, DOI 10.1016/0022-2836(79)90392-9; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; CAM K, 1991, J BACTERIOL, V173, P734, DOI 10.1128/jb.173.2.734-740.1991; DANIELS DL, 1983, LAMBDA, V2, P519; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DREYFUS M, 1988, J MOL BIOL, V204, P79, DOI 10.1016/0022-2836(88)90601-8; FAXEN M, 1991, NUCLEIC ACIDS RES, V19, P5247, DOI 10.1093/nar/19.19.5247; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; HOWARD BH, 1982, EUKARYOTIC VIRAL VEC, P211; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; JANSSEN GR, 1989, GENE DEV, V3, P415, DOI 10.1101/gad.3.3.415; JONES MO, 1979, P NATL ACAD SCI USA, V76, P150, DOI 10.1073/pnas.76.1.150; KING TC, 1987, ESCHERICHIA COLI SAL, V1, P703; KLOCK G, 1986, J MOL BIOL, V189, P633, DOI 10.1016/0022-2836(86)90493-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHREA M, 1978, J MOL BIOL, V121, P411, DOI 10.1016/0022-2836(78)90391-1; LOPEZCABRERA M, 1989, J BACTERIOL, V171, P321, DOI 10.1128/jb.171.1.321-328.1989; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZUSAWA S, 1982, GENE, V20, P317, DOI 10.1016/0378-1119(82)90200-1; MURRAY IA, 1989, GENE, V85, P283, DOI 10.1016/0378-1119(89)90420-4; NAGAI H, 1991, P NATL ACAD SCI USA, V88, P10515, DOI 10.1073/pnas.88.23.10515; Noller H. F, 1987, ESCHERICHIA COLI SAL, P104; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; OCONNOR M, 1989, EMBO J, V8, P4315, DOI 10.1002/j.1460-2075.1989.tb08618.x; OHTSUBO H, 1978, P NATL ACAD SCI USA, V75, P615, DOI 10.1073/pnas.75.2.615; POWERS T, 1988, J MOL BIOL, V201, P697, DOI 10.1016/0022-2836(88)90468-8; PTASHNE M, 1976, SCIENCE, V194, P156, DOI 10.1126/science.959843; REICHARDT L, 1971, P NATL ACAD SCI USA, V68, P2185, DOI 10.1073/pnas.68.9.2185; REICHARDT LF, 1975, J MOL BIOL, V93, P289, DOI 10.1016/0022-2836(75)90133-3; SCHERER GFE, 1980, NUCLEIC ACIDS RES, V8, P3895, DOI 10.1093/nar/8.17.3895; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SHIMATAKE H, 1981, NATURE, V292, P128, DOI 10.1038/292128a0; SHINEDLING S, 1987, MOL GEN GENET, V207, P224, DOI 10.1007/BF00331582; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Zimmermann R A, 1979, Methods Enzymol, V59, P551	48	90	93	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					513	522		10.1016/0092-8674(92)90175-C	http://dx.doi.org/10.1016/0092-8674(92)90175-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1386558				2022-12-24	WOS:A1992JH12400016
J	DUNN, MJ; CRISP, SJ; ROSE, ML; TAYLOR, PM; YACOUB, MH				DUNN, MJ; CRISP, SJ; ROSE, ML; TAYLOR, PM; YACOUB, MH			ANTIENDOTHELIAL ANTIBODIES AND CORONARY-ARTERY DISEASE AFTER CARDIAC TRANSPLANTATION	LANCET			English	Article								Accelerated coronary artery disease is the most serious complication after cardiac transplantation. The disease has a multifactorial aetiology, with little agreement about the relative importance of the various risk factors. We have investigated the frequency of anti-endothelial antibodies against human umbilical vein endothelial cells by one-dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis and western blotting. Peptide-specific anti-endothelial antibodies were found in 15/21 heart transplant recipients with accelerated coronary artery disease, and 1/20 transplant patients who had not developed the disease. Positive immunofluorescence of patients' serum on frozen sections of coronary vessels confirmed the endothelial specificity of antibodies. These results provide evidence of an immune aetiology for transplant-associated coronary artery disease and could have important implications for its diagnosis and therapy.			DUNN, MJ (corresponding author), NATL HEART & LUNG INST,DEPT CARDIOTHORAC SURG,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.							AUCHINCLOSS H, 1990, TRANSPLANT REV, V4, P14; Banner N R, 1987, Clin Transpl, P17; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNN MJ, 1991, TRANSPLANTATION, V51, P806, DOI 10.1097/00007890-199104000-00014; GAO S, 1990, SEMINARS THORACIC CA, P241; HEURKENS AHM, 1991, J IMMUNOL METHODS, V141, P33, DOI 10.1016/0022-1759(91)90207-V; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAGE C, IN PRESS AM J PATHOL; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALOMON RN, 1991, AM J PATHOL, V138, P791; SIMMONS J, 1991, 2D PAGE 91, P46; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827	15	171	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1566	1570		10.1016/0140-6736(92)91832-S	http://dx.doi.org/10.1016/0140-6736(92)91832-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351550				2022-12-24	WOS:A1992JB20200004
J	BOCK, T; PEDERSEN, CR; JOSEFSEN, K; BOTTAZZO, GF; PALMER, JP; BUSCHARD, K				BOCK, T; PEDERSEN, CR; JOSEFSEN, K; BOTTAZZO, GF; PALMER, JP; BUSCHARD, K			NO RISK OF DIABETES AFTER INSULIN-SHOCK TREATMENT	LANCET			English	Article							ISLET-CELL ANTIBODIES; AUTOANTIBODIES; MELLITUS	Prophylactic insulin treatment is effective in preventing diabetes in animal models of insulin-dependent diabetes mellitus (IDDM) but the safety of such preventive treatment in prediabetic human subjects remains unclear; insulin is a potential autoantigen that could accelerate beta-cell decompensation and onset of IDDM. We have investigated whether insulin treatment of non-diabetic diabetic subjects increases the risk of subsequent development of diabetes in a retrospective study of Danish patients who received insulin-shock treatment for psychiatric disorders. Mean age of the 481 patients at insulin-shock treatment was 32.6 (range 12.9-69.6) years. The patients received 59 (6-200) injections of 78 (16-261) IU bovine/porcine insulin. Hospital records provided an average of 22.0 (0.6-51.2) years' observation. During the observation time, IDDM developed in only 1 patient; 1.3 cases would be expected from Danish incidence data (p=0.75). Similarly, there was no significant difference between the observed number of cases of non-insulin-dependent diabetes mellitus (NIDDM) and the number expected from Danish prevalence data (12 vs 10.2; p=0.45). We collected blood samples from 27 of the patients. All but 2 (who had previously diagnosed NIDDM) had normal fasting blood glucose and plasma insulin concentrations, none had islet-cell antibodies, and only 2 had detectable insulin antibodies. Thus, the risk of diabetes was not increased by the use of many insulin injections in these non-diabetic subjects. We conclude that clinical trials on prevention of IDDM by prophylactic insulin treatment can be regarded as safe.	UNIV LONDON LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND; UNIV WASHINGTON,VET AFFAIRS MED CTR,SEATTLE,WA 98195	University of London; University College London; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BOCK, T (corresponding author), KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,DK-1399 COPENHAGEN K,DENMARK.			Buschard, Karsten/0000-0002-0126-7423	NIDDK NIH HHS [DK 02456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASPLIN CM, 1981, DIABETES CARE, V4, P337, DOI 10.2337/diacare.4.3.337; ATKINSON MA, 1990, DIABETES, V39, P933, DOI 10.2337/diabetes.39.8.933; ATKINSON MA, 1986, DIABETES, V35, P894, DOI 10.2337/diabetes.35.8.894; Beck-Nielsen H, 1990, Ugeskr Laeger, V152, P2; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BERSON SA, 1964, DIABETES, V13, P247; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BOTTAZZO GF, 1991, ANN MED, V23, P453, DOI 10.3109/07853899109148089; BOTTAZZO GF, 1980, LANCET, V1, P668; CHRISTAU B, 1982, DIABETOLOGIA, V23, P160; Christy M, 1979, Diabetes Care, V2, P127, DOI 10.2337/diacare.2.2.127; DAMSGAARD EM, 1987, DIABETES CARE, V10, P26, DOI 10.2337/diacare.10.1.26; DEAN BM, 1986, DIABETOLOGIA, V29, P339, DOI 10.1007/BF00452073; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; KLOPPEL G, 1976, ACTA ENDOCRINOL-COP, V83, P107; KUHL C, 1975, ACTA ENDOCRINOL-COP, V79, P7409; KURTZ AB, 1980, DIABETOLOGIA, V18, P147, DOI 10.1007/BF00290492; LACY PE, 1965, DIABETES, V14, P634, DOI 10.2337/diab.14.10.634; LIKE AA, 1986, DIABETES, V35, pA74; MCGRATH D, 1950, J MENT SCI, V96, P285; MORGAN CR, 1965, ANAT REC, V153, P49, DOI 10.1002/ar.1091530107; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; SUTTON M, 1988, METABOLISM, V37, P1005, DOI 10.1016/0026-0495(88)90058-3; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	24	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1504	1506		10.1016/0140-6736(92)91264-9	http://dx.doi.org/10.1016/0140-6736(92)91264-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351186				2022-12-24	WOS:A1992HZ17500004
J	MALGAROLI, A; TSIEN, RW				MALGAROLI, A; TSIEN, RW			GLUTAMATE-INDUCED LONG-TERM POTENTIATION OF THE FREQUENCY OF MINIATURE SYNAPTIC CURRENTS IN CULTURED HIPPOCAMPAL-NEURONS	NATURE			English	Article							PROTEIN KINASE-C; FROG NEUROMUSCULAR-JUNCTION; EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; PRESYNAPTIC ENHANCEMENT; TRANSMITTER RELEASE; QUANTAL ANALYSIS; RAT HIPPOCAMPUS; PERFORANT PATH; TRANSMISSION	Glutamate application at synapses between hippocampal neurons in culture produces long-term potentiation of the frequency of spontaneous miniature synaptic currents, together with long-term potentiation of evoked synaptic currents. The mini frequency potentiation is initiated postsynaptically and requires activity of NMDA receptors. Although the frequency of unitary quantal responses increases strongly, their amplitude remains little changed with potentiation. Tests of postsynaptic responsiveness rule out recruitment of latent glutamate receptor clusters. Thus, postsynaptic induction can lead to enhancement of presynaptic transmitter release. The sustained potentiation of mini frequency is expressed even in the absence of Ca2+ entry into presynaptic terminals.	STANFORD UNIV, MED CTR, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University			Malgaroli, Antonio/I-5090-2013	Malgaroli, Antonio/0000-0003-3758-7477				AMARAL DG, 1990, PROG BRAIN RES, V83, P1; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; BAXTER D, 1985, P NATL ACAD SCI USA, V80, P7347; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BROWN TH, 1979, BRAIN RES, V177, P194, DOI 10.1016/0006-8993(79)90931-4; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CHERNEVSKAYA NI, 1991, NATURE, V349, P418, DOI 10.1038/349418a0; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUBBARD JI, 1968, J PHYSIOL-LONDON, V197, P639, DOI 10.1113/jphysiol.1968.sp008579; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LEVTOV A, 1980, J PHYSIOL-LONDON, V309, P247, DOI 10.1113/jphysiol.1980.sp013507; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; Lynch G, 1991, Hippocampus, V1, P9, DOI 10.1002/hipo.450010103; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARTIN AR, 1977, HDB PHYSL          1, V1, P329; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEGAL M, 1989, NEUROSCI LETT, V101, P169, DOI 10.1016/0304-3940(89)90525-9; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; VORONIN LL, 1991, NEUROSCI RES COMMUN, V8, P87	55	341	343	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					134	139		10.1038/357134a0	http://dx.doi.org/10.1038/357134a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1349728				2022-12-24	WOS:A1992HU12200049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			2 NEW THERAPIES AVAILABLE UNDER TREATMENT IND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-24	WOS:A1992HT06800006
J	NIKONOWICZ, EP; PARDI, A				NIKONOWICZ, EP; PARDI, A			3-DIMENSIONAL HETERONUCLEAR NMR-STUDIES OF RNA	NATURE			English	Article							RIBOSOMAL-RNA; SPECTROSCOPY; PROTEINS; ASSIGNMENT; OLIGORIBONUCLEOTIDE; INTERLEUKIN-1-BETA; RESONANCES; SEQUENCE; C-13; DNA	MULTIDIMENSIONAL heteronuclear NMR has revolutionized solution structure determinations of proteins 1-3. But this technique has not been applied to nucleic acids because of difficulties in the synthesis of isotopically (C-13 and/or N-15) labeLled molecules. Here we report the application of three-dimensional heteronuclear NMR to the study of a uniformly C-13/N-15 or N-15-labelled RNA duplex of defined sequence. These experiments simplify resonance assignment and the analysis of proton-proton nuclear Overhauser effects 4 (and therefore distance information) in the molecule. Our results show that it is now possible to determine the structures of larger and more complex RNAs using multidimensional heteronuclear NMR.			NIKONOWICZ, EP (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; CECH TC, 1989, MOL BIOL RNA; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; FERSHT A, 1985, ENZYME STRUCTURE MEC, P389; FESIK SW, 1990, J AM CHEM SOC, V112, P886, DOI 10.1021/ja00158a069; FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; LORE GM, 1991, SCIENCE, V252, P1390; LUCIA JS, 1991, BIOCHEMISTRY-US, V30, P8242; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PATEL DJ, 1987, Q REV BIOPHYS, V20, P35, DOI 10.1017/S0033583500004224; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SIMON ES, 1990, J ORG CHEM, V55, P1834, DOI 10.1021/jo00293a030; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANDEVEN FJM, 1988, EUR J BIOCHEM, V178, P1; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	25	105	106	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					184	186		10.1038/355184a0	http://dx.doi.org/10.1038/355184a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1370345				2022-12-24	WOS:A1992GY62900066
J	PRESS, RI; PEEBLES, CL; KUMAGAI, Y; OCHS, RL; TAN, EM				PRESS, RI; PEEBLES, CL; KUMAGAI, Y; OCHS, RL; TAN, EM			ANTINUCLEAR AUTOANTIBODIES IN WOMEN WITH SILICONE BREAST IMPLANTS	LANCET			English	Article							HUMAN ADJUVANT DISEASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; AUGMENTATION MAMMOPLASTY; AUTOIMMUNE-DISEASE; RHEUMATIC DISEASES; SJOGRENS SYNDROME; SCLERODERMA; ANTIBODIES; SCLEROSIS	Clinical syndromes resembling autoimmune diseases have been reported in women who have had breast augmentation procedures. To see whether there is a humoral immune response in these diseases that is similar to the immune response in their idiopathic counterparts, we assessed the immunological specificity of antinuclear antibodies (ANAs) and certain epidemiological features in 24 patients, all of whom (with 1 exception) had received silicone gel breast implants. ANA specificities were identified by indirect immunofluorescence, immunodiffusion, western blot analysis, and immunoprecipitation of radiolabelled intracellular proteins. Of 11 patients who had symptoms and signs that met criteria for defined autoimmune diseases, 7 had scleroderma or subsets of this disorder and the others had systemic lupus erythematosus, rheumatoid arthritis, or overlapping autoimmune diseases. High ANA titres were present in 10 of these 11 patients and the ANA specificities were similar to those found in the idiopathic forms of the corresponding autoimmune diseases. Trauma, with resultant rupture of implants, accelerated onset of symptoms. 13 other patients had autoimmune disorders of a less clearly defined nature and low titres of ANAs whose specificities could not be identified. ANAs are associated with the development of autoimmune complications in women with silicone breast implants. Further studies are needed to see whether this relation is one of cause and effect and whether ANAs might be early serological markers preceding development of autoimmune symptoms.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, WM KECK AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA; IMAICHI HOSP, TOCHIGI 32112, JAPAN	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR032063, R01AR032063] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIAMS NIH HHS [AR32063] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; ARNETT F C, 1987, Arthritis and Rheumatism, V30, pS17; BALDWIN CM, 1983, ANN PLAS SURG, V10, P270, DOI 10.1097/00000637-198304000-00002; BALLOU SP, 1986, MANUAL CLIN LABORATO, P740; BLACK CM, 1983, LANCET, V1, P53; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; BYRON MA, 1984, BRIT J RHEUMATOL, V23, P227; CHAN EKL, 1992, MANUAL CLIN LABORATO, P755; ENDO LP, 1987, SEMIN ARTHRITIS RHEU, V17, P112, DOI 10.1016/0049-0172(87)90033-3; FOCK KM, 1984, J RHEUMATOL, V11, P98; FRITZLER MJ, 1985, CLIN IMMUNOL IMMUNOP, V36, P120, DOI 10.1016/0090-1229(85)90045-5; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HAUSTEIN UF, 1985, INT J DERMATOL, V24, P147, DOI 10.1111/j.1365-4362.1985.tb05745.x; HOCHBERG MC, 1981, EPIDEMIOL REV, V3, P27, DOI 10.1093/oxfordjournals.epirev.a036238; KAISER W, 1990, ANN RHEUM DIS, V49, P937, DOI 10.1136/ard.49.11.937; KASAKAWAR, 1987, MIXED CONNECTIVE TIS, P41; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; MARIK PE, 1990, S AFR MED J, V77, P212; MEDSGER TA, 1985, EPIDEMIOLOGY RHEUMAT; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; MIYOSHI K, 1964, IJISHIMPO, V2122, P9; OKANO Y, 1984, ANN RHEUM DIS, V43, P520, DOI 10.1136/ard.43.3.520; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; ROM WN, 1983, CHEST, V83, P515, DOI 10.1378/chest.83.3.515; SERGOTT TJ, 1986, PLAST RECONSTR SURG, V78, P104, DOI 10.1097/00006534-198607000-00018; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; VANVENROOIJ WJ, 1991, J IMMUNOL METHODS, V140, P181, DOI 10.1016/0022-1759(91)90369-Q; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WEINER SR, 1986, PLAST RECONSTR SURG, V77, P185, DOI 10.1097/00006534-198602000-00001; WELSH KT, 1988, SYSTEMIC SCLEROSIS S; WILSON MR, 1986, MANUAL CLIN LABORATO, P750	34	143	143	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 28	1992	340	8831					1304	1307		10.1016/0140-6736(92)92491-W	http://dx.doi.org/10.1016/0140-6736(92)92491-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360033	Bronze			2022-12-24	WOS:A1992KA26200002
J	ROSEVEAR, SK; HOLT, DW; LEE, TD; FORD, WCL; WARDLE, PG; HULL, MGR				ROSEVEAR, SK; HOLT, DW; LEE, TD; FORD, WCL; WARDLE, PG; HULL, MGR			SMOKING AND DECREASED FERTILIZATION RATES INVITRO	LANCET			English	Note							CIGARETTE-SMOKING; COTININE; NICOTINE; DISPOSITION; FLUID	To examine possible mechanisms for the association between cigarette smoking and reduced fertility, we have measured the concentration of the nicotine metabolite cotinine in ovarian follicular fluid collected at the time of oocyte recovery during treatment for in-vitro fertilisation. In a group of women in whom follicular fluid cotinine could not be detected (limit of accurate measurement 20 ng/ml) 116 oocytes were collected, of which 84 became fertilised (72%), whereas among women with cotinine concentration greater than 20 ng/ml 20/45 (44%) oocytes did so (p < 0.01). The median fertilisation rates for individuals (range 1-8 eggs each) in the high and low cotinine groups were 57% and 75%, respectively (p < 0.05). These findings suggest that infertile women should be advised to stop or reduce smoking generally, and especially before treatment by in-vitro fertilisation.	ST GEORGE HOSP, SCH MED, DEPT CARDIOL SCI, ANALYT UNIT, LONDON SW17 0RE, ENGLAND	St Georges University London	ROSEVEAR, SK (corresponding author), UNIV BRISTOL, ST MICHAELS HOSP, DEPT OBSTET & GYNAECOL, BRISTOL BS2 8EG, ENGLAND.							BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BARBIERI RL, 1986, FERTIL STERIL, V46, P232; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; HANSEL MC, 1986, ANN CLIN BIOCHEM, V23, P596, DOI 10.1177/000456328602300518; HOWE G, 1985, BRIT MED J, V290, P1697, DOI 10.1136/bmj.290.6483.1697; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; MCLACHLAN JA, 1976, FERTIL STERIL, V27, P1204; ROSENBERG J, 1980, CLIN PHARMACOL THER, V28, P517, DOI 10.1038/clpt.1980.196; WARDLE PG, 1986, HUM REPROD, V1, P455, DOI 10.1093/oxfordjournals.humrep.a136454; WEISS T, 1989, HUM REPROD, V4, P482, DOI 10.1093/oxfordjournals.humrep.a136931	11	79	81	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1195	1196		10.1016/0140-6736(92)92895-M	http://dx.doi.org/10.1016/0140-6736(92)92895-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359264				2022-12-24	WOS:A1992JY38600007
J	HERRERO, I; MIRASPORTUGAL, MT; SANCHEZPRIETO, J				HERRERO, I; MIRASPORTUGAL, MT; SANCHEZPRIETO, J			POSITIVE FEEDBACK OF GLUTAMATE EXOCYTOSIS BY METABOTROPIC PRESYNAPTIC RECEPTOR STIMULATION	NATURE			English	Article							PROTEIN-KINASE-C; ISOLATED NERVE-TERMINALS; LONG-TERM POTENTIATION; RAT CEREBROCORTICAL SYNAPTOSOMES; AMINO-ACID RECEPTORS; DIRECT ACTIVATION; DENTATE GYRUS; RELEASE; CA-2+; 4-AMINOPYRIDINE	GLUTAMATE is important in several forms of synaptic plasticity such as long-term potentiation, and in neuronal cell degeneration1,2. Glutamate activates several types of receptors, including a metabotropic receptor that is sensitive to trans-1-amino-cyclo-penthyl-1,3-dicarboxylate, coupled to G protein(s) and linked to inositol phospholipid metabolism3-6. The activation of the metabotropic receptor in neurons generates inositol 1,4,5-trisphosphate, which causes the release of Ca2+ from intracellular stores and diacylglycerol, which activates protein kinase C7-9. In nerve terminals, the activation of presynaptic protein kinase C with phorbol esters enhances glutamate release10. But the presynaptic receptor involved in this protein kinase C-mediated increase in the release of glutamate has not yet been identified. Here we demonstrate the presence of a presynaptic glutamate receptor of the metabotropic type that mediates an enhancement of glutamate exocytosis in cerebrocortical nerve terminals. Interestingly, this potentiation of glutamate release is observed only in the presence of arachidonic acid, which may reflect that this positive feedback control of glutamate exocytosis operates in concert with other pre- or postsynaptic events of the glutamatergic neurotransmission that generate arachidonic acid. This presynaptic glutamate receptor may have a physiological role in the maintenance of long-term potentiation where there is an increase in glutamate release mediated by postsynaptically generated arachidonic acid11.	UNIV COMPLUTENSE MADRID, FAC VET, DEPT BIOQUIM, E-28040 MADRID, SPAIN	Complutense University of Madrid			Miras-Portugal, Maria Teresa/L-7137-2014	Sanchez-Prieto, Jose/0000-0002-8513-3501				BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1988, NEUROLOGY NEUROBIOLO, V35, P3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERRERO I, 1991, J NEUROCHEM, V57, P718, DOI 10.1111/j.1471-4159.1991.tb03805.x; HERRERO I, 1991, NEUROSCI LETT, V126, P41, DOI 10.1016/0304-3940(91)90366-2; HERRERO I, 1992, FEBS LETT, V296, P317, DOI 10.1016/0014-5793(92)80312-5; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MANZONI OJJ, 1990, NEUROSCI LETT, V109, P146, DOI 10.1016/0304-3940(90)90553-L; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; MURPHY SN, 1988, P NATL ACAD SCI USA, V85, P8737, DOI 10.1073/pnas.85.22.8737; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; NICOLETTI F, 1988, NEUROPHARMACOLOGY, V27, P551, DOI 10.1016/0028-3908(88)90174-8; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; RUBIO I, 1991, J NEUROCHEM, V57, P1159, DOI 10.1111/j.1471-4159.1991.tb08274.x; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP D D, 1990, Society for Neuroscience Abstracts, V16, P618; SCHOEPP DD, 1989, J NEUROCHEM, V53, P273, DOI 10.1111/j.1471-4159.1989.tb07324.x; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VERHAGE M, 1989, J NEUROCHEM, V53, P1188, DOI 10.1111/j.1471-4159.1989.tb07413.x	34	355	374	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1992	360	6400					163	166		10.1038/360163a0	http://dx.doi.org/10.1038/360163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1359425				2022-12-24	WOS:A1992JX75200061
J	MODAN, B				MODAN, B			DIET AND CANCER - CAUSAL RELATION OR JUST WISHFUL THINKING	LANCET			English	Editorial Material							BREAST-CANCER; COLON CANCER; FIBER; RISK; EPIDEMIOLOGY; ETIOLOGY				MODAN, B (corresponding author), CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,IL-52621 TEL HASHOMER,ISRAEL.							Baker S. R., 1990, ADV MOD ENV TOXICOL, V18, P1; Burkitt D P, 1972, Lancet, V2, P1408; CARROLL KK, 1968, CAN MED ASSOC J, V98, P590; EIGHANY NA, 1990, EPIDEMIOLOGY, V1, P107; GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997; GRAHAM S, 1979, AM J EPIDEMIOL, V109, P1; HILL MJ, 1974, CANCER, V34, P815, DOI 10.1002/1097-0142(197409)34:3+<815::AID-CNCR2820340705>3.0.CO;2-6; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HOWELL MA, 1974, BRIT J CANCER, V29, P328, DOI 10.1038/bjc.1974.75; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; KMET J, 1972, SCIENCE, V175, P846, DOI 10.1126/science.175.4024.846; Kritchevsky D, 1986, Prog Clin Biol Res, V222, P495; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; MODAN B, 1975, J NATL CANCER I, V55, P15, DOI 10.1093/jnci/55.1.15; PHILLIPS RL, 1975, CANCER RES, V35, P3513; RUSSELL R, 1916, NOTES CAUSATION CANC; SLATTERY ML, 1988, J NATL CANCER I, V80, P1474, DOI 10.1093/jnci/80.18.1474; SNOW J, 1945, SNOW CHOLERA; TANNENBAUM A, 1953, ADV CANCER RES, V1, P451, DOI 10.1016/S0065-230X(08)60009-3; WYNDER EL, 1991, CANCER-AM CANCER SOC, V67, P746, DOI 10.1002/1097-0142(19910201)67:3<746::AID-CNCR2820670336>3.0.CO;2-1; 1987, REGULATING PESTICIDE	21	7	7	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					162	164		10.1016/0140-6736(92)93227-E	http://dx.doi.org/10.1016/0140-6736(92)93227-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352577				2022-12-24	WOS:A1992JE38200015
J	KISS, T; FILIPOWICZ, W				KISS, T; FILIPOWICZ, W			EVIDENCE AGAINST A MITOCHONDRIAL LOCATION OF THE 7-2/MRP RNA IN MAMMALIAN-CELLS	CELL			English	Editorial Material							RIBONUCLEASE-P; NUCLEAR GENE; MRP; SEQUENCES; DNA; TRANSCRIPTION; CONTAINS; ENZYME; SITE				KISS, T (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.			Kiss, Tamas/0000-0003-0293-3093				ALTMAN S, 1990, J BIOL CHEM, V265, P20053; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; Baserga R, 1969, Int Rev Exp Pathol, V7, P1; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; CREWS S, 1980, CELL, V19, P775, DOI 10.1016/S0092-8674(80)80053-5; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; Greenawalt J W, 1974, Methods Enzymol, V31, P310; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; NELSONREES WA, 1976, SCIENCE, V191, P96, DOI 10.1126/science.1246601; PACE NR, 1990, J BIOL CHEM, V265, P3587; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; REDDY R, 1981, J BIOL CHEM, V256, P8452; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; REIMER G, 1988, EXP CELL RES, V176, P117, DOI 10.1016/0014-4827(88)90126-7; STEELE WJ, 1965, J BIOL CHEM, V240, P1742; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; YUAN Y, 1989, J BIOL CHEM, V264, P14835; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266	35	100	102	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					11	16		10.1016/0092-8674(92)90528-K	http://dx.doi.org/10.1016/0092-8674(92)90528-K			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1377982				2022-12-24	WOS:A1992JC95700003
J	OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; HUIBREGTSE, K; VANDENBROUCKE, JP; TYTGAT, GNJ				OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; HUIBREGTSE, K; VANDENBROUCKE, JP; TYTGAT, GNJ			EVALUATION OF ENDOSCOPY FOR EARLY DETECTION OF GASTRIC-STUMP CANCER	LANCET			English	Article							SURGERY; LESIONS; COHORT	The value of endoscopic surveillance of postgastrectomy patients for the early detection of gastric-stump cancer is controversial. Using data from an Amsterdam postgastrectomy cohort of 2633 patients, we have done a retrospective analysis of the effect on mortality from gastric cancer of endoscopic surveillance in these patients. Between 1976 and 1982, 504 symptom-free patients from the Amsterdam cohort participated in an endoscopic surveillance programme. All patients were followed up until 1988. Relative to the general Dutch population, risk of death from gastric cancer was less among patients who took part in surveillance than among those who did not participate. However, differences were small and similar differences existed for risk of death from lung and colorectal cancers, suggesting the presence of selection. Our study seems to confirm that large-scale surveillance of postgastrectomy patients is not justified.	UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,1105 AZ AMSTERDAM,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,2333 AA LEIDEN,NETHERLANDS; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Johns Hopkins University	OFFERHAUS, GJA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				CAYGILL CPJ, 1986, LANCET, V1, P929; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; CRAANEN ME, 1991, DIGEST DIS SCI, V36, P1529, DOI 10.1007/BF01296393; LOGAN RFA, 1983, LANCET, V2, P667; OFFERHAUS GJA, 1989, CANCER, V64, P698, DOI 10.1002/1097-0142(19890801)64:3<698::AID-CNCR2820640322>3.0.CO;2-D; SAVALGI RS, 1990, LANCET, V336, P413, DOI 10.1016/0140-6736(90)91954-9; SCHUMAN BM, 1986, GASTROINTEST ENDOSC, V32, P117, DOI 10.1016/S0016-5107(86)71773-2; SONNENBERG A, 1984, GASTROENTEROLOGY, V87, P489; TERSMETTE AC, 1991, AM J EPIDEMIOL, V134, P14, DOI 10.1093/oxfordjournals.aje.a115988; TERSMETTE AC, 1991, GASTROENTEROLOGY, V101, P148, DOI 10.1016/0016-5085(91)90471-V	11	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					33	35		10.1016/0140-6736(92)92433-G	http://dx.doi.org/10.1016/0140-6736(92)92433-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351609				2022-12-24	WOS:A1992JC35400013
J	JAMES, AA				JAMES, AA			MOSQUITO MOLECULAR-GENETICS - THE HANDS THAT FEED BITE BACK	SCIENCE			English	Editorial Material							ANOPHELES-GAMBIAE COMPLEX				JAMES, AA (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.			James, Anthony/0000-0001-5577-3308				COLUZZI M, 1977, NATURE, V266, P832, DOI 10.1038/266832a0; CRAMPTON JM, 1990, MOL INSECT SCI; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; KAUFMAN PD, 1991, NUCLEIC ACIDS RES, V19, P6336, DOI 10.1093/nar/19.22.6336; MORRIS AC, 1991, NUCLEIC ACIDS RES, V19, P5895, DOI 10.1093/nar/19.21.5895; PASKEWITZ SM, 1990, MED VET ENTOMOL, V4, P367, DOI 10.1111/j.1365-2915.1990.tb00453.x; ZHENG LB, 1991, P NATL ACAD SCI USA, V88, P11187, DOI 10.1073/pnas.88.24.11187; 1991, MOSQUITO MOL GENETIC	8	114	119	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					37	38		10.1126/science.1352413	http://dx.doi.org/10.1126/science.1352413			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1352413				2022-12-24	WOS:A1992JC16500023
J	[Anonymous]				[Anonymous]			LOW-DOSE INTERFERON-ALPHA AND HIV-INFECTION	LANCET			English	Editorial Material																		1990, LANCET, V336, P935; INTERIM REPORT LOW D	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1106	1106						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349115				2022-12-24	WOS:A1992HR44600018
J	ECKEL, RH				ECKEL, RH			INSULIN RESISTANCE - AN ADAPTATION FOR WEIGHT MAINTENANCE	LANCET			English	Article							LIPOPROTEIN-LIPASE; PIMA-INDIANS; OBESE WOMEN; GLUCOSE; GAIN; RESPONSIVENESS; SENSITIVITY; METABOLISM; REDUCTION; RECEPTOR	Insulin resistance can be physiological, but most often is associated with metabolic disorders such as obesity and non-insulin dependent diabetes mellitus. The reduction in insulin action seen in insulin-resistant states affects metabolic fuel partitioning in a way that would prevent additional weight gain. Despite the potential adverse effects of cardiovascular risk factors that accompany insulin resistance, reductions in insulin action may well be necessary to prevent additional weight gain in those in whom excessive food intake is coupled with inactivity.			ECKEL, RH (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL, DENVER, CO 80262 USA.							BIELINSKI R, 1985, AM J CLIN NUTR, V42, P69, DOI 10.1093/ajcn/42.1.69; BLOCH CA, 1987, J PEDIATR-US, V110, P481, DOI 10.1016/S0022-3476(87)80522-X; BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W; DONAHUE RP, 1987, LANCET, V1, P821; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1987, J CLIN INVEST, V80, P992, DOI 10.1172/JCI113193; FARESE RV, 1991, METABOLISM, V40, P214, DOI 10.1016/0026-0495(91)90178-Y; FLATT JP, 1987, AM J CLIN NUTR, V45, P296, DOI 10.1093/ajcn/45.1.296; HAFFNER SM, 1989, ARTERIOSCLEROSIS, V9, P928, DOI 10.1161/01.ATV.9.6.928; HOLLENBECK CB, 1984, DIABETES, V33, P460, DOI 10.2337/diabetes.33.5.460; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; KRAMER FM, 1989, INT J OBESITY, V13, P123; LEBLANC J, 1982, METABOLISM, V31, P453, DOI 10.1016/0026-0495(82)90233-5; NEWMAN WP, 1983, METABOLISM, V32, P590, DOI 10.1016/0026-0495(83)90029-X; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; RANDLE PJ, 1963, LANCET, V1, P785; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSSINI AA, 1985, JOSLINS DIABETES MEL, P834; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TURNER RC, 1983, DIABETOLOGIA, V24, P404; WIGAND JP, 1979, DIABETES, V28, P287, DOI 10.2337/diabetes.28.4.287; ZURLO F, 1990, AM J PHYSIOL, V259, pE650	26	154	156	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1992	340	8833					1452	1453		10.1016/0140-6736(92)92633-Q	http://dx.doi.org/10.1016/0140-6736(92)92633-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360570				2022-12-24	WOS:A1992KC28400014
J	LEUNGHAGESTEIJN, CY; SPENCE, AM; STERN, BD; ZHOU, YW; SU, MW; HEDGECOCK, EM; CULOTTI, JG				LEUNGHAGESTEIJN, CY; SPENCE, AM; STERN, BD; ZHOU, YW; SU, MW; HEDGECOCK, EM; CULOTTI, JG			UNC-5, A TRANSMEMBRANE PROTEIN WITH IMMUNOGLOBULIN AND THROMBOSPONDIN TYPE-1 DOMAINS, GUIDES CELL AND PIONEER AXON MIGRATIONS IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GROWTH CONES; CIRCUMSPOROZOITE PROTEIN; NEURITE OUTGROWTH; MEMBRANE-PROTEINS; ATTACHMENT SITE; PHOSPHOLIPASE-C; M2 PROTEIN; GENE; SEQUENCE	The unc-5 gene is required for guiding pioneering axons and migrating cells along the body wall in C. elegans. In mutants, dorsal migrations are disrupted, but ventral and longitudinal movements are largely unaffected. The gene was tagged for molecular cloning by transposon insertions. Based on genomic and cDNA sequencing, the gene encodes UNC-5, a transmembrane protein of 919 aa. The predicted extracellular N-terminus comprises two immunoglobulin and two thrombospondin type 1 domains. Except for an SH3-like motif, the large intracellular C-terminus is novel. Mosaic analysis shows that unc-5 acts in migrating cells and pioneering neurons. We propose that UNC-5 is a transmembrane receptor expressed on the surface of motile cells and growth cones to guide dorsal movements.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; ROCHE INST MOLEC BIOL, DEPT CELL & DEV BIOL, NUTLEY, NJ 07110 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ONTARIO, CANADA	MRC Laboratory Molecular Biology; Johns Hopkins University; University of Toronto	LEUNGHAGESTEIJN, CY (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC IMMUNOL & NEUROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA.		Culotti, Joseph/G-6467-2013	Culotti, Joseph/0000-0001-6325-4612	NINDS NIH HHS [NS26295] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026295, R37NS026295] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; Bray D., 1992, CELL MOVEMENTS; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GOLDBERG DJ, 1989, TRENDS NEUROSCI, V12, P503, DOI 10.1016/0166-2236(89)90110-0; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HERMAN RK, 1989, NEUROGENETICS, V5, P1; HOLT GD, 1990, J BIOL CHEM, V265, P2852; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; ISHII N, UNPUB LAMININ RELATE; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; MORI I, 1988, GENETICS, V120, P397; NAEVE CW, 1990, EMBO J, V9, P3857, DOI 10.1002/j.1460-2075.1990.tb07604.x; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Rathjen FG, 1991, CURR OPIN CELL BIOL, V3, P992, DOI 10.1016/0955-0674(91)90119-J; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RUAN KS, 1984, P NATL ACAD SCI-BIOL, V81, P4018, DOI 10.1073/pnas.81.13.4018; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGRUE RJ, 1990, VIROLOGY, V179, P51, DOI 10.1016/0042-6822(90)90272-S; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SUN XJ, 1989, J BIOL CHEM, V264, P11288; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	78	348	367	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					289	299		10.1016/0092-8674(92)90357-I	http://dx.doi.org/10.1016/0092-8674(92)90357-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1384987				2022-12-24	WOS:A1992JU39500014
J	CARME, B				CARME, B			PSEUDORESISTANT MALARIA IN TROPICAL COUNTRIES	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM; CHEMOSENSITIVITY		FAC MED AMIENS,F-800054 AMIENS,FRANCE		CARME, B (corresponding author), CTR HOSP REG UNIV AMIENS,SERV PARASITOL,F-800054 AMIENS,FRANCE.							CARME B, 1991, LANCET, V338, P582, DOI 10.1016/0140-6736(91)91158-Q; CARME B, 1991, J INFECT DIS, V164, P828, DOI 10.1093/infdis/164.4.828; HOFFMAN SL, 1984, T ROY SOC TROP MED H, V78, P175, DOI 10.1016/0035-9203(84)90271-2; 1989, UN DIENSA STESA112 U; 1984, WHO TECH REP SER, V711	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					896	897		10.1016/0140-6736(92)93296-Y	http://dx.doi.org/10.1016/0140-6736(92)93296-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357307				2022-12-24	WOS:A1992JT32700015
J	PARKER, LL; PIWNICAWORMS, H				PARKER, LL; PIWNICAWORMS, H			INACTIVATION OF THE P34(CDC2)-CYCLIN-B COMPLEX BY THE HUMAN WEE1 TYROSINE KINASE	SCIENCE			English	Article							FISSION YEAST; CELL-CYCLE; P34CDC2 KINASE; SCHIZOSACCHAROMYCES-POMBE; PHOSPHORYLATION SITES; ACTIVATES P34CDC2; MITOTIC INDUCER; CDC25 PROTEIN; GENE; DEPHOSPHORYLATION	Entry into mitosis in Schizosaccharomyces pombe is negatively regulated by the wee1+ gene, which encodes a protein kinase with serine-, theonine-, and tyrosine-phosphorylating activities. The wee1+ kinase negatively regulates mitosis by phosphorylating p34cdc2 on tyrosine 15, thereby inactivating the p34cdc2-cyclin B complex. The human homolog of the wee1+ gene (WEE1Hu) was overproduced in bacteria and assayed in an in vitro system. Unlike its fission yeast homolog, the product of the WEE1Hu gene encoded a tyrosine-specific protein kinase. The human WEE1 kinase phosphorylated the p34cdc2-cyclin B complex on tyrosine 15 but not on threonine 14 in vitro and inactivated the p34cdc2-cyclin B kinase. This inhibition was reversed by the human Cdc25C protein, which catalyzed the dephosphorylation of p34cdc2. These results indicate that the product of the WEE1Hu gene directly regulates the p34cdc2-cyclin B complex in human cells and that a kinase other than that encoded by WEE1Hu phosphorylates p34cdc2 on threonine 14.	TUFTS UNIV, DEPT PHYSIOL, BOSTON, MA 02111 USA	Tufts University			Piwnica-Worms, Helen/C-5214-2012					BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER L, UNPUB; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1990, New Biologist, V2, P389; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	26	546	569	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1955	1957		10.1126/science.1384126	http://dx.doi.org/10.1126/science.1384126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1384126				2022-12-24	WOS:A1992JP59400034
J	KOROMILAS, AE; ROY, S; BARBER, GN; KATZE, MG; SONENBERG, N				KOROMILAS, AE; ROY, S; BARBER, GN; KATZE, MG; SONENBERG, N			MALIGNANT TRANSFORMATION BY A MUTANT OF THE IFN-INDUCIBLE DSRNA-DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; EIF-2-ALPHA KINASE; 3T3-F442A CELLS; INTERFERON; RECEPTOR; BINDING; AUTOPHOSPHORYLATION; INITIATION; EXPRESSION	The double-stranded RNA-dependent protein kinase (dsRNA-PK) is thought to be a key mediator of the antiviral and antiproliferative effects of interferons (IFNs). Studies examining the physiological function of the kinase suggest that it participates in cell growth and differentiation by regulating protein synthesis. Autophosphorylation and consequent activation of dsRNA-PK in vitro and in vivo result in phosphorylation of the alpha-subunit of eukaryotic initiation factor-2 (eIF-2) and inhibition of protein synthesis. Expression of a functionally defective mutant of human dsRNA-PK in NIH 3T3 cells resulted in malignant transformation, suggesting that dsRNA-PK may function as a suppressor of cell proliferation and tumorigenesis.	MCGILL UNIV, FAC MED, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, FAC MED, MCGILL CANC CTR, MONTREAL H3G 1Y6, QUEBEC, CANADA; UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	McGill University; McGill University; University of Washington; University of Washington Seattle					NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BELL JS, COMMUNICATION; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1990, J CELL BIOL, V10, P1541; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOROMILAS AE, UNPUB; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LAURENT AG, 1984, BIOCHEM BIOPH RES CO, V125, P1, DOI 10.1016/S0006-291X(84)80324-1; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; RAMIREZ M, 1992, CELL, V68, P585; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1992, J BIOL CHEM, V267, P5017; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	45	531	544	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1685	1689		10.1126/science.1382315	http://dx.doi.org/10.1126/science.1382315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1382315				2022-12-24	WOS:A1992JN50100032
J	BATES, I; BEDUADDO, G; RUTHERFORD, T; BEVAN, DH				BATES, I; BEDUADDO, G; RUTHERFORD, T; BEVAN, DH			SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES IN TROPICAL WEST AFRICA	LANCET			English	Note							BLOOD	Splenic lymphoma with villous lymphocytes (SLVL) is a monoclonal B-lymphoproliferative disorder characterised by splenomegaly and distinctive villous lymphocytes in the peripheral blood. It has not previously been reported from Africa, but we describe ten Ghanaian patients with SLVL seen at one hospital during a 4-year period. The clinical presentation is similar in Africa and in temperate regions, though the lymphocyte count is higher in African patients and the disorder predominantly affects middle-aged women rather than elderly men. It is likely that SLVL has previously been classified as splenic chronic lymphocytic leukaemia or hyper-reactive malarial splenomegaly.	KOMFO ANOKYE TEACHING HOSP,KUMASI,GHANA	Kwame Nkrumah University Science & Technology	BATES, I (corresponding author), ST GEORGE HOSP,SCH MED,DIV HAEMATOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATES I, 1991, J CLIN PATHOL, V44, P605, DOI 10.1136/jcp.44.7.605; BATES I, 1991, LANCET, V337, P505, DOI 10.1016/0140-6736(91)91293-4; MELO JV, 1987, LEUKEMIA, V1, P294; SONNET J, 1966, TROP GEOGR MED, V18, P272; SPIRANO P, 1986, HEMATOLOGICA, V71, P25; 1990, BRIT J HAEMATOL, V75, P449	8	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					575	577		10.1016/0140-6736(92)92108-R	http://dx.doi.org/10.1016/0140-6736(92)92108-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355156				2022-12-24	WOS:A1992JM33400005
J	MCINTOSH, EDG; MENSER, MA				MCINTOSH, EDG; MENSER, MA			A 50-YEAR FOLLOW-UP OF CONGENITAL-RUBELLA	LANCET			English	Article							DIABETES-MELLITUS	50 patients with congenital rubella, born in 1939-43, were reviewed in 1967. Here we report their outcome in 1 991. Since 1 967, there have been 7 deaths (3 cardiovascular, 3 malignant disease, 1 AIDS). 40 had full clinical assessment. The prevalence of diabetes mellitus is similar to that in 1967: 4 of the 5 reported diabetic then, remain so, and there is 1 new case. 1 subject has malignant melanoma and 3 have died from cancer. Although the incidence of malignant disease is not increased, the death rate is (standardised mortality rate 6.0, 95% CI 1.24-17.57). Longer follow-up will be required to confirm this observation.	ROYAL ALEXANDRA HOSP CHILDREN,DEPT MED,POB 34,CAMPERDOWN,NSW 2050,AUSTRALIA									FINE PEM, 1985, BRIT MED J, V290, P509, DOI 10.1136/bmj.290.6467.509; FORREST JM, 1971, LANCET, V2, P332; Gregg NM, 1941, T OPHTHALMOL SOC AUS, V3, P35; GREGG NM, 1945, MED J AUSTRALIA, V2, P122; MENSER MA, 1978, LANCET, V1, P57; MENSER MA, 1967, LANCET, V2, P1347; 1991, LANCET, V337, P668	7	57	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					414	415		10.1016/0140-6736(92)91483-O	http://dx.doi.org/10.1016/0140-6736(92)91483-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353568				2022-12-24	WOS:A1992JJ44900016
J	STEHOUWER, CDA; NAUTA, JJP; ZELDENRUST, GC; HACKENG, WHL; DONKER, AJM; DENOTTOLANDER, GJH				STEHOUWER, CDA; NAUTA, JJP; ZELDENRUST, GC; HACKENG, WHL; DONKER, AJM; DENOTTOLANDER, GJH			URINARY ALBUMIN EXCRETION, CARDIOVASCULAR-DISEASE, AND ENDOTHELIAL DYSFUNCTION IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							CORONARY HEART-DISEASE; VONWILLEBRAND-FACTOR; RISK-FACTORS; MICROALBUMINURIA PREDICTS; NEPHROPATHY; MORTALITY; PROTEINURIA; PLASMA; ABNORMALITIES; KIDNEY	Raised urinary albumin excretion (UAE) is associated with an increased risk of cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM). We have examined the role of endothelial dysfunction as a possible explanation for this association in 94 NIDDM patients by investigating UAE, new cardiovascular events, and plasma concentration of von Willebrand factor (vWF), an indicator of endothelial dysfunction. At baseline, 66 patients had normal UAE (< 15-mu-g/min), which remained normal in 33 (group 1) and increased in 33 (to median 31.5-mu-g/min, group 2). In 28 patients, baseline UAE was abnormal (67.1-mu-g/min, group 3). Follow-up ranged between 9 and 53 months. vWF did not change in group 1 (median 128% at baseline and 123% at follow-up), but increased in group 2 (from 116 to 219%, p < 0.0001) and group 3 (from 157 to 207%, p = 0.0005). Baseline level of and change in vWF were strongly related to the development of microalbuminuria (R2 = 0.60, p < 0.0001), but cardiovascular risk factors were not (R2 = 0.14). Raised baseline UAE was associated with an increased risk of new cardiovascular events only in patients with vWF concentrations above the median (relative risk 3.66, 95% Cl 1.3-11.9) and not in patients with lower vWF (0.19, 0.01-1.33). In addition, the cardiovascular risk associated with increased UAE was modified by low compared with high concentrations of serum high density lipoprotein cholesterol (2.86 [1.03-8.48] vs 0.15 [0.01-1.43]). Dysfunction of vascular endothelium may be a link between albuminuria and atherosclerotic cardiovascular disease in NIDDM.	BERGWEG HOSP,ENDOCRINOL LAB,ROTTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT THEORY MED EPIDEMIOL & BIOSTAT,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	STEHOUWER, CDA (corresponding author), BERGWEG HOSP,DEPT INTERNAL MED,ROTTERDAM,NETHERLANDS.		Stehouwer, Coen/AAB-3435-2021					BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BULPITT CJ, 1979, LANCET, V2, P134; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; ELLIS D, 1989, AM J KIDNEY DIS, V13, P321, DOI 10.1016/S0272-6386(89)80039-3; FITZGERALD AP, 1991, DIABETIC MED, V8, P475, DOI 10.1111/j.1464-5491.1991.tb01635.x; IWASHIMA Y, 1990, DIABETES, V39, P983, DOI 10.2337/diabetes.39.8.983; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; JANSSON JH, 1991, BRIT HEART J, V66, P351; Jarrett R J, 1984, Diabet Med, V1, P17; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, LANCET, V1, P461; KANWAR YS, 1984, LAB INVEST, V51, P7; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; MATTOCK MB, 1988, DIABETOLOGIA, V31, P82, DOI 10.1007/BF00395552; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NISKANEN L, 1990, DIABETOLOGIA, V33, P237, DOI 10.1007/BF00404802; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHMITZ A, 1990, DIABETIC MED, V7, P521, DOI 10.1111/j.1464-5491.1990.tb01435.x; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; STEHHOUWER CDA, 1991, DIABETES, V40, P1746; STEHOUWER CDA, 1991, DIABETES, V40, P971, DOI 10.2337/diabetes.40.8.971; STEHOUWER CDA, 1992, DIABETOLOGIA, V35, P555, DOI 10.1007/BF00400484; STEHOUWER CDA, 1990, ARCH INTERN MED, V150, P373, DOI 10.1001/archinte.150.2.373; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIBERTI GC, 1986, CLIN ENDOCRINOL META, V15, P753, DOI 10.1016/S0300-595X(86)80073-1; VUKOVICH TC, 1989, J CLIN ENDOCR METAB, V69, P84, DOI 10.1210/jcem-69-1-84; YUDKIN JS, 1988, LANCET, V2, P530	29	523	532	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					319	323		10.1016/0140-6736(92)91401-S	http://dx.doi.org/10.1016/0140-6736(92)91401-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353802				2022-12-24	WOS:A1992JH12500001
J	AWGULEWITSCH, A; JACOBS, D				AWGULEWITSCH, A; JACOBS, D			DEFORMED AUTOREGULATORY ELEMENT FROM DROSOPHILA FUNCTIONS IN A CONSERVED MANNER IN TRANSGENIC MICE	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; DIFFERENTIAL EXPRESSION; HOMEOTIC GENES; HINDBRAIN; ORGANIZATION; HOX-1.4; DOMAINS; MURINE; REGION; HOX	THE striking similarities in the structure, organization and anterior-posterior expression patterns between the murine Hox gene system and the Drosophila homeotic gene complexes1,2, called HOM-C (ref. 3), may point to highly conserved mechanisms for specifying positional identities (reviewed in ref. 4). Strong support for this concept lies in the observation of conserved colinearity between the genomic order of the Hox/HOM genes and their unique successive expression domains along the anterior-posterior axes of both mouse and fly embryos1,2. These unique and precise expression patterns appear to be facilitated by multiple cis-regulatory elements (reviewed in ref. 5). One of the few elements characterized in detail is the autoregulatory enhancer of the homeotic gene Deformed (Dfd)6-9, which supports expression in subregions of posterior head segments of Drosophila embryos7. Here we present evidence that this enhancer is capable of conferring reporter gene expression to a discrete subregion of the hindbrain in transgenic mouse embryos. Remarkably, this anterior-posterior subregion lies within the common anterior expression domain of the Dfd cognate Hox genes in the postotic hindbrain10,11. Our results indicate that the Dfd autoregulatory enhancer is part of a highly conserved mechanism for establishing region-specific gene expression along the anterior-posterior axis of the embryo.			AWGULEWITSCH, A (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.							AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM M, 1988, DEVELOPMENT, V104, P123; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; AWGULEWITSCH A, 1991, METHODS NUCLEIC ACID, P359; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; Dessain S, 1991, CURR OPIN GENET DEV, V1, P275, DOI 10.1016/S0959-437X(05)80082-6; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hogan B., 1986, MANIPULATING MOUSE E; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KEYNES R, 1990, NEURON, V2, P1; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; Maniatis T., 1982, MOL CLONING; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGinnis W, 1990, Adv Genet, V27, P363; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; RUGH R, 1990, MOUSE ITS REPRODUCTI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUGGLE CK, 1990, GENE DEV, V4, P180, DOI 10.1101/gad.4.2.180; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	33	71	71	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					341	344		10.1038/358341a0	http://dx.doi.org/10.1038/358341a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1353608				2022-12-24	WOS:A1992JE68400067
J	OKEEFE, SJ; TAMURA, J; KINCAID, RL; TOCCI, MJ; ONEILL, EA				OKEEFE, SJ; TAMURA, J; KINCAID, RL; TOCCI, MJ; ONEILL, EA			FK-506-SENSITIVE AND CSA-SENSITIVE ACTIVATION OF THE INTERLEUKIN-2 PROMOTER BY CALCINEURIN	NATURE			English	Article							EXPRESSION; CALMODULIN; DOMAIN; CELLS	ANTIGEN recognition by the T-cell receptor (TCR) initiates events including lymphokine gene transcription 1, particularly interleukin-2, that lead to T-cell activation. The immunosuppressive drugs, cyclosporin A (CsA) and FK-506, prevent T-cell proliferation by inhibiting a Ca2+-dependent event required for induction of interleukin-2 transcription 2. Complexes of FK-506 or CsA and their respective intracellular binding proteins inhibit the calmodulin-dependent protein phosphatase, calcineurin, in vitro 3. The pharmacological relevance of this observation to immunosuppression or drug toxicity is undetermined. Calcineurin, although present in lymphocytes 4, has not been implicated in TCR-mediated activation of lymphokine genes or in transcriptional regulation in general. Here we report that transfection of a calcineurin catalytic subunit increases the 50% inhibitory concentration (IC50) of the immunosuppressants FK-506 and CsA, and that a mutant subunit acts in synergy with phorbol ester alone to activate the interleukin-2 promoter in a drug-sensitive manner. These results implicate calcineurin as a component of the TCR signal transduction pathway by demonstrating its role in the drug-sensitive activation of the interleukin-2 promoter.	NIAAA,MOLEC & CELLULAR NEUROBIOL LAB,IMMUNOL SECT,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	OKEEFE, SJ (corresponding author), MERCK SHARP & DOHME LTD,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065, USA.							ALTMEYER A, 1991, INT J IMMUNOPHARMACO, V13, P1187, DOI 10.1016/0192-0561(91)90170-C; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KINCAID RL, 1986, BIOCHEM BIOPH RES CO, V140, P320, DOI 10.1016/0006-291X(86)91093-4; KINCAID RL, 1991, ADV PROT PHOSPHATASE, V6, P73; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAMURA J, 1990, FASEB J, V4, pA2236	19	855	877	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					692	694		10.1038/357692a0	http://dx.doi.org/10.1038/357692a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377361				2022-12-24	WOS:A1992JA43000072
J	LANCE, JW				LANCE, JW			TREATMENT OF MIGRAINE	LANCET			English	Article							MENSTRUAL MIGRAINE; NAPROXEN SODIUM; AMITRIPTYLINE; PROPHYLAXIS; ESTRADIOL; ATTACKS; THERAPY; DRUG				LANCE, JW (corresponding author), PRINCE WALES HOSP, INST NEUROL SCI, RANDWICK, NSW 2031, AUSTRALIA.							ADLER CS, 1987, PSYCHIATRIC ASPECTS; AMERY WK, 1983, HEADACHE, V23, P70, DOI 10.1111/j.1526-4610.1983.hed2302070.x; [Anonymous], 1991, Eur Neurol, V31, P314; ANTHONY M, 1969, ARCH NEUROL-CHICAGO, V21, P263, DOI 10.1001/archneur.1969.00480150053007; ANTHONY M, 1967, ARCH NEUROL-CHICAGO, V16, P544, DOI 10.1001/archneur.1967.00470230096013; BLAU JN, 1980, BRIT MED J, V281, P658, DOI 10.1136/bmj.281.6241.658; BROWN EG, 1991, EUR NEUROL, V31, P339, DOI 10.1159/000116762; CLEAL A, 1991, EUR NEUROL, V31, P323; COPPEN A, 1978, LANCET, V1, P63; Curran D.A., 1967, RESEARCH CLINICAL ST, V1, P74; DELIGNIERES B, 1986, BMJ-BRIT MED J, V293, P1540, DOI 10.1136/bmj.293.6561.1540; GOADSBY PJ, 1991, LANCET, V338, P782, DOI 10.1016/0140-6736(91)90666-D; GOMERSALL JD, 1973, J NEUROL NEUROSUR PS, V36, P684, DOI 10.1136/jnnp.36.4.684; GRAHAM AN, 1984, PROGR MIGRAINE RES, V2, P283; HIRT D, 1989, CEPHALALGIA S10, V9, P410; JOHNSON ES, 1985, CEPHALALGIA, V5, P5, DOI 10.1046/j.1468-2982.1985.0501005.x; KIMBALL RW, 1960, NEUROLOGY, V10, P107, DOI 10.1212/WNL.10.2.107; Lance J. W, 1986, MIGRAINE OTHER HEADA; LANCE JW, 1964, LANCET, V1, P1236; LITTLEWOOD JT, 1987, CURR PROBLEMS NEUROL, V4, P123; MAGOS AL, 1983, J NEUROL NEUROSUR PS, V46, P1044, DOI 10.1136/jnnp.46.11.1044; MCQUEEN J, 1989, ADV HEADACHE RES, P235; MELLOR C, 1991, EUR NEUROL, V31, P306; MEYER JS, 1983, HEADACHE, V23, P266, DOI 10.1111/j.1526-4610.1983.hed2306266.x; PRADALIER A, 1985, CEPHALALGIA, V5, P107, DOI 10.1046/j.1468-2982.1985.0502107.x; RASKIN NH, 1986, NEUROLOGY, V36, P995, DOI 10.1212/WNL.36.7.995; RASKIN NH, 1988, HEADACHE, P176; SORENSEN KV, 1988, ACTA NEUROL SCAND, V78, P346, DOI 10.1111/j.1600-0404.1988.tb03667.x; TFELTHANSEN P, 1980, J NEUROL NEUROSUR PS, V43, P369, DOI 10.1136/jnnp.43.4.369; 1988, CEPHALALGIA S7, V8, P13	30	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1992	339	8803					1207	1209		10.1016/0140-6736(92)91141-T	http://dx.doi.org/10.1016/0140-6736(92)91141-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349945				2022-12-24	WOS:A1992HU68400011
J	HERCBERGS, A; BROKSIMONI, F; HOLTZMAN, F; BARAM, J; LEITH, JT; BRENNER, HJ				HERCBERGS, A; BROKSIMONI, F; HOLTZMAN, F; BARAM, J; LEITH, JT; BRENNER, HJ			ERYTHROCYTE GLUTATHIONE AND TUMOR RESPONSE TO CHEMOTHERAPY	LANCET			English	Article							METABOLISM; CANCER; CELLS; INVITRO	There is much evidence that tumour glutathione (GSH) concentration is an important factor in resistance to cancer chemotherapy. Since measurement of tumour GSH would require an, invasive procedure in every patient, we have tried to find out whether GSH concentrations in peripheral-blood erythrocytes are related to the response to chemotherapy and thus whether they reflect those in tumour cells. Erythrocyte GSH concentrations were measured by spectrophotometry in peripheral blood from 28 patients with advanced breast cancer and 40 patients with other tumours before and after treatment with various conventional chemotherapeutic regimens. The mean pretreatment GSH concentration was lower in patients who showed a complete or partial response to chemotherapy than in those with stable or progressive disease in both the breast-cancer group (8.69 [95% confidence interval 5.99-11.39] vs 2.32 [1.23-3.41] mu-mol/g haemoglobin; p < 0.01) and the group with other tumours (5.94 [4.14-7.74) vs 2.83 [1.71-3.95] mu-mol/g; p < 0.01 ). The correlation of erythrocyte GSH concentration with response rate suggests that this measurement may be helpful in prediction of response to therapy.	SHEBA MED CTR,DEPT HEMATOL,RAMAT GAN,ISRAEL; SHEBA MED CTR,DEPT ONCOL,RAMAT GAN,ISRAEL; BROWN UNIV,DEPT RADIAT MED,RADIAT SERV,PROVIDENCE,RI 02912	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Brown University	HERCBERGS, A (corresponding author), CLEVELAND CLIN FDN,DEPT RADIAT THERAPY,DESK T18,1 CLIN CTR,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							ARRICK BA, 1984, CANCER RES, V44, P4224; ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; Beutler E., 1984, RED CELL METABOLISM, P131; BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7; CIMINO JA, 1987, P SOC EXP BIOL MED, V184, P151, DOI 10.3181/00379727-184-42459; DETHLEFSEN LA, 1986, INT J RADIAT ONCOL, V12, P1157, DOI 10.1016/0360-3016(86)90248-8; HAYWARD JL, 1977, BRIT J CANCER, V35, P292, DOI 10.1038/bjc.1977.42; HENDERSON IC, 1987, BREAST DISEASES, P428; HERCBERGS A, 1989, NEW ENGL J MED, V319, P1351; HERCBERGS A, 1988, P AN M AM SOC CLIN, V7, P20; LACRETA F, 1991, P AN M AM SOC CLIN, V10, P104; LEE FYF, 1989, CANCER RES, V49, P5244; MEIJER C, 1990, CANCER TREAT REV, V17, P389, DOI 10.1016/0305-7372(90)90081-P; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MENENDEZ CE, 1974, AM J PHYSIOL, V226, P1480, DOI 10.1152/ajplegacy.1974.226.6.1480; MITCHELL JB, 1989, INT J RADIAT ONCOL, V16, P1289, DOI 10.1016/0360-3016(89)90301-5; Ozols R F, 1986, Important Adv Oncol, P129; REID I, 1991, BRIT J CANCER, V64, P915, DOI 10.1038/bjc.1991.426; RIVLIN RS, FLAVINS FLAVOPROTEIN; Rosenberg SA., CANC PRINCIPLES PRAC, Ved, P895; SHOEMAKER JP, 1979, J NATL CANCER I, V62, P1575; Tate M. W., 1957, NONPARAMETRIC SHORTC; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615	23	53	54	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1074	1076		10.1016/0140-6736(92)90664-O	http://dx.doi.org/10.1016/0140-6736(92)90664-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349103				2022-12-24	WOS:A1992HR44600003
J	NICOLAIDES, KH; RODECK, CH				NICOLAIDES, KH; RODECK, CH			MATERNAL SERUM ANTI-D ANTIBODY CONCENTRATION AND ASSESSMENT OF RHESUS ISOIMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							ISOIMMUNIZATION		UNIV COLL & MIDDLESEX SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND	University of London; University College London	NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				MARSH W L, 1968, Journal of Medical Laboratory Technology, V25, P335; NICOLAIDES K H, 1986, Fetal Therapy, V1, P185; NICOLAIDES KH, 1988, LANCET, V1, P1073; NICOLINI U, 1988, BRIT MED J, V297, P1379, DOI 10.1136/bmj.297.6660.1379; RODECK CH, 1984, AM J OBSTET GYNECOL, V150, P769, DOI 10.1016/0002-9378(84)90683-5	5	59	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1155	1156		10.1136/bmj.304.6835.1155	http://dx.doi.org/10.1136/bmj.304.6835.1155			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1382765	Green Published, Bronze			2022-12-24	WOS:A1992HT23200023
J	SWERDLOW, AJ; DOUGLAS, AJ; HUDSON, GV; HUDSON, BV; BENNETT, MH; MACLENNAN, KA				SWERDLOW, AJ; DOUGLAS, AJ; HUDSON, GV; HUDSON, BV; BENNETT, MH; MACLENNAN, KA			RISK OF 2ND PRIMARY CANCERS AFTER HODGKINS-DISEASE BY TYPE OF TREATMENT - ANALYSIS OF 2846 PATIENTS IN THE BRITISH NATIONAL LYMPHOMA INVESTIGATION	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; CHEMOTHERAPY; RADIOTHERAPY; EXPERIENCE; MORTALITY	Objective - To analyse the risk of second primary cancers during long term follow up of patients with Hodgkin's disease. Design - Cohort study. Setting - The British National Lymphoma Investigation (a collaborative group of over 60 participating centres in Britain treating lymphomas). Patients - 2846 patients first treated for Hodgkin's disease during 1970-87, for whom follow up was complete in 99.8%. Main outcome measures - Second primary cancers; uniform pathology reviews confirmed the diagnosis of Hodgkin's disease and of second primary non-Hodgkin's lymphomas. Results - 113 second primary cancers occurred. Relative risk of cancer other than Hodgkin's disease was 2.7 (95% confidence interval 2.3 to 3.3) compared with the general population, with significant risks of leukaemia (16.0 (9.1 to 26.0)); non-Hodgkin's lymphoma (16.8 (9.8 to 26.9)); and cancers of the colon (3.2 (1.4 to 6.2)), lung (3.8 (2.6 to 5.4)), bone (15.1 (1.8 to 54.7)), and thyroid (9.4 (1.1 to 33.9)). Absolute excess risk associated with treatment was greater for solid tumours than for leukaemia and lymphomas. Relative risk of leukaemia increased soon after treatment, reaching a peak after five to nine years. It was increased substantially after chemotherapy (27.9 (12.7 to 52.9)), combined treatment with radiotherapy and chemotherapy (21.5 (7.9 to 46.8)), and relative to number of courses of chemotherapy but was not significantly increased after radiotherapy (2.5 (0.1 to 14.1)). Relative risk of non-Hodgkin's lymphoma increased in the first five years after treatment and remained high but showed no clear relation with type or extent of treatment. Relative risk of solid tumours was less raised initially but increased throughout follow up and for lung cancer 10 years or more after entry was 8.3 (4.0 to 15.3). The risk of solid tumours increased after treatments including radiotherapy and after chemotherapy alone. The risk after chemotherapy increased significantly with time since first treatment. Conclusions - The risk of solid cancer, not of leukaemia, is the major long term hazard of treatment for Hodgkin's disease, and this seemed to apply after chemotherapy as well as after radiotherapy. These risks of second cancers are important in choice of treatment and in follow up of patients, but they are small compared with the great improvements in survival which have been brought about by modern therapeutic methods for Hodgkin's disease.	UNIV COLL & MIDDLESEX SCH MED,DEPT ONCOL,LONDON,ENGLAND; MT VERNON HOSP,DEPT HISTOPATHOL,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust	SWERDLOW, AJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,EPIDEMIOL MONITORING UNIT,LONDON WC1E 7HT,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159				[Anonymous], 1974, IARC MONOGRAPHS EVAL, V4; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BENNETT MH, 1991, ANN ONCOL, V2, P83, DOI 10.1093/annonc/2.suppl_2.83; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BOICE JD, 1984, PROGR CANCER RES THE, V26; BOIVIN JF, 1984, JNCI-J NATL CANCER I, V72, P233; BOIVIN JF, 1988, CANCER, V61, P2541, DOI 10.1002/1097-0142(19880615)61:12<2541::AID-CNCR2820611225>3.0.CO;2-G; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COLEMAN CN, 1977, NEW ENGL J MED, V297, P1249, DOI 10.1056/NEJM197712082972303; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COLMAN M, 1988, RADIOTHER ONCOL, V11, P229, DOI 10.1016/0167-8140(88)90005-9; DAY NE, 1983, IARC SCI PUBL, V52, P137; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; HANCOCK BW, 1991, BRIT J CANCER, V63, P579, DOI 10.1038/bjc.1991.134; HENRYAMAR M, 1988, NATL CANCER I MONOGR, V6, P65; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINLEN LJ, 1982, CANCER EPIDEMIOL, P494; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; POLEDNAK AP, 1978, AM J EPIDEMIOL, V107, P179, DOI 10.1093/oxfordjournals.aje.a112524; SELBY P, 1990, BRIT J CANCER, V62, P279, DOI 10.1038/bjc.1990.278; SMITH PG, 1977, CANCER, V39, P1901, DOI 10.1002/1097-0142(197704)39:4+<1901::AID-CNCR2820390826>3.0.CO;2-T; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; TESTER WJ, 1984, J CLIN ONCOL, V2, P762, DOI 10.1200/JCO.1984.2.7.762; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1984, CANCER, V53, P62, DOI 10.1002/1097-0142(19840101)53:1<62::AID-CNCR2820530112>3.0.CO;2-3; YOUNG RC, 1990, J NCI MONOGR, V10, P55; 1981, IARC MONOGRAPHS EVAL, V26; 1967, MANUAL INT STATISTIC; 1989, EGRET; [No title captured]	35	193	197	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1137	1143		10.1136/bmj.304.6835.1137	http://dx.doi.org/10.1136/bmj.304.6835.1137			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392790	Green Published, Bronze			2022-12-24	WOS:A1992HT23200018
J	SUGITANI, M; INCHAUSPE, G; SHINDO, M; PRINCE, AM				SUGITANI, M; INCHAUSPE, G; SHINDO, M; PRINCE, AM			SENSITIVITY OF SEROLOGICAL ASSAYS TO IDENTIFY BLOOD-DONORS WITH HEPATITIS-C VIREMIA	LANCET			English	Note							NON-B HEPATITIS; NON-A	Blood donors at high risk of hepatitis C virus (HCV) infection were tested for viraemia by the polymerase chain reaction (PCR). PCR results were accepted as positive only if reactive in 3 of 4 tests and if confirmed in an independent laboratory. The sera were also tested by 6 different assays to determine the ability of current serological assays to detect viraemic blood donors. Of 19 PCR-positive sera, only 13 (68%) were detected by the most sensitive of the serological assays. If these results are confirmed, automated PCR assays may be required for blood-donor screening to prevent transmission of HCV.	NEW YORK BLOOD CTR,VIROL & PARASITOL LAB,310 E 67TH ST,NEW YORK,NY 10021; NIHON UNIV,SCH MED,DEPT PATHOL 1,TOKYO 173,JAPAN; NIH,LIVER DIS SECT,BETHESDA,MD 20892	New York Blood Center; Nihon University; National Institutes of Health (NIH) - USA								AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; HOSEIN B, 1991, P NATL ACAD SCI USA, V88, P3647, DOI 10.1073/pnas.88.9.3647; INCHAUSPE G, 1991, HEPATOLOGY, V14, P595, DOI 10.1016/0270-9139(91)90044-V; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; NASOFF MS, 1991, P NATL ACAD SCI USA, V88, P5462, DOI 10.1073/pnas.88.12.5462; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; ZANETTI AR, 1990, LANCET, V336, P448, DOI 10.1016/0140-6736(90)92003-Z	9	147	150	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1018	1019		10.1016/0140-6736(92)90538-E	http://dx.doi.org/10.1016/0140-6736(92)90538-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349053				2022-12-24	WOS:A1992HQ43500006
J	ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK				ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK			DECISIONS NEAR THE END OF LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NETHERLANDS; EUTHANASIA; ILL				ORENTLICHER, D (corresponding author), AMER MED ASSOC,COUNCIL ETH & JUDICIAL AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							BATTIN MP, 1991, FEB U FLOR COLL MED; BEAUCHAMP DW, 1989, MED ETHICS; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; BROCK DW, 1989, MED ETHICS; Buchanan AE, 1989, DECIDING OTHERS ETHI; Capron A M, 1986, Law Med Health Care, V14, P141; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; GELMAN D, 1990, NEWSWEEK        0723, P46; KAMISAR Y, 1958, MINN LAW REV, V42, P969; KASS LR, 1989, PUBLIC INTEREST, V94, P25; Lifton Robert J, 1986, NAZI DOCTORS MED KIL; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LYNN J, 1983, HASTING CANC RE 1013, P17; MERZ B, 1991, AM MED NEWS     1118, P29; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RAMSEY P, 1970, PATIENT PERSON, P113; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; SCHMITZ P, 1986, BY NO EXTRAORDINARY; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1988, LIFE SUSTAINING TECH; 1990, VITAL STATISTICS U A, V2; 1991, JUN P HOUS DEL AMA C, P261; 1987, GUIDELINES TERMINATI; 1989, CURRENT OPINIONS, P13; 1987, DEC P HOUS DEL AMA C, P170; 1990, DEC P HOUS DEL AMA C, P180; 1987, DECIDING FOREGO LIFE; 1989, JUN P HOUS DEL AMA C, P314; 1988, JUN P HOUS DEL AMA C, P258	34	174	175	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2229	2233						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372944				2022-12-24	WOS:A1992HN84100035
J	NINAN, TK; RUSSELL, G				NINAN, TK; RUSSELL, G			RESPIRATORY SYMPTOMS AND ATOPY IN ABERDEEN SCHOOLCHILDREN - EVIDENCE FROM 2 SURVEYS 25 YEARS APART	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; PREVALENCE; ADMISSIONS; MANAGEMENT; MORTALITY; INCREASE; ENGLAND; TRENDS; HEALTH; WALES	Objective-To estimate changes in the prevalence of respiratory symptoms and the reported diagnoses of asthma, eczema, and hay fever in primary school children in Aberdeen between 1964 and 1989. Design-Determination of incidence prevalence and prevalence from survey data. Setting-Aberdeen, Scotland. Participants-2743 primary school children (aged 8-13) from 1964 and 3942 from 1989. Main outcome measures-Survey data on whether, according to the parent or guardian, the child wheezed or was troubled with shortness of breath; the number of episodes of breathlessness in the past year; and whether asthma, eczema, or hay fever had ever been diagnosed. Results-Questionnaires were completed by the parents of 2510 children in 1964 and 3403 children in 1989. The prevalence of wheeze rose from 10.4% in 1964 to 19.8% in 1989, and the prevalence of episodes of shortness of breath increased from 5.4% to 10.0%. In both surveys wheeze and shortness of breath were more prevalent in boys than in girls. The reported diagnosis of asthma rose from 4.1% to 10.2%, hay fever from 3.2% to 11.9%, and eczema from 5.3% to 12%. The proportion of boys suffering from eczema rose from 47.7% to 60.0%. Hay fever showed a similar increase, from 49.4% to 60.1%, in boys over the 25 year period. Though the parents of a higher proportion of children with wheeze were aware of the diagnosis of asthma in 1989, because of the increased prevalence of wheeze the absolute number of parents of wheezy children who were not aware of a diagnosis of asthma increased from 7.4% to 9.6% of the population studied. Conclusion-The higher diagnosis rate for asthma is due not simply to changes in diagnostic fashion but reflects an increase over the past 25 years in the prevalence of respiratory symptoms, which in turn may reflect a more general change in the prevalence of atopy, the increase in which was particularly noticeable in boys. This increase explains some of the increase in hospital admission rates for children with asthma.	ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen	NINAN, TK (corresponding author), UNIV ABERDEEN,DEPT CHILD HLTH,ABERDEEN AB9 2ZD,SCOTLAND.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BAUMAN A, 1990, AUSTR MED RES J, V20, P105; BURNEY PGJ, 1986, LANCET, V2, P323; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; DAWSON B, 1969, LANCET, V1, P827; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; Gardner MJ, 1989, BRIT MED J LONDON; GERRARD JW, 1983, ANN ALLERGY, V51, P300; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HAY IFC, 1987, LANCET, V2, P609; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MAXKJELLMAN NJ, 1977, ACTA PEDIATR SCAND, V665, P465; MITCHELL EA, 1984, NEW ZEAL MED J, V97, P67; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; REINHARDT MC, 1983, ANN ALLERGY, V51, P311; TAYLOR B, 1984, LANCET, V1, P465; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	23	548	562	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					873	875		10.1136/bmj.304.6831.873	http://dx.doi.org/10.1136/bmj.304.6831.873			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392746	Green Published, Bronze			2022-12-24	WOS:A1992HM83500022
J	CARTER, RH; FEARON, DT				CARTER, RH; FEARON, DT			CD19 - LOWERING THE THRESHOLD FOR ANTIGEN RECEPTOR STIMULATION OF LYMPHOCYTES-B	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; CELL-SURFACE; IMMUNOGLOBULIN; CD4; PROLIFERATION; DOMAINS; SIGNAL	Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors. Coligation of the membrane protein CD19 with the antigen receptor of B lymphocytes decreased the threshold for antigen receptor-dependent stimulation by two orders of magnitude. B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. The B cell resolves its dilemma by having an accessory protein that enables activation when few antigen receptors are occupied.	JOHNS HOPKINS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	CARTER, RH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV MOLEC & CLIN RHEUMATOL, BALTIMORE, MD 21205 USA.				NIAID NIH HHS [AI-28191, AI-22833] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028191, R01AI022833] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1987, J IMMUNOL, V139, P678; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BRADBURY L, 1991, FASEB J, V5, pA611; CARTER R, UNPUB; CARTER RH, 1988, J IMMUNOL, V141, P457; CARTER RH, 1991, J IMMUNOL, V147, P3663; CHANGELIAN PS, 1985, J IMMUNOL, V134, P1851; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P34; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; NADLER LM, 1983, J IMMUNOL, V131, P244; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; TUVESON DA, 1991, J EXP MED, V173, P1083, DOI 10.1084/jem.173.5.1083; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMADA H, 1990, FASEB J, V4, pA1882; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	25	563	579	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1992	256	5053					105	107		10.1126/science.1373518	http://dx.doi.org/10.1126/science.1373518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1373518				2022-12-24	WOS:A1992HL82200038
J	RAVINE, D; WALKER, RG; GIBSON, RN; FORREST, SM; RICHARDS, RI; FRIEND, K; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; WALKER, RG; GIBSON, RN; FORREST, SM; RICHARDS, RI; FRIEND, K; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			PHENOTYPE AND GENOTYPE HETEROGENEITY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Article							LINKAGE HETEROGENEITY; GENETIC-HETEROGENEITY; CHROMOSOME-16; LOCUS; PKD1; DIAGNOSIS; FAMILIES; MARKER	It is now clear that mutations of at least two genetic loci can lead to autosomal dominant polycystic kidney disease (ADPKD). We have compared the clinical features of ADPKD caused by mutations at the PKD1 locus (linked to the alpha-globin complex on chromosome 16) with those of disease not linked to the locus (non-PKD1). We identified 18 families (285 affected members) with mutations at PKD1 and 5 families (49 affected individuals) in which involvement of this locus could be dismissed. Non-PKD1 patients lived longer than PKD1 patients (median survival 71.5 vs 56.0 years), had a lower risk of progressing to renal failure (odds ratio 0.35, 95% Cl 0.13-0.92), were less likely to have hypertension (odds ratio adjusted for age and family of origin 0.29, 0.11-0.80), were diagnosed at an older age (median 69.1 vs 44.8 years), and had fewer renal cysts at the time of diagnosis. Although most of the PKD1 families were ascertained through clinics treating patients with renal impairment, no non-PKD1 family was identified through this source. Non-PKD1 ADPKD has a much milder phenotype than that linked to PKD1. Partly as a result of this difference in severity, the reported prevalence of this genotype is probably an underestimate.	ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT NEPHROL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT RADIOL,PARKVILLE,VIC 3050,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital	RAVINE, D (corresponding author), UNIV HOSP WALES,INST MED GENET,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.		Richards, Robert/ABE-6423-2020; Ravine, David/A-6797-2008					BACHNER L, 1990, HUM GENET, V85, P221; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BREUNING MH, 1990, NUCLEIC ACIDS RES, V18, P3106, DOI 10.1093/nar/18.10.3106-a; BREUNING MH, 1987, LANCET, V2, P1359; BREUNING MH, 1990, J MED GENET, V27, P603, DOI 10.1136/jmg.27.10.603; DISNEY APS, 1990, 13TH AUSTR NZ COMB D, P22; GAL A, 1989, CLIN GENET, V35, P13; HARRIS PC, 1991, LANCET, V338, P1484, DOI 10.1016/0140-6736(91)92300-Q; HYLAND VJ, 1990, HUM GENET, V84, P286; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIMBERLING WJ, 1990, KIDNEY INT, V37, P249; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, AM J HUM GENET, V42, P498; MANDICH P, 1990, AM J MED GENET, V35, P579, DOI 10.1002/ajmg.1320350426; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3122, DOI 10.1093/nar/16.7.3122; NAROD S, 1991, CLIN GENET, V39, P125; Norby S, 1989, Prog Clin Biol Res, V305, P83; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; REEDERS ST, 1987, HUM GENET, V76, P348, DOI 10.1007/BF00272443; ROMEO G, 1988, LANCET, V2, P8; SNIJDEWINT FGM, 1990, NUCLEIC ACIDS RES, V18, P3108, DOI 10.1093/nar/18.10.3108-a; THOMPSON AD, IN PRESS GENOMICS; TUFVESON G, NEPHROL DIAL TRANS S, V4, P5; WEEKS DE, 1989, AM J HUM GENET, V45, P819	28	170	174	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1330	1333		10.1016/0140-6736(92)92503-8	http://dx.doi.org/10.1016/0140-6736(92)92503-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360045				2022-12-24	WOS:A1992KA26200014
J	KATO, H; INOUE, O; KAWASAKI, T; FUJIWARA, H; WATANABE, T; TOSHIMA, H				KATO, H; INOUE, O; KAWASAKI, T; FUJIWARA, H; WATANABE, T; TOSHIMA, H			ADULT CORONARY-ARTERY DISEASE PROBABLY DUE TO CHILDHOOD KAWASAKI-DISEASE	LANCET			English	Note							ANEURYSMS	We have surveyed adult survivors of childhood Kawasaki disease (KD) who had coronary artery disease that could be ascribed to KD. In response to questionnaires sent to cardiologists throughout Japan, 21 patients (1 7 men, 4 women, aged 20-63 years) with coronary lesions and a definite (2) or suspected (19) history of KD were reported. 5 patients had presented with acute myocardial infarction, 6 previous myocardial infarction, 9 angina pectoris, and 1 dilated cardiomyopathy. 16 patients had obstructions in two or more coronary arteries. 3 had died and 18 were alive with serious sequelae (mitral regurgitation, arrhythmias, congestive heart failure). Childhood KD should be included in the differential diagnosis of coronary artery disease in young adults.	KURUME UNIV,SCH MED,DEPT INTERNAL MED,KURUME,FUKUOKA 830,JAPAN; KAWASAKI DIS RES INFORMAT CTR,KAWASAKI,JAPAN; KYOTO UNIV,SCH MED,DEPT INTERNAL MED,KYOTO 606,JAPAN; AICHI MED SCH,DEPT INTERNAL MED,AICHI,JAPAN	Kurume University; Kyoto University; Aichi Medical University	KATO, H (corresponding author), KURUME UNIV,SCH MED,DEPT PEDIAT,67 ASAHI-MACHI,KURUME,FUKUOKA 830,JAPAN.							ISHIWATA S, 1992, AM J CARDIOL, V69, P692, DOI 10.1016/0002-9149(92)90168-X; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KATO H, 1986, J PEDIATR-US, V108, P923, DOI 10.1016/S0022-3476(86)80928-3; KATO H, 1975, J PEDIATR-US, V86, P892, DOI 10.1016/S0022-3476(75)80220-4; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; SAKAI Y, 1988, ANGIOLOGY, V39, P625, DOI 10.1177/000331978803900711	6	128	128	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1127	1129		10.1016/0140-6736(92)93152-D	http://dx.doi.org/10.1016/0140-6736(92)93152-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359212				2022-12-24	WOS:A1992JX13400005
J	STEINETZ, BG; WHITAKER, PG; EDWARDS, JRG				STEINETZ, BG; WHITAKER, PG; EDWARDS, JRG			MATERNAL RELAXIN CONCENTRATIONS IN DIABETIC PREGNANCY	LANCET			English	Article							HUMAN CHORIONIC-GONADOTROPIN; INSULIN BINDING; RECEPTOR-BINDING; PORCINE RELAXIN; ADIPOCYTES; MOTHERS; RADIOIMMUNOASSAY; PROGESTERONE; INFANTS; WOMEN	Maternal serum concentrations of relaxin, an insulin homologue produced both by the corpus luteum of pregnancy and by the fetoplacental unit, are highest in the first trimester and fall to their lowest level in the third trimester. Relaxin is thought to influence carbohydrate metabolism in the uterus, and it has been suggested that serum concentrations of relaxin in diabetic women are higher than those of non-diabetic women. We show that maternal serum relaxin concentrations are significantly higher at each stage of pregnancy in insulin-dependent diabetic mothers than in non-diabetic mothers. This elevation in relaxin concentrations is not related to other indices of diabetic control. The physiological importance of the higher concentrations of relaxin in the serum of diabetic women-in particular, whether they contribute to the higher incidence of major anomalies in the fetuses of diabetic mothers-is yet to be determined.	UNIV NEWCASTLE UPON TYNE,CLEFT PALATE RES UNIT,1-4 CLAREMONT TERRACE,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,PRINCESS MARY MATERN HOSP,DEPT OBSTET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; NYU,MED CTR,EXPTL MED & SURG PRIMATES LAB,TUXEDO PK,NY	Newcastle University - UK; Newcastle University - UK; New York University								BELL RJ, 1989, FERTIL STERIL, V52, P85; BELL RJ, 1987, OBSTET GYNECOL, V69, P585; CRELIN ES, 1969, T NEW YORK ACAD SCI, V31, P1049, DOI 10.1111/j.2164-0947.1969.tb02024.x; EDWARDS JRG, 1988, LANCET, V1, P1428; HANING RV, 1985, OBSTET GYNECOL, V66, P42; JARRETT JC, 1984, AM J OBSTET GYNECOL, V149, P250, DOI 10.1016/0002-9378(84)90223-0; JOHNSON MR, 1991, J CLIN ENDOCR METAB, V72, P1042, DOI 10.1210/jcem-72-5-1042; LADENHEIM RG, 1984, ENDOCRINOLOGY, V115, P752, DOI 10.1210/endo-115-2-752; LOUMAYE E, 1978, GYNECOL OBSTET INVES, V9, P262, DOI 10.1159/000300993; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1988, NEW ENGL J MED, V318, P671, DOI 10.1056/NEJM198803173181104; NEUFELD ND, 1978, J CLIN ENDOCR METAB, V47, P590, DOI 10.1210/jcem-47-3-590; OBYRNE EM, 1976, P SOC EXP BIOL MED, V152, P272, DOI 10.3181/00379727-152-39377; OBYRNE EM, 1978, J CLIN ENDOCR METAB, V47, P1106, DOI 10.1210/jcem-47-5-1106; OLEFSKY JM, 1982, ANN NY ACAD SCI, V380, P200, DOI 10.1111/j.1749-6632.1982.tb18043.x; PAGANO G, 1980, HORM METAB RES, V12, P177, DOI 10.1055/s-2007-996237; PAWLINA W, 1990, MOL CELL ENDOCRINOL, V72, P55, DOI 10.1016/0303-7207(90)90239-5; PEDERSEN J, 1980, PREGNANT DIABETIC HE; PEDERSEN O, 1981, J CLIN ENDOCR METAB, V53, P1160, DOI 10.1210/jcem-53-6-1160; QUAGLIARELLO J, 1980, J CLIN ENDOCR METAB, V51, P74, DOI 10.1210/jcem-51-1-74; QUAGLIARELLO J, 1979, AM J OBSTET GYNECOL, V135, P43; Sherwood O.D., 1988, P585; STEINETZ BG, IN PRESS ENDOCRINOLO; STEWART DR, 1990, J CLIN ENDOCR METAB, V70, P1771, DOI 10.1210/jcem-70-6-1771; STEWART MO, 1989, BRIT J OBSTET GYNAEC, V96, P415, DOI 10.1111/j.1471-0528.1989.tb02415.x; SUTTERDUB MT, 1973, HORM METAB RES, V5, P18, DOI 10.1055/s-0028-1093994; SUTTERDUB MT, 1984, J ENDOCRINOL, V102, P209, DOI 10.1677/joe.0.1020209; SZLACHTER BN, 1982, OBSTET GYNECOL, V59, P167; TOYODA N, 1985, ENDOCRINOLOGY, V116, P998, DOI 10.1210/endo-116-3-998; VASILENKO P, 1982, P SOC EXP BIOL MED, V169, P376; WEISS G, 1976, SCIENCE, V194, P948, DOI 10.1126/science.982052; WHITTAKER PG, 1990, OBSTET GYNECOL, V76, P223; WITT BR, 1990, FERTIL STERIL, V53, P1029	33	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					752	755		10.1016/0140-6736(92)92295-Q	http://dx.doi.org/10.1016/0140-6736(92)92295-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356178				2022-12-24	WOS:A1992JP86900004
J	WILSON, DI; GOODSHIP, JA; BURN, J; CROSS, IE; SCAMBLER, PJ				WILSON, DI; GOODSHIP, JA; BURN, J; CROSS, IE; SCAMBLER, PJ			DELETIONS WITHIN CHROMOSOME-22Q11 IN FAMILIAL CONGENITAL HEART-DISEASE	LANCET			English	Article							DIGEORGE SYNDROME	Because a locus on chromosome 22q11 is deleted in most individuals with DiGeorge and Shprintzen syndromes-conditions in which heart abnormalities are an important feature-we have looked for deletions in nine families with recurrent out flow-tract heart defects. In five families, chromosome 22 deletions were detected in all the living affected individuals studied and also in the clinically normal father of three affected children. The deletion was transmitted from parents to offspring and was associated with an increase in the severity of cardiac defects. No deletions were found in four families in which the parents were normal and affected siblings had anatomically identical defects. We propose that deletions within band q11 of chromosome 22 are an important cause of familial heart defects.	ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON,ENGLAND	Imperial College London	WILSON, DI (corresponding author), UNIV NEWCASTLE UPON TYNE,DIV HUMAN GENET,NEWCASTLE TYNE NE2 4AA,ENGLAND.		Scambler, Peter/AAZ-6026-2020; Wilson, David/A-6264-2010; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Wilson, David/0000-0001-8779-2060; Scambler, Peter J/0000-0002-1487-4628; Burn, John/0000-0002-9823-2322				[Anonymous], 1985, INT SYSTEM HUMAN CYT; BURN J, 1990, AM J HUM GENET S, V47, pA121; CAREY AH, IN PRESS AM J HUM GE; CONLEY ME, 1979, J PEDIATR-US, V94, P883, DOI 10.1016/S0022-3476(79)80207-3; CZEIZEL A, 1982, BRIT HEART J, V47, P290; DENNIS NR, 1981, J MED GENET, V18, P8, DOI 10.1136/jmg.18.1.8; DRISCOLL AD, 1992, AM J HUM GENET, V50, P924; LIPSON AH, 1991, J MED GENET, V28, P596, DOI 10.1136/jmg.28.9.596; SCAMBLER PJ, 1992, LANCET, V339, P1138, DOI 10.1016/0140-6736(92)90734-K; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; WHITTEMORE R, 1982, AM J CARDIOL, V50, P641, DOI 10.1016/0002-9149(82)90334-4; WILSON DI, 1991, BRIT HEART J, V66, P308; WILSON DI, 1992, APR P BRIT PAED ASS; ZELLERS TM, 1990, AM J CARDIOL, V65, P523, DOI 10.1016/0002-9149(90)90825-L	14	158	162	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					573	575		10.1016/0140-6736(92)92107-Q	http://dx.doi.org/10.1016/0140-6736(92)92107-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355155				2022-12-24	WOS:A1992JM33400004
J	SHIELD, JPH; STROBEL, S; LEVINSKY, RJ; MORGAN, G				SHIELD, JPH; STROBEL, S; LEVINSKY, RJ; MORGAN, G			IMMUNODEFICIENCY PRESENTING AS HYPERGAMMAGLOBULINEMIA WITH IGG2 SUBCLASS DEFICIENCY	LANCET			English	Article							IGA DEFICIENCY	Recurrent bacterial infections, lymphadenopathy, and failure to thrive are unlikely to be attributed to immune deficiency if they occur in the presence of hypergammaglobulinaemia, and other explanations will usually be sought. We describe eight patients who presented with all these features in infancy or early childhood. Deficiencies of immunoglobulin and antibody production were initially discounted, and the children were referred for investigation of possible lymphoma, autoimmune disease, or chronic viral infection. The patients were later referred to us for more detailed immunological investigation, which revealed low levels of IgG2 and poor specific antibody production to common pathogens. Treatment with intravenous immunoglobulin resulted in resolution of signs and symptoms in all patients. Thus we have shown that hypergammaglobulinaemia does not preclude the presence of immunoglobulin/antibody deficiency. We suggest that investigation of children with high levels of IgG and features of immunodeficiency should include IgG subclass analysis.	INST CHILD HLTH,HOST DEF UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; HOSP SICK CHILDREN,LONDON WC1N 3JH,ENGLAND	Imperial College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust			Shield, Julian PH/D-6297-2014	Shield, Julian PH/0000-0003-2601-7575				Aucouturier P, 1986, Monogr Allergy, V20, P62; BIRD D, 1985, ARCH DIS CHILD, V60, P204, DOI 10.1136/adc.60.3.204; GOLDBLATT D, 1989, R SOC MED SER INT C, V143, P19; MORGAN G, 1988, ARCH DIS CHILD, V63, P579, DOI 10.1136/adc.63.6.579; MORGAN G, 1985, ARCH DIS CHILD, V63, P771; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; Rosen F S, 1989, Semin Immunol, V1, P87; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SHAKELFORD PG, 1990, PAEDIATR RES, V17, P16; 1991, NEW ENGL J MED, V325, P73	10	24	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					448	450						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354783				2022-12-24	WOS:A1992JJ87700003
J	RAMSDELL, F; FOWLKES, BJ				RAMSDELL, F; FOWLKES, BJ			MAINTENANCE OF INVIVO TOLERANCE BY PERSISTENCE OF ANTIGEN	SCIENCE			English	Article							T-CELL-RECEPTOR; MAMMARY-TUMOR VIRUS; TRANSGENIC MICE; CLONAL ANERGY; TRANSPLANTATION TOLERANCE; NEGATIVE SELECTION; DELETION; INDUCTION; INACTIVATION; ELIMINATION	T cells of the immune system respond only to foreign antigens because those cells with reactivity for self proteins are either deleted during their development or rendered nonresponsive (anergic). The maintenance of the nonresponsive state was found to require the continual exposure of the anergic T cells to antigen. When anergic T cells were removed from the self antigen by adoptive transfer to a mouse strain lacking the antigen or by in vitro culture, nonresponsiveness was reversed and the anergic cells returned to normal functional status.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALTERS SE, 1991, J EXP MED, V173, P491, DOI 10.1084/jem.173.2.491; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1991, P NATL ACAD SCI USA, V88, P6682, DOI 10.1073/pnas.88.15.6682; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RAMSDELL F, UNPUB; RELLAHAN BL, 1990, J EXP MED, V172, P1071; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; TEW JG, 1980, IMMUNOL REV, V53, P29; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WIETIES K, 1990, P NATL ACAD SCI USA, V87, P6604, DOI 10.1073/pnas.87.17.6604; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	30	212	222	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1130	1134		10.1126/science.257.5073.1130	http://dx.doi.org/10.1126/science.257.5073.1130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1354889				2022-12-24	WOS:A1992JJ88400037
J	PAMER, EG; WANG, CR; FLAHERTY, L; LINDAHL, KF; BEVAN, MJ				PAMER, EG; WANG, CR; FLAHERTY, L; LINDAHL, KF; BEVAN, MJ			H-2M3 PRESENTS A LISTERIA-MONOCYTOGENES PEPTIDE TO CYTOTOXIC LYMPHOCYTES-T	CELL			English	Article							CLASS-I MOLECULES; MONOCLONAL-ANTIBODY; INTRACELLULAR GROWTH; CELL RECEPTOR; ANTIGEN; HEMOLYSIN; MOUSE; IMMUNITY; REGION; DELTA	We report evidence that a major histocompatibility complex-encoded nonclassic class I molecule presents a foreign peptide to cytotoxic T lymphocytes (CTL) during an infection. Mice immunized with virulent Listeria monocytogenes generate CD8+ CTL with alpha-beta receptors specific for a bacterial peptide presented by a conserved class I molecule encoded in the M region of the major histocompatibility complex. The Listeria peptide is digested by carboxypeptidase Y but resists aminopeptidase M, and only peptides with N-formyl methionine competitively block its presentation to CTL. Transfection with the H-2M3d ene enables a negative (H-2w17) cell line to present the bacterial peptide. One function, therefore, of H-2M3 is to present bacterial peptides to CTL during infection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; Wadsworth Center								ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BERCHE P, 1987, J IMMUNOL, V138, P2266; BISHOP DK, 1987, J IMMUNOL, V139, P2005; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BROCKE S, 1991, INFECT IMMUNON, V59, P4561; BROWN ML, 1992, J IMMUNOL, V148, P555; BRUNT LM, 1990, J IMMUNOL, V145, P3540; CONLAN JW, 1991, J EXP MED, V174, P741, DOI 10.1084/jem.174.3.741; DELIBERO G, 1986, J IMMUNOL, V137, P2688; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY L, 1990, CRIT REV IMMUNOL, V10, P131; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; HARTY JT, 1992, IN PRESS J EXP MED; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KUBO RT, 1989, J IMMUNOL, V142, P2736; LALANNE JL, 1982, NUCLEIC ACIDS RES, V10, P1039, DOI 10.1093/nar/10.3.1039; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINDAHL KF, 1980, J EXP MED, V152, P1583; LINDAHL KF, 1989, COLD SH Q B, V54, P563; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUCASLENARD J, 1971, ANNU REV BIOCHEM, V40, P409, DOI 10.1146/annurev.bi.40.070171.002205; LUKACS K, 1989, J IMMUNOL, V143, P3731; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; Maniatis T., 1982, MOL CLONING; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MILLIGAN GN, 1991, J EXP MED, V174, P133, DOI 10.1084/jem.174.1.133; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NOGUEIRA N, 1976, J EXP MED, V143, P1402, DOI 10.1084/jem.143.6.1402; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; POTTER TA, 1987, J IMMUNOL, V138, P1270; RIKIHISA Y, 1980, INFECT IMMUN, V30, P231, DOI 10.1128/IAI.30.1.231-243.1980; ROETZSCHKE O, 1990, Nature (London), V348, P252; ROSEN H, 1989, J EXP MED, V170, P27, DOI 10.1084/jem.170.1.27; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; Wang C.-R., 1991, NATO ASI Series Series H Cell Biology, V59, P441; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WOLF PR, 1990, J EXP MED, V172, P1795, DOI 10.1084/jem.172.6.1795; WU M, 1991, J EXP MED, V174, P213, DOI 10.1084/jem.174.1.213	56	201	203	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					215	223		10.1016/0092-8674(92)90097-V	http://dx.doi.org/10.1016/0092-8674(92)90097-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1353418				2022-12-24	WOS:A1992JE75700006
J	WALD, N; STONE, R; CUCKLE, HS; GRUDZINSKAS, JG; BARKAI, G; BRAMBATI, B; TEISNER, B; FUHRMANN, W				WALD, N; STONE, R; CUCKLE, HS; GRUDZINSKAS, JG; BARKAI, G; BRAMBATI, B; TEISNER, B; FUHRMANN, W			1ST TRIMESTER CONCENTRATIONS OF PREGNANCY ASSOCIATED PLASMA PROTEIN-A AND PLACENTAL PROTEIN-14 IN DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,DEPT CLIN MED,INST EPIDEMIOL & HLTH SERV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND; ROYAL LONDON HOSP,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND; CHAIM SHEBA MED CTR,INST HUMAN GENET,DEPT OBSTET & GYNECOL,IL-52621 TEL HASHOMER,ISRAEL; UNIV MILAN,IST OSTETR GINECOLOG L MANGIAGALLI,CLIN 2,PRENATAL DIAG UNIT,I-20122 MILAN,ITALY; STATENS SERUM INST,DIV IMMUNOL,DK-2300 COPENHAGEN,DENMARK; UNIV GIESSEN,INST HUMAN GENET,W-6300 GIESSEN,GERMANY	University of Leeds; Barts Health NHS Trust; Royal London Hospital; Chaim Sheba Medical Center; University of Milan; Statens Serum Institut; Justus Liebig University Giessen	WALD, N (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1A 7BE,ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					Brambati B., 1990, EMBRYO NORMAL ABNORM, P181; CUCKLE HS, 1988, LANCET, V2, P851	2	101	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					28	28		10.1136/bmj.305.6844.28	http://dx.doi.org/10.1136/bmj.305.6844.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1379094	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JC79900027
J	SHOJIKASAI, Y; YOSHIDA, A; SATO, K; HOSHINO, T; OGURA, A; KONDO, S; FUJIMOTO, Y; KUWAHARA, R; KATO, R; TAKAHASHI, M				SHOJIKASAI, Y; YOSHIDA, A; SATO, K; HOSHINO, T; OGURA, A; KONDO, S; FUJIMOTO, Y; KUWAHARA, R; KATO, R; TAKAHASHI, M			NEUROTRANSMITTER RELEASE FROM SYNAPTOTAGMIN-DEFICIENT CLONAL VARIANTS OF PC12 CELLS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; PHEOCHROMOCYTOMA CELLS; AFFINITY; BINDING	Synaptotagmin (p65) is an abundant synaptic vesicle protein of neurons and contains regions similar to the regulatory domain of protein kinase C. These domains are thought to be involved in calcium-dependent interaction with membrane phospholipids during exocytosis. To assess the functional role of synaptotagmin, synaptotagmin-deficient clonal variants of PC12 cells were isolated. All of the variant cells released catecholamine and adenosine triphosphate in response to elevated intracellular concentrations of calcium, which suggests that synaptotagmin is not essential for secretion of catecholamine and adenosine triphosphate from PC12 cells.			SHOJIKASAI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							BAEGE EE, 1991, NEURON, V6, P21; BITLER CM, 1986, J NEUROCHEM, V47, P1286; Bjerrum OJ., 1986, ELECTROPHORESIS 86, P315; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BURNSTOCK G, 1981, J PHYSIOL-LONDON, V313, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HATANAKA H, 1981, BRAIN RES, V222, P225, DOI 10.1016/0006-8993(81)91029-5; Katz B., 1966, NERVE MUSCLE SYNAPSE; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; OGURA A, 1984, BRAIN RES, V301, P323, DOI 10.1016/0006-8993(84)91101-6; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO Y, 1988, J BIOL CHEM, V263, P6927; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SHOJIKASAI Y, UNPUB; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKAHASHI M, 1983, J BIOL CHEM, V258, P944; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; Yoshida A, UNPUB	32	173	176	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1820	1823		10.1126/science.256.5065.1820	http://dx.doi.org/10.1126/science.256.5065.1820			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1352065				2022-12-24	WOS:A1992JA43400037
J	CHAUHAN, A; DILAWARI, JB; JAMEEL, S; KAUR, U; CHAWLA, YK; SHARMA, ML; GANGULY, NK				CHAUHAN, A; DILAWARI, JB; JAMEEL, S; KAUR, U; CHAWLA, YK; SHARMA, ML; GANGULY, NK			COMMON ETIOLOGIC AGENT FOR EPIDEMIC AND SPORADIC NON-A, NON-B HEPATITIS	LANCET			English	Note							TRANSMITTED NON-A	Enterovirus-like particles have been reported in the acute phase of both epidemic and sporadic non-A, non-B (NANB) hepatitis. To examine whether these particles were the causative agent in the two types of disease, 29 patients with acute viral hepatitis in a north Indian epidemic outbreak and 9 with sporadic acute disease were investigated. 25 (86%) of 29 patients with epidemic hepatitis and 5 (56%) of 9 with sporadic disease were diagnosed as having enterically-transmitted-NANB hepatitis by exclusion. Virus-like particles (VLP) of 30-34 nm were detected in stool of 1 patient with epidemic and 1 with sporadic hepatitis. The VLPs crossreacted serologically and a specific IgM response was seen in acute epidemic and sporadic serum samples. After inoculation with infected stool rhesus monkeys had a mild rise in liver enzymes, and bile samples contained VLPs. These results suggest that the aetiological agent in epidemic and sporadic disease is the same.	POSTGRAD INST MED EDUC & RES,DEPT HEPATOL,CHANDIGARH 160012,INDIA; POSTGRAD INST MED EDUC & RES,DEPT EXPTL MED,CHANDIGARH 160012,INDIA; INT CTR GENET ENGN & BIOTECHNOL,NEW DELHI,INDIA; PUNJAB UNIV,REG SOPHISTICATED INSTRUMENTAT CTR,CHANDIGARH,INDIA	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Panjab University			Bambery, Upjeet/G-7593-2011					Almeida J D, 1969, Adv Virus Res, V15, P307, DOI 10.1016/S0065-3527(08)60878-7; BALAYAN MS, 1987, SOVIET MED REV E, V2, P235; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1988, LANCET, V1, P819; DATTA R, 1987, J GASTROEN HEPATOL, V2, P333, DOI 10.1111/j.1440-1746.1987.tb00171.x; DOROSHENKO NV, 1989, VORP VIRUSOL, V45, P164; HUMPHREY CD, 1988, VIRAL HEPATITIS LIVE, P148; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; SREENIVASAN MA, 1984, J GEN VIROL, V65, P1005, DOI 10.1099/0022-1317-65-5-1005	9	27	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1509	1510		10.1016/0140-6736(92)91267-C	http://dx.doi.org/10.1016/0140-6736(92)91267-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351189				2022-12-24	WOS:A1992HZ17500007
J	ANDERSON, DJ; OBRIEN, TR; POLITCH, JA; MARTINEZ, A; SEAGE, GR; PADIAN, N; HORSBURGH, CR; MAYER, KH				ANDERSON, DJ; OBRIEN, TR; POLITCH, JA; MARTINEZ, A; SEAGE, GR; PADIAN, N; HORSBURGH, CR; MAYER, KH			EFFECTS OF DISEASE STAGE AND ZIDOVUDINE THERAPY ON THE DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN SEMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV INFECTION; RISK-FACTORS; TRANSMISSION; AIDS; QUANTITATION; ANTIBODY; CELLS; BLOOD; MEN	Objective.-To determine the prevalence and temporal expression of infectious human immunodeficiency virus type 1 (HIV-1) in the semen of HIV-1 seropositive men and to determine whether the detection of HIV-1 in semen is associated with disease stage, zidovudine treatment status, or other clinical factors. Design.-A microculture technique was used to detect infectious HIV-1 in semen from a cohort of 95 seropositive men. In addition, semen cultures were performed monthly for at least 6 months for 14 of the men. information was obtained by interview and extracted from medical records to identify clinical variables associated with HIV-1 in semen. Patients.-Sixty HIV-1 seropositive homosexual men participating in clinical studies at the Fenway Community Health Center, Boston, Mass, and 35 HIV seropositive bisexual or heterosexual men participating in the California Partner Study of the University of California, San Francisco. Main Outcome Measures.-Semen HIV-1 culture results, seminal leukocyte counts, Centers for Disease Control (CDC) disease stage, peripheral CD4+ cell counts, zidovudine therapy, HIV risk category. Results.-In the cross-sectional study, HIV-1 was cultured from the semen of nine (9%) of 95 men. Factors associated with detection of HIV-1 in semen were peripheral CD4+ cell counts of 0.20 X 10(9)/L (200/mu-L) or less (adjusted odds ratio [OR], 23.33; 95% confidence interval [CI], 2.89 to 175.63); symptomatic (CDC class IV) disease (adjusted OR, 6.56; 95% CI, 1.02 to 66.76); and seminal leukocytosis (> 1 x 10(9) white blood cells per liter of semen) (adjusted OR, 7.02; 95% CI, 1.28 to 39.29). Zidovudine therapy was associated with decreased detection of HIV-1 in semen (adjusted OR, 0.04; 95% Cl, 0.00 to 0.63). In the longitudinal study of 14 men who had neither peripheral CD4+ cells counts of 0.20 X 10(9)/L or less nor seminal leukocytosis, seminal HIV-1 was detected in at least one sample from six men (43%). Conclusion.-HIV-1 is more commonly found in semen from men with advanced HIV-1 infection and seminal leukocytosis but can also be cultured from semen of men with neither of these conditions. Zidovudine therapy may decrease the prevalence and/or titer of seminal HIV-1. However, all HIV-1-infected persons should continue to assume that they are potentially infectious through sexual contact.	CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; BOSTON DEPT HLTH & HOSP,INST URBAN HLTH RES,BOSTON,MA; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; MEM HOSP,INFECT DIS BRANCH,PAWTUCKET,RI 02860; FENWAY COMMUNITY HLTH CTR,BOSTON,MA	Centers for Disease Control & Prevention - USA; Boston University; University of California System; University of California San Francisco	ANDERSON, DJ (corresponding author), HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,FEARING RES LAB,ROOM 204,BOSTON,MA 02115, USA.			Anderson, Deborah/0000-0002-2848-7290; Horsburgh, C./0000-0001-6838-7895; Politch, Joseph/0000-0002-7022-0135	NIAID NIH HHS [AI25305] Funding Source: Medline; PHS HHS [U62/CCU100607, CCR903266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER NJ, 1987, FERTIL STERIL, V47, P192; ANDERESON DJ, 1990, 6TH P C AIDS, V1, P263; ANDERSON DJ, 1990, HETEROSEXUAL TRANSMI, P167; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CLUMECK N, 1989, NEW ENGL J MED, V321, P1460, DOI 10.1056/NEJM198911233212107; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEVINCENZI I, 1989, 5TH INT C ACQ IMM SY, P115; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GUPTA P, 1989, J VIROL, V63, P2361, DOI 10.1128/JVI.63.5.2361-2365.1989; HENRY K, 1988, JAMA-J AM MED ASSOC, V259, P3023, DOI 10.1001/jama.259.20.3023; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P68, DOI 10.2105/AJPH.78.1.68; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; OSHEA S, 1990, J MED VIROL, V31, P291, DOI 10.1002/jmv.1890310409; OSMOND D, 1988, AM J PUBLIC HEALTH, V78, P944, DOI 10.2105/AJPH.78.8.944; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PUDNEY J, 1991, AM J PATHOL, V39, P149; SEAGE GR, 1989, AM J PUBLIC HEALTH, V79, P1638, DOI 10.2105/AJPH.79.12.1638; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; WOLFF H, 1992, J ACQ IMMUN DEF SYND, V5, P65; WOLFF H, 1988, FERTIL STERIL, V49, P497; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; 1987, WHO LABORATORY MANUA, P27; [No title captured]	31	183	185	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2769	2774		10.1001/jama.267.20.2769	http://dx.doi.org/10.1001/jama.267.20.2769			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1349654				2022-12-24	WOS:A1992HV26500025
J	TOVO, PA; DEMARTINO, M; GABIANO, C; CAPPELLO, N; DELIA, R; LOY, A; PLEBANI, A; ZUCCOTTI, GV; DALLACASA, P; FERRARIS, G; CASELLI, D; FUNDARO, C; DARGENIO, P; GALLI, L; PRINCIPI, N; STEGAGNO, M; RUGA, E; PALOMBA, E				TOVO, PA; DEMARTINO, M; GABIANO, C; CAPPELLO, N; DELIA, R; LOY, A; PLEBANI, A; ZUCCOTTI, GV; DALLACASA, P; FERRARIS, G; CASELLI, D; FUNDARO, C; DARGENIO, P; GALLI, L; PRINCIPI, N; STEGAGNO, M; RUGA, E; PALOMBA, E			PROGNOSTIC FACTORS AND SURVIVAL IN CHILDREN WITH PERINATAL HIV-1 INFECTION	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; REGRESSION-MODELS; INFANTS; MOTHERS; TYPE-1; EXPRESSION; BLOOD; BORN	The signs that may arise after perinatal infection with human immunodeficiency virus type 1 (HIV-1) have been classified by the Centers for Disease Control, but the clinical usefulness of the classification system and the prognostic importance of each disease pattern have not been established. We sought to address these issues by analysing data from the italian Register for HIV infection in children. We studied 1887 children born to HIV-1-seropositive mothers. 1045 were identified at birth and the others were registered later (median age 4.8 [range 0.4-72] months). HIV-1-associated signs developed in 433 (81.8%) of 529 seropositive infected children at a median age of 5 (0.03-84) months. These signs appeared significantly earlier in the 102 children who died of HIV-1-related illness than in those who are still alive (median 3 [0.03-55] vs 6 [0.03-84] months; p < 0.001). The cumulative proportion surviving at age 9 years was 49.5% (95% confidence interval 27-65%) and the median survival time was 96.2 months. Separate analysis of the 112 seropositive infected children followed from birth and older than 15 months gave similar results. Hepatomegaly, splenomegaly, lymphadenopathy, parotitis, skin diseases, and recurrent respiratory tract infections formed the mildest disease pattern. Lymphoid interstitial pneumonitis and thrombocytopenia were signs of intermediate disease. By contrast, in multivariate analysis specific secondary infectious diseases, severe bacterial infections, progressive neurological disease, anaemia, and fever were significant and independent negative predictors of survival. Growth failure, persistent oral candidosis, hepatitis, and cardiopathy were associated in univariate analysis with significantly shorter survival. Our findings suggest that the outlook for children with perinatal HIV-1 infection is better than previously thought and that a new clinical staging system of single disease patterns is needed.	UNIV FLORENCE, DEPT PAEDIAT, I-50121 FLORENCE, ITALY; UNIV TURIN, DEPT GENET BIOL & MED CHEM, I-10124 TURIN, ITALY; UNIV PADUA, DEPT PAEDIAT, I-35100 PADUA, ITALY; UNIV GENOA, G GASLINI INST, DEPT INFECT DIS 1, I-16126 GENOA, ITALY; UNIV MILAN, DEPT PEDIAT 1, I-20122 MILAN, ITALY; UNIV MILAN, DEPT PAEDIAT 5, I-20122 MILAN, ITALY; UNIV BOLOGNA, INST CHILD HLTH & NEONATOL, I-40126 BOLOGNA, ITALY; INFANT & MATERNAL CTR DRUG DEPENDENT RELATED ILLNE, MILAN, ITALY; UNIV PAVIA, DEPT PAEDIAT, I-27100 PAVIA, ITALY; UNIV CATTOLICA SACRO CUORE, DEPT PAEDIAT, I-00168 ROME, ITALY; BAMBINO GESU PEDIAT HOSP, ROME, ITALY; UNIV MILAN, DEPT PAEDIAT 4, I-20122 MILAN, ITALY; UNIV ROME LA SAPIENZA, DEPT CHILD HLTH, I-00185 ROME, ITALY	University of Florence; University of Turin; University of Padua; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Milan; University of Milan; University of Bologna; University of Pavia; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Bambino Gesu; University of Milan; Sapienza University Rome	TOVO, PA (corresponding author), UNIV TURIN, DEPT PAEDIAT, PIAZZA POLONIA 94, I-10126 TURIN, ITALY.		Plebani, Alessandro/C-8593-2011; Cappello, Nazario/D-9530-2012; D'Argenio, Patrizia/ABA-3852-2021; Zuccotti, Gianvincenzo/H-8572-2017	Zuccotti, Gianvincenzo/0000-0002-2795-9874; Tovo, Pier Angelo/0000-0002-0192-3240; Guarino, Alfredo/0000-0003-0199-0336				ARICO M, 1991, CANCER, V68, P2473, DOI 10.1002/1097-0142(19911201)68:11<2473::AID-CNCR2820681125>3.0.CO;2-L; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; COX DR, 1972, J R STAT SOC B, V34, P187; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; DEMARTINO M, 1991, ARCH DIS CHILD, V66, P1235, DOI 10.1136/adc.66.10.1235; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; FERRIS S, 1990, 6TH INT C AIDS SAN F, V1, P261; GABIANO C, IN PRESS PEDIATRICS; HAUGER S B, 1991, Journal of Pediatrics, V119, pS25, DOI 10.1016/S0022-3476(05)81450-7; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAMPERT R, 1986, PEDIATR INFECT DIS J, V5, P374, DOI 10.1097/00006454-198605000-00020; LAURE F, 1988, LANCET, V2, P538; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PAWHA S, 1986, JAMA-J AM MED ASSOC, V225, P2299; PECKHAM CS, 1991, LANCET, V337, P253; PEDUZZI PN, 1980, BIOMETRICS, V36, P511, DOI 10.2307/2530219; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; TOVO PA, 1987, LANCET, V1, P1201; TOVO PA, 1988, LANCET, V2, P1043; TOVO PA, 1985, RIV ITAL PED, V11, P885; WAHN V, 1990, EUR J PEDIATR, V149, P330, DOI 10.1007/BF02171559; 1987, MMWR, V36, P225; 1987, MMWR, V36, P1	30	300	304	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1992	339	8804					1249	1253		10.1016/0140-6736(92)91592-V	http://dx.doi.org/10.1016/0140-6736(92)91592-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349667				2022-12-24	WOS:A1992HV19100002
J	LANZAVECCHIA, A; REID, PA; WATTS, C				LANZAVECCHIA, A; REID, PA; WATTS, C			IRREVERSIBLE ASSOCIATION OF PEPTIDES WITH CLASS-II MHC MOLECULES IN LIVING CELLS	NATURE			English	Article							INVARIANT CHAIN; T-CELLS; B-CELLS; HLA-DR; ANTIGEN PRESENTATION; PROTEIN ANTIGENS; LYMPHOCYTE-B; BREFELDIN-A; BINDING; IA	FUNCTIONAL, morphological and biochemical evidence indicates that class II major histocompatibility complex (MHC) molecules associate with processed peptides during biosynthesis 1-9. Peptide/MHC complexes in living cells have been reported to be less stable than similar complexes generated in vitro, which has led to the suggestion that there may be a peptide exchange mechanism operating in vivo 10-12. Although this could increase the capacity for binding incoming antigens, it would reduce the efficacy of processed antigenic peptides by exchanging these for self peptides. Here we measure the half-life of peptide/class II complexes in human antigen-presenting cells and find that it is very similar to the half-life of class II molecules themselves, indicating that peptides are bound irreversibly under physiological conditions. Thus class II MHC retains long-term 'memory' of past encounters with antigen to maximize the opportunity for T cell/antigen-presenting cell interaction.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	LANZAVECCHIA, A (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Watts, Colin/0000-0001-6183-2087	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIS JE, 1990, J IMMUNOL, V144, P990; FLAJNIK MF, 1991, P NATL ACAD SCI USA, V88, P537, DOI 10.1073/pnas.88.2.537; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1989, J IMMUNOL, V142, P12; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; JENSEN PE, 1989, J IMMUNOL, V143, P420; KAMPGEN E, 1991, P NATL ACAD SCI USA, V88, P3014, DOI 10.1073/pnas.88.8.3014; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LANZAVECCHIA A, 1987, IMMUNOL REV, V99, P39, DOI 10.1111/j.1600-065X.1987.tb01171.x; LEE JM, 1990, J IMMUNOL, V144, P1829; MATHIS L, 1983, P NATL ACAD SCI USA, V80, P6019; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NYGARD NR, 1991, J EXP MED, V174, P243, DOI 10.1084/jem.174.1.243; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PERNIS B, 1985, IMMUNOL TODAY, V6, P45, DOI 10.1016/0167-5699(85)90046-5; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014	40	175	181	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					249	252		10.1038/357249a0	http://dx.doi.org/10.1038/357249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1375347				2022-12-24	WOS:A1992HV19500057
J	MEGURO, H; MORI, H; ARAKI, K; KUSHIYA, E; KUTSUWADA, T; YAMAZAKI, M; KUMANISHI, T; ARAKAWA, M; SAKIMURA, K; MISHINA, M				MEGURO, H; MORI, H; ARAKI, K; KUSHIYA, E; KUTSUWADA, T; YAMAZAKI, M; KUMANISHI, T; ARAKAWA, M; SAKIMURA, K; MISHINA, M			FUNCTIONAL-CHARACTERIZATION OF A HETEROMERIC NMDA RECEPTOR CHANNEL EXPRESSED FROM CLONED CDNAS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; SELECTIVE ANTAGONIST; NEURONS; GLYCINE; FAMILY; RESPONSES; CLONING; COMPLEX	THE glutamate receptor (GluR) channel plays a kev part in brain function 1,2. Among GluR channel subtypes, the NMDA (N-methyl-D-aspartate) receptor channel which is highly permeable to Ca2+ is essential for the synaptic plasticity underlying memory, learning and development 3,4. Furthermore, abnormal activation of the NMDA receptor channel may trigger the neuronal cell death observed in various brain disorders 5,6. A complementary DNA encoding a subunit of the rodent NMDA receptor channel (NMDAR1 or zeta-1) has been cloned and its functional properties investigated 7,8. Here we report the identification and primary structure of a novel mouse NMDA receptor channel subunit, designated as epsilon-1, after cloning and sequencing the cDNA. The epsilon-1 subunit shows 11-18% amino-acid sequence identity with rodent GluR channel subunits that have been characterized so far and has structural features common to neurotransmitter-gated ion channels. Expression from cloned cDNAs of the epsilon-1 subunit together with the zeta-1 subunit in Xenopus oocytes yields functional GluR channels with high activity and characteristics of the NMDA receptor channel. Furthermore, the heteromeric NMDA receptor channel can be activated by glycine alone.	NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,ASAHIMACHI 1,NIIGATA 951,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPATHOL,NIIGATA 951,JAPAN; NIIGATA UNIV,SCH MED,DEPT MED 2,NIIGATA 951,JAPAN	Niigata University; Niigata University; Niigata University								BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORITA T, IN PRESS MOL BRAIN R; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAMAZAKI M, IN PRESS FEBS LETT; YAMAZAKI M, IN PRESS BIOCH BIOPH; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	35	772	797	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					70	74		10.1038/357070a0	http://dx.doi.org/10.1038/357070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1374164				2022-12-24	WOS:A1992HT22900060
J	USHERWOOD, T				USHERWOOD, T			SEX BIAS IN THE BMJ - AN AUDIT	BRITISH MEDICAL JOURNAL			English	Article											USHERWOOD, T (corresponding author), UNIV SHEFFIELD,DEPT GEN PRACTICE,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BURKHART S, 1987, BRIT MED J, V295, P1585, DOI 10.1136/bmj.295.6613.1585; Cameron Deborah., 1985, FEMINISM LINGUISTIC; HOFSTADTER D, 1986, METAMAGICAL THEMAS; HORNE EM, 1988, BRIT MED J, V296, P431, DOI 10.1136/bmj.296.6619.431; VETTERLINGBRAGG.M, 1981, SEXIST LANGUAGE MODE	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					880	881		10.1136/bmj.304.6831.880	http://dx.doi.org/10.1136/bmj.304.6831.880			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392749	Green Published, Bronze			2022-12-24	WOS:A1992HM83500026
J	STERN, LJ; WILEY, DC				STERN, LJ; WILEY, DC			THE HUMAN CLASS-II MHC PROTEIN HLA-DR1 ASSEMBLES AS EMPTY ALPHA-BETA-HETERODIMERS IN THE ABSENCE OF ANTIGENIC PEPTIDE	CELL			English	Article							B-CELL LINE; ENDOPLASMIC-RETICULUM; INVARIANT CHAIN; HISTOCOMPATIBILITY ANTIGENS; ENDOGENOUS ANTIGEN; T-CELLS; HLA-DR; MOLECULES; BINDING; IA	We have produced the human class II histocompatibility protein, HLA-DRI, as a soluble, secreted glycoprotein in insect cells infected with baculoviruses carrying truncated alpha and beta-subunit genes. The peptide-binding site is empty, and the empty molecules are fully competent to bind antigenic peptide. We used the empty molecules to measure an intrinsic rate for peptide association, and to investigate the role of peptide in stabilizing the class II structure. Peptide binding kinetics for the empty molecule are only 10-fold faster than for peptide exchange into an occupied site, suggesting that a conformational change may accompany peptide binding. The native alpha-beta-heterodimer assembles in the absence of antigenic peptide, but peptide binding stabilizes the empty heterodimer against aggregation and against SDS-induced denaturation.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute	STERN, LJ (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BUSCH R, 1990, J IMMUNOL METHODS, V134, P1, DOI 10.1016/0022-1759(90)90107-7; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARLOW E, 1988, ANTIBODIES LABORATOR; HOFMANN T, 1988, BIOCHEMISTRY-US, V27, P1140, DOI 10.1021/bi00404a010; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; NYGARD NR, 1991, J EXP MED, V174, P243, DOI 10.1084/jem.174.1.243; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SHACKELFORD DA, 1983, J IMMUNOL, V130, P274; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TIJSSEN P, 1985, LABORATORY TECHNIQUE, V15; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	69	299	330	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					465	477		10.1016/0092-8674(92)90184-E	http://dx.doi.org/10.1016/0092-8674(92)90184-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1371238				2022-12-24	WOS:A1992HD39800008
J	CHUCK, SL; LINGAPPA, VR				CHUCK, SL; LINGAPPA, VR			PAUSE TRANSFER - A TOPOGENIC SEQUENCE IN APOLIPOPROTEIN-B MEDIATES STOPPING AND RESTARTING OF TRANSLOCATION	CELL			English	Article							NEWLY SYNTHESIZED PROTEINS; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCE; MICROSOMAL-MEMBRANES; SECRETORY PROTEINS; MESSENGER-RNA; PRION PROTEIN; HEAT-SHOCK; PRE-GOLGI; DEGRADATION	Previously, we described the stepwise translocation of a large amino-terminal fragment of apolipoprotein B (apo Bl5) in which the nascent secretory chain translocates through a series of distinct, nonintegrated transmembrane intermediates with large domains exposed to the cytoplasm. Thus, apo B15 appears to stop and restart translocation at several points. We have identified a sequence of amino acids in apo B15 that confers this behavior on a heterologous chimeric protein. In addition, we dissect pausing into two distinct steps, stopping and restarting, thereby trapping otherwise transient intermediates. Finally, we demonstrate the function of a second "pause transfer" sequence over 200 amino acids downstream in apo B15 that restarts translocation posttranslationally, suggesting that multiple pause transfer sequences are involved in the biogenesis of apolipoprotein B.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHUCK, SL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FISHER WR, 1986, METHOD ENZYMOL, V128, P247; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PATERSON RG, 1987, CELL, V48, P441, DOI 10.1016/0092-8674(87)90195-4; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SABATINI DD, 1966, J MOL BIOL, V19, P503, DOI 10.1016/S0022-2836(66)80019-0; SATO R, 1990, J BIOL CHEM, V265, P11880; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SPIESS M, 1989, J BIOL CHEM, V264, P19117; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	53	111	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					9	21		10.1016/0092-8674(92)90202-N	http://dx.doi.org/10.1016/0092-8674(92)90202-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370657				2022-12-24	WOS:A1992GZ58300005
J	EISEMAN, E; BOLEN, JB				EISEMAN, E; BOLEN, JB			ENGAGEMENT OF THE HIGH-AFFINITY IGE RECEPTOR ACTIVATES SRC PROTEIN-RELATED TYROSINE KINASES	NATURE			English	Article							IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODIES; HISTAMINE-RELEASE; MAST-CELLS; CD4; PHOSPHORYLATION; ASSOCIATION; ANTIGENS; BINDING; SUBUNIT	THE high-affinity IgE receptor (Fc-epsilon RI), which is expressed on the surface of mast cells and basophils, has a central role in immediate allergic responses. In the rat basophilic leukaemia cell line RBL-2H3, which is a model system for the analysis of Fc-epsilon-RI-mediated signal transduction, surface engagement of Fc-epsilon-RI induces histamine release and the tyrosine phosphorylation of several distinct proteins 1. Although the alpha, beta and gamma-subunits of Fc-epsilon-RI lack intrinsic tyrosine protein kinase (TPK) activity, a kinase that copurifies with Fc-epsilon-RI phosphorylates the beta and gamma-subunits of the receptor on tyrosine residues 2,3. We report here that in RBL-2H3 cells, p56lyn and pp60c-src are activated after Fc-epsilon-RI crosslinking, and p56lyn coimmunoprecipitates with Fc-epsilon-RI. In the mouse mast-cell line PT-18, another cell type used to study FC-epsilon-RI-mediated signalling, tyrosine phosphorylation of proteins is also an immediate consequence of receptor crosslinking. Notably, the only detectable src protein-related TPK in PT-18 cells is p62c-yes, and it is this TPK that is activated on Fc-epsilon-RI engagement and coimmunoprecipitates with the receptor. Therefore, it seems that different src protein-related TPKs can associate with the same receptor and become activated after receptor engagement.			EISEMAN, E (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA.							BANIYASH M, 1987, J IMMUNOL, V138, P2999; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; HEMPSTEAD BL, 1981, BIOCHEM BIOPH RES CO, V98, P815, DOI 10.1016/0006-291X(81)91184-0; HOLOWKA D, 1980, J RECEPTOR RES, V1, P41, DOI 10.3109/10799898009039254; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUI FT, 1980, J IMMUNOL, V124, P2728; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; PLUZNIK DH, 1982, EXP HEMATOL, V10, P211; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	22	492	506	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					78	80						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1370575				2022-12-24	WOS:A1992GY22800055
J	HARVEY, JM; HOWIE, AJ; LEE, SJ; NEWBOLD, KM; ADU, D; MICHAEL, J; BEEVERS, DG				HARVEY, JM; HOWIE, AJ; LEE, SJ; NEWBOLD, KM; ADU, D; MICHAEL, J; BEEVERS, DG			RENAL BIOPSY FINDINGS IN HYPERTENSIVE PATIENTS WITH PROTEINURIA	LANCET			English	Note								27 patients with hypertension and persistent proteinuria were investigated by renal biopsy. The 13 patients without structural glomerular abnormalities were younger and had less proteinuria than the other 14, but otherwise the two groups had similar clinical features. 6 of the 14 had diffuse glomerular abnormalities; the other 8 had segmental sclerosing lesions, which were mainly in the hilum of the glomeruli, as seen in states of glomerular overload. Glomeruli in all groups were larger than those in normotensive people. It is possible that hypertension causes glomerular enlargement, proteinuria, and segmental glomerular lesions because of loss of functioning glomeruli due to ischaemia.	DUDLEY RD GEN HOSP,DEPT MED,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PATHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,DEPT NEPHROL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								BULPITT CJ, 1986, J HYPERTENS, V4, P93, DOI 10.1097/00004872-198602000-00015; GIFFORD RW, 1969, MILBANK FUND Q, V47, P170, DOI 10.2307/3349261; GOSLING P, 1989, CLIN SCI, V76, P39, DOI 10.1042/cs0760039; HOWIE AJ, 1989, J PATHOL, V157, P141, DOI 10.1002/path.1711570209; KINCAIDSMITH PS, 1982, HYPERTENSION MECHANI, P94; NEWBOLD KM, 1990, J PATHOL, V162, P329, DOI 10.1002/path.1711620409; NEWBOLD KM, 1990, J PATHOL, V160, P255, DOI 10.1002/path.1711600312; TOBIAN L, 1987, AM J CARDIOL, V60, P421; TOMSON CRV, 1991, J HUM HYPERTENS, V5, P189; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35	10	83	84	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1435	1436		10.1016/0140-6736(92)92624-O	http://dx.doi.org/10.1016/0140-6736(92)92624-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360561				2022-12-24	WOS:A1992KC28400005
J	TAKAHASHI, JS				TAKAHASHI, JS			CIRCADIAN CLOCK GENES ARE TICKING	SCIENCE			English	Editorial Material							VISUAL-SYSTEM; DNA-BINDING; DROSOPHILA; PERIOD; RHYTHMS; PROTEIN; TRANSCRIPTION; OSCILLATOR; PRODUCT; MYOD		NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA	Northwestern University	TAKAHASHI, JS (corresponding author), NORTHWESTERN UNIV, NATL SCI FDN, CTR BIOL TIMING, EVANSTON, IL 60208 USA.		Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878				BARGIELLO TA, IN PRESS BIOL B; BAYLIES MK, IN PRESS MOL GENETIC; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DUNLAP JC, 1989, IN PRESS ANN REV PHY, V45; EWER J, 1992, J NEUROSCI, V12, P3321; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN DE, 1991, IN PRESS P NATL ACAD, V88; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, IN PRESS MOL GENETIC; LIU X, 1992, J NEUROSCI, V12, P2735; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; ROSBASH M, COMMUNICATION; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YOUNG MW, COMMUNICATION; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	30	64	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					238	240		10.1126/science.1384127	http://dx.doi.org/10.1126/science.1384127			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384127				2022-12-24	WOS:A1992JR86000017
J	ZOUROS, E; FREEMAN, KR; BALL, AO; POGSON, GH				ZOUROS, E; FREEMAN, KR; BALL, AO; POGSON, GH			DIRECT EVIDENCE FOR EXTENSIVE PATERNAL MITOCHONDRIAL-DNA INHERITANCE IN THE MARINE MUSSEL MYTILUS	NATURE			English	Article							MATERNAL INHERITANCE; HETEROPLASMY; POPULATIONS; DROSOPHILA; MICE	INHERITANCE of Mitochondrial DNA in animals was thought to be strictly maternal1,2. Recently, evidence for incidental paternal mtDNA leakage was obtained in hybrid crosses of Drosophila3,4 and mice5. In mice, the frequency of paternal mtDNA contributions was estimated at 10(-4), Compared with maternal contributions. The common occurrence in the marine mussel Mytilus of heteroplasmic individuals with two or more types of highly diverged mtDNA molecules was interpreted as strong evidence for biparental mtDNA inheritance by some6, but not by others7. We report here results from pair-matings involving two species of mussels, Mytilus edulis and Mytilus trossulus. Extensive contribution of paternal mtDNA, amounting to several orders of magnitude higher than that inferred for Drosophila or mice, was observed in both intra- and interspecific crosses.	DALHOUSIE UNIV, MARINE GENE PROBE LAB, HALIFAX B3H 4J1, NS, CANADA; UNIV CRETE, DEPT BIOL, IRAKLION, GREECE; INST MARINE BIOL CRETE, IRAKLION, GREECE; FISHERIES & OCEANS CANADA, HALIFAX FISHERIES RES LAB, HALIFAX B3J 2S7, NS, CANADA	Dalhousie University; University of Crete; Fisheries & Oceans Canada	ZOUROS, E (corresponding author), DALHOUSIE UNIV, DEPT BIOL, HALIFAX B3H 4J1, NS, CANADA.							CHAPMAN RW, 1984, METHOD RAPID ISOLATI; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER C, 1990, P ROY SOC B-BIOL SCI, V242, P149, DOI 10.1098/rspb.1990.0118; GJETVAJ B, 1992, MOL BIOL EVOL, V9, P106; GYLLENSTEN U, 1985, J HERED, V76, P321, DOI 10.1093/oxfordjournals.jhered.a110103; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HOEH WR, 1991, SCIENCE, V251, P1488, DOI 10.1126/science.1672472; HOFFMANN RJ, 1992, GENETICS, V131, P397; KOEHLER CM, 1991, GENETICS, V129, P247; KOEHN RK, 1991, AQUACULTURE, V94, P125, DOI 10.1016/0044-8486(91)90114-M; KONDO R, 1990, GENETICS, V126, P657; LANSMAN RA, 1981, J MOL EVOL, V17, P214, DOI 10.1007/BF01732759; LANSMAN RA, 1983, P NATL ACAD SCI-BIOL, V80, P1969, DOI 10.1073/pnas.80.7.1969; LONGO FJ, 1969, J EXP ZOOL, V172, P97, DOI 10.1002/jez.1401720108; MAGOULAS A, IN PRESS MOL BIOL EV; MALLET AL, 1985, MAR BIOL, V87, P165, DOI 10.1007/BF00539424; MCDONALD JH, 1991, MAR BIOL, V111, P323, DOI 10.1007/BF01319403; MCDONALD JH, 1988, MAR BIOL, V99, P111, DOI 10.1007/BF00644984; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; SATTA Y, 1988, GENET RES, V52, P1, DOI 10.1017/S0016672300027245; WESTNEAT DF, 1988, NUCLEIC ACIDS RES, V16, P4161, DOI 10.1093/nar/16.9.4161	22	168	173	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 1	1992	359	6394					412	414		10.1038/359412a0	http://dx.doi.org/10.1038/359412a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1357555				2022-12-24	WOS:A1992JQ62400055
J	ZHENG, XM; WANG, Y; PALLEN, CJ				ZHENG, XM; WANG, Y; PALLEN, CJ			CELL-TRANSFORMATION AND ACTIVATION OF PP60(C-SRC) BY OVEREXPRESSION OF A PROTEIN TYROSINE PHOSPHATASE	NATURE			English	Article							MITOTIC ACTIVATION; PP60C-SRC; KINASE; PHOSPHORYLATION; MITOSIS; GENE; DEPHOSPHORYLATION; EXPRESSION; P60C-SRC; CLONING	THE kinase activity of pp60c-src is specifically and transiently increased during mitosis and repressed during interphase1. Loss of cell-cycle control of pp60c-src occurs on mutation of Tyr 527 to Phe or when pp60c-src is associated with polyoma middle-T-antigen, and these conditions result in cell transformation or tumorigenesis2,3. In both cases, pp60c-src has elevated kinase activity which is maintained throughout the cell cycle and accompanied by dephosphorylation of the carboxy-terminal negative regulatory4-7 Tyr 527 site, or mimicry of Tyr 527 dephosphorylation in the case of the mutant. Here we report that overexpression of the receptor-like protein tyrosine phosphatase PTP-alpha-8-10 results in persistent activation of pp60c-src kinase, with concomitant cell transformation and tumorigenesis. In PTP-alpha-overexpressing cells the pp60c-src kinase activation is accompanied by dephosphorylation at Tyr 527, and direct dephosphorylation of this site by purified PTP-alpha occurs in vitro. Our results suggest that PTP-alpha is involved in the regulation of cell proliferation, exerting at least some of its effects through pp60c-src kinase, and has oncogenic capability when overexpressed.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,CELL REGULAT LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Wang, Yue/H-2107-2011; Wang, Yue/AGN-6053-2022	Wang, Yue/0000-0002-1211-2822; Pallen, Catherine/0000-0002-3576-5295				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN JB, 1987, ONCOGENE RES, V1, P149; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUEGER NX, 1990, EMBO J, V9, P3241; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	30	437	462	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					336	339		10.1038/359336a0	http://dx.doi.org/10.1038/359336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383828				2022-12-24	WOS:A1992JP50300062
J	ZENZES, MT; WANG, P; CASPER, RF				ZENZES, MT; WANG, P; CASPER, RF			CHROMOSOME STATUS OF UNTRANSFERRED (SPARE) EMBRYOS AND PROBABILITY OF PREGNANCY AFTER INVITRO FERTILIZATION	LANCET			English	Article							FERTILIZATION	Many spontaneous abortions are associated with chromosomal abnormality of the fetus. In in-vitro fertilisation (IVF) the chromosome status of untransferred (''spare'') embryos and subsequent fate (pregnancy or not) of the transferred sibling embryos might be related. Since the spare and transferred embryos of a patient's cycle genetically are full siblings, the inherited chromosomal abnormalities in spare embryos have a 50% probability of also appearing in transferred embryos. We have tested whether chromosome analysis of spare embryos has predictive power for transferred embryos. 48 couples with a total of 437 embryos were selected because their spare embryos (1-4 per couple; 76 total) were successfully analysed for chromosome status. 16 patients became pregnant. These women produced a higher proportion of chromosomally normal spare embryos (9/24; 37.5%) than those who did not achieve pregnancy (1/52; 1.9%). The proportion of patients who had only normal embryos was significantly higher (p=0.012) in the pregnant group than in the non-pregnant group, and the proportion of patients who had only abnormal embryos was significantly higher (p=0.001) in the non-pregnant group. Patients with preclinical and clinical pregnancy losses had only chromosomally abnormal spare embryos; by contrast, 50% of spare embryos from patients with ectopic pregnancies were normal. The proportion of spare embryos that were normal (13%, 10/76), was similar to the livebirth rate of 11% per transferred embryo (19 infants from 171 transferred embryos). These results suggest that chromosome analysis of spare embryos may have predictive value for their transferred sibling embryos. We conclude that improving detection of chromosomally normal embryos for transfer should improve the success rate in IVF.	UNIV TORONTO, DEPT OBSTET & GYNAECOL, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto			Casper, Robert F./E-3775-2013	Casper, Robert F./0000-0002-6249-462X				Angell R R, 1988, J Reprod Fertil Suppl, V36, P73; BEIER H, 1991, GUIDELINES ESHRE ETH, V1, P21; BELSEY MA, 1980, LABORATORY MANUAL EX, P9; BRAUDE RR, 1986, HUMAN EMBRYO RES YES, P63; BREED ASPM, 1990, PRENATAL DIAG, V10, P101, DOI 10.1002/pd.1970100206; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; EIBEN B, 1990, AM J HUM GENET, V47, P656; GONEN Y, 1990, FERTIL STERIL, V53, P282; HARNDEN DG, 1985, CYTOGENET CELL GENET; HERTIG AT, 1949, AM J OBSTET GYNECOL, V58, P968, DOI 10.1016/0002-9378(49)90203-3; HOOK EB, IN PRESS PRENATAL DI; KLINE J, 1989, CONCEPTION BIRTH EPI, P81; LOPATA A, 1983, FERTIL STERIL, V40, P289; MILLER JF, 1980, LANCET, V2, P554; PLACHOT M, 1988, ANN NY ACAD SCI, V541, P384, DOI 10.1111/j.1749-6632.1988.tb22275.x; QUINN P, 1984, FERTIL STERIL, V41, P202; SUTTON HE, 1988, INTRO HUMAN GENETICS, P147; TARKOWSKI AK, 1966, CYTOGENETICS, V5, P394, DOI 10.1159/000129914; VANBLERKOM J, 1988, HUM REPROD, V3, P777, DOI 10.1093/oxfordjournals.humrep.a136783; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WRAMSBY H, 1987, HUM REPROD, V2, P233, DOI 10.1093/oxfordjournals.humrep.a136519; ZENZES MT, 1990, HUM REPROD, V5, P842, DOI 10.1093/oxfordjournals.humrep.a137195; ZENZES MT, 1992, FERTIL STERIL, V57, P143; ZENZES MT, 1992, HUM GENET, V88, P367, DOI 10.1007/BF00215667	24	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1992	340	8816					391	394		10.1016/0140-6736(92)91471-J	http://dx.doi.org/10.1016/0140-6736(92)91471-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353556				2022-12-24	WOS:A1992JJ44900004
J	STEITZ, JA				STEITZ, JA			SPLICING TAKES A HOLIDAY	SCIENCE			English	Editorial Material							PRE-MESSENGER-RNA; MITOCHONDRIAL TRANSFER-RNAS; JUNCTION SEQUENCES; MAMMALIAN INTRONS; GROUP-II; SITE; YEAST; CLEAVAGE; RIBONUCLEOPROTEIN; SPLICEOSOME				STEITZ, JA (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; LECUYER K, UNPUB; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P1; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; SAWA H, 1991, NUCLEIC ACIDS RES, V19, P3953, DOI 10.1093/nar/19.14.3953; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0	24	107	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					888	889		10.1126/science.1386941	http://dx.doi.org/10.1126/science.1386941			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1386941				2022-12-24	WOS:A1992JH82700019
J	RIDDELL, SR; WATANABE, KS; GOODRICH, JM; LI, CR; AGHA, ME; GREENBERG, PD				RIDDELL, SR; WATANABE, KS; GOODRICH, JM; LI, CR; AGHA, ME; GREENBERG, PD			RESTORATION OF VIRAL IMMUNITY IN IMMUNODEFICIENT HUMANS BY THE ADOPTIVE TRANSFER OF T-CELL CLONES	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CYTOMEGALO-VIRUS DISEASE; MARROW TRANSPLANTATION; INVIVO; REPLICATION; GENERATION; PNEUMONIA; MEMORY; DEATH; HOST	The adoptive transfer of antigen-specific T cells to establish immunity is an effective therapy for viral infections and tumors in animal models. The application of this approach to human disease would require the isolation and in vitro expansion of human antigen-specific T cells and evidence that such T cells persist and function in vivo after transfer. Cytomegalovirus-specific CD8+ cytotoxic T cell (CTL) clones could be isolated from bone marrow donors, propagated in vitro, and adoptively transferred to immunodeficient bone marrow transplant recipients. No toxicity developed and the clones provided persistent reconstitution of CD8+ cytomegalovirus-specific CTL responses.	UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RIDDELL, SR (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.		Agha, Mounzer/AAC-2520-2022; Wilson, Matthew H/K-3193-2013	Agha, Mounzer/0000-0002-2275-7544	NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORYSIEWICZ LK, 1983, EUR J IMMUNOL, V13, P804, DOI 10.1002/eji.1830131005; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRYNE JA, 1984, J VIROL, V51, P682; CHEEVER MA, 1986, J EXP MED, V163, P1100, DOI 10.1084/jem.163.5.1100; FAUCI AS, 1985, ANN INTERN MED, V102, P800, DOI 10.7326/0003-4819-102-6-800; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; GREENBERG PD, 1991, ADV IMMUNOL, V9, P280; GREENBERG PD, 1985, J IMMUNOL, V133, P3401; HOWES EL, 1979, NATURE, V277, P67, DOI 10.1038/277067a0; LAUBSCHER A, 1988, J IMMUNOL METHODS, V110, P69, DOI 10.1016/0022-1759(88)90084-1; Li C, UNPUB; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MACHER AM, 1983, NEW ENGL J MED, V309, P1454; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MEYERS JD, 1987, INFECTIONS TRANSPLAN, P17; MUTTER W, 1988, J EXP MED, V167, P1645, DOI 10.1084/jem.167.5.1645; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PETERSON PK, 1980, MEDICINE, V59, P283, DOI 10.1097/00005792-198007000-00004; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; QUINNAN GV, 1982, NEW ENGL J MED, V307, P6; REDDEHASE MJ, 1985, J VIROL, V55, P264, DOI 10.1128/JVI.55.2.264-273.1985; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL S, UNPUB; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1991, J IMMUNOL, V146, P2795; SCHRIER RD, 1986, J VIROL, V59, P127, DOI 10.1128/JVI.59.1.127-131.1986; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WALKER BD, 1988, NATURE, V336, P484; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0	32	1044	1153	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					238	241						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1352912				2022-12-24	WOS:A1992JC58500038
J	NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T				NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T			EFFECTS OF TOPICAL NASAL ANESTHESIA ON SHIFT OF BREATHING ROUTE IN ADULTS	LANCET			English	Article							RESPIRATORY ACTIVITY; MUSCLE-ACTIVITY; ANESTHESIA; PRESSURE; OBSTRUCTION; RECEPTORS; INFANTS; HUMANS; LAMBS; SLEEP	The position of the soft palate is known to determine the breathing route, but the physiological mechanisms that bring about a shift from nasal to oral breathing are unclear. To test the hypothesis that activation of receptors in the nasal passage may be involved in reflex initiation of oral breathing after nasal obstruction, we investigated respiratory responses to nasal occlusion before and after topical lignocaine anaesthesia of the nasal passages. Eleven volunteers were fitted with custom-made partitioned face masks, which separated nasal and oral passages. Air flow through each passage was detected by changes in airway pressure and carbon dioxide concentration. Nine subjects were habitual nasal breathers both before and after topical anaesthesia with 4% lignocaine. Among these subjects, the time to initiate oral breathing in response to nasal occlusion was significantly shorter before anaesthesia than afterwards (mean 4.4 [SD 2.5] vs 10.8 [7.4] s, p<0.01). Similarly, the time to resume nasal breathing after release of nasal occlusion was significantly shorter before topical anaesthesia than afterwards (6.9 [4.9] vs 12.1 [7.8] s, p<0.01). Topical anaesthesia did not affect respiration rate, end-tidal carbon dioxide concentration, or arterial oxygen saturation. These findings suggest that in human beings sensory information from receptors in the nasal passage has an important role in controlling the shift of breathing route.			NISHINO, T (corresponding author), NATL CANC CTR,DEPT ANESTHESIOL,TSUKIJI 5-1-1,CHUO KU,TOKYO 104,JAPAN.							DEWEESE EL, 1988, J APPL PHYSIOL, V64, P1346, DOI 10.1152/jappl.1988.64.4.1346; HARDING R, 1990, RESP PHYSIOL, V80, P71, DOI 10.1016/0034-5687(90)90007-L; HARDING R, 1987, RESP PHYSIOL, V68, P177, DOI 10.1016/S0034-5687(87)80004-X; HARDING R, 1991, J APPL PHYSIOL, V71, P1574, DOI 10.1152/jappl.1991.71.4.1574; KUNA ST, 1988, AM REV RESPIR DIS, V137, P656, DOI 10.1164/ajrccm/137.3.656; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MATHEW OP, 1984, RESP PHYSIOL, V58, P41, DOI 10.1016/0034-5687(84)90043-4; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; MCBRIDE B, 1981, J APPL PHYSIOL, V51, P1189, DOI 10.1152/jappl.1981.51.5.1189; MILLER MJ, 1985, J PEDIATR-US, V107, P465, DOI 10.1016/S0022-3476(85)80535-7; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V131, P343; RODENSTEIN DO, 1984, J APPL PHYSIOL, V57, P651, DOI 10.1152/jappl.1984.57.3.651; SANTAMBROGIO FB, 1985, J APPL PHYSIOL, V58, P1298, DOI 10.1152/jappl.1985.58.4.1298; SANTAMBROGIO G, 1983, RESP PHYSIOL, V54, P317, DOI 10.1016/0034-5687(83)90075-0; SANTAMBROGIO G, 1985, RESPIR PHYSL, V59, P34; Swift DL., 1977, RESPIRATORY DEFENSE, V5, P63; WHITE DP, 1985, AM REV RESPIR DIS, V132, P972; WOLFSDORF J, 1969, PEDIATRICS, V43, P799	18	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1497	1500		10.1016/0140-6736(92)91261-6	http://dx.doi.org/10.1016/0140-6736(92)91261-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351184				2022-12-24	WOS:A1992HZ17500002
J	BRYNDORF, T; CHRISTENSEN, B; PHILIP, J; HANSEN, W; YOKOBATA, K; BUI, N; GAISER, C				BRYNDORF, T; CHRISTENSEN, B; PHILIP, J; HANSEN, W; YOKOBATA, K; BUI, N; GAISER, C			NEW RAPID TEST FOR PRENATAL DETECTION OF TRISOMY-21 (DOWNS-SYNDROME) - PRELIMINARY-REPORT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INSITU HYBRIDIZATION; CHROMOSOME; INTERPHASE; GENE	Objective - To devise and evaluate a rapid screening method for detecting trisomy 21 (Down's syndrome) in samples of uncultured amniotic fluid cells. Design - Non-radioactive in situ hybridisation with HY128, a 500 000 base pair yeast artificial chromosome probe specific for chromosome 21. Blinded study of 12 karyotypically normal amniotic fluid samples and eight samples trisomic for chromosome 21. Setting - Cytogenetic and obstetric services at a tertiary referral centre, Copenhagen. Main outcome measures - Time necessary to complete the test. Proportion of cell nuclei containing two and three hybridisation signals in karyotypically normal and abnormal amniotic fluid samples. Results - The test could be completed within three to four days after amniocentesis. In the normal samples a mean of 73% (range 61-82%) of the amniotic cell nuclei showed two hybridisation signals and 6% (0-18%) showed three signals. By contrast, among the trisomic samples 29% (19-38%) of the nuclei exhibited two signals and 48% (31-60%) showed three signals. Conclusion - The technique clearly distinguished between normal and trisomic samples. Prenatal diagnosis with in situ hybridisation with chromosome specific probes was fast and may make it possible to screen for selected, aneuploidies. However, the technique is still at a preliminary stage and needs further evaluation and refinement.	BECTON DICKINSON IMMUNOCYTOMETRY SYST, SAN JOSE, CA 95131 USA	Becton Dickinson	BRYNDORF, T (corresponding author), UNIV COPENHAGEN HOSP, RIGSHOSP, DEPT OBSTET & GYNAECOL, CLIN GENET SECT, CHROMOSOME LAB, DK-2100 COPENHAGEN, DENMARK.							BURKE DT, 1991, METHOD ENZYMOL, V194, P251; CHRISTENSEN B, 1992, PRENAT DIAGN, V12, P251; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOSDEN CM, 1983, BRIT MED BULL, V39, P348, DOI 10.1093/oxfordjournals.bmb.a071847; GUYOT B, 1988, PRENATAL DIAG, V8, P485, DOI 10.1002/pd.1970080703; HOPMAN AHN, 1990, IN SITU HYBRIDIZATIO, P165; KLINGER KW, 1991, AM J HUM GENET, V49, P23; KUO W, 1991, AM J HUM GENET, V49, P382; KUO WL, 1991, AM J HUM GENET, V49, P112; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; WHITEMAN DAH, 1991, AM J HUM GENET, V49, P234; WILLARD HF, 1983, NUCLEIC ACIDS RES, V11, P2017, DOI 10.1093/nar/11.7.2017; YU LC, 1991, AM J HUM GENET, V49, P235	17	14	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1992	304	6841					1536	1539		10.1136/bmj.304.6841.1536	http://dx.doi.org/10.1136/bmj.304.6841.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1385745	Green Published, Bronze			2022-12-24	WOS:A1992HZ17800022
J	HATTERSLEY, AT; TURNER, RC; PERMUTT, MA; PATEL, P; TANIZAWA, Y; CHIU, KC; ORAHILLY, S; WATKINS, PJ; WAINSCOAT, JS				HATTERSLEY, AT; TURNER, RC; PERMUTT, MA; PATEL, P; TANIZAWA, Y; CHIU, KC; ORAHILLY, S; WATKINS, PJ; WAINSCOAT, JS			LINKAGE OF TYPE-2 DIABETES TO THE GLUCOKINASE GENE	LANCET			English	Article							INSULIN GENE; BETA-CELL; ONSET; YOUNG; MELLITUS; FAMILIES; GLUCOSE; TWINS	Maturity-onset diabetes of the young (MODY) is a subtype of type 2 diabetes that presents from the second decade and has an autosomal dominant mode of inheritance. We have investigated the glucokinase gene, a candidate gene for diabetes, in two MODY pedigrees. In a large 5-generation pedigree (BX) with 15 diabetic members, use of a microsatellite polymorphism revealed linkage of diabetes to the glucokinase locus on chromosome 7p. A peak lod score of 4.60 was obtained at a recombination fraction (theta) of zero. This finding suggests that a defective glucokinase gene contributes to the diabetes phenotype in this pedigree. This is not universal in MODY since linkage to the glucokinase locus was excluded in a second pedigree M (lod score= -7.36 at theta = 0). The affected members in pedigree BX were diagnosed either when young (in pregnancy or on screening) or when they presented symptomatically in middle and old age; most of them were treated by diet alone. Defects in the glucokinase gene may play an important part in the pathogenesis of type 2 diabetes.	JOHN RADCLIFFE HOSP,DEPT HAEMATOL,OXFORD OX3 9DU,ENGLAND; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110; UNIV LONDON KINGS COLL HOSP,DIABET UNIT,LONDON SE5 8RX,ENGLAND	University of Oxford; Washington University (WUSTL); King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	HATTERSLEY, AT (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020; Chiu, Ken/M-6473-2013	O'Rahilly, Stephen/0000-0003-2199-4449; Chiu, Ken/0000-0002-2226-1039; Hattersley, Andrew/0000-0001-5620-473X	NIDDK NIH HHS [DK 16746] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016746, R37DK016746] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREONE T, 1985, DIABETES, V34, P108, DOI 10.2337/diabetes.34.2.108; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BELL JI, 1983, BRIT MED J, V286, P590, DOI 10.1136/bmj.286.6365.590; BOWDEN DW, 1992, DIABETES, V41, P88, DOI 10.2337/diabetes.41.1.88; COOK JTE, 1991, DIABETES S1, V40, pA296; ELBIN SC, 1987, DIABETOLOGIA, V30, P641; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1991, Diabetologia, V34, pA71; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEVY JC, 1991, DIABETOLOGIA, V34, P488, DOI 10.1007/BF00403285; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; Maniatis T., 1982, MOL CLONING; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; ORAHILLY S, 1988, DIABETOLOGIA, V31, P792; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; ORAHILLY S, 1989, DIABETES RES CLIN EX, V10, P125; PATEL P, IN PRESS DIABETES; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; TATTERSALL RB, 1974, Q J MED, V43, P339; VINIK AJ, 1988, DIABETOLOGIA, V31, P778, DOI 10.1007/BF00274785; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1985, WHO TECH REP SER, V727	30	313	322	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1307	1310		10.1016/0140-6736(92)91958-B	http://dx.doi.org/10.1016/0140-6736(92)91958-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349989				2022-12-24	WOS:A1992HW83700001
J	LESOUEF, PN				LESOUEF, PN			VALIDITY OF METHODS USED TO TEST AIRWAY RESPONSIVENESS IN CHILDREN	LANCET			English	Editorial Material							BRONCHIAL HYPERRESPONSIVENESS; AUSTRALIAN SCHOOLCHILDREN; INHALATION CHALLENGE; RESPIRATORY SYMPTOMS; INHALED HISTAMINE; NORMAL INFANTS; METHACHOLINE; REACTIVITY; STANDARDIZATION; PREVALENCE	Methods to test airway responsiveness to inhaled agonists in children were originally developed for use in adults, and agonist dosage regimens do not adequately correct for the size of the child. Because small children receive a higher dose relative to their body size than do large children, the age-related decline in airway responsiveness reported in many recent studies might reflect failure to adequately size-correct test dosages rather than a genuine physiological event. Until the administered doses of inhaled agonists can be satisfactorily size-corrected, tests of airway responsiveness in children should be regarded as qualitative rather than quantitative.			LESOUEF, PN (corresponding author), PRINCESS MARGARET HOSP,DEPT RESP MED,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.		Le Souef, Peter N/H-5256-2014	Le Souef, Peter/0000-0003-0930-1654				AVITAL A, 1991, AM REV RESPIR DIS, V144, P36, DOI 10.1164/ajrccm/144.1.36; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUA H L, 1991, American Review of Respiratory Disease, V143, pA706; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1126, DOI 10.1136/adc.64.8.1126; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLLIS GG, 1990, LANCET, V336, P341, DOI 10.1016/0140-6736(90)91880-J; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GODFREY S, 1979, CLIN PAEDIATRIC PHYS; HOPP RJ, 1986, AM REV RESPIR DIS, V134, P994, DOI 10.1164/arrd.1986.134.5.994; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MONTGOMERY GL, 1990, AM REV RESPIR DIS, V142, P1372, DOI 10.1164/ajrccm/142.6_Pt_1.1372; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; STICK SM, 1991, AM REV RESPIR DIS, V144, P1012, DOI 10.1164/ajrccm/144.5.1012; STICK SM, 1990, AM REV RESPIR DIS, V142, P1143, DOI 10.1164/ajrccm/142.5.1143; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; YOUNG S, 1991, American Review of Respiratory Disease, V143, pA23	27	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1282	1284		10.1016/0140-6736(92)91602-5	http://dx.doi.org/10.1016/0140-6736(92)91602-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349677				2022-12-24	WOS:A1992HV19100012
J	TOOLE, MJ				TOOLE, MJ			MICRONUTRIENT DEFICIENCIES IN REFUGEES	LANCET			English	Editorial Material											TOOLE, MJ (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.							DESENCLOS JC, 1989, B WORLD HEALTH ORGAN, V67, P309; IRWIN MI, 1976, J NUTR, V106, P824; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; MAGAN AM, 1982, DISASTERS, V7, P93; MOREN A, 1990, LANCET, V335, P1403, DOI 10.1016/0140-6736(90)91283-G; NIEBURG P, 1988, B WORLD HEALTH ORGAN, V66, P698; ROE DA, 1973, PLAGUE CORN, P1; SOMMER A, 1983, LANCET, V2, P585; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3269; YIP R, 1987, OCT ANN M AM PUBL HL; 1989, NUTRITION TIMES DISA; 1967, WHO TECH REP SER, V362, P45; 1989, MMWR, V38, P455; 1989, MMWR, V38, P461; 1991, 1991 INT S RESP NUTR; 1991, MMWR, V40, P209	16	24	24	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1214	1216		10.1016/0140-6736(92)91143-V	http://dx.doi.org/10.1016/0140-6736(92)91143-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349947				2022-12-24	WOS:A1992HU68400013
J	SANTALUCIA, J; KIERZEK, R; TURNER, DH				SANTALUCIA, J; KIERZEK, R; TURNER, DH			CONTEXT DEPENDENCE OF HYDROGEN-BOND FREE-ENERGY REVEALED BY SUBSTITUTIONS IN AN RNA HAIRPIN	SCIENCE			English	Article							RIBOSOMAL-RNA; SECONDARY STRUCTURES; PHAGE-T4 LYSOZYME; DUPLEX STABILITY; SEQUENCE; ARCHITECTURE; PREDICTIONS	Prediction and modeling of RNA structure requires knowledge of the free energy contributions of various interactions. Many unusual hydrogen bonds were recently proposed in the structure of a GCAA hairpin determined from nuclear magnetic resonance. The contributions of these hydrogen bonds to the folding stability of the hairpin formed by rGGCGCAAGCC have now been investigated through the use of functional group substitutions. These and previous results suggest a strong context dependence for the free energy of hydrogen bond formation. The results also suggest that the phylogenetic preference for GNRA (where N = A, C, G, or U and R = A or G) tetraloops may have afunctional rather than thermodynamic basis.	UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627; POLISH ACAD SCI,INST BIOORGAN CHEM,PL-60704 POZNAN,POLAND	University of Rochester; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences			Schroeder, Susan/D-3946-2011	Kierzek, Ryszard/0000-0002-7644-0016	NIGMS NIH HHS [GM22939] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022939] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2422, DOI 10.1021/bi00432a013; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KIERZEK R, 1986, BIOCHEMISTRY-US, V25, P7840, DOI 10.1021/bi00372a009; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; RIESNER D, 1973, PHYSICO CHEMICAL PRO, V2, P237; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SANTALUCIA J, 1991, J AM CHEM SOC, V113, P4313, DOI 10.1021/ja00011a039; SANTALUCIA J, UNPUB; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	27	204	204	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					217	219		10.1126/science.1373521	http://dx.doi.org/10.1126/science.1373521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1373521				2022-12-24	WOS:A1992HM89600027
J	BEAR, CE; LI, CH; KARTNER, N; BRIDGES, RJ; JENSEN, TJ; RAMJEESINGH, M; RIORDAN, JR				BEAR, CE; LI, CH; KARTNER, N; BRIDGES, RJ; JENSEN, TJ; RAMJEESINGH, M; RIORDAN, JR			PURIFICATION AND FUNCTIONAL RECONSTITUTION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR)	CELL			English	Article							LIPID BILAYER-MEMBRANES; CHLORIDE CHANNEL; ACETYLCHOLINE-RECEPTOR; ESCHERICHIA-COLI; CELL LINE; PLANAR; PROTEINS; GENE; BACTERIORHODOPSIN; RENATURATION	Circumstantial evidence has accumulated suggesting that CFTR is a regulated low-conductance CI- channel. To test this postulate directly, we have purified to homogeneity a recombinant CFTR protein from a high-level baculovirus-infected insect cell line. Evidence of purity included one- and two-dimensional gel electrophoresis, N-terminal peptide sequence, and quantitative amino acid analysis. Reconstitution into proteoliposomes at less than one molecule per vesicle was accomplished by established procedures. Nystatin and ergosterol were included in these vesicles, so that nystatin conductance could serve as a quantitative marker of vesicle fusion with a planar lipid bilayer. Upon incorporation, purified CFTR exhibited regulated chloride channel activity, providing evidence that the protein itself is the channel. This activity exhibited the basic biophysical and regulatory properties of the type of CI- channel found exclusively in CFTR-expressing cell types and believed to underlie cAMP-evoked secretion in epithelial cells.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Alabama System; University of Alabama Birmingham	BEAR, CE (corresponding author), UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA.							ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; Dottin R P, 1979, Methods Enzymol, V68, P513; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; FLEM K, 1991, OCT N AM CYST C DALL; FURMAN RE, 1986, P NATL ACAD SCI USA, V83, P488, DOI 10.1073/pnas.83.2.488; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSHORNE RP, 1985, P NATL ACAD SCI USA, V82, P240, DOI 10.1073/pnas.82.1.240; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1985, BIOCHIM BIOPHYS ACTA, V822, P127, DOI 10.1016/0304-4157(85)90005-X; LONDON E, 1982, J BIOL CHEM, V257, P7003; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MONTAL M, 1984, BIOPHYS J, V45, P165, DOI 10.1016/S0006-3495(84)84145-4; NOWAK R, 1991, J NIH RES, V3, P30; REINHARDT R, 1987, J MEMBRANE BIOL, V95, P47, DOI 10.1007/BF01869629; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1991, ADV EXP MED BIOL, V290, P19; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARIBANSOHRABY S, 1984, NATURE, V308, P80, DOI 10.1038/308080a0; SCHINDLER H, 1984, P NATL ACAD SCI-BIOL, V81, P6222, DOI 10.1073/pnas.81.19.6222; SHEPPARD DN, 1992, FASEB J, V6, pA537; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2	44	830	852	0	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					809	818		10.1016/0092-8674(92)90155-6	http://dx.doi.org/10.1016/0092-8674(92)90155-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1371239				2022-12-24	WOS:A1992HF44000020
J	VERRALL, S; HALL, ZW				VERRALL, S; HALL, ZW			THE N-TERMINAL DOMAINS OF ACETYLCHOLINE-RECEPTOR SUBUNITS CONTAIN RECOGNITION SIGNALS FOR THE INITIAL STEPS OF RECEPTOR ASSEMBLY	CELL			English	Article							ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; BINDING-SITES; ALPHA-SUBUNIT; TORPEDO-CALIFORNICA; DELTA-SUBUNIT; ION CHANNELS; MUSCLE; MUTAGENESIS; SELECTION	Ligand-gated ion channels are oligomeric membrane proteins in which homologous subunits specifically recognize one another and assemble around an aqueous pore. To identity domains responsible for the specificity of subunit association, we used a dominant-negative assay in which truncated subunits of the mouse muscle acetylcholine receptor (AChR) were coexpressed with the four wild-type subunits in transfected COS cells. Fragments of the alpha, delta, and gamma-subunits consisting solely of the extracellular N-terminal domain blocked surface expression of the AChR and the formation of alpha-delta-heterodimers, an early step in the assembly pathway of the AChR. Immunoprecipitation and sucrose gradient sedimentation experiments showed that an N-terminal fragment of the alpha-subunit forms a specific complex with the intact delta-subunit. Thus the extracellular N-terminal domain of the alpha, delta, and gamma-subunits contains the information necessary for specific subunit association.			VERRALL, S (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA.							BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOWDING AJ, 1987, BIOCHEMISTRY-US, V26, P6372, DOI 10.1021/bi00394a010; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1988, J BIOL CHEM, V263, P12878; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KARLIN A, 1980, CELL SURF REV, V6, P191; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RALSTON E, 1989, J CELL BIOL, V109, P2345, DOI 10.1083/jcb.109.5.2345; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SMITH MM, 1987, J BIOL CHEM, V262, P4367; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	43	134	135	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					23	31		10.1016/0092-8674(92)90203-O	http://dx.doi.org/10.1016/0092-8674(92)90203-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370654				2022-12-24	WOS:A1992GZ58300006
J	TRAVIS, SPL; MCGRATH, JA; TURNBULL, AJ; SCHOFIELD, OM; CHAN, O; OCONNOR, AF; MAYOU, B; EADY, RAJ; THOMPSON, RPH				TRAVIS, SPL; MCGRATH, JA; TURNBULL, AJ; SCHOFIELD, OM; CHAN, O; OCONNOR, AF; MAYOU, B; EADY, RAJ; THOMPSON, RPH			ORAL AND GASTROINTESTINAL MANIFESTATIONS OF EPIDERMOLYSIS-BULLOSA	LANCET			English	Note							MONOCLONAL-ANTIBODY; DIAGNOSIS	The mouth, oesophagus, and anus are often involved in dystrophic and junctional epidermolysis bullosa, but the frequency is unknown. Among 246 patients with epidermolysis bullosa, dysphagia developed in 76% of those with recessive dystrophic, in 20% of those with dominant dystrophic, in 15% of those with junctional, and in 2% of those with simplex forms. Lingual adhesions or microstomia occurred in dystrophic epidermolysis bullosa only, but were eight times more common in recessive than in dominant subtypes. These lesions are provoked by the trauma of eating and further reduce food intake, which exacerbates constipation caused by anal blisters and results in malnutrition. Management requires specialised multidisciplinary care.	ST THOMAS HOSP,GASTROINTESTINAL LAB,LONDON SE1,ENGLAND; ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT RADIOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT OTOLARYNGOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT PLAST SURG,LONDON SE1,ENGLAND		TRAVIS, SPL (corresponding author), RADCLIFFE INFIRM,GASTROENTEROL UNIT,OXFORD OX2 6HE,ENGLAND.		McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964; Travis, Simon/0000-0002-2690-4361				COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FEURLE GE, 1984, GASTROENTEROLOGY, V87, P1376; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FOX T, 1879, LANCET, V1, P765; GRYBOSKI JD, 1988, ARCH DERMATOL, V124, P746, DOI 10.1001/archderm.124.5.746; HEAGERTY AHM, 1986, LANCET, V1, P860; HEAGERTY AHM, 1986, BRIT J DERMATOL, V115, P125, DOI 10.1111/j.1365-2133.1986.tb05707.x; NOWAK AJ, 1988, ARCH DERMATOL, V124, P742, DOI 10.1001/archderm.124.5.742; PEARSON RW, 1988, ARCH DERMATOL, V124, P718, DOI 10.1001/archderm.124.5.718; RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P374, DOI 10.1111/1523-1747.ep12265460; TIDMAN MJ, 1988, CLIN EXP DERMATOL, V13, P279, DOI 10.1111/j.1365-2230.1988.tb00702.x	12	34	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1505	1506		10.1016/0140-6736(92)92759-9	http://dx.doi.org/10.1016/0140-6736(92)92759-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361600				2022-12-24	WOS:A1992KD06900008
J	JOHAL, GS; BRIGGS, SP				JOHAL, GS; BRIGGS, SP			REDUCTASE-ACTIVITY ENCODED BY THE HM1 DISEASE RESISTANCE GENE IN MAIZE	SCIENCE			English	Article							HELMINTHOSPORIUM-CARBONUM; HC-TOXIN; DETOXIFICATION	The HM1 gene in maize controls both race-specific resistance to the fungus Cochliobolus carbonum race 1 and expression of the NADPH (reduced form of nicotinamide adenine dinucleotide phosphate)-dependent HC toxin reductase (HCTR), which inactivates HC toxin, a cyclic tetrapeptide produced by the fungus to permit infection. Several HM1 alleles were generated and cloned by transposon-induced mutagenesis. The sequence of wild-type HM1 shares homology with dihydroflavonol-4-reductase genes from maize, petunia, and snapdragon. Sequence homology is greatest in the betaalphabeta-dinucleotide binding fold that is conserved among NADPH- and NADH (reduced form of nicotinamide adenine dinucleotide)dependent reductases and dehydrogenases. This indicates that HM1 encodes HCTR.			JOHAL, GS (corresponding author), PIONEER HI BRED INT INC,DEPT BIOTECHNOL RES,JOHNSTON,IA 50131, USA.		Johal, Guri/F-5056-2017	Johal, Guri/0000-0001-8101-8410				ANZAI H, 1989, MOL GEN GENET, V219, P492, DOI 10.1007/BF00259626; ATHMA P, 1991, GENETICS, V128, P163; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; BEAVIS WD, 1991, THEOR APPL GENET, V82, P636, DOI 10.1007/BF00226803; BELD M, 1989, PLANT MOL BIOL, V13, P491, DOI 10.1007/BF00027309; BRIGGS SP, 1987, CURR TOP PLANT BIOCH, V6, P59; CHANDLER VL, 1986, P NATL ACAD SCI USA, V83, P1767, DOI 10.1073/pnas.83.6.1767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONE KC, 1988, PLANT TRANSPOSABLE E; DELLAPORTA SL, 1983, PLANT MOL BIOL REP, V1, P18; GROSS ML, 1982, TETRAHEDRON LETT, V23, P5381; HENRY RJ, 1991, PLANT MOL BIOL REP, V9, P139; JOHAL GS, 1990, MAIZE GENETICS COOPE, V64, P37; JOHAL GS, UNPUB; KAWAI M, 1983, BIOCHEM BIOPH RES CO, V111, P398, DOI 10.1016/0006-291X(83)90319-4; LIESCH JM, 1982, TETRAHEDRON, V38, P45, DOI 10.1016/0040-4020(82)85043-6; MEELEY RB, 1992, PLANT CELL, V4, P71, DOI 10.1105/tpc.4.1.71; MEELEY RB, 1991, PLANT PHYSIOL, V97, P1080, DOI 10.1104/pp.97.3.1080; MEYEROWITZ EM, 1982, CELL, V28, P165, DOI 10.1016/0092-8674(82)90386-5; MIAO VPW, 1992, APPL ENVIRON MICROB, V58, P801, DOI 10.1128/AEM.58.3.801-808.1992; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PERHAM RN, 1991, BIOESSAYS, V13, P515, DOI 10.1002/bies.950131005; RASMUSSEN JB, 1988, PHYSIOL MOL PLANT P, V32, P283, DOI 10.1016/S0885-5765(88)80023-7; ROBERTSON D, COMMUNICATION; SCHEFFER RP, 1965, PHYTOPATHOLOGY, V55, P1037; SHAH D M, 1983, Journal of Molecular and Applied Genetics, V2, P111; SISCO P, COMMUNICATION; WALTON JD, 1982, BIOCHEM BIOPH RES CO, V107, P785, DOI 10.1016/0006-291X(82)90592-7; WOLF SJ, 1991, PLANT SCI, V70, P127; YODER OC, 1980, ANNU REV PHYTOPATHOL, V18, P103, DOI 10.1146/annurev.py.18.090180.000535	31	342	440	5	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					985	987		10.1126/science.1359642	http://dx.doi.org/10.1126/science.1359642			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359642				2022-12-24	WOS:A1992JW79600032
J	TATSUKA, M; MITSUI, H; WADA, M; NAGATA, A; NOJIMA, H; OKAYAMA, H				TATSUKA, M; MITSUI, H; WADA, M; NAGATA, A; NOJIMA, H; OKAYAMA, H			ELONGATION FACTOR-1-ALPHA GENE DETERMINES SUSCEPTIBILITY TO TRANSFORMATION	NATURE			English	Article							NEOPLASTIC TRANSFORMATION; GROWTH-FACTOR; CELLS; PROTEIN; LINE	ELONGATION factor-1-alpha (EF-1-alpha), an essential component of the eukaryotic translational apparatus, is a GTP-binding protein that catalyses the binding of aminoacyl-transfer RNAs to the ribosome1-3. Expression of the EF-1-alpha gene decreases towards the end of the lifespans of mouse and human fibroblasts4,5, but forced expression of EF-1-alpha prolongs the lifespan of Drosophila melanogaster6. Eukaryotic initiation factor-4E, another component of the translational machinery, is mitogenic or oncogenic when constitutively expressed in some mammalian cells7-9. Thus, components of the protein synthesis apparatus seem to be involved in the control of cell proliferation. Using expression cloning, we have isolated a complementary DNA clone from a BALB/c 3T3 mouse fibroblast variant, A31-I-13 (ref. 10), which specifies a factor determining the susceptibility of BALB/c 3T3 to chemically and physically induced transformation. Here we report that the factor is EF-1-alpha and that its constitutive expression causes BALB/c 3T3 A31-I-1 (ref. 10), C3H10T1/2 (ref. 11) and Syrian hamster SHOK12 fibroblasts to become highly susceptible to transformation induced by 3-methylcholanthrene and ultraviolet light. EF-1-alpha messenger RNA is also constitutively expressed in a quiescent culture of the highly susceptible variant A31-I-13. We conclude that the removal of regulation of the expression of these components of the translational machinery may predispose cells to become more susceptible to malignant transformation.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,SUITA,OSAKA 565,JAPAN; KYOTO PHARMACEUT UNIV,INST MOLEC & CELLULAR BIOL PHARMACEUT SCI,DEPT MOLEC BIOREGULAT,KYOTO 607,JAPAN	Osaka University; Kyoto Pharmaceutical University								AUSABEL FM, 1987, CURRENT PROTOCOLS MO; BENEDETTI AD, 1990, P NATL ACAD SCI USA, V87, P8212; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BREITMAN ML, 1982, MOL CELL BIOL, V2, P966, DOI 10.1128/MCB.2.8.966; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CHEM C, 1987, MOL CELL BIOL, V7, P2745; CURRAN T, 1982, J VIROL, V44, P672; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HERSHEY JWB, 1980, BIOL COMPREHENSIVE T, V4; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HIRAKAWA T, 1982, SCIENCE, V216, P527, DOI 10.1126/science.6280280; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; Kakunaga T., 1985, IARC SCI PUBLICATION, V67; KARIRO T, 1978, BIOCHIM BIOPHYS ACTA, V505, P95; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LO KY, 1982, CANCER RES, V42, P2644; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SMITH M R, 1990, New Biologist, V2, P648; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATAUKA M, 1992, CANCER RES, V52, P4232; TATSUKA M, 1989, J CELL PHYSIOL, V139, P18, DOI 10.1002/jcp.1041390104; TATSUKA M, 1988, EXP CELL RES, V178, P154, DOI 10.1016/0014-4827(88)90386-2; WEBSTER GC, 1985, MOL BIOL AGING GENE, P263; YAGI T, 1989, MOL CARCINOGEN, V1, P222, DOI 10.1002/mc.2940010404; YAMASAKI H, 1985, CANCER RES, V45, P637; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	30	155	163	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					333	336		10.1038/359333a0	http://dx.doi.org/10.1038/359333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383827				2022-12-24	WOS:A1992JP50300061
J	DORIN, JR; DICKINSON, P; ALTON, EWFW; SMITH, SN; GEDDES, DM; STEVENSON, BJ; KIMBER, WL; FLEMING, S; CLARKE, AR; HOOPER, ML; ANDERSON, L; BEDDINGTON, RSP; PORTEOUS, DJ				DORIN, JR; DICKINSON, P; ALTON, EWFW; SMITH, SN; GEDDES, DM; STEVENSON, BJ; KIMBER, WL; FLEMING, S; CLARKE, AR; HOOPER, ML; ANDERSON, L; BEDDINGTON, RSP; PORTEOUS, DJ			CYSTIC-FIBROSIS IN THE MOUSE BY TARGETED INSERTIONAL MUTAGENESIS	NATURE			English	Article							EMBRYONIC STEM-CELLS; POTENTIAL DIFFERENCE; GENE; IDENTIFICATION; REGULATOR	Cystic fibrosis is a fatal genetic disorder which afflicts 50,000 people worldwide. A viable animal model would be invaluable for investigating and combating this disease. The mouse cystic fibrosis transmembrane conductance regulator gene was disrupted in embryonal stem cells using an insertional gene targeting vector. Germ-line chimaeras were derived and the off spring of heterozygous crosses studied. These homozygous mutant mice survive beyond weaning. In vivo electrophysiology demonstrates the predicted defect in chloride ion transport in these mice and can distinguish between each genotype. Histological analysis detects important hallmarks of human disease pathology, including abnormalities of the colon, lung and vas deferens. This insertional mouse mutation provides a valid model system for the development and testing of therapies for cystic fibrosis patients.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; NATL HEART & LUNG INST,ION TRANSPORT LAB,LONDON SW3 6LR,ENGLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; AFRC,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Imperial College London; University of Edinburgh			Dickinson, Paul/B-7598-2014; Clarke, Alan R/A-6256-2008; Porteous, David J/C-7289-2013; clarke, alan r/P-2820-2014; Porteous, David/AAA-3446-2021	Porteous, David J/0000-0003-1249-6106; Porteous, David/0000-0003-1249-6106; Clarke, Alan/0000-0002-4281-426X; Alton, Eric WFW/0000-0003-3852-6764				ALTON EWF, IN PRESS THORAX; ALTON EWFW, 1991, EUR RESPIR J, V4, P5; ALTON EWFW, 1990, EUR RESPIR J, V3, P922; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; Dorin Julia R., 1992, Transgenic Research, V1, P101, DOI 10.1007/BF02513027; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GOLDSTEIN JL, 1988, AM J PHYSIOL, V254, P718; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HASTY P, 1992, MOL CELL BIOL, V12, P1464; IVANSCHENKO T, 1991, GENOMICS, V10, P298; JACKSON ADM, 1989, CYSTIC FIBROSIS, P1; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWACHMAN H, 1965, PEDIATRICS, V36, P689; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SMITH SN, 1992, CLIN SCI, V82, P667, DOI 10.1042/cs0820667; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, P319; WINE JJ, 1992, NAT GENET, V1, P10, DOI 10.1038/ng0492-10	35	253	263	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					211	215		10.1038/359211a0	http://dx.doi.org/10.1038/359211a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1382232	Green Submitted			2022-12-24	WOS:A1992JN94400051
J	MALONE, RE; BULLARD, S; LUNDQUIST, S; KIM, S; TARKOWSKI, T				MALONE, RE; BULLARD, S; LUNDQUIST, S; KIM, S; TARKOWSKI, T			A MEIOTIC GENE CONVERSION GRADIENT OPPOSITE TO THE DIRECTION OF TRANSCRIPTION	NATURE			English	Article							INITIATION SITE; SACCHAROMYCES-CEREVISIAE; ARG4 LOCUS; DECREASING GRADIENTS; YEAST; RECOMBINATION; REPLACEMENT; SEQUENCES; SIDES	GENETIC recombination involves classical crossing-over and gene conversion (aberrant segregation). In fungi that produce an ascus containing four spores, a gene conversion event is manifested as 3:1 or 1:3 (or more rarely 4:0 or 0:4) segregations, in contrast to the normal mendelian 2:2 segregation1,2. Polarity is one of the properties of gene conversion; in almost all cases the frequency of conversion exhibits a gradient across the gene monitored1. The frequency of conversion is usually independent of the specific allele used as a marker, but dependent on its location. An interpretation of conversion polarity is that it is caused by the existence of specific initiation sites for meiotic recombination, located at the high end of the polarity gradient. Here we show that the polarity gradient for the HIS2 gene of Saccharomyces cerevisiae is high at the 3' end of the gene, implying that the promoter of HIS2 is not the initiation site.			MALONE, RE (corresponding author), UNIV IOWA, DEPT BIOL, IOWA CITY, IA 52242 USA.							DICAPRIO L, 1976, GENETICS, V84, P697; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; WHITE MA, 1992, CURR GENET, V21, P109, DOI 10.1007/BF00318468; WHITE MA, 1991, P NATL ACAD SCI USA, V88, P9755, DOI 10.1073/pnas.88.21.9755	11	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 10	1992	359	6391					154	155		10.1038/359154a0	http://dx.doi.org/10.1038/359154a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1355857				2022-12-24	WOS:A1992JM49400055
J	MORL, M; NIEMER, I; SCHMEIZER, C				MORL, M; NIEMER, I; SCHMEIZER, C			NEW REACTIONS CATALYZED BY A GROUP-II INTRON RIBOZYME WITH RNA AND DNA SUBSTRATES	CELL			English	Article							SELF-SPLICING RNA; TETRAHYMENA; INVITRO; ENDONUCLEASE; SELECTION; MATURASE; MOBILITY; ENZYME	Here we describe three novel reactions of the self-splicing group II intron bl1 (the first intron of the COB gene of yeast mitochondria) demonstrating its catalytic versatility: reversal of the first step of the self-splicing reaction catalyzed by a linear form of the intron utilizing the energy of a phosphoanhydride bond for transesterification, ligation of a single-stranded DNA to an RNA, and cleavage of a single-stranded DNA substrate. These results have the following evolutionary implications: use of the alpha-beta-bond of a terminal triphosphate for transesterification suggests that an RNA RNA replicase could use mononucleotide triphosphates as precursors, and cleavage of single-stranded DNA and DNA-RNA ligation suggests that excised group II introns might integrate directly into DNA without prior reverse transcription.			MORL, M (corresponding author), UNIV MUNICH,INST GENET & MIKROBIOL,MARIA WARD STR 1A,W-8000 MUNICH 19,GERMANY.			Morl, Mario/0000-0003-0972-9386				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	18	53	56	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					803	810		10.1016/0092-8674(92)90313-2	http://dx.doi.org/10.1016/0092-8674(92)90313-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381286				2022-12-24	WOS:A1992JL66300011
J	SNOUWAERT, JN; BRIGMAN, KK; LATOUR, AM; MALOUF, NN; BOUCHER, RC; SMITHIES, O; KOLLER, BH				SNOUWAERT, JN; BRIGMAN, KK; LATOUR, AM; MALOUF, NN; BOUCHER, RC; SMITHIES, O; KOLLER, BH			AN ANIMAL-MODEL FOR CYSTIC-FIBROSIS MADE BY GENE TARGETING	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; IDENTIFICATION; PANCREAS; CLONING; CELLS	Cystic fibrosis results from defects in the gene encoding a cyclic adenosine monophosphate-dependent chloride ion channel known as the cystic fibrosis transmembrane conductance regulator (CFTR). To create an animal model for cystic fibrosis, mice were generated from embryonic stem cells in which the CFTR gene was disrupted by gene targeting. Mice homozygous for the disrupted gene display many features common to young human cystic fibrosis patients, including failure to thrive, meconium ileus, alteration of mucous and serous glands, and obstruction of glandlike structures with inspissated eosinophilic material. Death resulting from intestinal obstruction usually occurs before 40 days of age.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL 42384] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DISANTAGNESE PA, 1984, CYSTIC FIBROSIS, P212; DONNISON AB, 1966, PEDIATRICS, V37, P833; Dorin Julia R., 1992, Transgenic Research, V1, P101, DOI 10.1007/BF02513027; Farber S, 1944, ARCH PATHOL, V37, P0238; FOX WW, 1976, PEDIATRICS, V54, P293; GILMAN M, 1989, CURRENT PROTOCOLS MO; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES ME, COMMUNICATION; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MCCARTHY VP, 1984, GASTROENTEROLOGY, V86, P564; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; OPPENHEIMER EH, 1973, ARCH PATHOL, V96, P149; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; STURGESS J, 1982, AM J PATHOL, V106, P303; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TAUSSIG LM, 1984, CYSTIC FIBROSIS, P115; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0	25	781	827	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1083	1088		10.1126/science.257.5073.1083	http://dx.doi.org/10.1126/science.257.5073.1083			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380723				2022-12-24	WOS:A1992JJ88400024
J	STEINER, JP; DAWSON, TM; FOTUHI, M; GLATT, CE; SNOWMAN, AM; COHEN, N; SNYDER, SH				STEINER, JP; DAWSON, TM; FOTUHI, M; GLATT, CE; SNOWMAN, AM; COHEN, N; SNYDER, SH			HIGH BRAIN DENSITIES OF THE IMMUNOPHILIN FKBP COLOCALIZED WITH CALCINEURIN	NATURE			English	Article							CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; T-CELL ACTIVATION; CYCLOPHILIN-CYCLOSPORINE-A; PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; B-50 GAP-43	THE immunophilins cyclophilin and FK506 binding protein (FKBP) are small, predominantly soluble proteins that bind the immunosuppressant drugs cyclosporin A and FK506, respectively, with high affinity, and which seem to mediate their pharmacological actions1,2. The Ca2+-dependent protein phosphatase, calcineurin, binds the cyclophilin-cyclosporin A and FKBP-FK506 complexes, indicating that calcineurin might mediate the actions of these drugs3. A physiological role for the immunophilins in the nervous system is implied by a close homology between the structure of NINA A, a protein in the neural retina of Drosophila, and cyclophilin4,5, as well as by the high density of FKBP messenger RNA in brain tissue6. Here we report that the levels of FKBP and mRNA in rat brain are extraordinarily high and that their regional localization is virtually identical to that of calcineurin, indicating that there may be a physiological link between calcineurin and the immunophilins. We also show that at low concentrations FK506 and cyclosporin A enhance the phosphorylation of endogenous protein substrates in brain tissue and in intact PC12 cells, indicating that these drugs may inhibit phosphatase activity by interacting with the immunophilin-calcineurin complexes.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BLOOD BANK,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Cohen, Noam/0000-0002-9462-3932; Fotuhi, Majid/0000-0002-0980-1176				ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4618; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BIERER BE, 1991, EUR J IMMUNOL, V21, P439, DOI 10.1002/eji.1830210228; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KIMBALL PM, 1988, CELL IMMUNOL, V113, P107, DOI 10.1016/0008-8749(88)90010-X; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LAD RP, 1991, MOL BRAIN RES, V9, P239, DOI 10.1016/0169-328X(91)90007-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TRENN G, 1989, J IMMUNOL, V142, P3796; TRIGGIANI M, 1989, INT ARCH ALLER A IMM, V88, P253, DOI 10.1159/000234801	31	324	376	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					584	587		10.1038/358584a0	http://dx.doi.org/10.1038/358584a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1380130				2022-12-24	WOS:A1992JH82900060
J	VELAZQUEZ, L; FELLOUS, M; STARK, GR; PELLEGRINI, S				VELAZQUEZ, L; FELLOUS, M; STARK, GR; PELLEGRINI, S			A PROTEIN TYROSINE KINASE IN THE INTERFERON-ALPHA/BETA SIGNALING PATHWAY	CELL			English	Article							INDUCED NUCLEAR FACTORS; DOUBLE-STRANDED-RNA; TRANSCRIPTIONAL ACTIVATION; STIMULATED TRANSCRIPTION; PROMOTER ELEMENT; RESPONSE ELEMENT; SYNTHETASE GENE; DNA; BINDING; GAMMA	The mutant human cell line 11,1 is unresponsive to interferon-alpha. Here we describe the genetic complementation of this mutant and the identification and cloning of the wild-type gene that corrects the defect. Using transfection with genomic DNA in conjunction with a powerful back-selection, we isolated a cosmid that reverts the mutant phenotype of 11,1 cells. The cosmid encodes a single message whose level is greatly reduced in mutant cells. Complementary DNAs were cloned and found to be virtually identical to tyk2, a human mRNA encoding a non-receptor protein tyrosine kinase of previously unknown function. This finding shows that tyk2 links the interferon alpha/beta-receptor to the cytoplasmic transcription factor that mediates activation of interferon-responsive genes.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	VELAZQUEZ, L (corresponding author), INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE.		Pellegrini, Sandra/Y-6351-2019; Pellegrini, Sandra -/G-5546-2015	Pellegrini, Sandra/0000-0001-5837-7589; Pellegrini, Sandra -/0000-0001-5837-7589				ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNARDS A, 1991, ONCOGENE, V6, P1185; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DELUCA JG, 1977, MUTAT RES, V46, P11, DOI 10.1016/0165-1161(77)90106-6; Demaeyer E., 1988, INTERFERONS OTHER RE; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LITT M, 1985, P NATL ACAD SCI USA, V82, P6206, DOI 10.1073/pnas.82.18.6206; Maniatis T., 1982, MOL CLONING; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MOGENSEN KE, 1989, EXPERIENTIA, V45, P500, DOI 10.1007/BF01990498; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PERUCHO M, 1980, NATURE, V285, P207, DOI 10.1038/285207a0; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Ruddle F. H., 1984, GENETIC ENG, V6, P319; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Wahl G. M., 1987, METHOD ENZYMOL, V152, P199; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	59	774	814	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					313	322		10.1016/0092-8674(92)90105-L	http://dx.doi.org/10.1016/0092-8674(92)90105-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1386289				2022-12-24	WOS:A1992JE75700014
J	GETZOFF, ED; CABELLI, DE; FISHER, CL; PARGE, HE; VIEZZOLI, MS; BANCI, L; HALLEWELL, RA				GETZOFF, ED; CABELLI, DE; FISHER, CL; PARGE, HE; VIEZZOLI, MS; BANCI, L; HALLEWELL, RA			FASTER SUPEROXIDE-DISMUTASE MUTANTS DESIGNED BY ENHANCING ELECTROSTATIC GUIDANCE	NATURE			English	Article							PULSE RADIOLYSIS; COPPER; ENZYME; SIMULATION; MECHANISM; DIFFUSION; SUBSTRATE; SEQUENCE; PROTEIN; SITE	THE enzyme Cu, Zn superoxide dismutase (SOD) protects against oxidative damage by dismuting the superoxide radical O2.- to molecular oxygen and hydrogen peroxide1-3 at the active-site Cu ion4,5 in a reaction that is rate-limited by diffusion3,6 and enhanced by electrostatic guidance7-10. SOD has evolved to be one of the fastest enzymes known (V(max) approximately 2 x 10(9) M-1 s-1)6,11. The new crystal structures of human SOD12 show that amino-acid site chains that are implicated in electrostatic guidance8 (Glu 132, Glu 133 and Lys 136) form a hydrogen-bonding network. Here we show that site-specific mutants that increase local positive charge while maintaining this orienting network (Glu --> Gln) have faster reaction rates and increased ionic-strength dependence, matching brownian dynamics simulations incorporating electrostatic terms. Increased positive charge alone is insufficient: one charge reversal (Glu --> Lys) mutant is slower than the equivalent charge neutralization (Glu --> Gln) mutant, showing that the newly introduced positive charge disrupts the orienting network. Thus, electrostatically facilitated diffusion rates can be increased by design, provided the detailed structural integrity of the active-site electrostatic network is maintained.	BROOKHAVEN NATL LAB, DEPT CHEM, LONG ISL, NY 11973 USA; UNIV FLORENCE, DEPT CHEM, I-50121 FLORENCE, ITALY; CHIRON CORP, EMERYVILLE, CA 94608 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; University of Florence; Novartis	GETZOFF, ED (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.			BANCI, LUCIA/0000-0003-0562-5774				ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; ALLISON SA, 1988, BIOPOLYMERS, V27, P251, DOI 10.1002/bip.360270207; ARGESE E, 1987, BIOCHEMISTRY-US, V26, P3224, DOI 10.1021/bi00385a043; BANCI L, 1990, INORG CHEM, V29, P2398, DOI 10.1021/ic00338a004; BEYER WF, 1987, J BIOL CHEM, V262, P11182; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CUDD A, 1982, J BIOL CHEM, V257, P1443; DAVIS ME, 1991, J COMPUT CHEM, V12, P909, DOI 10.1002/jcc.540120718; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; KLUG D, 1972, J BIOL CHEM, V247, P4839; Koppenol W.H., 1981, OXYGEN OXYRADICALS C, P671; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; PARGE HE, IN PRESS P NATN ACAD; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SCHWARZ HA, 1981, J CHEM EDUC, V58, P101, DOI 10.1021/ed058p101; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; SHEN J, 1991, CHEM PHYS, V158, P191, DOI 10.1016/0301-0104(91)87066-5; SINES JJ, 1990, BIOCHEMISTRY-US, V29, P9403, DOI 10.1021/bi00492a014; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TAINER JA, 1991, STUDY ENZYMES, V2, P499; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	32	363	367	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					347	351		10.1038/358347a0	http://dx.doi.org/10.1038/358347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1353610				2022-12-24	WOS:A1992JE68400069
J	DAMICO, G; GENTILE, MG; MANNA, G; FELLIN, G; CICERI, R; COFANO, F; PETRINI, C; LAVARDA, F; PEROLINI, S; PORRINI, M				DAMICO, G; GENTILE, MG; MANNA, G; FELLIN, G; CICERI, R; COFANO, F; PETRINI, C; LAVARDA, F; PEROLINI, S; PORRINI, M			EFFECT OF VEGETARIAN SOY DIET ON HYPERLIPEMIA IN NEPHROTIC SYNDROME	LANCET			English	Article							RENAL-DISEASE; HORMONAL RESPONSES; PROTEIN INTAKE; CHOLESTEROL; PLASMA; LIPOPROTEINS; PRESSURE; LIPIDS	Nephrotic patients with persistent proteinuria also have various lipid abnormalities that may promote atherosclerosis and more rapid progression of renal disease. We aimed to find out whether dietary manipulation can correct the hyperlipidaemia found in these patients. After a baseline control period of 8 weeks on their usual diets, 20 untreated patients with chronic glomerular diseases, stable long-lasting severe proteinuria (5.9 [SD 3.4] g/24 h) and hyperlipidaemia (mean serum cholesterol 8.69 [3.34] mmol/l) ate a vegetarian soy diet for 8 weeks. The diet was low in fat (28% of total calories) and protein (0.71 [0.36] g/kg ideal body weight daily), cholesterol free, and rich in monounsaturated and polyunsaturated fatty acids (polyunsaturated/saturated ratio 2.5) and in fibre (40 g/day). After the diet period the patients resumed their usual diets for 8 weeks (washout period). During the soy-diet period there were significant falls in serum cholesterol (total, low-density lipoprotein, and high-density lipoprotein) and apolipoproteins A and B, but serum triglyceride concentrations did not change. Urinary protein excretion fell significantly. The concentrations of all lipid fractions and the amount of proteinuria tended to return towards baseline values during the washout period. We do not know whether the favourable effect of this dietary manipulation on proteinuria was due to the qualitative or quantitative modifications of dietary protein intake or was a direct consequence of the manipulation of dietary lipid intake.	SAN CARLO HOSP,CLIN PATHOL LAB,I-20153 MILAN,ITALY; UNIV MILAN,DEPT FOOD SCI & MICROBIOL,I-20122 MILAN,ITALY	San Carlo Borromeo Hospital; University of Milan	DAMICO, G (corresponding author), SAN CARLO HOSP,DIV NEPHROL,VIA PIO II3,I-20153 MILAN,ITALY.		porrini, marisa/AAF-6788-2021	porrini, marisa/0000-0003-2693-3311				APPEL GB, 1985, NEW ENGL J MED, V312, P1544, DOI 10.1056/NEJM198506133122404; BARCELLI UO, 1991, KIDNEY INT, V39, pS57; BRUSSAARD JH, 1982, ATHEROSCLEROSIS, V42, P205, DOI 10.1016/0021-9150(82)90151-4; CONNOR WE, 1990, NEW ENGL J MED, V322, P193, DOI 10.1056/NEJM199001183220309; DAMICO G, 1991, CLIN NEPHROL, V6, P237; DIAMOND JR, 1988, KIDNEY INT, V33, P917, DOI 10.1038/ki.1988.87; FEEHALLY J, 1988, NEPHRON, V50, P247, DOI 10.1159/000185167; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; KASISKE BL, 1990, AM J KIDNEY DIS, V15, P8, DOI 10.1016/S0272-6386(12)80586-5; KAYSEN GA, 1989, J CLIN INVEST, V83, P1623, DOI 10.1172/JCI114060; KAYSEN GA, 1986, KIDNEY INT, V29, P572, DOI 10.1038/ki.1986.36; KAYSEN GA, 1991, AM J PHYSIOL, V260, pF177, DOI 10.1152/ajprenal.1991.260.2.F177; KEANE WF, 1990, NEW ENGL J MED, V323, P603, DOI 10.1056/NEJM199008303230910; KEANE WF, 1991, KIDNEY INT, V39, pS41; KESTIN M, 1990, AM J CLIN NUTR, V51, P1028, DOI 10.1093/ajcn/51.6.1028; KLAHR S, 1983, KIDNEY INT, V24, P579, DOI 10.1038/ki.1983.197; KONTESSIS P, 1990, KIDNEY INT, V38, P136, DOI 10.1038/ki.1990.178; LEVEY AS, 1989, KIDNEY INT, V36, pS73; MALLICK NP, 1981, NEPHRON, V27, P54, DOI 10.1159/000182024; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MEINERTZ H, 1989, AM J CLIN NUTR, V50, P786, DOI 10.1093/ajcn/50.4.786; MOORHEAD JF, 1989, AM J MED, V87, P12; NESTEL P, 1983, ARTERIOSCLEROSIS, V3, P132, DOI 10.1161/01.ATV.3.2.132; REMUZZI A, 1991, AM J KIDNEY DIS, V17, P317, DOI 10.1016/S0272-6386(12)80481-1; ROSENBERG ME, 1987, AM J PHYSIOL, V253, pF1083, DOI 10.1152/ajprenal.1987.253.6.F1083; SACKS FM, 1975, NEW ENGL J MED, V292, P1148, DOI 10.1056/NEJM197505292922203; SCHMITZ PG, 1989, SEMIN NEPHROL, V9, P354; SCHREINER GF, 1991, KIDNEY INT, V39, pS49; SHAEFER EJ, 1981, AM J CLIN NUTR, V34, P1758	29	92	93	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1131	1134		10.1016/0140-6736(92)90731-H	http://dx.doi.org/10.1016/0140-6736(92)90731-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349366				2022-12-24	WOS:A1992HT23600003
J	LLINAS, R; SUGIMORI, M; SILVER, RB				LLINAS, R; SUGIMORI, M; SILVER, RB			MICRODOMAINS OF HIGH CALCIUM-CONCENTRATION IN A PRESYNAPTIC TERMINAL	SCIENCE			English	Article							SQUID GIANT SYNAPSE; CENTRAL INHIBITORY SYNAPSE; TRANSMITTER RELEASE; CHANNELS; TRANSMISSION; AEQUORINS; INFLUX	Increases in intracellular calcium concentration are required for the release of neurotransmitter from presynaptic terminals in all neurons. However, the mechanism by which calcium exerts its effect is not known. A low-sensitivity calcium-dependent photoprotein (n-aequorin-J) was injected into the presynaptic terminal of the giant squid synapse to selectively detect high calcium concentration microdomains. During transmitter release, light emission occurred at specific points or quantum emission domains that remained in the same place during protracted stimulation. Intracellular calcium concentration microdomains on the order of 200 to 300 micromolar occur against the cytoplasmic surface of the plasmalemma during transmitter secretion, supporting the view that the synaptic vesicular fusion responsible for transmitter release is triggered by the activation of a low-affinity calcium-binding site at the active zone.	MARINE BIOL LAB,WOODS HOLE,MA 02543; CORNELL UNIV,DEPT PHYSIOL,ITHACA,NY 14853; CORNELL UNIV,PHYSIOL SECT,ITHACA,NY 14853	Marine Biological Laboratory - Woods Hole; Cornell University; Cornell University	LLINAS, R (corresponding author), NYU MED CTR,DEPT PHYSIOL & BIOPHYS,550 1ST AVE,NEW YORK,NY 10016, USA.			Sugimori, Mutsuyuki/0000-0002-2908-3167	NINDS NIH HHS [NS13742] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS013742] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; KATZ B, 1969, SHERRINGTON LECTURES, V10; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, BIOL BULL, V181, P316, DOI 10.1086/BBLv181n2p316; LLINAS R, 1972, SCIENCE, V176, P1127, DOI 10.1126/science.176.4039.1127; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; LLINAS R, 1977, SOC NEUROSCIENCE S, V2, P139; PUMPLIN DW, 1978, NEUROSCIENCE, V3, P685, DOI 10.1016/0306-4522(78)90065-9; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; SHIMOMURA O, 1990, BIOCHEM J, V270, P309, DOI 10.1042/bj2700309; SILVER RB, 1989, DEV BIOL, V131, P11; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SIMON SM, 1984, BIOPHYS J, V45, pA264; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708; YOUNG GPH, 1984, P NATL ACAD SCI-BIOL, V81, P5155, DOI 10.1073/pnas.81.16.5155; YOUNG JZ, 1973, BRAIN RES, V57, P457, DOI 10.1016/0006-8993(73)90149-2; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	20	749	759	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					677	679		10.1126/science.1350109	http://dx.doi.org/10.1126/science.1350109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1350109				2022-12-24	WOS:A1992HR18500037
J	KOSLOWSKY, DJ; GORINGER, HU; MORALES, TH; STUART, K				KOSLOWSKY, DJ; GORINGER, HU; MORALES, TH; STUART, K			INVITRO GUIDE RNA MESSENGER-RNA CHIMERA FORMATION IN TRYPANOSOMA-BRUCEI RNA EDITING	NATURE			English	Article							LIGASE; DNA	THE post-transcriptional processing of various mitochondrial transcripts in kinetoplastids, kRNA editing, adds and removes uridines, producing mature messenger RNAs 1,2. This editing seems to be directed by 'guide' RNAs (gRNAs) which are complementary to portions of the mature message 3. The editing mechanism has been proposed to entail transesterification 4,5. Detection of chimaeric gRNA-mRNA molecules, intermediates predicted by transesterification, support this model 4. We report here the in vitro formation of such chimaeras where endogenous gRNAs are covalently linked to added synthetic mRNA. Addition of gel-purified gRNAs to the standard reaction mix increases chimaera formation. This increase is not observed when the gRNA 3'-hydroxyl group is chemically modified, identifying this terminal hydroxyl as the reactive group. These results provide the first experimental evidence for an in vitro RNA editing event and support the involvement of transesterification as a chemical mechanism.			KOSLOWSKY, DJ (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.							BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; GORINGER HU, 1984, J BIOL CHEM, V259, P491; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; READ LK, IN PRESS NUCLEIC ACI; STUART K, 1983, J CELL BIOCHEM, V23, P13, DOI 10.1002/jcb.240230103; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; Stuart K, 1991, CURR OPIN GENET DEV, V1, P412, DOI 10.1016/S0959-437X(05)80308-9	13	55	55	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					807	809		10.1038/356807a0	http://dx.doi.org/10.1038/356807a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1374163				2022-12-24	WOS:A1992HR18600055
J	WATANABEFUKUNAGA, R; BRANNAN, CI; COPELAND, NG; JENKINS, NA; NAGATA, S				WATANABEFUKUNAGA, R; BRANNAN, CI; COPELAND, NG; JENKINS, NA; NAGATA, S			LYMPHOPROLIFERATION DISORDER IN MICE EXPLAINED BY DEFECTS IN FAS ANTIGEN THAT MEDIATES APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; LPR LPR MICE; GENE; RECEPTOR; GLD; LYMPHADENOPATHY; TOLERANCE; INDUCTION; LYMPHOCYTES; ENVIRONMENT	Fas antigen is a cell-surface protein that mediates apoptosis. It is expressed in various tissues including the thymus and has structural homology with a number of cell-surface receptors, including tumour necrosis factor receptor and nerve growth factor receptor. Mice carrying the lymphoproliferation (lpr) mutation have defects in the Fas antigen gene. The lpr mice develop lymphadenopathy and suffer from a systemic lupus erythematosus-like autoimmune disease, indicating an important role for Fas antigen in the negative selection of autoreactive T cells in the thymus.	OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN PL, 1991, REV IMMUNOL, V9, P243; FRIZZERA G, 1989, LEUKEMIA, V3, P1; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZUI S, 1984, J IMMUNOL, V133, P227; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; KATAGIRI T, 1988, J EXP MED, V167, P741, DOI 10.1084/jem.167.3.741; KIMURA M, 1991, EUR J IMMUNOL, V21, P63, DOI 10.1002/eji.1830210111; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MATSUMOTO K, 1991, J EXP MED, V173, P127, DOI 10.1084/jem.173.1.127; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUNTZ JD, 1990, J EXP MED, V172, P1805, DOI 10.1084/jem.172.6.1805; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; OHTEKI T, 1990, J EXP MED, V172, P7, DOI 10.1084/jem.172.1.7; PERKINS DL, 1990, J IMMUNOL, V145, P549; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; THEOFILOPOULOS AN, 1985, J EXP MED, V162, P1, DOI 10.1084/jem.162.1.1; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANEWIJK WA, 1991, REV IMMUNOL, V9, P591; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WATANABE T, 1991, BIOCHEM GENET, V29, P325, DOI 10.1007/BF00554140; WATANABEFUKUNAG.R, IN PRESS J IMMUN; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHOU T, 1991, J IMMUNOL, V147, P466	34	2577	2674	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					314	317		10.1038/356314a0	http://dx.doi.org/10.1038/356314a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1372394				2022-12-24	WOS:A1992HK79400054
J	SWAIN, A; COFFIN, JM				SWAIN, A; COFFIN, JM			MECHANISM OF TRANSDUCTION BY RETROVIRUSES	SCIENCE			English	Article							SINGLE REPLICATION CYCLE; ROUS-SARCOMA VIRUS; MUTATIONAL HOTSPOTS; BROAD-SPECTRUM; SHUTTLE VECTOR; ONCOGENE; RNA; POLYADENYLATION; HYPERMUTATIONS; SEQUENCE	Retroviruses can capture cellular sequences and express them as oncogenes. Capture has been proposed to be a consequence of the inefficiency of polyadenylation of the viral genome that allows the packaging of cellular sequences flanking the integrated provirus in virions; after transfer into virions, these sequences could be incorporated into the viral genome by illegitimate recombination during reverse transcription. As a test for this hypothesis, a tissue culture system was developed that mimics the transduction process and allows the analysis and quantitation of capture events in a single step. In this model transduction of sequences adjacent to a provirus depends on the formation of readthrough transcripts and their transmission in virions and leads to various recombinant structures whose formation is independent of sequence similarity at the crossover site. Thus, all events in the transduction process can be attributed to the action of reverse transcriptase on readthrough transcripts without involving deletions of cellular DNA.	TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,136 HARRISON AVE,BOSTON,MA 02111	Tufts University					NCI NIH HHS [R35 CA 44385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; DOGGETT DL, 1989, J VIROL, V63, P2108, DOI 10.1128/JVI.63.5.2108-2117.1989; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GOLDFARB MP, 1981, J VIROL, V38, P136, DOI 10.1128/JVI.38.1.136-150.1981; HERMAN SA, 1986, J VIROL, V60, P497, DOI 10.1128/JVI.60.2.497-505.1986; HERMAN SA, 1987, SCIENCE, V236, P845, DOI 10.1126/science.3033828; HUANG CC, 1986, CELL, V44, P935, DOI 10.1016/0092-8674(86)90016-4; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Maniatis T., 1982, MOL CLONING; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; RAINES MA, 1988, J VIROL, V62, P2437, DOI 10.1128/JVI.62.7.2437-2443.1988; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SWAIN A, 1989, J VIROL, V63, P3301, DOI 10.1128/JVI.63.8.3301-3306.1989; SWANSTROM R, 1983, P NATL ACAD SCI-BIOL, V80, P2519, DOI 10.1073/pnas.80.9.2519; Weiss R, 1985, RNA TUMOR VIRUSES	22	118	120	3	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					841	845		10.1126/science.1371365	http://dx.doi.org/10.1126/science.1371365			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1371365				2022-12-24	WOS:A1992HD54800035
J	JEGALIAN, BG; DEROBERTIS, EM				JEGALIAN, BG; DEROBERTIS, EM			HOMEOTIC TRANSFORMATIONS IN THE MOUSE INDUCED BY OVEREXPRESSION OF A HUMAN HOX3.3 TRANSGENE	CELL			English	Article							HUMAN HOMEOBOX GENES; SPINAL-CORD; DROSOPHILA; EXPRESSION; ANTENNAPEDIA; MURINE; ORGANIZATION; PROTEIN; SEQUENCE; HOX-1.1	A permanent transgenic mouse line was generated carrying 40 copies of the human Hox3.3 gene. The resulting mice express large amounts of Hox3.3 protein in posterior regions of the embryo where this homeodomain protein is normally not expressed. The transgene causes homeotic transformations of the skeleton, in particular the appearance of an extra pair of ribs in the lumbar region, transformation of the shape of posterior ribs into that of more anterior ones, and the joining of an additional pair of ribs to the sternum. The phenotype of this line resembles that obtained by the targeted loss-of-function mutation of Hox3.1 (Le Mouellic et al., 1992). In transient assays, the human Hox3.3 transgene leads to the formation of additional ribs in more posterior vertebrae as well.			JEGALIAN, BG (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.			De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD 21502-07] Funding Source: Medline; NIGMS NIH HHS [GM 08042-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acampora D, 1991, Oxf Surv Eukaryot Genes, V7, P1; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; COLETTA PL, 1991, MECH DEVELOP, V35, P129, DOI 10.1016/0925-4773(91)90063-C; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ESTIBEIRO JP, 1990, POSTIMPLANTATION MAM, P173; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GILMAN M, 1989, CURRENT PROTOCOLS MO, P471; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Green EL, 1941, GENETICS, V26, P192; GREEN MC, 1989, GENETIC VARIANTS STR; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HOGAN BLM, 1988, MANIPULATING MOUSE E; JEGALIAN BJ, 1992, IN PRESS MECH DEV; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KESSEL M, 1992, DEVELOPMENT, V115, P4487; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; OJEDA JL, 1970, STAIN TECHNOL, V45, P137; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4	46	159	163	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					901	910		10.1016/0092-8674(92)90387-R	http://dx.doi.org/10.1016/0092-8674(92)90387-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1360874				2022-12-24	WOS:A1992KB99000004
J	THOMAS, JE; GIBSON, GR; DARBOE, MK; DALE, A; WEAVER, LT				THOMAS, JE; GIBSON, GR; DARBOE, MK; DALE, A; WEAVER, LT			ISOLATION OF HELICOBACTER-PYLORI FROM HUMAN FECES	LANCET			English	Note							INFECTION; CHILDHOOD	Helicobacter pylori is arguably the commonest chronic infection in man. However, its route of transmission is unknown. We have isolated viable H pylori from the faeces of an infected individual from The Gambia. The organism was cultured on selective media after concentration of faecal bacteria by centrifugation in a buffer equilibrated with a microaerophilic gas mixture. Growth characteristics, microscopic appearances, and enzyme activities were the same as those of a typical gastric isolate of H pylori. Protein preparations derived from the new isolate and the typical strain were antigenically similar, and had very similar electrophoretic profiles (including two major protein bands of 62 and 26 kDa, corresponding to the urease enzyme subunits). With the same technique, organisms with the colony morphology, growth requirements, enzyme activities, and microscopic appearances of H pylori were isolated from the faeces of 9 of 23 randomly selected childen aged 3-27 months from a Gambian village with a high prevalence of H pylori infection in early life. Faecal-oral transmission is probably important in the spread of infection in such communities.	MRC,DUNN NUTR CTR,BANJUL,SENEGAMBIA		THOMAS, JE (corresponding author), MRC,DUNN NUTR CTR,MILTON RD,CAMBRIDGE CB4 1XJ,ENGLAND.		Gibson, Glenn R/A-9595-2009					COSTAS M, 1991, SCAND J GASTROENTERO, V26, P20, DOI 10.3109/00365529109093204; HOLCOMBE C, 1992, AM J GASTROENTEROL, V87, P28; KLEIN PD, 1991, LANCET, V337, P1503, DOI 10.1016/0140-6736(91)93196-G; KLEIN PD, 1989, CAMPYLOBACTER PYLORI, P83; MAPSTONE NP, 1992, IRISH J MED SCI S10, V161, P29; MARSHALL B J, 1984, Microbios Letters, V25, P83; MILLER L, 1988, J BIOL CHEM, V263, P5668; SHAMES B, 1989, J CLIN MICROBIOL, V27, P2849, DOI 10.1128/JCM.27.12.2849-2850.1989; THOMAS JE, 1990, J CLIN MICROBIOL, V28, P2641, DOI 10.1128/JCM.28.12.2641-2646.1990; THOMAS JE, 1991, GUT, V32, pA1231	10	421	441	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1194	1195		10.1016/0140-6736(92)92894-L	http://dx.doi.org/10.1016/0140-6736(92)92894-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359263				2022-12-24	WOS:A1992JY38600006
J	MATSUMURA, Y; TARIN, D				MATSUMURA, Y; TARIN, D			SIGNIFICANCE OF CD44 GENE-PRODUCTS FOR CANCER-DIAGNOSIS AND DISEASE EVALUATION	LANCET			English	Article							CELLS	With increasing emphasis on the early detection of cancer, the search is on for reliable markers that will be clinically helpful in the diagnosis of small tumours and in the assessment of their metastatic potential. This report presents evidence that an abnormal pattern of activity of the CD44 gene is a promising candidate for both of these purposes in various types of malignancy. By a mechanism known as alternative splicing this gene can produce different messenger RNA molecules (transcripts) which are detectable, after amplification, as separate bands in electrophoretic gels. In neoplasia many abnormal variant transcripts are produced. A previous finding in animal experiments, that one such variant might be important in metastasis, prompted our study of human tumour tissue, benign and malignant, and of corresponding normal tissues. We studied tumour tissue from 34 patients with neoplastic disease (mostly breast or colon cancer) and normal or non-malignant diseased breast or colonic tissue from 11 patients and peripheral blood leucocytes from 4 healthy volunteers. CD44 gene activity was studied by amplifying messenger RNA with the polymerase chain reaction (PCR) followed by electrophoresis and blot hybridisation. In malignant tissues there was gross overproduction of each of 9 or more alternatively-spliced large molecular variants in all samples, whereas in the control samples only the standard product was routinely detected with occasional minimal quantities of one or two small variants. Furthermore, the band pattern permitted differentiation between the 23 cases with metastatic tumours of the breast or colon and the 8 with no detectable metastases. Calibration studies seeding blood with tumour cells showed that the technique can detect as few as 10 tumour cells among 10(7) leucocytes (1 ml of blood). Analysis of CD44 splice variants may prove to have applications not just to the early detection of metastatic potential in surgical biopsy specimens but also, if our findings are confirmed, in readily available bodily fluids, to the early diagnosis of cancer in screening programmes, to the assessment of remaining disease in the body and to the early detection of recurrences.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND	University of Oxford			Matsumura, Yasuhiro/N-4472-2016					BIRCH M, 1991, CANCER RES, V51, P6660; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROST P, 1992, LANCET, V339, P1458, DOI 10.1016/0140-6736(92)92040-M; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HOFMANN M, 1991, CANCER RES, V51, P5292; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859	11	452	480	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1053	1058		10.1016/0140-6736(92)93077-Z	http://dx.doi.org/10.1016/0140-6736(92)93077-Z			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357452				2022-12-24	WOS:A1992JV77500002
J	FARQUHARSON, J; COCKBURN, F; PATRICK, WA; JAMIESON, EC; LOGAN, RW				FARQUHARSON, J; COCKBURN, F; PATRICK, WA; JAMIESON, EC; LOGAN, RW			INFANT CEREBRAL-CORTEX PHOSPHOLIPID FATTY-ACID COMPOSITION AND DIET	LANCET			English	Article							MEMBRANE PHOSPHOLIPIDS; HUMAN-BRAIN; LINOLENATE; RATS	It has not been established whether nutrition in early infancy affects subsequent neurodevelopment and function. If there is an effect, it seems probable that the essential fatty acids and their metabolites, the major constituents of brain structure, will be the most susceptible to dietary influence. We determined the phospholipid fatty-acid composition of cerebral cortex grey matter obtained from 20 term and 2 preterm infants who had died of "cot deaths" and related results to the milk diet the infants had received. Tissues were analysed by gas chromotography. The mean weight percentage of docosahexaenoic acid was significantly greater (p < 0.02) in 5 breast-milk-fed infants (9.7%) than in 5 age-comparable formula-milk-fed infants (7.6%). In these formula-fed babies, the overall percentage of long-chain polyunsaturated fatty acids was maintained by increased incorporation of the major n-6 series fatty acids. In 1 formula-fed preterm infant, in whom the lowest concentration of cortical docosahexaenoic acid was found, the compensatory effect was only partial with both n-9 series eicosatrienoic acid or Mead acid and docosatrienoic acid also detected in the phospholipid. Supplementation of formula milks for term infants with docosahexaenoic acid and those for preterm infants with both docosahexaenoic and arachidonic acid could prove beneficial to subsequent neurodevelopment.	UNIV GLASGOW,DEPT CHILD HLTH,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND; ROYAL HOSP SICK CHILDREN,DEPT PATHOL,GLASGOW G3 8SJ,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow								ANDERSON GJ, 1990, PEDIATR RES, V27, P89, DOI 10.1203/00006450-199001000-00023; ANDING RH, 1986, LIPIDS, V21, P697, DOI 10.1007/BF02537243; CARLSON SE, 1986, J NUTR, V116, P718, DOI 10.1093/jn/116.5.718; CLANDININ M T, 1981, Progress in Lipid Research, V20, P901, DOI 10.1016/0163-7827(81)90168-5; CLANDININ MT, 1980, EARLY HUM DEV, V4, P121, DOI 10.1016/0378-3782(80)90015-8; Crawford M A, 1977, Adv Exp Med Biol, V83, P135; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARANT I, 1990, JPEN-PARENTER ENTER, V14, P42, DOI 10.1177/014860719001400142; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MARTINEZ M, 1974, PEDIATR RES, V8, P93, DOI 10.1203/00006450-197402000-00005; OBRIEN JS, 1965, J LIPID RES, V6, P545; SVENNERHOLM L, 1973, BRAIN RES, V50, P341, DOI 10.1016/0006-8993(73)90735-X; YAMAMOTO N, 1987, J LIPID RES, V28, P144; 1991, ACTA PAEDIATR SCAND, V80, P887; 1977, DHSS12 REP	15	453	478	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					810	813		10.1016/0140-6736(92)92684-8	http://dx.doi.org/10.1016/0140-6736(92)92684-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357244				2022-12-24	WOS:A1992JR16800003
J	MANDEL, MA; BOWMAN, JL; KEMPIN, SA; MA, H; MEYEROWITZ, EM; YANOFSKY, MF				MANDEL, MA; BOWMAN, JL; KEMPIN, SA; MA, H; MEYEROWITZ, EM; YANOFSKY, MF			MANIPULATION OF FLOWER STRUCTURE IN TRANSGENIC TOBACCO	CELL			English	Article							MOSAIC VIRUS-35S PROMOTER; ARABIDOPSIS-THALIANA; FLORAL DEVELOPMENT; ANTIRRHINUM-MAJUS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; GENETIC INTERACTIONS; HOMEOTIC GENES; MORPHOGENESIS; EXPRESSION	Genetic studies suggest that three homeotic functions, designated A, B, and C, act alone and together to specify the fate of floral organ primordia in distantly related dicotyledonous plant species. To test the genetic model, we have generated transgenic tobacco plants that ectopically express the AGAMOUS gene from Brassica napus, which is necessary for the C function. Flowers on the resulting plants showed homeotic transformations of sepals into carpels and petals into stamens. These phenotypes are consistent with predictions from the genetic model, show that expression of AGAMOUS is sufficient to provide ectopic C function, and demonstrate that the structure of flowers can be manipulated in a predictable manner by altering the expression of a single regulatory gene. Furthermore, the generation of the predicted transformations by ectopic expression of the Brassica gene in transgenic tobacco indicates that gene functions are interchangable between phylogenetically distant species.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; CALTECH,DIV BIOL,PASADENA,CA 91125	University of California System; University of California San Diego; California Institute of Technology	MANDEL, MA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Ma, Hong/W-5251-2018; Meyerowitz, Elliot M/A-7118-2009	Ma, Hong/0000-0001-8717-4422; Bowman, John/0000-0001-7347-3691	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45697, 5T32-GM07616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; DUBOIS E, 1987, GENE, V55, P265, DOI 10.1016/0378-1119(87)90286-1; EVANS PT, 1989, DEV BIOL, V136, P273, DOI 10.1016/0012-1606(89)90148-6; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HICKS GS, 1970, CAN J BOTANY, V48, P133, DOI 10.1139/b70-017; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KOLTUNOW AM, 1990, PLANT CELL, V2, P1201, DOI 10.1105/tpc.2.12.1201; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1987, ANNU REV GENET, V21, P93, DOI 10.1146/annurev.genet.21.1.93; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Pruitt RE, 1987, GENETIC REGULATION D, P327; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	36	194	216	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					133	143		10.1016/0092-8674(92)90272-E	http://dx.doi.org/10.1016/0092-8674(92)90272-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1356631				2022-12-24	WOS:A1992JQ62300013
J	HAASS, C; SCHLOSSMACHER, MG; HUNG, AY; VIGOPELFREY, C; MELLON, A; OSTASZEWSKI, BL; LIEBERBURG, I; KOO, EH; SCHENK, D; TEPLOW, DB; SELKOE, DJ				HAASS, C; SCHLOSSMACHER, MG; HUNG, AY; VIGOPELFREY, C; MELLON, A; OSTASZEWSKI, BL; LIEBERBURG, I; KOO, EH; SCHENK, D; TEPLOW, DB; SELKOE, DJ			AMYLOID BETA-PEPTIDE IS PRODUCED BY CULTURED-CELLS DURING NORMAL METABOLISM	NATURE			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IDENTIFICATION; LOCALIZATION; TISSUES; BRAIN	ALZHEIMER's disease is characterized by the extracellular deposition in the brain and its blood vessels of insoluble aggregates of the amyloid beta-peptide (A-beta), a fragment, of about 40 amino acids in length, of the integral membrane protein beta-amyloid precursor protein (beta-APP)1. The mechanism of extracellular accumulation of A-beta in brain is unknown and no simple in vitro or in vivo model systems that produce extracellular A-beta have been described. We report here the unexpected identification of the 4K (M(r) 4,000) A-beta and a truncated form of A-beta (approximately 3K) in media from cultures of primary cells and untransfected and beta-APP-transfected cell lines grown under normal conditions. These peptides were immunoprecipitated readily from culture medium by A-beta-specific antibodies and their identities confirmed by sequencing. The concept that pathological processes are responsible for the production of A-beta must now be reassessed in light of the observation that A-beta is produced in soluble form in vitro and in vivo2 during normal cellular metabolism. Further, these findings provide the basis for using simple cell culture systems to identify drugs that block the formation or release of A-beta, the primary protein constituent of the senile plaques of Alzheimer's disease.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02155; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DEPT MED NEUROL,BOSTON,MA 02155; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94090	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HAASS, C (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02155, USA.			Schlossmacher, Michael/0000-0002-0394-0300				ANDERSON JP, IN PRESS J NEUROCHEM; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GABUZDA D H, 1992, Neurology, V42, P304; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENBERG SM, 1988, BLOOD, V72, P1968; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; MORI H, 1992, J BIOL CHEM, V267, P17082; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; SELKOE DJ, 1989, NEUROBIOL AGING, V10, P387, DOI 10.1016/0197-4580(89)90072-9; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	20	1739	1830	0	130	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					322	325		10.1038/359322a0	http://dx.doi.org/10.1038/359322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383826				2022-12-24	WOS:A1992JP50300057
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND GROUP-C DISTRIBUTION FOR ADVANCED METASTATIC OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-24	WOS:A1992JM84900003
J	SCHNEIDER, A; MONTAGUE, P; GRIFFITHS, I; FANARRAGA, M; KENNEDY, PGE; BROPHY, P; NAVE, KA				SCHNEIDER, A; MONTAGUE, P; GRIFFITHS, I; FANARRAGA, M; KENNEDY, PGE; BROPHY, P; NAVE, KA			UNCOUPLING OF HYPOMYELINATION AND GLIAL-CELL DEATH BY A MUTATION IN THE PROTEOLIPID PROTEIN GENE	NATURE			English	Article							JIMPY MUTANT MOUSE; MESSENGER-RNA; MYELIN; MICE; EXPRESSION; PLP; OLIGODENDROCYTES; BACKGROUNDS; MEMBRANES; DEFECT	PROTEOLIPID protein (PLP; M(r) 30,000) is a highly conserved major polytopic membrane protein in myelin but its cellular function remains obscure. Neurological mutant mice can often provide model systems for human genetic disorders. Mutations of the X-chromosome-linked PLP gene are lethal, identified first in the jimpy mouse1,2 and subsequently in patients with Pelizaeus-Merzbacher disease3,4. The unexplained phenotype of these mutations includes degeneration and premature cell death of oligodendrocytes with associated hypomyelination5. Here we show that a new mouse mutant rumpshaker6 is defined by the amino-acid substitution Ile-to-Thr at residue 186 in a membrane-embedded domain of PLP. Surprisingly, rumpshaker mice, although myelin-deficient, have normal longevity and a full complement of morphologically normal oligodendrocytes7. Hypomyelination can thus be genetically separated from the PLP-dependent oligodendrocyte degeneration. We suggest that PLP has a vital function in glial cell development, distinct from its later role in myelin assembly, and that this dichotomy of action may explain the clinical spectrum8 of Pelizaeus-Merzbacher disease.	UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY; UNIV GLASGOW, APPL NEUROBIOL GRP, GLASGOW G61 1QH, SCOTLAND; UNIV STIRLING, DEPT BIOL & MOLEC SCI, STIRLING FK9 4LA, SCOTLAND	Ruprecht Karls University Heidelberg; University of Glasgow; University of Stirling			Fanarraga, Monica/AAE-5804-2019; Fanarraga, Mónica L./M-6177-2014; Nave, Klaus-Armin/C-8883-2011	Fanarraga, Monica/0000-0003-4754-311X; Fanarraga, Mónica L./0000-0003-4754-311X; 				BARTLETT WP, 1988, GLIA, V1, P253, DOI 10.1002/glia.440010404; BILLINGSGAGLIARDI S, 1980, BRAIN RES, V194, P325, DOI 10.1016/0006-8993(80)91215-9; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DAUTIGNY A, 1986, NATURE, V321, P867, DOI 10.1038/321867a0; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; FANARRAGA ML, 1992, GLIA, V5, P161, DOI 10.1002/glia.440050302; GENCIC S, 1990, J NEUROSCI, V10, P117; GRIFFITHS IR, 1990, J NEUROCYTOL, V19, P273, DOI 10.1007/BF01217305; HELYNCK G, 1983, EUR J BIOCHEM, V133, P689, DOI 10.1111/j.1432-1033.1983.tb07518.x; HUDSON LD, 1987, P NATL ACAD SCI USA, V84, P1454, DOI 10.1073/pnas.84.5.1454; HUDSON LD, 1989, P NATL ACAD SCI USA, V86, P8128, DOI 10.1073/pnas.86.20.8128; HUDSON LD, 1990, ANN NY ACAD SCI, V605, P155, DOI 10.1111/j.1749-6632.1990.tb42390.x; IKENAKA K, 1992, J NEUROCHEM, V58, P2248, DOI 10.1111/j.1471-4159.1992.tb10970.x; KNAPP PE, 1986, J NEUROSCI, V6, P2813; KTIMMERMAN V, IN PRESS NATURE GENE; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MEYER C, 1974, J NEUROPATHOL EXP NE, V33, P343; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MITCHELL LS, IN PRESS J NEUROSCI; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; NAVE KA, 1989, CRIT REV NEUROBIOL, V5, P65; NAVE KA, 1986, P NATL ACAD SCI USA, V83, P9264, DOI 10.1073/pnas.83.23.9264; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sambrook J., 1989, MOL CLONING; SIDMAN RL, 1964, SCIENCE, V144, P309, DOI 10.1126/science.144.3616.309; SIETELBERGER F, 1970, HDB CLIN NEUROLOGY, P150; SKOFF RP, 1976, NATURE, V264, P560, DOI 10.1038/264560a0; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; VERMEESCH MK, 1990, DEV NEUROSCI-BASEL, V12, P303, DOI 10.1159/000111859; WOLF MK, 1983, BRAIN RES, V271, P121, DOI 10.1016/0006-8993(83)91371-9	32	182	185	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					758	761		10.1038/358758a0	http://dx.doi.org/10.1038/358758a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380672				2022-12-24	WOS:A1992JK69900054
J	FARLOW, M; GHETTI, B; BENSON, MD; FARROW, JS; VANNOSTRAND, WE; WAGNER, SL				FARLOW, M; GHETTI, B; BENSON, MD; FARROW, JS; VANNOSTRAND, WE; WAGNER, SL			LOW CEREBROSPINAL-FLUID CONCENTRATIONS OF SOLUBLE AMYLOID BETA-PROTEIN PRECURSOR IN HEREDITARY ALZHEIMERS-DISEASE	LANCET			English	Note							CEREBRAL-HEMORRHAGE; MUTATION	In Alzheimer's disease, deposits of amyloid beta-protein are apparently derived from intracellular processing of a large precursor protein. We have measured concentrations of this precursor in cerebrospinal fluid (CSF) from six members of a family affected by presenile Alzheimer's disease associated with a point mutation of the precursor gene. One gene carrier with clinical signs of the disorder had low CSF concentrations of the precursor, similar to those of three patients with sporadic Alzheimer's disease subsequently confirmed at necropsy. Two symptom-free gene carriers had CSF precursor concentrations similar to those of non-demented controls, though the value was lower in one, who had deficits revealed on neuropsychological testing, than in the other. These findings suggest that low concentrations of soluble amyloid precursor proteins in the CSF reflect the process that results in amyloid plaque formation and vascular deposition in Alzheimer's disease.	SALK INST BIOTECHNOL IND ASSOCIATES INC,505 COAST BLVD S,LA JOLLA,CA 92037; INDIANA UNIV,SCH MED,DEPT NEUROL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	Salk Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Irvine					NATIONAL INSTITUTE ON AGING [P30AG010133] Funding Source: NIH RePORTER; NIA NIH HHS [P30 AG10133] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		GHETTI B, 1992, BRAIN RES, V571, P133, DOI 10.1016/0006-8993(92)90519-F; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRUBB A, 1984, NEW ENGL J MED, V311, P1547, DOI 10.1056/NEJM198412133112406; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2251; VANNOSTRAND WE, IN PRESS ANN NEUROL	10	57	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					453	454		10.1016/0140-6736(92)91771-Y	http://dx.doi.org/10.1016/0140-6736(92)91771-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354785				2022-12-24	WOS:A1992JJ87700005
J	CLARKE, LL; GRUBB, BR; GABRIEL, SE; SMITHIES, O; KOLLER, BH; BOUCHER, RC				CLARKE, LL; GRUBB, BR; GABRIEL, SE; SMITHIES, O; KOLLER, BH; BOUCHER, RC			DEFECTIVE EPITHELIAL CHLORIDE TRANSPORT IN A GENE-TARGETED MOUSE MODEL OF CYSTIC-FIBROSIS	SCIENCE			English	Article							POTENTIAL DIFFERENCE; AIRWAY EPITHELIUM; INTESTINAL TRANSPORT; TRACHEAL EPITHELIUM; ADENYLATE-CYCLASE; RECTAL MUCOSA; ION-TRANSPORT; SECRETION; ACTIVATION; CHANNELS	The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes an adenosine 3',5'-monophosphate (cyclic AMP)-activated chloride channel. In cystic fibrosis (CF) patients, loss of CFTR function because of a genetic mutation results in defective cyclic AMP-mediated chloride secretion across epithelia. Because of their potential role as an animal model for CF, mice with targeted disruption of the murine CFTR gene [CFTR(-/-)] were tested for abnormalities in epithelial chloride transport. In both freshly excised tissue from the intestine and in cultured epithelia from the proximal airways, the cyclic AMP-activated chloride secretory response was absent in CFTR(-/-) mice as compared to littermate controls. Thus, disruption of the murine CFTR gene results in the chloride transport abnormalities predicted from studies of human CF epithelia.	UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill			Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NHLBI NIH HHS [HL 42384] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAXTER P, 1990, GUT, V31, P817, DOI 10.1136/gut.31.7.817; BAXTER PS, 1989, LANCET, V1, P464; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; BERSCHNEIDER HM, 1987, GASTROENTEROLOGY, V92, P1315; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CAREY HV, 1989, AM J PHYSIOL, V256, pR481, DOI 10.1152/ajpregu.1989.256.2.R481; CAREY HV, 1989, DIGEST DIS SCI, V34, P185, DOI 10.1007/BF01536049; CLARKE LL, IN PRESS AM J PHYSL; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; EGGERMONT E, 1991, EUR J PEDIATR, V150, P824, DOI 10.1007/BF01954999; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GOLDSTEIN JL, 1991, GASTROENTEROLOGY, V101, P1012, DOI 10.1016/0016-5085(91)90728-4; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HARDCASTLE J, 1991, GUT, V32, P1035, DOI 10.1136/gut.32.9.1035; HARDCASTLE J, 1987, MED SCI RES-BIOCHEM, V15, P471; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JORIS L, 1989, PFLUG ARCH EUR J PHY, V415, P118, DOI 10.1007/BF00373149; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; OLOUGHLIN EV, 1991, AM J PHYSIOL, V260, pG758, DOI 10.1152/ajpgi.1991.260.5.G758; ORLANDO RC, 1989, GASTROENTEROLOGY, V96, P1041, DOI 10.1016/0016-5085(89)91621-1; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHELDON RJ, 1989, J PHARMACOL EXP THER, V249, P572; SNOUWAERT J, 1992, SCIENCE, V253, P257; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TAYLOR CJ, 1988, GUT, V29, P957, DOI 10.1136/gut.29.7.957; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Willumsen NJ, 1989, AM J PHYSIOL, V256, pC1054, DOI 10.1152/ajpcell.1989.256.5.C1054; Yankaskas J R, 1987, Prog Clin Biol Res, V254, P139	36	276	294	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1125	1128		10.1126/science.257.5073.1125	http://dx.doi.org/10.1126/science.257.5073.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380724				2022-12-24	WOS:A1992JJ88400035
J	GEORGE, JR; OU, CY; PAREKH, B; BRATTEGAARD, K; BROWN, V; BOATENG, E; DECOCK, KM				GEORGE, JR; OU, CY; PAREKH, B; BRATTEGAARD, K; BROWN, V; BOATENG, E; DECOCK, KM			PREVALENCE OF HIV-1 AND HIV-2 MIXED INFECTIONS IN COTE-DIVOIRE	LANCET			English	Note							POLYMERASE CHAIN-REACTION; WESTERN BLOTS; DNA	We have investigated the cause of dual serological reactivity to human immunodeficiency virus (HIV) types 1 and 2, a common occurrence in West Africa. Serum specimens from 111 individuals from cote d'Ivoire classified by commercial western blot as HIV-1 (n = 15), HIV-2 (32), and dually reactive (64) were further tested by more specific serological tests (a synthetic peptide enzyme immunoassay [Pepti-LAV 1/2] and western blots prepared from antigen in which oligomeric forms of the transmembrane protein were disrupted by trichloroacetic acid [WB-TCA]). Peripheral blood mononuclear cells were tested for HIV-1 and HIV-2 with the polymerase chain reaction (PCR) and virus culture. Of 104 samples that were concordant by both WB-TCA and Pepti-LAV, 82 (79%) were confirmed by PCR results. Virus culture was concordant with serology for specimens (35/38) in which any virus was detected. Our findings indicate that mixed HIV-1/HIV-2 infections are common in Cote d'Ivoire, and suggest that natural infection by one HIV type does not prevent heterologous infection.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,INT ACT,ATLANTA,GA 30333; PROJECT RETROCI,ABIDJAN,COTE IVOIRE	Centers for Disease Control & Prevention - USA	GEORGE, JR (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,LAB INVEST BRANCH,ATLANTA,GA 30333, USA.		Brown, Verity/X-6637-2019	Brown, Verity/0000-0001-5762-1797; PAREKH, BHARAT/0000-0002-1088-4263				DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1991, AIDS, V5, pS21; GUERN ML, 1992, P NATL ACAD SCI USA, V89, P363; JACKSON J, 1990, ARCH PATHOL LAB MED, V144, P249; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; PAREKH BS, 1991, AIDS, V5, P1009, DOI 10.1097/00002030-199108000-00013; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; 1989, MMWR, V38, P17	10	82	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					337	339		10.1016/0140-6736(92)91406-X	http://dx.doi.org/10.1016/0140-6736(92)91406-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353806				2022-12-24	WOS:A1992JH12500005
J	SLYPER, AH				SLYPER, AH			A FRESH LOOK AT THE ATHEROGENIC REMNANT HYPOTHESIS	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; HIGH-DENSITY LIPOPROTEIN; POSTPRANDIAL LIPEMIA; MYOCARDIAL-INFARCTION; METABOLISM; CHOLESTEROL; ASSOCIATION; MEN				SLYPER, AH (corresponding author), MED COLL WISCONSIN,DEPT PEDIAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53209, USA.							ALBERS JJ, 1989, CLIN LAB MED, V9, P137, DOI 10.1016/S0272-2712(18)30646-2; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; DEGENNES JL, 1981, DIABETES METAB, V7, P161; GENEST J, 1986, ARTERIOSCLEROSIS, V6, P297, DOI 10.1161/01.ATV.6.3.297; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAMSTEN A, 1986, ATHEROSCLEROSIS, V59, P223, DOI 10.1016/0021-9150(86)90051-1; JONES HB, 1951, AM J MED, V11, P358, DOI 10.1016/0002-9343(51)90171-4; KAMEDA K, 1984, ATHEROSCLEROSIS, V5, P241; KRAUSS RM, 1987, LANCET, V2, P62; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MERRILL JR, 1989, ARTERIOSCLEROSIS, V9, P217, DOI 10.1161/01.ATV.9.2.217; MOORJANI S, 1986, METABOLISM, V35, P311, DOI 10.1016/0026-0495(86)90146-0; NIKKILA EA, 1971, ACTA MED SCAND, V190, P49; PATSCH JR, 1990, CIRCULATION, V82, P284; PATSCH JR, 1983, P NATL ACAD SCI-BIOL, V80, P1449, DOI 10.1073/pnas.80.5.1449; SIMPSON HS, 1990, ATHEROSCLEROSIS, V85, P193, DOI 10.1016/0021-9150(90)90111-U; SNIDERMAN A, 1991, ATHEROSCLEROSIS, V89, P109, DOI 10.1016/0021-9150(91)90050-D; SNIDERMAN AD, 1990, ARTERIOSCLEROSIS, V10, P665, DOI 10.1161/01.ATV.10.5.665; STEINER G, 1987, CIRCULATION, V75, P124, DOI 10.1161/01.CIR.75.1.124; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1984, J BIOL CHEM, V259, P9587; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	26	61	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					289	291		10.1016/0140-6736(92)92368-P	http://dx.doi.org/10.1016/0140-6736(92)92368-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353203				2022-12-24	WOS:A1992JG66500015
J	WANG, HY; WATKINS, DC; MALBON, CC				WANG, HY; WATKINS, DC; MALBON, CC			ANTISENSE OLIGODEOXYNUCLEOTIDES TO G(S) PROTEIN ALPHA-SUBUNIT SEQUENCE ACCELERATE DIFFERENTIATION OF FIBROBLASTS TO ADIPOCYTES	NATURE			English	Article							MESSENGER-RNA LEVELS; ADIPOSE CELL LINE; 3T3-L1 CELLS; ADENYLATE-CYCLASE; BETA-SUBUNITS; INHIBITION; STIMULATION; CONVERSION; EXPRESSION; RECEPTOR	FULLY-DIFFERENTIATED mouse 3T3-L1 fibroblasts accumulate large amounts of lipid at 7-10 days after induction by insulin or by dexamethasone and a methyl xanthine1-3. G proteins mediate transmembrane signalling from a diverse group of cell-surface receptors to effector units that include phospholipase C, adenylyl cyclase and ion channels4-6. They are also targets or regulation themselves7-10. 3T3-L1 fibroblasts display marked changes in levels of G protein when induced to differentiate to adipocytes11-15. Here we show that cholera toxin, which ADP-ribosylates and activates the G protein subunit G(s-alpha), blocks the induction of differentiation, whereas increasing intracellular cyclic AMP directly with the dibutyryl analogue or indirectly with pertussis toxin or forskolin does not affect differentiation. Oligodeoxynucleotides antisense to the sequence encoding G(s-alpha) accelerate differentiation markedly. The time course of adipogenesis declined from 7-10 days in controls to roughly 3 days in cultures treated with antisense-G(s-alpha) oligodeoxynucleotides, whereas oligodeoxynucleotides, antisense to G(i-alpha-1), G(i-alpha-3), and sense and missense to G(s-alpha), had no such effect. Antisense-G(s-alpha) alone induced differentiation by day 7, indicating that G(s-alpha) activity modulates differentiation in 3T3-L1 cells, acting in a new role which is independent of increased intracellular cAMP.	SUNY HLTH SCI CTR,DEPT PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794; NATL DEF MED CTR,DEPT BIOCHEM,TAIPEI 10764,TAIWAN	State University of New York (SUNY) System; National Defense Medical Center			malbon, craig/ABF-3604-2020					BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; GIERSCHIK P, 1986, FEBS LETT, V199, P103, DOI 10.1016/0014-5793(86)81233-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; LAI E, 1981, J BIOL CHEM, V256, P2866; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MALBON CC, 1988, TRENDS PHARMACOL SCI, V9, P33, DOI 10.1016/0165-6147(88)90240-4; MALBON CC, 1985, J BIOL CHEM, V260, P2558; ROS M, 1989, BIOCHEM J, V260, P271, DOI 10.1042/bj2600271; ROS M, 1988, J BIOL CHEM, V263, P4632; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1989, J BIOL CHEM, V264, P4186; YATANI A, 1988, J BIOL CHEM, V263, P9887	22	148	151	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					334	337		10.1038/358334a0	http://dx.doi.org/10.1038/358334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1379345				2022-12-24	WOS:A1992JE68400065
J	JONES, DRE; HOPKINSON, ND; POWELL, RJ				JONES, DRE; HOPKINSON, ND; POWELL, RJ			AUTOANTIBODIES IN PET DOGS OWNED BY PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS	LANCET			English	Article							ANTIBODIES; HOUSEHOLD	Systemic lupus erythematosus (SLE) occurs in human beings and in dogs. There is evidence to suggest that the disease is caused by a transmissible factor that may cross the species barrier. We investigated this possibility by looking for autoantibodies and serum protein abnormalities in serum samples from 15 pet dogs owned by patients with SLE and comparing results with those obtained with serum from 10 healthy dogs kept in a controlled environment and 9 dogs with autoimmune diseases. We used standard immunological assays modified for use with canine samples. Compared with the normal dogs, increased amounts of antibody to double-stranded DNA were found in serum from the SLE patients' dogs (median optical density [405 nm] = 0.117 vs 0.299; p = 0.0001), this latter amount being similar to that found in serum from the autoimmune group (0.201; p = 0.6). Abnormal serum protein electrophoresis patterns were found in samples from the autoimmune and SLE patients' dogs but not the normal dogs. These findings support the idea that exposure to common environmental factors or transmissible agents may have a role in causing SLE.			JONES, DRE (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT IMMUNOL,NOTTINGHAM NG7 2UH,ENGLAND.							BEAUCHER WN, 1977, NEW ENGL J MED, V296, P982, DOI 10.1056/NEJM197704282961707; Bennett D., 1987, Veterinary Annual, V27, P350; CLAIR D, 1980, ARTHRITIS RHEUM, V23, P251, DOI 10.1002/art.1780230219; COSTA O, 1984, VET IMMUNOL IMMUNOP, V7, P369, DOI 10.1016/0165-2427(84)90094-1; DEAPEN D M, 1986, Arthritis and Rheumatism, V29, pS26; FESSEL WJ, 1988, RHEUM DIS CLIN N AM, V14, P15; FRYE F L, 1976, Theriogenology, V6, P127; JONES DRE, 1987, VET IMMUNOL IMMUNOP, V16, P11, DOI 10.1016/0165-2427(87)90170-X; KALLICK CA, 1972, NATURE-NEW BIOL, V236, P145, DOI 10.1038/newbio236145a0; KRISTENSEN S, 1979, VET REC, V105, P422, DOI 10.1136/vr.105.18.422; LEWIS RM, 1974, NATURE, V252, P78, DOI 10.1038/252078a0; LEWIS RM, 1972, AM J PATHOL, V69, P537; LEWIS RM, 1971, J EXP MED, V134, P417, DOI 10.1084/jem.134.2.417; LEWIS RM, 1973, J CLIN INVEST, V52, P1893, DOI 10.1172/JCI107373; MAYR A, 1989, ZBL HYG UMWELTMED, V187, P508; MONIER JC, 1980, ARTHRITIS RHEUM, V23, P294, DOI 10.1002/art.1780230305; REINERTSEN JL, 1980, ARTHRITIS RHEUM-US, V23, P564, DOI 10.1002/art.1780230507; Shanley K J, 1985, Clin Dermatol, V3, P131, DOI 10.1016/0738-081X(85)90086-0; SHARP J T, 1971, Hospital Practice, V6, P142; SILMAN AJ, 1990, BRIT J RHEUMATOL, V29, P494; THOBURN R, 1972, P NATL ACAD SCI USA, V69, P3327, DOI 10.1073/pnas.69.11.3327; WALLACE DJ, 1987, DUBOIS LUPUS ERYTHEM; WALLINGTON TB, 1990, CLIN IMMUNOLOGY PRAC, P212; ZAMBINSKI M, 1989, 53RD P ANN GEN M CIN, pS25	24	20	20	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1378	1380		10.1016/0140-6736(92)91197-G	http://dx.doi.org/10.1016/0140-6736(92)91197-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350806				2022-12-24	WOS:A1992HX63600004
J	SMITH, CAD; GOUGH, AC; LEIGH, PN; SUMMERS, BA; HARDING, AE; MARANGANORE, DM; STURMAN, SG; SCHAPIRA, AHV; WILLIAMS, AC; SPURR, NK; WOLF, CR				SMITH, CAD; GOUGH, AC; LEIGH, PN; SUMMERS, BA; HARDING, AE; MARANGANORE, DM; STURMAN, SG; SCHAPIRA, AHV; WILLIAMS, AC; SPURR, NK; WOLF, CR			DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM AND SUSCEPTIBILITY TO PARKINSONS-DISEASE	LANCET			English	Article							COMPLEX-I DEFICIENCY; POOR METABOLIZERS; CYP2D LOCUS; 4-HYDROXYLATION; PHENOTYPES; NEUROTOXIN; OXIDATION; DEFECT	The pathogenesis of Parkinson's disease may be influenced by genetic and environmental factors. Cytochrome P450 mono-oxygenases help to protect against toxic environmental compounds and individual variations in cytochrome P450 expression might, therefore, influence susceptibility to environmentally linked diseases. The frequency of mutant CYP2D6 alleles was studied in 229 patients with Parkinson's disease and 720 controls. Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2.54-fold (95% CI 1.51-4.28) increased risk of Parkinson's disease. Determination of CYP2D6 phenotype and genotype may help to identify those at greatest risk of Parkinson's disease and may also help to identify the environmental or metabolic agents involved in the pathogenesis of this disease.	IMPERIAL CANC RES FUND, MOLEC PHARMACOL GRP, GEORGE SQ, EDINBURGH EH8 9XD, SCOTLAND; IMPERIAL CANC RES FUND, HUMAN GENET RESOURCES, CLARE HALL LABS, S MIMMS, ENGLAND; UNIV LONDON, INST PSYCHIAT, DEPT NEUROL, LONDON, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON WC2R 2LS, ENGLAND; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON, ENGLAND; UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, DEPT NEUROL, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT NEUROSCI, LONDON, ENGLAND	University of London; King's College London; University of London; King's College London; University of London; University College London; University of Birmingham; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Leigh, Peter/AAD-5638-2019; Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				BARBEAU A, 1985, LANCET, V2, P1213; BENITEZ J, 1990, J NEUROL NEUROSUR PS, V53, P289, DOI 10.1136/jnnp.53.4.289; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CHIBA Z, 1987, BIOCHEM BIOPH RES CO, V120, P574; COMELLA C L, 1987, Neurology, V37, P261; EICHELBAUM M, 1990, PHARMACOL THERAPEUT, V46, P377, DOI 10.1016/0163-7258(90)90025-W; FONNEPFISTER R, 1987, BIOCHEM BIOPH RES CO, V148, P1144, DOI 10.1016/S0006-291X(87)80252-8; GAEDIGK A, 1991, AM J HUM GENET, V48, P943; GIBB WRG, 1989, NEUROPATH APPL NEURO, V15, P27, DOI 10.1111/j.1365-2990.1989.tb01147.x; GOLBE LI, 1990, NEUROLOGY, V40, P7; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; GUDJONSSON O, 1990, BRIT J CLIN PHARMACO, V30, P301, DOI 10.1111/j.1365-2125.1990.tb03780.x; HANIOKA N, 1990, AM J HUM GENET, V47, P994; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; ISLAM SA, 1991, CARCINOGENESIS, V12, P2211, DOI 10.1093/carcin/12.12.2211; JOHNSON WG, 1991, NEUROLOGY, V41, P82, DOI 10.1212/WNL.41.5_Suppl_2.82; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KALLIO J, 1991, ACTA NEUROL SCAND, V83, P194, DOI 10.1111/j.1600-0404.1991.tb04676.x; Langdon J.S., 1985, RECENT ADV AQUACULTU, P79, DOI [10.4324/9780429303937-3, DOI 10.4324/9780429303937-3]; MARAGANORE DM, 1991, MOVEMENT DISORD, V6, P205, DOI 10.1002/mds.870060303; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NIZNIK HB, 1990, ARCH BIOCHEM BIOPHYS, V276, P424, DOI 10.1016/0003-9861(90)90741-G; POIRIER J, 1987, LANCET, V2, P386; PRICEEVANS DA, 1980, J MED GENET, V17, P102; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SPURR NK, 1991, METHOD ENZYMOL, V206, P149; STEIGER MJ, IN PRESS ACTA NEUROL; STEVENTON G B, 1989, Medical Science Research, V17, P163; WOLF CR, 1990, CANCER SURV, V9, P437; WOLF CR, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93163-J; WOLF CR, IN PRESS CARCINOGENE; YOUNGSTER SK, 1990, BIOCHEM BIOPH RES CO, V169, P758, DOI 10.1016/0006-291X(90)90396-5	34	455	460	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1992	339	8806					1375	1377		10.1016/0140-6736(92)91196-F	http://dx.doi.org/10.1016/0140-6736(92)91196-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350805				2022-12-24	WOS:A1992HX63600003
J	YEAGER, CL; ASHMUN, RA; WILLIAMS, RK; CARDELLICHIO, CB; SHAPIRO, LH; LOOK, AT; HOLMES, KV				YEAGER, CL; ASHMUN, RA; WILLIAMS, RK; CARDELLICHIO, CB; SHAPIRO, LH; LOOK, AT; HOLMES, KV			HUMAN AMINOPEPTIDASE-N IS A RECEPTOR FOR HUMAN CORONAVIRUS-229E	NATURE			English	Article							AMINO-ACID SEQUENCE; ENDOPEPTIDASE 24.11 ENKEPHALINASE; MEMBRANE ANTIGEN GP150; NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; LEUKEMIA ANTIGEN; GENE; KIDNEY; IDENTIFICATION; EXPRESSION	HUMAN coronaviruses (HCV) in two serogroups represented by HCV-229E and HCV-OC43 are an important cause of upper respiratory tract infections 1. Here we report that human aminopeptidase N, a cell-surface metalloprotease on intestinal, lung and kidney epithelial cells 2-5, is a receptor for human coronavirus strain HCV-229E, but not for HCV-OC43. A monoclonal antibody, RBS, blocked HCV-229E virus infection of human lung fibroblasts, immunoprecipitated aminopeptidase N and inhibited its enzymatic activity. HCV-229E-resistant murine fibroblasts became susceptible after transfection with complementary DNA encoding human aminopeptidase N. By contrast, infection of human cells with HCV-OC43 was not inhibited by antibody RBS and expression of aminopeptidase N did not enhance HCV-OC43 replication in mouse cells. A mutant aminopeptidase lacking the catalytic site of the enzyme did not bind HCV-229E or RBS and did not render murine cells susceptible to HCV-229E infection, suggesting that the virus-binding site may lie at or near the active site of the human aminopeptidase molecule.	UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	Uniformed Services University of the Health Sciences - USA; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center								ASHMUN RA, 1990, BLOOD, V75, P462; ASHMUN RA, IN PRESS BLOOD; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LOOK AT, 1985, J CLIN INVEST, V75, P569, DOI 10.1172/JCI111733; LOOK AT, 1986, J CLIN INVEST, V78, P914, DOI 10.1172/JCI112680; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LOOK AT, 1989, LEUCOCYTE TYPING, V4, P784; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MATSAS R, 1985, BIOCHEM J, V231, P445, DOI 10.1042/bj2310445; MCINTOSH K, 1990, VIROLOGY, P857; NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; RICH DH, 1984, J MED CHEM, V27, P417, DOI 10.1021/jm00370a001; SAKAGUCHI AY, 1982, SOMAT CELL GENET, V8, P83, DOI 10.1007/BF01538652; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; TURNER AJ, 1987, MAMMALIAN ECTOENZYME, P211; UMEZAWA H, 1985, J ANTIBIOT, V38, P1629, DOI 10.7164/antibiotics.38.1629; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WATT VM, 1989, J BIOL CHEM, V264, P5480; WILKES SH, 1985, J BIOL CHEM, V260, P3154; WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990; WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533; WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; [No title captured]	30	645	710	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					420	422		10.1038/357420a0	http://dx.doi.org/10.1038/357420a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1350662	Bronze, Green Published			2022-12-24	WOS:A1992HX17200069
J	LUNGU, O; SUN, XW; FELIX, J; RICHART, RM; SILVERSTEIN, S; WRIGHT, TC				LUNGU, O; SUN, XW; FELIX, J; RICHART, RM; SILVERSTEIN, S; WRIGHT, TC			RELATIONSHIP OF HUMAN PAPILLOMAVIRUS TYPE TO GRADE OF CERVICAL INTRAEPITHELIAL NEOPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENITAL-TRACT; LESIONS	Objective. - To determine the relationship of human papillomavirus (HPV) type to grade of cervical intraepithelial neoplasia (CIN) in a large series of cases. Design. - A survey of HPV types in CIN lesions detected using a new, highly accurate method for typing HPV that is based on restriction fragment length polymorphism analysis of amplimers produced during polymerase chain amplification of the conserved L1 region of HPV using consensus primers. Setting. - Private gynecologists' offices and inner-city colposcopy clinics. Patients. - A convenience sample of 276 HPV DNA-positive cervical biopsy specimens or samples from patients undergoing colposcopy for abnormal Papanicolaou smears. Intervention. - None. Main Outcome Measure(s). - Human papillomavirus type(s). Results. - Cervical intraepithelial neoplasia 1 lesions were relatively heterogeneous with regard to associated HPV types. Nineteen percent of CIN 1 lesions were associated with HPV types 6 or 11; 29% contained HPV types 16, 18, or 33; and 19% were associated with "novel types" of HPV. It was also found that 22% of CIN 1 lesions were associated with more than one HPV type. In contrast to CIN 1, both CIN 2 and CIN 3 were relatively homogeneous with regard to associated HPV types. Eighty-eight percent of CIN 2 and 3 lesions contained HPV types 16,18, or 33. Unlike CIN 1 lesions, which often contained multiple types of HPV, only 7% of CIN 2 and 3 lesions were associated with multiple HPV types. Conclusions. - Cervical intraepithelial neoplasia should be classified into two separate categories-low-grade and high-grade CIN. Since only 29% of low-grade lesions are associated with HPV types 16,18, or 33, HPV type could potentially play a role in determining the most appropriate clinical management of patients with low-grade CIN. However, prospective follow-up studies of lesional behavior based on HPV type are required before clinical recommendations can be made.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, DIV OBSTET GYNECOL PATHOL, ROOM 16-402 P&S, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT OBSTET & GYNECOL, NEW YORK, NY 10032 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; CORNELL MED SCH, DEPT PATHOL, NEW YORK, NY USA	Columbia University; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; Cornell University					NCI NIH HHS [CA27367] Funding Source: Medline; PHS HHS [CCU206822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRON BA, 1968, J NATL CANCER I, V41, P1343; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BURMER GC, 1990, AM J CLIN PATHOL, V94, P554, DOI 10.1093/ajcp/94.5.554; CAMPION MJ, 1986, LANCET, V2, P237; CRUM CP, 1985, J VIROL, V54, P675, DOI 10.1128/JVI.54.3.675-681.1985; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P191; FRANQUEMONT DW, 1989, AM J CLIN PATHOL, V92, P577, DOI 10.1093/ajcp/92.5.577; GRAVITT P, 1991, MOL CELL PROBE, V5, P65, DOI 10.1016/0890-8508(91)90039-M; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; LUNGU O, IN PRESS MOL CELL PR; Manos M. M., 1990, PCR PROTOCOLS GUIDE, P356; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; NUOVO GJ, 1990, GYNECOL ONCOL, V36, P256, DOI 10.1016/0090-8258(90)90184-M; REID R, 1987, AM J OBSTET GYNECOL, V156, P212, DOI 10.1016/0002-9378(87)90241-9; REID R, 1991, J FAM PRACTICE, V32, P183; RICHART RM, 1990, OBSTET GYNECOL, V75, P223; RICHART RM, 1990, OBSTET GYNECOL, V75, P131; ROMAN A, 1989, CLIN MICROBIOL REV, V2, P166, DOI 10.1128/CMR.2.2.166-190.1989; SINGER A, 1991, BRIT MED J, V302, P251, DOI 10.1136/bmj.302.6771.251; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; SYRJANEN KJ, 1991, PAPILLOMAVIRUS REP, V1, P1; WILLETT GD, 1989, INT J GYNECOL PATHOL, V8, P18, DOI 10.1097/00004347-198903000-00003; WRIGHT TC, 1990, GYNECOL ONCOL, V37, P151, DOI 10.1016/0090-8258(90)90327-H	25	108	114	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2493	2496		10.1001/jama.267.18.2493	http://dx.doi.org/10.1001/jama.267.18.2493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349360				2022-12-24	WOS:A1992HT06800029
J	FILSHIE, GM; MAYNARD, P; HUTTER, C; COOPER, JC; ROBINSON, G; RUBIN, P				FILSHIE, GM; MAYNARD, P; HUTTER, C; COOPER, JC; ROBINSON, G; RUBIN, P			URINARY 5-HYDROXYINDOLE ACETATE CONCENTRATION IN PREGNANCY INDUCED HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							ECLAMPSIA				FILSHIE, GM (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND.							HORN EH, 1990, BRIT MED J, V301, P794, DOI 10.1136/bmj.301.6755.794; JAAMERI KEU, 1965, GYNAECOLOGIA, V160, P315; JELEN I, 1979, BRIT J OBSTET GYNAEC, V86, P468, DOI 10.1111/j.1471-0528.1979.tb10791.x; WEINER CP, 1987, AM J OBSTET GYNECOL, V156, P885, DOI 10.1016/0002-9378(87)90345-0; WHIGHAM KAE, 1978, BRIT J OBSTET GYNAEC, V85, P28, DOI 10.1111/j.1471-0528.1978.tb15820.x	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1223	1223		10.1136/bmj.304.6836.1223	http://dx.doi.org/10.1136/bmj.304.6836.1223			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1381251	Green Published, Bronze			2022-12-24	WOS:A1992HT96400023
J	SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC				SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC			HOSPITAL ADMISSION AND THE START OF BENZODIAZEPINE USE	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary								Ashton H, 1986, ADVERSE DRUG REACT, V118, P440; CATALAN J, 1985, BMJ-BRIT MED J, V290, P1374, DOI 10.1136/bmj.290.6479.1374; EDWARDS C, 1991, BRIT J CLIN PHARMACO, V31, P190, DOI 10.1111/j.1365-2125.1991.tb05513.x; SHAN K, 1990, J ROY SOC MED, V83, P306, DOI 10.1177/014107689008300509; TREWIN VF, 1986, BR J PHARM PRACT, V8, P359	5	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					881	881		10.1136/bmj.304.6831.881	http://dx.doi.org/10.1136/bmj.304.6831.881			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392750	Green Published, Bronze			2022-12-24	WOS:A1992HM83500027
J	MARX, A; KIRCHNER, T; GREINER, A; MULLERHERMELINK, HK; SCHALKE, B; OSBORN, M				MARX, A; KIRCHNER, T; GREINER, A; MULLERHERMELINK, HK; SCHALKE, B; OSBORN, M			NEUROFILAMENT EPITOPES IN THYMOMA AND ANTIAXONAL AUTOANTIBODIES IN MYASTHENIA-GRAVIS	LANCET			English	Note							EPITHELIAL-CELLS	Expression by neoplastic thymic epithelial cells of acetylcholine-receptor (AChR) epitopes is associated with the presence of AChR autoantibodies and the development of myasthenia gravis. We studied thymic tumours from patients with and without myasthenia gravis for the expression of neurofilament epitopes by immunohistochemistry with four monoclonal antibodies. There was very little antibody binding in control samples (healthy thymus, or thymitis) or in medullary and mixed thymomas, but neurofilament epitopes were strongly expressed in all cortical thymomas and thymic carcinomas. In addition, the frequency of serum autoantibodies against axons was significantly higher among myasthenic patients with thymic epithelial tumours than among age-matched controls (7/10 vs 3/50; p < 0.01).	UNIV WURZBURG,DEPT NEUROL,W-8700 WURZBURG,GERMANY; MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	University of Wurzburg; Max Planck Society	MARX, A (corresponding author), UNIV WURZBURG,INST PATHOL,JOSEF SCHNEIDER STR 2,W-8700 WURZBURG,GERMANY.							DARDENNE M, 1987, AM J PATHOL, V126, P194; GILHUS NE, 1984, J NEUROIMMUNOL, V7, P55, DOI 10.1016/S0165-5728(84)80006-5; KIRCHNER T, 1987, LANCET, V1, P218; KIRCHNER T, 1988, AM J PATHOL, V130, P268; Kirchner Thomas, 1989, PROGR SURGICAL PATHO, P167; MARX A, 1990, LAB INVEST, V62, P279; MARX A, 1989, AM J PATHOL, V134, P864; MOLL R, 1987, MORPHOLOGICAL TUMOUR, P79; MULLER KMI, 1989, J NEUROL SCI, V93, P263, DOI 10.1016/0022-510X(89)90196-2	9	27	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					707	708		10.1016/0140-6736(92)90601-X	http://dx.doi.org/10.1016/0140-6736(92)90601-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1372058				2022-12-24	WOS:A1992HK32000006
J	FRESKGARD, PO; BERGENHEM, N; JONSSON, BH; SVENSSON, M; CARLSSON, U				FRESKGARD, PO; BERGENHEM, N; JONSSON, BH; SVENSSON, M; CARLSSON, U			ISOMERASE AND CHAPERONE ACTIVITY OF PROLYL ISOMERASE IN THE FOLDING OF CARBONIC-ANHYDRASE	SCIENCE			English	Article							CIS-TRANS ISOMERASE; BINDING; CYCLOPHILIN; AGGREGATION; CATALYSIS; PROTEINS; MODELS; SITE	Several proteins have been discovered that either catalyze slow protein-folding reactions or assist folding in the cell. Prolyl isomerase, which has been shown to accelerate rate-limiting cis-trans peptidyl-proline isomerization steps in the folding pathway, can also participate in the protein-folding process as a chaperone. This function is exerted on an early folding intermediate of carbonic anhydrase, which is thereby prevented from aggregating, whereas the isomerase activity is performed later in the folding process.	LINKOPING UNIV,DEPT CHEM,INST FYS MATTEKN K,S-58183 LINKOPING,SWEDEN; UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN	Linkoping University; Umea University			Freskgård, Per-Ola/AAY-4194-2021					BERGENHEM N, 1989, INT J PEPT PROT RES, V33, P140; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARLSSON U, 1975, EUR J BIOCHEM, V52, P25, DOI 10.1111/j.1432-1033.1975.tb03969.x; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; DRAKENBERG T, 1972, J PHYS CHEM-US, V76, P2178, DOI 10.1021/j100659a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRESKGARD PO, 1991, FEBS LETT, V289, P117, DOI 10.1016/0014-5793(91)80922-P; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HENDERSON LE, 1973, ANAL BIOCHEM, V51, P288, DOI 10.1016/0003-2697(73)90477-6; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V9, P11; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; WOLFENDEN R, 1991, CHEMTRACTS BIOCH MOL, V2, P52	26	187	200	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					466	468		10.1126/science.1357751	http://dx.doi.org/10.1126/science.1357751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1357751				2022-12-24	WOS:A1992JT77500036
J	AKABAS, MH; STAUFFER, DA; XU, M; KARLIN, A				AKABAS, MH; STAUFFER, DA; XU, M; KARLIN, A			ACETYLCHOLINE-RECEPTOR CHANNEL STRUCTURE PROBED IN CYSTEINE-SUBSTITUTION MUTANTS	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; AFFINITY BINDING-SITE; DELTA-SUBUNIT; H-3 CHLORPROMAZINE; ALPHA-SUBUNIT; TORPEDO-CALIFORNICA; NICOTINIC RECEPTOR; ION CHANNEL; NONCOMPETITIVE BLOCKERS; GAMMA-SUBUNIT	In order to understand the structural bases of ion conduction, ion selectivity, and gating in the nicotinic acetylcholine receptor, mutagenesis and covalent modification were combined to identify the amino acid residues that line the channel. The side chains of alternate residues-Ser248, Leu250, Ser252, and Thr254-in M2, a membrane-spanning segment of the alpha subunit, are exposed in the closed channel. Thus alpha248-254 probably forms a beta strand, and the gate is closer to the cytoplasmic end of the channel than any of these residues. On channel opening, Leu251 is also exposed. These results lead to a revised view of the closed and open channel structures.	COLUMBIA UNIV COLL PHYS & SURG,CTR MOLEC RECOGNIT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University				KARLIN, ARTHUR/0000-0002-4813-752X; Akabas, Myles/0000-0001-8781-7846	NINDS NIH HHS [NS07065, NS07258] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; CHARNET P, 1990, NEURON, V2, P87; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; COLQUHOUN D, 1981, NATURE, V294, P464, DOI 10.1038/294464a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANI JA, 1989, J NEUROSCI, V9, P884; DIPAOLA M, 1989, J BIOL CHEM, V264, P15457; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAKES KS, 1990, J BIOL CHEM, V265, P6984; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; Kenyon G L, 1977, Methods Enzymol, V47, P407; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LASTERS I, 1988, P NATL ACAD SCI USA, V85, P3338, DOI 10.1073/pnas.85.10.3338; LEATHY DJ, 1992, CELL, V68, P1145; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LO DC, 1991, NEURON, V6, P31, DOI 10.1016/0896-6273(91)90119-K; MCCREA PD, 1987, EMBO J, V6, P3619, DOI 10.1002/j.1460-2075.1987.tb02693.x; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; STAUFFER D, UNPUB; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; UNWIN N, 1989, NEURON, V3, P65; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	50	611	619	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					307	310		10.1126/science.1384130	http://dx.doi.org/10.1126/science.1384130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384130				2022-12-24	WOS:A1992JR86000037
J	SMITH, EF; SALE, WS				SMITH, EF; SALE, WS			REGULATION OF DYNEIN-DRIVEN MICROTUBULE SLIDING BY THE RADIAL SPOKES IN FLAGELLA	SCIENCE			English	Article							SWIMMING SPERM FLAGELLA; CHLAMYDOMONAS-FLAGELLA; GENETIC-ANALYSIS; SEA-URCHIN; INNER-ARM; MUTANTS; OUTER; REINHARDTII; COMPONENTS; DIRECTION	The regulation of microtubule sliding in flagellar axonemes was studied with the use of Chlamydomonas mutants and in vitro assays. Microtubule sliding velocities were diminished in axonemes from mutant cells missing radial spoke structures but could be restored upon reconstitution with dynein from axonemes with wild-type radial spokes. These experiments demonstrate that the radial spokes activate dynein's microtubule sliding activity.			SMITH, EF (corresponding author), EMORY UNIV,SCH MED,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 20497] Funding Source: Medline; NIGMS NIH HHS [GM 08367] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BROKAW CJ, 1991, J CELL BIOL, V114, P1201, DOI 10.1083/jcb.114.6.1201; BROKAW CJ, 1980, SCIENCE, V207, P1365, DOI 10.1126/science.6898364; BROKAW CJ, 1982, J CELL BIOL, V92, P722, DOI 10.1083/jcb.92.3.722; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; BROKAW CJ, 1989, SCIENCE, V243, P1593, DOI 10.1126/science.2928796; DIENER DR, 1990, P NATL ACAD SCI USA, V87, P5739, DOI 10.1073/pnas.87.15.5739; FOX LA, 1987, J CELL BIOL, V105, P1781, DOI 10.1083/jcb.105.4.1781; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; HUANG B, 1981, J CELL BIOL, V88, P80, DOI 10.1083/jcb.88.1.80; HUANG BPH, 1986, INT REV CYTOL, V99, P181; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KAMIYA R, 1989, CELL MOVEMENT DYNEIN, V1, pCH15; KURIMOTO E, 1991, CELL MOTIL CYTOSKEL, V19, P275, DOI 10.1002/cm.970190406; LUCK D, 1977, P NATL ACAD SCI USA, V74, P3456, DOI 10.1073/pnas.74.8.3456; LUCK DJL, 1989, CELL MOVEMENT DYNEIN, V1, pCH4; MUTO E, 1991, J CELL SCI, V99, P57; OKAGAKI T, 1986, J CELL BIOL, V103, P1895, DOI 10.1083/jcb.103.5.1895; OMOTO CK, 1980, J CELL BIOL, V87, P33, DOI 10.1083/jcb.87.1.33; PIPERNO G, 1991, J CELL BIOL, V112, P701, DOI 10.1083/jcb.112.4.701; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PIPERNO G, 1981, J CELL BIOL, V88, P73, DOI 10.1083/jcb.88.1.73; SALE WS, 1977, P NATL ACAD SCI USA, V74, P2045, DOI 10.1073/pnas.74.5.2045; SATIR P, 1968, J CELL BIOL, V39, P77, DOI 10.1083/jcb.39.1.77; SMITH EF, 1992, J CELL BIOL, V117, P573, DOI 10.1083/jcb.117.3.573; SUMMERS KE, 1971, P NATL ACAD SCI USA, V68, P3092, DOI 10.1073/pnas.68.12.3092; WARNER FD, 1974, J CELL BIOL, V63, P35, DOI 10.1083/jcb.63.1.35; WITMAN GB, 1978, J CELL BIOL, V76, P729, DOI 10.1083/jcb.76.3.729; WITMAN GB, 1992, CURR OPIN CELL BIOL, V4, P77	30	151	153	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1557	1559		10.1126/science.1387971	http://dx.doi.org/10.1126/science.1387971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1387971				2022-12-24	WOS:A1992JM57000035
J	PELTOLA, H; KILPI, T; ANTTILA, M				PELTOLA, H; KILPI, T; ANTTILA, M			RAPID DISAPPEARANCE OF HAEMOPHILUS-INFLUENZAE TYPE-B MENINGITIS AFTER ROUTINE CHILDHOOD IMMUNIZATION WITH CONJUGATE VACCINES	LANCET			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; NEISSERIA-MENINGITIDIS; BACTERIAL-MENINGITIS; MEMBRANE-PROTEIN; FIELD TRIAL; EFFICACY; INFANTS; CHILDREN; FINLAND; AGE	Mortality from meningitis caused by Haemophilus influenzae type b (Hib), a disease that affects mainly infants and young children, can reach 5% in industrialised countries and ten times that in non-industrialised countries. To determine the efficacy of vaccination against Hib, we carried out a retrospective survey of the incidence of Hib meningitis over five decades in the Greater Helsinki area of Finland, where all children with bacterial meningitis are treated in one of three centres. Except for a meningococcal epidemic in the early 1970s, Hib was the leading cause of childhood bacterial meningitis until the Hib conjugate vaccines changed the picture profoundly. In 1986-87 the polysaccharide-diphtheria toxoid conjugate (PRP-D) was given experimentally to 50% of infants. In 1988-89 all infants were vaccinated, 50% with PRP-D, 50% with another conjugate vaccine, the oligosaccharide-CRM197 protein conjugate (HbOC). Since 1990 a third conjugate vaccine, the polysaccharide-tetanus toxoid (PRP-T), has been administered routinely to all infants. The vaccines were administered at age 3-6 months, with a booster dose at 14-18 months. In the first 5 years of the Hib vaccination programme the number of cases of Hib meningitis in children aged 0-4 years fell sharply, from 30 in 1986 (the first year of the programme) to none in 1991. The decline contrasts sharply with the rising trend up to the mid 1980s. Vaccination seems to be the only explanation for the observed change in the epidemiology of Hib meningitis.	AURORA CITY HOSP,HELSINKI,FINLAND; NATL PUBL HLTH INST,SF-00280 HELSINKI 28,FINLAND	Finland National Institute for Health & Welfare	PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,11 STENBACKINKATU,SF-00290 HELSINKI 29,FINLAND.							ANDERSON PW, 1989, J IMMUNOL, V142, P2464; BIJLMER HA, 1991, VACCINE, V9, pS5, DOI 10.1016/0264-410X(91)90172-3; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; ESKOLA J, 1991, VACCINE, V9, pS14, DOI 10.1016/0264-410X(91)90174-5; FERRECCIO C, 1991, PEDIATR INFECT DIS J, V10, P764, DOI 10.1097/00006454-199110000-00009; FORSSELL P, 1967, LEIRAKSEN JULKAISUJA, V17, P137; GORDON LK, 1984, MODERN APPROACHES VA, P393; KAUHTIO J, 1958, Ann Paediatr Fenn, V4, P42; KAYHTY H, 1991, AM J DIS CHILD, V145, P223; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; KOSKINIEMI M, 1978, ACTA PAEDIATR SCAND, V67, P17, DOI 10.1111/j.1651-2227.1978.tb16271.x; MAKELA PH, 1977, J INFECT DIS, V136, pS43; MARBURG S, 1986, J AM CHEM SOC, V108, P5282, DOI 10.1021/ja00277a037; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; PELTOLA H, 1989, LANCET, V1, P1281; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; 1990, MORBID MORTAL WKLY R, V39, P924	25	284	291	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					592	594		10.1016/0140-6736(92)92117-X	http://dx.doi.org/10.1016/0140-6736(92)92117-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355165				2022-12-24	WOS:A1992JM33400014
J	AMSTERCHODER, O; WRIGHT, A				AMSTERCHODER, O; WRIGHT, A			MODULATION OF THE DIMERIZATION OF A TRANSCRIPTIONAL ANTITERMINATOR PROTEIN BY PHOSPHORYLATION	SCIENCE			English	Article							DNA-BINDING PROTEINS; ESCHERICHIA-COLI; LEUCINE ZIPPER; BGL OPERON	The transcriptional antiterminator protein BgIG inhibits transcription termination of the bgl operon in Escherichia coli when it is in the nonphosphorylated state. The BgIG protein is now shown to exist in two configurations, an active, dimeric nonphosphorylated form and an inactive, monomeric phosphorylated form. The migration of BgIG on native polyacrylamide gels was consistent with it existing as a dimer when nonphosphorylated and as a monomer when phosphorylated. Only the nonphosphorylated dimer was found to bind to the target RNA. When the dimerization domain of the lambda-repressor was replaced with BgIG, the resulting chimera behaved like an intact lambda-repressor in its ability to repress lambda-gene expression, which suggests that BgIG dimerizes in vivo. Repression by the lambda-BgIG hybrid was significantly reduced by BgIF, the BgIG kinase, an effect that was relieved by conditions that stimulate dephosphorylation of BgIG by BgIF. These results suggest that the phosphorylation and the dephosphorylation of BgIG regulate its activity by controlling its dimeric state.			AMSTERCHODER, O (corresponding author), TUFTS UNIV,DEPT MOLEC BIOL & MICROBIOL,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.							AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, UNPUB; BRYAN JK, 1977, ANAL BIOCHEM, V78, P523; DIAZTORRES MR, UNPUB; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Hu Jintao, COMMUNICATION; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REVEL HR, 1967, VIROLOGY, V31, P688, DOI 10.1016/0042-6822(67)90197-3; REYNOLDS AE, 1986, J MOL BIOL, V191, P85, DOI 10.1016/0022-2836(86)90424-9; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; STEINMETZ M, 1988, GENETICS BIOTECHNOLO, V2, P11; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	21	122	122	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1395	1398		10.1126/science.1382312	http://dx.doi.org/10.1126/science.1382312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382312				2022-12-24	WOS:A1992JL61200032
J	COWAN, SW; SCHIRMER, T; RUMMEL, G; STEIERT, M; GHOSH, R; PAUPTIT, RA; JANSONIUS, JN; ROSENBUSCH, JP				COWAN, SW; SCHIRMER, T; RUMMEL, G; STEIERT, M; GHOSH, R; PAUPTIT, RA; JANSONIUS, JN; ROSENBUSCH, JP			CRYSTAL-STRUCTURES EXPLAIN FUNCTIONAL-PROPERTIES OF 2 ESCHERICHIA-COLI PORINS	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTER; INTEGRAL MEMBRANE-PROTEIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; MACROMOLECULAR CRYSTALLOGRAPHY; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-CAPSULATUS; ELECTRON-MICROSCOPY; BACTERIAL PORIN; PHOE PORIN	Porins form aqueous channels that aid the diffusion of small hydrophilic molecules across the outer membrane of Gram-negative bacteria. The crystal structures of matrix porin and phosphoporin both reveal trimers of identical subunits, each subunit consisting of a 16-stranded anti-parallel beta-barrel containing a pore. A long loop inside the barrel contributes to a constriction of the channel where the charge distribution affects ion selectivity. The structures explain at the molecular level functional characteristics and their alterations by known mutations.	UNIV BASEL,BIOCTR,DEPT STRUCT BIOL,CH-4056 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND	University of Basel; University of Basel								BAUER K, 1989, J BIOL CHEM, V264, P16393; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BOSCH D, 1989, MOL GEN GENET, V216, P144, DOI 10.1007/BF00332243; BRUNGER AT, 1990, XPLOR MANUAL; BUHLER LK, 1991, J BIOL CHEM, V266, P24446; DARGENT B, 1986, EMBO J, V5, P773, DOI 10.1002/j.1460-2075.1986.tb04280.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; GARAVITO RM, 1980, J CELL BIOL, V86, P327, DOI 10.1083/jcb.86.1.327; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; HANCOCK REW, 1987, J BACTERIOL, V169, P929, DOI 10.1128/jb.169.3.929-933.1987; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HONGER A, 1990, J STRUCT BIOL, V103, P185; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, MANUAL O; KLEBBA PE, 1990, J BIOL CHEM, V265, P6800; KORTELAND J, 1985, EUR J BIOCHEM, V152, P691, DOI 10.1111/j.1432-1033.1985.tb09249.x; LAKEY JH, 1991, FEBS LETT, V278, P31, DOI 10.1016/0014-5793(91)80076-F; LESK AM, 1989, PROTEINS, V5, P139, DOI 10.1002/prot.340050208; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MICHEL H, 1983, TRENDS BIOCHEM SCI, V8, P56, DOI 10.1016/0968-0004(83)90390-0; MISRA R, 1988, J BACTERIOL, V170, P3611, DOI 10.1128/jb.170.8.3611-3617.1988; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; PAUPTIT RA, 1991, J STRUCT BIOL, V107, P136, DOI 10.1016/1047-8477(91)90017-Q; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROCQUE WJ, 1990, BIOCHEMISTRY-US, V29, P5344, DOI 10.1021/bi00474a020; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; ROSENBUSCH JP, 1990, EXPERIENTIA, V46, P167; ROSENBUSCH JP, 1977, SOLUBILIZATION LIPOP, P59; Rossmann M. G., 1972, MOL REPLACEMENT METH; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; Schirmer T, 1991, CURR OPIN STRUC BIOL, V1, P539, DOI 10.1016/S0959-440X(05)80075-2; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEIERT M, 1992, Experientia (Basel), V48, pA22; STEVEN AC, 1977, J CELL BIOL, V72, P292, DOI 10.1083/jcb.72.2.292; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; VANDERLEY P, 1986, J BIOL CHEM, V261, P2222; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; 1979, SERC UK4 DAR LAB COL	58	1345	1370	0	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					727	733		10.1038/358727a0	http://dx.doi.org/10.1038/358727a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380671				2022-12-24	WOS:A1992JK69900043
J	FISHERHOCH, SP; PEREZORONOZ, GI; JACKSON, EL; HERMANN, LM; BROWN, BG				FISHERHOCH, SP; PEREZORONOZ, GI; JACKSON, EL; HERMANN, LM; BROWN, BG			FILOVIRUS CLEARANCE IN NONHUMAN-PRIMATES	LANCET			English	Article							EBOLA; MONKEYS; VIRUS	There has been concern in the USA and Europe about filovirus outbreaks in recently imported monkeys, and possible transmission to human beings. Healthy monkeys have been found to have low-titre immunofluorescence antibody (IFA) to Asian filoviruses (Reston and Pennsylvania viruses) as well as to the African filoviruses that caused fulminating human outbreaks in the 1970s (Ebola [Zaire] and Sudan viruses). We have assessed whether such monkeys are a risk to man. We studied 42 non-human primates; 31 were experimentally infected with African and Asian filoviruses, 6 were infected during a documented Reston filovirus outbreak, and 5 had serological evidence suggestive of recent filovirus infection. During the first 15 days after infection, virus could be routinely recovered from serum or biopsy or necropsy tissue, and Asian filovirus RNA could be detected by polymerase chain reaction. 20 to 600 days after challenge, filovirus could no longer be recovered nor viral RNA detected in 141 serum, liver, spleen, or kidney specimens. Animals surviving filovirus infection develop high-titre, cross-reacting filovirus-specific antibody 14 to 21 days after infection, and this coincides with virus clearance. Healthy monkeys with low-titre filovirus antibody may be regarded as uninfected.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,ANIM RESOURCES BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1978, Bull World Health Organ, V56, P271; FISHERHOCH SP, IN PRESS J INFECT DI; HENRICKSON RV, 1983, LANCET, V2, P388; HEYMANN DL, 1980, J INFECT DIS, V142, P372, DOI 10.1093/infdis/142.3.372; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON BK, 1982, T ROY SOC TROP MED H, V76, P307, DOI 10.1016/0035-9203(82)90175-4; MARTINI G A, 1971, P1; MIRANDA MEG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91199-5; SANCHEZ A, 1992, J GEN VIROL, V73, P347, DOI 10.1099/0022-1317-73-2-347; STEGALL MD, 1989, TRANSPLANTATION, V48, P944, DOI 10.1097/00007890-198912000-00009; TOMORI O, 1988, AM J TROP MED HYG, V38, P407, DOI 10.4269/ajtmh.1988.38.407; 1990, MMWR, V39, P296; 1978, B WEHO, V56, P247; 1992, WEEKLY EPIDEMIOL REP, V67, P142; 1989, MMWR, V38, P831; 1990, MMWR, V39, P22	16	29	29	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					451	453		10.1016/0140-6736(92)91770-9	http://dx.doi.org/10.1016/0140-6736(92)91770-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354784				2022-12-24	WOS:A1992JJ87700004
J	BERRY, M; GROSVELD, F; DILLON, N				BERRY, M; GROSVELD, F; DILLON, N			A SINGLE POINT MUTATION IS THE CAUSE OF THE GREEK FORM OF HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN	NATURE			English	Article							GAMMA-GLOBIN GENE; ERYTHROID-SPECIFIC PROTEIN; DISTAL CCAAT BOX; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; BINDING; HEMOGLOBIN; REGION; DNA; BREAKPOINT	IN normal humans the fetal stage-specific gamma-globin genes are silenced after birth and not expressed in the adult. Exceptions are seen in cases of hereditary persistence of fetal haemoglobin (HPFH). These are clinically important because the elevated levels of gamma-globin can alleviate beta-thalassaemia and sickle cell anaemia. One class of mutations is associated with point mutations in the promoter of the gamma-globin genes (non-deletion HPFH), whereas others seem to be caused by large deletions 3' to the gamma-globin genes1. To test whether the point mutation found in the Greek non-deletion HPFH2,3 (guanine to adenine at nucleotide position -117) is the cause of the raised gamma-globin levels in the adult stage and is not just a linked polymorphism, we engineered this mutation into a gamma-globin gene. When this gene was introduced into mice, the presence of the -117 mutation results in persistence of gamma-globin expression at a high level and a concomitant decrease in beta-globin expression in fetal and adult mice. We show that these changes correlate with the loss of binding of the transcription factor GATA1 to the gamma-globin promoter, suggesting that it may act as a negative regulator of the gamma-globin gene in adults.			BERRY, M (corresponding author), NATL INST MED RES,GENE STRUCT & EXPRESS LAB,RIDGEWAY,LONDON NW7 1AA,ENGLAND.							ANAGNOU NP, 1990, CLIN RES, V38, pA301; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; DIGNAM J, 1983, NUCLEIC ACIDS RES, V113, P1475; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FEINGOLD EA, 1989, BLOOD, V74, P2178; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GIGLIONI B, 1984, EMBO J, V3, P2641, DOI 10.1002/j.1460-2075.1984.tb02187.x; GILMAN J, 1988, NUCLEIC ACIDS RES, V18, P10635; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONCZ M, 1989, OXFORD SURVEYS EUKAR, P163; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STAMATOYANNOPOU.G, 1991, REGULATION HEMOGLOBI, pCH6; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; Weatherall D.J., 1981, THALASSAEMIA SYNDROM, V3rd ed.; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596	25	123	126	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					499	502		10.1038/358499a0	http://dx.doi.org/10.1038/358499a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1379347	Green Submitted			2022-12-24	WOS:A1992JG73900048
J	SPITERI, MA; KLENERMAN, P; SHEPPARD, MN; PADLEY, S; CLARK, TJK; NEWMANTAYLOR, A				SPITERI, MA; KLENERMAN, P; SHEPPARD, MN; PADLEY, S; CLARK, TJK; NEWMANTAYLOR, A			SEASONAL CRYPTOGENIC ORGANIZING PNEUMONIA WITH BIOCHEMICAL CHOLESTASIS - A NEW CLINICAL ENTITY	LANCET			English	Article							OBLITERANS-ORGANIZING PNEUMONIA; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE	The term crytogenic organising pneumonia has been used for the combination of dyspnoea, cough, pleuritic pain, widespread shadows on chest radiographs, and histological evidence of intra-alveolar organisation with buds of granulation tissue within the alveoli. We report 12 patients with seasonal recurrence of this disorder for between 3 and 11 years. In all 12 patients, symptoms recurred between late February and early May every year, tending to increase in severity each year, and resolved between June and January. Chest radiography and computed tomography showed bilateral consolidation. Lung biopsy samples showed intra-alveolar buds of granulation tissue. There were many neutrophils within the lumina of medium-sized airways and terminal bronchioles showed evidence of obstruction by granulation tissue. Functionally, the predominant defect was restrictive and only 2 patients (life-long non-smokers) had airflow limitation. All 12 patients had very high activities of liver enzymes, suggesting intrahepatic cholestasis, but no other evidence of liver disease. Cultures of blood, sputum, lung tissue, and bronchoalveolar lavage fluid, viral screening, and complement fixation tests were consistently negative. In all patients all abnormalities responded rapidly to oral steroid therapy. These findings suggest a seasonal syndrome of organising pneumonia and biochemical abnormalities indicative of intrahepatic cholestasis. No aetiological factor has been identified, but the nature and periodicity of the illness point to an inhaled agent present in the environment for a limited period every year.	ROYAL BROMPTON HOSP,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	Royal Brompton Hospital; Imperial College London			Sheppard, Mary N/AAB-3364-2019	Sheppard, Mary N/0000-0003-2724-3881; klenerman, paul/0000-0003-4307-9161				BELSEY R, 1960, BRIT J DIS CHEST, V54, P342, DOI 10.1016/S0007-0971(60)80068-X; BONKOWSKY HL, 1975, JAMA-J AM MED ASSOC, V1284, P233; CORDIER JF, 1989, CHEST, V96, P999, DOI 10.1378/chest.96.5.999; DAVISON AG, 1983, Q J MED, V207, P382; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; FORCE MLG, 1987, AM REV RESPIR DIS, V133, P705; HASLAM P L, 1987, European Journal of Respiratory Diseases Supplement, V71, P120; JEDERLINIC PJ, 1988, MEDICINE, V67, P154, DOI 10.1097/00005792-198805000-00002; Laennec Rene-Theophile-Hyacinthe, 1826, TRAITE AUSCULTATION, V1; MCCARTHY D S, 1973, Clinical Allergy, V3, P339, DOI 10.1111/j.1365-2222.1973.tb01341.x; MCLOUD TC, 1986, RADIOLOGY, V159, P1; MULLER NL, 1990, AM J ROENTGENOL, V154, P983; NEVILLE E, 1975, POSTGRAD MED J, V51, P361, DOI 10.1136/pgmj.51.596.361; Nishimura K, 1989, Rinsho Hoshasen, V34, P127; PEYROL S, 1990, AM J PATHOL, V137, P155; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; RUDD RM, 1981, AM REV RESPIR DIS, V124, P1; SULAVIK SB, 1989, CHEST, V96, P967, DOI 10.1378/chest.96.5.967; TESCHLER H, 1991, American Review of Respiratory Disease, V143, pA53; WOODHEAD MA, 1987, LANCET, V1, P671	20	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					281	284		10.1016/0140-6736(92)92366-N	http://dx.doi.org/10.1016/0140-6736(92)92366-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353201				2022-12-24	WOS:A1992JG66500013
J	KAELBLING, M; BURK, RD; ATKIN, NB; JOHNSON, AB; KLINGER, HP				KAELBLING, M; BURK, RD; ATKIN, NB; JOHNSON, AB; KLINGER, HP			LOSS OF HETEROZYGOSITY ON CHROMOSOME-17P AND MUTANT P53 IN HPV-NEGATIVE CERVICAL CARCINOMAS	LANCET			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; LUNG-CANCER; SUPPRESSION; MUTATIONS	Inactivation of the protein product of the wild-type tumour suppressor gene p53 through complexing of the protein with the E6 oncoprotein of human papillomaviruses (HPV) in HPV-infected cells is thought to be important in the aetiology of cervical carcinoma. Mutations of p53 have also been reported in HPV-negative carcinomas, and we now demonstrate loss of heterozygosity (LOH) of chromosome region 17p13 (in which p53 is located) in such tumours. Immunocytochemical staining with monoclonal antimutant-p53 antibody revealed that the carcinomas with LOH on 17p and completely lacking HPV DNA sequences had mutant p53. Thus the LOH had apparently resulted in the loss of the wild-type allele. Consequently, in both HPV-positive and HPV-negative tumours there is loss of function of wild-type p53, in the former because the protein product of the p53 gene complexes with that of the viral E6 gene, in the latter because the protein is altered, presumably as a result of a direct alteration of the p53 gene but possibly because of other posttranslational changes. That this mutant allele of the tumour suppressor gene may sometimes behave like an oncogene is suggested by the presence of more than the expected number of copies of the remaining chromosome 17 homologue in some carcinomas.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; MT VERNON HOSP,DEPT CANC RES,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA051395] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51395, CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1988, CYTOGENET CELL GENET, V47, P106, DOI 10.1159/000132521; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CROOK T, 1991, ONCOGENE, V6, P873; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KAELBLING M, 1986, CYTOGENET CELL GENET, V41, P65, DOI 10.1159/000132206; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	12	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					140	142		10.1016/0140-6736(92)93214-8	http://dx.doi.org/10.1016/0140-6736(92)93214-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352566				2022-12-24	WOS:A1992JE38200003
J	LIU, J; LISSENS, W; DEVROEY, P; VANSTEIRTEGHEM, A; LIEBAERS, I				LIU, J; LISSENS, W; DEVROEY, P; VANSTEIRTEGHEM, A; LIEBAERS, I			EFFICIENCY AND ACCURACY OF POLYMERASE-CHAIN-REACTION ASSAY FOR CYSTIC-FIBROSIS ALLELE DELTA-F508 IN SINGLE CELL	LANCET			English	Article							HUMAN PREIMPLANTATION EMBRYOS; ENZYMATIC AMPLIFICATION; DNA AMPLIFICATION; IDENTIFICATION; DIAGNOSIS; INVITRO; BIOPSY; GENE; PCR	Diagnosis of genetic disorders in the embryo before implantation, though possible by removal of one or two blastomeres at the eight-cell stage, is still experimental because the procedures of gene analysis of DNA from a single cell are not yet reliable enough for clinical application. We have evaluated the efficiency and accuracy of polymerase-chain-reaction (PCR) amplification of a single-copy gene, wild-type or cystic fibrosis DELTA-F508 allele, on single sperm cells from a donor known to be a heterozygous carrier of the DELTA-F508 mutation. DNA from single spermatozoa was decontaminated by restriction-enzyme treatment, then the region around the DELTA-F508 site was amplified by nested PCR. The distribution of the wild-type and mutant alleles (59 [55%] and 48 [45%, respectively]) in the 107 single spermatozoa did not differ from that expected (50% each). 1 sample did not provide an amplified signal. To check that the two alleles would be amplified with equal efficiency when they were both present within a cell, we did PCR for 51 two-sperm samples. Again the distribution did not deviate from that expected (17 [33%] both wild-type; 21 [41 %] one wild-type, one DELTA-F508; 13 [26%] both DELTA-F508 vs 25%; 50%; 25% expected). None of the 74 blanks in these experiments was contaminated. We conclude that our DELTA-F508 single-cell assay is efficient and accurate and can be used for analysis of blastomere DNA to diagnose cystic fibrosis before embryo implantation.	VRIJE UNIV BRUSSELS HOSP,DEPT MED GENET,LAARBEEKLAAN 101,B-1090 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,CTR REPROD MED,B-1050 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,DEPT MED GENET,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Lissens, Willy/B-2892-2013	Lissens, Willy/0000-0003-3875-9955				GYLLENSTEN U, 1990, PCR PROTOCOLS GUIDE, P300; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; JINNO Y, 1990, NUCLEIC ACIDS RES, V18, P6739, DOI 10.1093/nar/18.22.6739; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; NAVIDI W, 1991, HUM REPROD, V6, P836, DOI 10.1093/oxfordjournals.humrep.a137438; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; STROM CM, 1990, LANCET, V336, P306, DOI 10.1016/0140-6736(90)91835-X; VARAWALLA NY, 1991, PRENATAL DIAG, V11, P775, DOI 10.1002/pd.1970111006	15	44	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1190	1192		10.1016/0140-6736(92)91133-S	http://dx.doi.org/10.1016/0140-6736(92)91133-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349937				2022-12-24	WOS:A1992HU68400003
J	REGNSTROM, J; NILSSON, J; TORNVALL, P; LANDOU, C; HAMSTEN, A				REGNSTROM, J; NILSSON, J; TORNVALL, P; LANDOU, C; HAMSTEN, A			SUSCEPTIBILITY TO LOW-DENSITY-LIPOPROTEIN OXIDATION AND CORONARY ATHEROSCLEROSIS IN MAN	LANCET			English	Article							HERITABLE HYPERLIPIDEMIC RABBIT; GRADIENT ULTRACENTRIFUGATION; DEGRADATION; PROGRESSION; PLASMA; INVIVO	Animal studies indicate a possible role for lipid oxidation in the development of atherosclerosis. We set out to investigate whether there was a relation between the ability of low-density lipoprotein (LDL) to resist oxidation in vitro and the severity of coronary atherosclerosis in man. 35 unselected young (mean [SD] age 39.9 [4.2] years) male survivors of myocardial infarction underwent angiography, and LDL was isolate from their plasma by density gradient ultracentrifugation. In-vitro LDL susceptibility to oxidation was assessed by determination of the lag phase for the formation of conjugated dienes in the presence of copper ions. An inverse relation was found between lag phase and quantitative estimates of global coronary atherosclerosis (r = - 0.45; p < 0.02). Multivariate analysis indicated that the lag phase for oxidative modification of LDL and LDL cholesterol concentration correlated independently with seversity of coronary atherosclerosis. The lag phase for oxidation of LDL was also related to the triglyceride content of the LDL fraction (r = - 0.55; p < 0.002). The finding that susceptibility of LDL oxidation is associated with severity of coronary atherosclerosis may indicate that lipid oxidation promotes premature coronary atherosclerosis and that individuals with an LDL enriched in triglycerides are at particular risk.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MED,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT THORAC RADIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	REGNSTROM, J (corresponding author), KAROLINSKA INST,KAROLINSKA HOSP,KING GUSTAF VTH RES INST,BOX 60004,S-10401 STOCKHOLM 60,SWEDEN.							AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Carlson K, 1973, J Clin Pathol Suppl (Assoc Clin Pathol), V5, P32; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; HAMSTEN A, 1986, CIRCULATION, V73, P1097, DOI 10.1161/01.CIR.73.6.1097; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X	19	507	519	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1183	1186		10.1016/0140-6736(92)91129-V	http://dx.doi.org/10.1016/0140-6736(92)91129-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349935				2022-12-24	WOS:A1992HU68400001
J	DEWAEGH, SM; LEE, VMY; BRADY, ST				DEWAEGH, SM; LEE, VMY; BRADY, ST			LOCAL MODULATION OF NEUROFILAMENT PHOSPHORYLATION, AXONAL CALIBER, AND SLOW AXONAL-TRANSPORT BY MYELINATING SCHWANN-CELLS	CELL			English	Article							HEREDITARY HYPERTROPHIC NEUROPATHY; MONOCLONAL-ANTIBODIES DISTINGUISH; MOTOR NEURON DISEASE; TREMBLER MOUSE; MAMMALIAN NEUROFILAMENTS; CYTOSKELETAL PROTEINS; STRUCTURAL PROTEINS; GENE-EXPRESSION; GANGLION-CELLS; SCIATIC-NERVE	Studies in Trembler and control mice demonstrated that myelinating Schwann cells exert a profound influence on axons. Extensive contacts between myelin and axons have been considered structural. However, demyelination decreases neurofilament phosphorylation, slow axonal transport, and axonal diameter, as well as significantly increasing neurofilament density. In control sciatic nerves with grafted Trembler nerve segments, these changes were spatially restricted: they were confined to axon segments without normal myelination. Adjacent regions of the same axons had normal diameters, neurofilament phosphorylation, cytoskeletal organization, and axonal transport rates. Close intercellular contacts between myelinating Schwann cells and axons modulate a kinase-phosphatase system acting on neurofilaments and possibly other substrates. Myelination by Schwann cells sculpts the axon-altering functional architecture, electrical properties, and neuronal morphologies.	UNIV PENN,SCH MED,DEPT PATHOL,MED LAB,PHILADELPHIA,PA 19104	University of Pennsylvania	DEWAEGH, SM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS023868, R01NS018616, R01NS023868, R01NS023320] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18616, NS23868, NS23320] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; BERTHOLD CH, 1982, AXOPLASMIC TRANSPORT, P40; BIZZI A, 1986, ACTA NEUROPATHOL, V71, P154, DOI 10.1007/BF00687978; Brady ST, 1982, AXOPLASMIC TRANSPORT, P206; BREEN KC, 1988, FEBS LETT, V241, P213, DOI 10.1016/0014-5793(88)81064-0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDEN MJ, 1987, NEUROCHEM PATHOL, V7, P189; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CARDEN MJ, 1986, NEUROCHEM PATHOL, V5, P15; CZOSNEK H, 1980, J CELL BIOL, V85, P726, DOI 10.1083/jcb.85.3.726; DEWAEGH S, 1990, J NEUROSCI, V10, P1855; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; Griffin JW, 1988, INTRINSIC DETERMINAN, P403; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J NEUROSCI, V5, P2920; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; JOHNSON GVW, 1988, BRAIN RES, V456, P95, DOI 10.1016/0006-8993(88)90350-2; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasec R, 1988, INTRINSIC DETERMINAN, P1; LASEK RJ, 1983, COLD SPRING HARB SYM, V48, P731, DOI 10.1101/SQB.1983.048.01.076; LEE VMY, 1986, J NEUROSCI, V6, P2179; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; LOW PA, 1976, J NEUROL SCI, V30, P343, DOI 10.1016/0022-510X(76)90139-8; LOW PA, 1976, J NEUROL SCI, V30, P327, DOI 10.1016/0022-510X(76)90138-6; LOW PA, 1975, J NEUROL SCI, V26, P565, DOI 10.1016/0022-510X(75)90057-X; MCQUARRIE IG, 1986, J NEUROSCI, V6, P1593; MEDORI R, 1988, J NEUROSCI, V8, P1814; MEDORI R, 1988, NEUROLOGY, V38, P59; MONACO S, 1989, NEUROPATHOLOGY, V48, P26; NIXON RA, 1986, J BIOL CHEM, V261, P6298; OBLINGER MM, 1988, J NEUROSCI, V8, P1747; OBLINGER MM, 1987, J NEUROSCI, V7, P453; PAGGI P, 1987, J NEUROSCI, V7, P2397; PARHAD I, 1987, AXONAL TRANSPORT, P473; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; ROOTS BI, 1983, SCIENCE, V221, P971, DOI 10.1126/science.6192501; SCHMIDT ML, 1987, LAB INVEST, V56, P282; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; TASHIRO T, 1987, AXONAL TRANSPORT, P201; TOYOSHIMA I, 1989, J NEUROL SCI, V89, P269, DOI 10.1016/0022-510X(89)90028-2; TRAPP BD, 1990, ANN NY ACAD SCI, V605, P29, DOI 10.1111/j.1749-6632.1990.tb42378.x; WATSON DF, 1989, J NEUROCHEM, V53, P1818, DOI 10.1111/j.1471-4159.1989.tb09248.x; WILLARD M, 1983, CELL, V35, P551, DOI 10.1016/0092-8674(83)90189-7; WONG J, 1987, METAB BRAIN DIS, V2, P291, DOI 10.1007/BF00999699	55	649	652	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					451	463		10.1016/0092-8674(92)90183-D	http://dx.doi.org/10.1016/0092-8674(92)90183-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1371237				2022-12-24	WOS:A1992HD39800007
J	RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA				RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA			AMBULATORY OXYGEN IN CHRONIC HEART-FAILURE	LANCET			English	Note							OBSTRUCTIVE AIRWAYS DISEASE; PORTABLE OXYGEN; EXERCISE CAPACITY	Ambulatory oxygen therapy may be of benefit in bicycle exercise tests. We have assessed the effects of ambulatory oxygen during walk tests in 12 patients with chronic heart failure. In 6 min walks with the patient breathing air, mean (SD) arterial oxygen saturation (SaO2) fell from 94.4 (3.7)% at rest to 90.1 (6.1)% (p = 0.014) on exercise. 2 l/min oxygen increased resting SaO2 from 93.7 (4.0)% (air cylinder) to 96.5 (3.0)% (p < 0.001) with no effect on minimum SaO2, distance, or breathlessness. During endurance walks, 4 l/min oxygen increased minimum SaO2 from 90.4 (5.6)% to 93.5 (4.7)% (p = 0.011) but also had no effect on breathlessness or distance. Ambulatory oxygen in currently available cylinders cannot be recommended for patients with chronic heart failure.	LONDON CHEST HOSP,DEPT THORAC MED,BONNER RD,LONDON E2 9JX,ENGLAND; LONDON CHEST HOSP,DEPT CARDIOL,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; COCKROFT AL, 1989, Q J MED, V268, P669; DAVIDSON AC, 1988, THORAX, V43, P965, DOI 10.1136/thx.43.12.965; DAVIES S W, 1992, Pharmaceutical Medicine (London), V5, P239; DAVIES SW, 1991, BRIT HEART J, V65, P179; LEGGETT RJE, 1977, BRIT MED J, V2, P84, DOI 10.1136/bmj.2.6079.84; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; LOCK SH, 1991, RESP MED, V85, P407, DOI 10.1016/S0954-6111(06)80186-1; MOORE DP, 1992, LANCET, V339, P850, DOI 10.1016/0140-6736(92)90288-E; WATERHOUSE JC, 1983, THORAX, V38, P302, DOI 10.1136/thx.38.4.302	10	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1192	1193		10.1016/0140-6736(92)92893-K	http://dx.doi.org/10.1016/0140-6736(92)92893-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359262				2022-12-24	WOS:A1992JY38600005
J	BAGHURST, PA; MCMICHAEL, AJ; WIGG, NR; VIMPANI, GV; ROBERTSON, EF; ROBERTS, RJ; TONG, SL				BAGHURST, PA; MCMICHAEL, AJ; WIGG, NR; VIMPANI, GV; ROBERTSON, EF; ROBERTS, RJ; TONG, SL			ENVIRONMENTAL EXPOSURE TO LEAD AND CHILDRENS INTELLIGENCE AT THE AGE OF 7 YEARS - THE PORT-PIRIE COHORT STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-LEVEL EXPOSURE; BLOOD-LEAD; IRON-DEFICIENCY; EARLY-CHILDHOOD; SOCIAL-CLASS; PERFORMANCE; ATTAINMENT; BEHAVIOR; IQ	Background. Exposure to lead in early childhood is thought to result in delayed neuropsychological development. As yet there is little longitudinal evidence to establish whether these effects persist into later childhood. Methods. We measured IQ scores in 494 seven-year-old children from the lead-smelting community of Port Pirie, Australia, in whom developmental deficits associated with elevated blood lead concentrations had already been reported at the ages of two and four years. Exposure to lead was estimated from the lead concentrations in maternal blood samples drawn antenatally and at delivery and from blood samples drawn from the children at birth (umbilical-cord blood), at the ages of 6 and 15 months and 2 years, and annually thereafter. Data relating to known covariates of child development were collected systematically for each child throughout the first seven years of life. Results. We found inverse relations between IQ at the age of seven years and both antenatal and postnatal blood lead concentrations. After adjustment by multiple regression for sex, parents' level of education, maternal age at delivery, parents' smoking status, socioeconomic status, quality of the home environment, maternal IQ, birth weight, birth order, feeding method (breast, bottle, or both), duration of breast-feeding, and whether the child's natural parents were living together, the relation with lead exposure was still evident for postnatal blood samples, particularly within the age range of 15 months to 4 years. For an increase in blood lead concentration from 10 mug per deciliter (0.48 mumol per liter) to 30 mug per deciliter (1.45 mumol per liter), expressed as the average of the concentrations at 15 months and 2, 3, and 4 years, the estimated reduction in the IQ of the children was in the range of 4.4 points (95 percent confidence interval, 2.2 to 6.6) to 5.3 points (95 percent confidence interval, 2.8 to 7.8). This reduction represents an approximate deficit in IQ of 4 to 5 percent. Conclusions. Low-level exposure to lead during early childhood is inversely associated with neuropsychological development through the first seven years of life.	CHILD ADOLESCENT & FAMILY HLTH SERV,ADELAIDE,SA,AUSTRALIA; ADELAIDE CTR WOMENS & CHILDRENS HLTH,DEPT CHEM PATHOL,ADELAIDE,SA,AUSTRALIA; NATL HLTH EDUC INST,DEPT SPECIAL PROGRAMMES,BEIJING,PEOPLES R CHINA; UNIV ADELAIDE,DEPT COMMUNITY MED,ADELAIDE,SA 5001,AUSTRALIA; FLINDERS UNIV,SCH NURSING,ADELAIDE,SA,AUSTRALIA; UNIV NEWCASTLE,FAC MED,NEWCASTLE,NSW 2308,AUSTRALIA	University of Adelaide; Flinders University South Australia; University of Newcastle	BAGHURST, PA (corresponding author), CSIRO,DIV HUMAN NUTR,POB 10041,GOUGER ST,ADELAIDE,SA 5000,AUSTRALIA.							BAGHURST P, 1985, ENVIRON RES, V38, P24, DOI 10.1016/0013-9351(85)90069-6; BAGHURST PA, 1992, ARCH ENVIRON HEALTH, V47, P203, DOI 10.1080/00039896.1992.9938350; BELLINGER D, 1989, INT J EPIDEMIOL, V18, P180, DOI 10.1093/ije/18.1.180; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BINDER S, 1991, STRATEGIC PLAN ELIMI; BRADLEY RH, 1979, AM J MENT DEF, V84, P235; COONEY GH, 1989, NEUROTOXICOL TERATOL, V11, P95, DOI 10.1016/0892-0362(89)90047-0; DANIEL A, 1984, COMMUNITY HEALTH ST, V8, P218; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1988, SCI TOTAL ENVIRON, V71, P453, DOI 10.1016/0048-9697(88)90218-5; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FULTON M, 1987, LANCET, V1, P1221; GILBERT SG, 1987, TOXICOL APPL PHARM, V91, P484, DOI 10.1016/0041-008X(87)90070-6; HARVEY PG, 1984, SCI TOTAL ENVIRON, V40, P45, DOI 10.1016/0048-9697(84)90341-3; HATZAKIS A, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P211; Kaufman A.S., 1979, INTELLIGENT TESTING; LANSDOWN R, 1986, INT ARCH OCC ENV HEA, V57, P225, DOI 10.1007/BF00405790; LEE WR, 1990, BMJ-BRIT MED J, V301, P504, DOI 10.1136/bmj.301.6751.504; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MCMICHAEL AJ, 1985, MED J AUSTRALIA, V143, P499, DOI 10.5694/j.1326-5377.1985.tb119911.x; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P293; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; NEEDLEMAN HL, 1991, ANNU REV PUBL HEALTH, V12, P111, DOI 10.1146/annurev.pu.12.050191.000551; POCOCK SJ, 1987, INT J EPIDEMIOL, V16, P57, DOI 10.1093/ije/16.1.57; Rothman K, 1986, MODERN EPIDEMIOLOGY; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; WALTER T, 1989, PEDIATRICS, V84, P7; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; Wechsler D, 1974, WECHSLER ADULT INTEL; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213; WINNEKE G, 1983, INT ARCH OCC ENV HEA, V51, P231, DOI 10.1007/BF00377755; 1988, JAMA-J AM MED ASSOC, V260, P1523; 1986, EPA600883028AF ENV C; 1985, 27871985 STAND ASS A	38	406	412	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1279	1284		10.1056/NEJM199210293271805	http://dx.doi.org/10.1056/NEJM199210293271805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1383818				2022-12-24	WOS:A1992JV25900005
J	TAKAHAMA, Y; SHORES, EW; SINGER, A				TAKAHAMA, Y; SHORES, EW; SINGER, A			NEGATIVE SELECTION OF PRECURSOR THYMOCYTES BEFORE THEIR DIFFERENTIATION INTO CD4+CD8+ CELLS	SCIENCE			English	Article							RECEPTOR TRANSGENIC MICE; BETA-T-CELL; IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; CLONAL ELIMINATION; CD4+8+ THYMOCYTES; ANTIGEN RECEPTOR; INVIVO; INTERMEDIATE; GENERATION	Thymic selection of the developing T cell repertoire is thought to occur at the CD4+CD8+ stage of differentiation and to be determined by the specificity of the T cell receptors (TCRs) that CD4+CD8+ thymocytes express. However, TCR signals can inhibit the differentiation of precursor thymocytes into CD4+CDB+ cells, which suggests that selection might occur earlier than thought. Indeed, in a negatively selecting male thymus, CD4-CD8(lo) precursor thymocytes that express a transgenic TCR to male antigen are developmentally arrested as a consequence of antigen encounter and fail to become CD4+CD8+. Thus, negative selection can occur before the CD4+CD8+ stage of differentiation.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Takahama, Yousuke/A-5863-2010	Takahama, Yousuke/0000-0002-4992-9174				BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; Maniatis T., 1982, MOL CLONING; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TAKAHAMA Y, UNPUB; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THEILER K, 1989, HOUSE MOUSE; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	31	108	109	2	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					653	656		10.1126/science.1357752	http://dx.doi.org/10.1126/science.1357752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1357752				2022-12-24	WOS:A1992JU74500058
J	MOSS, SF; LEGON, S; BISHOP, AE; POLAK, JM; CALAM, J				MOSS, SF; LEGON, S; BISHOP, AE; POLAK, JM; CALAM, J			EFFECT OF HELICOBACTER-PYLORI ON GASTRIC SOMATOSTATIN IN DUODENAL-ULCER DISEASE	LANCET			English	Article							CAMPYLOBACTER PYLORI; GENE-EXPRESSION; ACID SECRETION; ANTRAL GASTRIN; G-CELL; SEQUENCE; BASAL	Infection of the gastric antrum by Helicobacter pylori is associated with recurrent duodenal ulcer disease but the mechanism of ulcerogenesis is unclear. Since pathways inhibiting gastric secretion are defective in patients with duodenal ulcers, we investigated whether H pylori interferes with the normal gastric inhibition that is mediated by somatostatin. We studied 28 patients with active duodenal ulcers in whom H pylori was eradicated successfully. In 18 patients, we measured the density of antral somatostatin-immunoreactive cells and in a further 10 subjects, the amount of somatostatin mRNA before and after eradication of H pylori was determined. After eradication, the median density of somatostatin-immunoreactive cells increased significantly from 9 (range 3-47) to 19 (6-57) cells per mm muscularis mucosa (p=0.025). The median somatostatin mRNA/rRNA ratio increased from 50 (25-160) to 95 (40-180) (p=0.01). The number of gastrin cells and quantity of gastrin mRNA did not change significantly. Our results suggest that in duodenal ulcer disease, gastric secretory function is disinhibited through the suppression Of mucosal somatostatin.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London	MOSS, SF (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAIR AJ, 1987, J CLIN INVEST, V79, P582, DOI 10.1172/JCI112850; BRAND SJ, 1988, J CLIN INVEST, V82, P1059, DOI 10.1172/JCI113662; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER RG, 1985, GUT, V26, P232, DOI 10.1136/gut.26.3.232; DOCKRAY GJ, 1991, GASTROENTEROLOGY, V100, P1187; GOLODNER E H, 1992, Gastroenterology, V102, pA630; GRAHAM D Y, 1991, Gastroenterology, V100, pA75; HOWARD A, 1992, BIOCHEM BIOPH RES CO, V183, P499, DOI 10.1016/0006-291X(92)90510-R; ITO R, 1984, P NATL ACAD SCI-BIOL, V81, P4662, DOI 10.1073/pnas.81.15.4662; KANEKO H, 1992, DIGEST DIS SCI, V37, P409, DOI 10.1007/BF01307736; KING W W, 1992, Gastroenterology, V102, pA646; KIRKPATRICK PM, 1980, GASTROENTEROLOGY, V79, P4; LEVI S, 1989, BRIT MED J, V299, P1504, DOI 10.1136/bmj.299.6714.1504; LEVI S, 1989, LANCET, V1, P1167; MALAGELADA JR, 1977, GASTROENTEROLOGY, V73, P989; MCCOLL KEL, 1989, LANCET, V2, P499; MOSS S, 1992, GUT, V33, P289, DOI 10.1136/gut.33.3.289; MOSS SF, 1992, GUT, V33, pS28; SHEN LP, 1982, P NATL ACAD SCI-BIOL, V79, P4575, DOI 10.1073/pnas.79.15.4575; SOLCIA E, 1988, DIGESTION, V41, P185, DOI 10.1159/000199786; TARNASKY P R, 1991, Gastroenterology, V100, pA845; WALSH JH, 1975, J CLIN INVEST, V55, P462, DOI 10.1172/JCI107952; WU V, 1991, GASTROENTEROLOGY, V101, P1552, DOI 10.1016/0016-5085(91)90391-W	23	276	280	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					930	932		10.1016/0140-6736(92)92816-X	http://dx.doi.org/10.1016/0140-6736(92)92816-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357347				2022-12-24	WOS:A1992JT82300002
J	MIZUKAMI, Y; MA, H				MIZUKAMI, Y; MA, H			ECTOPIC EXPRESSION OF THE FLORAL HOMEOTIC GENE AGAMOUS IN TRANSGENIC ARABIDOPSIS PLANTS ALTERS FLORAL ORGAN IDENTITY	CELL			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; THALIANA; TRANSFORMATION; MORPHOGENESIS; SEQUENCES; PRODUCT	The Arabidopsis floral homeotic gene AGAMOUS (AG) is required for development of the reproductive organs (stamens and carpels). In ag mutants, the loss of AG function leads to the conversion of these organs to the perianth organs (petals and sepals). In contrast, mutations in another floral homeotic gene, APETALA2 (AP2), result in the replacement of the perianth organs by the reproductive organs. On the basis of these observations, it has been proposed that AG and AP2 act in an antagonistic fashion. To test this hypothesis, we have studied the effects of ectopically expressed AG in transgenic Arabidopsis plants. The flowers of the transgenic plants exhibit a range of phenotypes mirroring those of ap2 mutants. These experiments provide direct evidence of the proposed antagonism between AG and AP2 functions, and the results strongly suggest that AG does indeed inhibit AP2 function.			MIZUKAMI, Y (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Ma, Hong/W-5251-2018	Ma, Hong/0000-0001-8717-4422				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MATZKE MA, 1990, DEV GENET, V11, P214, DOI 10.1002/dvg.1020110307; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; Pruitt RE, 1987, GENETIC REGULATION D, P327; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	355	387	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					119	131		10.1016/0092-8674(92)90271-D	http://dx.doi.org/10.1016/0092-8674(92)90271-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1356630				2022-12-24	WOS:A1992JQ62300012
J	ROWE, WJ				ROWE, WJ			EXTRAORDINARY UNREMITTING ENDURANCE EXERCISE AND PERMANENT INJURY TO NORMAL HEART	LANCET			English	Article							MYOCARDIAL NECROSIS; SERUM MAGNESIUM; VARIANT ANGINA; CATECHOLAMINES; PATHOGENESIS; ISCHEMIA; DAMAGE; SPASM	This hypothesis is that permanent cardiac injury could develop in some endurance athletes despite the absence of coronary atherosclerosis and ventricular hypertrophy. The proposed mechanism by which this injury could arise involves two physiological "vicious cycles". The first vicious cycle would occur between severe ischaemia and high catecholamines, the second would be between coronary vasospasm (induced by high catecholamines) and endothelial injury. The likelihood of the injury becoming permanent might increase if there is insufficient time between bouts of endurance exercise for regression of ischaemia and endothelial repair. Furthermore, magnesium ion deficiency, which can be induced by exercise, could exacerbate these vicious cycles and also contribute to catecholamine-induced thrombogenesis. In addition to ischaemia, there are several mechanisms, including the effect of free fatty acids liberated by the lipolytic effect of high catecholamines, that could cause direct myocardial injury.										ASTRAND PO, 1986, TXB WORK PHYSL PHYSL, P685; Badimon L., 1992, THROMBOSIS CARDIOVAS, P17; BELLER GA, 1975, AVIAT SPACE ENVIR MD, V46, P709; BENNET WC, 1935, TARAHUMARA INDIAN TR, P113; CHILIAN WM, 1986, CIRC RES, V58, P68, DOI 10.1161/01.RES.58.1.68; DEARMAN J, 1983, J SPORT MED PHYS FIT, V23, P30; EATON SB, 1988, PALEOLITHIC PRESCRIP, P32; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ESCOURROU P, 1984, J APPL PHYSIOL, V57, P1507, DOI 10.1152/jappl.1984.57.5.1507; FACTOR SM, 1985, PROG CARDIOVASC DIS, V27, P395, DOI 10.1016/0033-0620(85)90002-7; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GEFT IL, 1982, CIRCULATION, V66, P1150, DOI 10.1161/01.CIR.66.6.1150; GERTZ SD, 1981, CIRCULATION, V63, P476, DOI 10.1161/01.CIR.63.3.476; GOTO K, 1990, AM J CARDIOL, V65, P709, DOI 10.1016/0002-9149(90)91375-G; GREEN LH, 1976, ANN INTERN MED, V84, P704, DOI 10.7326/0003-4819-84-6-704; HIRAMATSU K, 1984, CLIN EXP PHARMACOL P, V11, P171, DOI 10.1111/j.1440-1681.1984.tb00254.x; KNOCHEL JP, 1961, AM J MED, V30, P299, DOI 10.1016/0002-9343(61)90101-2; KONDO T, 1987, CARDIOVASC RES, V21, P248, DOI 10.1093/cvr/21.4.248; LAKS MM, 1991, CATECHOLAMINES HEART, P103; MAJUMDER S, 1991, CATECHOLAMINES HEART, P267; MARON MB, 1977, EUR J APPL PHYSIOL O, V36, P231, DOI 10.1007/BF00423048; MCKECHNIE JK, 1979, S AFR MED J, V56, P261; PRASAD DM, 1980, SCIENCE, V208, P198; PREVITALI M, 1989, AM HEART J, V117, P92, DOI 10.1016/0002-8703(89)90661-3; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; ROWE WJ, 1991, CHEST, V99, P1306, DOI 10.1378/chest.99.5.1306; RYZEN E, 1990, J AM COLL NUTR, V9, P114; SCHWARTZ SM, 1975, AM J PATHOL, V81, P15; SEELIG MS, 1974, AM J CLIN NUTR, V27, P59, DOI 10.1093/ajcn/27.1.59; STENDIGLINDBERG G, 1987, J AM COLL NUTR, V6, P35; TODD GL, 1985, J MOL CELL CARDIOL, V17, P647, DOI 10.1016/S0022-2828(85)80064-X; WENGER NK, 1974, HEART ARTERIES VEINS, P1546; YASUE H, 1978, CIRCULATION, V58, P56, DOI 10.1161/01.CIR.58.1.56	33	56	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					712	714		10.1016/0140-6736(92)92243-9	http://dx.doi.org/10.1016/0140-6736(92)92243-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355810				2022-12-24	WOS:A1992JN78000015
J	HINDS, PW; MITTNACHT, S; DULIC, V; ARNOLD, A; REED, SI; WEINBERG, RA				HINDS, PW; MITTNACHT, S; DULIC, V; ARNOLD, A; REED, SI; WEINBERG, RA			REGULATION OF RETINOBLASTOMA PROTEIN FUNCTIONS BY ECTOPIC EXPRESSION OF HUMAN CYCLINS	CELL			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; GENE-PRODUCT; SUSCEPTIBILITY GENE; SACCHAROMYCES-CEREVISIAE; G1-SPECIFIC CYCLINS; CANDIDATE ONCOGENE; KINASE COMPLEX; G1 PHASE	The retinoblastoma susceptibility gene (RB) product, the retinoblastoma protein (pRb), functions as a regulator of cell proliferation. Introduction of the RB gene into SAOS-2 osteosarcoma cells, which lack functional pRb, prevents cell cycle progression. Such growth-suppressive functions can be modulated by phosphorylation of pRb, which occurs via cell cycle-regulated kinases. We show that constitutively expressed cyclins A and E can overcome pRb-mediated suppression of proliferation. pRb becomes hyperphosphorylated in cells overexpressing these cyclins, and this phosphorylation is essential for cyclin A- and cyclin E-mediated rescue of pRb-blocked cells. This suggests that G1 and S phase cyclins can act as regulators of pRb function in the cell cycle by promoting pRb phosphorylation.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Scripps Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	HINDS, PW (corresponding author), WHITEHEAD INST, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Dulic, Vjekoslav/0000-0003-1201-3901	NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038328, R01GM038328, P01GM046006] Funding Source: NIH RePORTER; NCI NIH HHS [CA55909] Funding Source: Medline; NIGMS NIH HHS [GM38328, GM46006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1992, IN PRESS SCIENCE; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MOTOKURA T, 1992, IN PRESS J BIOL CHEM; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	68	1007	1022	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					993	1006		10.1016/0092-8674(92)90249-C	http://dx.doi.org/10.1016/0092-8674(92)90249-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1388095				2022-12-24	WOS:A1992JN78100014
J	TOMKINS, CM				TOMKINS, CM			HIV TRANSMISSION AND THE LAW	LANCET			English	Editorial Material							POLICY; AIDS				TOMKINS, CM (corresponding author), MED DEF UNION,LONDON,ENGLAND.							BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1951; KRASNIK A, 1989, SOC SCI MED, V29, P577, DOI 10.1016/0277-9536(89)90203-7; LANSDELL GT, 1991, MED J AUSTRALIA, V154, P61, DOI 10.5694/j.1326-5377.1991.tb112856.x; IN PRESS AUSTR HIV A	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					543	543		10.1016/0140-6736(92)91732-N	http://dx.doi.org/10.1016/0140-6736(92)91732-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL234	1354289				2022-12-24	WOS:A1992JL23400017
J	AUBRY, JP; POCHON, S; GRABER, P; JANSEN, KU; BONNEFOY, JY				AUBRY, JP; POCHON, S; GRABER, P; JANSEN, KU; BONNEFOY, JY			CD21 IS A LIGAND FOR CD23 AND REGULATES IGE PRODUCTION	NATURE			English	Article							HUMAN LYMPHOCYTES-B; MHC CLASS-II; C3D RECEPTOR; SOLUBLE CD23; MONOCLONAL-ANTIBODIES; SEQUENCE HOMOLOGY; EBV/C3D RECEPTOR; INTERFERON-ALPHA; CELLS EXPRESS; ANTIGEN	THE molecule CD23, a low-affinity receptor for IgE (Fc-epsilon-R2)1,2, is a type II transmembrane molecule expressed on many haemopoietic cell types3,4. CD23 has pleiotropic roles in the control of lymphocyte behaviour5-9, suggesting that CD23 may interact with another ligand in addition to IgE. To identify such a CD23 ligand, we expressed and purified full-length recombinant CD23, incorporated it into fluorescent liposomes and used these as a probe. We report here that fluorescent liposomes carrying CD23 interact specifically with the cell-surface protein CD21, identified as the receptor for Epstein-Barr virus and the complement receptor-2 on B cells, some T cells and follicular dendritic cells. In addition, fluorescent CD23-liposomes were shown to bind to hamster kidney cells (BHK-21) transfected with CD21 complementary DNA. The interaction between fluorescent CD23-liposomes and B cells or CD21-transfected BHK-21 cells was specifically inhibited by anti-CD21 and anti-CD23 monoclonal antibodies. Western blotting analysis revealed that C-14-labelled liposomes carrying CD23, in contrast to anti-CD21 antibodies, reacted with a subtype of CD21 molecules. Triggering of CD21 either with an anti-CD21 antibody or with recombinant soluble CD23 was shown to increase specifically interleukin-4-induced IgE production from blood mononuclear cells. These results demonstrate that the cell-surface protein CD21 is a ligand for CD23 and that the pairing of these molecules may participate in the control of IgE production.	GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline								BILLAUD M, 1989, J VIROL, V63, P4121, DOI 10.1128/JVI.63.10.4121-4128.1989; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1988, J EXP MED, V167, P57, DOI 10.1084/jem.167.1.57; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; CAIRNS J, 1990, EUR J IMMUNOL, V20, P534; CANTALOUBE JF, 1990, EUR J IMMUNOL, V20, P409, DOI 10.1002/eji.1830200226; DELCAYRE AX, 1991, EMBO J, V10, P919, DOI 10.1002/j.1460-2075.1991.tb08025.x; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P99; FISCHER E, 1991, J IMMUNOL, V146, P865; FLORESROMO L, 1990, EUR J IMMUNOL, V20, P2465, DOI 10.1002/eji.1830201116; FRADE R, 1985, P NATL ACAD SCI USA, V82, P1490, DOI 10.1073/pnas.82.5.1490; GORDON J, 1986, EUR J IMMUNOL, V16, P1075, DOI 10.1002/eji.1830160908; GORDON J, 1989, IMMUNOL TODAY, V10, P153, DOI 10.1016/0167-5699(89)90171-0; GRABER P, 1992, J IMMUNOL METHODS, V149, P215, DOI 10.1016/0022-1759(92)90253-P; HUTTFLECHER LM, 1987, J VIROL, V651, P774; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; JANSEN KU, 1991, J RECEPTOR RES, V11, P507, DOI 10.3109/10799899109066424; KOLB JP, 1990, J IMMUNOL, V145, P429; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; MOSSALAYI MD, 1990, BLOOD, V75, P1924; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; NADLER LM, 1981, J IMMUNOL, V126, P1941; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; POCHON S, IN PRESS J EXP MED; REYNES M, 1985, J IMMUNOL, V135, P2687; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; TEW JG, 1979, IMMUNOLOGY, V37, P69; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; WILSON BS, 1985, BLOOD, V66, P824; YOUNG LS, 1986, LANCET, V1, P240; YUKAWA K, 1987, J IMMUNOL, V138, P2576	37	450	467	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					505	507		10.1038/358505a0	http://dx.doi.org/10.1038/358505a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1386409				2022-12-24	WOS:A1992JG73900050
J	WHITE, HD				WHITE, HD			THROMBOLYTIC THERAPY FOR PATIENTS WITH MYOCARDIAL-INFARCTION PRESENTING AFTER 6 HOURS	LANCET			English	Editorial Material							LEFT-VENTRICULAR VOLUME; CORONARY-OCCLUSION; REPERFUSION; MORTALITY; TRIAL				WHITE, HD (corresponding author), GREEN LANE HOSP, CARDIOVASC RES UNIT, AUCKLAND 3, NEW ZEALAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1991, LANCET, V337, P271; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V1, P397; BROWN EJ, 1991, J AM COLL CARDIOL, V17, P1641, DOI 10.1016/0735-1097(91)90660-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1987, EUR HEART J, V8, P634; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; JEREMY RW, 1987, J AM COLL CARDIOL, V9, P989, DOI 10.1016/S0735-1097(87)80298-X; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; SAGER PT, 1988, J AM COLL CARDIOL, V12, P19, DOI 10.1016/0735-1097(88)90350-6; WHITE H, 1988, LANCET, V2, P914; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1991, 40TH AM COLL CARD AN	20	21	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1992	340	8813					221	222		10.1016/0140-6736(92)90478-L	http://dx.doi.org/10.1016/0140-6736(92)90478-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353145				2022-12-24	WOS:A1992JE75800013
J	RABACCHI, S; BAILLY, Y; DELHAYEBOUCHAUD, N; MARIANI, J				RABACCHI, S; BAILLY, Y; DELHAYEBOUCHAUD, N; MARIANI, J			INVOLVEMENT OF THE N-METHYL D-ASPARTATE (NMDA) RECEPTOR IN SYNAPSE ELIMINATION DURING CEREBELLAR DEVELOPMENT	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; PURKINJE-CELLS; CLIMBING FIBERS; MULTIPLE INNERVATION; RAT CEREBELLUM; OLIVOCEREBELLAR RELATIONSHIPS; POSTNATAL-DEVELOPMENT; NERVOUS-SYSTEM; STRIATE CORTEX; VISUAL-CORTEX	In many instances, the establishment of highly specific neuronal connections during development results from the rearrangement of axonal projections through the trimming of exuberant collaterals or the elimination of functional synapses or both. Although the involvement of the N-methyl D-aspartate (NMDA) subtype of the glutamate receptor has been demonstrated in the shaping of axonal arbors, its participation in the process of selective stabilization of synapses remains an open issue. In this study, the effects of chronic in vivo application of D,L-2-amino-5-phosphonovaleric acid (D,L-APV), a selective antagonist of the NMDA receptor, on the synapse elimination process that takes place in the developing cerebellum of the rat have been analyzed. D,L-APV treatment prevented the regression of supernumerary climbing fiber synapses in 49 percent of the recorded Purkinje cells, while the inactive isomer L-APV was ineffective. Thus, activation of the NMDA receptor is a critical step in the regression of functional synapses during development.	UNIV PARIS 06,F-75230 PARIS 05,FRANCE; CNRS,INST NEUROSCI,NEUROBIOL DEV LAB,F-75005 PARIS,FRANCE	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)								ALKON DL, 1984, SCIENCE, V226, P1037, DOI 10.1126/science.6093258; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BEAR MF, 1990, J NEUROSCI, V10, P909; BENOIT P, 1984, DEV BRAIN RES, V14, P310, DOI 10.1016/0165-3806(84)90320-1; BENOIT P, 1987, DEV BRAIN RES, V34, P51, DOI 10.1016/0165-3806(87)90194-5; BENOIT P, 1975, BRAIN RES, V99, P354, DOI 10.1016/0006-8993(75)90036-0; BOURRAT F, 1984, DEV BRAIN RES, V16, P241, DOI 10.1016/0165-3806(84)90029-4; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1976, ARCH ITAL BIOL, V114, P49; CREPEL F, 1976, J NEUROBIOL, V7, P579, DOI 10.1002/neu.480070610; CREPEL F, 1981, DEV BRAIN RES, V1, P59, DOI 10.1016/0165-3806(81)90094-8; CREPEL F, 1976, J NEUROBIOL, V7, P567, DOI 10.1002/neu.480070609; CREPEL F, 1980, NATURE, V283, P482; DAVIES J, 1982, BRAIN RES, V235, P378, DOI 10.1016/0006-8993(82)91017-4; DELHAYEBOUCHAUD N, 1985, J COMP NEUROL, V232, P299, DOI 10.1002/cne.902320303; DUPONT JL, 1987, DEV BRAIN RES, V34, P59, DOI 10.1016/0165-3806(87)90195-7; FOX K, 1989, J NEUROSCI, V9, P2443; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GARTHWAITE J, 1989, NEUROSCIENCE, V29, P401, DOI 10.1016/0306-4522(89)90067-5; HAHN J, 1991, NATURE, V351, P568; HUSSAIN S, 1991, NEUROPHARMACOLOGY, V30, P1029, DOI 10.1016/0028-3908(91)90130-4; INNOCENTI GM, 1981, TRENDS NEUROSCI, V4, P142, DOI 10.1016/0166-2236(81)90047-3; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KRUPA M, 1990, EUR J NEUROSCI, V2, P312, DOI 10.1111/j.1460-9568.1990.tb00423.x; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MARIANI J, 1982, J NEUROBIOL, V13, P119, DOI 10.1002/neu.480130204; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MARIANI J, 1981, J NEUROSCI, V1, P696, DOI 10.1523/JNEUROSCI.01-07-00696.1981; MARIANI J, 1981, J NEUROSCI, V1, P703, DOI 10.1523/JNEUROSCI.01-07-00703.1981; MARIANI J, 1987, NEWS PHYSIOL SCI, V2, P93; MARIANI J, 1990, DEV BRAIN RES, V57, P63, DOI 10.1016/0165-3806(90)90185-2; MARIANI J, 1983, PROG BRAIN RES, V58, P383, DOI 10.1016/S0079-6123(08)60041-2; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; SANDOVAL ME, 1978, NEUROSCIENCE, V3, P199, DOI 10.1016/0306-4522(78)90101-X; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; WIKLUND L, 1982, SCIENCE, V216, P78, DOI 10.1126/science.6121375; WOODWARD DJ, 1974, J NEUROBIOL, V5, P283, DOI 10.1002/neu.480050402	47	290	295	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1823	1825		10.1126/science.1352066	http://dx.doi.org/10.1126/science.1352066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1352066				2022-12-24	WOS:A1992JA43400038
J	LARON, Z; ANIN, S; KLIPPERAURBACH, Y; KLINGER, B				LARON, Z; ANIN, S; KLIPPERAURBACH, Y; KLINGER, B			EFFECTS OF INSULIN-LIKE GROWTH-FACTOR ON LINEAR GROWTH, HEAD CIRCUMFERENCE, AND BODY-FAT IN PATIENTS WITH LARON-TYPE DWARFISM	LANCET			English	Article							HORMONE-RECEPTOR GENE; FACTOR-I; BINDING-PROTEIN; IGF-I; DEFICIENCY; THERAPY	Patients with Laron-type dwarfism are clinically indistinguishable from those with isolated growth hormone (GH) deficiency, yet have high circulating GH concentrations associated with an inability to generate endogenous insulin-like growth factor I (IGF-I). Biosynthetic IGF-I was administered subcutaneously once daily for 3 to 10 months to 5 children with Laron-type dwarfism aged 3.3 to 14.5 years. There was a rapid stimulation of linear growth in body limbs, with a striking increase in head circumference, increased body weight, and a reduction in subcutaneous fat. Administration of IGF-I to patients with Laron-type dwarfism seems to have a beneficial effect on growth similar to that observed with long-term administration of GH in children with GH deficiency.			LARON, Z (corresponding author), TEL AVIV UNIV,SACKLER FAC MED,CHILDRENS MED CTR,INST PAEDIAT & ADOLESCENT ENDOCRINOL,IL-49100 PETAH TIQWA,ISRAEL.							ACETO T, 1972, J CLIN ENDOCR METAB, V35, P483, DOI 10.1210/jcem-35-4-483; AMSELEM S, 1989, NEW ENGL J MED, V321, P989, DOI 10.1056/NEJM198910123211501; BAUMANN G, 1987, J CLIN ENDOCR METAB, V65, P814, DOI 10.1210/jcem-65-4-814; ESHET R, 1984, ISRAEL J MED SCI, V20, P8; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; JORGENSEN JOL, 1989, LANCET, V1, P1221; JOSEFSBERG Z, 1987, HORM RES, V27, P126, DOI 10.1159/000180800; LARON Z, 1990, ACTA ENDOCRINOL-COP, V123, P378, DOI 10.1530/acta.0.1230378; LARON Z, 1991, CLIN ENDOCRINOL, V35, P145, DOI 10.1111/j.1365-2265.1991.tb03513.x; LARON Z, 1988, LANCET, V2, P1170; LARON Z, 1966, ISRAEL J MED SCI, V2, P152; LARON Z, 1968, HELV PAEDIATR ACTA, V23, P37; LARON Z, 1979, CLIN ENDOCRINOL, V10, P393, DOI 10.1111/j.1365-2265.1979.tb02094.x; LARON Z, 1971, J CLIN ENDOCR METAB, V33, P332, DOI 10.1210/jcem-33-2-332; LARON Z, 1989, ACTA ENDOCRINOL-COP, V121, P603, DOI 10.1530/acta.0.1210603; LARON Z, 1974, HORM METAB RES S, V5, P162; LARON Z, 1972, GROWTH GROWTH HORMON, P458; Laron Z, 1984, ADV INTERNAL MED PED, P117; MEACHAM LR, 1990, 72ND P ANN M AM END, P373; NELLHAUS G, 1968, PEDIATRICS, V41, P106; NIWA M, 1986, ANN NY ACAD SCI, V469, P31, DOI 10.1111/j.1749-6632.1986.tb26482.x; TAKANO K, 1990, ENDOCRINOL JAPON, V37, P309; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613	24	172	173	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1258	1261		10.1016/0140-6736(92)91594-X	http://dx.doi.org/10.1016/0140-6736(92)91594-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349669				2022-12-24	WOS:A1992HV19100004
J	GISHIZKY, ML; WITTE, ON				GISHIZKY, ML; WITTE, ON			INITIATION OF DEREGULATED GROWTH OF MULTIPOTENT PROGENITOR CELLS BY BCR-ABL INVITRO	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; MYELOID-LEUKEMIA; MICE; TRANSFORMATION; INDUCTION; CULTURES; PROTEIN; BCR/ABL; REGION	Expression of the bcr-abl oncogene in multipotent progenitor cells (MPPCs) is implicated as a key event in the development of chronic myelogenous leukemia. Bone marrow enriched for MPPCs was infected with a retrovirus that carried bcr-abl. The mixed-lineage colonies that resulted were responsive to growth factors and could differentiate. These cells later became growth factor-independent but, when injected into severe combined immunodeficient mice, were not leukemogenic. Thus, the presence of bcr-abl alone does not cause growth factor independence, although it initiates a stepwise process. This system may prove useful in the study of other oncogenes that cause leukemia.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	GISHIZKY, ML (corresponding author), UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024, USA.							AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BODINE DM, 1991, BLOOD, V78, P914; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COLLINS SJ, 1990, CHRONIC MYELOGENOUS, P253; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EPSTEIN J, 1990, NEW ENGL J MED, V322, P664, DOI 10.1056/NEJM199003083221005; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; GISHIZKY ML, 1991, ONCOGENE, V6, P1299; GISHIZKY ML, UNPUB; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCCARTHY DM, 1984, LANCET, V2, P1362; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; NOWELL PC, 1960, SCIENCE, V132, P1497; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TOWATARI M, 1991, BLOOD, V78, P2178, DOI 10.1182/blood.V78.9.2178.bloodjournal7892178; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; [No title captured]	36	155	160	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					836	839		10.1126/science.1375394	http://dx.doi.org/10.1126/science.1375394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375394				2022-12-24	WOS:A1992HT23500045
J	NICOLAIDES, KH; AZAR, G; BYRNE, D; MANSUR, C; MARKS, K				NICOLAIDES, KH; AZAR, G; BYRNE, D; MANSUR, C; MARKS, K			FETAL NUCHAL TRANSLUCENCY - ULTRASOUND SCREENING FOR CHROMOSOMAL DEFECTS IN 1ST TRIMESTER OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							CYSTIC HYGROMA; 1ST-TRIMESTER DIAGNOSIS; RECURRENCE	Objective-To examine the significance of fetal nuchal translucency at 10-14 weeks' gestation in the prediction of abnormal fetal karyotype. Design-Prospective screening study. Setting-The Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London. Subjects-827 fetuses undergoing first trimester karyotyping by aminocentesis or chorionic villus sampling. Main outcome measure-Incidence of chromosomal defects. Results-The incidence of chromosomal defects was 3% (28 of 827 cases). In the 51 (6%) fetuses with nuchal translucency 3-8 mm thick the incidence of chromosomal defects was 35% (18 cases). In contrast, only 10 of the remaining 776 (1%) fetuses were chromosomally abnormal. Conclusion-Fetal nuchal translucency greater-than-or-equal-to 3 mm is a useful first trimester marker for fetal chromosomal abnormalities.			NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				AZAR GB, IN PRESS FETAL DIAGN; BRONSHTEIN M, 1989, AM J OBSTET GYNECOL, V161, P78, DOI 10.1016/0002-9378(89)90237-8; BYRNE D, 1991, ULTRASOUND OBSTETRIC, V1, P234; CULLEN MT, 1990, PRENATAL DIAG, V10, P643, DOI 10.1002/pd.1970101004; DALLAPICCOLA B, 1984, PRENATAL DIAG, V4, P383, DOI 10.1002/pd.1970040510; GUSTAVII B, 1984, ACTA OBSTET GYN SCAN, V63, P377, DOI 10.3109/00016348409155537; NICOLAIDES KH, 1985, BRIT J OBSTET GYNAEC, V92, P671, DOI 10.1111/j.1471-0528.1985.tb01446.x; NICOLAIDES KH, IN PRESS FETAL DIAGN; PONS JC, 1989, EUR J OBSTET GYN R B, V33, P141, DOI 10.1016/0028-2243(89)90206-2; REUSS A, 1987, EUR J OBSTET GYN R B, V26, P271, DOI 10.1016/0028-2243(87)90079-7; REUSS A, 1987, PRENATAL DIAG, V7, P299, DOI 10.1002/pd.1970070412; VANDERPUTTE SCJ, 1977, VIRCHOWS ARCH A, V376, P233	12	707	766	0	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					867	869		10.1136/bmj.304.6831.867	http://dx.doi.org/10.1136/bmj.304.6831.867			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392745	Bronze, Green Published			2022-12-24	WOS:A1992HM83500020
J	LANE, EB; RUGG, EL; NAVSARIA, H; LEIGH, IM; HEAGERTY, AHM; ISHIDAYAMAMOTO, A; EADY, RAJ				LANE, EB; RUGG, EL; NAVSARIA, H; LEIGH, IM; HEAGERTY, AHM; ISHIDAYAMAMOTO, A; EADY, RAJ			A MUTATION IN THE CONSERVED HELIX TERMINATION PEPTIDE OF KERATIN-5 IN HEREDITARY SKIN BLISTERING	NATURE			English	Article							AMINO-ACID-SEQUENCE; INTERMEDIATE FILAMENTS; EPIDERMOLYSIS BULLOSA; EXPRESSION; CELLS; EPITHELIA; PATTERNS; ANTIBODY; PROTEINS; TUMORS	IN the hereditary blistering condition epidermolysis bullosa simplex, the skin blisters on trauma following rupture of epidermal basal cells. Clinical variations range from severely incapacitating, especially in early childhood, to mild forms that may not even present clinically. Dowling-Meara epidermolysis bullosa simplex is characterized by clusters of epidermal blisters and keratin clumping in the cytoplasm 1; recent reports describe potentially causal mutations in keratin 14 (refs 2, 3). Here we describe a 'complementary' mutation at the other end of the other keratin expressed by these cells (K5, coexpressed with K14), a change from a Glu to a Gly in the helix termination peptide, detected by altered antibody binding and confirmed by sequencing using the polymerase chain reaction. The two conserved helix boundary peptides are predicted to be essential for filament assembly, and the requirement for two complementary (type I and type II) keratins is absolute. Epidermolysis bullosa simplex diseases demonstrate the function of the keratin cytoskeleton in resisting compaction stresses which otherwise lead to cell lysis.	EXPTL DERMATOL LAB,LONDON E1 2BL,ENGLAND; IMPERIAL CANC RES FUND,SKIN TUMOUR LAB,LONDON E1 2BL,ENGLAND; N STAFFORDSHIRE ROYAL INFIRM,DEPT DERMATOL,STOKE ON TRENT ST4 7LN,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,INST DERMATOL,DEPT CELL PATHOL,LONDON SE1 7EH,ENGLAND	University of London; Queen Mary University London; Cancer Research UK; Keele University; University Hospital of North Staffordshire NHS Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	LANE, EB (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT ANAT & PHYSIOL,CANC RES CAMPAIGN,CELL STRUCT RES GRP,DUNDEE DD1 4HN,SCOTLAND.							ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BONIFAS JM, 1991, J INVEST DERMATOL, V96, pA550; CHAPMAN S J, 1985, European Journal of Cell Biology, V39, P352; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COOPER D, 1984, DIFFERENTIATION, V28, P30, DOI 10.1111/j.1432-0436.1984.tb00263.x; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; ECKERT RL, 1988, DNA-J MOLEC CELL BIO, V7, P337, DOI 10.1089/dna.1.1988.7.337; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; HATZFELD M, 1991, J CELL SCI, V99, P351; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; Lane E B, 1990, Semin Cancer Biol, V1, P165; LEIGH IM, 1984, BRIT J DERMATOL, V111, P527, DOI 10.1111/j.1365-2133.1984.tb06621.x; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MISCHKE D, 1990, AM J HUM GENET, V46, P548; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1988, VIRCHOWS ARCH B, V58, P105; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PURKIS PE, 1990, J CELL SCI, V97, P39; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Sambrook J., 1989, MOL CLONING LAB MANU; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; TREVOR K T, 1990, New Biologist, V2, P1004; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F	29	355	360	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					244	246		10.1038/356244a0	http://dx.doi.org/10.1038/356244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1372711				2022-12-24	WOS:A1992HJ94400059
J	SHERIDAN, WP; BEGLEY, CG; JUTTNER, CA; SZER, J; TO, LB; MAHER, D; MCGRATH, KM; MORSTYN, G; FOX, RM				SHERIDAN, WP; BEGLEY, CG; JUTTNER, CA; SZER, J; TO, LB; MAHER, D; MCGRATH, KM; MORSTYN, G; FOX, RM			EFFECT OF PERIPHERAL-BLOOD PROGENITOR CELLS MOBILIZED BY FILGRASTIM (G-CSF) ON PLATELET RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY	LANCET			English	Article							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; NON-LYMPHOBLASTIC LEUKEMIA; NEUTROPHIL RECOVERY; EARLY REMISSION; GRANULOCYTE; MALIGNANCIES; RECONSTITUTION; COLLECTION	The haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF; filgrastim) substantially shortens the period of severe neutropenia that follows high-dose chemotherapy and autologous bone-marrow infusion by stimulating granulopoiesis. Filgrastim also increases numbers of circulating progenitor cells. We have studied the ability of filgrastim to mobilise peripheral-blood progenitor cells and assessed their efficacy when infused after chemotherapy on recovery of neutrophil and platelet counts. 17 patients with non-myeloid malignant disorders received filgrastim (12-mu-g/kg daily for 6 days) by continuous subcutaneous infusion. Numbers of granulocyte-macrophage progenitors in peripheral-blood increased a median of 58-fold over pretreatment values, and numbers of erythroid progenitors increased a median of 24-fold. Three leucapheresis procedures collected a mean total of 33 (SEM 5.7) x 10(4) granulocyte-macrophage progenitors per kg body weight. After high-dose chemotherapy in 14 of the patients (busulphan and cyclophosphamide), these cells were used to augment autologous bone-marrow rescue and posttransplant filgrastim treatment. Platelet recovery was significantly faster in these patients than in controls who received the same treatment apart from the infusion of peripheral-blood progenitors; the platelet count reached 50 x 10(9)/l a median of 15 days after infusion of haemopoietic cells in the study patients compared with 39 days in controls (p = 0.0006). The accelerated neutrophil recovery associated with filgrastim treatment after chemotherapy was maintained. This method may be widely applicable to aid both neutrophil and platelet recovery after high-dose chemotherapy; it will allow investigation of peripheral-blood progenitor-cell allotransplantation.	ALFRED UNIV,CLIN HAEMATOL & BONE MARROW TRANSPLANTAT UNIT,ALFRED,NY 14802; LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIAGNOST HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL ADELAIDE HOSP,CLIN HAEMATOL & BONE MARROW TRANSPLANTAT UNIT,ADELAIDE,SA 5000,AUSTRALIA	State University of New York (SUNY) System; Alfred University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Adelaide Hospital	SHERIDAN, WP (corresponding author), ROYAL MELBOURNE HOSP,DEPT CLIN HAEMATOL & MED ONCOL,PARKVILLE,VIC 3050,AUSTRALIA.			Szer, Jeff/0000-0001-6783-2301; Sheridan, William/0000-0001-8320-1323				ANTMAN K, 1991, AUTOLOGOUS BONE MARR, P305; BLAZAR BR, 1989, BLOOD, V73, P849; DEVEREAUX S, 1989, BONE MARROW TRANSPL, V4, P49; DUHRSEN U, 1988, BLOOD, V72, P2074; FERRERO D, 1989, BLOOD, V73, P402; GABRILOVE JL, 1988, J CLIN INVEST, V82, P1454, DOI 10.1172/JCI113751; GIANNI AM, 1989, LANCET, V2, P580; GIANNI AM, 1990, BONE MARROW TRANSPL, V6, P143; GORIN NC, 1986, CLIN HAEMATOL, V15, P19, DOI 10.1016/S0308-2261(86)80004-2; HAAS R, 1990, EXP HEMATOL, V18, P94; HARA H, 1989, EXP HEMATOL, V17, P816; MCNIECE I, 1989, BLOOD, V74, P110; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1986, BLOOD, V67, P257; MOLINEUX G, 1990, BLOOD, V76, P2153; MORSTYN G, 1991, CANCER CHEMOTHERAPY, P307; NEMUNAITIS J, 1988, BLOOD, V72, P834; OFFIT K, 1990, BLOOD, V75, P1346; PETERS WP, 1991, AUTOLOGOUS BONE MARR, P313; PETZ LD, 1987, BLOOD, V70, P1331; SHERIDAN WP, 1989, MED J AUSTRALIA, V151, P379, DOI 10.5694/j.1326-5377.1989.tb101219.x; SHERIDAN WP, 1989, LANCET, V2, P891; SOCINSKI MA, 1988, LANCET, V1, P1194; TAYLOR KM, 1989, J CLIN ONCOL, V7, P1791, DOI 10.1200/JCO.1989.7.12.1791; TO LB, 1984, BRIT J HAEMATOL, V58, P399, DOI 10.1111/j.1365-2141.1984.tb03987.x; TO LB, 1990, BONE MARROW TRANSPL, V6, P109; TO LB, 1987, BONE MARROW TRANSPL, V2, P103	27	933	961	0	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					640	644		10.1016/0140-6736(92)90795-5	http://dx.doi.org/10.1016/0140-6736(92)90795-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1371817				2022-12-24	WOS:A1992HH74300004
J	MAHOWALD, AP				MAHOWALD, AP			GERM PLASM REVISITED AND ILLUMINATED	SCIENCE			English	Editorial Material							POLAR GRANULES; ANTEROPOSTERIOR POLARITY; DROSOPHILA EMBRYO; LOCALIZATION; GENE; VASA; EGG				MAHOWALD, AP (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.							BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; BOSWELL RE, 1985, COMPREHENSIVE INSECT, V1, P387; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HAY B, 1990, DEVELOPMENT, V109, P425; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1971, J EXP ZOOL, V176, P345, DOI 10.1002/jez.1401760309; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MAHOWALD AP, 1971, DEV BIOL, V24, P37, DOI 10.1016/0012-1606(71)90045-5; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WARING GL, 1978, DEV BIOL, V6, P197	26	24	24	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1216	1217		10.1126/science.1372132	http://dx.doi.org/10.1126/science.1372132			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1372132				2022-12-24	WOS:A1992HG67700030
J	VANACKER, BAC; KOOMEN, GCM; KOOPMAN, MG; DEWAART, DR; ARISZ, L				VANACKER, BAC; KOOMEN, GCM; KOOPMAN, MG; DEWAART, DR; ARISZ, L			CREATININE CLEARANCE DURING CIMETIDINE ADMINISTRATION FOR MEASUREMENT OF GLOMERULAR-FILTRATION RATE	LANCET			English	Article							MARKER; PHARMACOKINETICS; IMPROVES	Creatinine clearance inaccurately estimates true glomerular filtration rate (GFR) because of tubular secretion of creatinine. We studied the ability of oral cimetidine, a blocker of tubular creatinine secretion, to improve the accuracy of measuring creatinine clearance. Clearances of inulin and endogenous creatinine were simultaneously measured in 16 patients with renal disease before administration of cimetidine and during 8 successive 3 h clearance periods with cimetidine 400 mg as priming dose followed by 200 mg every 3 h. At baseline, creatinine relative to inulin clearance (Cl(C)/Cl(I)) ranged from 1.14 to 2.27. With cimetidine, Cl(C)/Cl(I) approached unity in 8 patients (mean 1.02 [SD 0.03]), but considerably exceeded unity in 8 others (1.33 [0.14]). Plasma cimetidine/creatinine ratio was smaller in this second group, due to significantly higher renal clearance of cimetidine (333 [136] vs 165 [89] ml/min, p=0.01). In a further study, cimetidine dose and, consequently plasma cimetidine concentration, was increased in 6 additional patients who had incomplete inhibition previously. This increased dose completely inhibited tubular creatinine secretion in the third until the sixth hour, so that creatinine clearance equalled GFR. Provided an adequate dose of cimetidine is given, 24 h creatinine clearance during administration of drug measures GFR accurately in patients with renal disease. However, because of the maximum daily dose of cimetidine that is advised, short clearance times (3 h) are recommended.	UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN CHEM,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VANACKER, BAC (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT MED,RENAL UNIT F4-215,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.							BAUER JH, 1982, AM J KIDNEY DIS, V2, P337, DOI 10.1016/S0272-6386(82)80091-7; BERLYNE GM, 1964, LANCET, V2, P874; BRATER C, 1992, KIDNEY PHYSL PATHOPH, P3597; BROWN P, 1977, CLIN CHIM ACTA, V76, P103, DOI 10.1016/0009-8981(77)90123-1; BURGESS E, 1982, RENAL PHYSIOL BIOCH, V5, P27; CARRIE BJ, 1980, AM J MED, V69, P177, DOI 10.1016/0002-9343(80)90376-9; GIOVANNETTI S, 1991, NEPHRON, V59, P11, DOI 10.1159/000186510; GISCLON LG, 1988, DRUG METAB DISPOS, V16, P331; HILBRANDS LB, 1991, KIDNEY INT, V40, P1171, DOI 10.1038/ki.1991.331; HOOD B, 1971, Scandinavian Journal of Urology and Nephrology, V5, P154, DOI 10.3109/00365597109133594; KOOPMAN MG, 1989, CLIN SCI, V77, P105, DOI 10.1042/cs0770105; LEVINSKY NG, 1959, AM J PHYSIOL, V196, P549, DOI 10.1152/ajplegacy.1959.196.3.549; Miller BF, 1938, J CLIN INVEST, V17, P31, DOI 10.1172/JCI100925; PETRI M, 1988, KIDNEY INT, V34, P832, DOI 10.1038/ki.1988.257; ROUBENOFF R, 1990, ANN INTERN MED, V113, P501, DOI 10.7326/0003-4819-113-7-501; Shannon JA, 1935, J CLIN INVEST, V14, P403, DOI 10.1172/JCI100691; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; SOMOGYI A, 1983, CLIN PHARMACOKINET, V8, P463, DOI 10.2165/00003088-198308060-00001; VANACKER BAC, 1992, J LAB CLIN MED, V120, P400; VANGINNEKEN CAM, 1989, CLIN PHARMACOKINET, V16, P38, DOI 10.2165/00003088-198916010-00003; WEBER JA, 1991, CLIN CHEM, V37, P695; ZIEMNIAK JA, 1981, CLIN CHEM, V27, P272	22	138	138	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1326	1329		10.1016/0140-6736(92)92502-7	http://dx.doi.org/10.1016/0140-6736(92)92502-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360044	Bronze			2022-12-24	WOS:A1992KA26200013
J	MOMBAERTS, P; CLARKE, AR; RUDNICKI, MA; IACOMINI, J; ITOHARA, S; LAFAILLE, JJ; WANG, LL; ICHIKAWA, Y; JAENISCH, R; HOOPER, ML; TONEGAWA, S				MOMBAERTS, P; CLARKE, AR; RUDNICKI, MA; IACOMINI, J; ITOHARA, S; LAFAILLE, JJ; WANG, LL; ICHIKAWA, Y; JAENISCH, R; HOOPER, ML; TONEGAWA, S			MUTATIONS IN T-CELL ANTIGEN RECEPTOR GENES ALPHA-BLOCK AND BETA-BLOCK THYMOCYTE DEVELOPMENT AT DIFFERENT STAGES	NATURE			English	Article							MOUSE PGK-1 GENE; TRANSGENIC MICE; EXPRESSION; CHAIN; ORGANIZATION; DIVERSITY; ANTIBODY; SEQUENCE; PROMOTER; MUTANT	Analysis of mice carrying mutant T-cell antigen receptor (TCR) genes indicates that TCR-beta gene rearrangement or expression is critical for the differentiation of CD4-CD8- thymocytes to CD4+CD8+ thymocytes, as well as for the expansion of the pool of CD4+CD8+ cells. TCR-alpha is irrelevant in these developmental processes. The development of gammadelta T cells does not depend on either TCR-alpha or TCR-beta.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV EDINBURGH,AFRC,CTR GENOME RES,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV EDINBURGH,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Edinburgh; Massachusetts Institute of Technology (MIT); University of Edinburgh			Itohara, Shigeyoshi/I-8769-2012; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Itohara, Shigeyoshi/0000-0002-2410-9989; Clarke, Alan/0000-0002-4281-426X				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HAAS W, 1992, CURR OPIN IMMUNOL, V4, P147, DOI 10.1016/0952-7915(92)90004-X; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; HOCKETT R D JR, 1989, New Biologist, V1, P266; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P293; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; SHORTMAN K, 1992, CURR OPIN IMMUNOL, V4, P140, DOI 10.1016/0952-7915(92)90003-W; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	29	968	983	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					225	231		10.1038/360225a0	http://dx.doi.org/10.1038/360225a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359428				2022-12-24	WOS:A1992JY96000041
J	SHATZ, CJ				SHATZ, CJ			DIVIDING UP THE NEOCORTEX	SCIENCE			English	Editorial Material							CAT STRIATE CORTEX; CORTICAL AREAS; CONNECTIONS; NEURONS; SEGMENTATION; SPECIFICITY; HINDBRAIN				SHATZ, CJ (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV NEUROBIOL, BERKELEY, CA 94720 USA.							BARBE MF, 1991, J NEUROSCI, V11, P519; BOLTZ J, 1990, NATURE, V346, P359; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; FISHELL CA, 1992, SOC NEUR ABSTR, V18, P926; Frantz G. D., 1992, Society for Neuroscience Abstracts, V18, P957; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; KATZ LC, 1991, EUR J NEUROSCI, V3, P1, DOI 10.1111/j.1460-9568.1991.tb00805.x; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; STERN CD, 1988, TRENDS NEUROSCI, V11, P190, DOI 10.1016/0166-2236(88)90120-8; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	27	31	32	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					237	238		10.1126/science.1357747	http://dx.doi.org/10.1126/science.1357747			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357747				2022-12-24	WOS:A1992JR86000016
J	ROBERTS, JD; POLANER, DM; LANG, P; ZAPOL, WM				ROBERTS, JD; POLANER, DM; LANG, P; ZAPOL, WM			INHALED NITRIC-OXIDE IN PERSISTENT PULMONARY-HYPERTENSION OF THE NEWBORN	LANCET			English	Note							RELAXING FACTOR	Nitric oxide (NO) has vasodilatory effects on the pulmonary vasculature in adults and animals. We examined the effects on systemic oxygenation and blood pressure of inhaling up to 80 parts per million by volume of NO at F(i)O2 0.9 for up to 30 minutes by 6 infants with persistent pulmonary hypertension of the newborn (PPHN). In all infants this treatment rapidly and significantly increased preductal oxygen saturation (SpO2); in 5 infants postductal SpO2 and oxygen tensions also increased. Inhalation of NO did not cause systemic hypotension or raise methaemoglobin. These data suggest that low levels of inhaled NO have an important role in the reversal of hypoxaemia due to PPHN.	MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ROBERTS, JD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114, USA.		Polaner, David M/AAX-2514-2021	Polaner, David M/0000-0001-8716-6289	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042397] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42397] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CLUTTONBROCK J, 1967, BRIT J ANAESTH, V39, P388, DOI 10.1093/bja/39.5.388; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS J D JR, 1992, American Review of Respiratory Disease, V145, pA208	8	693	719	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					818	819		10.1016/0140-6736(92)92686-A	http://dx.doi.org/10.1016/0140-6736(92)92686-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357245				2022-12-24	WOS:A1992JR16800005
J	MCKEITH, I; FAIRBAIRN, A; PERRY, R; THOMPSON, P; PERRY, E				MCKEITH, I; FAIRBAIRN, A; PERRY, R; THOMPSON, P; PERRY, E			NEUROLEPTIC SENSITIVITY IN PATIENTS WITH SENILE DEMENTIA OF LEWY BODY TYPE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To determine the outcome of administration of neuroleptics to patients with senile dementia of Lewy body type confirmed at necropsy. Design-Retrospective analysis of clinical notes blind to neuropathological diagnosis. Setting-Specialist psychogeriatric assessment units referring cases for necropsy to a teaching hospital neuropathology service. Patients-41 elderly patients with diagnosis of either Alzheimer type dementia (n=21) or Lewy body type dementia (n=20) confirmed at necropsy. Main outcome measures-Clinical state including extrapyramidal features before and after neuroleptic treatment and survival analysis of patients showing severe neuroleptic sensitivity compared with the remainder in the group. Results-16 (80%) patients with Lewy body type dementia received neuroleptics, 13 (81%) of whom reacted adversely; in seven (54%) the reactions were severe. Survival analysis showed an increased mortality in the year after presentation to psychiatric services compared with patients with mild or no neuroleptic sensitivity (hazard ratio 2.70 (95% confidence interval 2.50-8.99); (chi-2=2.68, p=0.05). By contrast, only one (7%) of 14 patients with Alzheimer type dementia given neuroleptics showed severe neuroleptic sensitivity. Conclusions-Severe, and often fatal, neuroleptic sensitivity may occur in elderly patients with confusion, dementia, or behavioural disturbance. Its occurrence may indicate senile dementia of Lewy body type and this feature has been included in clinical diagnostic criteria for this type of dementia.	GATESHEAD MENTAL HLTH UNIT,OLD AGE PSYCHIAT,GATESHEAD,ENGLAND; NEWCASTLE GEN HOSP,MRC,NEUROCHEM PATHOL UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	MCKEITH, I (corresponding author), NEWCASTLE GEN HOSP,OLD AGE PSYCHIAT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.		McKeith, Ian/AAH-3382-2021	McKeith, Ian/0000-0002-9250-0568				ADOZZONIZIO G, 1991, INT J GERIATRIC PSYC, V6, P547; GILLEARD CJ, 1983, ACTA PSYCHIAT SCAND, V68, P419, DOI 10.1111/j.1600-0447.1983.tb00950.x; HANSEN L, 1990, NEUROLOGY, V40, P1; LENNOX G, 1989, J NEUROL NEUROSUR PS, V52, P1236, DOI 10.1136/jnnp.52.11.1236; MCKEITH IG, IN PRESS PSYCHOL MED; PERRY EK, 1991, ANN NY ACAD SCI, V640, P197; PERRY RH, 1990, J NEUROL SCI, V95, P119, DOI 10.1016/0022-510X(90)90236-G; ZIMMER JG, 1984, AM J PUBLIC HEALTH, V74, P1118, DOI 10.2105/AJPH.74.10.1118	8	447	452	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					673	678		10.1136/bmj.305.6855.673	http://dx.doi.org/10.1136/bmj.305.6855.673			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1356550	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JP51100018
J	REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA				REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA			CARDIAC RESUSCITATION WITH PERCUTANEOUS CARDIOPULMONARY SUPPORT	LANCET			English	Note							ACUTE MYOCARDIAL-INFARCTION; BYPASS; SHOCK	Percutaneous cardiopulmonary support (CPS) was initiated in 9 patients to provide haemodynamic stability after failure of conventional resuscitation. 4 patients were in cardiogenic shock and 4 remained in asystole, with 1 in resistant ventricular fibrillation, after cardiac arrest. During CPS for those in cardiogenic shock, the mean intra-arterial pressures ranged from 65 to 100 mm Hg (mean 84), at flow rates of between 3 to 5 l/min (mean 3.9). 2 patients underwent technically successful coronary angioplasty. No patient in this group survived. In the cardiac arrest group, acceptable mean intra-arterial blood pressures were achieved (mean 95, range 90-100 mm Hg) at flow rates of between 2 to 3 l/min (mean 2.6). All 5 subjects underwent technically successful coronary angioplasty whilst on CPS. 4 survived. 2 were alive and well at 12 months follow-up, 1 of whom had returned to work; the third is alive and well at 4 months.			REES, MR (corresponding author), KILLINGBECK HOSP,REG CARDIOTHORAC CTR,CARDIAC RES UNIT,YORK RD,LEEDS LS14 6UQ,ENGLAND.		Rees, Michael/Y-4640-2019					AFIFI AA, 1974, AM J CARDIOL, V33, P826, DOI 10.1016/0002-9149(74)90628-6; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; LITZIE AK, 1987, P AM ACAD CV PERFUSI, V8, P60; PROCTOR E., 1967, CARDIOVASC RES, V1, P189, DOI 10.1093/cvr/1.2.189; ROZENBAUM EA, 1988, CRIT CARE MED, V16, P583, DOI 10.1097/00003246-198806000-00003; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SHAWL FA, 1989, AM J CARDIOL, V64, P967, DOI 10.1016/0002-9149(89)90791-1; TOPOL E, 1988, ACUTE CORONARY INTER, P195	8	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					513	514		10.1016/0140-6736(92)91711-G	http://dx.doi.org/10.1016/0140-6736(92)91711-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354278				2022-12-24	WOS:A1992JL23400005
J	VELHO, G; FROGUEL, P; CLEMENT, K; PUEYO, ME; RAKOTOAMBININA, B; ZOUALI, H; PASSA, P; COHEN, D; ROBERT, JJ				VELHO, G; FROGUEL, P; CLEMENT, K; PUEYO, ME; RAKOTOAMBININA, B; ZOUALI, H; PASSA, P; COHEN, D; ROBERT, JJ			PRIMARY PANCREATIC BETA-CELL SECRETORY DEFECT CAUSED BY MUTATIONS IN GLUCOKINASE GENE IN KINDREDS OF MATURITY ONSET DIABETES OF THE YOUNG	LANCET			English	Article							INSULIN RELEASE; GLUCOSE; HUMANS	Maturity-onset diabetes of the young (MODY), characterised by non-insulin-dependent diabetes mellitus (NIDDM) with an early age of onset, is a genetically heterogeneous disorder. In most MODY kindreds described in France, chronic hyperglycaemia is caused by mutations in the gene encoding pancreatic beta-cell and liver glucokinase (GCK). We here report the beta-cell secretory profiles of nine patients from four GCK-linked MODY kindreds. First-phase insulin secretion assessed by an intravenous glucose test was comparable in patients and seven controls. However, beta-cell secretory response to continuous glucose stimulus during a hyperglycaemic glucose clamp was significantly reduced: mean plasma insulin values of 12 (SD 7) vs 40 (11) mU/l (p=0.0001) and mean plasma C-peptide values 1.20 (0.30) vs 2.61 (0.37) (p=0.0001).This secretory profile is different from those for NIDDM with late age of onset or MODY not linked to GCK. Fasting plasma insulin and C-peptide in patients were inappropriately low in relation to concomitant plasma glucose level. Furthermore, during a hyperinsulinaemic euglycaemic clamp, endogenous insulin secretion at euglycaemia (5 mmol/l) was suppressed in patients but not in controls. These results suggest that mutant GCK may lead to chronic hyperglycaemia by raising the threshold of circulating glucose level which induces insulin secretion. These data provide the first demonstration of a primary pancreatic secretory defect associated with a form of NIDDM.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,UNITE ENDOCRINOL & DIABETOL PEDIAT,INSERM,U30,F-75730 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	VELHO, G (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Velho, Gilberto/Q-6724-2017; Clément, karine/R-1120-2017; FROGUEL, Philippe/O-6799-2017	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784				ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BRUNZELL JD, 1976, J CLIN ENDOCR METAB, V42, P222, DOI 10.1210/jcem-42-2-222; CALLESESCANDON J, 1987, DIABETES, V36, P1167, DOI 10.2337/diabetes.36.10.1167; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Efendic S, 1988, Adv Exp Med Biol, V246, P167; FAJANS S S, 1986, Diabetes Metabolism Reviews, V2, P347; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; LUZI L, 1989, AM J PHYSIOL, V257, pE241, DOI 10.1152/ajpendo.1989.257.2.E241; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NAIDOO C, 1986, DIABETES CARE, V9, P57, DOI 10.2337/diacare.9.1.57; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; STOFFEL M, 1992, IN PRESS P NATL ACAD, V89; TCHHOBROUTSKY G, 1991, DIABETOLOGIA, V34, P67; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1985, TECH REP SER WHO, V727	24	200	202	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					444	448		10.1016/0140-6736(92)91768-4	http://dx.doi.org/10.1016/0140-6736(92)91768-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354782				2022-12-24	WOS:A1992JJ87700002
J	GUAN, JL; SHALLOWAY, D				GUAN, JL; SHALLOWAY, D			REGULATION OF FOCAL ADHESION-ASSOCIATED PROTEIN TYROSINE KINASE BY BOTH CELLULAR ADHESION AND ONCOGENIC TRANSFORMATION	NATURE			English	Article							PHOSPHORYLATION; PP60C-SRC; CELLS; ANTIBODIES; SITES	INCREASING evidence indicates that the integrin family of cell adhesion receptors can transduce biochemical signals from the extracellular matrix to the cell interior to modulate cell growth and differentiation1. We have shown that integrin/ligand interactions can trigger tyrosine phosphorylation of a protein of M(r) 120,000 (pp120), so it is possible that signal transduction by integrins might involve activation of intracellular protein tyrosine kinases as an early event in cell binding to the extracellular matrix2. Here we report that pp120 is identical to the focal adhesion-associated protein tyrosine kinase pp125FAK (refs 3,4). We show that tyrosine phosphorylation of this protein is modulated both by cell adhesion and transformation by pp60v-src, and that these changes in phosphorylation are correlated with increased pp125FAK tyrosine kinase activity. A model is proposed to relate these findings to the molecular basis of anchorage-independent growth of transformed cells.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University	GUAN, JL (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PATHOL,CANC BIOL LABS,ITHACA,NY 14853, USA.							GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WITTELSBERGER SC, 1981, CELL, V24, P859, DOI 10.1016/0092-8674(81)90111-2	14	791	804	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					690	692		10.1038/358690a0	http://dx.doi.org/10.1038/358690a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379699				2022-12-24	WOS:A1992JJ88200061
J	COOKSON, WOCM; YOUNG, RP; SANDFORD, AJ; MOFFATT, MF; SHIRAKAWA, T; SHARP, PA; FAUX, JA; JULIER, C; LESOUEF, PN; NAKAMURA, Y; LATHROP, GM; HOPKIN, JM				COOKSON, WOCM; YOUNG, RP; SANDFORD, AJ; MOFFATT, MF; SHIRAKAWA, T; SHARP, PA; FAUX, JA; JULIER, C; LESOUEF, PN; NAKAMURA, Y; LATHROP, GM; HOPKIN, JM			MATERNAL INHERITANCE OF ATOPIC IGE RESPONSIVENESS ON CHROMOSOME-11Q	LANCET			English	Article							SERUM IGE; ALLERGY; RESPONSES; GENETICS; ASTHMA; TWINS	Atopy is a common familial state underlying allergic asthma and rhinitis. Lately, we have assigned a gene for atopy to chromosome 11 q by linkage to the marker D11S97. Since previous studies have suggested that the risk of atopy is higher for children of atopic mothers than for those of atopic fathers, we sought differences between maternal and paternal patterns of transmission at the 11q13 locus among pairs of siblings in families affected by atopy. When we defined atopy as the presence of a positive skinprick test (greater-than-or-equal-to 2 mm) to any of a panel of common allergens, a higher than normal concentration of total serum IgE, or a positive radioallergosorbent test for a specific IgE, we found that 125 (62%) of the sibling-pairs affected by atopy shared the maternal 11q13 allele and 78 (38%) did not. This distribution differs significantly from the expected 50/50 distribution (p=0.001). Of paternally derived alleles, 83 (46%) were shared and 96 (54%) were not (not significantly different from 50/50). The result was similar whatever definition of atopy was used and with other genetic markers on 11q. These findings show that transmission of atopy at the chromosome 11q locus is detectable only through the maternal line. The pattern of inheritance is consistent either with paternal genomic imprinting or with maternal modification of developing immune responses.	CTR ETUD POLYMORPHISME HUMAINE,PARIS,FRANCE; CHURCHILL HOSP,OLSER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Oxford; Japanese Foundation for Cancer Research	COOKSON, WOCM (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND.		JULIER, Cécile/M-9824-2017; Le Souef, Peter N/H-5256-2014; Cookson, William/HHC-1790-2022	JULIER, Cécile/0000-0002-1538-0240; Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1989, LANCET, V1, P1292; HALL JG, 1990, ARCH DIS CHILD-FETAL, V65, P1013, DOI 10.1136/adc.65.10_Spec_No.1013; HANSON B, 1985, J ALLERGY CLIN IMMUN, V75, P155, DOI 10.1016/0091-6749(85)90337-9; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90, DOI 10.1159/000233072; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOLT PG, 1990, IMMUNOLOGY, V1, P3; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; PEAT JK, 1987, CLIN ALLERGY, V17, P271; RUIZ RGG, 1991, SCHWEIZ MED WSCH S40, V121, P129; SETTIPANE RA, 1989, ALLERGY PROC, V9, P555; SHIRAKAWA T, 1991, CYTOGENET CELL GENET, V58, P1970; SHIRAKAWA T, IN PRESS AM J EPIDEM; SOLTER D, 1988, ANNU REV GENET, V22, P127; TOKINO T, 1991, AM J HUM GENET, V48, P258; WAYE JS, 1987, HUM GENET, V77, P151, DOI 10.1007/BF00272383; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	29	297	309	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					381	384		10.1016/0140-6736(92)91468-N	http://dx.doi.org/10.1016/0140-6736(92)91468-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353553				2022-12-24	WOS:A1992JJ44900001
J	LIM, R; DYMOND, DS				LIM, R; DYMOND, DS			SHOULD ANTIANGINAL MEDICATION BE STOPPED FOR EXERCISE TESTING	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE				LIM, R (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CARDIOL,LONDON EC1A 7BE,ENGLAND.		Lim, Richard/J-7102-2012	Lim, Richard/0000-0002-4914-7244				ELAMIN MS, 1982, BRIT HEART J, V48, P311; GOHLKE H, 1983, CIRCULATION, V68, P979, DOI 10.1161/01.CIR.68.5.979; HO WCS, 1985, AM J CARDIOL, V55, P258; JONES RH, 1981, CIRCULATION, V64, P586, DOI 10.1161/01.CIR.64.3.586; KRONE RJ, 1987, AM J CARDIOL, V60, P23, DOI 10.1016/0002-9149(87)90977-5; Lim R, 1991, Int J Card Imaging, V7, P125, DOI 10.1007/BF01798052; LIM R, 1992, AM J CARDIOL, V69, P733, DOI 10.1016/0002-9149(92)90496-L; LIM R, 1991, Journal of the American College of Cardiology, V17, p183A; STONE D, 1980, BRIT HEART J, V44, P208; WILCOX I, 1991, J AM COLL CARDIOL, V18, P677, DOI 10.1016/0735-1097(91)90789-C	10	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					161	162		10.1016/0140-6736(92)93226-D	http://dx.doi.org/10.1016/0140-6736(92)93226-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352576				2022-12-24	WOS:A1992JE38200014
J	HALL, P; BOICE, JD; BERG, G; BJELKENGREN, G; ERICSSON, UB; HALLQUIST, A; LIDBERG, M; LUNDELL, G; MATTSSON, A; TENNVALL, J; WIKLUND, K; HOLM, LE				HALL, P; BOICE, JD; BERG, G; BJELKENGREN, G; ERICSSON, UB; HALLQUIST, A; LIDBERG, M; LUNDELL, G; MATTSSON, A; TENNVALL, J; WIKLUND, K; HOLM, LE			LEUKEMIA INCIDENCE AFTER I-131 EXPOSURE	LANCET			English	Article							CANCER; MORTALITY; LEUKEMIA; RADIOTHERAPY; I-131; RISK	Leukaemia is one of the most prominent late effects of exposure to ionising radiation. We have studied the incidence of leukaemia among 46 988 Swedish patients exposed to iodine-131 (I-131) for diagnostic reasons or to treat hyperthyroidism or thyroid cancer. The observed number of leukaemias was compared with that expected based on incidence data from the general population. The mean absorbed dose to the bone marrow was estimated as 14 mGy (range 0.01-2.226). 195 leukaemias occurred more than 2 years after exposure, and the standardised incidence ratio (SIR) was 1.09 (95% confidence interval 0.94-1.25). Similar, but again not significantly, increased risks were seen for chronic lymphocytic leukaemia (CLL) (SIR=1.08), a malignant condition not found to be increased after irradiation, and for non-CLL (SIR=1.09). The risk of leukaemia did not vary by sex, age, time, or radiation dose from I-131. One reason for the absence of a radiation effect, other than chance, includes the possible lowering of risk when exposure is protracted over time as occurs with I-131. Excess leukaemia risks of more than 25% could thus be excluded with high assurance in this population of mainly adults. These results should be reassuring to patients exposed to I-131 in medical practice and to most individuals exposed to the fall-out from the Chernobyl accident.	KAROLINSKA HOSP,RADIUM HEMMET,CTR ONCOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC PREVENT,S-10401 STOCKHOLM,SWEDEN; SODER SJUKHUSET,DEPT HOSP PHYS,STOCKHOLM,SWEDEN; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892; SAHLGRENS UNIV HOSP,DEPT GEN ONCOL,S-41345 GOTHENBURG,SWEDEN; MALMO GEN HOSP,DEPT GEN ONCOL,S-21401 MALMO,SWEDEN; MALMO GEN HOSP,DEPT INTERNAL MED,S-21401 MALMO,SWEDEN; UMEA UNIV HOSP,DEPT GEN ONCOL,S-90185 UMEA,SWEDEN; UNIV LUND HOSP,DEPT GEN ONCOL,S-22185 LUND,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Sodersjukhuset Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sahlgrenska University Hospital; Umea University; Lund University; Skane University Hospital	HALL, P (corresponding author), KAROLINSKA HOSP,RADIUM HEMMET,DEPT GEN ONCOL,S-10401 STOCKHOLM,SWEDEN.		Tennvall, Jan/F-8760-2014		DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP051034] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-51034] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKIN M, 1990, OXFORD STATISTICAL S, V4; [Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1991, COMP DOS COEFF BAS I, V21, P493; ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BRINCKER H, 1973, BRIT J CANCER, V28, P232, DOI 10.1038/bjc.1973.142; COLEMAN MP, 1989, IARC89006 INT AG RES; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; EDMONDS CJ, 1986, BRIT J RADIOL, V59, P45, DOI 10.1259/0007-1285-59-697-45; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; HOFFMAN DA, 1984, RAD CARCINOGENESIS E, P273; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HOLM LE, 1989, JNCI-J NATL CANCER I, V81, P302, DOI 10.1093/jnci/81.4.302; INSKIP PD, 1990, RADIAT RES, V122, P107, DOI 10.2307/3577593; International Committee on Radiological Protection Publication 53, 1988, ANN ICRP, V18; LEWIS CA, 1988, BRIT J RADIOL, V61, P212, DOI 10.1259/0007-1285-61-723-212; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SAENGER EL, 1968, J AMER MED ASSOC, V205, P855, DOI 10.1001/jama.205.12.855; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; 1988, HLTH RISKS RADON OTH, V4	25	95	97	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					1	4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351599				2022-12-24	WOS:A1992JC35400001
J	BURNET, NG; NYMAN, J; TURESSON, I; WURM, R; YARNOLD, JR; PEACOCK, JH				BURNET, NG; NYMAN, J; TURESSON, I; WURM, R; YARNOLD, JR; PEACOCK, JH			PREDICTION OF NORMAL-TISSUE TOLERANCE TO RADIOTHERAPY FROM INVITRO CELLULAR RADIATION SENSITIVITY	LANCET			English	Note							REPAIR CAPACITY; SURVIVAL-CURVE; TUMORS	The success of radiotherapy depends on the total radiation dose, which is limited by the tolerance of surrounding normal tissues. Since there is substantial variation among patients in normal-tissue radiosensitivity, we have tested the hypothesis that in-vitro cellular radiosensitivity is correlated with in-vivo normal-tissue responses. We exposed skin fibroblast cell lines from six radiation-treated patients to various doses of radiation and measured the proportions surviving. There was a strong relation between fibroblast sensitivity in vitro and normal-tissue reactions, especially acute effects. Assessment of radiosensitivity could lead to improved tumour cure rates by enabling radiation doses to be tailored to the individual.	SAHLGRENS UNIV HOSP,DEPT ONCOL,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital	BURNET, NG (corresponding author), INST CANC RES,RADIOTHERAPY RES UNIT,15 COTSWOLD RD,SUTTON SM2 5PX,SURREY,ENGLAND.		Burnet, Neil/L-1025-2019					AGREN A, 1990, INT J RADIAT ONCOL, V19, P1077, DOI 10.1016/0360-3016(90)90037-K; DEACON J, 1984, RADIOTHER ONCOL, V2, P317, DOI 10.1016/S0167-8140(84)80074-2; FERTIL B, 1988, RADIAT RES, V116, P74, DOI 10.2307/3577479; FUKS Z, 1991, INT J RADIAT ONCOL, V21, P537, DOI 10.1016/0360-3016(91)90668-T; STEEL GG, 1991, RADIOTHER ONCOL, V20, P71; SUTTON ML, 1986, RADIOTHERAPY CLIN PR, P1; TURESSON I, 1989, RADIOTHER ONCOL, V15, P169, DOI 10.1016/0167-8140(89)90131-X; TURESSON I, 1990, INT J RADIAT ONCOL, V19, P1569, DOI 10.1016/0360-3016(90)90374-S; TURESSON I, 1989, RADIOTHER ONCOL, V15, P217, DOI 10.1016/0167-8140(89)90089-3; WEST CML, 1991, BRIT J CANCER, V64, P197, DOI 10.1038/bjc.1991.270	10	138	139	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1570	1571		10.1016/0140-6736(92)91833-T	http://dx.doi.org/10.1016/0140-6736(92)91833-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351551				2022-12-24	WOS:A1992JB20200005
J	FROST, P; LEVIN, B				FROST, P; LEVIN, B			CLINICAL IMPLICATIONS OF METASTATIC PROCESS	LANCET			English	Article							CLONAL ORIGIN; HUMAN-TUMORS; CANCER; CHROMOSOME-1; CELLS		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77025; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,GI ONCOL & DIGEST DIS SECT,HOUSTON,TX 77025	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BELL C, 1991, CANCER GENET CYTOGEN, V54, P153, DOI 10.1016/0165-4608(91)90203-7; BELL C, 1990, INT J CANCER, V645, P968; DUFFY MJ, 1987, EUR J CANCER CLIN ON, V23, P583, DOI 10.1016/0277-5379(87)90326-9; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FIALKOW PJ, 1979, ANNU REV MED, V30, P135, DOI 10.1146/annurev.me.30.020179.001031; FOULDS L, 1954, CANCER RES, V14, P327; FOULDS L, 1975, NEOPLASTIC DEV, P675; FROST P, 1989, Cancer Bulletin (Houston), V41, P139; FROST P, 1990, CANCER METAST REV, V9, P93, DOI 10.1007/BF00047591; Garrido F, 1991, Semin Cancer Biol, V2, P3; GIAVAZZI R, 1991, CANCER RES, V266, P14869; GORELIK E, 1988, BIOCHEM CELL BIOL, V66, P617, DOI 10.1139/o88-071; GRANT SGN, 1991, CANCER RES, V51, P4917; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANNA N, 1983, CIBA S FUND CANC RES, V36, P309; KELLY SA, 1991, CANCER RES, V51, P4020; KENDAL WS, 1986, PATHOL IMMUNOPATH R, V5, P455, DOI 10.1159/000157032; Linehan W.M., 1989, CANCER PRINCIPLES PR, P979; Liotta L A, 1988, Prog Clin Biol Res, V256, P3; Liotta LA, 1989, CANCER PRINCIPLES PR, P98; McCarthy J B, 1991, Semin Cancer Biol, V2, P155; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; ROWLEY JD, 1978, VIRCHOWS ARCH B, V29, P129; SIRDANSKY D, 1992, NEW ENGL J MED, V326, P737; STAROSELSKY AN, IN PRESS INT J CANCE; TARIN D, 1984, CANCER RES, V44, P3584; TARIN D, 1984, INVAS METAST, V4, P1; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WAGHORNE C, 1988, CANCER RES, V48, P6109; WEISS L, 1988, INT J CANCER, V41, P450, DOI 10.1002/ijc.2910410323	35	55	56	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1458	1461		10.1016/0140-6736(92)92040-M	http://dx.doi.org/10.1016/0140-6736(92)92040-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351135				2022-12-24	WOS:A1992HY31700013
J	JIANG, H; ZHANG, SL; PERNIS, B				JIANG, H; ZHANG, SL; PERNIS, B			ROLE OF CD8+ T-CELLS IN MURINE EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOREGULATION; SUPPRESSION; CLONES; INVIVO	The course of experimental allergic encephalomyelitis (EAE), an animal model for multiple sclerosis, is affected by immunoregulatory T lymphocytes. When animals are immunized with encephalitogenic peptide of myelin basic protein and recover from the first episode of EAE, they become resistant to a second induction of this disease. Animals depleted of CD8+ T cells by antibody-mediated clearance were used to examine the role of CD8+ T cells in EAE. These cells were found to be major participants in the resistance to a second induction of EAE but were not essential for spontaneous recovery from the first episode of the disease.			JIANG, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.							ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; EICHELBERGER M, 1991, J EXP MED, V174, P857; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; KARPUS WJ, 1989, J IMMUNOL, V143, P3942; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LECLERC C, 1990, J IMMUNOL, V145, P1343; SAKAI K, 1986, J IMMUNOL, V137, P1527; SEDGWICK JD, 1988, EUR J IMMUNOL, V18, P495, DOI 10.1002/eji.1830180402; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; SUN DM, 1991, CELL IMMUNOL, V137, P292, DOI 10.1016/0008-8749(91)90080-U; WILLENBORG DO, 1986, J IMMUNOL, V136, P1676; ZAMVIL SS, 1985, J EXP MED, V162, P2107, DOI 10.1084/jem.162.6.2107; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	13	312	324	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1213	1215		10.1126/science.256.5060.1213	http://dx.doi.org/10.1126/science.256.5060.1213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1375398				2022-12-24	WOS:A1992HV19200039
J	KRIVINE, A; FIRTION, G; CAO, L; FRANCOUAL, C; HENRION, R; LEBON, P				KRIVINE, A; FIRTION, G; CAO, L; FRANCOUAL, C; HENRION, R; LEBON, P			HIV REPLICATION DURING THE 1ST WEEKS OF LIFE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFANTS BORN; TRANSMISSION; CHILDREN; TYPE-1; DNA; AMPLIFICATION; RETROVIRUS; INFECTION	Diagnosis of HIV infection among children born to HIV-positive mothers can be made in the first 12 months, but few studies have examined HIV status during the first weeks of life. In a prospective longitudinal study of 50 infants born to HIV-1 seropositive women, blood samples were obtained at birth and at 4-9 weeks and 5-9 months of age, and were tested for HIV-1 by the polymerase chain reaction (PCR), viral culture, and p24 antigen measurements. 16 were diagnosed as HIV-infected by the age of 4-9 weeks according to both PCR and culture; by contrast, infection could be detected in only 5 children at birth. No changes in HIV status were observed between 4-9 weeks and 5-9 months in the 44 children who could be retested. Perinatal HIV-1 infection can therefore be diagnosed in the first 2 months of life, either by PCR or viral culture. Our inability to detect HIV-1 infection at birth in almost 70% of babies subsequently found infected suggests an active replication of HIV during the first weeks of life. Our results might favour the hypothesis that transmission of HIV-1 takes place either at the end of pregnancy or at delivery.	UNIV PARIS 05,HOP ST VINCENT DE PAUL,DEPT GYNAECOL & OBSTET,F-75014 PARIS,FRANCE; CLIN UNIV PORT ROYAL,DEPT GYNAECOL & OBSTET,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	KRIVINE, A (corresponding author), UNIV PARIS 05,HOP ST VINCENT DE PAUL,DEPT VIROL,82 AVE DENFERT ROCHEREAU,F-75014 PARIS,FRANCE.							BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JOVAISAS E, 1985, LANCET, V2, P1129; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAURE F, 1988, LANCET, V2, P538; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; OTTMANN M, 1991, J VIROL METHODS, V31, P273, DOI 10.1016/0166-0934(91)90165-V; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RUBINSTEIN A, 1983, JAMA-J AM MED ASSOC, V249, P2345; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPRECHER S, 1986, LANCET, V2, P288; WEINBRECK P, 1988, LANCET, V1, P482; ZIEGLER JB, 1985, LANCET, V1, P896; 1991, LANCET, V337, P253	23	170	173	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1187	1189		10.1016/0140-6736(92)91131-Q	http://dx.doi.org/10.1016/0140-6736(92)91131-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349936				2022-12-24	WOS:A1992HU68400002
J	SHARIFF, A; LUNA, EJ				SHARIFF, A; LUNA, EJ			DIACYLGLYCEROL-STIMULATED FORMATION OF ACTIN NUCLEATION SITES AT PLASMA-MEMBRANES	SCIENCE			English	Article							PROTEIN KINASE-C; DICTYOSTELIUM-DISCOIDEUM; HUMAN-NEUTROPHILS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYMORPHONUCLEAR LEUKOCYTES; AMEBOID CELLS; SHAPE CHANGES; POLYMERIZATION; INHIBITOR; CYTOSKELETON	Diacylglycerols, which are generated during phospholipase-catalyzed hydrolysis of phospholipids, stimulated actin polymerization in the presence of highly purified plasma membranes from the cellular slime mold Dictyostelium discoideum. The increased rate of actin polymerization apparently resulted from de novo formation of actin nucleation sites rather than uncapping of existing filament ends, because the membranes lacked detectable endogenous actin. The increased actin nucleation was mediated by a peripheral membrane component other than protein kinase C, the classical target of diacylglycerol action. These results indicate that diacylglycerols increase actin nucleation at plasma membranes and suggest a mechanism whereby signal transduction pathways may control cytoskeletal assembly.			SHARIFF, A (corresponding author), WORCESTER FDN EXPTL BIOL INC,CELL BIOL GRP,SHREWSBURY,MA 01545, USA.		Luna, Elizabeth/B-4364-2012		NIGMS NIH HHS [GM-33048, R01 GM033048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; EBERLE M, 1990, J BIOL CHEM, V265, P16725; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRIEDEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6513, DOI 10.1073/pnas.80.21.6513; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; KELLER HU, 1989, J CELL SCI, V93, P457; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAL AA, 1984, J BIOL CHEM, V259, P8794; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LUDERUS MEE, 1989, FEBS LETT, V253, P71, DOI 10.1016/0014-5793(89)80932-9; LUNA EJ, 1984, J CELL BIOL, V99, P58, DOI 10.1083/jcb.99.1.58; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OMANN GM, 1989, J BIOL CHEM, V264, P16355; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; PHATAK PD, 1988, J IMMUNOL, V141, P2929; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; SHARIFF A, 1990, J CELL BIOL, V110, P681, DOI 10.1083/jcb.110.3.681; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TRANTER MP, 1989, J CELL BIOL, V109, P2833, DOI 10.1083/jcb.109.6.2833; WUESTEHUBE LJ, 1987, J CELL BIOL, V105, P1741, DOI 10.1083/jcb.105.4.1741; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; ZIMMERMANN A, 1988, J CELL SCI, V90, P657	37	135	135	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					245	247		10.1126/science.1373523	http://dx.doi.org/10.1126/science.1373523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1373523				2022-12-24	WOS:A1992HM89600037
J	WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM				WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM			ORDERING AND ADMINISTRATION OF SEDATIVES AND ANALGESICS DURING THE WITHHOLDING AND WITHDRAWAL OF LIFE-SUPPORT FROM CRITICALLY ILL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAZEPAM; MIDAZOLAM; DECISION	Objective. - To determine why and how sedatives and analgesics are ordered and administered during the withholding and withdrawal of life support from critically ill patients. Design. - Prospective case series. Setting. - Medical-surgical intensive care units at a county hospital and a university hospital. Patients. - Consecutive 1-year sample of 22 patients from whom life support was withheld or withdrawn in one intensive care unit at a county hospital and a random sample of 22 similar patients in the intensive care unit in the university hospital over the same period. Main Outcome Measures. - Physicians and nurses were interviewed to determine their reasons for ordering and administering drugs, and medical records were reviewed to document amounts of drugs ordered and administered. Results. - Drugs were given to 75% of patients during withholding and withdrawal of life support. Patients who did not receive medication were comatose and considered incapable of benefiting from sedation and analgesia. The median time until death following the initiation of the withholding or withdrawal of life support was 3.5 hours in the patients who received drugs and 1.3 hours in those patients who did not (P, not significant). Physicians ordered drugs to decrease pain in 88% of patients, to decrease anxiety in 85%, to decrease air hunger in 76%, to comfort families in 82%, and to hasten death in 39%; in no instance was hastening death the only reason cited. The amounts of benzodiazepines and opiates averaged 2.2 mg/h of diazepam and 3.3 mg/h of morphine sulfate in the 24 hours before withholding and withdrawal of life support and 9.8 mg/h and 11.2 mg/h in the 24 hours thereafter (P < .025 and P < .001, respectively). Conclusions. - Large doses of sedatives and analgesics were ordered primarily to relieve pain and suffering during the withholding and withdrawal of life support, and death was not hastened by drug administration.	SAN FRANCISCO GEN HOSP,ROOM 5K1,1001 POTRERO AVE,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SOCIAL WORK,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; BERGGREN L, 1987, ACTA ANAESTH SCAND, V31, P667, DOI 10.1111/j.1399-6576.1987.tb02643.x; CLOUSER KD, 1977, ANN INTERN MED, V87, P622, DOI 10.7326/0003-4819-87-5-622; FLAKE JW, 1985, ANESTH ANALG, V64, P897; FORRESTER A, 1980, ANESTHESIOLOGY, V53, P494; GEORGE KA, 1977, BRIT J CLIN PHARMACO, V4, P45, DOI 10.1111/j.1365-2125.1977.tb00665.x; GREENBLATT DJ, 1981, BR J PHARM S, V11, pS2; HAMMOND J, 1989, CRIT CARE MED, V17, P136, DOI 10.1097/00003246-198902000-00006; JAFFE JH, 1981, PHARM BASIS THERAPEU; JONSEN AR, 1983, ANN INTERN MED, V99, P261, DOI 10.7326/0003-4819-99-2-261; JONSEN AR, 1986, CLIN ETHICS, P120; KEATS AS, 1985, ANNU REV PHARMACOL, V25, P41, DOI 10.1146/annurev.pa.25.040185.000353; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; PORRO GB, 1988, GASTROINTEST ENDOSC, V34, P252, DOI 10.1016/S0016-5107(88)71323-1; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIL MH, 1988, CRIT CARE MED, V16, P636, DOI 10.1097/00003246-198806000-00015; WHITE PF, 1988, PLAST RECONSTR SURG, V81, P703, DOI 10.1097/00006534-198805000-00009; ZAWACKI B, 1989, CRIT CARE MED, V17, P198; 1986, AM REV RESPIR DIS, V134, P1327	22	170	170	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					949	953						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1370853				2022-12-24	WOS:A1992HD15500028
J	TIMMONS, MJ				TIMMONS, MJ			MALIGNANT-MELANOMA EXCISION MARGINS - MAKING A CHOICE	LANCET			English	Editorial Material							RECURRENCE; WIDE				TIMMONS, MJ (corresponding author), ST LUKES HOSP,DEPT PLAST SURG,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.							ACKERMAN AB, 1983, HUM PATHOL, V14, P743, DOI 10.1016/S0046-8177(83)80298-6; Ames FC, 1992, CUTANEOUS MELANOMA, P287; BOULAY M, 1888, ARCH GEN MED, V2, P157; Butterworth T, 1934, J AMER MED ASSOC, V102, P739, DOI 10.1001/jama.1934.02750100005002; CASCINELLI N, 1980, EUR J CANCER, V16, P1079; DIETERICH P, 1887, ARCH KLIN CHIR BERLI, V35, P289; EVANS J, 1990, BRIT J PLAST SURG, V43, P426, DOI 10.1016/0007-1226(90)90007-M; FALLOWFIELD ME, 1990, HISTOPATHOLOGY, V17, P397, DOI 10.1111/j.1365-2559.1990.tb00758.x; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; GRIFFITHS RW, 1986, BRIT J SURG, V73, P349, DOI 10.1002/bjs.1800730507; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; Handley WS, 1907, LANCET, V1, P927; Handley WS, 1907, LANCET, V1, P996; KELLY JW, 1984, ANN SURG, V200, P759; Norris W., 1857, 8 CASES MELANOSIS PA; PACK GT, 1952, ANN SURG, V136, P905, DOI 10.1097/00000658-195212000-00001; RAMPEN F, 1981, EUR J CANCER, V17, P589, DOI 10.1016/0014-2964(81)90062-1; RAVEN RW, 1950, ANN ROY COLL SURG, V6, P28; TAYLOR BA, 1985, EUR J SURG ONCOL, V11, P7; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438	20	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1393	1395		10.1016/0140-6736(92)92570-6	http://dx.doi.org/10.1016/0140-6736(92)92570-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360100				2022-12-24	WOS:A1992KB20200014
J	CLEMENTS, JD; LESTER, RAJ; TONG, G; JAHR, CE; WESTBROOK, GL				CLEMENTS, JD; LESTER, RAJ; TONG, G; JAHR, CE; WESTBROOK, GL			THE TIME COURSE OF GLUTAMATE IN THE SYNAPTIC CLEFT	SCIENCE			English	Article							METHYL-D-ASPARTATE; CULTURED HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; CENTRAL NERVOUS-SYSTEM; KINETIC-ANALYSIS; RAT HIPPOCAMPUS; ACID RECEPTORS; BINDING-SITES; CURRENTS; ACETYLCHOLINE	The peak concentration and rate of clearance of neurotransmitter from the synaptic cleft are important determinants of synaptic function, yet the neurotransmitter concentration time course is unknown at synapses in the brain. The time course of free glutamate in the cleft was estimated by kinetic analysis of the displacement of a rapidly dissociating competitive antagonist from N-methyl-D-aspartate (NMDA) receptors during synaptic transmission. Glutamate peaked at 1.1 millimolar and decayed with a time constant of 1.2 milliseconds at cultured hippocampal synapses. This time course implies that transmitter saturates postsynaptic NMDA receptors. However, glutamate dissociates much more rapidly from alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Thus, the time course of free glutamate predicts that dissociation contributes to the decay of the AMPA receptor-mediated postsynaptic current.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	CLEMENTS, JD (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		yasin, raiesa/F-9500-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH046613, R01MH046613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026494, R29NS026494, R01NS021419] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46613] Funding Source: Medline; NINDS NIH HHS [NS26494, NS21419] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTOL TM, 1991, BIOPHYS J, V59, P1209; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; BENVENISTE M, 1991, BRIT J PHARMACOL, V104, P207, DOI 10.1111/j.1476-5381.1991.tb12409.x; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; COLQUHOUN D, IN PRESS J PHYSL LON; ECCLES JC, 1958, PROC R SOC SER B-BIO, V148, P38, DOI 10.1098/rspb.1958.0003; EVANS RH, 1979, BRIT J PHARMACOL, V67, P591, DOI 10.1111/j.1476-5381.1979.tb08706.x; EVANS RH, 1978, BRAIN RES, V148, P536, DOI 10.1016/0006-8993(78)90744-8; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GAGE PW, 1975, J PHYSIOL-LONDON, V244, P385, DOI 10.1113/jphysiol.1975.sp010805; HARRIS KM, 1986, NEUROSCIENCE, V19, P857, DOI 10.1016/0306-4522(86)90304-0; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; LAND BR, 1984, P NATL ACAD SCI-BIOL, V81, P1594, DOI 10.1073/pnas.81.5.1594; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCLENNAN H, 1979, BRAIN RES, V169, P83, DOI 10.1016/0006-8993(79)90375-5; MONAGHAN DT, 1988, P NATL ACAD SCI USA, V85, P9836, DOI 10.1073/pnas.85.24.9836; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P1, DOI 10.1016/0306-4522(88)90123-6; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RIVEROS N, 1986, BRAIN RES, V386, P405, DOI 10.1016/0006-8993(86)90181-2; Salpeter MM, 1987, VERTEBRATE NEUROMUSC, V23, P1; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THEDINGA KH, 1989, NEUROSCI LETT, V104, P217, DOI 10.1016/0304-3940(89)90357-1; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	36	818	851	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1498	1501		10.1126/science.1359647	http://dx.doi.org/10.1126/science.1359647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1359647				2022-12-24	WOS:A1992JZ62500033
J	MANDEL, MA; GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF				MANDEL, MA; GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF			MOLECULAR CHARACTERIZATION OF THE ARABIDOPSIS FLORAL HOMEOTIC GENE APETALA1	NATURE			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; LINKAGE MAP; YEAST; THALIANA; SRF	THE first step in flower development is the transition of an inflorescence meristem into a floral meristem. Each floral meristem differentiates into a flower consisting of four organ types that occupy precisely defined positions within four concentric whorls. Genetic studies in Arabidopsis thaliana and Antirrhinum majus have identified early-acting genes that determine the identity of the floral meristem, and late-acting genes that determine floral organ identity1-5. In Arabidopsis, at least two genes, APETALA1 and LEAFY, are required for the transition of an inflorescence meristem into a floral meristem1. We have cloned the APETALA1 gene and here we show that it encodes a putative transcription factor that contains a MADS-domain2. APETALA1 RNA is uniformly expressed in young flower primordia, and later becomes localized to sepals and petals. Our results suggest that APETALA1 acts locally to specify the identity of the floral meristem, and to determine sepal and petal development.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								BOWMAN JL, 1991, DEVELOPMENT, V112, P1; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	23	908	1014	4	123	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					273	277						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359429				2022-12-24	WOS:A1992JY96000057
J	FUGHBERMAN, A; EPSTEIN, S				FUGHBERMAN, A; EPSTEIN, S			TAMOXIFEN - DISEASE PREVENTION OR DISEASE SUBSTITUTION	LANCET			English	Editorial Material							BONE-MINERAL CONTENT; BREAST-CANCER; ADJUVANT TAMOXIFEN; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR RISK; SERUM-LIPOPROTEINS; TRIAL; DENSITY; TUMORS		UNIV ILLINOIS,SCH PUBL HLTH,BOX 6998,CHICAGO,IL 60680; NATL WOMENS HLTH NETWORK,WASHINGTON,DC	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Fugh-Berman, Adriane/0000-0002-1717-7617				BRUNING PF, 1988, BRIT J CANCER, V58, P497, DOI 10.1038/bjc.1988.248; BUSH TL, 1988, CLIN CHEM, V34, pB60; CHING CK, 1992, LANCET, V339, P940, DOI 10.1016/0140-6736(92)90991-B; FENDL KC, 1992, CANCER RES, V52, P235; FENTIMAN IS, 1989, BRIT J CANCER, V60, P262, DOI 10.1038/bjc.1989.266; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1990, J CLIN ONCOL, V8, P1019, DOI 10.1200/JCO.1990.8.6.1019; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GOTFREDSEN A, 1984, CANCER, V53, P853, DOI 10.1002/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M; JORDAN VC, 1992, J NATL CANCER I, V84, P231, DOI 10.1093/jnci/84.4.231; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; LOVE RR, 1988, BREAST CANCER RES TR, V12, P279; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOGUCHI M, 1987, BRIT J SURG, V74, P586, DOI 10.1002/bjs.1800740714; PAVLIDIS NA, 1992, CANCER, V69, P2961, DOI 10.1002/1097-0142(19920615)69:12&lt;2961::AID-CNCR2820691215&gt;3.0.CO;2-W; POWLES TJ, 1989, BRIT J CANCER, V60, P126, DOI 10.1038/bjc.1989.235; RALOFF J, 1992, SCI NEWS, V141, P266; ROSSNER S, 1984, ATHEROSCLEROSIS, V52, P339, DOI 10.1016/0021-9150(84)90064-9; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SHULTZ MM, 1985, YALE LAW J, V95, P219, DOI 10.2307/796352; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; WOLTER J, 1988, P AN M AM SOC CLIN, V7, P10; 1987, FDA ADVERSE REACTION	25	71	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1143	1145		10.1016/0140-6736(92)93161-F	http://dx.doi.org/10.1016/0140-6736(92)93161-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359220				2022-12-24	WOS:A1992JX13400013
J	THOROGOOD, M; COWEN, P; MANN, J; MURPHY, M; VESSEY, M				THOROGOOD, M; COWEN, P; MANN, J; MURPHY, M; VESSEY, M			FATAL MYOCARDIAL-INFARCTION AND USE OF PSYCHOTROPIC-DRUGS IN YOUNG-WOMEN	LANCET			English	Note								We have observed an unexpected 17-fold increase in risk of total myocardial infarction (relative risk 16.9, 95% confidence interval 3.9-72.8) associated with current use of psychotropic drugs. This incidental finding, in a case-control study of cardiovascular mortality in women aged 16-39 not designed to test any hypothesis about psychotropic drugs, should be treated cautiously. There is, however, evidence of a relation between psychiatric morbidity and cardiovascular disease and the association recorded here requires further investigation.	LITTLEMORE HOSP,MRC,PSYCHOPHARMACOL RES UNIT,OXFORD,ENGLAND; UNIV OTAGO,DEPT HUMAN NUTR,DUNEDIN,NEW ZEALAND; UK OFF POPULAT CENSUSES & SURVEYS,HLTH STAT UNIT,LONDON WC2,ENGLAND; UNIV OXFORD,HLTH CARE EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Otago; University of Oxford	THOROGOOD, M (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Cowen, Philip/0000-0001-5518-6138				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; BRESLOW NE, STATISTICAL METHODS, V1; CARNEY RM, 1990, PSYCHOSOM MED, V52, P603, DOI 10.1097/00006842-199011000-00001; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; HAINES AP, 1987, BRIT MED J, V295, P297, DOI 10.1136/bmj.295.6593.297; TALBOTT E, 1981, AM J EPIDEMIOL, V114, P671, DOI 10.1093/oxfordjournals.aje.a113238; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; THOROGOOD M, IN PRESS AM J EPIDEM; WEISSMAN MM, 1990, AM J PSYCHIAT, V147, P1504	10	69	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1067	1068		10.1016/0140-6736(92)93081-W	http://dx.doi.org/10.1016/0140-6736(92)93081-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357456				2022-12-24	WOS:A1992JV77500006
J	BOBAK, M; LEON, DA				BOBAK, M; LEON, DA			AIR-POLLUTION AND INFANT-MORTALITY IN THE CZECH REPUBLIC, 1986-88	LANCET			English	Article							RESPIRATORY HEALTH; PARTICLES; CHILDREN	An ecological study of infant mortality and air pollution was conducted in the Czech Republic. Routinely collected data on infant mortality and air pollution in the period 1986-88 were analysed for the 46 of the 85 districts in the republic for which both were available. The independent effects of total suspended particulates (TSP-10), sulphur dioxide (SO2), and oxides of nitrogen (NO(x)) adjusted for district socioeconomic characteristics, such as income, car ownership, and abortion rate, were estimated by logistic regression. We found weak positive associations between neonatal mortality and quintile of TSP-10 and SO2. Stronger adjusted effects were seen for postneonatal mortality, with a consistent increase in risk from the lowest to the highest TSP-10 quintile (p<0.001). Weaker and less consistent evidence of a positive association with NO(x) (p = 0.061) was observed. The strongest effects were seen for postneonatal respiratory mortality, which increased consistently from lowest to highest TSP-10 quintile (p = 0.013). There was also a suggestion of a positive association with SO2 (p = 0.062). The highest to lowest quintile risk ratios for postneonatal respiratory mortality were 2.41 (95% Cl 1.10-5.28) for TSP-10, 3.91 (0.90-16.9) for SO2, and 1.20 (0.37-3.91) NO(x). The specificity of the association between air pollution quintile (especially TSP-10) and postneonatal respiratory mortality is consistent with the known effects of air pollution on respiratory disease morbidity in children. These ecological associations require confirmation in an individually based study.	CHARLES UNIV, FAC MED 3, DEPT EPIDEMIOL, CS-11636 PRAGUE 1, CZECHOSLOVAKIA	Charles University Prague	BOBAK, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Bobak, Martin/0000-0002-2633-6851	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRESLOW NE, 1987, IARC SCI PUBL, V82; COLLINS JJ, 1971, AM J EPIDEMIOL, V93, P10, DOI 10.1093/oxfordjournals.aje.a121224; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; HOLLAND WW, 1979, AM J EPIDEMIOL, V110, P525, DOI 10.1093/oxfordjournals.aje.a112836; Lave LB, 1977, AIR POLLUTION HUMAN; Penna M L, 1991, Bull Pan Am Health Organ, V25, P47; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; READ C, 1991, AIR POLLUTION CHILD; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; 1987, AIR QUALITY GUIDELIN; 1990, ENV CZECH REPUBLIC; 1988, EGRET USERS MANUAL	12	137	140	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					1010	1014		10.1016/0140-6736(92)93017-H	http://dx.doi.org/10.1016/0140-6736(92)93017-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357409				2022-12-24	WOS:A1992JV01400011
J	CRAIG, PS; LIU, DS; MACPHERSON, CNL; SHI, DZ; REYNOLDS, D; BARNISH, G; GOTTSTEIN, B; WANG, ZR				CRAIG, PS; LIU, DS; MACPHERSON, CNL; SHI, DZ; REYNOLDS, D; BARNISH, G; GOTTSTEIN, B; WANG, ZR			A LARGE FOCUS OF ALVEOLAR ECHINOCOCCOSIS IN CENTRAL CHINA	LANCET			English	Article							HYDATID-DISEASE; CYSTIC ECHINOCOCCOSIS; MULTILOCULARIS; ALBENDAZOLE; INFECTION; POPULATION; REGION	Human alveolar echinococcosis (AE) is a rare and highly pathogenic helminthic zoonosis due to infection with the intermediate stage of the small fox tapeworm, Echinococcus multilocularis. Parasite transmission is restricted to northern latitudes, including central and north China, from where few clinical and no detailed community studies have been reported. In August, 1991, 65 (5%) of 1312 people residing in three rural communes of Zhang County, Gansu Province, China were diagnosed as having hepatic AE after mass ultrasound scanning with serological back-up. This represents one of the highest prevalence rates of AE ever recorded. It is also the first time that mass ultrasound scanning and serology have been used together in an AE endemic region. The region was selected one year earlier, when a preliminary serosurvey on 606 unselected people in the same locality resulted in an 8.8% serum antibody positive rate with a 76% rate of confirmation of hepatic AE in 37 individuals who could be followed up in 1991. Seropositivity rates varied for villages between 0 and 20.5%. Overall, females (7.8%) had a significantly greater risk of infection than males (2.5%), especially in the 31-50 age group, a difference which may be related to contact with dogs and dog faeces over many years. Age-specific prevalence of AE increased from 0% in the under-5-year group to 8.2% in those aged 31-50. The youngest case was 11 years and the mean age of diagnosis was 40 years. Adult tapeworms of E multilocularis were identified from the small intestines of 10% of domestic dogs. Sylvatic animal hosts of the parasite have not yet been identified. The high prevalence of human AE in this region of central China is most probably due to semi-domestic transmission of E multilocularis between wild rodents and dogs, together with the poverty and poor hygiene in these rural communities.	LANZHOU MED COLL, DEPT PARASITOL, LANZHOU, PEOPLES R CHINA; UNIV W INDIES, FAC MED, SCH VET MED, ST AUGUSTINE, TRINIDAD TOBAGO; UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, ENGLAND; UNIV ZURICH, INST PARASITOL, CH-8006 ZURICH, SWITZERLAND; PUBL HLTH BUR, Ganzhou, PEOPLES R CHINA	Lanzhou University; University West Indies Mona Jamaica; University West Indies Saint Augustine; Liverpool School of Tropical Medicine; University of Liverpool; University of Zurich	CRAIG, PS (corresponding author), UNIV SALFORD, DEPT BIOL SCI, SALFORD M5 4WT, LANCS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUER H, 1991, PARASITOL RES, V77, P430, DOI 10.1007/BF00931640; BCHIR A, 1991, ACTA TROP, V49, P149, DOI 10.1016/0001-706X(91)90062-O; BRESSONHADNI S, 1991, HEPATOLOGY, V13, P1061, DOI 10.1002/hep.1840130610; CHI P, 1990, TROP MED PARASITOL, V41, P157; COLTORTI E, 1988, T ROY SOC TROP MED H, V82, P607, DOI 10.1016/0035-9203(88)90527-5; CRAIG PS, 1991, PARASITOL TODAY, V7, P46, DOI 10.1016/0169-4758(91)90188-T; DIDIER D, 1985, RADIOLOGY, V154, P179, DOI 10.1148/radiology.154.1.3880602; GOTTSTEIN B, 1987, T ROY SOC TROP MED H, V81, P960, DOI 10.1016/0035-9203(87)90365-8; GOTTSTEIN B, 1985, LANCET, V1, P1097; GOTTSTEIN B, 1991, 15TH EXTR C CEL 50 Y, P831; GROVE DI, 1990, HIST HUMAN HELMINTHO, P343; Habluetzel A., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P15, DOI 10.1016/0035-9203(89)90597-X; HORTON RJ, 1989, T ROY SOC TROP MED H, V83, P97, DOI 10.1016/0035-9203(89)90724-4; JIANG C, 1991, CHIN END DIS B, V6, P82; JIANG CP, 1981, CHINESE MED J-PEKING, V94, P771; LU YQ, 1988, CHIN J ULTRASOUND ME, V4, P78; MACPHERSON CNL, 1987, LANCET, V2, P259; MATOSSIAN RM, 1977, B WORLD HEALTH ORGAN, V55, P499; PODOPRIGORA GI, UNPUB WHO GUIDELINES; Rausch R.L., 1986, P44; RAUSCH RL, 1990, ANN TROP MED PARASIT, V84, P239, DOI 10.1080/00034983.1990.11812463; ROGAN MT, 1991, T ROY SOC TROP MED H, V85, P773, DOI 10.1016/0035-9203(91)90451-4; Schantz P.M., 1986, P69; SCHANTZ PM, 1991, PARASITOL TODAY, V7, P35, DOI 10.1016/0169-4758(91)90185-Q; STEHRGREEN JK, 1988, AM J TROP MED HYG, V38, P380, DOI 10.4269/ajtmh.1988.38.380; TODOROV T, 1988, T ROY SOC TROP MED H, V82, P453, DOI 10.1016/0035-9203(88)90161-7; Vuitton D, 1990, Hepatology, V12, P617, DOI 10.1002/hep.1840120329; WATSONJONES DL, 1988, ANN TROP MED PARASIT, V82, P343, DOI 10.1080/00034983.1988.11812256; WEN H, 1990, CHIN MED J, V70, P47; WILSON JF, 1987, AM J TROP MED HYG, V37, P162, DOI 10.4269/ajtmh.1987.37.162; WILSON JF, 1980, AM J TROP MED HYG, V29, P1340, DOI 10.4269/ajtmh.1980.29.1340; YAO P, 1965, CHINESE J SURG, V13, P461; 1987, LANCET, V1, P21; 1981, GUIDELINES ECHINOCOC	34	147	157	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1992	340	8823					826	831		10.1016/0140-6736(92)92693-A	http://dx.doi.org/10.1016/0140-6736(92)92693-A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357252				2022-12-24	WOS:A1992JR16800012
J	KINSELLA, JP; NEISH, SR; SHAFFER, E; ABMAN, SH				KINSELLA, JP; NEISH, SR; SHAFFER, E; ABMAN, SH			LOW-DOSE INHALATIONAL NITRIC-OXIDE IN PERSISTENT PULMONARY-HYPERTENSION OF THE NEWBORN	LANCET			English	Note								We studied the effects of inhaled nitric oxide (NO) in 9 newborn infants with severe persistent pulmonary hypertension (PPHN) who were candidates for extracorporeal membrane oxygenation treatment. With low doses of NO (10-20 ppm) all showed rapid improvement in oxygenation without reduction of systemic blood pressure. In 6 infants treated with inhaled NO for 24 h, clinical improvement was sustained at 6 ppm.	CHILDRENS HOSP,DEPT PEDIAT,DIV CARDIOL,DENVER,CO 80218; CHILDRENS HOSP,DEPT PEDIAT,DIV PULM MED,DENVER,CO 80218; UNIV COLORADO,SCH MED,DENVER,CO 80202	Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KINSELLA, JP (corresponding author), CHILDRENS HOSP,DEPT PEDIAT,DIV NEONATOL,BOX B-070,1056 E 19TH AVE,DENVER,CO 80218, USA.		Neish, Steven/AAJ-7974-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041012, R29HL041012, P50HL046481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41012, HL-01932, HL-46481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAN SH, 1990, AM J PHYSIOL, V259, pH1921, DOI 10.1152/ajpheart.1990.259.6.H1921; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KINSELLA JP, 1992, J PEDIATR SURG, V27, P44, DOI 10.1016/0022-3468(92)90102-D; KINSELLA JP, AM J PHYSL, V32; LEVIN DL, 1976, J PEDIATR-US, V89, P626, DOI 10.1016/S0022-3476(76)80405-2; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1991, CIRCULATION S2, V84, pA1279	8	592	613	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					819	820		10.1016/0140-6736(92)92687-B	http://dx.doi.org/10.1016/0140-6736(92)92687-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357246				2022-12-24	WOS:A1992JR16800006
J	PIETERSZ, RNI; REESINK, HW; PAUW, W; DEKKER, WJA; BUISMAN, L				PIETERSZ, RNI; REESINK, HW; PAUW, W; DEKKER, WJA; BUISMAN, L			PREVENTION OF YERSINIA-ENTEROCOLITICA GROWTH IN RED-BLOOD-CELL CONCENTRATES	LANCET			English	Note							PHAGOCYTOSIS; TEMPERATURE; STORAGE	In response to concern about Yersinia enterocolitica contamination of blood products, we have studied the effects on Y enterocolitica growth of holding whole blood at 22-degrees-C for 20 h and then removing leucocytes. Thirty pools of three bags of blood were inoculated with Y enterocolitica (2 x 10(1)-3 x 10(4) colony-forming units/ml). One bag in each pool was processed to red-blood-cell concentrate after 6 h at 4-degrees-C (RBC); the other two were held at 22-degrees-C for 20 h before processing to buffy-coat-depleted RBC (BCd-RBC). One of these bags was then depleted of leucocytes by filtration (Ld-RBC). All bags were stored at 4-degrees-C for 5 weeks. R B C bags showed Y enterocolitica growth after the shortest storage times, followed by BCd-RBC then Ld-RBC (p < 0.03-0.001). We recommend that whole blood should be held at 22-degrees-C to make use of inherent bactericidal activity; leucocytes should then be removed.	SLOTERVAART HOSP,DEPT MICROBIOL,AMSTERDAM,NETHERLANDS	Slotervaart Hospital	PIETERSZ, RNI (corresponding author), RED CROSS BLOOD BANK,POSTBOX 9137,1006 AC AMSTERDAM,NETHERLANDS.							GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; HOGMAN CF, 1991, TRANSFUSION, V31, P620, DOI 10.1046/j.1537-2995.1991.31791368338.x; HOPPE PA, 1992, TRANSFUSION, V32, P199, DOI 10.1046/j.1537-2995.1992.32392213799.x; MANARA FS, 1985, BIOCHEM BIOPH RES CO, V132, P696, DOI 10.1016/0006-291X(85)91188-X; PETERSON PK, 1977, INFECT IMMUN, V15, P175, DOI 10.1128/IAI.15.1.175-179.1977; PIETERSZ RNI, 1987, VOX SANG, V53, P203, DOI 10.1111/j.1423-0410.1987.tb05067.x; PIETERSZ RNI, 1989, VOX SANG, V56, P145, DOI 10.1111/j.1423-0410.1989.tb02017.x; PIETERSZ RNI, 1989, VOX SANG, V57, P29, DOI 10.1111/j.1423-0410.1989.tb04980.x; STOSSEL TP, 1975, SEMIN HEMATOL, V12, P83; 1991, MORBID MORTAL WEEKLY, V40, P176	10	63	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					755	756		10.1016/0140-6736(92)92296-R	http://dx.doi.org/10.1016/0140-6736(92)92296-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356179				2022-12-24	WOS:A1992JP86900005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WIDE ACCESS PROTOCOLS FOR BREAST IMPLANTS APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-24	WOS:A1992JM84900005
J	DUNN, DT; NEWELL, ML; ADES, AE; PECKHAM, CS				DUNN, DT; NEWELL, ML; ADES, AE; PECKHAM, CS			RISK OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMISSION THROUGH BREAST-FEEDING	LANCET			English	Article							POSTNATAL TRANSMISSION; INFECTION; HIV; INFANT; MOTHER; WOMEN; MILK	Detection of human immunodeficiency virus type 1 (HIV-1) in breast milk by culture and polymerase chain reaction does not necessarily mean that breastfeeding is a route of transmission, although evidence from several case-reports points in that direction. We undertook a systematic review of published studies meeting criteria that allowed determination of quantitative risk of transmission via breastfeeding. Based on four studies in which mothers acquired HIV-1 postnatally, the estimated risk of transmission is 29% (95% CI 16-42%). Analysis of five studies showed that when the mother was infected prenatally, the additional risk of transmission through breastfeeding, over and above transmission in utero or during delivery, is 14% (95% CI 7-22%). Where there are safe alternatives to breastfeeding, universal named testing of pregnant women would provide an opportunity to advise more infected women not to breastfeed and might thereby reduce the number of vertically infected children. Since breastfeeding protects against infant deaths from infectious diseases, breastfeeding is still recommended where infectious diseases are a common cause of death in childhood, despite the additional risk of HIV transmission.			DUNN, DT (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699; Dunn, David/0000-0003-1836-4446				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BAUMSLAG N, 1987, LANCET, V2, P401; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COLEBUNDERS R, 1988, LANCET, V2, P1487; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; HEYMANN SJ, 1990, AM J PUBLIC HEALTH, V80, P1305, DOI 10.2105/AJPH.80.11.1305; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; JELLIFFE DB, 1992, NEW ENGL J MED, V326, P642; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; LEDERMAN SA, 1992, PEDIATRICS, V89, P290; NEWELL M-L, 1990, AIDS (London), V4, pS111; OXTOBY MJ, 1988, PEDIATR INFECT DIS J, V7, P825, DOI 10.1097/00006454-198807120-00001; PALASANTHIRAN P, IN PRESS J INFECT DI; ROGERS MF, 1987, LANCET, V2, P1278; RUFF A, 1992, 8 INT C AIDS AMST; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; THIRY L, 1985, LANCET, V2, P891; VANDEPERRE P, 1992, LANCET, V339, P1490; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VICTORA CG, 1987, LANCET, V2, P319; ZIEGLER JB, 1985, LANCET, V1, P896; 1988, LANCET, V2, P1043; 1985, MMWR, V34, P721; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1992, WEEKLY EPIDEMIOL REC, V67, P177	30	594	606	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					585	588		10.1016/0140-6736(92)92115-V	http://dx.doi.org/10.1016/0140-6736(92)92115-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355163				2022-12-24	WOS:A1992JM33400012
J	JONGENS, TA; HAY, B; JAN, LY; JAN, YN				JONGENS, TA; HAY, B; JAN, LY; JAN, YN			THE GERM CELL-LESS GENE-PRODUCT - A POSTERIORLY LOCALIZED COMPONENT NECESSARY FOR GERM-CELL DEVELOPMENT IN DROSOPHILA	CELL			English	Article							MEDIATED ENHANCER DETECTION; MATERNAL-EFFECT MUTATIONS; POLAR GRANULES; SEQUENCE SIMILARITY; DETERMINANT NANOS; CYCLIN-B; MELANOGASTER; EMBRYOS; PROTEIN; RNA	The first cell fate specification process in the Drosophila embryo, formation of the germline precursors, requires posteriorly localized germ plasm. We have cloned a gene, germ cell-less (gcl), required for germline formation. Posterior localization of the gcl messenger RNA (mRNA) requires the function of those genes essential for the localization of both nanos RNA, which specifies the abdomen, and the germ cell determinants. Mothers with reduced gcl function give rise to sterile adult progeny that lack germ cells. In embryos with reduced maternal gcl product, the germ cell precursors fail to form properly. Consistent with this phenotype, gcl protein specifically associates with those nuclei that later become the nuclei of the germ cell precursors. These observations suggest that gcl functions in the germ cell specification pathway.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC CELLULAR & DEV BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley	JONGENS, TA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299	NIGMS NIH HHS [GM PHS2271] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAMS HW, 1974, INT REV CYTOL, V39, P413, DOI 10.1016/S0074-7696(08)60944-4; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davidson E. H., 1986, GENE ACTIVITY EARLY; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENGSTROM E, 1982, DEV BIOL, V91, P163; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FOE VE, 1983, J CELL SCI, V61, P31; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JOWETT T, 1986, DROSOPHILA PRACTICAL; KALFAYAN L, 1982, CELL, V29, P91, DOI 10.1016/0092-8674(82)90093-9; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King R. C., 1970, OVARIAN DEV DROSOPHI; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1979, DEV BIOL, V69, P118, DOI 10.1016/0012-1606(79)90279-3; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOHLER J, 1986, GENETICS, V112, P803; NIKI Y, 1984, DEV BIOL, V103, P182, DOI 10.1016/0012-1606(84)90019-8; NIKI Y, 1986, DEV BIOL, V113, P255, DOI 10.1016/0012-1606(86)90127-2; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; RAFF JW, 1990, DEVELOPMENT, V110, P1249; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSENBERG UB, 1985, NATURE, V313, P703, DOI 10.1038/313703a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; THERKAUF WE, 1992, IN PRESS J CELL BIOL, V116; UNDERWOOD EM, 1980, DEV BIOL, V77, P303, DOI 10.1016/0012-1606(80)90476-5; VAESSIN H, 1987, EMBO (European Molecular Biology Organization) Journal, V6, P3431; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0	63	147	151	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					569	584		10.1016/0092-8674(92)90427-E	http://dx.doi.org/10.1016/0092-8674(92)90427-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1380406				2022-12-24	WOS:A1992JJ88600007
J	RELMAN, DA; SCHMIDT, TM; MACDERMOTT, RP; FALKOW, S				RELMAN, DA; SCHMIDT, TM; MACDERMOTT, RP; FALKOW, S			IDENTIFICATION OF THE UNCULTURED BACILLUS OF WHIPPLES DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYLOGENETIC ANALYSIS; INFECTION; GRANULOMAS; ORGANISMS; EVOLUTION; BACTERIA; AGENT; AIDS	Background. Whipple's disease is a systemic disorder known for 85 years to be associated with an uncultured, and therefore unidentified, bacillus. Methods. We used a molecular genetic approach to identify this organism. The bacterial 16S ribosomal RNA (rRNA) sequence was amplified directly from tissues of five unrelated patients with Whipple's disease by means of the polymerase chain reaction, first with broad-range primers and then with specific primers. We determined and analyzed the nucleotide sequence of the amplification products. Results. A unique 1321-base bacterial 16S rRNA sequence was amplified from duodenal tissue of one patient. This sequence indicated the presence of a previously un characterized organism. We then detected this sequence in tissues from all 5 patients with Whipple's disease, but in none of those from 10 patients without the disorder. According to phylogenetic analysis, this bacterium is a gram-positive actinomycete that is not closely related to any known genus. Conclusions. We have identified the uncultured bacillus associated with Whipple's disease. The phylogenetic relations of this bacterium, its distinct morphologic characteristics, and the unusual features of the disease are sufficient grounds for naming this bacillus Tropheryma whippelii gen. nov. sp. nov. Our findings also provide a basis for a specific diagnostic test for this organism.	STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, CTR DIGEST DIS, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; MIAMI UNIV, DEPT MICROBIOL, OXFORD, OH 45056 USA; UNIV PENN, DEPT MED, DIV GASTROENTEROL, PHILADELPHIA, PA 19104 USA	Stanford University; Stanford University; Stanford University; University System of Ohio; Miami University; University of Pennsylvania				Relman, David A./0000-0001-8331-1354; Schmidt, Thomas/0000-0002-8209-6055	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R01DK021474, R37DK021474] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26195] Funding Source: Medline; NIDDK NIH HHS [DK-38707, DK-21474] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; CHEARS WC, 1961, GASTROENTEROLOGY, V41, P129; CHO C, 1984, GASTROENTEROLOGY, V87, P941; CIMPRICH RE, 1977, VET PATHOL, V14, P95, DOI 10.1177/030098587701400201; CLANCY RL, 1975, BRIT MED J, V3, P568, DOI 10.1136/bmj.3.5983.568; Clark JB, 1972, CRIT REV MICROBIOL, V1, P521; COLLINS MD, 1989, INT J SYST BACTERIOL, V39, P1, DOI 10.1099/00207713-39-1-1; DOBBINS WO, 1981, GASTROENTEROLOGY, V80, P1468; DOBBINS WO, 1987, WHIPPLES DISEASE; EDEN PA, 1991, INT J SYST BACTERIOL, V41, P324, DOI 10.1099/00207713-41-2-324; FELDMAN M, 1989, GASTROENTEROLOGY, V96, P1207, DOI 10.1016/0016-5085(89)91643-0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; FOX GE, 1992, INT J SYST BACTERIOL, V42, P166, DOI 10.1099/00207713-42-1-166; GILLIN JS, 1983, GASTROENTEROLOGY, V85, P1187; GOODFELLOW M, 1989, BERGEYS MANUAL SYSTE, V4, P2333; GUPTA S, 1986, GASTROENTEROLOGY, V90, P1286, DOI 10.1016/0016-5085(86)90398-7; Jukes TH., 1969, MAMMALIAN PROTEIN ME, P21, DOI [DOI 10.1093/BIOINFORMATICS/BTM404, 10.1016/B978-1-4832-3211-9.50009-7]; KHAVARI PA, 1991, ARCH DERMATOL, V127, P543, DOI 10.1001/archderm.127.4.543; LUSCOMBE BM, 1974, J GEN MICROBIOL, V82, P213, DOI 10.1099/00221287-82-2-213; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P2017, DOI 10.1093/nar/19.suppl.2017; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROTH RI, 1983, NEW ENGL J MED, V309, P1324; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; SOUTHERN JF, 1989, JAMA-J AM MED ASSOC, V261, P1467, DOI 10.1001/jama.261.10.1467; SPAPEN HDM, 1989, DIGEST DIS SCI, V34, P640, DOI 10.1007/BF01536345; STACKEBRANDT E, 1983, J GEN MICROBIOL, V129, P1831; STAHL DA, 1990, J BACTERIOL, V172, P116, DOI 10.1128/JB.172.1.116-124.1990; STROM RL, 1983, NEW ENGL J MED, V309, P1323; TRACY TE, 1991, BIOTECHNIQUES, V11, P68; WANG HH, 1986, NEW ENGL J MED, V314, P1577; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILLIAMS ST, 1989, BERGEYS MANUAL SYSTE; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YARDLEY JH, 1961, B JOHNS HOPKINS HOSP, V109, P80	39	903	924	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					293	301		10.1056/NEJM199207303270501	http://dx.doi.org/10.1056/NEJM199207303270501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1377787				2022-12-24	WOS:A1992JF65500001
J	HENDRICKSE, MT; THULUVATH, PJ; TRIGER, DR				HENDRICKSE, MT; THULUVATH, PJ; TRIGER, DR			NATURAL-HISTORY OF AUTONOMIC NEUROPATHY IN CHRONIC LIVER-DISEASE	LANCET			English	Article							CIRRHOSIS; PROGNOSIS; PRESSURE	To determine the natural history of autonomic neuropathy in chronic liver disease we used standard cardiovascular autonomic tests to evaluate prospectively 60 patients (33 male, 27 female) with initially well-preserved hepatic function. On initial testing, 27 patients (45%, median [range] age 56 [32-67] years) had vagal neuropathy. Autonomic dysfunction was equally common in patients with alcohol-related and non-alcoholic-related liver disease. The cumulative 4-year mortality rate in patients with vagal neuropathy was 30% compared with 6% in those with normal autonomic function. Multiple logistic regression analysis showed that presence of vagal neuropathy and severity of hepatic damage were independent predictors of mortality. Serial testing showed that whereas disease progression occurred in some patients, in others mild abnormalities in autonomic function were reversible. Vagal dysfunction is common in well-compensated chronic liver disease and its presence identifies a subgroup of patients with a substantially worse outlook.	ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield								DALY LE, 1991, INTERPRETATION USES, P258; EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; EWING DJ, 1980, Q J MED, V49, P95; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; HENDRICKSE MT, 1990, GUT, V31, pA1164; JOHNSON RH, 1988, J NEUROL NEUROSUR PS, V51, P476, DOI 10.1136/jnnp.51.4.476; LLACH J, 1988, GASTROENTEROLOGY, V94, P482, DOI 10.1016/0016-5085(88)90441-6; LUNZER M, 1973, GUT, V14, P354, DOI 10.1136/gut.14.5.354; LUNZER MR, 1975, LANCET, V2, P382; MACGILCHRIST AJ, 1990, AM J GASTROENTEROL, V85, P288; O'Brien IA, 1991, Q J MED, V79, P495; PAGE MM, 1978, LANCET, V1, P14; PUGH RWH, 1983, BRIT J SURG, V60, P646; SATCHELL PM, 1988, AUTONOMIC FAILURE, P159; SCHUMER M, 1988, AM J MED, V85, P144, DOI 10.1016/0002-9343(88)90407-X; TAGEJENSEN U, 1988, J HEPATOL, V6, P350, DOI 10.1016/S0168-8278(88)80053-9; TAN ETH, 1984, J NEUROL NEUROSUR PS, V47, P1335, DOI 10.1136/jnnp.47.12.1335; THULUVATH PJ, 1989, Q J MED, V72, P737; 1985, WHO TECH REP SER, V727, P10; 1989, LANCET, V2, P721	20	153	158	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1462	1464		10.1016/0140-6736(92)92042-E	http://dx.doi.org/10.1016/0140-6736(92)92042-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351136				2022-12-24	WOS:A1992HY31700014
J	DUJARDIN, B; DESCHAMPHELEIRE, I; SENE, H; NDIAYE, F				DUJARDIN, B; DESCHAMPHELEIRE, I; SENE, H; NDIAYE, F			VALUE OF THE ALERT AND ACTION LINES ON THE PARTOGRAM	LANCET			English	Article								A partogram based on a World Health Organisation model has been used for many years in the peripheral maternity clinics of Pikine, Senegal, to monitor labour. We have assessed the value of the partogram and efficacy of the alert and action lines. 1022 pregnant women were monitored by partogram during 4 months. The alert line was crossed in 100 (9.8%) of these cases and the frequency of neonatal resuscitation was higher for this group (relative risk 4.0, 95% confidence interval 2.3-7.1; p < 0.0001), as was the number of "fresh" stillbirths (5.3, 1.8-15.6; p < 0.01) (recent death may have occurred during labour). Among the women who crossed the alert but not the action line, neonatal resuscitation was also four times more likely than for the normal labour group (4.0, 2.1-7.6; p < 0.001), and the fresh stillbirth rate was higher but not significantly so. For women who crossed both lines, the fresh stillbirth rate was ten times higher than for women in the normal labour group (9.9, 2.8-34.7; p < 0001). Crossing the alert line had a sensitivity of 27%, a specificity of 93%, and a positive predictive value of 17% for neonatal resuscitation. If the action line was chosen as the decision level, the positive predictive value remained the same but the sensitivity was only 8%. Health workers intervened (eg, artificial rupture of the membranes, administration of oxytocics) in half the dystocic cases. Of the women who did not receive any such treatment 44% crossed the action line compared with only 26% of those who did receive treatment (p = 0.06) The results show the usefulness and efficacy of the partogram and underscore the value of medical intervention as soon as the alert line is crossed.	BELGIUM MED COOPERAT PRIMARY HLTH CARE,PIKINE,SENEGAMBIA; YEMBEUL HLTH CTR,PIKINE,SENEGAMBIA; DEGGO HLTH CTR,DAKAR,SENEGAMBIA		DUJARDIN, B (corresponding author), INST TROP MED PRINCE LEOPOLD,PUBL HLTH RES & TRAINING UNIT,NATINALESTR 155,B-2000 ANTWERP,BELGIUM.							BIRD GC, 1978, TROP DOCT, V8, P78, DOI 10.1177/004947557800800213; DROUIN P, 1979, OBSTET GYNECOL, V53, P741; MAHLER H, 1987, LANCET, V1, P668; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P592; STUDD J, 1973, BRIT MED J, V4, P451, DOI 10.1136/bmj.4.5890.451; 1988, WHOMCH883; 1988, WHOMCH891; 1986, CHRONIQUE OMS, V40, P193; 1988, WHOMCH884; 1988, WHOMCH892	10	36	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1336	1338		10.1016/0140-6736(92)91969-F	http://dx.doi.org/10.1016/0140-6736(92)91969-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350000				2022-12-24	WOS:A1992HW83700012
J	SIMON, SM; BLOBEL, G				SIMON, SM; BLOBEL, G			SIGNAL PEPTIDES OPEN PROTEIN-CONDUCTING CHANNELS IN ESCHERICHIA-COLI	CELL			English	Article							SYNTHESIZING SECRETORY PROTEIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; RECOGNITION PARTICLE; PHOSPHOLIPID-VESICLES; NASCENT PREPROLACTIN; MICROSOMAL-MEMBRANES; PLANAR MEMBRANE; PLASMA-MEMBRANE; TRANSLOCATION	Plasma membrane vesicles and protoplasts of Escherichia coli were fused to planar lipid bilayers and studied with electrophysiological techniques. Large transmembrane aqueous channels were opened when 0.2 nM LamB signal peptide was added to the cytoplasmic side of the membrane. These aqueous pores are similar in conductance to those previously observed in mammalian endoplasmic reticulum when puromycin is used to release and thus unplug nascent translocating chains. Signal sequences have been previously shown to be necessary and sufficient for targeting proteins to cellular membranes. These results demonstrate that signal peptides are sufficient for opening the protein-conducting channels. We suggest that they are the physiological ligands that open protein-conducting channels at the initiation of protein translocation across prokaryotic plasma membrane and mammalian endoplasmic reticulum.	ROCKEFELLER UNIV, CELL BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	SIMON, SM (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Simon, Sanford/0000-0002-8615-4224	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047005] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM47005-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BIRDSELL DC, 1967, J BACTERIOL, V93, P427, DOI 10.1128/JB.93.1.427-437.1967; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; COBET WWE, 1989, J BIOL CHEM, V264, P10169; COHEN FS, 1989, J GEN PHYSIOL, V93, P201, DOI 10.1085/jgp.93.2.201; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DIERSTEIN R, 1985, J BIOL CHEM, V260, P5919; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FRANK G, 1978, FEBS LETT, V96, P183, DOI 10.1016/0014-5793(78)81090-4; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; JOSEFSSON LG, 1983, METHOD ENZYMOL, V97, P77; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUBBEN TH, 1987, SCIENCE, V238, P1112, DOI 10.1126/science.238.4830.1112; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; MILLER C, 1976, J MEMBRANE BIOL, V30, P283, DOI 10.1007/BF01869673; MOSTOV KE, 1981, NATURE, V292, P87, DOI 10.1038/292087a0; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NGUYEN M, 1987, J BIOL CHEM, V262, P3929; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; ROBERTS RB, 1963, STUDIES BIOSYNTHESIS; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; ZIMMERBERG J, 1980, J GEN PHYSIOL, V75, P241, DOI 10.1085/jgp.75.3.241; ZIMMERMANN R, 1990, BIOCHIMIE, V72, P95, DOI 10.1016/0300-9084(90)90134-3	43	199	201	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					677	684		10.1016/0092-8674(92)90231-Z	http://dx.doi.org/10.1016/0092-8674(92)90231-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1375130				2022-12-24	WOS:A1992HV08900012
J	HARLEY, HG; RUNDLE, SA; REARDON, W; MYRING, J; CROW, S; BROOK, JD; HARPER, PS; SHAW, DJ				HARLEY, HG; RUNDLE, SA; REARDON, W; MYRING, J; CROW, S; BROOK, JD; HARPER, PS; SHAW, DJ			UNSTABLE DNA-SEQUENCE IN MYOTONIC-DYSTROPHY	LANCET			English	Article								A variable DNA sequence has been detected in patients with myotonic dystrophy. We set out to determine whether identification of this specific molecular defect would improve clinical management of patients and families with myotonic dystrophy. 127 affected patients who were studied had an expanded DNA fragment not seen in 73 normal controls. The increase in length of the fragment correlated broadly with disease severity, and we noted expansion of the sequence in successive generations of the same family. Progressive expansion of the affected gene provides a molecular explanation for an apparently earlier onset in successive generations (anticipation) in myotonic dystrophy and supports the role of an unstable repeat sequence as the basis of the defect. The specificity of this finding will assist in accurate diagnosis of myotonic dystrophy and genetic counselling of affected families.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	HARLEY, HG (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 6EJ,WALES.			Brook, John David/0000-0002-5946-6740	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; Fleiseher B., 1918, ALBRECHT GRAEFES ARC, V96, P91, DOI DOI 10.1007/BF02018704; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HARPER PS, IN PRESS AM J HUM GE; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; SHAW DJ, 1989, BRIT MED BULL, V45, P745, DOI 10.1093/oxfordjournals.bmb.a072355; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P	13	178	185	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1125	1128		10.1016/0140-6736(92)90729-M	http://dx.doi.org/10.1016/0140-6736(92)90729-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349364				2022-12-24	WOS:A1992HT23600001
J	KREIDER, BL; BENEZRA, R; ROVERA, G; KADESCH, T				KREIDER, BL; BENEZRA, R; ROVERA, G; KADESCH, T			INHIBITION OF MYELOID DIFFERENTIATION BY THE HELIX-LOOP-HELIX PROTEIN ID	SCIENCE			English	Article							DNA-BINDING; NEGATIVE REGULATOR; SEX DETERMINATION; PROGENITOR-CELL; DROSOPHILA; GENE; TRANSCRIPTION; DAUGHTERLESS; MOTIF; EXTRAMACROCHAETAE	Id is a helix-loop-helix (HLH) protein that represses activity of several basic helix-loop-helix (bHLH) proteins involved in cell type-specific transcription and cell lineage commitment. The myeloid precursor cell line 32DC13(G) expressed Id messenger RNA, which was transiently decreased when cells were induced to terminally differentiate with granulocyte-colony-stimulating factor. Concomitant with the decrease of Id messenger RNA was the appearance in nuclear extracts of DNA binding proteins that recognized a canonical E-box motif, a DNA binding site for some bHLH proteins. Constitutive expression of an Id complementary DNA in 32DC13(G) cells blocked their ability to differentiate and to induce E-box-binding activity. These results suggest that Id and, hence, bHLH proteins function in the process of myeloid differentiation.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; WISTAR INST,PHILADELPHIA,PA 19104; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; The Wistar Institute; Fred Hutchinson Cancer Center					NCI NIH HHS [CA 21124, CA 10815, CA 25875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, P01CA025875, P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; KREIDER B, UNPUB; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHTA M, 1989, PATHOL IMMUNOPATH R, V8, P1, DOI 10.1159/000157134; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185	31	242	246	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1700	1702		10.1126/science.1372755	http://dx.doi.org/10.1126/science.1372755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1372755				2022-12-24	WOS:A1992HK81200036
J	LAPIDOT, T; PFLUMIO, F; DOEDENS, M; MURDOCH, B; WILLIAMS, DE; DICK, JE				LAPIDOT, T; PFLUMIO, F; DOEDENS, M; MURDOCH, B; WILLIAMS, DE; DICK, JE			CYTOKINE STIMULATION OF MULTILINEAGE HEMATOPOIESIS FROM IMMATURE HUMAN-CELLS ENGRAFTED IN SCID MICE	SCIENCE			English	Article							HUMAN-BONE-MARROW; STEM-CELLS; CORD BLOOD; IDENTIFICATION; LEUKEMIA; CULTURE; RAT	Severe combined immunodeficient (SCID) mice transplanted with human bone marrow were treated with human mast cell growth factor, a fusion of interleukin-3 and granulocyte-macrophage colony-stimulating factor (PIXY321), or both, starting immediately or 1 month later. Immature human cells repopulated the mouse bone marrow with differentiated human cells of multiple myeloid and lymphoid lineages; inclusion of erythropoietin resulted in human red cells in the peripheral blood. The bone marrow of growth factor-treated mice contained both multipotential and committed myeloid and erythroid progenitors, whereas mice not given growth factors had few human cells and only granulocyte-macrophage progenitors. Thus, this system allows the detection of immature human cells, identification of the growth factors that regulate them, and the establishment of animal models of human hematopoietic diseases.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Immunex Corporation; University of Toronto			Lapidot, Tsvee/A-1812-2010; Pflumio, Francoise/E-2074-2017	Pflumio, Francoise/0000-0001-8995-596X; Dick, John/0000-0002-9527-8317				CAROW CE, 1991, BLOOD, V78, P2216, DOI 10.1182/blood.V78.9.2216.bloodjournal7892216; CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809; DICK JE, 1986, TRENDS GENET, V2, P165, DOI 10.1016/0168-9525(86)90212-X; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; EAVES AC, 1984, CLIN HAEMATOL, V13, P371; FAUSER AA, 1978, BLOOD, V52, P1243; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; FULOP GM, 1986, J IMMUNOL, V136, P4438; GLUCK U, 1989, EXP HEMATOL, V17, P398; KAMELREID S, 1991, BLOOD, V78, P2973; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KAMELREID S, IN PRESS LEUKEMIA; LEARY AG, 1987, BLOOD, V69, P953; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCUNE J, 1991, ANNU REV IMMUNOL, V9, P399, DOI 10.1146/annurev.iy.09.040191.002151; MOORE MAS, 1991, BLOOD, V78, P1; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; PHILLIPS RA, 1985, COMP DIFFERENT ASSAY; ROWLEY SD, 1987, BLOOD, V69, P804; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; SZEBO K, 1990, CELL, V63, P225; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; TORBETT BE, 1991, IMMUNOL REV, V124, P139, DOI 10.1111/j.1600-065X.1991.tb00620.x; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS DE, 1991, CANCER S, V10, P2705; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	30	467	506	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1137	1141		10.1126/science.1372131	http://dx.doi.org/10.1126/science.1372131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1372131				2022-12-24	WOS:A1992HF63200045
J	GRAFFE, M; DONDON, J; CAILLET, J; ROMBY, P; EHRESMANN, C; EHRESMANN, B; SPRINGER, M				GRAFFE, M; DONDON, J; CAILLET, J; ROMBY, P; EHRESMANN, C; EHRESMANN, B; SPRINGER, M			THE SPECIFICITY OF TRANSLATIONAL CONTROL SWITCHED WITH TRANSFER-RNA IDENTITY RULES	SCIENCE			English	Article							SYNTHETASE EXPRESSION INVIVO; ESCHERICHIA-COLI; GENE-REGULATION; MESSENGER-RNA; THREONINE; LIGASE; LEVEL	The interaction of Escherichia coli threonyl-transfer RNA (tRNA) synthetase with the leader sequence of its own messenger RNA inhibits ribosome binding, resulting in negative translational feedback regulation. The leader sequence resembles the substrate (tRNA(Thr)) of the enzyme, and the nucleotides that mediate the correct recognition of the leader and the tRNA may be the same. A mutation suggested by tRNA identity rules that switches the resemblance of the leader sequence from tRNA(Thr) to tRNA(Met) causes the translation of the threonly-tRNA synthetase messenger RNA to become regulated by methionyl-tRNA synthetase. This identity swap in the leader messenger RNA indicates that tRNA identity rules may be extended to interactions of synthetases with other RNAs.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; INST BIOL MOLEC & CELLULAIRE,F-67084 STRASBOURG,FRANCE				ROMBY, Pascale/AGP-3328-2022					BUTLER JS, 1986, J BACTERIOL, V165, P198, DOI 10.1128/jb.165.1.198-203.1986; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LESTIENNE P, 1984, JB IOL CHEM, V2529, P5232; LINDAHL L, 1986, ANNU REV GENET, V20, P297; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MILLER JH, 1972, MOL GENETICS; MOINE H, 1990, J MOL BIOL, V216, P299, DOI 10.1016/S0022-2836(05)80321-3; MOINE H, 1988, P NATL ACAD SCI USA, V85, P7892, DOI 10.1073/pnas.85.21.7892; NEIDHARDT FC, 1977, J BACTERIOL, V129, P378, DOI 10.1128/JB.129.1.378-387.1977; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINGER M, 1986, P NATL ACAD SCI USA, V83, P4384, DOI 10.1073/pnas.83.12.4384; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; SPRINGER MS, UNPUB	17	43	43	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					994	996		10.1126/science.1372129	http://dx.doi.org/10.1126/science.1372129			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1372129				2022-12-24	WOS:A1992HE60500044
J	BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG				BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG			EFFECTS OF DUAL-CHAMBER PACING WITH SHORT ATRIOVENTRICULAR DELAY IN DILATED CARDIOMYOPATHY	LANCET			English	Article							PULSED DOPPLER ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; CONGESTIVE HEART-FAILURE; COMPARATIVE SURVIVAL; HEMODYNAMIC BENEFIT; GAS-EXCHANGE; BLOCK; EXERCISE; REGURGITATION; PACEMAKERS	Mitral or tricuspid regurgitation of long duration may so shorten the ventricular filling time in dilated cardiomyopathy that stroke volume is limited. We assessed the effects of changing the atrioventricular interval during temporary or permanent dual-chamber DDD pacing in twelve dilated cardiomyopathy patients with short ventricular filling times due to regurgitation. We measured ventricular filling time and cardiac output with doppler echocardiography and exercise capacity on a treadmill, at baseline and with the best atrioventricular delay during pacing. The durations of both mitral and tricuspid regurgitation were significantly shorter at the shorter atrioventricular interval (mean reductions 85 [95% Cl 60-110] ms and 110 [75-150] ms, respectively; p<0.001 for both). There were consequent increases in left-ventricular and right-ventricular filling times (65 [35-95] ms and 90 [60-120] ms, p<0.001). For each 50 ms reduction in atrioventricular delay, left-ventricular filling time increased by 35 ms in six subjects with presystolic mitral regurgitation and right-ventricular filling time by 30 ms in nine subjects with presystolic tricuspid regurgitation. At the short atrioventricular interval, cardiac output was greater than baseline (by 1.1 [0.8-1.4] I/min, p<0.01) and there were rises in exercise duration (104 [45-165] s, p<0.05) and maximum oxygen consumption (2.1 [1.5-2.7]ml kg-1min-1, p<0.05). There was a decrease in the Likert visual analogue score of breathlessness at peak exercise (8.6 [SD 2.1] vs 4.9 [3.1], p<0.01 ). Although from a small sample, these findings suggest that DDD pacing with a short atrioventricular delay may have therapeutic potential in patients with dilated cardiomyopathy, even in the absence of conventional indications for pacemaker implantation.			BRECKER, SJD (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT CARDIAC,SYDNEY ST,LONDON SW3 6NP,ENGLAND.							ALPERT MA, 1986, J AM COLL CARDIOL, V7, P925, DOI 10.1016/S0735-1097(86)80358-8; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; BULLER NP, 1988, BRIT HEART J, V59, P212; DAVIES NJH, 1979, RESP PHYSIOL, V36, P261, DOI 10.1016/0034-5687(79)90029-X; DICARLO LA, 1987, AM HEART J, V114, P746, DOI 10.1016/0002-8703(87)90784-8; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; IWASE M, 1986, AM J CARDIOL, V58, P104, DOI 10.1016/0002-9149(86)90251-1; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; LEE CH, 1991, BRIT HEART J, V65, P342; LIPKIN DP, 1985, BRIT HEART J, V54, P321; MBASSOUROUM M, IN PRESS BR HEART J; MEHTA D, 1989, BRIT HEART J, V61, P161; NG KSK, 1989, BRIT HEART J, V62, P246; OCCHETTA E, 1990, PACE, V13, P916, DOI 10.1111/j.1540-8159.1990.tb02129.x; OLDERSHAW PJ, 1983, BRIT HEART J, V49, P568; PANIDIS IP, 1986, J AM COLL CARDIOL, V7, P768, DOI 10.1016/S0735-1097(86)80335-7; REITER MJ, 1982, AM J CARDIOL, V49, P687, DOI 10.1016/0002-9149(82)91947-6; RITTER P, 1989, EUR HEART J, V10, P637, DOI 10.1093/oxfordjournals.eurheartj.a059541; ROKEY R, 1986, AM J CARDIOL, V57, P692, DOI 10.1016/0002-9149(86)90864-7; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; RUTISHAUSER W, 1966, CIRCULATION, V34, P807, DOI 10.1161/01.CIR.34.5.807; RYDEN L, 1988, PACE, V11, P1051, DOI 10.1111/j.1540-8159.1988.tb03951.x; SACHER HL, 1989, ANGIOLOGY, V40, P489, DOI 10.1177/000331978904000511; SCHNITTGER I, 1988, J AM COLL CARDIOL, V11, P83, DOI 10.1016/0735-1097(88)90170-2; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079; WISH M, 1987, AM J CARDIOL, V60, P566, DOI 10.1016/0002-9149(87)90306-7; XIAO HB, 1991, BRIT HEART J, V66, P443; ZILE MR, 1987, J AM COLL CARDIOL, V10, P702, DOI 10.1016/S0735-1097(87)80215-2; 1983, J AM COLL CARDIOL, V2, P755	30	243	263	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1308	1312		10.1016/0140-6736(92)92492-X	http://dx.doi.org/10.1016/0140-6736(92)92492-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360034				2022-12-24	WOS:A1992KA26200003
J	LOK, ASF; KWAN, WK; MOECKLI, R; YARBOUGH, PO; CHAN, RT; REYES, GR; LAI, CL; CHUNG, HT; LAI, TST				LOK, ASF; KWAN, WK; MOECKLI, R; YARBOUGH, PO; CHAN, RT; REYES, GR; LAI, CL; CHUNG, HT; LAI, TST			SEROEPIDEMIOLOGICAL SURVEY OF HEPATITIS-E IN HONG-KONG BY RECOMBINANT-BASED ENZYME IMMUNOASSAYS	LANCET			English	Article							NON-B-HEPATITIS; TRANSMITTED NON-A; WATERBORNE NON-A; E VIRUS; IDENTIFICATION	The agent that causes the enterally transmitted form of non-A, non-B hepatitis has been cloned and called hepatitis E virus (HEV). We have carried out a seroepidemiological survey on the prevalence of hepatitis E in Hong Kong. In a retrospective study, serum from 394 patients with acute viral hepatitis and 355 healthy subjects was tested for antibodies to HEV (anti-HEV) with a recombinant-based enzyme immunoassay. 65 (16.5%) patients with hepatitis were positive for IgM anti-HEV and 23 (5.8%) were also positive for IgM anti-HEV. Of 18 patients diagnosed as having acute non-A, non-B, non-C hepatitis, 6 were IgM anti-HEV positive. 17 (6%) patients in whom acute hepatitis A was diagnosed were also infected with HEV. None of 70 patients with acute hepatitis B or C or exacerbation of chronic hepatitis B was IgM anti-HEV positive. 57 (16.1%) of the healthy subjects were positive for IgG anti-HEV. The prevalence of IgG anti-HEV was higher in subjects over 20 years old than in younger subjects (24% vs 4%, p < 0.0001). IgG anti-HEV was detected in 26% of subjects who were positive for IgG antibody to HAV and in 7% of those negative for that antibody (p < 0.0001). We demonstrated the validity of the recombinant-based enzyme immunoassays for the diagnosis of hepatitis E. Our results suggest that hepatitis E accounts for a third of non-A, non-B, non-C hepatitis in Hong Kong and that coinfection of hepatitis A and E can occur.	UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG; PRINCESS MARGARET HOSP,INFECT DIS UNIT,HONG KONG,HONG KONG; PRINCESS MARGARET HOSP,MED UNIT,HONG KONG,HONG KONG; GENELABS INC,REDWOOD CITY,CA	University of Hong Kong			Lok, Anna/B-8292-2009; Lai, Ching Lung/C-4298-2009	Yang, Shuman/0000-0002-9638-0890; Lai, Ching-Lung/0000-0002-5927-2436				ARANKALLE VA, 1988, LANCET, V1, P550; BRADLEY D, 1988, J GEN VIROL, V69, P731, DOI 10.1099/0022-1317-69-3-731; CHIN KP, 1991, J MED VIROL, V34, P191, DOI 10.1002/jmv.1890340312; GOLDSMITH R, 1992, LANCET, V339, P328, DOI 10.1016/0140-6736(92)91647-Q; GUST ID, 1987, J INFECT DIS, V156, P630, DOI 10.1093/infdis/156.4.630; KRAWCZYNSKI K, 1989, J INFECT DIS, V159, P1042, DOI 10.1093/infdis/159.6.1042; RAMALINGASWAMI V, 1988, LANCET, V1, P571; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; SKIDMORE SJ, 1992, J MED VIROL, V37, P58, DOI 10.1002/jmv.1890370110; SKIDMORE SJ, 1991, LANCET, V337, P1541, DOI 10.1016/0140-6736(91)93227-Z; SONG DY, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P528; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; 1990, LANCET, V336, P1158	15	104	105	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1205	1208		10.1016/0140-6736(92)92901-Q	http://dx.doi.org/10.1016/0140-6736(92)92901-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359270				2022-12-24	WOS:A1992JY38600013
J	STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RAMOS, H; ZEEVI, A; RUDERT, WA; KOCOVA, M; RICORDI, C; ILDSTAD, S; MURASE, N				STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RAMOS, H; ZEEVI, A; RUDERT, WA; KOCOVA, M; RICORDI, C; ILDSTAD, S; MURASE, N			SYSTEMIC CHIMERISM IN HUMAN FEMALE RECIPIENTS OF MALE LIVERS	LANCET			English	Note							PCR	We have previously reported data from clinical and laboratory animal observations which suggest that organ tolerance after transplantation depends on a state of balanced lymphodendritic cell chimerism between the host and donor graft. We have sought further evidence to support this hypothesis by investigating HLA-mismatched liver allograft recipients. 9 of 9 female recipients of livers from male donors had chimerism in their allografts and extrahepatic tissues, according to in-situ hybridisation and molecular techniques 10 to 19 years post-transplantation. In 8 women with good graft function, evidence of the Y chromosome was found in the blood (6/8), skin (8/8), and lymph nodes (7/8). A ninth patient whose transplant failed after 12 years from recurrent chronic viral hepatitis had chimerism in her lymph nodes, skin, jejunum, and aorta at the time of retransplantation. Although cell migration is thought to take place after all types of transplantation, the large population of migratory cells in, and the extent of their seeding from, hepatic grafts may explain the privileged tolerogenicity of the liver compared with other organs.	UNIV PITTSBURGH,HLTH SCI CTR,PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PEDIAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,HLTH SCI CTR,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153	NIDDK NIH HHS [DK 29961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; KASHIWAGI N, 1969, Surgical Forum (Chicago), V20, P374; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, IN PRESS TRANSPLANT; STARZL TE, IN PRESS N ENGL J ME; STARZL TE, 1969, EXPERIENCE HEPATIC T, P184; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6	8	324	333	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					876	877		10.1016/0140-6736(92)93286-V	http://dx.doi.org/10.1016/0140-6736(92)93286-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357298	Green Accepted			2022-12-24	WOS:A1992JT32700005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DRUG APPROVED TO TREAT BENIGN PROSTATIC HYPERPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-24	WOS:A1992JM84900004
J	FEANY, MB; LEE, S; EDWARDS, RH; BUCKLEY, KM				FEANY, MB; LEE, S; EDWARDS, RH; BUCKLEY, KM			THE SYNAPTIC VESICLE PROTEIN SV2 IS A NOVEL TYPE OF TRANSMEMBRANE TRANSPORTER	CELL			English	Article							SEROTONIN TRANSPORTER; RAT-BRAIN; CLONING; EXPRESSION; GLYCOPROTEIN	The primary function of synaptic vesicles is to store and release neurotransmitter. Synaptic vesicles are locally recycled following exocytosis and rapidly refilled with neurotransmitter from the cytoplasm by a process that depends on the electrochemical gradient generated by a proton pump. Little is known about the molecules that import neurotransmitter into synaptic vesicles. We report here that the sequence of the synaptic vesicle protein SV2 identifies this protein as a novel type of transmembrane transporter. The deduced amino acid sequence of SV2 contains two sets of six predicted transmembrane domains: the six most N-terminal transmembrane domains are highly homologous to a subfamily of transporters that includes the human glucose transporter, while the six most C-terminal domains are homologous to the plasma membrane transporters for neurotransmitters. We propose that SV2 mediates transport of neurotransmitters into synaptic vesicles.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	FEANY, MB (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024, USA.			Feany, Mel/0000-0003-0315-7970; Buckley, Kathleen/0000-0003-0283-4917				AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5778, DOI 10.1021/bi00140a013; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CARLSON SS, 1983, J BIOL CHEM, V258, P1082; CARONI P, 1985, NATURE, V314, P441, DOI 10.1038/314441a0; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Esko J D, 1986, Methods Enzymol, V129, P237; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIGGINS C, 1989, NATURE, V341, P103, DOI 10.1038/341103a0; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KILTY J, 1991, SCIENCE, V254, P579; LIU Y, 1992, IN PRESS P NATL ACAD; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	25	221	228	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					861	867		10.1016/0092-8674(92)90319-8	http://dx.doi.org/10.1016/0092-8674(92)90319-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1355409				2022-12-24	WOS:A1992JL66300017
J	MALMBERG, AB; YAKSH, TL				MALMBERG, AB; YAKSH, TL			HYPERALGESIA MEDIATED BY SPINAL GLUTAMATE OR SUBSTANCE-P RECEPTOR BLOCKED BY SPINAL CYCLOOXYGENASE INHIBITION	SCIENCE			English	Article							ASPIRIN-LIKE DRUGS; EXCITATORY AMINO-ACIDS; PROSTAGLANDIN SYNTHESIS; ARACHIDONIC-ACID; NEURONS; RAT; ACTIVATION; CORD; SENSITIZATION; STIMULATION	Inhibition of cyclooxygenase by nonsteroidal anti-inflammatory drugs (NSAIDs) in the periphery is commonly accepted as the primary mechanism by which these agents produce a selective attenuation of pain (analgesia). NSAIDs are now shown to exert a direct spinal action by blocking the excessive sensitivity to pain (hyperalgesia) induced by the activation of spinal glutamate and substance P receptors. These findings demonstrate that the analgesic effects of NSAIDs can be dissociated from their anti-inflammatory actions. Spinal prostanoids are thus critical for the augmented processing of pain information at the spinal level.			MALMBERG, AB (corresponding author), UNIV CALIF SAN DIEGO, DEPT ANESTHESIOL 0818, LA JOLLA, CA 92093 USA.		Yaksh, Tony/D-4119-2009		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002110] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02110] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AANONSEN LM, 1990, PAIN, V41, P309, DOI 10.1016/0304-3959(90)90008-2; AANONSEN LM, 1991, PAIN, V131, P71; BRUNE K, 1991, EXPERIENTIA, V47, P257, DOI 10.1007/BF01958153; CODERRE TJ, 1991, NEUROSCI LETT, V131, P71, DOI 10.1016/0304-3940(91)90339-U; DICKENSON AH, 1987, NEUROSCI LETT, V83, P207, DOI 10.1016/0304-3940(87)90242-4; DOUGHERTY PM, 1991, BRAIN RES, V542, P15, DOI 10.1016/0006-8993(91)90991-4; DROWER EJ, 1987, EUR J PHARMACOL, V133, P249, DOI 10.1016/0014-2999(87)90020-3; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P86, DOI 10.1111/j.1476-5381.1973.tb08270.x; GUZMAN F, 1964, ARCH INT PHARMACOD T, V149, P571; HAGEN AA, 1977, STROKE, V8, P672, DOI 10.1161/01.STR.8.6.672; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HEAPY C G, 1987, British Journal of Pharmacology, V90, p164P; Janis R.A., 1987, ADV DRUG RES, V16, P309; KURAISHI Y, 1989, NEUROSCIENCE, V30, P241, DOI 10.1016/0306-4522(89)90369-2; Lim R K, 1970, Annu Rev Physiol, V32, P269, DOI 10.1146/annurev.ph.32.030170.001413; LIM RKS, 1964, ARCH INT PHARMACOD T, V152, P25; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALMBERG AB, 1977, PAIN, V4, P161; MALMBERG AB, IN PRESS J PHARM EXP; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; MCCORMACK K, 1991, DRUGS, V41, P533, DOI 10.2165/00003495-199141040-00003; MONCADA S, 1979, INFLAMMATION HDB EXP, P588; NICOL GD, 1992, J NEUROSCI, V12, P1917; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; RAMWELL PW, 1966, AM J PHYSIOL, V211, P998, DOI 10.1152/ajplegacy.1966.211.4.998; SCHAIBLE HG, 1988, J PHYSIOL-LONDON, V403, P91, DOI 10.1113/jphysiol.1988.sp017240; SKILLING SR, 1988, J NEUROCHEM, V51, P127, DOI 10.1111/j.1471-4159.1988.tb04845.x; SORKIN LS, UNPUB; TAIWO YO, 1986, BRAIN RES, V373, P81, DOI 10.1016/0006-8993(86)90317-3; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P137; UDA R, 1990, BRAIN RES, V510, P26, DOI 10.1016/0006-8993(90)90723-O; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WOOD PL, 1984, ANALGESICS NEUROCHEM, P175; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YAKSH TL, 1982, ACETYLSALICYLIC ACID, P137; YAMAMOTO T, 1991, LIFE SCI, V49, P1955, DOI 10.1016/0024-3205(91)90637-Q; YAMAMOTO T, IN PRESS ANESTHESIOL	39	520	532	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1992	257	5074					1276	1279		10.1126/science.1381521	http://dx.doi.org/10.1126/science.1381521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1381521				2022-12-24	WOS:A1992JL05000033
J	THOMAIDES, TN; CHAUDHURI, KR; MAULE, S; WATSON, L; MARSDEN, CD; MATHIAS, CJ				THOMAIDES, TN; CHAUDHURI, KR; MAULE, S; WATSON, L; MARSDEN, CD; MATHIAS, CJ			GROWTH-HORMONE RESPONSE TO CLONIDINE IN CENTRAL AND PERIPHERAL PRIMARY AUTONOMIC FAILURE	LANCET			English	Article							SECRETION; HYPERGLYCEMIA; OUTFLOW	Patients with primary autonomic failure may have either pure autonomic failure (PAF) or multiple system atrophy (MSA) in which there is additional neurological involvement. Distinction between PAF and MSA at an early stage is important because a wide range of complications is associated with MSA, which has a poor response to drug therapy and a less favourable prognosis. We have investigated the growth hormone (GH) releasing effects of clonidine in patients with PAF and MSA to see whether this hormonal response could serve as a neuroendocrine marker to distinguish between the groups. Age-matched normal subjects were studied as controls. Both groups of patients had severe postural hypotension due to primary sympathetic failure of presumed central origin in MSA and peripheral origin in PAF. After clonidine, plasma GH concentrations increased in controls and PAF, with no change in MSA. Changes in plasma glucose and insulin concentrations were similar in all groups. Clonidine, therefore, stimulates growth hormone release in PAF but not MSA and may serve as a neuroendocrine marker in differentiating patients with MSA and a central autonomic defect from those with PAF with a peripheral defect.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT MED,CARDIOVASC MED UNIT,LONDON SW7 2AZ,ENGLAND; NATL HOSP NEUROL & NEUROSURG,LONDON,ENGLAND; UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,AUTON UNIT,LONDON,ENGLAND	Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London				Ray Chaudhuri, K/0000-0003-2815-0505	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBAROTH J, 1989, CLIN ENDOCRINOL, V30, P485, DOI 10.1111/j.1365-2265.1989.tb01419.x; Armstrong E, 1991, Clin Auton Res, V1, P135, DOI 10.1007/BF01826210; BANNISTER R, 1988, AUTONOMIC FAILURE TX, P281; BANNISTER R, 1992, AUTONOMIC FAILURE TX, P255; BARBIERI C, 1980, J PHARMACOL EXP THER, V214, P433; BRAMNERT M, 1984, J CLIN ENDOCR METAB, V58, P374, DOI 10.1210/jcem-58-2-374; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHEKLEY SA, 1981, BRIT J PSYCHIAT, V138, P51; DACOSTA DF, 1984, CLIN EXP HYPERTENS A, V6, P1843, DOI 10.3109/10641968409046089; DELITALA G, 1983, J CLIN ENDOCR METAB, V57, P1145, DOI 10.1210/jcem-57-6-1145; GEMMILL JD, 1988, LANCET, V1, P1018; GILAD I, 1979, LANCET, V2, P1242; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; HUNT GE, 1986, PSYCHONEUROENDOCRINO, V11, P317, DOI 10.1016/0306-4530(86)90017-X; KOONER JS, 1991, CIRCULATION, V84, P75, DOI 10.1161/01.CIR.84.1.75; LAL S, 1981, HORM METAB RES, V13, P648, DOI 10.1055/s-2007-1019362; MAY CN, 1988, CLIN SCI, V75, P71, DOI 10.1042/cs0750071; MAY CN, 1990, NEUROPHARMACOLOGY, V29, P545, DOI 10.1016/0028-3908(90)90066-Z; MAZZA E, 1990, Endocrinologia Experimentalis, V24, P211; MULLER EE, 1988, ADV BIOSCI, V69, P173; POLINSKY RJ, 1992, AUTONOMIC FAILURE TX, P334; RAJPUT AH, 1990, CLIN NEUROPHARMACOL, V13, P553, DOI 10.1097/00002826-199012000-00007; REID JL, 1981, BRIT J CLIN PHARMACO, V12, P295, DOI 10.1111/j.1365-2125.1981.tb01217.x; REID JL, 1977, CLIN PHARMACOL THER, V21, P375; RUDMAN D, 1981, J CLIN INVEST, V67, P1364	25	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					263	266		10.1016/0140-6736(92)92355-J	http://dx.doi.org/10.1016/0140-6736(92)92355-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353191				2022-12-24	WOS:A1992JG66500003
J	GORDON, RD; KLEMM, SA; TUNNY, TJ; STOWASSER, M				GORDON, RD; KLEMM, SA; TUNNY, TJ; STOWASSER, M			PRIMARY ALDOSTERONISM - HYPERTENSION WITH A GENETIC-BASIS	LANCET			English	Article							SUPPRESSIBLE HYPER-ALDOSTERONISM	Exciting developments in knowledge of primary aldosteronism include description of new subtypes and elucidation of the genetic basis of one variety. Furthermore, relatively simple biochemical screening (aldosterone/renin ratio) has disclosed that primary aldosteronism is more common than previously thought, by diagnosing patients at an earlier, normokalaemic stage. The mutant gene discovered in the glucocorticoid-suppressible variety (FHI) codes for an aldosterone biosynythetic enzyme normally controlled by angiotensin II, and now controlled by corticotropin. The zona fasciculata is hyperplastic and makes aldosterone and "hybrid steroids" 18-oxocortisol and 18-hydroxycortisol in excess, in response to ACTH but not to angiotensin II. Adrenal tumours have not yet been described in this condition. Aldosterone-producing adenomas (Conn's syndrome) are also commonly composed of zona fasciculata-like cells, make "hybrid steroids" in excess and are very sensitive to ACTH but not to angiotensin II. We have described a new variety of aldosterone-producing adenoma which is responsive to angiotensin II (AII-responsive APA), consists of at least 20% zona glomerulosa-like cells, and does not make "hybrid steroids" in excess. We have also described a new familial variety of primary aldosteronism that includes tumours and is not glucocorticoid-suppressible (FHII). We propose that primary aldosteronism is a spectrum of genetic diseases expressed as either hyperplasia or neoplasia, and that morphological and genetic diversity explains biochemical and clinical behaviour.			GORDON, RD (corresponding author), UNIV QUEENSLAND,GREENSLOPES HOSP,DEPT MED,ENDOCRINE HYPERTENS RES UNIT,BRISBANE,QLD 4120,AUSTRALIA.		Stowasser, Michael/F-4121-2010; Gordon, Richard D/K-2555-2012					AXELROD L, 1992, NEW ENGL J MED, V326, P1617, DOI 10.1056/NEJM199206113262406; GOMEZSANCHEZ CE, 1988, J CLIN ENDOCR METAB, V67, P444, DOI 10.1210/jcem-67-3-444; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; GORDON RD, 1991, CLIN EXP PHARMACOL P, V18, P283, DOI 10.1111/j.1440-1681.1991.tb01446.x; GORDON RD, 1987, CLIN EXPT PHARM PHYS, V17, P175; HAMLET SM, 1985, CLIN EXP PHARMACOL P, V12, P249, DOI 10.1111/j.1440-1681.1985.tb02641.x; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; HOEFNAGELS WHL, 1982, NEW ENGL J MED, V306, P427; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MATSUO K, 1985, ACTA PATHOL JAPON, V35, P1511; MCKENNA TJ, 1991, J CLIN ENDOCR METAB, V73, P952, DOI 10.1210/jcem-73-5-952; MIURA K, 1968, J CLIN ENDOCR METAB, V28, P1807, DOI 10.1210/jcem-28-12-1807; STOWASSER M, 1992, CLIN EXP PHARMACOL P, V19, P319, DOI 10.1111/j.1440-1681.1992.tb00462.x; STOWASSER M, 1991, J HYPERTENS, V9, pS264; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; TUNNY TJ, 1991, CLIN ENDOCRINOL, V34, P363, DOI 10.1111/j.1365-2265.1991.tb00306.x; WOODLAND E, 1985, CLIN EXP PHARMACOL P, V12, P245, DOI 10.1111/j.1440-1681.1985.tb02640.x	17	85	87	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					159	161		10.1016/0140-6736(92)93225-C	http://dx.doi.org/10.1016/0140-6736(92)93225-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352575				2022-12-24	WOS:A1992JE38200013
J	SCHNEIDER, JS; POPE, A; SIMPSON, K; TAGGART, J; SMITH, MG; DISTEFANO, L				SCHNEIDER, JS; POPE, A; SIMPSON, K; TAGGART, J; SMITH, MG; DISTEFANO, L			RECOVERY FROM EXPERIMENTAL PARKINSONISM IN PRIMATES WITH GM1 GANGLIOSIDE TREATMENT	SCIENCE			English	Article							DOPAMINERGIC-NEURONS; NERVOUS-SYSTEM; MPTP; MONKEYS; BRAIN; STRIATUM; DEFICITS; DISEASE; RATS	A parkinsonian syndrome can be produced in nonhuman primates by administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Parkinsonian-like symptoms induced acutely by MPTP were ameliorated after treatment with G(M1) ganglioside, a substance shown to have neurotrophic effects on the damaged dopamine system in rodents. Treatment with G(M)1 ganglioside also increased striatal dopamine and metabolite levels and enhanced the dopaminergic innervation of the striatum as demonstrated by tyrosine hydroxylase immunohistochemistry. These results suggest that G(M1) ganglioside may hold promise as a therapeutic agent for the treatment of Parkinson's disease.	HAHNEMANN UNIV, SCH MED, INST NEUROSCI, PHILADELPHIA, PA 19102 USA	Drexel University	SCHNEIDER, JS (corresponding author), HAHNEMANN UNIV, SCH MED, CTR NEUROL RES, DEPT NEUROL, PHILADELPHIA, PA 19102 USA.							AGNATI LF, 1983, ACTA PHYSIOL SCAND, V119, P347, DOI 10.1111/j.1748-1716.1983.tb07350.x; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; ELSWORTH JD, 1987, BRAIN RES, V415, P293, DOI 10.1016/0006-8993(87)90211-3; FALARDEAU P, 1988, NEUROSCI LETT, V86, P225, DOI 10.1016/0304-3940(88)90575-7; GHIDONI R, 1989, NEUROCHEM INT, V15, P455, DOI 10.1016/0197-0186(89)90164-2; HADJICONSTANTINOU M, 1989, BRAIN RES, V484, P297, DOI 10.1016/0006-8993(89)90373-9; HADJICONSTANTINOU M, 1986, NEUROPHARMACOLOGY, V25, P1075; Hornykiewicz O, 1986, ADV NEUROL, V45, P19; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; KOFMAN OS, 1991, J CAN SCI NEUROL, V18, P83; KOVELOWSKI CJ, 1990, SOC NEUR ABSTR, V16, P1341; KURLAN R, 1991, MOVEMENT DISORD, V6, P111, DOI 10.1002/mds.870060205; Kurland L. T, 1958, PATHOGENESIS TREATME, P5; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MELAMED E, 1988, PARKINSONS DISEASE M, P87; Nagai Y, 1988, NEW TRENDS GANGLIOSI, P329; RAHMANN H, 1983, NEUROCHEM INT, V5, P539, DOI 10.1016/0197-0186(83)90044-X; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; SABEL BA, 1984, SCIENCE, V225, P340, DOI 10.1126/science.6740316; SCHNEIDER JS, 1990, BRAIN RES, V519, P122, DOI 10.1016/0006-8993(90)90069-N; SCHNEIDER JS, 1992, J NEUROSCI RES, V31, P112, DOI 10.1002/jnr.490310116; SCHNEIDER JS, 1988, BRAIN, V111, P1265, DOI 10.1093/brain/111.6.1265; SCHNEIDER JS, 1990, BRAIN RES, V534, P25, DOI 10.1016/0006-8993(90)90108-N; SCHNEIDER JS, IN PRESS VULNERABLE; SCHOENBERG BS, 1986, ADV NEUROL, V45, P277; SKAPER SD, 1989, MOL NEUROBIOL, V3, P173, DOI 10.1007/BF02935630; STULL N, 1991, Society for Neuroscience Abstracts, V17, P702; TAYLOR JR, 1990, PROG BRAIN RES, V82, P543; TAYLOR JR, 1990, BRAIN, V113, P617, DOI 10.1093/brain/113.3.617; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; TETRUD JW, 1989, NEW ENGL J MED, V321, P1364; TILSON HA, 1988, J NEUROSCI RES, V19, P88, DOI 10.1002/jnr.490190112; TOFFANO G, 1984, BRAIN RES, V296, P233, DOI 10.1016/0006-8993(84)90061-1; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; YU RK, 1988, NEW TRENDS GANGLIOSI, P461; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	36	186	188	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					843	846		10.1126/science.1350379	http://dx.doi.org/10.1126/science.1350379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1350379				2022-12-24	WOS:A1992HT23500047
J	ROSENFELD, MA; YOSHIMURA, K; TRAPNELL, BC; YONEYAMA, K; ROSENTHAL, ER; DALEMANS, W; FUKAYAMA, M; BARGON, J; STIER, LE; STRATFORDPERRICAUDET, L; PERRICAUDET, M; GUGGINO, WB; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				ROSENFELD, MA; YOSHIMURA, K; TRAPNELL, BC; YONEYAMA, K; ROSENTHAL, ER; DALEMANS, W; FUKAYAMA, M; BARGON, J; STIER, LE; STRATFORDPERRICAUDET, L; PERRICAUDET, M; GUGGINO, WB; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			INVIVO TRANSFER OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TO THE AIRWAY EPITHELIUM	CELL			English	Article							DEPENDENT PROTEIN-KINASE; INSITU HYBRIDIZATION; CHLORIDE CHANNELS; ADENOVIRUS TYPE-5; ESCHERICHIA-COLI; MESSENGER-RNAS; CELL-LINE; EXPRESSION; DNA; IDENTIFICATION	Direct transfer of the normal cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene to airway epithelium was evaluated using a replication-deficient recombinant adenovirus (Ad) vector containing normal human CFTR cDNA (Ad-CFTR). In vitro Ad-CFTR-infected CFPAC-1 CF epithelial cells expressed human CFTR mRNA and protein and demonstrated correction of defective cAMP-mediated Cl-permeability. Two days after in vivo intratracheal introduction of Ad-CFTR in cotton rats, in situ analysis demonstrated human CFTR gene expression in lung epithelium. PCR amplification of reverse transcribed lung RNA demonstrated human CFTR transcripts derived from Ad-CFTR, and Northern analysis of lung RNA revealed human CFTR transcripts for up to 6 weeks. Human CFTR protein was detected in epithelial cells using anti-human CFTR antibody 11-14 days after infection. While the safety and effectiveness remain to be demonstrated, these observations suggest the feasibility of in vivo CFTR gene transfer as therapy for the pulmonary manifestations of CF.	TRANSGENE SA,STRASBOURG,FRANCE; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Transgene SA; UNICANCER; Gustave Roussy; Johns Hopkins University	ROSENFELD, MA (corresponding author), NHLBI,PULM BRANCH,BETHESDA,MD 20892, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122, R01HL040178] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40178, HL 47122] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DELEVAL MR, 1991, J THORAC CARDIOV SUR, V101, P633; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Evans MJ, 1989, LUNG CELL BIOL, P1; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAJAHMAD Y, 1986, J VIROL, V57, P267, DOI 10.1128/JVI.57.1.267-274.1986; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ MS, 1990, VIROLOGY, P01679; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JEFFERSON DM, 1990, AM J PHYSIOL, V259, pL496, DOI 10.1152/ajplung.1990.259.6.L496; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; ROSENFELD MA, 1991, CLIN RES, V39, pA311; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Strauss SE, 1984, ADENOVIRUSES, P451; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TRESIZE AEO, 1991, NATURE, V353, P434; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Weibel E.R., 1991, LUNG SCI F, V1, P711; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	53	907	1513	1	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					143	155		10.1016/0092-8674(92)90213-V	http://dx.doi.org/10.1016/0092-8674(92)90213-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370653				2022-12-24	WOS:A1992GZ58300016
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			THE PRO REGION OF BPTI FACILITATES FOLDING	CELL			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTEIN-DISULFIDE-ISOMERASE; NUCLEAR-MAGNETIC-RESONANCE; INTERMEDIATE; SEQUENCES; PATHWAY; DITHIOTHREITOL; POLYPEPTIDE; REQUIREMENT; MICROSOMES	The in vitro folding pathway of bovine pancreatic trypsin inhibitor (BPTI) has been described previously in terms of the disulfide-bonded intermediates that accumulate during folding of the protein. Folding is slow, occurring in hours at pH 7.3, 25-degrees-C. In addition, approximately half of the BPTI molecules become trapped as a dead-end, native-like intermediate. In vivo, BPTI is synthesized as a precursor protein that includes a 13 residue amino-terminal pro region. This pro region contains a cysteine residue. We find that, in vitro, both the rate of formation and the yield of properly folded BPTI are increased substantially in a recombinant model of pro-BPTI. The cysteine residue is necessary for this effect. Moreover, a single cysteine residue, tethered to the carboxy-terminal end of BPTI with a flexible linker of repeating Ser-Gly-Gly residues, is sufficient to assist in disulfide formation. Thus, the pro region appears to facilitate folding by providing a tethered, solvent-accessible, intramolecular thiol-disulfide reagent.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT PHYS, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02142 USA.				NIAID NIH HHS [T32AI07348] Funding Source: Medline; NIGMS NIH HHS [GM41307] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041307] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHAU MH, 1991, FEBS LETT, V291, P296, DOI 10.1016/0014-5793(91)81305-R; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; DARBY NJ, 1992, J MOL BIOL, V224, P905, DOI 10.1016/0022-2836(92)90458-V; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; DOERING D, 1992, THESIS MIT CAMBRIDGE; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; FIELDS C G, 1991, Peptide Research, V4, P95; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HURLE MR, 1992, PROTEIN SCI, V1, P91; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KOSEN PA, 1992, BIOCHEMISTRY-US, V31, P5705, DOI 10.1021/bi00140a004; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIN TY, 1991, P NATL ACAD SCI USA, V88, P10573, DOI 10.1073/pnas.88.23.10573; NADERI HM, 1991, CONFORMATIONS FORCES, P86; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTHWARF DM, 1992, P NATL ACAD SCI USA, V89, P7944, DOI 10.1073/pnas.89.17.7944; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; VANMIERLO CPM, 1992, P NATL ACAD SCI USA, V89, P6775, DOI 10.1073/pnas.89.15.6775; VANMIERLO CPM, 1991, J MOL BIOL, V222, P373, DOI 10.1016/0022-2836(91)90217-T; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	57	133	139	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					841	851		10.1016/0092-8674(92)90559-U	http://dx.doi.org/10.1016/0092-8674(92)90559-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1384990				2022-12-24	WOS:A1992JZ63300013
J	MARKUSSIS, V; BESHYAH, SA; FISHER, C; SHARP, P; NICOLAIDES, AN; JOHNSTON, DG				MARKUSSIS, V; BESHYAH, SA; FISHER, C; SHARP, P; NICOLAIDES, AN; JOHNSTON, DG			DETECTION OF PREMATURE ATHEROSCLEROSIS BY HIGH-RESOLUTION ULTRASONOGRAPHY IN SYMPTOM-FREE HYPOPITUITARY ADULTS	LANCET			English	Article							HUMAN GROWTH-HORMONE; CARDIOVASCULAR-DISEASE; CAROTID ATHEROSCLEROSIS; FOLLOW-UP; PROGRESSION; ARTERIOSCLEROSIS; REGRESSION; POPULATION; ULTRASOUND; MORTALITY	Retrospective analysis suggests that there is increased mortality from vascular disease in hypopituitary adults, but vascular status before death is unknown. High resolution B-mode ultrasonic imaging of both carotid and femoral arteries was therefore done in 34 adult hypopituitary patients on routine replacement therapy and was compared with that in 39 matched controls. Changes were related to risk factors for vascular disease. Carotid intima-media thickness was greater in patients than in controls (mean [SD] 0.74 [0.16] vs 0.65 [0.13] mm, p < 0.02). This difference was seen in middle-aged and elderly patients. More patients than controls had one or more atheromatous plaques (65% vs 41%, p < 0.05). The percentage of individual arteries with a plaque was also higher in patients (32% vs 18%, p < 0.005). In multiple regression analysis, patients' age was the dominant factor determining carotid intima-media thickness. Symptom-free adults with hypopituitarism show an increased prevalence of atherosclerosis.	ST MARYS HOSP, SCH MED, METAB MED UNIT, LONDON W2 1PG, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, SCH MED, IRVINE LAB, HARROW HA1 3UJ, MIDDX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, SCH MED, ACAD SURG UNIT, HARROW HA1 3UJ, MIDDX, ENGLAND	Imperial College London; Imperial College London; Imperial College London; Imperial College London			Beshyah, Salem/H-3213-2016; Beshyah, Salem A/I-1533-2019	Beshyah, Salem/0000-0003-3650-9741; Beshyah, Salem A/0000-0003-3650-9741				BELCARO G, 1990, CURR THER RES CLIN E, V48, P116; BLACKETT PR, 1982, METABOLISM, V31, P117, DOI 10.1016/0026-0495(82)90121-4; ERNST E, 1991, BRIT MED J, V303, P596, DOI 10.1136/bmj.303.6803.596; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GARDNER MJ, 1989, STATISTICS CONFIDENC, P20; ISHIBASHI S, 1985, ACTA ENDOCRINOL-COP, V110, P456, DOI 10.1530/acta.0.1100456; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LIBBER SM, 1990, MEDICINE, V69, P46, DOI 10.1097/00005792-199001000-00004; MARGITIC SE, 1991, ARTERIOSCLER THROMB, V11, P443, DOI 10.1161/01.ATV.11.2.443; MERIMEE TJ, 1973, DIABETES, V22, P813, DOI 10.2337/diab.22.11.813; MERIMEE TJ, 1972, METABOLISM, V21, P1053, DOI 10.1016/0026-0495(72)90036-4; MERIMEE TJ, 1968, METABOLISM, V17, P1005, DOI 10.1016/0026-0495(68)90006-1; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; RICOTTA JJ, 1987, J VASC SURG, V6, P512, DOI 10.1067/mva.1987.avs0060512; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; TEALE JD, 1986, ANN CLIN BIOCHEM, V23, P413, DOI 10.1177/000456328602300406; WARRICK GR, 1982, CLIN CHEM, V28, P1379; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; WUSTER C, 1991, KLIN WOCHENSCHR, V69, P769, DOI 10.1007/BF01797616	24	360	367	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1188	1192		10.1016/0140-6736(92)92892-J	http://dx.doi.org/10.1016/0140-6736(92)92892-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359261				2022-12-24	WOS:A1992JY38600004
J	MARTIN, J; HORWICH, AL; HARTL, FU				MARTIN, J; HORWICH, AL; HARTL, FU			PREVENTION OF PROTEIN DENATURATION UNDER HEAT-STRESS BY THE CHAPERONIN HSP60	SCIENCE			English	Article							ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; SHOCK PROTEINS; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; ATP HYDROLYSIS; COMPLEX; IMPORT; GROE; RECONSTITUTION	The increased synthesis of heat shock proteins is a ubiquitous physiological response of cells to environmental stress. How these proteins function in protecting cellular structures is not yet understood. The mitochondrial heat shock protein 60 (Hsp60) has now been shown to form complexes with a variety of polypeptides in organelles exposed to heat stress. The Hsp60 was required to prevent the thermal inactivation in vivo of native dihydrofolate reductase (DHFR) imported into mitochondria. In vitro, Hsp60 bound to DHFR in the course of thermal denaturation, preventing its aggregation, and mediated its adenosine triphosphate-dependent refolding at increased temperatures. These results suggest a general mechanism by which heat shock proteins of the Hsp60 family stabilize preexisting proteins under stress conditions.	SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LABS,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Memorial Sloan Kettering Cancer Center; Yale University; Howard Hughes Medical Institute; Yale University			Hartl, F. Ulrich/Y-8206-2019					APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DAUM G, 1982, J BIOL CHEM, V257, P3075; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GARVEY EP, 1989, BIOCHEMISTRY-US, V28, P2083, DOI 10.1021/bi00431a018; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KITTCHEL BB, 1978, BIOCHIM BIOPHYS ACTA, V534, P89; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Martin J., UNPUB; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN MY, 1992, EMBO J, V11, P71; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TEINTZE M, 1982, J BIOL CHEM, V257, P364; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	39	252	256	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					995	998		10.1126/science.1359644	http://dx.doi.org/10.1126/science.1359644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359644				2022-12-24	WOS:A1992JW79600035
J	ROTHSTEIN, JD; GUIDOTTI, A; TINUPER, P; CORTELLI, P; AVONI, P; PLAZZI, G; LUGARESI, E; SCHOCH, P; MONTAGNA, P				ROTHSTEIN, JD; GUIDOTTI, A; TINUPER, P; CORTELLI, P; AVONI, P; PLAZZI, G; LUGARESI, E; SCHOCH, P; MONTAGNA, P			ENDOGENOUS BENZODIAZEPINE RECEPTOR LIGANDS IN IDIOPATHIC RECURRING STUPOR	LANCET			English	Note								"Endozepines" are endogenous ligands for the benzodiazepine recognition sites on gamma-aminobutyric acid A receptors in the nervous system. Idiopathic recurring stupor (IRS) is a syndrome of spontaneous stupor or coma that is not associated with known metabolic, toxic, or structural abnormalities but can be reversed by flumazenil, a pure benzodiazepine antagonist. We measured endozepine-2 and endozepine-4 by high-performance liquid chromatography and radioreceptor assay in serum and cerebrospinal fluid from three patients with IRS. During episodes of stupor there was a large (up to 300-fold compared with control patients) increase of endozepine-4 content in cerebrospinal fluid and serum, but a return to normal concentrations between attacks. Endozepine-4 may contribute to, or be the cause of, IRS. The reasons for abnormal concentrations of endozepine in blood and brain are unknown.	GEORGETOWN UNIV,FIDIA GEORGETOWN INST NEUROSCI,WASHINGTON,DC 20057; UNIV BOLOGNA,INST NEUROL,I-40126 BOLOGNA,ITALY; HOFFMANN LA ROCHE AG,DIV PHARMA,PRECLIN RES,BASEL,SWITZERLAND	Georgetown University; University of Bologna; Roche Holding	ROTHSTEIN, JD (corresponding author), JOHNS HOPKINS UNIV,DEPT NEUROL,MEYER 5-119,600 N WOLFE ST,BALTIMORE,MD 21205, USA.		Cortelli, Pietro/K-6063-2016; Avoni, Patrizia/AAC-1879-2020; rothstein, jeffrey d/C-9470-2013; Tinuper, Paolo/AAB-7760-2020; Plazzi, Giuseppe/AAB-9627-2020	Cortelli, Pietro/0000-0002-3633-8818; tinuper, paolo/0000-0002-0588-3063; AVONI, PATRIZIA/0000-0003-0719-6803; Plazzi, Giuseppe/0000-0002-1051-0472	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001355] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01355] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COSTA E, 1987, PSYCHOPHARMACOLOGY 3, P425; GRIMM G, 1988, LANCET, V1, P1292; IZQUIERDO I, 1991, TRENDS PHARMACOL SCI, V12, P260, DOI 10.1016/0165-6147(91)90567-C; MENNINI T, 1983, ADV BIOCHEM PSYCHOPH, V38, P189; MULLEN KD, 1990, LANCET, V336, P81, DOI 10.1016/0140-6736(90)91594-Z; NUTT DJ, 1990, ARCH GEN PSYCHIAT, V47, P917; OLASMAA M, 1990, J NEUROCHEM, V55, P2015, DOI 10.1111/j.1471-4159.1990.tb05790.x; ROTHSTEIN JD, 1992, J NEUROCHEM, V58, P2102, DOI 10.1111/j.1471-4159.1992.tb10952.x; TINUPER P, 1992, ANN NEUROL, V31, P503, DOI 10.1002/ana.410310507; UNSELD E, 1989, BIOCHEM PHARMACOL, V38, P2473, DOI 10.1016/0006-2952(89)90091-9	10	47	47	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1002	1004		10.1016/0140-6736(92)93011-B	http://dx.doi.org/10.1016/0140-6736(92)93011-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357403				2022-12-24	WOS:A1992JV01400005
J	DEGRAAF, MJM				DEGRAAF, MJM			40 YEARS OF BEING TREATED FOR NOCTURNAL ENURESIS	LANCET			English	Editorial Material											DEGRAAF, MJM (corresponding author), UNIV LIMBURG,ACAD HOSP,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.							GILRUSHTON H, 1989, J PEDIATR, V114, P691; NORGAARD JP, 1985, J UROLOGY, V134, P1029, DOI 10.1016/S0022-5347(17)47581-1; RITTIG S, 1989, AM J PHYSIOL, V256, P664	3	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					957	958		10.1016/0140-6736(92)92828-4	http://dx.doi.org/10.1016/0140-6736(92)92828-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357357				2022-12-24	WOS:A1992JT82300014
J	CROS, P; ALLIBERT, P; MANDRAND, B; TIERCY, JM; MACH, B				CROS, P; ALLIBERT, P; MANDRAND, B; TIERCY, JM; MACH, B			OLIGONUCLEOTIDE GENOTYPING OF HLA POLYMORPHISM ON MICROTITRE PLATES	LANCET			English	Article							LINKAGE DISEQUILIBRIUM; TYPING ANALYSIS; CLASS-II; HYBRIDIZATION; DNA; IDENTIFICATION; PROBES	Molecular analysis of mutations and polymorphisms that are of medical importance requires both accuracy and simplicity. In organ transplantation there is a need for an HLA typing procedure that combines the remarkable accuracy of oligonucleotide genotyping with the simplicity of conventional serological typing. We describe a simple semiautomated method of HLA class II typing consisting of an oligonucleotide hybridisation assay done on microtitre plates followed by automatic colorimetric reading. Individual HLA-DR generic typing for 30 DR specificities, including subtypes of DR1, DR2, DR13, DR14, and DR52, is done on a single plate. The entire typing assay can be completed in less than 4 hours. The procedure has been validated on more than a thousand haplotypes in prospective DR typing of kidney transplant patients, leukaemic patients, and their potential donors. The simplicity of this assay makes it suitable for routine laboratory use. It can be applied to genetic testing in general, including the testing of patients with multiple mutations.	BIOMERIEUX,NUCLEIC ACID PROBES LAB,LYON,FRANCE; HOP CANTONAL GENEVA,DIV IMMUNOL & ALLERGOL,TRANSPLANTAT IMMUNOL UNIT,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND	bioMerieux; University of Geneva; University of Geneva								ANGELINI G, 1986, P NATL ACAD SCI USA, V83, P4489, DOI 10.1073/pnas.83.12.4489; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; DUNN AR, 1977, CELL, V12, P23, DOI 10.1016/0092-8674(77)90182-9; GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390; KELLER GH, 1989, DNA PROBES, P141; MACH B, 1991, HUM IMMUNOL, V30, P278, DOI 10.1016/0198-8859(91)90007-V; MACH B, 1990, MOL BIOL HLA CLASS 2, P201; MOREL C, 1990, HUM IMMUNOL, V29, P64, DOI 10.1016/0198-8859(90)90070-6; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; TIERCY JM, 1991, TISSUE ANTIGENS, V37, P161, DOI 10.1111/j.1399-0039.1991.tb01865.x; TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121; TIERCY JM, 1988, P NATL ACAD SCI USA, V85, P198, DOI 10.1073/pnas.85.1.198; TIERCY JM, 1990, EUR J IMMUNOL, V20, P237, DOI 10.1002/eji.1830200202; TIERCY JM, 1991, TRANSPLANTATION, V51, P1110, DOI 10.1097/00007890-199105000-00034; WAKE CT, 1982, NATURE, V300, P372, DOI 10.1038/300372a0	16	67	72	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					870	873		10.1016/0140-6736(92)93284-T	http://dx.doi.org/10.1016/0140-6736(92)93284-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357296				2022-12-24	WOS:A1992JT32700003
J	HENDEY, B; KLEE, CB; MAXFIELD, FR				HENDEY, B; KLEE, CB; MAXFIELD, FR			INHIBITION OF NEUTROPHIL CHEMOKINESIS ON VITRONECTIN BY INHIBITORS OF CALCINEURIN	SCIENCE			English	Article							FREE CALCIUM; POLYMORPHONUCLEAR LEUKOCYTES; CELLULAR-REGULATION; CYCLOSPORINE-A; PROTEIN; DOMAIN; FIBRONECTIN; RECEPTORS; CELLS; IDENTIFICATION	Migration of human polymorphonuclear neutrophils on vitronectin is dependent on repeated transient increases in the concentration of intracellular free calcium ([Ca2+]i). A specific peptide inhibitor of the Ca2+-calmodulin-dependent phosphatase calcineurin was introduced into the cytoplasm of neutrophils. The peptide inhibited neutrophil migration on vitronectin by interfering with the release of the cells from sites of attachment. A similar reduction in motility on vitronectin occurred when cells were treated with the immunosuppressant FK506, which also inhibits calcineurin when bound to its binding protein, FKBP. These results indicate that a rise in [Ca2+]i reduces integrin-mediated adhesion to vitronectin by a mechanism that requires calcineurin activity.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; NCI,BIOCHEM LAB,BETHESDA,MD 20892	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014150, R01GM034770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34770, GM14150] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANTLER PD, 1985, J CELL BIOL, V101, P207, DOI 10.1083/jcb.101.1.207; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; RATAN RR, 1986, P NATL ACAD SCI USA, V83, P5136, DOI 10.1073/pnas.83.14.5136; RECHSTEINER M, 1987, METHOD ENZYMOL, V149, P42; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1988, J CELL SCI S, V9, P99; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929	29	183	183	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					296	299		10.1126/science.1384129	http://dx.doi.org/10.1126/science.1384129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384129				2022-12-24	WOS:A1992JR86000033
J	ANDERSON, MP; WELSH, MJ				ANDERSON, MP; WELSH, MJ			REGULATION BY ATP AND ADP OF CFTR CHLORIDE CHANNELS THAT CONTAIN MUTANT NUCLEOTIDE-BINDING DOMAINS	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; MULTIDRUG RESISTANCE; R-DOMAIN; EXPRESSION; MUTATIONS; IDENTIFICATION; TRANSPORT; CELLS; PHOSPHORYLATION	Regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is unusual in that phosphorylated channels require cytosolic adenosine triphosphate (ATP) to open. The CFTR contains two regions predicted to be nucleotide-binding domains (NBDs); site-directed mutations in each NBD have now been shown to alter the relation between ATP concentration and channel activity, which indicates that ATP stimulates the channel by direct interaction with both NBDs. The two NBDs are not, however, functionally equivalent: adenosine diphosphate (ADP) competitively inhibited the channel by interacting with NBD2 but not by interacting with NBD1. Four cystic fibrosis-associated mutations in the NBDs reduced absolute chloride channel activity, and one mutation also decreased the potency with which ATP stimulates channel activity. Dysfunction of ATP-dependent stimulation through the NBDs may be the basis for defective CFTR chloride channel activity in some cystic fibrosis patients.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA.			Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAUDET A, COMMUNICATION; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BLACK ME, 1990, J BIOL CHEM, V265, P17584; BLOXMAN DP, 1973, ENZYMES, P262; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DEVOTO M, 1991, AM J HUM GENET, V48, P1127; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LISSENS W, COMMUNICATION; NEET KE, 1983, CONT ENZYME KINETICS, P267; PASTAN I, 1991, FASEB J, V5, P2523, DOI 10.1096/fasebj.5.11.1868977; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith R.M., 1975, CRITICAL STABILITY C; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; Tsui L C, 1991, Adv Hum Genet, V20, P153; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	37	202	208	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1701	1704		10.1126/science.1382316	http://dx.doi.org/10.1126/science.1382316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1382316				2022-12-24	WOS:A1992JN50100036
J	ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M				ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M			LISTERIOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA WHO WERE TREATED WITH FLUDARABINE AND PREDNISONE	ANNALS OF INTERNAL MEDICINE			English	Article						LISTERIA INFECTIONS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; FLUDARABINE; PREDNISONE; ANTIGENS, CD4; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS	INFECTIONS; THERAPY; AGENT	Objective. To determine whether therapy with fludarabine plus prednisone in patients with chronic lymphocytic leukemia increases the risk for developing listeriosis. Design: Retrospective cohort study based on hospital surveillance data. Setting: Referral cancer center. Participants: A total of 795 patients with chronic lymphocytic leukemia who received care at The University of Texas M. D. Anderson Cancer Center between 1980 and 1990. Interventions: Patients were treated with fludarabine alone or fludarabine and prednisone. Measurements: The listeriosis attack rate was analyzed according to the type of treatment received. Results: Seven of 408 patients in the fludarabine group developed listeriosis (1.7%; 95% Cl, 0.2% to 6%) compared with 0 of 387 patients who received conventional chemotherapy alone (0% to 0.9%; P = 0.015). The 7 patients were among 248 patients who were treated with both fludarabine and prednisone; none of 160 patients treated with fludarabine alone developed listeriosis (P = 0.045 by the Fisher exact test). A dramatic reduction in CD4 counts occurred in patients after fludarabine and prednisone treatment and coincided with the development of listeriosis. Conclusion: The administration of fludarabine plus prednisone is associated with an increased incidence of listeriosis in patients with chronic lymphocytic leukemia. The depletion of CD4 cells may underlie the pathogenesis.			ANAISSIE, E (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 47, HOUSTON, TX 77030 USA.							AMPEL MN, 1990, 30TH P INT C ANT AG; ARMSTRONG D, 1990, PRINCIPLES PRACTICE, P1587; AROESTY JM, 1962, NEW YORK STATE J MED, V62, P1946; Bille J, 1988, B BUNDESAMTES GESUND, V3, P28; BOLDT DH, 1984, CANCER RES, V44, P4661; COX DR, 1953, BIOMETRIKA, V40, P354, DOI 10.1093/biomet/40.3-4.354; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; HANSEN MM, 1973, SCAND J HAEMATOL, P1; HANTEL A, 1989, CANCER, V64, P516, DOI 10.1002/1097-0142(19890715)64:2<516::AID-CNCR2820640226>3.0.CO;2-I; HEATH ME, 1985, AM J HEMATOL, V19, P63, DOI 10.1002/ajh.2830190109; KEATING MJ, 1988, LEUKEMIA, V2, P157; KEATING MJ, 1989, BLOOD, V74, P19; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; LOURIA DB, 1970, ANN NY ACAD SCI, V174, P545, DOI 10.1111/j.1749-6632.1970.tb45580.x; LOURIA DB, 1967, ANN INTERN MED, V67, P261, DOI 10.7326/0003-4819-67-2-261; MONSERRATCOSTA E, 1977, SANGRE, V22, P968; MYERS TJ, 1980, CANCER, V46, P619, DOI 10.1002/1097-0142(19800801)46:3<619::AID-CNCR2820460332>3.0.CO;2-I; NIEMAN RE, 1980, REV INFECT DIS, V2, P207; PISCIOTTA AV, 1957, ARCH INTERN MED, V99, P334, DOI 10.1001/archinte.1957.00260030012002; REVOL L, 1974, ENCY MED CHIRURGICAL; ROBERTSON LE, 1990, BLOOD, V76, pA314; SAMRA Y, 1984, POSTGRAD MED J, V60, P267, DOI 10.1136/pgmj.60.702.267; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHWARTZ B, 1988, LANCET, V2, P779; SHAW RK, 1960, ARCH INTERN MED, V106, P467, DOI 10.1001/archinte.1960.03820040005002; SPITZER PG, 1986, REV INFECT DIS, V8, P427; TRAVADE P, 1986, PRESSE MED, V15, P1715; TWOMEY JJ, 1973, ARCH INTERN MED, V132, P562, DOI 10.1001/archinte.132.4.562; UTMANN JE, 1959, ANN INTERN MED, V51, P501; WINSLOW DL, 1982, ANTIMICROB AGENTS CH, V22, P51, DOI 10.1128/AAC.22.1.51; 1989, MMWR, V38, P267	32	110	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					466	469		10.7326/0003-4819-117-6-466	http://dx.doi.org/10.7326/0003-4819-117-6-466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1354425				2022-12-24	WOS:A1992JN25700004
J	KILIDIREAS, K; LATOV, N; STRAUSS, DH; GORIG, AD; HASHIM, GA; GORMAN, JM; SADIQ, SA				KILIDIREAS, K; LATOV, N; STRAUSS, DH; GORIG, AD; HASHIM, GA; GORMAN, JM; SADIQ, SA			ANTIBODIES TO THE HUMAN 60 KDA HEAT-SHOCK PROTEIN IN PATIENTS WITH SCHIZOPHRENIA	LANCET			English	Article							RHEUMATOID-ARTHRITIS; LYMPHOCYTE-T; MYCOBACTERIAL; CELLS; AUTOANTIBODIES; AUTOIMMUNITY; BACTERIAL; SURFACE; ANTIGEN; MYELIN	Immune mechanisms are thought to be important in a subpopulation of patients with schizophrenia. We examined the specificity of neural antibodies in patients with schizophrenia to identify a possible antigen. Serum antibodies from patients with schizophrenia and control subjects were tested for binding to protein extracts of human neuroblastoma cells by western blot. Protein antigens were characterised by aminoterminal and internal aminoacid sequence analysis. 14 of 32 (44%) otherwise healthy patients with schizophrenia had antibodies to a neuroblastoma protein of molecular weight 60 kDa. By partial sequence analysis, this protein was identified as the 60 kDa human heat-shock protein (hsp) that is the P1 mitochondrial protein, and which is 50% homologous to the mycobacterial 65 kDa hsp. Antigens that crossreact with hsp65 have been implicated in the pathogenesis of adjuvant-induced arthritis in rats and autoimmune diabetes in mice. Of 100 normal subjects or disease controls, antibodies to hsp60 were found in only 8 patients, all of whom had active infectious or inflammatory disease. Our results support the presence of abnormal immune reactivity involving hsp60 in a subset of patients with schizophrenia. The immune response may be related to the pathogenesis of the disease.	COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL,BLACK BLDG,ROOM 3-323,630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT SURG, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, DEPT CLIN PSYCHOBIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute			Sadiq, Saud/AAA-9871-2020		NIMH NIH HHS [MH00416] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGUAS AP, 1990, INFECT IMMUN, V58, P1461, DOI 10.1128/IAI.58.5.1461-1470.1990; BRUDZYNSKI K, 1992, DIABETOLOGIA, V35, P316, DOI 10.1007/BF00401198; COHEN IR, 1990, ISRAEL J MED SCI, V26, P673; COULIE PG, 1985, J EXP MED, V161, P88, DOI 10.1084/jem.161.1.88; DEGRAEFFMEEDER ER, 1990, AM J PATHOL, V137, P1013; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; JARJOUR W, 1990, J EXP MED, V172, P1857, DOI 10.1084/jem.172.6.1857; JARJOUR WN, 1991, ARTHRITIS RHEUM-US, V34, P1133, DOI 10.1002/art.1780340909; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KIRCH DG, 1985, BIOL PSYCHIAT, V20, P1039, DOI 10.1016/0006-3223(85)90002-2; KOGA T, 1989, SCIENCE, V245, P1112, DOI 10.1126/science.2788923; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCALLISTER CG, 1989, ARCH GEN PSYCHIAT, V46, P890; MUNK ME, 1989, J IMMUNOL, V143, P2844; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; SADIQ SA, 1991, J NEUROSCI RES, V29, P319, DOI 10.1002/jnr.490290307; SCHATTNER A, 1990, REV INFECT DIS, V12, P204; SIROTA P, 1990, ISRAEL J MED SCI, V26, P694; SPATZ LA, 1990, J IMMUNOL, V144, P2821; SPIVAK B, 1991, AM J PSYCHIAT, V148, P244; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUNDIN U, 1989, Brain Behavior and Immunity, V3, P345, DOI 10.1016/0889-1591(89)90033-0; TSOULFA G, 1989, ANN RHEUM DIS, V48, P118, DOI 10.1136/ard.48.2.118; van Eden W, 1987, Concepts Immunopathol, V4, P144; VANDENBERG LH, 1990, J NEUROSCI RES, V25, P295, DOI 10.1002/jnr.490250305; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VILLEMAIN F, 1989, AM J PSYCHIAT, V2, P417; WANDWURTTENBERGER A, 1991, EUR J IMMUNOL, V21, P1089, DOI 10.1002/eji.1830210437; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	30	74	76	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1992	340	8819					569	572		10.1016/0140-6736(92)92105-O	http://dx.doi.org/10.1016/0140-6736(92)92105-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355154				2022-12-24	WOS:A1992JM33400003
J	MORI, H; MASAKI, H; YAMAKURA, T; MISHINA, M				MORI, H; MASAKI, H; YAMAKURA, T; MISHINA, M			IDENTIFICATION BY MUTAGENESIS OF A MG2+-BLOCK SITE OF THE NMDA RECEPTOR CHANNEL	NATURE			English	Article							METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; ANTICONVULSANT MK-801; ACTIVATED CHANNELS; CORTICAL-NEURONS; RESPONSES; ZINC; PERMEABILITY	THE N-methyl-D-aspartate (NMDA) receptor channel is highly permeable to Ca2+ but is blocked by Mg2+ in a voltage-dependent manner1-4. These characteristics are essential for the NMDA receptor channel to mediate the induction of long-term potentiation of synaptic efficacy, a form of activity-dependent synaptic plasticity thought to underlie memory, learning and development5-8. Recent studies have revealed the molecular and functional diversity of the NMDA receptor channel subunits, which are classified into the epsilon and zeta families according to the amino-acid sequence homology9-12. Here we report that replacement by glutamine of asparagine 598 in putative transmembrane segment M2 of the zeta-1 subunit, strongly reduces the sensitivity of the heteromeric epsilon-2/zeta-1 NMDA receptor channel to Mg2+ block. The corresponding mutation of the epsilon-2 subunit has a similar effect. Furthermore, the heteromeric epsilon-2/zeta-1 NMDA receptor channel with the mutation on both subunits shows greatly reduced sensitivity to MK-801, a channel blocker of the NMDA receptor channel13,14, but is still susceptible to inhibition by Zn2+ 15,16. These findings suggest that the conserved asparagine residue in segment M2 constitutes a Mg2+-block site of the NMDA receptor channel, and that the MK-801 site overlaps the Mg2+ site.	NIIGATA UNIV, BRAIN RES INST, DEPT NEUROPHARMACOL, ASAHIMACHI 1, NIIGATA 95021, JAPAN	Niigata University								ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASHCER P, 1986, J PHYSIOL-LONDON, V377, pP35; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; HERRON CE, 1986, NATURE, V322, P265, DOI 10.1038/322265a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	25	218	220	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1992	358	6388					673	675		10.1038/358673a0	http://dx.doi.org/10.1038/358673a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1386653				2022-12-24	WOS:A1992JJ88200055
J	BLAU, JN				BLAU, JN			CLASSICAL MIGRAINE - SYMPTOMS BETWEEN VISUAL AURA AND HEADACHE ONSET	LANCET			English	Article								The gap between the end of the visual aura and headache onset in classical migraine has been called the free interval. In a retrospective study of twenty-five migraineurs who had noted a gap, only three reported feeling normal at that time: twenty-two described alterations in mood, detachment from the environment or other people, fears, disturbances of speech or thought, or somatic symptoms. The interval lasted less than an hour in seventeen of the twenty-two but in five persisted for 1 to 5 hours. These symptoms suggest involvement of the frontal and temporal cortices as well as the hypothalamus; they do not conform to Leao's spreading depression or a vascular mechanism, but are in keeping with a diffuse cerebral process with focal manifestations.			BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BLAU JN, 1992, LANCET, V339, P1202, DOI 10.1016/0140-6736(92)91140-4; BLAU JN, 1986, PRELUDE MIGRAINE ATT, P39; LAURITZEN M, 1984, BRAIN, V107, P457; PATON L, 1919, P ROY SOC MED, V12, P53; SELBY DK, 1983, GERIATRICS, V38, P42; WOLFF HG, 1963, HEADACHE OTHER HEAD, P230; 1988, CEPHALALGIA S7, V8, P21	7	24	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					355	356		10.1016/0140-6736(92)91415-5	http://dx.doi.org/10.1016/0140-6736(92)91415-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353815				2022-12-24	WOS:A1992JH12500014
J	LIN, HC; SUDHOF, TC; ANDERSON, RGW				LIN, HC; SUDHOF, TC; ANDERSON, RGW			ANNEXIN-VI IS REQUIRED FOR BUDDING OF CLATHRIN-COATED PITS	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY LIPOPROTEIN; ANTICOAGULANT PROTEIN; MEMBRANE-FUSION; CALCIUM; CALPACTIN; BINDING; KINASE; CELLS; PHOSPHOLIPASE-A2	Isolated plasma membranes attached to a solid substratum at 4-degrees-C have numerous clathrin-coated pits. These pits initially are flat but become deeply invaginated after warming to 37-degrees-C. The pits remain tethered to the membrane in this rounded condition unless supplied with ATP, Ca2+, and cytosol. We now show that when cytosol is treated to remove the Ca2+-dependent, phospholipid-binding protein annexin VI, coated pit budding no longer takes place. Addition of purified annexin VI back to the annexin VI-depleted cytosol restores budding activity to normal. Purified annexin VI alone shows only a modest budding activity, suggesting that the cytosol contains a factor(s) in addition to annexin VI that is required for full activity. Cytosol-dependent activation of annexin VI requires both ATP and Ca2+. Annexin VI appears to be not only an active component in the detachment of coated pits from the membrane but also a site for regulating the formation of coated vesicles.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LIN, HC (corresponding author), UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA.				NHLBI NIH HHS [HL39644, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL039644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Anderson R G, 1986, Methods Enzymol, V129, P201; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Anderson RM, 1991, INFECT DIS HUMANS DY, P13; BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; Darnell J., 1990, MOL CELL BIOL; ERNST JD, 1991, J IMMUNOL, V146, P3110; ERNST JD, 1991, J BIOL CHEM, V266, P6670; ERNST JD, 1990, J CLIN INVEST, V85, P1065, DOI 10.1172/JCI114537; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P78, DOI 10.1002/jcb.240460112; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P86, DOI 10.1002/jcb.240460113; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JOHNSTON PA, 1990, BIOCHEM SOC T, V18, P1097, DOI 10.1042/bst0181097; KRAUS FN, 1990, CELL CALCIUM, V11, P625; KWIATKOWSKA K, 1991, EXP CELL RES, V196, P255, DOI 10.1016/0014-4827(91)90259-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; NEWMAN R, 1989, J MOL BIOL, V206, P213, DOI 10.1016/0022-2836(89)90534-2; OHALLORAN TJ, 1992, IN PRESS J CELL BIOL; OSHRY L, 1991, BIOCHIM BIOPHYS ACTA, V1066, P239, DOI 10.1016/0005-2736(91)90192-B; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SEKIMOTO S, 1991, J NEUROCHEM, V56, P1774, DOI 10.1111/j.1471-4159.1991.tb02080.x; SUDHOF TC, 1982, EMBO J, V1, P1167, DOI 10.1002/j.1460-2075.1982.tb00008.x; SUDHOF TC, 1984, BIOCHEMISTRY-US, V23, P1103; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; VANDEURS B, 1989, INT REV CYTOL, V117, P131; ZAKS WJ, 1990, J BIOENERG BIOMEMBR, V22, P97, DOI 10.1007/BF00762942; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	52	129	129	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					283	291		10.1016/0092-8674(92)90102-I	http://dx.doi.org/10.1016/0092-8674(92)90102-I			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1386288				2022-12-24	WOS:A1992JE75700011
J	MACCHIARINI, P; FONTANINI, G; HARDIN, MJ; SQUARTINI, F; ANGELETTI, CA				MACCHIARINI, P; FONTANINI, G; HARDIN, MJ; SQUARTINI, F; ANGELETTI, CA			RELATION OF NEOVASCULARIZATION TO METASTASIS OF NON-SMALL-CELL LUNG-CANCER	LANCET			English	Note							ANGIOGENESIS; VESSELS	The growth of a tumour beyond a certain size requires angiogenesis. We assessed whether intensity of angiogenesis correlates with metastasis of non-small-cell lung cancer by counting microvessels and grading their density within the initial carcinomas in 87 T1N0M0 patients. After radical surgery, metastases developed in 22. Both microvessel count and density grades correlated significantly with metastatic disease as well as tumour size and proliferative activity. The likelihood of metastasis increased as the vessel count increased. On multivariate analysis, the microvessel density count was the only independent predictor of metastasis.	UNIV PISA,INST PATHOL ANAT & HISTOL,I-56100 PISA,ITALY; UNIV ALABAMA,DEPT BIOSTAT,BIRMINGHAM,AL 35294; UNIV PISA,SERV THORAC SURG,I-56100 PISA,ITALY	University of Pisa; University of Alabama System; University of Alabama Birmingham; University of Pisa			Macchiarini, Paolo/E-6878-2013; Fontanini, Gabriella/O-7636-2015	Fontanini, Gabriella/0000-0003-1957-2052				EAVES G, 1972, J PATHOL, V109, P233; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONTANINI G, IN PRESS CANCER; Hsu S.M., 1984, ADV IMMUNOHISTOCHEMI, P31; LIOTTA LA, 1974, CANCER RES, V34, P997; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; SRIVASTAVA A, 1988, AM J PATHOL, V133, P19; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	10	788	853	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					145	146		10.1016/0140-6736(92)93217-B	http://dx.doi.org/10.1016/0140-6736(92)93217-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1378165				2022-12-24	WOS:A1992JE38200005
J	KOURI, YH; BASCH, RS; KARPATKIN, S				KOURI, YH; BASCH, RS; KARPATKIN, S			B-CELL SUBSETS AND PLATELET COUNTS IN HIV-1 SEROPOSITIVE SUBJECTS	LANCET			English	Note								A subset of B lymphocytes positive for the CD5 antigen have been implicated in several autoimmune disorders. To investigate their role in human immunodeficiency virus type 1 (HIV-1) infection, we studied peripheral-blood B and T lymphocytes from HIV-1-positive patients with (n = 13) and without (n = 18) thrombocytopenia, 8 patients with classic autoimmune thrombocytopenia, and 16 healthy controls. The proportion of CD5-positive B cells was significantly higher in the HIV-1-positive thrombocytopenic patients than in the healthy controls, as a result of both higher numbers of CD5-positive B cells and lower numbers of CD5-negative B cells. Platelet count was positively correlated with CD5-negative B-cell count (r = 0.6, P < 0.001) and negatively correlated with proportion of B cells that were CD5 positive (r = -0.5, p < 0.01) among the HIV-1-positive patients. The high concentrations of IgM-containing immune complexes in HIV-1-positive patients with autoimmune disorders may be due to changes in the CD5-positive B-cell subset.	NYU MED CTR, DEPT MED, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Basch, Ross/0000-0001-6666-2718	NHLBI NIH HHS [HL133336] Funding Source: Medline; NIA NIH HHS [AGO48660] Funding Source: Medline; NIDA NIH HHS [DADA04315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL133336, R01HL133336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARAUJO PMF, 1987, SCAND J IMMUNOL, V25, P497, DOI 10.1111/j.1365-3083.1987.tb02221.x; BOUMSELL L, 1980, J EXP MED, V152, P229, DOI 10.1084/jem.152.1.229; Burastero S E, 1989, Contrib Microbiol Immunol, V11, P231; HARDY RR, 1987, SCIENCE, V236, P81, DOI 10.1126/science.3105057; KARPATKIN S, 1988, P NATL ACAD SCI USA, V85, P9763, DOI 10.1073/pnas.85.24.9763; KARPATKIN S, 1992, J CLIN INVEST, V89, P356, DOI 10.1172/JCI115593; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; PAINTER CJ, 1988, J EXP MED, V167, P1137, DOI 10.1084/jem.167.3.1137; ZAULI G, 1991, J ACQ IMMUN DEF SYND, V4, P1251	10	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1992	339	8807					1445	1446		10.1016/0140-6736(92)92033-C	http://dx.doi.org/10.1016/0140-6736(92)92033-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1376384				2022-12-24	WOS:A1992HY31700006
J	EVANS, RJ; DERKACH, V; SURPRENANT, A				EVANS, RJ; DERKACH, V; SURPRENANT, A			ATP MEDIATES FAST SYNAPTIC TRANSMISSION IN MAMMALIAN NEURONS	NATURE			English	Article							MOUSE VAS-DEFERENS; AUTONOMIC NEUROTRANSMISSION; SURAMIN; CELLS; RAT; AUTORECEPTORS; VESICLES; SINGLE	IN addition to its diverse functions inside cells, ATP can act at several types of cell-surface receptor 1-3. One of these (P2X-purinoceptor) is believed to be a ligand-gated cation channel 1-6. The presence of P2X receptors on autonomic, sensory and central neurons suggests that ATP might be released to act as a fast excitatory synaptic transmitter. Here we record excitatory synaptic potentials and currents from cultured coeliac ganglion neurons which are mimicked by ATP, blocked by the P2-purinoceptor antagonist suramin, desensitized by alpha,beta-methylene-ATP and unaffected by antagonists acting at nicotine, 5-hydroxytryptamine, N-methyl-D-aspartate (NMDA), non-NMDA glutamate, gamma-aminobutyric acid (GABA), noradrenaline or adenosine receptors. We conclude that ATP is the neurotransmitter at this neuroneuronal synapse.			EVANS, RJ (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.							ALM P, 1979, NEUROSCIENCE, V4, P145, DOI 10.1016/0306-4522(79)90224-0; BEAN BP, 1990, J NEUROSCI, V10, P11; BEAN BP, 1990, J NEUROSCI, V10, P1; BENHAM CD, 1987, J PHYSIOL-LONDON, V387, P473, DOI 10.1113/jphysiol.1987.sp016585; BURNSTOCK G, 1991, NUCLEOS NUCLEOT NUCL, V10, P917, DOI 10.1080/07328319108047230; BURNSTOCK G, 1986, ACTA PHYSIOL SCAND, V126, P67, DOI 10.1111/j.1748-1716.1986.tb07790.x; BURNSTOCK G, 1990, NEUROCHEM INT, V17, P357, DOI 10.1016/0197-0186(90)90158-P; COGGAN JS, 1991, J AUTONOM NERV SYST, V34, P147, DOI 10.1016/0165-1838(91)90081-D; DUNN PM, 1988, BRIT J PHARMACOL, V93, P243, DOI 10.1111/j.1476-5381.1988.tb11427.x; EVANS RJ, IN PRESS BR J PHARM; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIED G, 1980, ACTA PHYSL SCAND, V493, P546; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; LAGERCRANTZ H, 1976, NEUROSCIENCE, V1, P81, DOI 10.1016/0306-4522(76)90002-6; NAKAZAWA K, 1990, BRIT J PHARMACOL, V101, P224, DOI 10.1111/j.1476-5381.1990.tb12117.x; SHEN KZ, 1990, J PHYSL, V431, P585; STARKE K, 1987, REV PHYSIOL BIOCH P, V107, P73, DOI 10.1007/BFb0027645; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V342, P198, DOI 10.1007/BF00166965; VONKUGELGEN I, 1989, N-S ARCH PHARMACOL, V340, P760, DOI 10.1007/BF00169686; WHITE TD, 1988, PHARMACOL THERAPEUT, V38, P129, DOI 10.1016/0163-7258(88)90095-2	24	508	515	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					503	505		10.1038/357503a0	http://dx.doi.org/10.1038/357503a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1351659				2022-12-24	WOS:A1992HY05200065
J	ALDERMAN, MH				ALDERMAN, MH			WHICH ANTIHYPERTENSIVE DRUGS 1ST - AND WHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HYPERTENSION				ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10461 USA.							[Anonymous], 1970, JAMA, V213, P1143; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DOLLERY CT, 1987, J HYPERTENS, V5, pS75; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; GOLDSTEIN G, 1990, HYPERTENSION, V15, P361, DOI 10.1161/01.HYP.15.4.361; HUNT D, 1992, LANCET, V339, P753; KAPLAN NM, 1991, AM J HYPERTENS, V4, P970, DOI 10.1093/ajh/4.12.970; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANGANO DT, 1991, CIRCULATION, V84, P1879, DOI 10.1161/01.CIR.84.4.1879; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PEART S, 1985, British Medical Journal, V291, P97; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; SHEKELLE RB, 1984, ATHER REV, V12, P113; STASON WB, 1989, HYPERTENSION S, V13, P45; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1971, CIRCULATION, V44, pA263; 1991, JAMA-J AM MED ASSOC, V266, P3255; 1990, NATIONAL DISEASE THE, V1; 1991, BIRTHS MARRIAGE DIVO, V39	22	37	37	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2786	2787		10.1001/jama.267.20.2786	http://dx.doi.org/10.1001/jama.267.20.2786			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1349655				2022-12-24	WOS:A1992HV26500028
J	JAFFE, DB; JOHNSTON, D; LASSERROSS, N; LISMAN, JE; MIYAKAWA, H; ROSS, WN				JAFFE, DB; JOHNSTON, D; LASSERROSS, N; LISMAN, JE; MIYAKAWA, H; ROSS, WN			THE SPREAD OF NA+ SPIKES DETERMINES THE PATTERN OF DENDRITIC CA2+ ENTRY INTO HIPPOCAMPAL-NEURONS	NATURE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; RAT HIPPOCAMPUS; CALCIUM; EXCITABILITY; ORGANIZATION; INDICATORS; ACTIVATION; INDUCTION; SYNAPSES	THE dendrites of many types of neurons contain voltage-dependent Na+ and Ca2+ conductances that generate action potentials (see ref. 1 for review). The function of these spikes is not well understood, but the Ca2+ entry stimulated by spikes probably affects Ca2+-dependent processes in dendrites. These include synaptic plasticity 2,3, cytotoxicity 4 and exocytosis 5. Several lines of evidence suggest that dendritic spikes occur within subregions of the dendrites 6-8. To study the mechanism that govern the spread of spikes in the dendrites of hippocampal pyramidal cells, we imaged Ca2+ entry with Fura-2 (ref. 9) and Na+ entry with a newly developed Na+-sensitive dye 10). Our results indicate that Ca2+ entry into dendrites is triggered by Na+ spikes that actively invade the dendrites. The restricted spatial distribution of Ca2+ entry seems to depend on the spread of Na+ spikes in the dendrites, rather than on a limited distribution of Ca2+ channels. In addition, we have observed an activity-dependent process that modulates the invasion of spikes into the dendrites and progressively restricts Ca2+ entry to more proximal dendritic regions.	NEW YORK MED COLL,DEPT PHYSIOL,VALHALLA,NY 10595; BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; YAMAGATA UNIV,SCH MED,DEPT PHYSIOL,YAMAGATA 99023,JAPAN; MARINE BIOL LAB,WOODS HOLE,MA 02543	New York Medical College; Baylor College of Medicine; Brandeis University; Yamagata University; Marine Biological Laboratory - Woods Hole					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016295] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS016295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1987, J PHYSIOL-LONDON, V383, P509; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; JOHNSTON D, 1983, J NEUROPHYSIOL, V50, P464, DOI 10.1152/jn.1983.50.2.464; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LASSERROSS N, 1992, P ROY SOC B-BIOL SCI, V247, P35, DOI 10.1098/rspb.1992.0006; LASSERROSS N, 1991, J NEUROSCI METH, V36, P253, DOI 10.1016/0165-0270(91)90051-Z; LEV-RAM V, 1990, Society for Neuroscience Abstracts, V16, P894; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LLINAS RR, 1987, P NATL ACAD SCI USA, V84, P3047, DOI 10.1073/pnas.84.9.3047; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MASUKAWA LM, 1984, J NEUROSCI, V4, P217; MINTA A, 1989, J BIOL CHEM, V264, P19449; MIYAKAWA H, 1986, BRAIN RES, V5399, P303; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; ROSS W N, 1991, Society for Neuroscience Abstracts, V17, P581; ROSS WN, 1990, PROC R SOC SER B-BIO, V240, P173, DOI 10.1098/rspb.1990.0032; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WONG RKS, 1979, SCIENCE, V204, P1228, DOI 10.1126/science.451569	28	377	379	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					244	246		10.1038/357244a0	http://dx.doi.org/10.1038/357244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1350327				2022-12-24	WOS:A1992HV19500055
J	MITCHELL, IC; TURK, JL; MITCHELL, DN				MITCHELL, IC; TURK, JL; MITCHELL, DN			DETECTION OF MYCOBACTERIAL RIBOSOMAL-RNA IN SARCOIDOSIS WITH LIQUID-PHASE HYBRIDIZATION	LANCET			English	Article							DNA; IDENTIFICATION; HYBRIDIZATION; TUBERCULOSIS	Because sarcoidosis resembles tuberculosis clinically and histologically, it has been suggested that mycobacteria might have a role in the pathogenesis of the disorder. Mycobacteria have not been found in sarcoid tissues by conventional culture techniques, so we have used a liquid-phase hybridisation method to see whether we could detect mycobacterial rRNA in such tissues. RNA was extracted from five sarcoid and five normal spleens. Extracts were assayed by liquid-phase DNA/RNA hybridisation with a DNA probe specific for the rRNA of the Mycobacterium tuberculosis complex. Hybridisation obtained with the sarcoid spleens, from which mycobacteria were neither seen on microscopy nor cultured with standard methods, was 4.8 times higher than that with normal spleens (p < 0.001). Our demonstration of mycobacterial nucleic-acid components in sarcoid splenic tissues supports the notion that mycobacteria play a part in the cause of sarcoidosis.	ROYAL COLL SURG ENGLAND,HUNTERIAN INST,DEPT PATHOL,LONDON WC2A 3PN,ENGLAND; ROYAL BROMPTON HOSP,LONDON,ENGLAND	Royal College of Surgeons of England; University of London; Royal Brompton Hospital								BERCOVIER H, 1986, BIOCHEM BIOPH RES CO, V136, P1136, DOI 10.1016/0006-291X(86)90452-3; BURNET FM, 1959, CLONAL SELECTION THE, P160; GONZALEZ R, 1987, DIAGN MICR INFEC DIS, V8, P69, DOI 10.1016/0732-8893(87)90152-0; Graham D, 1988, SARCOIDOSIS OTHER GR, P161; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HANNGREN A, 1987, SARCOIDOSIS, V4, P104; KIRBY KS, 1968, METHOD ENZYMOL, P87; KOHNE DE, 1981, J GEN VIROL, V56, P223, DOI 10.1099/0022-1317-56-2-223; KOHNE DE, 1986, AM CLIN PROD REV, V5, P20; KOHNE DE, 1971, PROCEDURES NUCLEIC A, V2, P500; MCFADDEN JJ, 1987, BIOCHEM SOC T, V15, P548, DOI 10.1042/bst0150548; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420	13	96	99	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1015	1017		10.1016/0140-6736(92)90536-C	http://dx.doi.org/10.1016/0140-6736(92)90536-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1373786				2022-12-24	WOS:A1992HQ43500004
J	BRADBURY, NA; JILLING, T; BERTA, G; SORSCHER, EJ; BRIDGES, RJ; KIRK, KL				BRADBURY, NA; JILLING, T; BERTA, G; SORSCHER, EJ; BRIDGES, RJ; KIRK, KL			REGULATION OF PLASMA-MEMBRANE RECYCLING BY CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS; PROTEIN-KINASE; CHLORIDE; CONDUCTANCE; CELLS	The gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) is defective in patients with cystic fibrosis. Although the protein product of the CFTR gene has been proposed to function as a chloride ion channel, certain aspects of its function remain unclear. The role of CFTR in the adenosine 3',5'-monophosphate (cAMP)-dependent regulation of plasma membrane recycling was examined. Adenosine 3',5'-monophosphate is known to regulate endocytosis and exocytosis in chloride-secreting epithelial cells that express CFTR. However, mutant epithelial cells derived from a patient with cystic fibrosis exhibited no cAMP-dependent regulation of endocytosis and exocytosis until they were transfected with complementary DNA encoding wild-type CFTR. Thus, CFTR is critical for cAMP-dependent regulation of membrane recycling in epithelial tissues, and this function of CFTR could explain in part the pleiotropic nature of cystic fibrosis.	UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Sorscher, Eric J./0000-0001-9341-3354; Jilling, Tamas/0000-0002-6200-3851				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERTA G, UNPUB; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; BRADBURY NA, UNPUB; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GASSER KW, 1988, AM J PHYSIOL, V254, pG93, DOI 10.1152/ajpgi.1988.254.1.G93; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JILLING T, 1990, AM J PHYSIOL, V259, pC1010, DOI 10.1152/ajpcell.1990.259.6.C1010; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; POLLARD HB, 1984, J BIOL CHEM, V259, P1114; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SORSCHER EJ, 1991, LANCET, V337, P1115, DOI 10.1016/0140-6736(91)92785-Z; SORSCHER EJ, 1992, AM J PHYSIOL, V262, pC136, DOI 10.1152/ajpcell.1992.262.1.C136; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC233	21	329	330	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					530	532		10.1126/science.1373908	http://dx.doi.org/10.1126/science.1373908			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373908				2022-12-24	WOS:A1992HQ18700066
J	PETTOELLOMANTOVANI, M; CASADEVALL, A; KOLLMANN, TR; RUBINSTEIN, A; GOLDSTEIN, H				PETTOELLOMANTOVANI, M; CASADEVALL, A; KOLLMANN, TR; RUBINSTEIN, A; GOLDSTEIN, H			ENHANCEMENT OF HIV-1 INFECTION BY THE CAPSULAR POLYSACCHARIDE OF CRYPTOCOCCUS-NEOFORMANS	LANCET			English	Note							INVITRO	Patients with AIDS who become infected with Cryptococcus neoformans have a poor prognosis. We speculated that the presence of cryptococcal capsular polysaccharide may enhance HIV-1 infection. In an in-vitro study, the presence of cryptococcal polysaccharide significantly increased (p < 0.05) production of p24 antigen after infection of H9 cells with HIV-1 -infected H9 cells. We also found similar results when lymphocytes from an HIV-1 -infected patient were co-cultured with mononuclear cells from an uninfected individual. Our findings suggest a new pathogenic role for the capsular polysaccharide-namely, the capacity to enhance HIV-1 infectivity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT,FORSCHHEIMER BLDG,ROOM 403, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			MANTOVANI, Massimo PETTOELLO/AAC-1990-2019	MANTOVANI, Massimo PETTOELLO/0000-0002-0688-1131; Kollmann, Tobias/0000-0003-2403-9762	NATIONAL CANCER INSTITUTE [R35CA039838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI020671, P30AI027741, R01AI020671] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39838] Funding Source: Medline; NIAID NIH HHS [AI-20671, AI-27741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BHATTACHARJEE AK, 1984, REV INFECT DIS, V6, P619; ENG RHK, 1986, AM J MED, V81, P19, DOI 10.1016/0002-9343(86)90176-2; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOLDSTEIN H, 1991, AIDS, V5, P1447, DOI 10.1097/00002030-199112000-00006; KOZEL TR, 1971, INFECT IMMUN, V3, P287, DOI 10.1128/IAI.3.2.287-294.1971; MILLER GPG, 1984, J IMMUNOL, V133, P166; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; Treseler C B, 1990, Infect Dis Clin North Am, V4, P789; WISEMAN G, 1991, AIDS RES HUM RETROV, V7, P839, DOI 10.1089/aid.1991.7.839	10	79	82	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1992	339	8784					21	23		10.1016/0140-6736(92)90142-P	http://dx.doi.org/10.1016/0140-6736(92)90142-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1370335				2022-12-24	WOS:A1992GY04300004
